WO2016091888A2 - Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics - Google Patents

Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics Download PDF

Info

Publication number
WO2016091888A2
WO2016091888A2 PCT/EP2015/078999 EP2015078999W WO2016091888A2 WO 2016091888 A2 WO2016091888 A2 WO 2016091888A2 EP 2015078999 W EP2015078999 W EP 2015078999W WO 2016091888 A2 WO2016091888 A2 WO 2016091888A2
Authority
WO
WIPO (PCT)
Prior art keywords
refseq
homo sapiens
pdac
individual
mrna
Prior art date
Application number
PCT/EP2015/078999
Other languages
French (fr)
Other versions
WO2016091888A3 (en
Inventor
Nelson Dusetti
Juan Lucio Iovanna
Ezequiel CALVO
Odile GAYET
Céline LONCLE
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Centre Hospitalier Universitaire De Quebec
Centre National De La Recherche Scientifique (Cnrs)
Université D'aix-Marseille
Institut Jean Paoli & Irene Calmettes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre Hospitalier Universitaire De Quebec, Centre National De La Recherche Scientifique (Cnrs), Université D'aix-Marseille, Institut Jean Paoli & Irene Calmettes filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of WO2016091888A2 publication Critical patent/WO2016091888A2/en
Publication of WO2016091888A3 publication Critical patent/WO2016091888A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the invention relates to the field of transcriptomics, for effective treatment and follow-up of individuals having Pancreatic Ductal Adenocarcinoma (PDAC). It also relates to kits, compositions and solid supports, suitable for use in methods for determining the prognosis of an individual having PDAC, or the efficiency of a compound for treating PDAC in said individual.
  • PDAC Pancreatic Ductal Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma is one of the most lethal human malignancies and a major health problem. PDAC causes about 10,000 deaths per year in France and 230,000 in the worldwide (Jemal et al; Cancer statistics, 2003. CA: a cancer journal for clinicians 2003, 53:5-26). The ratio of incidence/death is almost 1 indicating that virtually all patients presenting a PDAC will be killed by their disease. This is due to their short survival median that is about 6 months, the shortest of all tumors, because the treatments are relatively inefficient. Despite considerable research efforts in the past decades, conventional treatment approaches, including surgery, radiation, chemotherapy, or combinations of these, had very limited impact. The prognosis is dismal with only 20% of patients alive one year after diagnosis (Jemal et al, 2003). Given this scenario, the search for new treatments that will counter PDAC progression and thereby increase patient life expectancy and quality of life has been given high priority.
  • PDAC Pancreatic Ductal Adenocarcinoma
  • the drugs received by patients suffering from PDAC are chosen according to their general performance status and the stage of their disease. No study of the tumor can predict its responsiveness to the treatment, nor give a prognosis to the disease progression.
  • the object ivc response rate was 31.6% for multidrug FOLFIRINOX-treated patients, and only 9.4% for patients treated with gemcitabine, thus showing that about 70% to 90% of patients were not responders respectively (Conroy et al.; The New England Journal of Medicine; 2011; 364: 1817-25).
  • PDAC tumors are hypovascularised and very rich in stroma, representing from 15 to 90% of the tumor mass, which may form a barrier for drug delivery to the transformed cells.
  • future therapeutic agents are expected to be "patients-targeted” in order to specifically affect PDAC cells by targeting their weaknesses, while leaving normal tissues preferably undamaged.
  • the availability of improved prognosis or monitoring methods would allow a better selection of patients for appropriate therapeutic treatments, including before and after surgery. Such methods would also allow a better selection of patients which may benefit from surgery, in particular by determining the level of differentiation of the Pancreatic Adenocarcinoma.
  • PDAC tumors can contain from 15 to 90% of stroma tissue associated with variable areas of inflammation and necrosis.
  • in vitro or ex vivo methods for determining the efficiency of therapeutic treatments of PDAC which includes therapeutic treatments with active principles such as gemcitabine, oxaliplatin, 5-fluorouracil (5FU), docetaxel, Irinotecan, and/or derivatives thereof, for treating said individual.
  • active principles such as gemcitabine, oxaliplatin, 5-fluorouracil (5FU), docetaxel, Irinotecan, and/or derivatives thereof.
  • in vitro or ex vivo methods for screening compounds which are efficient for treating PDAD in an individual, or alternatively for improving the prognosis, the condition or clinical outcome, of an individual having PDAC.
  • compositions and/or kits and/or solid supports which are suitable for use for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating said individual.
  • PDAC Pancreatic Adenocarcinoma
  • the present invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
  • PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDM;
  • the invention also relates to a composition
  • a composition comprising:
  • At least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR;
  • MUC3A NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI;
  • the invention also relates to a kit comprising:
  • PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
  • At least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ;
  • the invention also relates to a solid support comprising:
  • At least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR;
  • PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ; ITGAIO; MTIA; VIM; CCNEl; THBS3; TRAF5; LTA4H; SAMHDl; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
  • FIG. 1 RNA expression analysis of PDAC.
  • A Principal Component Analysis obtained from the Affymetrix data. Each patient is represented in double since data was obtained from two independents experiments. Grey plots are representing long- term survival patients whereas black plots are representing patients with short-term survival.
  • B Histogram representing the survival time of patients included in this study.
  • C The Heatmap showing the RNA expression profile of patients with long-term and short-term survival.
  • Figure 2 Primary cell cultures of PDAC samples. Histogram representing the duplication folds in 24 hours of each cell line.
  • FIG. 3 Chemogram. PDAC-derived cells were treated with increasing concentrations of Gemcitabine, Docetaxel, 5-Fluouracil (5FU), Oxaliplatin and the active metabolite of Irinotecan known as SN-38 and the survival cells were measured after 72 h of treatment. A sensitivity profile was obtained for each drug. The point indicated with a red discontinue line was used to establish the score used in Figure 4.
  • Figure 4 RNA expression and drug sensitivity. Heatmaps and Dendograms showing the RNA expression profiles of PDAC-derived cells with resistance or sensitivity to the treatments with (A) Gemcitabine, (B) Oxaliplatin, (C) 5-Fluouracil (5FU), (D) Docetaxel, and (E) SN-38.
  • A Gemcitabine
  • B Oxaliplatin
  • C 5-Fluouracil
  • D Docetaxel
  • E SN-38.
  • the invention has for purpose to meet the aforementioned needs.
  • the inventors have explored the possibility that the variable sensitivity of patients with PDAC to therapeutic treatment that is known in the art is mainly due to the intrinsic molecular characteristics of the cancer cells.
  • the inventors have conceived an assay allowing the availability of human PDAC tumor tissue which is devoid of surrounding stromal cells. More precisely, the inventors have used xenografted PDAC tissue in order to characterize the whole expression profile of the tumor tissue, so that tumors would maintain their morphological characteristics but lose the stroma cells, the inflammatory cells and cells undergoing necrosis.
  • the inventors have developed an efficient strategy in which PDAC samples from patients were obtained by Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA) biopsies or surgery, their cells maintained as a primary culture and tumors as breathing tumors by xenografting in immunosuppressed mice. For these patients a clinical follow up was obtained. On the breathing tumors the RNA expression profile was analysed by using DNA microarray chips.
  • EUS-FNA Endoscopic Ultrasound-Guided Fine-Needle Aspiration
  • PCA Principal components analysis
  • the inventors have shown that the transcriptome analysis of tumor tissue samples obtained from patients is indicative of the long- or short-time survival of those patients, which also corresponds to the level of differentiation of the PDAC tumor (moderately- or poorly-differentiated respectively).
  • Using cultured patient's tumor cells allowed the present inventors to analyze the relative sensitivity of these tumor cells to several anticancer drugs in vitro by developing a chemiogram assay, with a plurality of known anticancer drugs, for the purpose of obtaining an individual profile of drug sensitivity. As shown in the examples herein, the response to each drug tested was patient-dependent. Surprisingly, using this assay, the inventors have shown that the transcriptome analysis of patient's tumor tissue or of patient's tumor cells allows predicting the sensitivity of patients having PDAC to known drugs, including anticancer drugs, as well as to candidate drug compounds. The inventors have also shown that the assay described herein allows predicting the clinical outcome of those patients.
  • a gene comprised in a set of genes as disclosed herein may also be termed a "PDAC marker gene" for the purpose of the present specification.
  • subsets of PDAC-marker genes may be determined from the whole collection of gene sets described in the present specification. Although any combination of the PDAC-marker genes disclosed herein may be used for the purpose of performing the methods according to the invention, it is readily understood that, for practical reasons, the use of only sub-sets of the disclosed PDAC-marker genes allows performing the methods according to the invention more rapidly, and also less costly, than when an entire gene set is assayed.
  • the finding of a decreased expression level of one or more PDAC-marker genes comprised in the said first group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual is indicative of a good clinical outcome of the said PDAC-affected individual.
  • the finding of an increased expression level of one or more PDAC-marker genes comprised in the said second group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual is indicative of a good clinical outcome of the said PDAC-affected individual.
  • the finding of an increased expression level of one or more PDAC-marker genes comprised in the said second group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual treated with one given compound is indicative of a therapeutic activity of the said given compound for the said PDAC- affected individual.
  • the combination of (i) the finding of a decreased expression of one or more PDAC-marker genes comprised in the said first group or subset of PDAC- marker genes and (ii) the finding of an increased expression of one or more PDAC-marker genes comprised in the said second group or subset of PDAC-marker genes, in a sample originating from a PDAC-affected individual treated with one given compound is indicative of a therapeutic activity of the said given compound for the said PDAC-affected individual.
  • the inventors have determined that the prognosis of clinical outcome of an individual having PDAC or the efficiency of one compound for treating PDAC in the said individual is good when:
  • PDAC-marker gene means a gene for which the expression level is a parameter contributing to indicate (i) the prognosis, condition or clinical outcome, of an individual affected with PDAC or (ii) the sensitivity of the tumor tissue of a PDAC-affected individual to a compound used, or alternatively assayed, for the purpose of a PDAC therapeutic treatment.
  • the expression level of a PDAC-marker gene according to the invention encompasses (i) the R A level which is found in a sample as a consequence of the corresponding gene transcription and (ii) the protein level which is found in a sample as the consequence of the translation of the corresponding RNA.
  • the inventors have also shown herein that a particular variation of the first group relatively to the second group represents a novel "signature" in PDAC tumors.
  • each one of the collections of genes which are recited in tables 3 to 8 is considered, which includes table 3, 4, 5, 6, 7, 8, and preferred subsets of genes, which includes tables 9, 10, 11, 12, 13 and 14.
  • one up-regulated PDAC marker gene in one group may also be considered as an up-regulated in another group.
  • one down-regulated PDAC marker gene in one group may also be considered as down- regulated in another group.
  • one compound identified as efficient for treating PDAC in one individual would necessarily improve the prognosis, or clinical outcome of the said individual. Although such correlation is likely to occur for a vast majority of compounds, it is also known in the Art that the improvement of clinical outcome in an individual having PDAC is also dependent on other factors.
  • one PDAC-marker gene which has been identified as being particularly indicative of the efficiency of one compound for treating PDAC in an individual, is also indicative to the same extent of the efficient of another compound for treating PDAC in the same individual.
  • each collection of PDAC-marker genes is grouped based on its preferred use as a PDAC-marker gene, which may include:
  • the invention thus relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
  • Steps al) and a2) may be performed at the same time period or at distinct time periods.
  • steps al) and a2) are performed at distinct time periods, these steps may be performed in a chronological sequence comprising performing step al) before step a2). Alternatively, these steps may be performed in a chronological sequence comprising performing step a2) before step al).
  • the expression level of a PDAC-marker gene is preferably a relative value that is obtained after comparison of the absolute expression level value with a reference expression value.
  • a "reference value” or “reference expression value” refers to any value measured in one or more comparable control cells, tissue samples and/or individuals, including groups of individuals, which may or may not be disease free, and which in particular may be PDAC disease free.
  • the said reference value may be from the same individual or from another individual who is normal or does not present with the same disease from which the disease or test sample is obtained.
  • the reference value can be determined from one or more control cells, tissue samples and/or individuals that is/are not diagnosed with PDAC, or alternatively measured from the same individual prior to administration of the said compound.
  • the multivariate statistical analysis is Principal Component Analysis (PCA).
  • a PCA is based on a similarity (or distance) matrix between objects.
  • it is common to use a correlation matrix.
  • the prognosis of said individual as determined in step b) is good if said individual has a higher life expectancy than said reference, which includes determining whether said individual has a short-term or long-term life expectancy compared to a reference value.
  • the efficiency of said compound as determined in step b) is good if the condition of said individual is expected to improve after administration of said compound, or alternatively if the life expectancy of said individual is expected to improve after administration of said compound.
  • PDAC encompasses the prognosis, in a patient wherein the occurrence of PDAC has already been diagnosed, of various events, including:
  • the invention relates to an in vitro or ex vivo method as defined above, for determining the short-term and long-term survival of said individual; or alternatively for determining the level of differentiation of Pancreatic Adenocarcinoma in said individual.
  • “short-term” and “long-term” survival relate to the life expectancy of one given individual having Pancreatic Adenocarcinoma (PDAC).
  • PDAC Pancreatic Adenocarcinoma
  • a “short-term survival” may refer to a life expectancy of one given individual having PDAC which does not exceed 8 months.
  • a “long-term survival” may refer to a life expectancy of one given individual having PDAC which exceeds 8 months.
  • determining the prognosis of an individual having PDAC also encompasses determining whether said individual has a good prognosis, or clinical outcome, compared to a reference individual having PDAC, of which life expectancy is determinable.
  • a method for determining the prognosis of an individual having PDAC encompasses methods for determining whether said individual has a short- term or a long-term survival rate.
  • the method when used for determining the efficiency of a compound for treating Pancreatic Adenocarcinoma (PDAC) in said individual, it can be used for screening purposes.
  • PDAC Pancreatic Adenocarcinoma
  • the invention also relates to in vitro or ex vivo methods for screening compounds, including novel compounds, which are efficient for treating PDAD in an individual, or alternatively for improving the prognosis, the condition or clinical outcome, of an individual having PDAC.
  • determining the efficiency of a compound for treating PDAC in said individual encompasses determining if the compound is suitable for killing cells, in particular primary cells or xenografts, derived from said PDAC.
  • Quantification of this efficiency may be further tested in vitro by performing a chemiogram on primary cultured derived from the PDAC, as shown in Example 2.
  • the efficiency of a compound for treating PDAC in said individual may also be indicative of the efficiency of a compound for improving the condition of said individual.
  • the efficiency of a compound for treating PDAC in said individual may also be indicative of the efficiency of a compound for improving the prognosis of said individual. It is also disclosed herein a subset of genes which have been identified as particularly efficient PDAC-marker genes, and which are listed in tables 9 to 14.
  • PDAC-marker genes consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
  • the second group of PDAC-marker genes includes the PDAC- marker genes which are preferably up-regulated when the prognosis of one individual having PDAC is good, or alternatively when a given compound is deemed as efficient for treating PDAC in the said individual.
  • the invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic
  • Adenocarcinoma or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
  • the method further includes a step of providing a biological sample from said individual having PDAC.
  • the invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
  • the biological sample from said individual is a tumour sample derived from a Pancreatic Adenocarcinoma (PDAC), including a tumor sample derived from the head or the tail of the pancreas.
  • PDAC Pancreatic Adenocarcinoma
  • the tumour sample derived from PDAC can be a sample collected by endoscopic aspiration, including Endoscopic Ultrasound-Guided Fine-Needle Aspiration, or by surgery.
  • the expression of at least one gene may also encompass, in a more indirect manner, measuring the expression of at least one protein encoded by said at least one gene.
  • Such probes are generally used in combination with other probes, in a manner suitable for amplification using a variety of polymerase chain reaction methods.
  • the expression of at least one gene in steps al and a2) can be achieved by using at least one labelled or unlabelled probe that is complementary to the product of at least one gene selected from the first group; and at least one labelled or unlabelled probe that is complementary to the product of at least one gene selected from the second group.
  • the nucleic acid to be detected including mR As
  • a probe for example by running the isolated nucleic acid on an agarose gel and transferring the nucleic acid from the gel to a membrane, such as nitrocellulose.
  • the probe(s) are immobilized on a solid surface and the nucleic acid is contacted with the probe(s), for example, in an Affymetrix gene chip array.
  • a method of choice for measuring the expression of a nucleic acid is by using microarrays, such as microarrays of the Affymetrix type.
  • measuring the expression of at least one gene includes measuring the expression of at least two, three, four, five, six, seven, eight, nine, ten, or even more than ten genes, which includes 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or even more than 100 genes, which also includes measuring the expression of all the genes belonging to the first group and all the genes belonging to the second group.
  • the first group may consist of at least one gene selected from: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
  • nucleic acid selected from a second group consisting of: SEQ ID NOs 9-13; SEQ ID NOs 17-19; SEQ ID NOs 27-30; SEQ ID NO 33; SEQ ID NOs 36-37; SEQ ID NOs
  • the invention relates to a method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), comprising the steps of:
  • aO providing a biological sample from said individual having PDAC; al) measuring, in said biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1;
  • the invention relates to an in vitro or ex vivo method for determining the efficiency of a compound for treating PDAC in an individual, comprising at least the steps of:
  • the invention relates to an in vitro or ex vivo method as defined above, for determining the efficiency of a compound for treating PDAC in an individual, wherein the compound is selected from the group consisting of: gemcitabine; oxaliplatin; 5-fluorouracil (5FU); docetaxel; Irinotecan or SN-38; and/or derivatives thereof and/or combinations thereof.
  • the compound is selected from the group consisting of: gemcitabine; oxaliplatin; 5-fluorouracil (5FU); docetaxel; Irinotecan or SN-38; and/or derivatives thereof and/or combinations thereof.
  • the invention relates to an in vitro or ex vivo method for determining the efficiency of Irinotecan for treating PDAC in an individual, comprising at least the steps of:
  • the invention relates to an in vitro or ex vivo method for determining the efficiency of oxaliplatin for treating PDAC in an individual, comprising at least the steps of:
  • Docetaxel (IUPAC name: l,7P, 10P-trihydroxy-9-oxo-5P,20-epoxytax-l l-ene-
  • Bevacizumab (Van Cutsem et al.; Journal of clinican oncology: official journal of the American Society of Cinical Oncology; 2009; 27:2231-7), Erlotinib (Moore et al; Journal of clinican oncology: official journal of the American Society of Cinical Oncology; 2007; 25: 1960-6) and Axitinib are also examples of compounds for treating PDAC.
  • PDAC marker genes selected from a first group consisting of: ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7;
  • the first group may consist of one or more gene selected from: DDX26B and WDR78;
  • the second group may consist of one or more gene selected from: SMAD4.
  • the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe being complementary to:
  • nucleic acid selected from a first group consisting of: SEQ ID NOs 31-32; or
  • nucleic acid selected from a second group consisting of SEQ ID NO 33.
  • the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe being complementary to: - at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 38-43; or
  • nucleic acid selected from a first group consisting of: SEQ ID NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOS 38-43 or
  • the invention further relates to a kit comprising:
  • PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
  • At least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 1-8; SEQ ID NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOs 48-53 and
  • PDAC samples Patients included in this project correspond to the Institut Paoli Calmettes clinical trial number 2011 -AO 1439-32 (PaCaOmics project). Consents of informed patients were collected. The tumor tissue used for xenograft development was deemed excess to that required for the patient's diagnosis and standard of care and treatment. All samples were anonymized and obtained in accordance with institutional review boards. Postsurgical anatomopathology reports were provided for specimens from each patient. Histopathologic evaluation was performed on 5- ⁇ H&E-stained sections of patient tumors and xenograft and examined under a light microscope. These sections were compared to the original human tumor when available.
  • Arrays were processed using the Affymetrix GeneChip Fluidic Station 450 (protocol EukGE-WS2v5_450) and scanned using a GeneChip Scanner 3000 G7 (Affymetrix).
  • the GeneChip Operating Software (Affymetrix GCOS vl.4) was used to obtain chip images with quality control performed using the AffyQCReport software. Background subtraction and normalization of probe set intensities were performed using the method of Robust Multiarray Analysis (RMA) (Irizarry et al, 2003). PCA analysis was performed using Genomics Suite software (from Partek, St Louis, MO). Gene set enrichment analysis (GSEA) was performed on the Broad Institute Platform and statistical significance (false discovery rate, FDR) was set at 0.25. Microarray analysis was performed by the CRCHUL (CHUQ) Gene Expression Platform, Quebec, Canada.
  • RMA Robust Multiarray Analysis
  • the fold-change column indicates the variation of the expression of the corresponding gene product, compared to a reference value.
  • the reference value is calculated as shown in the Material & Methods section, using Gene set enrichment analysis (GSEA) performed on the Broad Institute Platform and statistical significance (false discovery rate, FDR) was set at 0.25.
  • GSEA Gene set enrichment analysis
  • the gene symbol is indicated (if available), along with a reference number for its corresponding product in the corresponding database (REFSEQ, ENSEMBL, GENBANK, and/or LNCipedia).
  • AK022139 // GenBank // Homo sapiens cDNA 5,23E-08 -2,05368 FLJ12077 fis, clone HEMBB1002453. // chr6 // 9
  • NM 000311 // RefSeq // Homo sapiens prion protein PRNP 5,37E-07 2,41853 (PRNP), transcript variant 1 , mRNA. /
  • NM 000366 // RefSeq // Homo sapiens tropomyosin 1 TPM1 1.09E-10 -2,75385 (alpha) (TPM1), transcript variant 5,
  • NM 000367 // RefSeq // Homo sapiens thiopurine S- TPMT 4,01E-06 -2,27401 methyltransferase (TPMT), mRNA. // chr
  • NM 001006657 // RefSeq // Homo sapiens WD repeat WDR35 9,35E-06 2,09791 domain 35 (WDR35), transcript variant
  • NM 001010887 // RefSeq // Homo sapiens alkaline ACER2 l,09E-05 -2,73782 ceramidase 2 (ACER2), mRNA. // chr9 //
  • NM 001012515 // RefSeq // Homo sapiens ferrochela- FECH l,48E-05 1,57238 tase (FECH), nuclear gene encoding mit
  • NM 001033 // RefSeq // Homo sapiens ribonucleotide RRM1 6,48E-07 1,68276 reductase Ml (RRM1), mRNA. // chrl 1
  • NM 001040022 // RefSeq // Homo sapiens signal- SIRPA 4,48E-06 -2,56297 regulatory protein alpha (SIRPA), transcr
  • NM 001056 // RefSeq // Homo sapiens sulfotransfer- SULT1C2 7,47E-07 -8,03899 ase family, cytosolic, 1C, member 2 (S
  • NM 001080416 // RefSeq // Homo sapiens v-myb MYBL1 6J2E-06 4,84232 myeloblastosis viral oncogene homolog (avi).
  • NM 001080527 // RefSeq // Homo sapiens myosin MY07B 4,01E-06 -2,9353 VIIB (MY07B), mRNA. // chr2 // 100 // 76
  • NM 001083 // RefSeq // Homo sapiens phosphoPDE5A 2,09E-07 -3,28726 diesterase 5A, cGMP-specific (PDE5A), transc
  • NM 001098484 // RefSeq // Homo sapiens solute SLC4A4 3.18E-13 -20,7327 carrier family 4, sodium bicarbonate cotr
  • NM 001098511 // RefSeq // Homo sapiens kinesin KIF2A 6,33E-06 1,7595 heavy chain member 2A (KIF2A), transcrip
  • NM 001105248 // RefSeq // Homo sapiens transTMC5 l,26E-07 -7,77774 membrane channel-like 5 (TMC5), transcript
  • NM_001130524 // RefSeq // Homo sapiens adaptor- AP1M1 2,07E-06 1,79694 related protein complex 1, mu 1 subunit
  • NM OOl 130963 // RefSeq // Homo sapiens transTMEM19 9,14E-06 2,00629 membrane protein 1 4 A (TMEM194A), transcrip 4A
  • NM 001144832 // RefSeq // Homo sapiens tetratrico- TTC39A 3.78E-11 -2,58826 peptide repeat domain 39A (TTC39A), tr
  • NM 001144889 // RefSeq // Homo sapiens solute SLC23A3 1.05E-06 -1,6463 carrier family 23 (nucleobase transporter
  • NM_001159352 // RefSeq // Homo sapiens regeneratREG4 2,61E-08 -27,5098 ing islet-derived family, member 4 (REG
  • NM OOl 164664 // RefSeq // Homo sapiens microtuMAST4 U5E-05 1,81579 bule associated serine/threonine kinase f
  • NM_001171203 // RefSeq // Homo sapiens ubiquitin UBAP1 1.01E-07 -1,76989 associated protein 1 (UBAP1), transcri
  • NM 002431 // RefSeq // Homo sapiens menage a Peru MNAT1 5,02E-07 1,53426 homo log 1, cyclin H assembly factor
  • NM 002670 // RefSeq // Homo sapiens plastin 1 PLS1 l,69E-06 -2,96555 (PLS1), transcript variant 2, mRNA. // ch
  • NM 002851 // RefSeq // Homo sapiens protein tyroPTPRZ1 4,83E-07 9,17265 sine phosphatase, receptor-type, Z poly
  • NM 002895 // RefSeq // Homo sapiens retinoblasto- RBLl 7,24E-07 1,86968 ma-like 1 (pl07) (RBLl), transcript var
  • NM 003155 // RefSeq // Homo sapiens stanniocalcin STC1 5,57E-06 7,56609 1 (STC1), mRNA. // chr8 // 100 // 86
  • NM 003171 // RefSeq // Homo sapiens suppressor of SUPV3L1 5,39E-07 1,92745 varl, 3-like 1 (S. cerevisiae) (SUPV3
  • NM 003314 // RefSeq // Homo sapiens tetratricopep- TTC1 4,66E-07 1,54851 tide repeat domain 1 (TTC1), mRNA. //
  • NM 003468 // RefSeq // Homo sapiens frizzled famiFZD5 l,34E-05 -1,91449 ly receptor 5 (FZD5), mRNA. // chr2 //
  • NM 003740 // RefSeq // Homo sapiens potassium KCNK5 8,27E-10 -3,26274 channel, subfamily K, member 5 (KCNK5), m
  • NM 003839 // RefSeq // Homo sapiens tumor necroTNFRSF1 3,34E-11 -4,92878 sis factor receptor superfamily, member 1A
  • NM 003927 // RefSeq // Homo sapiens methyl-CpG MBD2 2,55E-05 1,59749 binding domain protein 2 (MBD2), transcr
  • NM 004055 // RefSeq // Homo sapiens calpain 5 CAPN5 l,52E-06 -3,40528 (CAPN5), mRNA. // chrl 1 // 100 // 74 // 2
  • NM 004079 // RefSeq // Homo sapiens cathepsin S CTSS 2,44E-06 -2,56738 (CTSS), transcript variant 1, mRNA. //
  • NM 004170 // RefSeq // Homo sapiens solute carrier SLC1A1 6,50E-09 -7,74362 family 1 (neuronal/epithelial high a
  • NM 004235 // RefSeq // Homo sapiens Kruppel-like KLF4 7,12E-06 -1,74298 factor 4 (gut) (KLF4), mRNA. // chr9 /
  • NM 004293 // RefSeq // Homo sapiens guanine GDA 2,00E-07 -4,98333 deaminase (GDA), transcript variant 2, mRNA
  • NM 004329 // RefSeq // Homo sapiens bone morpho- BMPR1A 6,24E-06 1,69451 genetic protein receptor, type IA (BMPR1
  • NM 004390 // RefSeq // Homo sapiens cathepsin H CTSH 3,10E-09 -2,87544 (CTSH), mRNA. // chrl5 // 100 // 38 //
  • NM 004420 // RefSeq // Homo sapiens dual specificiDUSP8 l,51E-05 -1,70935 ty phosphatase 8 (DUSP8), mRNA. // ch
  • NM 004472 // RefSeq // Homo sapiens forkhead box FOXD1 9,61E-07 2,86306 Dl (FOXD1), mRNA. // chr5 // 100 // 67
  • NM 004477 // RefSeq // Homo sapiens FSHD region FRG1 3,07E-06 1,62969 gene 1 (FRG1), mRNA. // chr4 // 100 //
  • NM 004497 // RefSeq // Homo sapiens forkhead box FOXA3 2,81E-05 -1,7194 A3 (FOXA3), mRNA. // chrl9 // 100 // 1
  • NM 004636 // RefSeq // Homo sapiens sema domain, SEMA3B 6,84E-06 -2,39322 immunoglobulin domain (Ig), short basi
  • NM_004672 // RefSeq // Homo sapiens mitogen- MAP3K6 U9E-05 1,6318 activated protein kinase kinase kinase 6 (M
  • NM 004938 // RefSeq // Homo sapiens death- DAP 1 8J8E-08 -4,66228 associated protein kinase 1 (DAPK1), mRNA. // Reference (REF- Gene p-value Fold-
  • NM 005261 // RefSeq // Homo sapiens GTP binding GEM 1.58E-05 2,01863 protein overexpressed in skeletal muscl
  • NM_005276 // RefSeq // Homo sapiens glycerol-3- GPD1 4,69E-06 -1,81233 phosphate dehydrogenase 1 (soluble) (GPD
  • NM 005746 // RefSeq // Homo sapiens nicotinamide NAMPT 2,29E-05 2,00349 phosphoribosyltransferase (NAMPT), mRN
  • NM_005967 // RefSeq // Homo sapiens NGFI-A bindNAB2 l,71E-05 1,71749 ing protein 2 (EGR1 binding protein 2)
  • NM 006017 // RefSeq // Homo sapiens prominin 1 PROM1 7,29E-16 -14,3953 (PROM1), transcript variant 1, mRNA. //
  • NM 006282 // RefSeq // Homo sapiens serSTK4 7,94E-06 1,6133 ine/threonine kinase 4 (STK4), mRNA. // chr20 //
  • NM 006442 // RefSeq // Homo sapiens DR1- DRAP1 l,98E-09 1,73334 associated protein 1 (negative cofactor 2 alpha
  • NM 006738 // RefSeq // Homo sapiens A kinase AKAP13 l,57E-05 -1,65705 (PRKA) anchor protein 13 (AKAP13), transcr
  • NM 006871 // RefSeq // Homo sapiens receptor- RIPK3 l,88E-05 -2,47697 interacting serine-threonine kinase 3 (RIP
  • NM 006930 // RefSeq // Homo sapiens S-phase ki- SKP1 3,46E-07 1,79509 nase-associated protein 1 (SKP1), transcr
  • NM 007011 // RefSeq // Homo sapiens abhydrolase ABHD2 l,22E-07 -2,19797 domain containing 2 (ABHD2), transcript
  • NM 007220 // RefSeq // Homo sapiens carbonic an- CA5B 2,03E-06 1,76794 hydrase VB, mitochondrial (CA5B), nuclea
  • NM 007223 // RefSeq // Homo sapiens G protein- GPR176 2,58E-07 2,32054 coupled receptor 176 (GPR176), mRNA. // c
  • NM 012120 // RefSeq // Homo sapiens CD2- CD2AP U8E-07 -1,53535 associated protein (CD2AP), mRNA. // chr6 // 10
  • NM 012177 // RefSeq // Homo sapiens F-box protein FBX05 l,48E-05 1,89663 5 (FBX05), transcript variant 1, mRNA
  • NM 012200 // RefSeq // Homo sapiens beta- 1,3- B3GAT3 U9E-09 1,55988 glucuronyltransferase 3 (glucuronosyltrans
  • NM 012238 // RefSeq // Homo sapiens sirtuin 1 SIRT1 8,30E-07 2,02532 (SIRT1), transcript variant 1, mRNA. // c
  • NM 012289 // RefSeq // Homo sapiens kelch-like KEAPl l,96E-06 1,52174 ECH-associated protein 1 (KEAPl), transc
  • NM 012291 // RefSeq // Homo sapiens extra spindle ESPL1 l,69E-06 1,56875 pole bodies homolog 1 (S. cerevisiae)
  • NM_012454 // RefSeq // Homo sapiens T-cell lymTIAM2 l,09E-07 -2,32022 phoma invasion and metastasis 2 (TIAM2),
  • NM 013230 // RefSeq // Homo sapiens CD24 moleCD24 8,43E-09 -10,0061 cule (CD24), mRNA. // chrY // 68 // 100 //
  • NM 013337 // RefSeq // Homo sapiens translocase of TIMM22 1J2E-05 1,71899 inner mitochondrial membrane 22 homo
  • NM_013389 // RefSeq // Homo sapiens NPC1 (Nie- NPC1L1 3,07E-18 -10,3772 Reference (REF- Gene p-value Fold-
  • NM 013390 // RefSeq // Homo sapiens transmemTMEM2 1,33E-10 -4,63651 brane protein 2 (TMEM2), transcript variant
  • NM 013402 // RefSeq // Homo sapiens fatty acid de- FADS1 l,26E-05 1,66257 saturase 1 (FADS1), mRNA. // chrl l //
  • NM_013437 // RefSeq // Homo sapiens low density LRP12 6,94E-08 3,00003 lipoprotein receptor-related protein 12
  • NM 014035 // RefSeq // Homo sapiens sorting nexin SNX24 5,84E-06 1,79881 24 (SNX24), mRNA. // chr5 // 100 // 3
  • NM 014241 // RefSeq // Homo sapiens protein tyroPTPLA U8E-08 4,17505 sine phosphatase-like (proline instead
  • NM 014373 // RefSeq // Homo sapiens G protein- GPR160 2,35E-06 -2,82018 coupled receptor 160 (GPR160), mRNA. // c
  • NM 014470 // RefSeq // Homo sapiens Rho family RNDl 1J0E-05 -1,70826 GTPase 1 (RND1), mRNA. // chrl2 // 100 /
  • NM 014698 // RefSeq // Homo sapiens transmemTMEM63 1J6E-06 -2,15003 brane protein 63A (TMEM63A), mRNA. // chrl A
  • NM 014824 // RefSeq // Homo sapiens FCH and FCHSD2 2,55E-08 2,06135 double SH3 domains 2 (FCHSD2), mRNA. // chr
  • NM_014829 // RefSeq // Homo sapiens DEAD (Asp- DDX46 1.57E-10 1,62102 Glu-Ala-Asp) box polypeptide 46 (DDX46),
  • NM 014982 // RefSeq // Homo sapiens pecanex ho- PCNX 5,56E-06 1,58249 molog (Drosophila) (PCNX), mRNA. // chrl4
  • NM_015027 // RefSeq // Homo sapiens pyridoxal- PDXDC1 2,38E-07 -1,50753 dependent decarboxylase domain containing
  • NM 015523 // RefSeq // Homo sapiens REX2, RNA REX02 5,69E-06 1,83576 exonuclease 2 homolog (S. cerevisiae) (RE
  • NM 01 960 // RefSeq // Homo sapiens cutC copper CUTC 3,69E-07 1,75155 transporter homolog (E. coli) (CUTC), m
  • NM 016010 // RefSeq // Homo sapiens zinc finger, ZC2HC1A 6,63E-07 1,84085 C2HC-type containing 1A (ZC2HC1A), mRN
  • NM 016240 // RefSeq // Homo sapiens scavenger SCARA3 l,29E-06 2,75506 receptor class A, member 3 (SCARA3), tran
  • NM 016283 // RefSeq // Homo sapiens TAF9 RNA TAF9 2,42E-07 1,69866 polymerase II, TATA box binding protein (T
  • NM 016356 // RefSeq // Homo sapiens doublecortin DCDC2 l,67E-07 -4,51992 domain containing 2 (DCDC2), transcrip
  • NM_016361 // RefSeq // Homo sapiens acid phosphaACP6 l,94E-06 -1,85025 tase 6, lysophosphatidic (ACP6), mRNA.
  • NM 016657 // RefSeq // Homo sapiens KDEL (Lys- KDELR3 l,44E-05 -2,03177 Asp-Glu-Leu) endoplasmic reticulum protei
  • NM 017420 // RefSeq // Homo sapiens SIX ho- SIX4 3,46E-07 2,29441 meobox 4 (SIX4), mRNA. // chrl4 // 100 // 67
  • NM 017640 // RefSeq // Homo sapiens leucine rich LRRC16A 2,35E-07 -3,77497 repeat containing 16A (LRRC16A), trans
  • NM 017688 // RefSeq // Homo sapiens B-box and BSPRY 6J6E-06 -1,95831 SPRY domain containing (BSPRY), mRNA. //
  • NM_017708 // RefSeq // Homo sapiens family with FAM83E 3,92E-09 -2,24897 sequence similarity 83, member E (FAM83
  • NM 017712 // RefSeq // Homo sapiens pyroglutamyl- PGPEP1 8,l lE-06 -2,26798 peptidase I (PGPEP1), mRNA. // chrl9 /
  • NM_017755 // RefSeq // Homo sapiens NOP2/Sun NSUN2 2,61E-05 1,50241 RNA methyltransferase family, member 2 (NS
  • NM 017816 // RefSeq // Homo sapiens Lyl antibody LYAR U5E-08 2,74029 reactive homolog (mouse) (LYAR), trans Reference (REF- Gene p-value Fold-
  • NM_018121 // RefSeq // Homo sapiens family with FAM178A 5,42E-10 1,63729 sequence similarity 178, member A (FAM1
  • NM_018178 // RefSeq // Homo sapiens golgi phos- GOLPH3 5,58E-08 -1,71613 phoprotein 3 -like (GOLPH3L), mRNA. // chr L
  • NM 018226 // RefSeq // Homo sapiens arginyl ami- RNPEPL1 4,58E-10 -1,58752 nopeptidase (aminopeptidase B)-like 1 (R
  • NM 018240 // RefSeq // Homo sapiens kin of IRRE KIRREL 1.79E-06 2,74686 like (Drosophila) (KIRREL), mRNA. // ch
  • NM 018268 // RefSeq // Homo sapiens WD repeat WDR41 2,86E-06 1,54487 domain 41 (WDR41), mRNA. // chr5 // 100 /
  • NM 018290 // RefSeq // Homo sapiens phosphoglu- PGM2 2,48E-05 1,59095 comutase 2 (PGM2), mRNA. // chr4 // 100 /
  • NM 018319 // RefSeq // Homo sapiens tyrosyl-DNA TDP1 4,16E-08 1,61671 phosphodiesterase 1 (TDP1), transcript
  • NM O 18343 // RefSeq // Homo sapiens RIO kinase 2 RIOK2 4,34E-09 1,94851 (yeast) (RIOK2), transcript variant 1,
  • NM_018429 // RefSeq // Homo sapiens B double BDP1 4,88E-10 1,634 prime 1 , subunit of RNA polymerase III tra
  • NM 018456 // RefSeq // Homo sapiens ELL associatEAF2 1.94E-06 -2,25283 ed factor 2 (EAF2), mRNA. // chr3 // 10
  • NM O 18842 // RefSeq // Homo sapiens BAI1- BAIAP2L l,50E-05 -2,70286 associated protein 2-like 1 (BAIAP2L1), mRNA. 1
  • NM_018999 // RefSeq // Homo sapiens family with FAM190B 2,54E-08 2,05467 sequence similarity 190, member B (FAM1
  • NM 019030 // RefSeq // Homo sapiens DEAH (Asp- DHX29 3,32E-07 1,8447 Glu-Ala-His) box polypeptide 29 (DHX29),
  • NM O 19072 // RefSeq // Homo sapiens small gluta- SGTB l,96E-05 2,70842 mine-ricfi tetratricopeptide repeat (TPR)
  • NM 020117 // RefSeq // Homo sapiens leucyl-tRNA LARS 3,63E-06 1,91859 synthetase (LARS), mRNA. // chr5 // 100
  • NM 020340 // RefSeq // Homo sapiens KIAA1244 KIAA124 l,34E-06 -2,24402 (KIAA1244), mRNA. // chr6 // 100 // 100 // 4
  • NM 020343 // RefSeq // Homo sapiens Ral GTPase RALGA- 2,29E-05 -2,4487 activating protein, alpha subunit 2 (cat PA2
  • NM 020453 // RefSeq // Homo sapiens ATPase, class ATP10D 1J3E-07 2,49698 V, type 10D (ATP10D), mRNA. // chr4 /
  • NM 020529 // RefSeq // Homo sapiens nuclear factor NFKBIA 8,81E-06 1,76041 of kappa light polypeptide gene enha
  • NM 020722 // RefSeq // Homo sapiens KIAA1211 KIAA121 l,83E-09 -2,59744 (KIAA1211), mRNA. // chr4 // 100 // 74 // 1
  • NM_020773 // RefSeq // Homo sapiens TBCl domain TBC1D14 7,69E-07 1,61063 family, member 14 (TBC1D14), transcript
  • NM 020801 // RefSeq // Homo sapiens arrestin doARRDC3 4J1E-07 2,20374 main containing 3 (ARRDC3), mRNA. // chr
  • NM 020859 // RefSeq // Homo sapiens shroom family SHROOM 2,94E-08 -3,96414 member 3 (SHROOM3), mRNA. // chr4 // 3
  • NM 020873 // RefSeq // Homo sapiens leucine rich LRRNl U7E-05 -3,09541 repeat neuronal 1 (LRRNl), mRNA. // ch Reference (REF- Gene p-value Fold-
  • NM 020886 // RefSeq // Homo sapiens ubiquitin speUSP28 9,84E-06 1,71757 cific peptidase 28 (USP28), mRNA. // c
  • NM 021200 // RefSeq // Homo sapiens pleckstrin PLEKHB1 9,82E-06 -1,71345 homology domain containing, family B (ev
  • NM_021214 // RefSeq // Homo sapiens family with FAM108C l,02E-05 -2,18379 sequence similarity 108, member CI (FAM 1
  • NM 022145 // RefSeq // Homo sapiens centromere CENPK l,55E-05 1,89702 protein K (CENPK), transcript variant 1 ,
  • NM 022346 // RefSeq // Homo sapiens non-SMC NCAPG l,62E-08 2,18889 condensin I complex, subunit G (NCAPG), mRN
  • NM_022825 // RefSeq // Homo sapiens porcupine PORCN 3,48E-06 1,81584 homo log (Drosophila) (PORCN), transcript
  • NM 022909 // RefSeq // Homo sapiens centromere CENPH 5J4E-08 2,64595 protein H (CENPH), mRNA. // chr5 // 100
  • NM 022970 // RefSeq // Homo sapiens fibroblast FGFR2 l,07E-06 -3,05461 growth factor receptor 2 (FGFR2), transc
  • NM 024092 // RefSeq // Homo sapiens transmemTMEM10 l,08E-07 1,95659 brane protein 109 (TMEM109), mRNA. // chrl 1 9
  • NM 024101 // RefSeq // Homo sapiens melanophilin MLPH l,50E-05 -2,76966 (MLPH), transcript variant 1 , mRNA. //
  • NM 024306 // RefSeq // Homo sapiens fatty acid 2- FA2H l,04E-05 -3,1323 hydroxylase (FA2H), mRNA. // chrl 6 //
  • NM_024576 // RefSeq // Homo sapiens opioid growth OGFRLl 6,24E-06 2,03059 factor receptor-like 1 (OGFRLl), mRNA
  • NM_024577 // RefSeq // Homo sapiens SH3 domain SH3TC2 6,82E-06 1,9706 and tetratricopeptide repeats 2 (SH3TC2)
  • NM 024608 // RefSeq // Homo sapiens nei endonu- NEIL1 l,56E-07 -2,12245 clease VHI-like 1 (E. coli) (NEIL1), tra
  • NM_024628 // RefSeq // Homo sapiens solute carrier SLC12A8 U9E-06 -1,75792 family 12 (potassium/chloride transp
  • NM 024712 // RefSeq // Homo sapiens engulfment ELM03 2,17E-05 -1,62831 and cell motility 3 (ELM03), mRNA. // ch
  • NM 024727 // RefSeq // Homo sapiens leucine rich LRRC31 2,12E-05 -3,81382 repeat containing 31 (LRRC31), mRNA. /
  • NM 024756 // RefSeq // Homo sapiens multimerin 2 MMRN2 5,36E-06 1,59057 (MMRN2), mRNA. // chrlO // 100 // 57 /
  • NM 024795 // RefSeq // Homo sapiens transmemTM4SF20 4J8E-08 -13,9678 brane 4 L six family member 20 (TM4SF20), m
  • NM 024834 // RefSeq // Homo sapiens minichromo- MCMBP 3,57E-06 1,77466 some maintenance complex binding protein
  • NM 024921 // RefSeq // Homo sapiens premature POF1B 6,45E-06 -5,26964 ovarian failure, IB (POF1B), mRNA. // chr
  • NM_024954 // RefSeq // Homo sapiens ubiquitin doUBTD1 l,25E-08 1,67307 main containing 1 (UBTD1), mRNA. // chr
  • NM 02 004 // RefSeq // Homo sapiens coiled-coil CCDC15 U7E-06 2,41792 domain containing 15 (CCDC15), mRNA. //
  • NM 025132 // RefSeq // Homo sapiens WD repeat WDR19 7,52E-06 2,35118 domain 19 (WDR19), mRNA. // chr4 // 100 /
  • NM 02 164 // RefSeq // Homo sapiens SIK family SIK3 2,05E-05 1,5795 kinase 3 (SIK3), mRNA. // chrl 1 // 100 /
  • NM 025245 // RefSeq // Homo sapiens pre-B-cell PBX4 4,16E-06 1,59466 leukemia homeobox 4 (PBX4), transcript v
  • NM 030622 // RefSeq // Homo sapiens cytochrome CYP2S1 U7E-05 -4,58802 P450, family 2, subfamily S, polypeptide
  • NM 030628 // RefSeq // Homo sapiens integrator INTS5 3,61E-08 1,52049 complex subunit 5 (INTS5), mRNA. // chrl
  • NM 030630 // RefSeq // Homo sapiens chromosome C17orf28 4,89E-12 -5,3555 17 open reading frame 28 (C17orf28), mRN
  • NM 030783 // RefSeq // Homo sapiens phosphatidyl- PTDSS2 6,59E-09 1,67521 serine synthase 2 (PTDSS2), mRNA. // ch
  • NM 030926 // RefSeq // Homo sapiens integral memITM2C 2,54E-08 -2,17254 brane protein 2C (ITM2C), transcript va
  • NM 030964 // RefSeq // Homo sapiens sprouty homo- SPRY4 l,92E-05 1,83423 log 4 (Drosophila) (SPRY4), transcript
  • NM 031217 // RefSeq // Homo sapiens kinesin family KIF18A 2,64E-08 2,08959 member 18A (KIF18A), mRNA. // chrl 1
  • NM 031302 // RefSeq // Homo sapiens glycosyltrans- GLT8D2 4,68E-06 3,41962 ferase 8 domain containing 2 (GLT8D2),
  • NM 031415 // RefSeq // Homo sapiens gasdermin C GSDMC 2,15E-05 6,33453 (GSDMC), mRNA. // chr8 // 100 // 86 //
  • NM 031419 // RefSeq // Homo sapiens nuclear factor NFKBIZ UOE-05 -2,14027 of kappa light polypeptide gene enha
  • NM 031439 // RefSeq // Homo sapiens SRY (sex deSOX7 3,13E-08 2,17199 termining region Y)-box 7 (SOX7), mRNA.
  • NM_031463 // RefSeq // Homo sapiens hydroxyste- HSDL1 2,24E-07 1,93101 roid dehydrogenase like 1 (HSDL1), transc
  • NM 031469 // RefSeq // Homo sapiens SH3 domain SH3BGR 2,54E-06 -3,87722 binding glutamic acid-rich protein like L2
  • NM 031966 // RefSeq // Homo sapiens cyclin B 1 CCNB1 U3E-08 2,1201 (CCNB1), mRNA. // chr5 // 100 // 85 // 17
  • NM_032042 // RefSeq // Homo sapiens family with FAM172A 2,47E-08 1,53397 sequence similarity 172, member A (FAM1
  • NM 032175 // RefSeq // Homo sapiens UTP15, U3 UTP15 l,09E-06 1,72995 small nucleolar ribonucleoprotein, homolo
  • NM 032208 // RefSeq // Homo sapiens anthrax toxin ANTXRl 4,13E-07 3,60105 receptor 1 (ANTXR1), transcript varia
  • NM 032898 // RefSeq // Homo sapiens centrosomal CEP 19 7,28E-07 1,54008 protein 19kDa (CEP 19), mRNA. // chr3 //
  • NM 033102 // RefSeq // Homo sapiens solute carrier SLC45A3 7J2E-07 -2,37482 family 45, member 3 (SLC4 A3), mRNA.
  • NM 033386 // RefSeq // Homo sapiens MICAL-like 1 MICALL1 7,37E-07 1,64994 (MICALL1), mRNA. // chr22 // 100 // 85
  • NM 033498 // RefSeq // Homo sapiens hexokinase 1 HK1 U6E-05 1,87167 (HK1), nuclear gene encoding mitochond
  • NM 052950 // RefSeq // Homo sapiens WD repeat WDFY2 3,51E-08 2,25194 and FYVE domain containing 2 (WDFY2), mRN
  • NM_052966 // RefSeq // Homo sapiens family with FAM129A 2,64E-05 2,4835 sequence similarity 129, member A (FAM1
  • NM_058237 // RefSeq // Homo sapiens protein phosPPP4R4 6,13E-06 2,69477 phatase 4, regulatory subunit 4 (PPP4R4
  • NM_080656 // RefSeq // Homo sapiens CDKN2A CDKN2AI l,92E-07 1,79298 interacting protein N-terminal like (CDKN2AI PNL
  • NM_133372 // RefSeq // Homo sapiens folliculin inteFNIP1 3,56E-08 1,7533 racting protein 1 (FNIP1), transcrip
  • NM 133447 // RefSeq // Homo sapiens ankyrin repeat AGAP11 2,43E-08 2,62118 and GTPase domain Arf GTPase activat
  • NM 138370 // RefSeq // Homo sapiens protein kinase PKDCC l,61E-09 -3,33428 domain containing, cytoplasmic homol
  • NM 138409 // RefSeq // Homo sapiens melanocortin MRAP2 2,31E-05 -3,30067 2 receptor accessory protein 2 (MRAP2)
  • NM 138424 // RefSeq // Homo sapiens kinesin family KIF12 l,53E-06 -1,95439 member 12 (KIF12), mRNA. // chr9 //
  • NM_138694 // RefSeq // Homo sapiens polycystic PKHD1 l,42E-05 -3,1775 kidney and hepatic disease 1 (autosomal
  • NM 139053 // RefSeq // Homo sapiens EPS8-like 3 EPS8L3 2,06E-07 -5,96732 (EPS8L3), transcript variant 1, mRNA. /
  • NM 139241 // RefSeq // Homo sapiens FYVE, FGD4 l,50E-05 -3,20747 RhoGEF and PH domain containing 4 (FGD4), mRN
  • NM 144626 // RefSeq // Homo sapiens transmemTMEM12 l,91E-09 -1,77259 brane protein 125 (TMEM125), mRNA. // chrl 5
  • NM 144633 // RefSeq // Homo sapiens potassium KCNH8 l,14E-05 -4,08341 voltage-gated channel, subfamily H (eag-r
  • NM_ 144691 // RefSeq // Homo sapiens calpain 12 CAPN12 9,60E-08 -1,76735 Reference (REF- Gene p-value Fold-
  • NM 145051 // RefSeq // Homo sapiens ring finger RNF183 5,47E-08 -2,08144 protein 183 (RNF183), mRNA. // chr9 //

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

An in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of: a1) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group of PDAC marker genes consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; a2) measuring, in a biological sample from said individual, the expression level of one or more gene selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D; b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps a1) and a2).

Description

METHODS, KITS AND COMPOSITIONS FOR PHENOTYPING PANCREATIC DUCTAL ADENOCARCINOMA BEHAVIOUR BY
TRANSCRIPTOMIC S
FIELD OF THE INVENTION
The invention relates to the field of transcriptomics, for effective treatment and follow-up of individuals having Pancreatic Ductal Adenocarcinoma (PDAC). It also relates to kits, compositions and solid supports, suitable for use in methods for determining the prognosis of an individual having PDAC, or the efficiency of a compound for treating PDAC in said individual.
BACKGROUND OF THE INVENTION
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem. PDAC causes about 10,000 deaths per year in France and 230,000 in the worldwide (Jemal et al; Cancer statistics, 2003. CA: a cancer journal for clinicians 2003, 53:5-26). The ratio of incidence/death is almost 1 indicating that virtually all patients presenting a PDAC will be killed by their disease. This is due to their short survival median that is about 6 months, the shortest of all tumors, because the treatments are relatively inefficient. Despite considerable research efforts in the past decades, conventional treatment approaches, including surgery, radiation, chemotherapy, or combinations of these, had very limited impact. The prognosis is dismal with only 20% of patients alive one year after diagnosis (Jemal et al, 2003). Given this scenario, the search for new treatments that will counter PDAC progression and thereby increase patient life expectancy and quality of life has been given high priority.
Recently phase III clinical trials in unselected PDAC populations have been reported with Bevacizumab (Van Cutsem et al; Journal of clinican oncology: official journal of the American Society of Cinical Oncology; 2009; 27:2231-7), Erlotinib (Moore et al.; Journal of clinican oncology: official journal of the American Society of Cinical Oncology; 2007; 25: 1960-6) and Axitinib (Kindler et al; The Lancet Oncology; 2011; 12:256-62), that are molecularly targeted agents, combined with gemcitabine. All these trials do not show robust survival benefits, probably because they were assayed on unselected PDAC populations that were highly heterogeneous.
This may be explained by the fact that each PDAC has a combination of several modifications in intracellular pathways that will results in a variable susceptibility to drugs, metastasis development and therefore survival.
Thus, a major impediment to the effective treatment of patients with PDAC (Pancreatic Ductal Adenocarcinoma) is the molecular heterogeneity of the disease, which is reflected in an equally diverse pattern of clinical responses to therapy.
The proposed treatments do not take into account this heterogeneity. Yet, the drugs received by patients suffering from PDAC are chosen according to their general performance status and the stage of their disease. No study of the tumor can predict its responsiveness to the treatment, nor give a prognosis to the disease progression. For example, the object ivc response rate was 31.6% for multidrug FOLFIRINOX-treated patients, and only 9.4% for patients treated with gemcitabine, thus showing that about 70% to 90% of patients were not responders respectively (Conroy et al.; The New England Journal of Medicine; 2011; 364: 1817-25).
Another explanation for the low-efficiency, or high-resistance, to systemic therapies is that PDAC tumors are hypovascularised and very rich in stroma, representing from 15 to 90% of the tumor mass, which may form a barrier for drug delivery to the transformed cells.
Particularly, future therapeutic agents are expected to be "patients-targeted" in order to specifically affect PDAC cells by targeting their weaknesses, while leaving normal tissues preferably undamaged.
Notably, the availability of improved prognosis or monitoring methods would allow a better selection of patients for appropriate therapeutic treatments, including before and after surgery. Such methods would also allow a better selection of patients which may benefit from surgery, in particular by determining the level of differentiation of the Pancreatic Adenocarcinoma.
Gene profiling of whole PDAC tumors has been largely reported in the prior Art (see Abdollahi et al, 2007; Abiatari et al, 2009; Buchholz et al, 2005a; Buchholz et al, 2005b; Cavard et al, 2009; Crnogorac-Jurcevic et al, 2002; Gress et al, 1997; Ishikawa et al, 2005; Marcotte et al, 2012; Verma et al, 2012; Wang et al, 2013). However, the low reproducibility of those studies had discouraged the authors to go on exploring this direction.
The reasons for the failure of those approaches may be due to inappropriate tools, tools of insufficient quality, poor quality of the samples, or they may also be inherent to the pathology itself since PDAC tumors can contain from 15 to 90% of stroma tissue associated with variable areas of inflammation and necrosis.
Another approach has been recently reported, laser-capture of transformed epithelial cells is used, followed by their pangenomic expression analysis (Collisson et al; Nature Medicine; 2011; 17:500-3).
This study showed a significant correlation between the expression profile and the patient outcome, including responsiveness to some treatments. However, according to this prior art technique, analysis was performed only on surgically resected tumors, which correspond to a minority of patients with a relative better prognosis because they were detected earlier. Another deficiency of this prior art technique is that tissue samples were obtained from formalin- fixed paraffin-embedded (FFPE) tissue specimens collected from 1993 to 2006, wherein the RNA contained therein was likely to be altered and thus of highly variable quality.
Thus, and to the inventors knowledge, there are still no available prognostic biomarkers, or combinations of biomarkers for patients with PDAC; nor biomarkers of predictive response, or efficiency, to possible treatments.
Thus, there remains a need for in vitro or ex vivo methods for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating said individual.
In particular, there remains a need for in vitro or ex vivo methods for determining the short-term and long-term survival of said individual; or alternatively for determining the level of differentiation of Pancreatic Adenocarcinoma in said individual.
In particular, there also remains a need for in vitro or ex vivo methods for determining the efficiency of therapeutic treatments of PDAC, which includes therapeutic treatments with active principles such as gemcitabine, oxaliplatin, 5-fluorouracil (5FU), docetaxel, Irinotecan, and/or derivatives thereof, for treating said individual. There also remains a need for in vitro or ex vivo methods for screening compounds which are efficient for treating PDAD in an individual, or alternatively for improving the prognosis, the condition or clinical outcome, of an individual having PDAC.
There also remains a need for compositions and/or kits and/or solid supports, which are suitable for use for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating said individual.
SUMMARY OF THE INVENTION
The present invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDM;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1 ; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
The invention further relates to kits and compositions and solid supports, suitable for use in methods for determining the prognosis of an individual having PDAC, or the efficiency of a compound for treating PDAC in said individual.
Thus, the invention also relates to a composition comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR;
MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI;
MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ; ITGAIO; MTIA; VIM; CCNEl; THBS3; TRAF5; LTA4H; SAMHDl; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
The invention also relates to a kit comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ;
ITGAIO; MTIA; VIM; CCNEl; THBS3; TRAF5; LTA4H; SAMHDl; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
The invention also relates to a solid support comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR;
MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ; ITGAIO; MTIA; VIM; CCNEl; THBS3; TRAF5; LTA4H; SAMHDl; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D. BRIEF DESCRIPTION OF THE FIGURES
Figure 1; RNA expression analysis of PDAC. (A) Principal Component Analysis obtained from the Affymetrix data. Each patient is represented in double since data was obtained from two independents experiments. Grey plots are representing long- term survival patients whereas black plots are representing patients with short-term survival. (B) Histogram representing the survival time of patients included in this study. (C) The Heatmap showing the RNA expression profile of patients with long-term and short-term survival. Figure 2: Primary cell cultures of PDAC samples. Histogram representing the duplication folds in 24 hours of each cell line.
Figure 3: Chemogram. PDAC-derived cells were treated with increasing concentrations of Gemcitabine, Docetaxel, 5-Fluouracil (5FU), Oxaliplatin and the active metabolite of Irinotecan known as SN-38 and the survival cells were measured after 72 h of treatment. A sensitivity profile was obtained for each drug. The point indicated with a red discontinue line was used to establish the score used in Figure 4.
Figure 4: RNA expression and drug sensitivity. Heatmaps and Dendograms showing the RNA expression profiles of PDAC-derived cells with resistance or sensitivity to the treatments with (A) Gemcitabine, (B) Oxaliplatin, (C) 5-Fluouracil (5FU), (D) Docetaxel, and (E) SN-38.
DETAILED DESCRIPTION OF THE INVENTION
The invention has for purpose to meet the aforementioned needs.
The inventors have explored the possibility that the variable sensitivity of patients with PDAC to therapeutic treatment that is known in the art is mainly due to the intrinsic molecular characteristics of the cancer cells.
In order to test this hypothesis, the inventors have conceived an assay allowing the availability of human PDAC tumor tissue which is devoid of surrounding stromal cells. More precisely, the inventors have used xenografted PDAC tissue in order to characterize the whole expression profile of the tumor tissue, so that tumors would maintain their morphological characteristics but lose the stroma cells, the inflammatory cells and cells undergoing necrosis.
Thus, the inventors have developed an efficient strategy in which PDAC samples from patients were obtained by Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA) biopsies or surgery, their cells maintained as a primary culture and tumors as breathing tumors by xenografting in immunosuppressed mice. For these patients a clinical follow up was obtained. On the breathing tumors the RNA expression profile was analysed by using DNA microarray chips.
Using Principal Component Analysis (PCA), the inventors have then determined, for a plurality of tumor samples or primary cell cultures thereof, the RNA expression profile of a collection of PDAC-marker genes.
Principal Component Analysis (PCA) is a statistical method that transforms data to a new coordinate system such that the greatest variance by any projection of the data comes to lie on the first coordinate (called the first principal component), the second greatest variance on the second coordinate, and so on. PCA can be used for dimensionality reduction in a data set by retaining those characteristics of the data set that contribute most to its variance, by keeping lower- order principal components and ignoring higher-order ones.
Thus, Principal components analysis (PCA) is a statistical technique for determining the key variables in a multidimensional data set that explain the differences in the observations, and which can then be used to simplify the analysis and visualization of multidimensional data sets. PCA is known in the Art and is further detailed in Raychaudhuri et al. (« Principal Components analysis to summarize microarray experiments: application to sporulation time series; Pac Symp Biocomput. 2000: 455-466).
In particular, the inventors have shown that the transcriptome analysis of tumor tissue samples obtained from patients is indicative of the long- or short-time survival of those patients, which also corresponds to the level of differentiation of the PDAC tumor (moderately- or poorly-differentiated respectively).
Without wishing to be bound by any particular theory, the inventors believe that the predictability of this expression analysis is explained by the fact that it was performed with human tumor tissue samples comprising almost exclusively cancerous cells, in contrast to the prior art studies.
Another originality of to the present inventors assay resides in the use of an in vitro test with cells from tumors as primary culture for defining the precise sensitivity to the anticancer drugs. This approach has proven to be useful herein, in order to determine the sensitivity of a patient's tumor tissue to a panel of candidate therapeutic molecules because the assay described herein allows performing a large dose-response analysis (from 0.001 to 1000 μΜ) towards a plurality of drugs.
Using cultured patient's tumor cells allowed the present inventors to analyze the relative sensitivity of these tumor cells to several anticancer drugs in vitro by developing a chemiogram assay, with a plurality of known anticancer drugs, for the purpose of obtaining an individual profile of drug sensitivity. As shown in the examples herein, the response to each drug tested was patient-dependent. Surprisingly, using this assay, the inventors have shown that the transcriptome analysis of patient's tumor tissue or of patient's tumor cells allows predicting the sensitivity of patients having PDAC to known drugs, including anticancer drugs, as well as to candidate drug compounds. The inventors have also shown that the assay described herein allows predicting the clinical outcome of those patients.
Surprisingly, the inventors have also found that the specific transcriptome analysis performed according to the invention allows predicting the sensitivity of cells to the five anticancer drugs that are the most frequently used for treating patients with PDAC.
It is disclosed herein a collection of sets of genes, the expression level of which, or alternatively the expression levels of specific combinations thereof, is indicative of the clinical outcome, or condition, of patients affected with PDAC, which clinical outcome encompasses a prognosis of progression of PDAC in PDAC-affected patients.
It is also disclosed herein a collection of sets of genes, the expression level of which, or alternatively the expression levels of specific combinations thereof, is indicative of the sensitivity of the PDAC tumor originating from a PDAC-affected individual to a treatment with one or more selected compounds, which encompasses treatment with one or more known drug compounds, including one or more known anti-cancer drugs. A gene comprised in a set of genes as disclosed herein may also be termed a "PDAC marker gene" for the purpose of the present specification.
As it is shown in the present specification, the assay that has been conceived by the inventors has allowed determining a large number of PDAC-marker genes that are all usable (i) for the purpose of predicting the clinical outcome of patients affected with PDAC and (ii) for predicting the sensitivity of a particular PDAC-affected patient to one or more drugs.
As it is also disclosed herein, subsets of PDAC-marker genes may be determined from the whole collection of gene sets described in the present specification. Although any combination of the PDAC-marker genes disclosed herein may be used for the purpose of performing the methods according to the invention, it is readily understood that, for practical reasons, the use of only sub-sets of the disclosed PDAC-marker genes allows performing the methods according to the invention more rapidly, and also less costly, than when an entire gene set is assayed.
Based on the variation of the expression of the sets of PDAC-marker genes described herein, the inventors have notably categorized the said PDAC-marker genes into two distinct groups, according to the sense of variation of their expression level compared to a reference value, namely (i) PDAC-marker genes whose relative expression level is increased in PDAC-affected patients and (ii) PDAC-marker genes whose relative expression level is decreased in PDAC-affected patients.
Then, according to the present invention, the finding of a decreased expression level of one or more PDAC-marker genes comprised in the said first group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual is indicative of a good clinical outcome of the said PDAC-affected individual.
Alternatively, the finding of a decreased expression level of one or more
PDAC-marker genes comprised in the said first group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual treated with one given compound may be indicative of a therapeutic activity of the said given compound for the said PDAC- affected individual.
Then, according to the present invention, the finding of an increased expression level of one or more PDAC-marker genes comprised in the said second group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual is indicative of a good clinical outcome of the said PDAC-affected individual.
Alternatively, the finding of an increased expression level of one or more PDAC-marker genes comprised in the said second group or subset of PDAC-marker genes in a sample originating from a PDAC-affected individual treated with one given compound is indicative of a therapeutic activity of the said given compound for the said PDAC- affected individual.
In certain embodiments, the combination of (i) the finding of a decreased expression of one or more PDAC-marker genes comprised in the said first group or subset of PDAC-marker genes and (ii) the finding of an increased expression of one or more PDAC-marker genes comprised in the said second group of PDAC-marker genes, in a sample originating from a PDAC-affected individual is indicative of a good clinical outcome of the said PDAC-affected individual.
Alternatively, the combination of (i) the finding of a decreased expression of one or more PDAC-marker genes comprised in the said first group or subset of PDAC- marker genes and (ii) the finding of an increased expression of one or more PDAC-marker genes comprised in the said second group or subset of PDAC-marker genes, in a sample originating from a PDAC-affected individual treated with one given compound is indicative of a therapeutic activity of the said given compound for the said PDAC-affected individual.
The inventors have determined that an increased predicting value, either relating to the individual clinical outcome or relating to the individual's tumor sensitivity to drugs, may be obtained by measuring the expression level of at least one PDAC-marker gene belonging to each of the first and second group described above, or subsets.
In particular the inventors have determined that the prognosis of clinical outcome of an individual having PDAC or the efficiency of one compound for treating PDAC in the said individual is good when:
- (i) the expression level value of one or more PDAC-marker genes selected from the first group of PDAC-marker genes described herein is below a first reference value, and (ii) the expression level value of one or more PDAC-marker genes selected from the second group of PDAC-marker genes described herein is above a second reference value; or alternatively when - the expression level ratio [expression level value of one or more PDAC-marker genes selected from the said first group / expression level value of one or more PDAC-marker genes selected from the said second group] is below a reference expression level ratio. As used herein, the term "PDAC-marker gene" means a gene for which the expression level is a parameter contributing to indicate (i) the prognosis, condition or clinical outcome, of an individual affected with PDAC or (ii) the sensitivity of the tumor tissue of a PDAC-affected individual to a compound used, or alternatively assayed, for the purpose of a PDAC therapeutic treatment.
As used herein, the expression level of a PDAC-marker gene according to the invention encompasses (i) the R A level which is found in a sample as a consequence of the corresponding gene transcription and (ii) the protein level which is found in a sample as the consequence of the translation of the corresponding RNA. Thus, the inventors have also shown herein that a particular variation of the first group relatively to the second group represents a novel "signature" in PDAC tumors.
It is disclosed herein a collection of sets of genes which have been identified as PDAC-marker genes, in tables 3 to 8.
For each group, the PDAC-marker genes which have a negative fold-change represent a down-regulated gene. Accordingly, the PDAC-marker genes which have a positive fold-change represent an up-regulated gene.
In view of the above, each one of the collections of genes which are recited in tables 3 to 8 is considered, which includes table 3, 4, 5, 6, 7, 8, and preferred subsets of genes, which includes tables 9, 10, 11, 12, 13 and 14.
According to a most general embodiment, one up-regulated PDAC marker gene in one group may also be considered as an up-regulated in another group. Thus, one down-regulated PDAC marker gene in one group may also be considered as down- regulated in another group. However it does not necessarily flow from the above that one compound identified as efficient for treating PDAC in one individual would necessarily improve the prognosis, or clinical outcome of the said individual. Although such correlation is likely to occur for a vast majority of compounds, it is also known in the Art that the improvement of clinical outcome in an individual having PDAC is also dependent on other factors.
It also does not necessarily flow from the above, that a compound that has been identified as efficient for treating PDAC in one individual is necessarily efficient, or efficient to the same extent, for treating another individual.
It also does not necessarily flow from the above that one PDAC-marker gene which has been identified as being particularly indicative of the efficiency of one compound for treating PDAC in an individual, is also indicative to the same extent of the efficient of another compound for treating PDAC in the same individual.
In view of the above, the PDAC-marker genes that have been identified herein have been grouped based on their preferred use in tables 3 to 8, which includes tables 9 to 14.
Thus, each collection of PDAC-marker genes is grouped based on its preferred use as a PDAC-marker gene, which may include:
(i) determining the prognosis of an individual having PDAC;
(ii) determining the efficiency of a compound for treating PDAC in said individual; wherein said compound is preferably chosen from Irinotecan; oxaliplatin: gemcitabine; docetaxel or 5-fluorouracil. According to this most general embodiment, the invention thus relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from tables 3 to 8, which includes tables 9 to 14; a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- markers chosen from tables 3 to 8, which includes tables 9 to 14;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
Steps al) and a2) may be performed at the same time period or at distinct time periods.
In the embodiments wherein steps al) and a2) are performed at distinct time periods, these steps may be performed in a chronological sequence comprising performing step al) before step a2). Alternatively, these steps may be performed in a chronological sequence comprising performing step a2) before step al).
In the sense of the invention, the expression "comprising the steps of may encompass "consisting of the steps of
The expression level of a PDAC-marker gene is preferably a relative value that is obtained after comparison of the absolute expression level value with a reference expression value. In the sense of the invention, a "reference value" or "reference expression value" refers to any value measured in one or more comparable control cells, tissue samples and/or individuals, including groups of individuals, which may or may not be disease free, and which in particular may be PDAC disease free. The said reference value may be from the same individual or from another individual who is normal or does not present with the same disease from which the disease or test sample is obtained.
Thus, a "reference value" can be an absolute or relative value, a range of values, an average value, a median value, a mean value, a ratio, or a value as compared to a particular control or baseline value. A reference value can be based on an individual sample value, such as, a value obtained from a sample from an individual with PDAC, but at an earlier point in time or prior to treatment, or a value obtained from a sample from a patient diagnosed with PDAC other than the individual being tested, or a "normal" individual, that is an individual not diagnosed with PDAC. The reference value can be based on a large number of samples, such as from patients diagnosed with PDAC, or normal individuals, or based on a pool of samples including or excluding the sample to be tested
When the method is for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), the reference value can be determined from one or more control cells, tissue samples and/or individuals, that is/are not diagnosed with PDAC
When the method is for determining the efficiency of a compound for treating an individual having Pancreatic Adenocarcinoma (PDAC), the reference value can be determined from one or more control cells, tissue samples and/or individuals that is/are not diagnosed with PDAC, or alternatively measured from the same individual prior to administration of the said compound.
The man skilled in the Art can readily determine, based on his/her general knowledge, a suitable reference value, including absolute and relative reference values, for each sample and/or group of samples.
In particular, a variation of the expression level of one given PDAC-marker gene, or collection of PDAC-marker genes from a reference value, including an absolute or a relative value, can be determined using multivariate statistical analysis.
More particularly, multivariate statistical analysis is selected from the group consisting of principal component analysis, discriminant analysis, principal component analysis with discriminant analysis, partial least squares, partial least squares with discriminant analysis, canonical correlation, kernel principal component analysis, nonlinear principal component analysis, factor analysis, multidimensional scaling, and cluster analysis.
According to an exemplary embodiment, the multivariate statistical analysis is Principal Component Analysis (PCA).
Principal Component Analysis can be performed using the Partek Genomics
Suite®.
As in cluster analysis, a PCA is based on a similarity (or distance) matrix between objects. In gene expression, it is common to use a correlation matrix.
In that case, the first principal component is the direction along which there is the greatest variation in the data. If one has J genes, the first principal component is described by a vector of "loadings" of length J, consisting of weights to be applied to each gene's expression; a loading close to 0 implies that a gene does not vary much across arrays. Large negative and large positive loadings imply that a gene shows considerable variation across arrays in the dataset. The second principal component is created so that it is orthogonal to the first principal component. It can be interpreted as the weighted average across the genes that explains the largest amount of variation in the data after controlling for the variation explained by the first principal component. The principles of determination of a reference value and multiavariate stastical analysis of Gene Expression are known in the Art, and further detailed in Parmigiani et al. (The Analysis of Gene Expression Data: Methods and Software; Springer).
In particular the prognosis of said individual as determined in step b) is good if said individual has a higher life expectancy than said reference, which includes determining whether said individual has a short-term or long-term life expectancy compared to a reference value.
The efficiency of said compound as determined in step b) is good if the condition of said individual is expected to improve after administration of said compound, or alternatively if the life expectancy of said individual is expected to improve after administration of said compound.
As intended herein, the expression "prognosis " or "prognosis of progression of
PDAC" encompasses the prognosis, in a patient wherein the occurrence of PDAC has already been diagnosed, of various events, including:
(i) the chances of occurrence of metastasis;
(ii) the chances of occurrence of loco-regional recurrence of cancer, including PDAC; and
(iii) the chances of occurrence of "short-term!'' or "long-term" survival following testing with the in vitro or ex vivo prognosis method according to the invention.
According to one particular embodiment, the invention relates to an in vitro or ex vivo method as defined above, for determining the short-term and long-term survival of said individual; or alternatively for determining the level of differentiation of Pancreatic Adenocarcinoma in said individual. In the sense of the invention, "short-term" and "long-term" survival relate to the life expectancy of one given individual having Pancreatic Adenocarcinoma (PDAC). In particular, a "short-term survival" may refer to a life expectancy of one given individual having PDAC which does not exceed 8 months. A "long-term survival" may refer to a life expectancy of one given individual having PDAC which exceeds 8 months.
Thus, determining the prognosis of an individual having PDAC also encompasses determining whether said individual has a good prognosis, or clinical outcome, compared to a reference individual having PDAC, of which life expectancy is determinable.
In view of the above, a method for determining the prognosis of an individual having PDAC encompasses methods for determining whether said individual has a short- term or a long-term survival rate.
Advantageously, when the method is used for determining the efficiency of a compound for treating Pancreatic Adenocarcinoma (PDAC) in said individual, it can be used for screening purposes.
Accordingly, the invention also relates to in vitro or ex vivo methods for screening compounds, including novel compounds, which are efficient for treating PDAD in an individual, or alternatively for improving the prognosis, the condition or clinical outcome, of an individual having PDAC.
In the sense of the invention, "determining the efficiency of a compound for treating PDAC in said individual" encompasses determining if the compound is suitable for killing cells, in particular primary cells or xenografts, derived from said PDAC.
Quantification of this efficiency may be further tested in vitro by performing a chemiogram on primary cultured derived from the PDAC, as shown in Example 2.
The efficiency of a compound for treating PDAC in said individual may also be indicative of the efficiency of a compound for improving the condition of said individual.
Thus, the efficiency of a compound for treating PDAC in said individual may also be indicative of the efficiency of a compound for improving the prognosis of said individual. It is also disclosed herein a subset of genes which have been identified as particularly efficient PDAC-marker genes, and which are listed in tables 9 to 14.
In particular, it is disclosed herein a first group, or subset, of 28 PDAC-marker gene consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFSl; DDX26B; WDR78; AGMO; and EDNl . The first group of PDAC-marker genes includes the PDAC-marker genes which are preferably down-regulated when the prognosis of one individual having PDAC is good, or alternatively when a given compound is deemed as efficient for treating PDAC in the said individual.
It is also disclosed herein a second group, or subset, of 19 PDAC-marker genes consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D. The second group of PDAC-marker genes includes the PDAC- marker genes which are preferably up-regulated when the prognosis of one individual having PDAC is good, or alternatively when a given compound is deemed as efficient for treating PDAC in the said individual. According to a particular embodiment, the invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic
Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: CACNA1D;
CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3;
YAEIDI; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B;
PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFSl; DDX26B; WDR78;
AGMO; and EDNl;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1 ; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
According to some embodiments, the method further includes a step of providing a biological sample from said individual having PDAC.
According to said embodiment, the invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
aO) providing a biological sample from said individual having PDAC; al) measuring, in said biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFT ; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; CNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1;
a2) measuring, in said biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl; ITGAIO; MTIA; VIM; CCNEl; THBS3; TRAF5; LTA4H; SAMHDl; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
As intended herein, a "tumor sample or "tumor tissue sample" encompasses (i) a global primary tumor (as a whole), (ii) a tissue sample from the center of the tumor, (iii) a tissue sample from the tissue directly surrounding the tumor which tissue may be more specifically named the "invasive margin" of the tumor, (iv) lymphoid islets in close proximity with the tumor, (v) the lymph nodes located at the closest proximity of the tumor, (vi) a tumor tissue sample collected prior surgery (for follow-up of patients after treatment for example), (vii) a tumor tissue sample collected after surgery, (viii) a tumor tissue sample derived from the head of the pancreas, (viii) a tumor tissue sample derived from the tail of the pancreas, and (ix) a distant metastasis.
According to a preferred embodiment, the biological sample from said individual is a tumour sample derived from a Pancreatic Adenocarcinoma (PDAC), including a tumor sample derived from the head or the tail of the pancreas.
A tumor tissue sample, irrespective of whether it is derived from the tail or the head of the pancreas, the center of the tumor, from the invasive margin of the tumor, or from the closest lymph nodes, encompasses pieces or slices of tissue, or even cell samples, that have been removed from the tumor, including following a surgical tumor resection or following the collection of a tissue sample for biopsy, for further quantification of one or several biological markers, notably through histology or immunohistochemistry methods, through flow cytometry methods and through methods of gene or protein expression analysis, including genomic and proteomic analysis.
The tumour sample derived from PDAC can be a sample collected by endoscopic aspiration, including Endoscopic Ultrasound-Guided Fine-Needle Aspiration, or by surgery.
More particularly, the tumour sample is a biological sample selected from the group consisting of a xenograft or a primary culture, including a primary culture of epithelial cells.
In the sense of the invention, "measuring the expression of at least one gene" encompasses measuring the expression of at least one nucleic acid encoded by said at least one gene, which includes RNA molecules encoded by said at least one gene. In a non- limitative manner, the product of one gene may comprise RNA molecules including mRNA, tRNA, rRNA, small-interfering RNAs (siRNA), non-coding RNAs and microRNAs, which can be modified or not.
The expression of at least one gene may also encompass, in a more indirect manner, measuring the expression of at least one protein encoded by said at least one gene.
Methods for measuring the expression of at least one gene in a biological sample are known in the Art. In a non- limitative manner, the expression of a protein may be achieved using Western blot, Slot blot, Dot blot, ELISA (Enzyme Linked Immuno-Sorbent Assay), immunofluorescence, electronic or confocal microscopy FRET (fluorescence resonance energy transfer), TR-FRET (time resolved FRET/FRET), FLIM (fluorescence lifetime imaging microscopy), FSPIM (fluorescence spectral imaging microscopy), FRAP (fluorescence recovery after photobleaching, flux cytometry, enzymatic tests.
Preferably, measuring the expression of at least one gene includes measuring the expression of at least one nucleic acid encoded by said at least one gene.
In a non- limitative manner, the expression of a nucleic acid may be achieved using polymerase-chain reaction (PCR), reverse transcriptase polymerase-chain reaction (RT-PCR), Northern Blot, Ribonuclease protection assays, microarrays, in situ hybridation.
In the sense of the invention, a "probe" refers to a nucleic acid that is complementary to another nucleic acid, for which the concentration must be assessed in one given sample. Such probe may be in a labelled or unlabelled form, and encompasses both DNA oligonucleotides and RNA oligonucleotides, and mixtures thereof.
Such probes are generally used in combination with other probes, in a manner suitable for amplification using a variety of polymerase chain reaction methods.
According to one exemplary embodiment, the expression of at least one gene in steps al and a2) can be achieved by using at least one labelled or unlabelled probe, preferably selected from the group consisting of DNA oligonucleotides and RNA oligonucleotides.
Thus, according to said exemplary embodiment, the expression of at least one gene in steps al and a2) can be achieved by using at least one labelled or unlabelled probe that is complementary to the product of at least one gene selected from the first group; and at least one labelled or unlabelled probe that is complementary to the product of at least one gene selected from the second group.
As used herein, amplification probes, or « primers », are defined as being a pair of nucleic acid molecules that can anneal to 5" or 3" regions of a gene and/or a gene product (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are of at least 7 nucleotides in length, which includes from about 7 to 50 nucleotides in length, which includes 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50 nucleotides in length, in particular 10 to 30 nucleotides in length.
Amplification probes generally flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.
In one preferred embodiment, the expression level of a PDAC marker gene is assessed by preparing mRNA/cDNA (i.e. a transcribed polynucleotide) from cells in a patient tumor tissue sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide which is a complement of a marker nucleic acid, or a fragment thereof. cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods.
In a related embodiment, a mixture of nucleic acids obtained from the sample is contacted with a substrate having fixed thereto a probe complementary to or homologous with at least a portion (e.g. at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues) of a biological marker nucleic acid. If polynucleotides complementary to or homologous with are differentially detectable on the substrate (e.g. detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g. a "gene chip" microarray of polynucleotides fixed at selected positions). When a method of assessing marker expression is used which involves hybridization of one nucleic acid with another (i.e. a probe), it is preferred that the hybridization be performed under stringent hybridization conditions.
In one format, the nucleic acid to be detected, including mR As, is immobilized on a solid surface and contacted with a probe, for example by running the isolated nucleic acid on an agarose gel and transferring the nucleic acid from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the nucleic acid is contacted with the probe(s), for example, in an Affymetrix gene chip array. Thus, according to one exemplary embodiment, a method of choice for measuring the expression of a nucleic acid is by using microarrays, such as microarrays of the Affymetrix type. In the sense of the invention, "measuring the expression of at least one gene" includes measuring the expression of at least two, three, four, five, six, seven, eight, nine, ten, or even more than ten genes, which includes 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or even more than 100 genes, which also includes measuring the expression of all the genes belonging to the first group and all the genes belonging to the second group.
Preferred combinations of PDAC marker genes have been further individualized for determining the efficiency of a selection of compounds, and for determining the prognosis of an individual having PDAC, which advantageously can encompass the heterogeneity of PDAC tumors for each individual.
According to a general embodiment:
- the first group may consist of at least one gene selected from: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- the second group may consist of at least one gene selected from: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTBl; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
Of note, each one of those combinations is considered individually.
References for each preferred combination are further detailed in tables 9 to 14, as defined in example 2, and in the sequence listing. Each PDAC-marker gene is grouped based on its preferred use as a biomarker. According to said general embodiment, when the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe is complementary to: - at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 1-8; SEQ ID NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOs 38-43 or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 9-13; SEQ ID NOs 17-19; SEQ ID NOs 27-30; SEQ ID NO 33; SEQ ID NOs 36-37; SEQ ID
NOs 44-47.
Methods for determining the prognosis of an individual having PDAC According to some embodiments, the invention relates to an in vitro or ex vivo method as defined above, for determining the prognosis of an individual having Pancreatic
Adenocarcinoma (PDAC).
In particular, the invention relates to an in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 3, which includes table 9;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- markers chosen from table 3, which includes table 9;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
More particularly, the invention relates to a method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; b) determining the prognosis of said individual from the measurement performed in steps al) and a2).
According to said embodiment, the invention also relates to a method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), comprising the steps of:
aO) providing a biological sample from said individual having PDAC; al) measuring, in said biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1;
a2) measuring, in said biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM;
b) determining the prognosis of said individual from the measurement performed in steps al) and a2).
The first group may consist of at least one PDAC-marker gene selected from: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1.
The second group may consist of at least one PDAC-marker gene selected from: DUSP5; FJX1; ITGA10; MT1A; VIM.
Methods for determining the efficiency of a compound on PDAC
According to some embodiments, the invention relates in particular to an in vitro or ex vivo method as defined above, for determining the efficiency of a compound for treating Pancreatic Adenocarcinoma (PDAC) in an individual.
In particular, the invention relates to an in vitro or ex vivo method for determining the efficiency of a compound for treating PDAC in an individual, comprising at least the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 4 to 8; a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- markers chosen from table 4 to 8;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
According to one particular embodiment, the invention relates to an in vitro or ex vivo method as defined above, for determining the efficiency of a compound for treating PDAC in an individual, wherein the compound is selected from the group consisting of: gemcitabine; oxaliplatin; 5-fluorouracil (5FU); docetaxel; Irinotecan or SN-38; and/or derivatives thereof and/or combinations thereof.
According to one embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of Irinotecan for treating PDAC in an individual, comprising at least the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 4, which includes table 10;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- marker genes chosen from table 4, which includes table 10;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2). According to one embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of oxaliplatin for treating PDAC in an individual, comprising at least the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 5, which includes table 11; a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- marker genes chosen from table 5, which includes table 11;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
According to one embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of gemcitabine for treating PDAC in an individual, comprising at least the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 6, which includes table 12;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- markers chosen from table 6, which includes table 12;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
According to one embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of docetaxel for treating PDAC in an individual, comprising at least the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 7, which includes table 13;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- markers chosen from table 7, which includes table 13;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2). According to one embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of 5-fluorouracil (5FU) for treating PDAC in an individual, comprising at least the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC-marker genes selected from a first group of down-regulated PDAC- markers chosen from table 8, which includes table 14;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group of up-regulated PDAC- markers chosen from table 8, which includes table 14;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and a2).
Gemcitabine (IUPAC name: 4-ammo-l-(2-deoxy-2,2-difIuoro-P-D-erythro- pentofuranosyl)pyrimidin-2(lH)-on) is a nucleoside analogue which has shown effect for the treatment of neoplastic conditions in both in vitro and in in vivo studies. Gemcitabine is activated inside the cell by deoxycytidine kinase to its active form, the triphosphate of Gemcitabine (dFdCTP). Parallel to this Gemcitabine is deactivated by deoxycytidine deaminase to the corresponding uracil derivative (inactive). Gemcitabine is generally sold under its generic name « gemcitabine hydrochloride » and/or its tradename GEMZAR® (Lilly).
Oxaliplatin (IUPAC name : [(lR,2R)-cyclohexane-l,2-diamine](ethanedioato- 0,0')platinum(II)) is a cytostatic, platinum-based, antineoplastic agent which is useful in the therapeutic treatment of various types of susceptible cancers and tumors. Oxaliplatin is generally sold under its generic name « oxaliplatin » and/or its tradenames OXALIPLATIN® or ELOXATIN® (Sanofi Aventis).
5-Fluorouracil (5FU) (IUPAC name : 5-Fluoro-lH,3H-pyrimidine-2,4-dione) is a pyrimidine analog used as an antitumour agent or as an intermediate for various antitumour agents, and is generally sold under its generic name « fluorouracil », and/or its tradenames ADRUCIL®, CARAC®, EFUDEX®, and EFUDIX®.
Docetaxel (IUPAC name: l,7P, 10P-trihydroxy-9-oxo-5P,20-epoxytax-l l-ene-
2a,4,13a-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2- hydroxy-3-phenylpropanoate}) is an anti-mitotic member of the taxane drug class, which also includes the chemotherapeutic medication paclitaxel. Docetaxel is generally sold under its generic name « docetaxel » and/or its tradenames DOCECAD® or TAXOTERE® (Sanofi Aventis).
Irinotecan (IUPAC name : (S)-4,l l-diethyl-3,4,12,14-tetrahydro-4-hydroxy- 3,14-dioxo 1 H-pyrano [3 ' ,4 ' : 6,7] -indolizino [ 1 ,2-b]quino lin-9-yl- [ 1 ,4 'bipiperidine] - 1 '- carboxylate) is an antineoplastic enzyme inhibitor generally sold under its generic name « ininotecan hydrochloride » and/or its tradename CAMPTOSAR® (Pfizer). According to an exemplary embodiment, an active metabolite of Irinotecan that is particularly considered by the invention is SN-38, or 7-Ethyl-lO-hydroxy-camptothecin. SN-38 is generally formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1 Al .
In the sense of the invention, a compound is understood as any compound which may have a potential therapeutic effect for treating Pancreactic Adenocarcinoma in said individual, or alternatively for improving or maintaining the prognosis of said individual.
In the sense of the invention, a "derivative" of said compound may comprise any active metabolite that is susceptible to be obtained in vivo from said compound after its administration, which thus includes any active metabolite of said compound, and/or salt thereof.
Of note, the aforementioned compounds and derivatives thereof may be considered either alone or in combination, without departing from the scope of the invention. In particular, any pharmaceutical composition comprising said compounds, either alone or in combination is considered by the invention.
When the aforementioned compounds are considered in combination, they may be administered either individually or sequentially.
In particular, 5-Fluorouracil (5-FU), Irinotecan and oxaliplatin are three compounds used in combination in the FOLFIRINOX chemotherapy regimen for treatment of advanced pancreatic cancer (Conroy et al.;. "The role of the FOLFIRINOX regimen for advanced pancreatic cancer". Current Oncology Reports; 2013 15 (2): 182-189).
Thus, the following combinations of compounds are particularly considered:
- 5-fluorouracil (5FU); Irinotecan; oxaliplatin;
- 5-fluorouracil (5FU); oxaliplatin; -5-fluorouracil (5FU); Irinotecan;
and derivatives thereof; each one of those combinations being administered alone or in complement to other compounds, including adjuvants, and more particulaty vitamin B derivatives such as folinic acid (leucovorin); and their salts.
Other combinations of compounds are also considered, including:
- gemcitabine; docetaxel; 5-fiuorouracil (5FU); Irinotecan; oxaliplatin;
- gemcitabine; docetaxel; 5-fiuorouracil (5FU); Irinotecan;
- gemcitabine; docetaxel; 5-fluorouracil (5FU); oxaliplatin;
- gemcitabine; docetaxel; 5-fluorouracil (5FU);
- gemcitabine; docetaxel; Irinotecan; oxaliplatin;
- gemcitabine; docetaxel; Irinotecan;
- gemcitabine; docetaxel; oxaliplatin;
- gemcitabine; docetaxel;
- docetaxel; 5-fluorouracil (5FU); Irinotecan; oxaliplatin;
- docetaxel; 5-fluorouracil (5FU); Irinotecan;
- docetaxel; 5-fluorouracil (5FU); oxaliplatin;
- docetaxel; 5-fluorouracil (5FU);
- docetaxel; Irinotecan; oxaliplatin;
- docetaxel; Irinotecan;
and derivatives thereof; each one of those combinations being administered alone or in complement to other compounds, including adjuvants, and more particulaty vitamin B derivatives such as folinic acid (leucovorin); and their salts.
Bevacizumab (Van Cutsem et al.; Journal of clinican oncology: official journal of the American Society of Cinical Oncology; 2009; 27:2231-7), Erlotinib (Moore et al; Journal of clinican oncology: official journal of the American Society of Cinical Oncology; 2007; 25: 1960-6) and Axitinib are also examples of compounds for treating PDAC.
In a non- limitative manner, examples of compounds which are also considered by the invention are disclosed in US 6384019 Bl, WO 2006090029 Al, US 20040138142 Al, US 3971784 A, EP 0222155 Al. According to one particular embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of Irinotecan and derivatives thereof, including SN-38, for treating PDAC in an individualcomprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: HSD17B3; YAE1D1; and MIPOL1;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group consisting of: CCNEl ; THBS3; and TRAF5;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
According to one particular embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of oxalip latin and derivatives thereof, for treating PDAC in an individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group consisting of: LTA4H; SAMHD1; SNORD14E; PRKX;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2). According to one particular embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of gemcitabine and derivatives thereof, for treating PDAC in an individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group consisting of: PKIA; RHOBTB1; AK128855; CMBL;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
According to one particular embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of docetaxel and derivatives thereof, for treating PDAC in an individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: DDX26B and WD 78;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group consisting of: SMAD4;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
According to one particular embodiment, the invention relates to an in vitro or ex vivo method for determining the efficiency of 5-fluorouracil (5FU) and derivatives thereof, for treating PDAC in an individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: AGMO and EDN1;
a2) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a second group consisting of: ARRB2 and HIST2H3D;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
According to some embodiments, the methods described herein further include a step aO) of providing a biological sample from said individual having PDAC. Compositions, kits and solid supports
The invention further relates to compositions and/or kits and solid supports which are suitable for use in any method according to the invention.
In particular, the invention relates to compositions and/or kits and/or solid supports comprising probes and/or combinations of probes, including pairs of probes, which can be used for measuring the expression of at least one gene according to the invention.
Thus, the compositions and kits and solid supports may comprise at least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a first group of down-regulated PDAC-marker genes; and at least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a second group of up-regulated PDAC-marker genes.
Most preferably, the compositions, kits and solid supports consist of such probes and/or combinations of probes.
Indeed, for practical reasons, the use of only sub-sets of the disclosed PDAC- marker genes allows performing the methods according to the invention more rapidly, and also less costly, than when an entire gene set is assayed.
According to one general embodiment, the compositions and kits and solid supports comprise, or consist of:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from said first group of down-regulated PDAC- marker genes chosen from tables 3 to 8, which includes tables 9 to 14; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from said second group of up-regulated PDAC- marker genes chosen from tables 3 to 8, which includes tables 9 to 14.
Thus, the compositions and kits and solid supports may comprise at least one labelled or unlabelled probe that is complementary to the product of at least one gene selected from a first group of down-regulated PDAC-marker genes; and at least one labelled or unlabelled probe that is complementary to the product of at least one gene selected from a second group of up-regulated PDAC-marker genes.
In particular, the compositions and kits and solid supports comprise, or even consist of: - at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from said first group of down-regulated PDAC- marker genes chosen from tables 9 to 14; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from said second group of up-regulated PDAC- marker genes chosen from tables 9 to 14.
In a non- limitative manner, kits may be in the form of combinations of probes, preferably pairs of probes, and combinations of compositions comprising said probes or pairs of probes, including kits for producing microarrays.
The invention further relates to solid supports comprising said probes and combinations of probes, including solid supports which are suitable for use as microarrays.
Probes of the invention can be complementary to, or homologous with, at least a portion of nucleic acid, including 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues, which encompasses at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39,40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 nucleotide residues, which may be consecutive or not, and preferably which are complementary consecutive nucleotide residues.
Probes of the invention can be of various length, which includes probes having a length of at least (meaning equal or superior to) 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 nucleotide residues.
In certain embodiments, a kit or a solid support or a composition according to the invention comprises one or a combination or a set of pairs of probes, each kind of pair of probes hybridising specifically with one nucleic acid encoded by a gene of the invention.
In one embodiment, said kit or composition or solid support comprises a combination or a set of pair of probes comprising at least two kind of pair of probes, each kind of pair of probes hybridising with at least one nucleic acid encoded by a gene selected from the first group and at least one nucleic acid encoded by a gene product selected from the second group. Thus, a kit or composition of solid support may comprise 2 to 50 kinds of pair or probes, each kind of pair of probes hybridizing specifically with one nucleic acid encoded by a gene of the invention, which includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,or 50 kinds of pairs of probes, each kind of pair of probes hybridizing specifically against one nucleic acid encoded by a gene of the invention.
When the sequences of probes or combinations of probes are chosen in order to hybridise specifically with one nucleic acid encoded by a gene of the invention, it is understood that such hybridisation should be as specific as possible to the said gene. Thus, such probes or combinations of probes should preferably hybridise with a characteric part of the said nucleic acid, which generally excludes the poly-adenylation motif.
According to a first particular selection of PDAC-marker genes:
- the first group may consist of one or more PDAC-marker genes selected from: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; and
- the second group may consist of one or more PDAC-marker genes selected from: DUSP5; FJX1; ITGA10; MT1A; and VIM.
According to said first particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one PDAC- marker genes by using at least one probe, the said labelled or unlabelled probe being complementary to:
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 1-8; or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 9-13. According to a second particular selection of PDAC-marker genes:
- the first group may consist of one or more PDAC-marker genes selected from: HSD17B3; YAE1D1; MIPOL1; and
- the second group may consist of one or more PDAC-marker genes selected from: CCNE1; THBS3; and TRAF5.
According to said second particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one PDAC-marker genes by using at least one probe, the said labelled or unlabelled probe being complementary to:
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 14-16; or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 17-19.
According to a third particular selection of PDAC-marker genes:
- the first group may consist of one or more PDAC-marker genes selected from: ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; and
- the second group may consist of one or more PDAC-marker genes selected from: LTA4H; SAMHD 1 ; SNORD 14E; PRKX.
According to said third particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one PDAC- marker gene by using at least one probe, the said labelled or unlabelled probe being complementary to:
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 20-26; or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 27-30.
According to a fourth particular selection of PDAC-marker genes:
- the first group may consist of one or more gene selected from: DDX26B and WDR78; and
- the second group may consist of one or more gene selected from: SMAD4.
According to said fourth particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe being complementary to:
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 31-32; or
- at least one nucleic acid selected from a second group consisting of SEQ ID NO 33.
According to a fifth particular selection of PDAC-marker genes:
- the first group may consist of one or more gene selected from: AGMO and EDN1; and
- the second group may consist of one or more gene selected from: ARRB2 and HIST2H3D. According to said fifth particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe being complementary to:
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 34-35; or - at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 36-37.
According to a sixth particular selection of PDAC-marker genes:
- the first group may consist of one or more PDAC-marker genes selected from: KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; and
- the second group may consist of one or more PDAC-marker genes selected from: PKIA; RHOBTB1; AK128855; CMBL.
According to said sixth particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe being complementary to: - at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 38-43; or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 44-47.
The above mentioned selections may be further categorized in two parts whether they belong to (i) preferred PDAC marker genes for determining the prognosis of an individual having PDAC; and (ii) preferred PDAC marker genes for determining the efficiency of a compound for treating PDAC in said individual.
According to a seventh particular selection of PDAC-marker genes:
- the first group may consist of one or more PDAC-marker genes selected from: HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; CNK1; HIST1H3E;
SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- the second group may consist of one or more PDAC-marker genes selected from: CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D. According to said seventh particular selection of PDAC-marker genes, when the aforementioned methods include a step of measuring the expression of at least one gene by using at least one probe, the said labelled or unlabelled probe being complementary to:
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOS 38-43 or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 17-19; SEQ ID NOs 27-30; SEQ ID NO 33; SEQ ID NOs 36-37; SEQ ID NOs 44-47.
The invention further relates to a composition comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNAID; CFTR;
MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1;
MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7;
KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDNl; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
The invention further relates to a kit comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNAID; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D. The invention further relates to a solid support comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJX1 ; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
The invention further relates to a composition, a kit, or a solid support as defined above, comprising:
- at least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 1-8; SEQ ID NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOs 48-53 and
- at least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 9-13; SEQ
ID NOs 17-19; SEQ ID NOs 27-30; SEQ ID NO 33; SEQ ID NOs 36-37 and SEQ ID NO 44-47.
As already mentioned, the term "comprising" encompasses "consisting of.
The invention further relates to a composition, a kit, or a solid support as defined above, for use for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating said individual. EXAMPLES
MATERIAL & METHODS
PDAC samples: Patients included in this project correspond to the Institut Paoli Calmettes clinical trial number 2011 -AO 1439-32 (PaCaOmics project). Consents of informed patients were collected. The tumor tissue used for xenograft development was deemed excess to that required for the patient's diagnosis and standard of care and treatment. All samples were anonymized and obtained in accordance with institutional review boards. Postsurgical anatomopathology reports were provided for specimens from each patient. Histopathologic evaluation was performed on 5-μιη H&E-stained sections of patient tumors and xenograft and examined under a light microscope. These sections were compared to the original human tumor when available.
Studies on cancer cells, analyzed on whole tumors, introduce a high background in systemic analysis. Therefore, we have optimized the conditions of primary culture for PDAC cells obtained by Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS- FNA), a technique systematically employed for diagnosis in our hospitals, and by surgery. Each sample obtained from EUS-FNA was mixed with 100 μΐ of Matrigel (BD Biosciences) and injected in the upper right flank in a nude mouse. Each sample derived from surgery resection was fragmented, mixed with 100 μΐ of Matrigel and implanted with a trocar (10 Gauge) in the subcutaneous right upper flank of an anesthetized and disinfected mouse. When tumors reached 1 cm3, mice were sacrificed and tumors removed.
The samples which are reported herein are derived from individuals with the following characteristics:
Table 1: Samples characteristics
Models Age/Sex Pathology Stage PFS S A/D
D-IPC 53/F Resectable invasive pancreatic cancer ρΤ3Ν1Μ0 6 24 A
located on the body. Final histological Models Age/Sex Pathology Stage PFS S VI) datas found moderately differentiated
ductal adenocarcinoma (4cm) with
perinervous/vascular emboli and lymph
node invasion. Progression with
carcinomatosis and metastasis
01.001 69/M Head pancreatic ductal pT3NlMl 5 7 D adenocarcinoma with pulmonary
metastatis at diagnosis
HN-01 43/M Tail pancreatic adenocarcinoma with pT3NlMl 3 8 D liver metastasis at diagnosis
HN-03 70/M Resectable invasive head pancreatic ρΤ3Ν1Μ0 18 A cancer. Locally lung adenocarcinoma 2
years earlier treated by surgery. Final
pancreatic histology datas found
moderately differentiated ductal
adenocarcinoma with lymph node
invasion. No metastasis. No
progression until censured date
J-IPC 60/M Resectable invasive head pancreatic ρΤ3Ν1Μ0 8 22 A cancer. Final histology datas found
moderately differentiated ductal
adenocarcinoma, tumor size 2.5 cm,
with incomplete carcinologic surgery
(Rl based on vasculary invasion).
Progression with liver metastasis
AD- 82/F Resectable invasive pancreatic cancer ρΤ3Ν1Μ0 12 A
IPC
located on the tail. Melanoma disease
treated by surgery one year earlier.
Final pancreatic histological datas
found moderately differentiated
adenocarcinoma (3.5 cm) with Models Age/Sex Pathology Stage PFS S VI) perinervous/vascular emboli and lymph
node invasion. Incomplete carcino logic
surgery (Rl based on pancreatic
margins). No metastasis. No
progression until censured date
AH- 76/M Resectable invasive pancreatic cancer pT3NlM0 6 12 A
IPC
located on the head. Final histological
datas found moderately to poorly
differentiated ductal adenocarcinoma
(3 cm) with perinervous/vascular
emboli and lymph node invasion.
Regional recurrence but no metastasis
AO- 64/F Resectable invasive pancreatic cancer ρΤ3Ν1Μ0 2 3 D IPC
located on the head. Final histological
datas found moderately differentiated
ductal adenocarcinoma, tumor size 3.5
cm, with perinervous emboli and
lymph node invasion. Explosive
progression with liver, lung,
carcinomatosis metastasis during
adjuvant treatment
01.030 67/F Head pancreatic ductal ρΤ3Ν1Μ1 1 3 D
adenocarcinoma with liver, pulmonary
and lymph node metastatis at
diagnosis. No response to
chemotherapy treatment with
pulmonary emboli and visceral
progression
HN-14 70/M Head pancreatic adenocarcinoma with ρΤ3Ν1Μ1 8 10 A
lung metastasis at diagnosis.
Progression lung metastasis during Models Age/Sex Pathology Stage PFS S VI) chemotherapy
C-NOR 64/M Resectable isthmic pancreatic ρΤ3Ν1Μ0 7 12 D adenocarcinoma. Final histological
datas found good differentiated ductal
adenocarcinoma, tumor size 2.5 cm.
Liver and bone metastatic progression
E-NOR 74/M Resectable invasive pancreatic cancer pT3NlM0 17 A located on the tail. Epidermoid lung
cancer treated by surgery +
chemotherapy one year earlier. Final
pancreatic histological datas found
good and poorly differentiated ductal
adenocarcinoma, tumor size 3 cm, with
lymph node invasion. No metastasis.
No progression until censured date.
H- 70/M Resectable invasive head pancreatic pT3NlM0 18 A
NOR
cancer. Locally lung adenocarcinoma 2
years earlier treated by surgery. Final
pancreatic histological datas found
moderately differentiated ductal
adenocarcinoma with lymph node
invasion. No metastasis. No
progression until censured date
B-TIM 77/M Resectable invasive pancreatic cancer ρΤ3Ν1Μ0 6 12 D located on the tail. Final pancreatic
histological datas found moderately
differentiated ductal adenocarcinoma,
tumor size 4 cm, with perinervous
emboli and lymph node invasion. Liver
metastatic progression
L-IPC 60/M Resectable invasive pancreatic cancer ρΤ3Ν1Μ0 2 5 D Models Age/Sex Pathology Stage PFS
located on the head. Final pancreatic
histological datas found poorly
differentiated carcinoma, with an
anaplastic form, tumor size 3.5 cm,
with perinervous emboli and lymph
node invasion. Rapid lung and liver
metastatic progression during
chemotherapy.
Foie-8b 56/F Pancreatic adenocarcinoma with liver ρΤ3Ν1Μ1
metastasis at diagnosis. No response to
chemotherapy course
A- 89/M Resectable invasive pancreatic cancer pT2NlM0
NOR
located on the tail. Final histological
datas found poorly differentiated
adenocarcinoma, tumor size 1.8 cm,
with perinervous emboli and lymph
node invasion. No metastasis. No
progression until censured date.
PFS = Progression Free Survival (in months)
S= Survival (in months)
A/D= Alive/Dead (respectively)
Xenografted tumor processing and cell culture: Tumors obtained from the mice were split into several small pieces and used for cell culture, histological analyses, reimplantation into mouse and frozen. The fragment designated to cell culture was processed in a biosafety chamber: after a fine mincing, it was treated with collagenase type V and trypsin/EDTA and suspended in DMEM supplemented with 1% w/w Penicillin/Streptomycin and 10% Fetal Bovine Serum. After centrifugation, cells were re- suspended in a media adapted from Schreiber et al. (Schreiber et al, 2004). Cells were then cultured in SFDM media at 37°C with 5% C02. Amplified cells were stored in N2. Cells were weaned from antibiotics for at least 48 h before performing tests. Gene expression microarrays: For R A preparation samples xenografted tumor were removed from the mouse at passage 2 and immediately drawn in cold guanidinium thiocyanate (4 M) solution, followed by protein denaturation and RNAs extraction according to Chirgwin's protocol (Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27; 18(24):5294-9). Total RNA (1.0 μg) was isolated and reverse transcribed for hybridization to the human oligonuleotide array Human Gene 2.0 (Genechip, Affymetrix) as described previously (Hamidi et al.: Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. The Journal of clinical investigation 2012, 122:2092-103).
Arrays were processed using the Affymetrix GeneChip Fluidic Station 450 (protocol EukGE-WS2v5_450) and scanned using a GeneChip Scanner 3000 G7 (Affymetrix). The GeneChip Operating Software (Affymetrix GCOS vl.4) was used to obtain chip images with quality control performed using the AffyQCReport software. Background subtraction and normalization of probe set intensities were performed using the method of Robust Multiarray Analysis (RMA) (Irizarry et al, 2003). PCA analysis was performed using Genomics Suite software (from Partek, St Louis, MO). Gene set enrichment analysis (GSEA) was performed on the Broad Institute Platform and statistical significance (false discovery rate, FDR) was set at 0.25. Microarray analysis was performed by the CRCHUL (CHUQ) Gene Expression Platform, Quebec, Canada.
Chemiograms: Cells were screened for chemio sensitivity to the 5 clinically used drugs in patients with a PDAC: gemcitabine, 5-fluorouracil, oxaliplatin, docetaxel, and irinotecan active metabolite SN38. These cells were treated for 72 h at increasing concentrations from 0 to 1000 μΜ. Five thousand cells per well in 96-wells plates were plated in SFBM medium. Twenty four hours later the medium was supplemented with increasing concentrations of drugs and incubating by an additional 72 h period. Each drug was done in triplicate and experiments were repeated two or three times. Cell viability was estimated after addition of the PrestoBlue reagent (Life Technologies) by 3 h following the PrestoBlue cell viability reagent protocol provided by the supplier. Cell viability was measured at day 0 and day 3 to calculate the replication rate of the cells. EXAMPLE 1. Correlation between transcriptome and clinical outcome.
A total of 11 primary tumors obtained from surgery and 6 biopsies from EUS- FNA were implanted subcutaneously into mice and preserved as xenografts by reimplantation. The histopathological and clinical characteristics of the patients are displayed in supplementary Table 1. Histologically, all specimens were pancreatic ductal adenocarcinomas, which were moderately to poorly differentiated. Growth rates to reach a tumor volume of 1 cm3 ranged from 2 to 6 months. Histopathologically comparisons between patient's primary tumors and xenograft were performed. H&E-stained tissue sections showed that xenografts retained the original morphology of the human primary tumor. The relative state of differentiation was also retained upon passaging until at least 6 times (data not shown). As is typical of PDAC, a high degree of stroma density was observed in the primary tumors but was progressively lost in xenografts.
Total RNA was obtained from 17 xenografts and the transcriptome performed by Affymetrix microchips. The first approach to grouping patients by their expression profile was done using a Principal Component Analysis (PCA) analysis. We found that the transcriptome from two patients-derived xenografts, L-IPC and 01.001, highly detached from the main group of patients. We analyzed their clinical data and found that both corresponded to a two particularly short-term survival patients with poorly-differentiated PDAC (Figure 1). We then explored the presence of other short-term survival patients with poorly-differentiated PDAC within our collection and found that 3 additional patients- derived xenografts, named 01.030, AO-IPC and Foie_8b, corresponded to patients with short-survival times of less than 8 months (Figure 1) and that their tumors were also poorly-differentiated (data not shown). More interestingly, we found that their transcriptome resulted relatively close to the L-IPC and 01.001 ones, indicating a relatively similar expression profile in short-term survival patients with poorly-differentiated tumors (data not shown).
We next performed a heatmap analysis to identify all genes differentially expressed between short-term and long-term survival patients. Five hundred and five genes appeared as overexpressed and 439 genes underexpressed in short-term compared to the long-term survivors as showed in Figure 2C and on table 3 and 9. Importantly, a Gene Ontology analysis, with a Fold Change of > 1.5 and a False Discovery Rate of > 0.001, on differential expression showed a significantly gene enrichment in biological process associated with cancer such as cell cycle, mitosis, response to cellular stresses, DNA metabolism, chromosome organization and cellular metabolism. Interestingly, the majority of these genes were overexpressed in short-term survivals with poorly-differentiated PDAC suggesting that these pathways were preferentially activated.
EXAMPLE 2. Correlation between transcriptome and drug resistance in
PDAC
I- Seventeen primary cultures of PDAC cells were obtained from xenografts derived from PDAC patients. Cells were characterized to assess their epithelial origin by immunofluorescence with CK19 antibody, Kras mutation were identified by PCR followed by DNA sequencing and their transformed status was confirmed by subcutaneous injection of 107 cells in nude mice. All these primary cell cultures are strongly stained with the anti- CK19 antibody, carry the Kras mutation at position 12 or 61 and produced big tumors in mice within the 8 weeks after injection (data not shown). Fibroblast contamination was estimated by immunofluorescence using the anti-S100A4 antibody. No more than 5% of fibroblast contamination was observed. Cell lines were microscopically analyzed presenting a high degree of heterogeneity between them. To study their sensitivity to chemotherapeutical drugs the cells were submitted to increasing concentrations (from 0.001 to 1000 μΜ) of a set of anticancer drugs and their sensitivity measured to obtaining a dose-response curve characterizing each patient.
Using this approach we were able to estimate their relative chemo sensitivity. As shown in Figure 3, each patient-derived cell line shows its own chemogram. Whereas L-IPC, H-N14, H-N01, 01.030 and D-IPC are the 5 most sensitive patient derived cells lines to gemcitabine; the J-IPC, 01.030, L-IPC, H-N14 and B-Tim are the most sensitives to SN-38 (the active irinotecan metabolite); L-IPC, E-NOR, H-NOR, Foie_8b and H-N03 are sensitives to 5FU; Foie_8b, L-IPC, A-NOR, 01.030 and H-NOR are sensitives to oxal- iplatin and L-IPC, HN-14, A-NOR, AH-IPC and J-IPC to docetaxel. Concerning the most chemoresistant cells, we found that the 5 more resistant were Foie_8b, H-N03, H-NOR, 01.001 and C-NOR to gemcitabine; D-IPC, 01.001, A-DIPC, E-NOR and C-NOR to SN- 38; A-DIPC, AO-IPC, C-NOR, AH-IPC and H-N14 for 5FU; AO-IPC, H-N14, AH-IPC, C-NOR and J-IPC to oxaliplatin and H-NOR, 01-001, 01-030, AO-IPC, D-IPC to docetaxel (Table 1). Altogether, these results suggest that each PDAC-derived primary culture line has a particular profile of response. In other words, sensitivity or resistance to one drug does not necessarily predict sensitivity or resistance to another one in an identical manner.
An interesting point to be noted is that after 72 hours of incubation some drugs were unable to kill all the cells even with very high concentration such as 1000 μΜ for gemcitabine, oxaliplatin, docetaxel or 5FU or 100 μΜ for SN-38 (Figure 3). For example, 20 to 50% of cells were resistant to 1000 μΜ of gemcitabine; 5 to 30% remained alive when treated with 100 μΜ of SN-38; 10 to 70% when treated with 1000 μΜ 5FU; 0 to 25% for 1000 μΜ oxaliplatin. A particular behavior was found when cells were treated with docetaxel, whereas small doses of some drugs as low as 0.001 μΜ were able to kill from 90 to 20%, depending of the primary culture, increasing the doses to 3.9 μΜ resulted in almost no changes in its effect. However, almost all cells were killed by 62.5 μΜ.
These results suggest that there is more than one cellular population within the tumor, each with a different sensitivity, including complete insensitivity, to drugs which is agreement with the intratumoral heterogeneity of PDAC.
Concerning the most resistant cells to the drugs, we found that the 5 more resistant were Foie_8b, H-N03, H-NOR, 01.001 and C-NOR for gemcitabine; D-IPC, 01.001, A-DIPC, E-NOR and C-NOR for SN38; A-DIPC, AO-IPC, C-NOR, AH-IPC and H-N14 for 5FU; AO-IPC, H- 14, AH-IPC, C-NOR and J-IPC for oxaliplatin and D-IPC, AH-IPC, 01.001, C-NOR and AD-IPC for docetaxel. Altogether, these results suggest that each PDAC-derived cell have a particular profile of response. In other words, sensitivity or resistance for one drug does not necessarily predict sensitivity or resistance for another one in an identical manner
The most sensitive and most resistant cell lines were determined based on the scores obtained for each line and further detailled hereafter in table 2: Table 2: Resistance score by cell line
Figure imgf000049_0001
II- To study whether or not there is a correlation between drug resistance and sensitivity with the transcriptome we selected the 4 most sensitive and the 4 most resistant cell lines and analyzed a possible relationship with the transcriptome by performing a heatmap analysis.
As described in Figure 4, sets of genes were identified as specifically overex- pressed or underexpressed in resistant and in sensitive cells. These modulations in the expression profiles allowed us to identify 671 genes associated with gemcitabine, 1107 with oxaliplatin, 308 with 5FU, 149 with docetaxel and only 46 with SN-38 respectively (see figure 4). Ninety eight genes were common between oxaliplatin and 5FU, which is in agreement with their close mechanism of action. On the contrary, there are a small number of common genes associated with sensitivity and resistance to the other drugs.
Lastly, another important point to be noted is the fact that genes which are the most associated to the sensitivity or to the resistance to the drugs are not common with genes which are the most associated to short-term or long-term survival, as shown in Figure 4, indicating that both survival and drug sensitivity may relate, at least in part, to different mechanisms.
Herebelow (see tables 3 to 8) are listed collections of sets of genes, of which the variation of the expression level is based on the reference value established by PC A analysis, along with its corresponding individual p-values and fold-changes.
Those sets of genes are grouped based on their preferred use as combinations of PDAC marker genes for:
- determining the prognosis of an individual having PDAC (table 3);
- determining, on a PDAC tumor sample from said individual, the efficiency of SN-38/Irinotecan (table 4); oxaliplatin (table 5); gemcitabine (table 6); docetaxel (table 7) and 5-fluorouracil (table 8).
The fold-change column indicates the variation of the expression of the corresponding gene product, compared to a reference value. The reference value is calculated as shown in the Material & Methods section, using Gene set enrichment analysis (GSEA) performed on the Broad Institute Platform and statistical significance (false discovery rate, FDR) was set at 0.25.
The gene symbol is indicated (if available), along with a reference number for its corresponding product in the corresponding database (REFSEQ, ENSEMBL, GENBANK, and/or LNCipedia).
Table 3: Short VS Long-term survival
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
AF007194 // GenBank // Homo sapiens mucin MUC3A 1.54E-12 -18,8374 (MUC3) mRNA, partial cds. // chr7 // 83 // 77
AJ001402 // GenBank // Homo sapiens mRNA for MUC5AC 1.90E-08 -10,2058 MUC5AC protein (tracheal), partial. // chr
AJ420564 // GenBank // Homo sapiens mRNA full LOC1004 5.72E-06 -3,74451 length insert cDNA clone EUROIMAGE 153400 22737
AK022139 // GenBank // Homo sapiens cDNA 5,23E-08 -2,05368 FLJ12077 fis, clone HEMBB1002453. // chr6 // 9
AK023317 // GenBank // Homo sapiens cDNA HSPA9 3,89E-07 2,10736 FLJ13255 fis, clone OVARC1000800, moderately s
AK0 6431 // GenBank // Homo sapiens cDNA FLG-AS1 2, 19E-06 2, 1437 Reference (REF- Gene p-value
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol
FLJ31869 fis, clone NT2RP7002151. // chrl // 1
AK092802 // GenBank // Homo sapiens cDNA 3,62E-09 FLJ35483 fis, clone SMINT2008277. // chrl 1 //
AK094 59 // GenBank // Homo sapiens cDNA 4,80E-06 FLJ37240 fis, clone BRAMY2003926. // chr8 // 1
AK095353 // GenBank // Homo sapiens cDNA 8J7E-06 FLJ38034 fis, clone CTONG2013393. // chrX // 9
AK095849 // GenBank // Homo sapiens cDNA SNHG1 6,87E-06 FLJ38530 fis, clone HCHON2001039. // chrl 1 //
AK097323 // GenBank // Homo sapiens cDNA 3.79E-06 FLJ40004 fis, clone STOMA2004194. // chrl4 //
AK097428 // GenBank // Homo sapiens cDNA LOC2860 2,58E-09 FLJ40109 fis, clone TESTI2007685. // chr7 // 1 09
AK123096 // GenBank // Homo sapiens cDNA 4,31E-07 FLJ41101 fis, clone BLADE2004670. // chrl 1 //
AK123177 // GenBank // Homo sapiens cDNA ClorH32 3,30E-07 FLJ41182 fis, clone BRACE2043349. // chrl // 1
AK125494 // GenBank // Homo sapiens cDNA FAM177B 2,27E-07 FLJ43505 fis, clone PEBLM2007140. // chrl // 1
AK125871 // GenBank // Homo sapiens cDNA 1.66E-09 FLJ43883 fis, clone TESTI4009123. // chr2 // 1
AK128707 // GenBank // Homo sapiens cDNA LOCIOOI U9E-07 FLJ46874 fis, clone UTE U3014274. // chrl2 // 29940
AK303587 // GenBank // Homo sapiens cDNA TRDJ2 5,92E-06 FLJ52041 complete cds. // chrl 4 // 100 // 100
AK307179 // GenBank HTC // Homo sapiens cDNA, C12orf36 5,80E-06 FLJ97127. // chrl2 // 80 // 36 II II 5
BC035345 // GenBank // Homo sapiens, clone IM- 3,87E-06 AGE:5180681, mR A. // chrl4 // 100 // 100
BC040 15 // GenBank // Homo sapiens cDNA clone 1.88E-05 IMAGE:5745842, partial cds. // chrX // 1
BC044941 // GenBank HTC // Homo sapiens similar FAM215B 8,26E-07 to Apoptosis-related protein 2 (APR-2),
BC045769 // GenBank // Homo sapiens hypothetical LOC3391 U 1E-06 protein LOC339192, mRNA (cDNA clone IM 92
BC047238 // GenBank // Homo sapiens chromosome Clorf51 2,01E-08 1 open reading frame 51 , mRNA (cDNA clon
BC047404 // GenBank // Homo sapiens cDNA clone LOC1005 5,12E-09 IMAGE:5300528. // chrlO // 100 // 100 // 07212
BC052236 // GenBank // Homo sapiens chromosome C19orf21 8,34E-07 19 open reading frame 21, mRNA (cDNA clo
DQ080207 // GenBank // Homo sapiens MIG7 MIG7 1.58E-06 (MIG7) mRNA, complete cds. // chrl // 92 // 93
DQ080207 // GenBank // Homo sapiens MIG7 MIG7 1.82E-05 (MIG7) mRNA, complete cds. // chrl // 95 // 83
Figure imgf000052_0001
gene:
Figure imgf000053_0001
gene
Figure imgf000054_0001
gene
Figure imgf000055_0001
gene
Figure imgf000056_0001
gene:E
Figure imgf000057_0001
gen
Figure imgf000058_0001
Figure imgf000059_0001
gene:
Figure imgf000060_0001
gene
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
GENSCAN00000014965 // ENSEMBL // 1.98E-09 -11,2116 cdna:genscan chromo- some:GRCh37:7: 141672558:141941111 :1
GENSCAN00000014965 // ENSEMBL // 3,19E-09 -8,64275 cdna:genscan chromo- some:GRCh37:7: 141672558:141941111 :1
NM_000024 // RefSeq // Homo sapiens adrenoceptor ADRB2 1.97E-10 3,37262 beta 2, surface (ADRB2), mRNA. // chr5
NM 000046 // RefSeq // Homo sapiens arylsulfatase ARSB 2,09E-06 1,59341 B (ARSB), transcript variant 1, mRNA.
NM 000053 // RefSeq // Homo sapiens ATPase, ATP7B 2,91E-08 -4,8711 Cu++ transporting, beta polypeptide (ATP7B)
NM_000082 // RefSeq // Homo sapiens excision reERCC8 2,02E-06 1,73062 pair cross-complementing rodent repair d
NM 000112 // RefSeq // Homo sapiens solute carrier SLC26A2 5,44E-07 1,73286 family 26 (sulfate transporter), mem
NM 000150 // RefSeq // Homo sapiens fucosyltrans- FUT6 1.34E-05 -1,85068 ferase 6 (alpha (1,3) fucosyltransferas
NM 000166 // RefSeq // Homo sapiens gap junction GJB1 8.51E-10 -3,23481 protein, beta 1, 32kDa (GJB1), transcr
NM 000179 // RefSeq // Homo sapiens mutS homo- MSH6 2.73E-06 1,55527 log 6 (E. coli) (MSH6), mRNA. // chr2 // 1
NM 000260 // RefSeq // Homo sapiens myosin VIIA MY07A 1.35E-06 -1,63887 (MY07A), transcript variant 1, mRNA. //
NM 000311 // RefSeq // Homo sapiens prion protein PRNP 5,37E-07 2,41853 (PRNP), transcript variant 1 , mRNA. /
NM 000329 // RefSeq // Homo sapiens retinal pigRPE65 1.50E-08 2,62922 ment epithelium-specific protein 65kDa (
NM 000343 // RefSeq // Homo sapiens solute carrier SLC5A1 8,88E-10 -4,59938 family 5 (sodium/glucose cotransport
NM 000366 // RefSeq // Homo sapiens tropomyosin 1 TPM1 1.09E-10 -2,75385 (alpha) (TPM1), transcript variant 5,
NM 000367 // RefSeq // Homo sapiens thiopurine S- TPMT 4,01E-06 -2,27401 methyltransferase (TPMT), mRNA. // chr
NM_000433 // RefSeq // Homo sapiens neutrophil NCF2 9,32E-07 3,01189 cytosolic factor 2 (NCF2), transcript va
NM 000458 // RefSeq // Homo sapiens HNF1 ho- HNF1B 6.12E-11 -7,59197 meobox B (HNF1B), transcript variant 1, mRNA
NM_000492 // RefSeq // Homo sapiens cystic fibrosis CFTR 8,40E-12 -19,4273 transmembrane conductance regulator
NM 000507 // RefSeq // Homo sapiens fructose- 1,6- FBP1 1.94E-07 -4,34747 bisphosphatase 1 (FBP1), transcript va
NM 000681 // RefSeq // Homo sapiens adrenoceptor ADRA2A 2,09E-10 -6,8359 alpha 2A (ADRA2A), mRNA. // chr 10 // 1
NM 000690 // RefSeq // Homo sapiens aldehyde ALDH2 2,35E-05 -3,53973 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change dehydrogenase 2 family (mitochondrial) (AL
NM 000720 // RefSeq // Homo sapiens calcium chanCACNA1 7,09E-18 -5,47623 nel, voltage-dependent, L type, alpha 1 D
NM 000767 // RefSeq // Homo sapiens cytochrome CYP2B6 9,15E-06 -4,09662 P450, family 2, subfamily B, polypeptide
NM 000772 // RefSeq // Homo sapiens cytochrome CYP2C18 4,19E-07 -11,3016 P450, family 2, subfamily C, polypeptide
NM 000789 // RefSeq // Homo sapiens angiotensin I ACE U0E-06 -1,64035 converting enzyme (peptidyl-dipeptida
NM 000899 // RefSeq // Homo sapiens KIT ligand KITLG 4,02E-06 -3,34446 (KITLG), transcript variant b, mRNA. //
NM 000901 // RefSeq // Homo sapiens nuclear recepNR3C2 5,08E-06 -2,5153 tor subfamily 3, group C, member 2 (NR
NM 000919 // RefSeq // Homo sapiens peptidylgly- PAM 4,26E-11 1,95029 cine alpha-amidating monooxygenase (PAM)
NM 0010017 1 // RefSeq // Homo sapiens chromoC10orf55 l,50E-05 2,25223 some 10 open reading frame 55 (C10orf55),
NM_001002796 // RefSeq // Homo sapiens multiple MCTP1 l,82E-08 5,08908 C2 domains, transmembrane 1 (MCTP1), tr
NM 001006657 // RefSeq // Homo sapiens WD repeat WDR35 9,35E-06 2,09791 domain 35 (WDR35), transcript variant
NM 001008723 // RefSeq // Homo sapiens coiled-coil CCDC147 7J9E-08 1,73869 domain containing 147 (CCDC147), mRN
NM 001008749 // RefSeq // Homo sapiens RAB19, RAB19 4,86E-07 -2,11397 member RAS oncogene family (RAB 19), mRNA.
NM_001008938 // RefSeq // Homo sapiens cytoskele- CKAP5 l,66E-08 1,55595 ton associated protein 5 (CKAP5), trans
NM 001009999 // RefSeq // Homo sapiens lysine (K)- KDM1A 6,12E-06 2,1216 specific demethylase 1A (KDM1A), tran
NM 001010887 // RefSeq // Homo sapiens alkaline ACER2 l,09E-05 -2,73782 ceramidase 2 (ACER2), mRNA. // chr9 //
NM 001010922 // RefSeq // Homo sapiens BCL2-like BCL2L15 6,58E-10 -6,27269 15 (BCL2L15), mRNA. // chrl // 100 //
NM 001011663 // RefSeq // Homo sapiens polycomb PCGF6 l,06E-07 2,25652 group ring finger 6 (PCGF6), transcript
NM 001012515 // RefSeq // Homo sapiens ferrochela- FECH l,48E-05 1,57238 tase (FECH), nuclear gene encoding mit
NM 001012662 // RefSeq // Homo sapiens solute SLC3A2 5,87E-06 1,55809 carrier family 3 (activators of dibasic a
NM 001012761 // RefSeq // Homo sapiens RGM doRGMB 3,00E-06 2,11088 main family, member B (RGMB), mRNA. // chr
NM 001018077 // RefSeq // Homo sapiens nuclear NR3C1 2,89E-08 1,84521 receptor subfamily 3, group C, member 1
NM 001024611 // RefSeq // Homo sapiens leucine LRRC66 l,66E-06 -5,9514 rich repeat containing 66 (LRRC66), mRNA Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM OO 1024948 // RefSeq // Homo sapiens foraiin FNBP1L 4J3E-06 -3,19797 binding protein 1-like (FNBP1L), transcri
NM OO 1029996 // RefSeq // Homo sapiens primary PCDP1 l,21E-05 -3,09884 ciliary dyskinesia protein 1 (PCDP1), mR
NM 001033 // RefSeq // Homo sapiens ribonucleotide RRM1 6,48E-07 1,68276 reductase Ml (RRM1), mRNA. // chrl 1
NM OO 1034194 // RefSeq // Homo sapiens exosome EXOSC9 4,34E-06 1,72092 component 9 (EXOSC9), transcript variant
NM_001034850 // RefSeq // Homo sapiens family FAM134B 2,59E-05 -2,70656 with sequence similarity 134, member B (F
NM 001039395 // RefSeq // Homo sapiens spermatoSPATA6L l,39E-05 -2,31593 genesis associated 6-like (SPATA6L), mRN
NM 001040022 // RefSeq // Homo sapiens signal- SIRPA 4,48E-06 -2,56297 regulatory protein alpha (SIRPA), transcr
NM 001042413 // RefSeq // Homo sapiens GLIS faGLIS3 l,28E-06 -2,46753 mily zinc finger 3 (GLIS3), transcript va
NM_001042471 // RefSeq // Homo sapiens gasdermin GSDMB l,51E-06 -3,22959
B (GSDMB), transcript variant 1, mRNA.
NM OO 1042481 // RefSeq // Homo sapiens FERM FRMD6 2,07E-07 3,59922 domain containing 6 (FRMD6), transcript var
NM 001047 // RefSeq // Homo sapiens steroid-5- SRD5A1 3,13E-07 1,802 alpha-reductase, alpha polypeptide 1 (3-o
NM 001056 // RefSeq // Homo sapiens sulfotransfer- SULT1C2 7,47E-07 -8,03899 ase family, cytosolic, 1C, member 2 (S
NM 001077181 // RefSeq // Homo sapiens CDC14 CDC14B l,03E-07 -1,92902 cell division cycle 14 homolog B (S. cerev
NM 001080416 // RefSeq // Homo sapiens v-myb MYBL1 6J2E-06 4,84232 myeloblastosis viral oncogene homolog (avi
NM_001080429 // RefSeq // Homo sapiens calmoduCAM- 3,64E-06 -2,00599 lin regulated spectrin-associated protein SAPS
NM 001080527 // RefSeq // Homo sapiens myosin MY07B 4,01E-06 -2,9353 VIIB (MY07B), mRNA. // chr2 // 100 // 76
NM 001083 // RefSeq // Homo sapiens phosphoPDE5A 2,09E-07 -3,28726 diesterase 5A, cGMP-specific (PDE5A), transc
NM_001085377 // RefSeq // Homo sapiens mutated in MCC 3,38E-07 2,52646 colorectal cancers (MCC), transcript
NM 001085411 // RefSeq // Homo sapiens NAD kiNADKD1 l,36E-05 1,74438 nase domain containing 1 (NADKD1), transcr
NM 001098484 // RefSeq // Homo sapiens solute SLC4A4 3.18E-13 -20,7327 carrier family 4, sodium bicarbonate cotr
NM 001098511 // RefSeq // Homo sapiens kinesin KIF2A 6,33E-06 1,7595 heavy chain member 2A (KIF2A), transcrip
NM 001099287 // RefSeq // Homo sapiens NIPA-like NIPAL4 2,97E-05 1,58641 domain containing 4 (NIPAL4), transcri
NM 001100399 // RefSeq // Homo sapiens PDS5, PDS5A 2,19E-08 1,54595 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change regulator of cohesion maintenance, homo log
NM 001100812 // RefSeq // Homo sapiens chemo- CXCL16 1J2E-05 -3,95261 kine (C-X-C motif) ligand 16 (CXCL16), tran
NM_001104546 // RefSeq // Homo sapiens ribonucle- RPP30 4,65E-09 2,18302 ase P/MRP 30kDa subunit (RPP30), transc
NM 001105248 // RefSeq // Homo sapiens transTMC5 l,26E-07 -7,77774 membrane channel-like 5 (TMC5), transcript
NM 001112 // RefSeq // Homo sapiens adenosine ADARBl 2,98E-08 2,41172 deaminase, RNA-specific, Bl (ADARBl), tra
NM 001112706 // RefSeq // Homo sapiens scinderin SCIN 4,31E-07 -4,31068
(SCIN), transcript variant 1, mRNA. //
NM 001114106 // RefSeq // Homo sapiens solute SLC44A3 1J9E-05 -4,21928 carrier family 44, member 3 (SLC44A3), tr
NM 001114132 // RefSeq // Homo sapiens neuro- NBEAL1 4,52E-06 -1,65626 beachin-like 1 (NBEAL1), mRNA. // chr2 // 1
NM OOl 123 // RefSeq // Homo sapiens adenosine ADK U0E-07 2,39255 kinase (ADK), transcript variant 1, mRNA.
NM OOl 126129 // RefSeq // Homo sapiens GINS GINS3 2,44E-05 1,61209 complex subunit 3 (Psf3 homolog) (GINS3), t
NM 001127357 // RefSeq // Homo sapiens putative PHTF2 4,54E-06 1,81065 homeodomain transcription factor 2 (PHT
NM_001130524 // RefSeq // Homo sapiens adaptor- AP1M1 2,07E-06 1,79694 related protein complex 1, mu 1 subunit
NM OOl 130823 // RefSeq // Homo sapiens DNA (cy- DNMT1 8,25E-06 1,69113 tosine-5-)-methyltransferase 1 (DNMT1), t
NM OOl 130960 // RefSeq // Homo sapiens phospho- PLCH1 2,80E-05 -3,10193 lipase C, eta 1 (PLCH1), transcript varia
NM OOl 130963 // RefSeq // Homo sapiens transTMEM19 9,14E-06 2,00629 membrane protein 1 4 A (TMEM194A), transcrip 4A
NM OOl 131007 // RefSeq // Homo sapiens KIAA092 6,64E-09 2,93127
KIAA0922 (KIAA0922), transcript variant 1, mRNA. 2
NM OOl 134437 // RefSeq // Homo sapiens pleckstrin PHLDB2 l,99E-05 2,03956 homo logy-like domain, family B, membe
NM_001134779 // RefSeq // Homo sapiens importin IPOl l l,31E-07 1,91863 11 (IPOl 1), transcript variant 1, mRNA.
NM OOl 135050 // RefSeq // Homo sapiens immunoIGSF9 1J4E-09 -2,27848 globulin superfamily, member 9 (IGSF9), tr
NM OOl 135648 // RefSeq // Homo sapiens protein PTPR 4,19E-08 -2,11352 tyrosine phosphatase, receptor type, K (
NM OOl 136191 // RefSeq // Homo sapiens KN motif KANK2 8,39E-06 1,54045 and ankyrin repeat domains 2 (KANK2), t
NM OOl 136216 // RefSeq // Homo sapiens transTMEM51 l,88E-06 -2,37228 membrane protein 51 (TMEM51), transcript va
NM OOl 142286 // RefSeq // Homo sapiens structural SMC6 U7E-05 1,59291 maintenance of chromosomes 6 (SMC6), Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 001142550 // RefSeq // Homo sapiens WD repeat WDR47 1J1E-07 1,66269 domain 47 (WDR47), transcript variant
NM 001143820 // RefSeq // Homo sapiens v-ets eryETS1 9,39E-06 1,99545 throblastosis virus E26 oncogene homolo
NM 001143962 // RefSeq // Homo sapiens calpain 8 CAPN8 8,27E-06 -5,968 (CAPN8), mRNA. // chrl // 100 // 52 //
NM 001143979 // RefSeq // Homo sapiens nudE nuNDE1 5,62E-06 1,59099 clear distribution E homolog 1 (A. nidula
NM 001144832 // RefSeq // Homo sapiens tetratrico- TTC39A 3.78E-11 -2,58826 peptide repeat domain 39A (TTC39A), tr
NM 001144889 // RefSeq // Homo sapiens solute SLC23A3 1.05E-06 -1,6463 carrier family 23 (nucleobase transporter
NM 001144994 // RefSeq // Homo sapiens chromoC2orf72 4.11E-07 -2,59372 some 2 open reading frame 72 (C2orf72), mR
NM OOl 145 // RefSeq // Homo sapiens angiogenin, ANG 4,28E-07 -2,88934 ribonuclease, RNase A family, 5 (ANG),
NM_001145065 // RefSeq // Homo sapiens family FAM190A 1.78E-06 -2,82469 with sequence similarity 190, member A (F
NM OOl 145313 // RefSeq // Homo sapiens fibron- FSD1L 6,52E-06 2,39936 ectin type III and SPRY domain containing
NM 001145775 // RefSeq // Homo sapiens FK506 FKBP5 4,88E-08 1,82034 binding protein 5 (FKBP5), transcript vari
NM OOl 146188 // RefSeq // Homo sapiens TOX high TOX3 1.42E-07 -5,22885 mobility group box family member 3 (TOX
NM 001153 // RefSeq // Homo sapiens annexin A4 ANXA4 2.31E-10 -2,5913 (ANXA4), mRNA. // chr2 // 100 // 68 // 1
NM_001159352 // RefSeq // Homo sapiens regeneratREG4 2,61E-08 -27,5098 ing islet-derived family, member 4 (REG
NM OOl 164386 // RefSeq // Homo sapiens Rap guaRAPGEF6 5,16E-08 1,72561 nine nucleotide exchange factor (GEF) 6 (
NM_001164507 // RefSeq // Homo sapiens nebulin NEB 2,85E-07 -4,39602 (NEB), transcript variant 1, mRNA. // ch
NM OOl 164664 // RefSeq // Homo sapiens microtuMAST4 U5E-05 1,81579 bule associated serine/threonine kinase f
NM OOl 164694 // RefSeq // Homo sapiens iodotyro- IYD 2.92E-11 -3,82576 sine deiodinase (IYD), transcript varian
NM OOl 166271 // RefSeq // Homo sapiens spermatoSPATA13 1.67E-05 -1,6413 genesis associated 13 (SPATA13), transcr
NM OOl 170464 // RefSeq // Homo sapiens cyclin- CDK17 1.83E-05 2,31788 dependent kinase 17 (CDK17), transcript v
NM_001171203 // RefSeq // Homo sapiens ubiquitin UBAP1 1.01E-07 -1,76989 associated protein 1 (UBAP1), transcri
NM OOl 171631 // RefSeq // Homo sapiens nitric NOSTRIN 2,82E-08 -4,42321 oxide synthase trafficker (NOSTRIN), tran
NM OOl 172 // RefSeq // Homo sapiens arginase, type ARG2 5,23E-07 2,01206 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
II (ARG2), nuclear gene encoding mit
NM 001172895 // RefSeq // Homo sapiens caveolin CAV1 8,57E-08 3,53007 1, caveolae protein, 22kDa (CAV1), tran
NM 001182 // RefSeq // Homo sapiens aldehyde deALDH7A 2,92E-07 1,91575 hydrogenase 7 family, member A 1 (ALDH7A1 1
NM 001184690 // RefSeq // Homo sapiens nephro- NPNT 2J8E-05 -4,26002 nectin (NPNT), transcript variant 1, mRNA.
NM_001184783 // RefSeq // Homo sapiens voltage- VDAC2 l,86E-07 1,58317 dependent anion channel 2 (VDAC2), nucle
NM 001184975 // RefSeq // Homo sapiens protein PACSIN3 8,66E-09 2,33726 kinase C and casein kinase substrate in
NM 001190482 // RefSeq // Homo sapiens proprotein PCSK5 8,80E-10 -5,22046 convertase subtilisin/kexin type 5 (P
NM 001190708 // RefSeq // Homo sapiens MT- MTRNR2 2,65E-05 -1,60716 RNR2-like 10 (MTRNR2L10), mRNA. // chrX // 10 L10
NM 001195381 // RefSeq // Homo sapiens G protein- GPR35 1J5E-05 -2,77572 coupled receptor 35 (GPR35), transcrip
NM 001198608 // RefSeq // Homo sapiens microtu- MAP7 l,92E-06 -3,19656 bule-associated protein 7 (MAP7), transcr
NM 001199397 // RefSeq // Homo sapiens NIMA NEK1 4,29E-09 1,7036 (never in mitosis gene a)-related kinase 1
NM 001199799 // RefSeq // Homo sapiens immuno- ILDR1 9,62E-06 -2,39787 globulin-like domain containing receptor 1
NM 001201480 // RefSeq // Homo sapiens oxysterol OSBPL6 6,57E-07 4,23777 binding protein-like 6 (OSBPL6), trans
NM 001201483 // RefSeq // Homo sapiens enolase 1, ENOl l,31E-06 1,70797 (alpha) (ENOl), transcript variant 2,
NM 001242348 // RefSeq // Homo sapiens uncharac- LOC1002 5,55E-08 1,61643 terized LOCI 00287177 (LOCI 00287177), mRN 87177
NM 001242729 // RefSeq // Homo sapiens Rho guaARHGEF 2,66E-07 -5,69206 nine nucleotide exchange factor (GEF) 38 38
NM_001242903 // RefSeq // Homo sapiens A kinase AKAP1 2,08E-05 -1,63284 (PRKA) anchor protein 1 (AKAP1), transc
NM 001256617 // RefSeq // Homo sapiens tubulin, TUB- 2,06E-08 1,69833 gamma complex associated protein 2 (TUB GCP2
NM 001258355 // RefSeq // Homo sapiens hepatocyte HNF4A 5,19E-07 -3,42073 nuclear factor 4, alpha (HNF4A), tran
NM 001258438 // RefSeq // Homo sapiens threonyl- TARS l,54E-05 1,59711 tRNA synthetase (TARS), transcript vari
NM 001316 // RefSeq // Homo sapiens CSE1 chroCSE1L 4,15E-06 1,88153 mosome segregation 1-like (yeast) (CSE1L),
NM 001398 // RefSeq // Homo sapiens enoyl CoA ECH1 5,35E-06 -1,80321 hydratase 1, peroxisomal (ECH1), mRNA. //
NM_001425 // RefSeq // Homo sapiens epithelial EMP3 5,54E-07 5,39192 membrane protein 3 (EMP3), mRNA. // chrl Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 001482 // RefSeq // Homo sapiens glycine ami- GATM l,93E-06 -3,08419 dinotransferase (L-arginine:glycine amid
NM_001486 // RefSeq // Homo sapiens glucokinase GCKR 5,61E-06 -3,36354 (hexokinase 4) regulator (GCKR), mRNA.
NM_001498 // RefSeq // Homo sapiens glutamate- GCLC l,89E-08 1,66864 cysteine ligase, catalytic subunit (GCLC)
NM_001628 // RefSeq // Homo sapiens aldo-keto reAKR1B1 2,14E-06 2,47241 ductase family 1, member Bl (aldose red
NM 001644 // RefSeq // Homo sapiens apolipoprotein APO- l,59E-08 -7,48678 B mRNA editing enzyme, catalytic pol BEC1
NM 001740 // RefSeq // Homo sapiens calbindin 2 CALB2 l,27E-08 9,78639 (CALB2), transcript variant CALB2, mRNA
NM 001745 // RefSeq // Homo sapiens calcium modCAMLG l,07E-06 2,21494 ulating ligand (CAMLG), mRNA. // chr5 //
NM 001799 // RefSeq // Homo sapiens cyclin- CDK7 l,36E-08 1,8092 dependent kinase 7 (CDK7), mRNA. // chr5 //
NM 001910 // RefSeq // Homo sapiens cathepsin E CTSE 3,07E-09 -18,1044 (CTSE), transcript variant 1 , mRNA. //
NM_001931 // RefSeq // Homo sapiens dihy- DLAT 9,46E-08 1,779 drolipoamide S-acetyltransferase (DLAT), nuclea
NM 001947 // RefSeq // Homo sapiens dual specificiDUSP7 l,84E-06 1,70218 ty phosphatase 7 (DUSP7), mRNA. // ch
NM_001983 // RefSeq // Homo sapiens excision reERCC1 5,00E-06 1,84238 pair cross-complementing rodent repair d
NM_002079 // RefSeq // Homo sapiens glutamic- GOT1 l,52E-06 1,76056 oxaloacetic transaminase 1 , soluble (aspar
NM_002153 // RefSeq // Homo sapiens hydroxyste- HSD17B2 1.32E-13 -14,8399 roid (17-beta) dehydrogenase 2 (HSD17B2),
NM 002317 // RefSeq // Homo sapiens lysyl oxidase LOX 1.70E-05 2,66729 (LOX), transcript variant 1, mRNA. //
NM 002372 // RefSeq // Homo sapiens mannosidase, MAN2A1 2J1E-05 1,68938 alpha, class 2A, member 1 (MAN2A1), mR
NM 002423 // RefSeq // Homo sapiens matrix metal- MMP7 1.62E-05 -8,00839 lopeptidase 7 (matrilysin, uterine) (MM
NM 002431 // RefSeq // Homo sapiens menage a trois MNAT1 5,02E-07 1,53426 homo log 1, cyclin H assembly factor
NM 002447 // RefSeq // Homo sapiens macrophage MST1R 1.19E-05 -2,05841 stimulating 1 receptor (c-met-related ty
NM 002483 // RefSeq // Homo sapiens carcinoem- CEACAM 3,06E-06 -22,3709 bryonic antigen-related cell adhesion mole 6
NM 002495 // RefSeq // Homo sapiens NADH dehyNDUFS4 2,04E-06 1,65785 drogenase (ubiquinone) Fe-S protein 4, 18k
NM 002622 // RefSeq // Homo sapiens prefoldin PFDN1 1.87E-08 1,72168 subunit 1 (PFDN1), mRNA. // chr5 // 100 /
NM 002644 // RefSeq // Homo sapiens polymeric PIGR 1.79E-06 -18,0893 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change immunoglobulin receptor (PIGR), mRNA. //
NM 002670 // RefSeq // Homo sapiens plastin 1 PLS1 l,69E-06 -2,96555 (PLS1), transcript variant 2, mRNA. // ch
NM 002743 // RefSeq // Homo sapiens protein kinase PRKCSH 2,93E-08 1,5656 C substrate 80K-H (PRKCSH), transcri
NM 002775 // RefSeq // Homo sapiens HtrA serine HTRA1 2,85E-06 4,27353 peptidase 1 (HTRA1), mRNA. // chrlO //
NM 002851 // RefSeq // Homo sapiens protein tyroPTPRZ1 4,83E-07 9,17265 sine phosphatase, receptor-type, Z poly
NM 002890 // RefSeq // Homo sapiens RAS p21 proRASA1 2,83E-07 1,9742 tein activator (GTPase activating protei
NM 002895 // RefSeq // Homo sapiens retinoblasto- RBLl 7,24E-07 1,86968 ma-like 1 (pl07) (RBLl), transcript var
NM_002913 // RefSeq // Homo sapiens replication RFC1 3,l lE-06 1,85897 factor C (activator 1) 1, 145kDa (RFC1)
NM 002939 // RefSeq // Homo sapiens ribonucle- RNHl l,42E-09 1,62874 ase/angiogenin inhibitor 1 (RNHl), transcr
NM 003025 // RefSeq // Homo sapiens SH3 -domain SH3GL1 3,39E-07 1,50451 GRB2-like 1 (SH3GL1), transcript variant
NM 003048 // RefSeq // Homo sapiens solute carrier SLC9A2 1,58E-10 -4,82266 family 9, subfamily A (NHE2, cation
NM 003059 // RefSeq // Homo sapiens solute carrier SLC22A4 6,92E-06 2,13731 family 22 (organic cation/ergothione
NM_003082 // RefSeq // Homo sapiens small nuclear SNAPC1 2,60E-05 2,04491 RNA activating complex, polypeptide 1
NM 003100 // RefSeq // Homo sapiens sorting nexin SNX2 4,87E-06 1,70353 2 (SNX2), mRNA. // chr5 // 100 // 70
NM 003146 // RefSeq // Homo sapiens structure SSRPl 1J7E-06 1,50754 specific recognition protein 1 (SSRPl), m
NM 003155 // RefSeq // Homo sapiens stanniocalcin STC1 5,57E-06 7,56609 1 (STC1), mRNA. // chr8 // 100 // 86
NM 003171 // RefSeq // Homo sapiens suppressor of SUPV3L1 5,39E-07 1,92745 varl, 3-like 1 (S. cerevisiae) (SUPV3
NM 003249 // RefSeq // Homo sapiens thimet oligo- THOP1 5,00E-06 1,61004 peptidase 1 (THOP1), mRNA. // chrl9 //
NM 003314 // RefSeq // Homo sapiens tetratricopep- TTC1 4,66E-07 1,54851 tide repeat domain 1 (TTC1), mRNA. //
NM 003380 // RefSeq // Homo sapiens vimentin VIM 7,03E-06 3,82123 (VIM), mRNA. // chrlO // 100 // 55 // 18 /
NM 003389 // RefSeq // Homo sapiens coronin, actin COR02A l,20E-06 -2,77405 binding protein, 2A (COR02A), transc
NM 003468 // RefSeq // Homo sapiens frizzled famiFZD5 l,34E-05 -1,91449 ly receptor 5 (FZD5), mRNA. // chr2 //
NM 003473 // RefSeq // Homo sapiens signal transSTAM 7,44E-06 1,87745 ducing adaptor molecule (SH3 domain and Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 003558 // RefSeq // Homo sapiens phosphatidyl- PIP5K1B 3,49E-09 -5,27062 inositol-4-phosphate 5-kinase, type I,
NM 003561 // RefSeq // Homo sapiens phospholipase PLA2G10 1J2E-08 -6,64273 A2, group X (PLA2G10), mRNA. // chrl6
NM 003621 // RefSeq // Homo sapiens PTPRF interPPFIBP2 2,55E-06 -2,44237 acting protein, binding protein 2 (lipri
NM 003637 // RefSeq // Homo sapiens integrin, alpha ITGA10 7,88E-09 4,32095 10 (ITGA10), mRNA. // chrl // 100 /
NM 003657 // RefSeq // Homo sapiens breast carciBCAS1 9,67E-07 -5,32311 noma amplified sequence 1 (BCAS1), mRNA
NM 003688 // RefSeq // Homo sapiens cal- CASK 1J9E-06 -1,70133 cium/calmodulin-dependent serine protein kinase
NM 003730 // RefSeq // Homo sapiens ribonuclease RNASET2 2J6E-06 -2,68746 T2 (RNASET2), mRNA. // chr6 // 100 //
NM 003740 // RefSeq // Homo sapiens potassium KCNK5 8,27E-10 -3,26274 channel, subfamily K, member 5 (KCNK5), m
NM 003786 // RefSeq // Homo sapiens ATP-binding ABCC3 3,65E-07 -3,12547 cassette, sub-family C (CFTR/MRP), memb
NM_003803 // RefSeq // Homo sapiens myomesin 1, MYOM1 2,32E-05 -3,392 185kDa (MYOM1), transcript variant 1, m
NM 003839 // RefSeq // Homo sapiens tumor necroTNFRSF1 3,34E-11 -4,92878 sis factor receptor superfamily, member 1A
NM 003883 // RefSeq // Homo sapiens histone HDAC3 7,46E-10 1,70453 deacetylase 3 (HDAC3), mRNA. // chr5 // 100
NM 003889 // RefSeq // Homo sapiens nuclear recepNR1I2 3,82E-07 -4,09907 tor subfamily 1, group I, member 2 (NR
NM 003927 // RefSeq // Homo sapiens methyl-CpG MBD2 2,55E-05 1,59749 binding domain protein 2 (MBD2), transcr
NM 004055 // RefSeq // Homo sapiens calpain 5 CAPN5 l,52E-06 -3,40528 (CAPN5), mRNA. // chrl 1 // 100 // 74 // 2
NM 004079 // RefSeq // Homo sapiens cathepsin S CTSS 2,44E-06 -2,56738 (CTSS), transcript variant 1, mRNA. //
NM 004126 // RefSeq // Homo sapiens guanine nuGNG11 U2E-05 5,04648 cleotide binding protein (G protein), gam
NM 004133 // RefSeq // Homo sapiens hepatocyte HNF4G l,38E-07 -3,44075 nuclear factor 4, gamma (HNF4G), mRNA. /
NM 004134 // RefSeq // Homo sapiens heat shock HSPA9 4J8E-08 1,73539 70kDa protein 9 (mortalin) (HSPA9), nucl
NM 004170 // RefSeq // Homo sapiens solute carrier SLC1A1 6,50E-09 -7,74362 family 1 (neuronal/epithelial high a
NM 004235 // RefSeq // Homo sapiens Kruppel-like KLF4 7,12E-06 -1,74298 factor 4 (gut) (KLF4), mRNA. // chr9 /
NM 004240 // RefSeq // Homo sapiens thyroid horTRIP 10 l,49E-05 1,51893 mone receptor interactor 10 (TRIP 10), mR
NM 004249 // RefSeq // Homo sapiens RAB28, RAB28 l,60E-06 1,54275 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change member RAS oncogene family (RAB28), transcri
NM 004281 // RefSeq // Homo sapiens BCL2- BAG3 5,51E-06 1,74201 associated athanogene 3 (BAG3), mRNA. // chrlO
NM 004282 // RefSeq // Homo sapiens BCL2- BAG2 7,40E-07 2,96914 associated athanogene 2 (BAG2), mRNA. // chr6
NM 004293 // RefSeq // Homo sapiens guanine GDA 2,00E-07 -4,98333 deaminase (GDA), transcript variant 2, mRNA
NM 004307 // RefSeq // Homo sapiens amyloid beta APBB2 2,83E-06 1,97486 (A4) precursor protein-binding, family
NM 004329 // RefSeq // Homo sapiens bone morpho- BMPR1A 6,24E-06 1,69451 genetic protein receptor, type IA (BMPR1
NM 004390 // RefSeq // Homo sapiens cathepsin H CTSH 3,10E-09 -2,87544 (CTSH), mRNA. // chrl5 // 100 // 38 //
NM 004417 // RefSeq // Homo sapiens dual specificiDUSP1 l,68E-07 2,1245 ty phosphatase 1 (DUSP1), mRNA. // ch
NM 004420 // RefSeq // Homo sapiens dual specificiDUSP8 l,51E-05 -1,70935 ty phosphatase 8 (DUSP8), mRNA. // ch
NM 004472 // RefSeq // Homo sapiens forkhead box FOXD1 9,61E-07 2,86306 Dl (FOXD1), mRNA. // chr5 // 100 // 67
NM 004477 // RefSeq // Homo sapiens FSHD region FRG1 3,07E-06 1,62969 gene 1 (FRG1), mRNA. // chr4 // 100 //
NM 004497 // RefSeq // Homo sapiens forkhead box FOXA3 2,81E-05 -1,7194 A3 (FOXA3), mRNA. // chrl9 // 100 // 1
NM_004607 // RefSeq // Homo sapiens tubulin foldTBCA 7,79E-07 1,62625 ing cofactor A (TBCA), mRNA. // chr5 //
NM 004636 // RefSeq // Homo sapiens sema domain, SEMA3B 6,84E-06 -2,39322 immunoglobulin domain (Ig), short basi
NM 004641 // RefSeq // Homo sapiens myeMLLT10 4,l lE-07 1,81768 loid/lymphoid or mixed-lineage leukemia (trithor
NM 004661 // RefSeq // Homo sapiens cell division CDC23 4,16E-09 1,6899 cycle 23 homo log (S. cerevisiae) (CDC
NM_004672 // RefSeq // Homo sapiens mitogen- MAP3K6 U9E-05 1,6318 activated protein kinase kinase kinase 6 (M
NM 004724 // RefSeq // Homo sapiens ZW10, ki- ZW10 6,66E-06 1,60086 netochore associated, homo log (Drosophila)
NM 004726 // RefSeq // Homo sapiens RALBP1 asREPS2 6,02E-11 -3,83928 sociated Eps domain containing 2 (REPS2),
NM 004817 // RefSeq // Homo sapiens tight junction TJP2 l,28E-05 -1,93552 protein 2 (zona occludens 2) (TJP2),
NM 004852 // RefSeq // Homo sapiens one cut ONECUT 1.48E-12 -3,51155 homeobox 2 (ONECUT2), mRNA. // chrl8 // 100 2
NM 004866 // RefSeq // Homo sapiens secretory carSCAMPI 1.16E-07 1,53148 rier membrane protein 1 (SCAMPI), mRNA
NM 004938 // RefSeq // Homo sapiens death- DAP 1 8J8E-08 -4,66228 associated protein kinase 1 (DAPK1), mRNA. // Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 004978 // RefSeq // Homo sapiens potassium KCNC4 9,13E-06 -1,68861 voltage-gated channel, Shaw-related subfa
NM_004995 // RefSeq // Homo sapiens matrix metal- MMP 14 l,91E-05 1,68308 lopeptidase 14 (membrane-inserted) (MMP
NM 004999 // RefSeq // Homo sapiens myosin VI MY06 5,62E-09 -2,15877 (MY06), mRNA. // chr6 // 100 // 97 // 31
NM 005060 // RefSeq // Homo sapiens RAR-related RORC 6.72E-07 -2,2321 orphan receptor C (RORC), transcript va
NM 005257 // RefSeq // Homo sapiens GATA bindGATA6 2,25E-07 -4,74869 ing protein 6 (GATA6), mRNA. // chrl8 // 1
NM 005261 // RefSeq // Homo sapiens GTP binding GEM 1.58E-05 2,01863 protein overexpressed in skeletal muscl
NM 005271 // RefSeq // Homo sapiens glutamate GLUD1 9,93E-07 1,57385 dehydrogenase 1 (GLUD1), nuclear gene enc
NM_005276 // RefSeq // Homo sapiens glycerol-3- GPD1 4,69E-06 -1,81233 phosphate dehydrogenase 1 (soluble) (GPD
NM 005349 // RefSeq // Homo sapiens recombination RBPJ 1.46E-05 1,56501 signal binding protein for immunoglob
NM 005429 // RefSeq // Homo sapiens vascular endoVEGFC 3,21E-06 2,75523 thelial growth factor C (VEGFC), mRNA.
NM 005445 // RefSeq // Homo sapiens structural SMC3 1.36E-05 1,73547 maintenance of chromosomes 3 (SMC3), mRN
NM 005472 // RefSeq // Homo sapiens potassium KCNE3 1.64E-06 -5,41251 voltage-gated channel, Isk-related family
NM 005486 // RefSeq // Homo sapiens target of TOM1L1 1.76E-05 -1,86045 mybl (chicken)-like 1 (TOM1L1), mRNA. //
NM_005550 // RefSeq // Homo sapiens kinesin family KIFC3 4,08E-07 1,80767 member C3 (KIFC3), transcript varian
NM 005573 // RefSeq // Homo sapiens lamin Bl LMNB1 3,09E-07 1,602 (LMNB1), transcript variant 1, mRNA. // ch
NM_005578 // RefSeq // Homo sapiens LIM domain LPP 4,17E-07 -1,65196 containing preferred translocation partn
NM 005724 // RefSeq // Homo sapiens tetraspanin 3 TSPAN3 3.10E-11 -2,17613 (TSPAN3), transcript variant 1 , mRNA.
NM 005727 // RefSeq // Homo sapiens tetraspanin 1 TSPAN1 8,67E-07 -3,00503 (TSPAN1), mRNA. // chrl // 100 // 71
NM_005732 // RefSeq // Homo sapiens RAD50 hom- RAD50 3,84E-06 1,58783 olog (S. cerevisiae) (RAD50), mRNA. // chr
NM 005733 // RefSeq // Homo sapiens kinesin family KIF20A 1.53E-07 1,72119 member 20A (KIF20A), mRNA. // chr5 /
NM 005746 // RefSeq // Homo sapiens nicotinamide NAMPT 2,29E-05 2,00349 phosphoribosyltransferase (NAMPT), mRN
NM 005764 // RefSeq // Homo sapiens PDZK1 interPDZK1IP 8,36E-07 -3,77744 acting protein 1 (PDZK1IP1), mRNA. // ch 1
NM 005767 // RefSeq // Homo sapiens lysophospha- LPAR6 3,24E-06 -1,82469 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change tidic acid receptor 6 (LPAR6), transcrip
NM 005780 // RefSeq // Homo sapiens lipoma LHFP 5,61E-06 1,54322 HMGIC fusion partner (LHFP), mRNA. // chrl3
NM 005865 // RefSeq // Homo sapiens protease, serPRSS16 l,36E-06 -1,60344 ine, 16 (thymus) (PRSS16), mRNA. // ch
NM_00 869 // RefSeq // Homo sapiens CWC27 CWC27 l,04E-05 1,75413 spliceosome-associated protein homo log (S. ce
NM_005967 // RefSeq // Homo sapiens NGFI-A bindNAB2 l,71E-05 1,71749 ing protein 2 (EGR1 binding protein 2) (
NM 005969 // RefSeq // Homo sapiens nucleosome NAP1L4 U5E-06 1,53719 assembly protein 1-like 4 (NAP1L4), mRNA
NM 005982 // RefSeq // Homo sapiens SIX ho- SIX1 3,40E-07 1,77984 meobox 1 (SIX1), mRNA. // chrl4 // 100 // 45
NM 006017 // RefSeq // Homo sapiens prominin 1 PROM1 7,29E-16 -14,3953 (PROM1), transcript variant 1, mRNA. //
NM 006083 // RefSeq // Homo sapiens IK cytokine, IK 6,35E-06 1,53955 down-regulator of HLA II (IK), mRNA. /
NM 006149 // RefSeq // Homo sapiens lectin, galac- LGALS4 l,69E-09 -12,2815 toside-binding, soluble, 4 (LGALS4), m
NM 006282 // RefSeq // Homo sapiens serSTK4 7,94E-06 1,6133 ine/threonine kinase 4 (STK4), mRNA. // chr20 //
NM 006397 // RefSeq // Homo sapiens ribonuclease RNASEH 2J8E-07 1,8307 H2, subunit A (RNASEH2A), mRNA. // chr 2A
NM 006442 // RefSeq // Homo sapiens DR1- DRAP1 l,98E-09 1,73334 associated protein 1 (negative cofactor 2 alpha
NM 006615 // RefSeq // Homo sapiens calpain 9 CAPN9 2,07E-05 -4,01722 (CAPN9), transcript variant 1 , mRNA. // c
NM 006633 // RefSeq // Homo sapiens IQ motif conIQGAP2 7,41E-10 -11,3352 taining GTPase activating protein 2 (IQ
NM 006738 // RefSeq // Homo sapiens A kinase AKAP13 l,57E-05 -1,65705 (PRKA) anchor protein 13 (AKAP13), transcr
NM 006769 // RefSeq // Homo sapiens LIM domain LM04 2,19E-05 -2,69509 only 4 (LM04), mRNA. // chrl // 100 // 6
NM 006809 // RefSeq // Homo sapiens translocase of TOMM34 3,00E-05 1,8995 outer mitochondrial membrane 34 (TOM
NM 006871 // RefSeq // Homo sapiens receptor- RIPK3 l,88E-05 -2,47697 interacting serine-threonine kinase 3 (RIP
NM 006887 // RefSeq // Homo sapiens zinc finger ZFP36L2 7.74E-07 -1,97496 protein 36, C3H type-like 2 (ZFP36L2),
NM_006895 // RefSeq // Homo sapiens histamine N- HNMT 3,00E-07 -3,01755 methyltransferase (HNMT), transcript va
NM 006930 // RefSeq // Homo sapiens S-phase ki- SKP1 3,46E-07 1,79509 nase-associated protein 1 (SKP1), transcr
NM 006933 // RefSeq // Homo sapiens solute carrier SLC5A3 U 1E-09 2,57353 family 5 (sodium/myo-inositol cotran Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 006951 // RefSeq // Homo sapiens TAF5 RNA TAF5 3,01E-06 1,7264 polymerase II, TATA box binding protein (T
NM 006999 // RefSeq // Homo sapiens PAP associatPAPD7 8,53E-09 1,79709 ed domain containing 7 (PAPD7), transcr
NM 007011 // RefSeq // Homo sapiens abhydrolase ABHD2 l,22E-07 -2,19797 domain containing 2 (ABHD2), transcript
NM 007103 // RefSeq // Homo sapiens NADH dehyNDUFV1 6,58E-08 1,51326 drogenase (ubiquinone) flavoprotein 1, 51k
NM 007129 // RefSeq // Homo sapiens Zic family ZIC2 2,40E-06 2,36547 member 2 (ZIC2), mRNA. // chrl3 // 100 /
NM 007173 // RefSeq // Homo sapiens protease, sePRSS23 l,35E-06 2,20939 rine, 23 (PRSS23), mRNA. // chrl 1 // 10
NM 007186 // RefSeq // Homo sapiens centrosomal CEP250 5,88E-09 1,96026 protein 250kDa (CEP250), mRNA. // chr20
NM 007195 // RefSeq // Homo sapiens polymerase POLI l,48E-05 2,05477 (DNA directed) iota (POLI), mRNA. // chr
NM 007213 // RefSeq // Homo sapiens PRAl domain PRAF2 6,40E-06 1,8937 family, member 2 (PRAF2), mRNA. // chrX
NM 007220 // RefSeq // Homo sapiens carbonic an- CA5B 2,03E-06 1,76794 hydrase VB, mitochondrial (CA5B), nuclea
NM 007223 // RefSeq // Homo sapiens G protein- GPR176 2,58E-07 2,32054 coupled receptor 176 (GPR176), mRNA. // c
NM 012112 // RefSeq // Homo sapiens TPX2, micro- TPX2 l,37E-05 1,62922 tubule-associated, homolog (Xenopus laev
NM 012120 // RefSeq // Homo sapiens CD2- CD2AP U8E-07 -1,53535 associated protein (CD2AP), mRNA. // chr6 // 10
NM 012177 // RefSeq // Homo sapiens F-box protein FBX05 l,48E-05 1,89663 5 (FBX05), transcript variant 1, mRNA
NM 012200 // RefSeq // Homo sapiens beta- 1,3- B3GAT3 U9E-09 1,55988 glucuronyltransferase 3 (glucuronosyltrans
NM 012238 // RefSeq // Homo sapiens sirtuin 1 SIRT1 8,30E-07 2,02532 (SIRT1), transcript variant 1, mRNA. // c
NM 012289 // RefSeq // Homo sapiens kelch-like KEAPl l,96E-06 1,52174 ECH-associated protein 1 (KEAPl), transc
NM 012291 // RefSeq // Homo sapiens extra spindle ESPL1 l,69E-06 1,56875 pole bodies homolog 1 (S. cerevisiae)
NM 012340 // RefSeq // Homo sapiens nuclear factor NFATC2 2,94E-06 -1,82662 of activated T-cells, cytoplasmic, c
NM_012454 // RefSeq // Homo sapiens T-cell lymTIAM2 l,09E-07 -2,32022 phoma invasion and metastasis 2 (TIAM2),
NM 013230 // RefSeq // Homo sapiens CD24 moleCD24 8,43E-09 -10,0061 cule (CD24), mRNA. // chrY // 68 // 100 //
NM 013337 // RefSeq // Homo sapiens translocase of TIMM22 1J2E-05 1,71899 inner mitochondrial membrane 22 homo
NM_013389 // RefSeq // Homo sapiens NPC1 (Nie- NPC1L1 3,07E-18 -10,3772 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change mann-Pick disease, type CI, gene)-like 1 (
NM 013390 // RefSeq // Homo sapiens transmemTMEM2 1,33E-10 -4,63651 brane protein 2 (TMEM2), transcript variant
NM 013402 // RefSeq // Homo sapiens fatty acid de- FADS1 l,26E-05 1,66257 saturase 1 (FADS1), mRNA. // chrl l //
NM_013437 // RefSeq // Homo sapiens low density LRP12 6,94E-08 3,00003 lipoprotein receptor-related protein 12
NM_013451 // RefSeq // Homo sapiens myoferlin MYOF 3,39E-06 1,73353 (MYOF), transcript variant 1, mRNA. // ch
NM 014035 // RefSeq // Homo sapiens sorting nexin SNX24 5,84E-06 1,79881 24 (SNX24), mRNA. // chr5 // 100 // 3
NM 014226 // RefSeq // Homo sapiens MOK protein MOK l,31E-06 2,08795 kinase (MOK), mRNA. // chrl4 // 100 //
NM 014241 // RefSeq // Homo sapiens protein tyroPTPLA U8E-08 4,17505 sine phosphatase-like (proline instead
NM 014312 // RefSeq // Homo sapiens V-set and VSIG2 2,28E-08 -4,2413 immunoglobulin domain containing 2 (VSIG2
NM 014326 // RefSeq // Homo sapiens death- DAPK2 3,02E-06 -2,27857 associated protein kinase 2 (DAPK2), mRNA. //
NM 014344 // RefSeq // Homo sapiens four jointed FJX1 l,35E-07 4,3145 box 1 (Drosophila) (FJX1), mRNA. // ch
NM 014373 // RefSeq // Homo sapiens G protein- GPR160 2,35E-06 -2,82018 coupled receptor 160 (GPR160), mRNA. // c
NM 014391 // RefSeq // Homo sapiens ankyrin repeat ANKRD 1 2,66E-06 3,95638 domain 1 (cardiac muscle) (ANKRD 1 ),
NM 014394 // RefSeq // Homo sapiens growth horGHITM 1.77E-07 1,54607 mone inducible transmembrane protein (GHI
NM 014470 // RefSeq // Homo sapiens Rho family RNDl 1J0E-05 -1,70826 GTPase 1 (RND1), mRNA. // chrl2 // 100 /
NM 014473 // RefSeq // Homo sapiens DIM1 di- DIMT1 6,66E-06 1,8146 methyladenosine transferase 1 homolog (S. ce
NM 014553 // RefSeq // Homo sapiens transcription TFCP2L1 l,03E-08 -3,83608 factor CP2-like 1 (TFCP2L1), mRNA. //
NM 014639 // RefSeq // Homo sapiens tetratricopep- TTC37 3J2E-06 1,6999 tide repeat domain 37 (TTC37), mRNA. /
NM 014669 // RefSeq // Homo sapiens nucleoporin NUP93 2,55E-05 1,64157 93kDa (NUP93), transcript variant 1, mR
NM 014698 // RefSeq // Homo sapiens transmemTMEM63 1J6E-06 -2,15003 brane protein 63A (TMEM63A), mRNA. // chrl A
NM 014755 // RefSeq // Homo sapiens SERTA doSERTAD2 6J4E-08 2,02911 main containing 2 (SERTAD2), mRNA. // chr2
NM 014801 // RefSeq // Homo sapiens pecanex-like 2 PCNXL2 3,16E-07 -2,62205 (Drosophila) (PCNXL2), mRNA. // chrl
NM 014808 // RefSeq // Homo sapiens FERM, FARP2 3J0E-07 -1,55286 RhoGEF and pleckstrin domain protein 2 (FARP2 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 014819 // RefSeq // Homo sapiens praja ring finPJA2 3,45E-11 1,80215 ger 2, E3 ubiquitin protein ligase (P
NM 014824 // RefSeq // Homo sapiens FCH and FCHSD2 2,55E-08 2,06135 double SH3 domains 2 (FCHSD2), mRNA. // chr
NM_014829 // RefSeq // Homo sapiens DEAD (Asp- DDX46 1.57E-10 1,62102 Glu-Ala-Asp) box polypeptide 46 (DDX46),
NM 014840 // RefSeq // Homo sapiens NUAK famiNUAK1 5,87E-07 2,11629 ly, SNFl-like kinase, 1 (NUAK1), mRNA. //
NM 014861 // RefSeq // Homo sapiens ATPase, ATP2C2 3,96E-07 -3,56944 Ca++ transporting, type 2C, member 2 (ATP2C
NM_014874 // RefSeq // Homo sapiens mitofusin 2 MFN2 2,44E-05 1,6586 (MFN2), nuclear gene encoding mitochond
NM_014935 // RefSeq // Homo sapiens pleckstrin PLEK- U3E-05 -2,79537 homology domain containing, family A mem HA6
NM 014982 // RefSeq // Homo sapiens pecanex ho- PCNX 5,56E-06 1,58249 molog (Drosophila) (PCNX), mRNA. // chrl4
NM 015018 // RefSeq // Homo sapiens dopey family DOPEY 1 l,37E-05 -1,63396 member 1 (DOPEY 1), transcript variant
NM_015027 // RefSeq // Homo sapiens pyridoxal- PDXDC1 2,38E-07 -1,50753 dependent decarboxylase domain containing
NM 015041 // RefSeq // Homo sapiens clusterin assoCLUAP1 l,80E-08 1,85354 ciated protein 1 (CLUAP1), transcript
NM 015179 // RefSeq // Homo sapiens ribosomal RRP12 l,66E-05 1,65573 RNA processing 12 homolog (S. cerevisiae)
NM 015187 // RefSeq // Homo sapiens sel-1 suppresSEL1L3 2,19E-05 -3,25169 sor of lin-12-like 3 (C. elegans) (SEL
NM 01 198 // RefSeq // Homo sapiens cordon-bleu COBL 8,52E-07 -2,38065 homolog (mouse) (COBL), mRNA. // chr7 /
NM 015261 // RefSeq // Homo sapiens non-SMC NCAPD3 l,68E-05 1,60627 condensin II complex, subunit D3 (NCAPD3),
NM 015265 // RefSeq // Homo sapiens SATB ho- SATB2 7,52E-07 1,87255 meobox 2 (SATB2), transcript variant 2, mRNA
NM 015279 // RefSeq // Homo sapiens TBCl domain TBC1D30 U 1E-08 -2,71759 family, member 30 (TBC1D30), mRNA. // c
NM 015342 // RefSeq // Homo sapiens peptidylprolyl PPWD1 7,10E-06 1,55324 isomerase domain and WD repeat conta
NM 015465 // RefSeq // Homo sapiens gem (nuclear GEMIN5 2,65E-05 1,82836 organelle) associated protein 5 (GEMIN
NM 015523 // RefSeq // Homo sapiens REX2, RNA REX02 5,69E-06 1,83576 exonuclease 2 homolog (S. cerevisiae) (RE
NM 015675 // RefSeq // Homo sapiens growth arrest GADD45 6,24E-08 2,82559 and DNA-damage-inducible, beta (GADD4 B
NM 015714 // RefSeq // Homo sapiens G0/G 1 switch G0S2 l,84E-05 2,47245 2 (G0S2), mRNA. // chrl // 100 // 100 /
NM 015831 // RefSeq // Homo sapiens acetylcho- ACHE 4J4E-07 -2,30919 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change linesterase (ACHE), transcript variant E4-
NM 015873 // RefSeq // Homo sapiens villin-like VILL U5E-07 -3,1407 (VILL), mRNA. // chr3 // 100 // 65 // 1
NM 015942 // RefSeq // Homo sapiens MTERF doMTERFD 2,80E-07 1,51271 main containing 1 (MTERFD1), nuclear gene e 1
NM 01 960 // RefSeq // Homo sapiens cutC copper CUTC 3,69E-07 1,75155 transporter homolog (E. coli) (CUTC), m
NM 016010 // RefSeq // Homo sapiens zinc finger, ZC2HC1A 6,63E-07 1,84085 C2HC-type containing 1A (ZC2HC1A), mRN
NM 016032 // RefSeq // Homo sapiens zinc finger, ZDHHC9 l,92E-05 -1,53184 DHHC-type containing 9 (ZDHHC9), trans
NM 016218 // RefSeq // Homo sapiens polymerase POLK 6,87E-06 1,5116 (DNA directed) kappa (POLK), mRNA. // ch
NM 016240 // RefSeq // Homo sapiens scavenger SCARA3 l,29E-06 2,75506 receptor class A, member 3 (SCARA3), tran
NM 016277 // RefSeq // Homo sapiens RAB23, RAB23 2,87E-05 2,19716 member RAS oncogene family (RAB23), transcri
NM 016283 // RefSeq // Homo sapiens TAF9 RNA TAF9 2,42E-07 1,69866 polymerase II, TATA box binding protein (T
NM 016308 // RefSeq // Homo sapiens cytidine moCMPK1 1J4E-05 -1,53193 nophosphate (UMP-CMP) kinase 1, cytosoli
NM 016356 // RefSeq // Homo sapiens doublecortin DCDC2 l,67E-07 -4,51992 domain containing 2 (DCDC2), transcrip
NM_016361 // RefSeq // Homo sapiens acid phosphaACP6 l,94E-06 -1,85025 tase 6, lysophosphatidic (ACP6), mRNA.
NM 016441 // RefSeq // Homo sapiens cysteine rich CRIM1 l,47E-05 1,58447 transmembrane BMP regulator 1 (chordi
NM 016657 // RefSeq // Homo sapiens KDEL (Lys- KDELR3 l,44E-05 -2,03177 Asp-Glu-Leu) endoplasmic reticulum protei
NM 017420 // RefSeq // Homo sapiens SIX ho- SIX4 3,46E-07 2,29441 meobox 4 (SIX4), mRNA. // chrl4 // 100 // 67
NM 017640 // RefSeq // Homo sapiens leucine rich LRRC16A 2,35E-07 -3,77497 repeat containing 16A (LRRC16A), trans
NM 017688 // RefSeq // Homo sapiens B-box and BSPRY 6J6E-06 -1,95831 SPRY domain containing (BSPRY), mRNA. //
NM_017708 // RefSeq // Homo sapiens family with FAM83E 3,92E-09 -2,24897 sequence similarity 83, member E (FAM83
NM 017712 // RefSeq // Homo sapiens pyroglutamyl- PGPEP1 8,l lE-06 -2,26798 peptidase I (PGPEP1), mRNA. // chrl9 /
NM_017752 // RefSeq // Homo sapiens TBCl domain TBC1D8B 4,81E-07 -2,5223 family, member 8B (with GRAM domain) (T
NM_017755 // RefSeq // Homo sapiens NOP2/Sun NSUN2 2,61E-05 1,50241 RNA methyltransferase family, member 2 (NS
NM 017816 // RefSeq // Homo sapiens Lyl antibody LYAR U5E-08 2,74029 reactive homolog (mouse) (LYAR), trans Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 017824 // RefSeq // Homo sapiens membrane- MARCH5 1.07E-06 1,58164 associated ring finger (C3HC4) 5 (MARCH5),
NM_017848 // RefSeq // Homo sapiens family with FAM120C 1.59E-05 1,64572 sequence similarity 120C (FAM120C), tra
NM O 17893 // RefSeq // Homo sapiens sema domain, SEMA4G 1.24E-06 -3,82476 immunoglobulin domain (Ig), transmembr
NM O 17987 // RefSeq // Homo sapiens RUN and RUFY2 9,92E-07 1,59015 FYVE domain containing 2 (RUFY2), transcrip
NM 018120 // RefSeq // Homo sapiens armadillo reARMC1 2,89E-06 1,50314 peat containing 1 (ARMC1), mRNA. // chr
NM_018121 // RefSeq // Homo sapiens family with FAM178A 5,42E-10 1,63729 sequence similarity 178, member A (FAM1
NM O 18131 // RefSeq // Homo sapiens centrosomal CEP55 2,15E-06 2,29507 protein 55kDa (CEP55), transcript varia
NM_018178 // RefSeq // Homo sapiens golgi phos- GOLPH3 5,58E-08 -1,71613 phoprotein 3 -like (GOLPH3L), mRNA. // chr L
NM 018226 // RefSeq // Homo sapiens arginyl ami- RNPEPL1 4,58E-10 -1,58752 nopeptidase (aminopeptidase B)-like 1 (R
NM 018240 // RefSeq // Homo sapiens kin of IRRE KIRREL 1.79E-06 2,74686 like (Drosophila) (KIRREL), mRNA. // ch
NM 018268 // RefSeq // Homo sapiens WD repeat WDR41 2,86E-06 1,54487 domain 41 (WDR41), mRNA. // chr5 // 100 /
NM O 18270 // RefSeq // Homo sapiens chromosome C20orf20 2,04E-06 1,76087 20 open reading frame 20 (C20orf20), mRN
NM O 18288 // RefSeq // Homo sapiens PHD finger PHF10 5,27E-06 1,72185 protein 10 (PHF10), transcript variant 1
NM 018290 // RefSeq // Homo sapiens phosphoglu- PGM2 2,48E-05 1,59095 comutase 2 (PGM2), mRNA. // chr4 // 100 /
NM O 18302 // RefSeq // Homo sapiens chromosome C4orfl9 3.79E-06 -3,1795 4 open reading frame 19 (C4orfl9), trans
NM O 18303 // RefSeq // Homo sapiens exocyst comEXOC2 2,80E-05 1,56773 plex component 2 (EXOC2), mRNA. // chr6
NM 018319 // RefSeq // Homo sapiens tyrosyl-DNA TDP1 4,16E-08 1,61671 phosphodiesterase 1 (TDP1), transcript
NM O 18343 // RefSeq // Homo sapiens RIO kinase 2 RIOK2 4,34E-09 1,94851 (yeast) (RIOK2), transcript variant 1,
NM O 18397 // RefSeq // Homo sapiens choline dehyCHDH 9.72E-06 -2,38333 drogenase (CHDH), nuclear gene encoding
NM O 18409 // RefSeq // Homo sapiens LRP2 binding LRP2BP 7,40E-06 1,55085 protein (LRP2BP), mRNA. // chr4 // 100
NM_018429 // RefSeq // Homo sapiens B double BDP1 4,88E-10 1,634 prime 1 , subunit of RNA polymerase III tra
NM 018456 // RefSeq // Homo sapiens ELL associatEAF2 1.94E-06 -2,25283 ed factor 2 (EAF2), mRNA. // chr3 // 10
NM O 18651 // RefSeq // Homo sapiens zinc finger ZNF167 2,44E-05 -1,73535 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change protein 167 (ZNF 167), transcript varian
NM O 18842 // RefSeq // Homo sapiens BAI1- BAIAP2L l,50E-05 -2,70286 associated protein 2-like 1 (BAIAP2L1), mRNA. 1
NM O 18964 // RefSeq // Homo sapiens solute carrier SLC37A1 2,09E-05 -2,19597 family 37 (glycerol-3-phosphate tran
NM 018976 // RefSeq // Homo sapiens solute carrier SLC38A2 6,35E-11 2,11953 family 38, member 2 (SLC38A2), mRNA.
NM O 18984 // RefSeq // Homo sapiens slingshot hoSSH1 l,04E-06 1,70245 mo log 1 (Drosophila) (SSH1), transcript
NM O 18989 // RefSeq // Homo sapiens RNA binding RBM27 6,36E-09 1,53409 motif protein 27 (RBM27), mRNA. // chr5
NM_018999 // RefSeq // Homo sapiens family with FAM190B 2,54E-08 2,05467 sequence similarity 190, member B (FAM1
NM 019030 // RefSeq // Homo sapiens DEAH (Asp- DHX29 3,32E-07 1,8447 Glu-Ala-His) box polypeptide 29 (DHX29),
NM O 19072 // RefSeq // Homo sapiens small gluta- SGTB l,96E-05 2,70842 mine-ricfi tetratricopeptide repeat (TPR)
NM O 19859 // RefSeq // Homo sapiens 5- HTR7 U5E-05 2,20274 hydroxytryptamine (serotonin) receptor 7, adenyla
NM 020117 // RefSeq // Homo sapiens leucyl-tRNA LARS 3,63E-06 1,91859 synthetase (LARS), mRNA. // chr5 // 100
NM 020208 // RefSeq // Homo sapiens solute carrier SLC6A20 3J8E-14 -6,2697 family 6 (proline ΙΜΓΝΟ transporter)
NM 020340 // RefSeq // Homo sapiens KIAA1244 KIAA124 l,34E-06 -2,24402 (KIAA1244), mRNA. // chr6 // 100 // 100 // 4
NM 020343 // RefSeq // Homo sapiens Ral GTPase RALGA- 2,29E-05 -2,4487 activating protein, alpha subunit 2 (cat PA2
NM 020453 // RefSeq // Homo sapiens ATPase, class ATP10D 1J3E-07 2,49698 V, type 10D (ATP10D), mRNA. // chr4 /
NM 020529 // RefSeq // Homo sapiens nuclear factor NFKBIA 8,81E-06 1,76041 of kappa light polypeptide gene enha
NM 020722 // RefSeq // Homo sapiens KIAA1211 KIAA121 l,83E-09 -2,59744 (KIAA1211), mRNA. // chr4 // 100 // 74 // 1
NM 020726 // RefSeq // Homo sapiens neurolysin NLN 2,99E-05 1,79955 (metallopeptidase M3 family) (NLN), nucl
NM 020770 // RefSeq // Homo sapiens cingulin CGN l,08E-05 -2,87225 (CGN), mRNA. // chrl // 100 // 79 // 15 //
NM_020773 // RefSeq // Homo sapiens TBCl domain TBC1D14 7,69E-07 1,61063 family, member 14 (TBC1D14), transcript
NM 020801 // RefSeq // Homo sapiens arrestin doARRDC3 4J1E-07 2,20374 main containing 3 (ARRDC3), mRNA. // chr
NM 020859 // RefSeq // Homo sapiens shroom family SHROOM 2,94E-08 -3,96414 member 3 (SHROOM3), mRNA. // chr4 // 3
NM 020873 // RefSeq // Homo sapiens leucine rich LRRNl U7E-05 -3,09541 repeat neuronal 1 (LRRNl), mRNA. // ch Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 020886 // RefSeq // Homo sapiens ubiquitin speUSP28 9,84E-06 1,71757 cific peptidase 28 (USP28), mRNA. // c
NM 021200 // RefSeq // Homo sapiens pleckstrin PLEKHB1 9,82E-06 -1,71345 homology domain containing, family B (ev
NM_021214 // RefSeq // Homo sapiens family with FAM108C l,02E-05 -2,18379 sequence similarity 108, member CI (FAM 1
NM 021947 // RefSeq // Homo sapiens serine race- SRR 9,89E-08 2,02806 mase (SRR), mRNA. // chrl7 // 100 // 100
NM 021999 // RefSeq // Homo sapiens integral memITM2B l,44E-05 -1,5076 brane protein 2B (ITM2B), mRNA. // chrl
NM 022145 // RefSeq // Homo sapiens centromere CENPK l,55E-05 1,89702 protein K (CENPK), transcript variant 1 ,
NM 022346 // RefSeq // Homo sapiens non-SMC NCAPG l,62E-08 2,18889 condensin I complex, subunit G (NCAPG), mRN
NM 022449 // RefSeq // Homo sapiens RAB17, RAB17 8,42E-06 -1,80027 member RAS oncogene family (RAB17), transcri
NM_022481 // RefSeq // Homo sapiens ArfGAP with ARAP3 2,20E-06 1,77549 RhoGAP domain, ankyrin repeat and PH do
NM_022825 // RefSeq // Homo sapiens porcupine PORCN 3,48E-06 1,81584 homo log (Drosophila) (PORCN), transcript
NM 022909 // RefSeq // Homo sapiens centromere CENPH 5J4E-08 2,64595 protein H (CENPH), mRNA. // chr5 // 100
NM 022970 // RefSeq // Homo sapiens fibroblast FGFR2 l,07E-06 -3,05461 growth factor receptor 2 (FGFR2), transc
NM 024092 // RefSeq // Homo sapiens transmemTMEM10 l,08E-07 1,95659 brane protein 109 (TMEM109), mRNA. // chrl 1 9
NM 024101 // RefSeq // Homo sapiens melanophilin MLPH l,50E-05 -2,76966 (MLPH), transcript variant 1 , mRNA. //
NM 024306 // RefSeq // Homo sapiens fatty acid 2- FA2H l,04E-05 -3,1323 hydroxylase (FA2H), mRNA. // chrl 6 //
NM 024320 // RefSeq // Homo sapiens proline rich PRR15L U7E-07 -5,5807 15-like (PRR15L), mRNA. // chrl7 // 10
NM 024420 // RefSeq // Homo sapiens phospholipase PLA2G4A 2,07E-08 -3,367 A2, group IVA (cytosolic, calcium-dep
NM 024539 // RefSeq // Homo sapiens ring finger RNF128 l,50E-07 -4,2009 protein 128, E3 ubiquitin protein ligas
NM_024576 // RefSeq // Homo sapiens opioid growth OGFRLl 6,24E-06 2,03059 factor receptor-like 1 (OGFRLl), mRNA
NM_024577 // RefSeq // Homo sapiens SH3 domain SH3TC2 6,82E-06 1,9706 and tetratricopeptide repeats 2 (SH3TC2)
NM 024608 // RefSeq // Homo sapiens nei endonu- NEIL1 l,56E-07 -2,12245 clease VHI-like 1 (E. coli) (NEIL1), tra
NM_024628 // RefSeq // Homo sapiens solute carrier SLC12A8 U9E-06 -1,75792 family 12 (potassium/chloride transp
NM 024642 // RefSeq // Homo sapiens UDP-N- GALNT12 3,20E-06 -3,80907 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change acetyl-alpha-D-galactosamine:polypeptide N-ac
NM 024712 // RefSeq // Homo sapiens engulfment ELM03 2,17E-05 -1,62831 and cell motility 3 (ELM03), mRNA. // ch
NM 024727 // RefSeq // Homo sapiens leucine rich LRRC31 2,12E-05 -3,81382 repeat containing 31 (LRRC31), mRNA. /
NM 024754 // RefSeq // Homo sapiens pentatricopep- PTCD2 l,69E-06 1,81064 tide repeat domain 2 (PTCD2), mRNA. //
NM 024756 // RefSeq // Homo sapiens multimerin 2 MMRN2 5,36E-06 1,59057 (MMRN2), mRNA. // chrlO // 100 // 57 /
NM 024790 // RefSeq // Homo sapiens centrosome CSPP1 2J7E-05 1,6024 and spindle pole associated protein 1 (C
NM 024795 // RefSeq // Homo sapiens transmemTM4SF20 4J8E-08 -13,9678 brane 4 L six family member 20 (TM4SF20), m
NM 024834 // RefSeq // Homo sapiens minichromo- MCMBP 3,57E-06 1,77466 some maintenance complex binding protein
NM 024921 // RefSeq // Homo sapiens premature POF1B 6,45E-06 -5,26964 ovarian failure, IB (POF1B), mRNA. // chr
NM 024936 // RefSeq // Homo sapiens zinc finger, ZCCHC4 l,01E-05 1,548 CCHC domain containing 4 (ZCCHC4), mRN
NM_024954 // RefSeq // Homo sapiens ubiquitin doUBTD1 l,25E-08 1,67307 main containing 1 (UBTD1), mRNA. // chr
NM 02 004 // RefSeq // Homo sapiens coiled-coil CCDC15 U7E-06 2,41792 domain containing 15 (CCDC15), mRNA. //
NM 025106 // RefSeq // Homo sapiens SPSB1 3,18E-06 1,7784 splA/ryanodine receptor domain and SOCS box contain
NM 025132 // RefSeq // Homo sapiens WD repeat WDR19 7,52E-06 2,35118 domain 19 (WDR19), mRNA. // chr4 // 100 /
NM 02 164 // RefSeq // Homo sapiens SIK family SIK3 2,05E-05 1,5795 kinase 3 (SIK3), mRNA. // chrl 1 // 100 /
NM 025245 // RefSeq // Homo sapiens pre-B-cell PBX4 4,16E-06 1,59466 leukemia homeobox 4 (PBX4), transcript v
NM 030622 // RefSeq // Homo sapiens cytochrome CYP2S1 U7E-05 -4,58802 P450, family 2, subfamily S, polypeptide
NM 030628 // RefSeq // Homo sapiens integrator INTS5 3,61E-08 1,52049 complex subunit 5 (INTS5), mRNA. // chrl
NM 030630 // RefSeq // Homo sapiens chromosome C17orf28 4,89E-12 -5,3555 17 open reading frame 28 (C17orf28), mRN
NM 030751 // RefSeq // Homo sapiens zinc fmger E- ZEB1 l,20E-05 3,43139 box binding homeobox 1 (ZEB1), transc
NM_030767 // RefSeq // Homo sapiens AT-hook tranAKNA 2,96E-06 -1,50389 scription factor (AKNA), mRNA. // chr9
NM 030783 // RefSeq // Homo sapiens phosphatidyl- PTDSS2 6,59E-09 1,67521 serine synthase 2 (PTDSS2), mRNA. // ch
NM_030919 // RefSeq // Homo sapiens family with FAM83D l,30E-05 1,69234 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change sequence similarity 83, member D (FAM83
NM 030926 // RefSeq // Homo sapiens integral memITM2C 2,54E-08 -2,17254 brane protein 2C (ITM2C), transcript va
NM 030964 // RefSeq // Homo sapiens sprouty homo- SPRY4 l,92E-05 1,83423 log 4 (Drosophila) (SPRY4), transcript
NM 031212 // RefSeq // Homo sapiens solute carrier SLC25A2 1J8E-05 1,67648 family 25 (mitochondrial iron transp 8
NM 031217 // RefSeq // Homo sapiens kinesin family KIF18A 2,64E-08 2,08959 member 18A (KIF18A), mRNA. // chrl 1
NM 031302 // RefSeq // Homo sapiens glycosyltrans- GLT8D2 4,68E-06 3,41962 ferase 8 domain containing 2 (GLT8D2),
NM 031415 // RefSeq // Homo sapiens gasdermin C GSDMC 2,15E-05 6,33453 (GSDMC), mRNA. // chr8 // 100 // 86 //
NM 031419 // RefSeq // Homo sapiens nuclear factor NFKBIZ UOE-05 -2,14027 of kappa light polypeptide gene enha
NM 031439 // RefSeq // Homo sapiens SRY (sex deSOX7 3,13E-08 2,17199 termining region Y)-box 7 (SOX7), mRNA.
NM 0314 7 // RefSeq // Homo sapiens membrane- MS4A8B 5,01E-06 -3,62687 spanning 4-domains, subfamily A, member 8B
NM_031463 // RefSeq // Homo sapiens hydroxyste- HSDL1 2,24E-07 1,93101 roid dehydrogenase like 1 (HSDL1), transc
NM 031469 // RefSeq // Homo sapiens SH3 domain SH3BGR 2,54E-06 -3,87722 binding glutamic acid-rich protein like L2
NM 031966 // RefSeq // Homo sapiens cyclin B 1 CCNB1 U3E-08 2,1201 (CCNB1), mRNA. // chr5 // 100 // 85 // 17
NM_032042 // RefSeq // Homo sapiens family with FAM172A 2,47E-08 1,53397 sequence similarity 172, member A (FAM1
NM 032175 // RefSeq // Homo sapiens UTP15, U3 UTP15 l,09E-06 1,72995 small nucleolar ribonucleoprotein, homolo
NM 032208 // RefSeq // Homo sapiens anthrax toxin ANTXRl 4,13E-07 3,60105 receptor 1 (ANTXR1), transcript varia
NM 032898 // RefSeq // Homo sapiens centrosomal CEP 19 7,28E-07 1,54008 protein 19kDa (CEP 19), mRNA. // chr3 //
NM 033049 // RefSeq // Homo sapiens mucin 13, cell MUC13 3,33E-08 -18,5751 surface associated (MUC13), mRNA. //
NM 033102 // RefSeq // Homo sapiens solute carrier SLC45A3 7J2E-07 -2,37482 family 45, member 3 (SLC4 A3), mRNA.
NM 033103 // RefSeq // Homo sapiens rhophilin, Rho RHPN2 1,02E-10 -3,25777 GTPase binding protein 2 (RHPN2), mR
NM 033266 // RefSeq // Homo sapiens endoplasmic ERN2 5,59E-06 -4,31539 reticulum to nucleus signaling 2 (ERN2)
NM 033386 // RefSeq // Homo sapiens MICAL-like 1 MICALL1 7,37E-07 1,64994 (MICALL1), mRNA. // chr22 // 100 // 85
NM_033421 // RefSeq // Homo sapiens sorting nexin SNX21 2J4E-05 1,58739 family member 21 (SNX21), transcript Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 033498 // RefSeq // Homo sapiens hexokinase 1 HK1 U6E-05 1,87167 (HK1), nuclear gene encoding mitochond
NM 052950 // RefSeq // Homo sapiens WD repeat WDFY2 3,51E-08 2,25194 and FYVE domain containing 2 (WDFY2), mRN
NM_052966 // RefSeq // Homo sapiens family with FAM129A 2,64E-05 2,4835 sequence similarity 129, member A (FAM1
NM 058165 // RefSeq // Homo sapiens monoacyl- MOGAT1 U8E-07 -4,14775 glycerol O-acyltransferase 1 (MOGAT1), mRNA
NM_058237 // RefSeq // Homo sapiens protein phosPPP4R4 6,13E-06 2,69477 phatase 4, regulatory subunit 4 (PPP4R4
NM 080489 // RefSeq // Homo sapiens syndecan binSDCBP2 4,40E-07 -2,35397 ding protein (syntenin) 2 (SDCBP2), tra
NM_080656 // RefSeq // Homo sapiens CDKN2A CDKN2AI l,92E-07 1,79298 interacting protein N-terminal like (CDKN2AI PNL
NM_133372 // RefSeq // Homo sapiens folliculin inteFNIP1 3,56E-08 1,7533 racting protein 1 (FNIP1), transcrip
NM 133447 // RefSeq // Homo sapiens ankyrin repeat AGAP11 2,43E-08 2,62118 and GTPase domain Arf GTPase activat
NM 133637 // RefSeq // Homo sapiens DEAQ box DQX1 2,98E-05 -3,15917 RNA-dependent ATPase 1 (DQX1), mRNA. // ch
NMJ38333 // RefSeq // Homo sapiens family with FAM122A 7,29E-07 -1,51479 sequence similarity 122A (FAM122A), mRN
NM 138370 // RefSeq // Homo sapiens protein kinase PKDCC l,61E-09 -3,33428 domain containing, cytoplasmic homol
NM_138383 // RefSeq // Homo sapiens metastasis MTSS1L 3,48E-06 2,34633 suppressor 1-like (MTSS1L), mRNA. // chr
NM 138409 // RefSeq // Homo sapiens melanocortin MRAP2 2,31E-05 -3,30067 2 receptor accessory protein 2 (MRAP2)
NM 138424 // RefSeq // Homo sapiens kinesin family KIF12 l,53E-06 -1,95439 member 12 (KIF12), mRNA. // chr9 //
NM_138694 // RefSeq // Homo sapiens polycystic PKHD1 l,42E-05 -3,1775 kidney and hepatic disease 1 (autosomal
NM 138962 // RefSeq // Homo sapiens musashi ho- MSI2 9,15E-06 -2,292 molog 2 (Drosophila) (MSI2), transcript v
NM 139053 // RefSeq // Homo sapiens EPS8-like 3 EPS8L3 2,06E-07 -5,96732 (EPS8L3), transcript variant 1, mRNA. /
NM 139241 // RefSeq // Homo sapiens FYVE, FGD4 l,50E-05 -3,20747 RhoGEF and PH domain containing 4 (FGD4), mRN
NM 144626 // RefSeq // Homo sapiens transmemTMEM12 l,91E-09 -1,77259 brane protein 125 (TMEM125), mRNA. // chrl 5
NM 144632 // RefSeq // Homo sapiens transmemTMEM18 3,69E-06 -1,57896 brane protein 182 (TMEM182), mRNA. // chr2 2
NM 144633 // RefSeq // Homo sapiens potassium KCNH8 l,14E-05 -4,08341 voltage-gated channel, subfamily H (eag-r
NM_ 144691 // RefSeq // Homo sapiens calpain 12 CAPN12 9,60E-08 -1,76735 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
(CAPN12), mRNA. // chrl9 // 100 // 100 /
NM 144717 // RefSeq // Homo sapiens interleukin 20 IL20RB 9,68E-06 3,15609 receptor beta (IL20RB), mRNA. // chr
NM 145051 // RefSeq // Homo sapiens ring finger RNF183 5,47E-08 -2,08144 protein 183 (RNF183), mRNA. // chr9 //
NM 14 168 // RefSeq // Homo sapiens short chain SDR42E1 U3E-05 -1,60021 dehydrogenase/reductase family 42E, mem
NM 145246 // RefSeq // Homo sapiens fragile site, FRA10AC l,46E-05 1,63614 folic acid type, rare, fra(10)(q23.3) 1
NM 145291 // RefSeq // Homo sapiens zinc finger ZBTB49 3,59E-09 1,72442 and BTB domain containing 49 (ZBTB49),
NM 145798 // RefSeq // Homo sapiens oxysterol OSBPL7 7,80E-08 -2,63201 binding protein-like 7 (OSBPL7), mRNA. //
NM 145865 // RefSeq // Homo sapiens ankyrin repeat ANKS4B 4,67E-06 -3,31564 and sterile alpha motif domain conta
NM l 52309 // RefSeq // Homo sapiens phosphoinosi- PIK3AP1 l,13E-08 -3,16626 tide-3 -kinase adaptor protein 1 (PIK3AP
NM 152406 // RefSeq // Homo sapiens actin filament AFAP1L1 4,90E-06 2,48081 associated protein 1-like 1 (AFAP1L1
NM 152407 // RefSeq // Homo sapiens GrpE-like 2, GRPEL2 3,64E-07 1,73853 mitochondrial (E. coli) (GRPEL2), nucl
NM 152546 // RefSeq // Homo sapiens serum reSRFBP1 8,49E-07 1,57634 sponse factor binding protein 1 (SRFBP1), m
NM 152599 // RefSeq // Homo sapiens major facilitaMFSD6L U0E-06 -1,51532 tor superfamily domain containing 6-1
NM 152624 // RefSeq // Homo sapiens DCP2 decap- DCP2 U8E-09 1,59207 ping enzyme homolog (S. cerevisiae) (DCP2
NM 152701 // RefSeq // Homo sapiens ATP-binding ABCA13 l,54E-05 -2,9658 cassette, sub-family A (ABC 1), member 1
NM 152716 // RefSeq // Homo sapiens protein assoPATL1 3,39E-09 1,54271 ciated with topoisomerase II homolog 1
NM_153223 // RefSeq // Homo sapiens centrosomal CEP 120 3,35E-09 1,85572 protein 120kDa (CEP 120), transcript var
NM 153229 // RefSeq // Homo sapiens transmemTMEM92 8,93E-06 -2,16814 brane protein 92 (TMEM92), transcript varia
NM 153246 // RefSeq // Homo sapiens chromosome C6orf223 6,92E-07 -1,94305 6 open reading frame 223 (C6orf223), tra
NM 153354 // RefSeq // Homo sapiens transmemTMEM16 l,38E-07 1,57601 brane protein 161B (TMEM161B), mRNA. // chr IB
NM l 53676 // RefSeq // Homo sapiens Usher synUSH1C 3,88E-06 -4,27153 drome 1C (autosomal recessive, severe) (US
NM 153704 // RefSeq // Homo sapiens transmemTMEM67 2,64E-05 1,82612 brane protein 67 (TMEM67), transcript varia
NM 153705 // RefSeq // Homo sapiens DEL (Lys- KDELC2 2,23E-05 1,92081 Asp-Glu-Leu) containing 2 (KDELC2), mRNA. Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 153811 // RefSeq // Homo sapiens solute carrier SLC38A6 1.64E-09 1,93536 family 38, member 6 (SLC38A6), trans
NM_170739 // RefSeq // Homo sapiens mitochondrial MRPL11 2,54E-05 1,53304 ribosomal protein LI 1 (MRPL11), nucle
NM_172069 // RefSeq // Homo sapiens pleckstrin PLEKHH 2,90E-06 -3,63821 homology domain containing, family H (wi 2
NM 172089 // RefSeq // Homo sapiens TNFSF 12- TNFSF 12- 9,22E-07 -1,94812 TNFSF13 readthrough (TNFSF 12-TNFSF 13), mRNA TNFSF13
NM 173500 // RefSeq // Homo sapiens tau tubulin TTBK2 4,81E-08 1,66259 kinase 2 (TTBK2), mRNA. // chrl5 // 100
NM 173596 // RefSeq // Homo sapiens solute carrier SLC39A5 1.61E-06 -2,73305 family 39 (metal ion transporter), m
NM 173630 // RefSeq // Homo sapiens rotatin RTTN 1.21E-06 1,77726 (RTTN), mRNA. // chrl8 // 100 // 100 // 45
NMJ73829 // RefSeq // Homo sapiens SREK1- SREK1IP 1.22E-06 1,53161 interacting protein 1 (SREK1IP1), mRNA. // ch 1
NM 173853 // RefSeq // Homo sapiens keratinocyte KRTCAP 8,65E-07 -2,07297 associated protein 3 (KRTCAP3), transc 3
NM 174954 // RefSeq // Homo sapiens ATPase, ATP2A3 5.79E-09 -3,10241 Ca++ transporting, ubiquitous (ATP2A3), tra
NM 175617 // RefSeq // Homo sapiens metallothi- MT1E 8.72E-14 2,60459 onein IE (MT1E), mRNA. // chrl6 // 100 //
NM_175748 // RefSeq // Homo sapiens ubiquitin proUBR7 3,13E-07 1,53645 tein ligase E3 component n-recognin 7
NM 175887 // RefSeq // Homo sapiens proline rich PRR15 2,56E-06 -2,69486 15 (PRR15), mRNA. // chr7 // 100 // 77
NM 176813 // RefSeq // Homo sapiens anterior gradiAGR3 1.41E-11 -11,9405 ent 3 homolog (Xenopus laevis) (AGR3)
NM 176870 // RefSeq // Homo sapiens metallothi- MT1M l,12E-08 4,8387 onein 1M (MT1M), mRNA. // chrl6 // 100 //
NM 177937 // RefSeq // Homo sapiens golgi memGOLM1 2,44E-08 -2,46822 brane protein 1 (GOLM1), transcript varian
NM l 77964 // RefSeq // Homo sapiens LY6/PLAUR LYPD6B 9,53E-09 -4,00458 domain containing 6B (LYPD6B), mRNA. // c
NM 178313 // RefSeq // Homo sapiens spectrin, beta, SPTBN1 3,39E-08 -1,82948 non-erythrocytic 1 (SPTBN1), transc
NM 178314 // RefSeq // Homo sapiens Rab interacRILPL1 1.27E-05 1,86601 ting lysosomal protein- like 1 (RILPL1),
NM 178832 // RefSeq // Homo sapiens MORN repeat MORN4 4,07E-06 2,34797 containing 4 (MORN4), transcript varian
NM_178868 // RefSeq // Homo sapiens CKLF-like CMTM8 2,53E-07 -2,21936 MARVEL transmembrane domain containing 8
NM 181471 // RefSeq // Homo sapiens replication RFC2 5,39E-07 1,6244 factor C (activator 1) 2, 40kDa (RFC2),
NM 181659 // RefSeq // Homo sapiens nuclear recep- NCOA3 6,18E-06 1,60504 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change tor coactivator 3 (NCOA3), transcript
NM_181802 // RefSeq // Homo sapiens ubiquitin- UBE2C 2,23E-06 1,79928 conjugating enzyme E2C (UBE2C), transcrip
NM 182513 // RefSeq // Homo sapiens SPC24, SPC24 l,61E-05 1,66149 NDC80 kinetochore complex component, homolog
NM 182848 // RefSeq // Homo sapiens claudin 10 CLDN10 4J4E-10 -12,9355 (CLD 10), transcript variant a, mRNA. //
NM_182948 // RefSeq // Homo sapiens protein kiPRKACB l,98E-05 -3,27267 nase, cAMP-dependent, catalytic, beta (PR
NM l 83001 // RefSeq // Homo sapiens SHC (Src SHC1 l,23E-07 1,50809 homology 2 domain containing) transforming
NM 194283 // RefSeq // Homo sapiens DnaJ (Hsp40) DNAJC21 3,30E-06 1,53247 homolog, subfamily C, member 21 (DNAJC
NM_197977 // RefSeq // Homo sapiens zinc finger ZNF189 l,59E-05 -2,00268 protein 189 (ZNF189), transcript varian
NM 198270 // RefSeq // Homo sapiens Nance-Horan NHS l,82E-06 -2,55426 syndrome (congenital cataracts and dent
NM 198681 // RefSeq // Homo sapiens pleckstrin PLEKHG 3,12E-07 2,01973 homology domain containing, family G (wi 5
NM 201649 // RefSeq // Homo sapiens solute carrier SLC6A9 4,39E-11 1,80695 family 6 (neurotransmitter transport
NM 203394 // RefSeq // Homo sapiens E2F transcripE2F7 9,51E-06 2,81599 tion factor 7 (E2F7), mRNA. // chrl2 /
NM 207317 // RefSeq // Homo sapiens zinc finger ZNF474 3,99E-06 2,28257 protein 474 (ZNF474), mRNA. // chr5 //
NM_212503 // RefSeq // Homo sapiens cyclin- CDK18 2,40E-05 -1,51027 dependent kinase 18 (CDK18), transcript vari
NM_213566 // RefSeq // Homo sapiens DNA fragDFFA l,62E-05 1,62044 mentation factor, 45kDa, alpha polypeptide
NR 000022 // RefSeq // Homo sapiens small nucleoSNORD14 8,55E-06 1,5123 lar RNA, C/D box 14A (SNORD14A), small A
NR_001278 // RefSeq // Homo sapiens cytochrome CYP2B7P 2,91E-05 -3,48269 P450, family 2, subfamily B, polypeptide 1
NR_001447 // RefSeq // Homo sapiens metallothi- MT1L 5,37E-09 5,33311 onein 1L (gene/pseudogene) (MT1L), non-co
NR 002950 // RefSeq // Homo sapiens small nucleoSNO- 2J3E-05 1,52306 lar RNA, H/ACA box 2A (SNORA2A), small RA2A
NR 003059 // RefSeq // Homo sapiens small nucleoSNORD71 3,18E-07 -1,64467 lar RNA, C/D box 71 (SNORD71), small nu
NR_003610 // RefSeq // Homo sapiens pyridoxal- PDXDC2 3,67E-06 -2,30662 dependent decarboxylase domain containing P
NR_003715 // RefSeq // Homo sapiens maltase- LOC9343 9,97E-10 -12,1234 glucoamylase (alpha-glucosidase) pseudogene 2
NR_003717 // RefSeq // Homo sapiens maltase- LOCIOOI 7,05E-10 -18,7092 glucoamylase (alpha-glucosidase) pseudogene 24692 Reference (REF- Gene p-value
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol
NR_024084 // RefSeq // Homo sapiens SAP30-like SAP30L 1.65E-07 (SAP30L), transcript variant 4, non-codi
NR_024345 // RefSeq // Homo sapiens HNF1A 2.75E-11 tisense RNA 1 (non-protein coding) (HNF1A-A ASl
NR_024413 // RefSeq // Homo sapiens uncharacter- FLJ42393 3,56E-06 ized LOC401105 (FLJ42393), non-coding RN
NR_024546 // RefSeq // Homo sapiens thioredoxin- TXNL1 6,86E-06 like 1 (TXNL1), transcript variant 2, n
NR_026586 // RefSeq // Homo sapiens EF-hand calci- EFCAB2 2,79E-05 um binding domain 2 (EFCAB2), transcri
NR_027136 // RefSeq // Homo sapiens chromosome 1 Clorfl26 1.30E-09 open reading frame 126 (Clorfl26), non
NR_027654 // RefSeq // Homo sapiens SMAD family SMAD6 1.74E-05 member 6 (SMAD6), transcript variant 3,
NR_027921 // RefSeq // Homo sapiens CCL14- CCL14- 6,01E-06 CCL15 readthrough (CCL14-CCL15), transcript v CCL15
NR_029497 // RefSeq // Homo sapiens microRNA 24 MIR24-2 1.53E-06 2 (MIR24-2), microRNA. // chrl9 // 100
NR_029578 // RefSeq // Homo sapiens microRNA MIR192 2,12E-07 192 (MIR192), microRNA. // chrl 1 // 100 //
NR_029635 // RefSeq // Homo sapiens microRNA MIR221 1.23E-05 221 (MIR221), microRNA. // chrX // 100 //
NR_029636 // RefSeq // Homo sapiens microRNA MIR222 2,21E-06 222 (MIR222), microRNA. // chrX // 100 //
NR_030295 // RefSeq // Homo sapiens microRNA MIR569 1.62E-12 569 (MIR569), microRNA. // chr3 // 100 //
NR_033807 // RefSeq // Homo sapiens cytochrome CYP3A5 2,65E-05 P450, family 3, subfamily A, polypeptide
NR_033876 // RefSeq // Homo sapiens long interg LINC0051 U7E-05 non-protein coding RNA 511 (LINC005 1
NR_033932 // RefSeq // Homo sapiens uncharacter- FLJ35946 4,86E-06 ized protein FLJ35946 (FLJ35946), non-co
NR_034091 // RefSeq // Homo sapiens uncharacter- LOCIOOI 2,17E-07 ized LOC100129046 (LOC100129046), non-co 29046
NR_036057 // RefSeq // Homo sapiens microRNA MIR3115 2,37E-05 3115 (MIR3115), microRNA. // chrl // 100 /
NR_036491 // RefSeq // Homo sapiens F-box protein FBX043 1.78E-05 43 (FBX043), transcript variant 1, no
NR_036497 // RefSeq // Homo sapiens LPP antisense LPP-AS2 5,58E-07 RNA 2 (non-protein coding) (LPP-AS2),
NR_036575 // RefSeq // Homo sapiens uncharacter- LOC7299 2,96E-07 ized LOC729966 (LOC729966), non-coding R 66
NR_036581 // RefSeq // Homo sapiens uncharacter- LOC1002 8,16E-06 ized LOCI 00289255 (LOCI 00289255), non-co 89255
NR_037167 // RefSeq // Homo sapiens quinone oxi- LOC7301 3,69E-06 Reference (REF- Gene p-value
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol
doreductase-like protein 2 pseudogene (L 02
NR_037631 // RefSeq // Homo sapiens uncharacter- LOC 1002 1.41E-06 ized LOC 100288911 (LOC 100288911 ), non-co 88911
NR_038258 // RefSeq // Homo sapiens transmem- TPTE2P5 2,03E-06 brane phosphoinositide 3 -phosphatase and te
NR_038269 // RefSeq // Homo sapiens uncharacter- LOC1005 1.58E-08 ized LOC 100506844 (LOC 100506844), non-co 06844
NR_038291 // RefSeq // Homo sapiens uncharacter- LOC1005 5,53E-07 ized LOC100507127 (LOC100507127), non-co 07127
NR_038834 // RefSeq // Homo sapiens uncharacter- LOC1005 7,31E-09 ized LOC 100505989 (LOC 100505989), non-co 05989
NR_038842 // RefSeq // Homo sapiens uncharacter- LOC7284 6,13E-06 ized LOC728431 (LOC728431), non-coding R 31
NR_038849 // RefSeq // Homo sapiens uncharacter- LOC1005 1.64E-11 ized LOC 100505633 (LOC 100505633), non-co 05633
NR_038886 // RefSeq // Homo sapiens uncharacter- LOC1005 1.37E-05 ized LOC100506385 (LOC100506385), transc 06385
NR_039667 // RefSeq // Homo sapiens microRNA MIR378H 4,25E-07 378h (MIR378H), microRNA. // chr5 // 100 /
NR_039990 // RefSeq // Homo sapiens uncharacter- LOC1005 6,69E-07 ized LOC 100507299 (LOC 100507299), non-co 07299
NR_045994 // RefSeq // Homo sapiens eukaryot ETF1 4,02E-08 translation termination factor 1 (ETF1),
NR_046207 // RefSeq // Homo sapiens solute carrier SLC12A2 4.70E-07 family 12 (sodium/potassium/chloride
NR_046320 // RefSeq // Homo sapiens glutathione GPX2 1.44E-06 peroxidase 2 (gastrointestinal) (GPX2),
NR_046533 // RefSeq // Homo sapiens CLDN10 an- CLDN10- 4,53E-06 tisense RNA 1 (non-protein coding) (CLDN10 AS1
NR_046840 // RefSeq // Homo sapiens ARHGEF38 ARHGEF 6,87E-06 intronic transcript 1 (non-protein coding) 38-IT1
NR_047477 // RefSeq // Homo sapiens FRMD6 an- FRMD6- 4,03E-07 tisense RNA 2 (non-protein coding) (FRMD6-A AS2
TCONS 00001602-XLOC 000932 // Rinn lincRNA 1.21E-07 // linc-DPYD-1 chrl :-:98389796-98394621 // c
TCONS 00003042-XLOC 001738 // Rinn lincRNA 2,66E-05 // linc-XIRP2-4 chr2:+:166651360-166666520 /
TCONS_00003266-XLOC_002070 // Rinn lincRNA 6,88E-06 // linc-HAAO-6 chr2:-:43324883-43329829 // c
TCONS_00003518-XLOC_002531 // Rinn lincRNA 3,53E-06 // linc-COL6A3-2 chr2:-:238337562-238343465
TCONS_00003519-XLOC_002536 // Rinn lincRNA 5,35E-07 // linc-PER2-l chr2:-:239207350-239209261 //
TCONS_00004225-XLOC_002067 // Rinn lincRNA 6,90E-10 // linc-HAAO-4 chr2:-:43199537-43228604 // c Reference (REF- Gene p-value
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol
TCONS 00005686-XLOC 002962 // Rinn lincRNA 4,04E-06 // linc-LPP-5 chr3:+: 187166632- 187167238 //
TCONS 00005695-XLOC 002973 // Rinn lincRNA 5,33E-07 // linc-HESl-3 chr3:+: 193558616-193561016 //
TCONS_00006739-XLOC_003378 // Rinn lincRNA 1.82E-05 // linc-ATP13A4-2 chr3:-:193551437-193555388
TCONS_00007517-XLOC_003515 // Rinn lincRNA 7,44E-06 // linc-WDR19 chr4:+:39135532-39137228 // ch
TCONS 00009612-XLOC 004747 // Rinn lincRNA 1.12E-05 // linc-MYOlO-3 chr5:-:18704541-18746282 //
TCONS 00010966-XLOC 004901 // Rinn lincRNA 2,57E-08 // linc-DMGDH-1 chr5:-:78654496-78663947 //
TCONS OOOl 1960-XLOC 005473 // Rinn lincRNA 1.10E-09 // linc-MAP7-BP chr6:+: 136871938-136872729 /
TCONS 00012690-XLOC 005677 // Rinn lincRNA 2,61E-05 // linc-POU5Fl-l c r6:-:31139385-31144598 //
TCONS 00012969-XLOC 006009 // Rinn lincRNA 9,60E-07 // linc-IL6-l chr7:+:22629323-22631241 // ch
TCONS_00013399-XLOC_006028 // Rinn lincRNA 2.91E-12 // linc-TAXIBPl chr7:+:27427803-27449622 //
TCONS_00013576-XLOC_006231 // Rinn lincRNA 1.98E-05 // linc-ARF5-8 chr7:+: 124638323-124641124 //
TCONS_00014003-XLOC_006644 // Rinn lincRNA 1.28E-06 // linc-ZNF467-2 chr7:-:149903392-149917567
TCONS 00015651-XLOC 007291 // Rinn lincRNA 7,93E-06 // linc-CNTLN-4 chr9:+: 16121130-16122432 //
TCONS 00015691-XLOC 007398 // Rinn lincRNA 1.49E-06 // linc-TMCl-2 chr9:+:748722 1-74872699 // c
TCONS 00016324-XLOC 007698 // Rinn lincRNA 1.64E-05 // linc-FAM75A6-4 chr9:-:46122188-46123597 /
TCONS 00017313-XLOC 008149 // Rinn lincRNA 7,53E-08 // linc-CXorS6-l chrX:-:45629145-45629608 /
TCONS 00018036-XLOC 008937 // Rinn lincRNA 2,06E-07 // linc-ITPRIP-1 chrlO:-: 106111348-106113333
TCONS_00018334-XLOC_008611 // Rinn lincRNA 3,23E-08 // linc-SMC3 chrl0:+:l 12306237-112307703 //
TCONS_00018558-XLOC_008875 // Rinn lincRNA 2,38E-05 // linc-DYDCl-3 chrl0:-:83633134-83634234 //
TCONS_00019615-XLOC_009415 // Rinn lincRNA 1.65E-05 // linc-APIP-1 chrl 1 x35086672-35095505 //
TCONS 00020456-XLOC 009788 // Rinn lincRNA U9E-05 // linc-HMGA2 chrl2:+:65996599-66010730 // c
TCONS 00021594-XLOC 010491 // Rinn lincRNA 2,69E-07 // linc-COL4A2-7 chrl3:+:109934320-109940081
TCONS 00021940-XLOC 010534 // Rinn lincRNA 1.90E-05 Reference (REF- Gene p-value
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol
// Iinc-C1QTNF9B chrl3:-:24911521-24913410 /
TCONS 00022264-XLOC 010579 // Rinn lincR A 1.34E-06 // linc-MRPS31 chrl3:-:41448189-41455780 //
TCONS 00022761-XLOC 011044 // Rinn lincRNA 7,84E-08 // linc-C14orf39 chrl4:-:61108285-61109382 /
TCONS 00023506-XLOC 011350 // Rinn lincRNA 4,32E-08 // linc-FURIN chrl5:+:91382984-91384570 // c
TCONS_00023790-XLOC_011585 // Rinn lincRNA 1.53E-05 // linc-VPS33B-2 chrl5:-:93137349-93139933 /
TCONS_00024596-XLOC_011889 // Rinn lincRNA 8,95E-07 // linc-SMGl chrl6:-: 19365543-19405174 // ch
TCONS_00025308-XLOC_012111 // Rinn lincRNA 3.78E-06 // linc-SHISA6-2 chrl7:+: 10750779-10751687 /
TCONS 00025543-XLOC 012370 // Rinn lincRNA 5,23E-10 // linc-TEKTl-3 chrl7:-:6778552-6784435 // c
TCONS 00026289-XLOC 012631 // Rinn lincRNA 1.35E-07 // linc-TUBB6 chrl8:+: 12288321-12291290 // c
TCONS_12_00004461-XLOC_12_002271 // Broad 1.08E-05 TUCP // linc-FSHB-2 chrl l :+:29059301-29085806
TCONS_12_00005499-XLOC_12_002886 // Broad LOC3744 1.56E-05 TUCP // linc-CLEC2D-l chrl2:+:9795445-9814706 43
TCONS_12_00014416-XLOC_12_007884 // Broad 1.80E-09 TUCP // linc-CMPK2-10 chr2:-:8708041-8720165
TCONS_12_00015910-XLOC_12_008203 // Broad LOCIOOI 1.66E-09 TUCP // linc-BUBl-2 chr2:-:l 11996295-11225259 28130
TCONS_12_00016754-XLOC_12_008600 // Broad FAM182A 1.89E-07 TUCP // linc-DEFB 115-3 chr20:+:26035249-26067
TCONS_12_00020301-XLOC_12_010491 // Broad 2,25E-13 TUCP // linc-ATP13A4-3 chr3:-:193560348-19356
TCONS_12_00020391-XLOC_12_010558 // Broad LOC9362 9,71E-07 TUCP // linc-SlOOP-2 chr4:+:6676003-6678711 / 2
TCONS_12_00022010-XLOC_12_011291 // Broad 3,21E-06 TUCP // linc-RNF150-2 chr4:-: 142242282-142247
TCONS_12_00022497-XLOC_12_011737 // Broad ZNF474 2,13E-05 TUCP // linc-SNCAIP chr5:+:121492826-12151544
TCONS 12 00023557-XLOC 12 011793 // Broad 4.70E-07 TUCP // linc-SPRY4-BP chr5: K 141704857-141843
TCONS_12_00023567-XLOC_12_011805 // Broad 4,38E-08 TUCP // linc-SH3TC2-BP chr5:+:148442879-14845
U02020 // GenBank // Human pre-B cell enhancing NAMPT 1.25E-07 factor (PBEF) mRNA, complete cds. // ch
XR_109952 // RefSeq // PREDICTED: Homo sapiens LOC1005 5,86E-06 hypothetical LOC100507307 (LOCI 00507307) 07307
XR l 10188 // RefSeq // PREDICTED: Homo sapiens LOC1005 3,36E-06 hypothetical LOC100507624 (LOCI 00507624) 07624 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
XR 133524 // RefSeq // PREDICTED: Homo sapiens LOC1006 6,22E-06 -1,59858 hypothetical LOC100653206 (LOCI 00653206) 53206
Table 4: Efficiency of SN-38 (Irinotecan active metabolite)
Figure imgf000097_0001
CoA dioxygenase domain containing 1 (P
NM OOl 126 // RefSeq // Homo sapiens adenylosucADSS l,51E-05 1,29195 cinate synthase (ADSS), mR A. // chrl //
NM OOl 130009 // RefSeq // Homo sapiens Gen endo- GEN1 U3E-06 1,42069 nuclease homo log 1 (Drosophila) (GEN1),
NM OOl 195296 // RefSeq // Homo sapiens mirror- MIPOL1 l,52E-06 -1,61943 image Polydactyly 1 (MIPOL1), transcript
NM 001238 // RefSeq // Homo sapiens cyclin El CCNE1 6J5E-08 1,70632 (CCNE1), mRNA. // chrl9 // 100 // 100 //
NM 004339 // RefSeq // Homo sapiens pituitary tuPTTG1IP U 1E-05 1,26909 mor-transforming 1 interacting protein
NM 004619 // RefSeq // Homo sapiens TNF receptor- TRAF5 2,68E-05 3,13128 associated factor 5 (TRAF5), transcrip
NM 004719 // RefSeq // Homo sapiens SR-related SCAF11 4,64E-05 1,20729 CTD-associated factor 11 (SCAF11), mRNA.
NM 006026 // RefSeq // Homo sapiens HI histone H1FX l,40E-05 1,43588 family, member X (HI FX), mRNA. // chr3 /
NM 012241 // RefSeq // Homo sapiens sirtuin 5 SIRT5 4,97E-05 1,44938 (SIRT5), transcript variant 1, mRNA. // c
NM 014246 // RefSeq // Homo sapiens cadherin, EGF CELSR1 5,57E-05 2,8642 LAG seven-pass G-type receptor 1 (fla
NM 018259 // RefSeq // Homo sapiens tetratricopep- TTC17 5,96E-05 1,3538 tide repeat domain 17 (TTC17), mRNA. /
NM 018413 // RefSeq // Homo sapiens carbohydrate CHST11 2,41E-05 2,8737 (chondroitin 4) sulfotransferase 11 (C
NM 018602 // RefSeq // Homo sapiens DnaJ (Hsp40) DNAJA4 l,84E-05 -1,87107 homo log, subfamily A, member 4 (DNAJA4
NM_020192 // RefSeq // Homo sapiens Yael domain YAE1D1 9J0E-07 -1,61835 containing 1 (YAE1D1), mRNA. // chr7 //
NM 021982 // RefSeq // Homo sapiens SEC24 famiSEC24A 2.78E-05 -1,38482 ly, member A (S. cerevisiae) (SEC24A), tr
NM_138768 // RefSeq // Homo sapiens myeloma MYEOV U8E-05 1,4116 overexpressed (in a subset of t(l 1 ; 14) posi
NM_152744 // RefSeq // Homo sapiens sidekick cell SDK1 l,82E-05 -1,34953 adhesion molecule 1 (SD 1), transcrip
NM 181719 // RefSeq // Homo sapiens transmemTMC04 5J7E-05 1,27538 brane and coiled-coil domains 4 (TMC04), mR
NR_002196 // RefSeq // Homo sapiens H19, imH19 l,34E-06 4,35208 printed maternally expressed transcript (non
NR 003008 // RefSeq // Homo sapiens small Cajal SCAR- 4,59E-05 3,57866 body-specific RNA 5 (SCARNA5), guide RN NA5
NR_026862 // RefSeq // Homo sapiens protein phosPPP1R3E 6J7E-06 1,3635 phatase 1, regulatory subunit 3E (PPP1R
NR_036474 // RefSeq // Homo sapiens G patch doGPATCH 4,93E-06 -1,2289 main containing 8 (GPATCH8), transcript v 8
NR 040252 // RefSeq // Homo sapiens ankyrin repeat ANKS3 l,21E-05 1,20509 and sterile alpha motif domain conta NR_045553 // RefSeq // Homo sapiens thrombospon- THBS3 8,00E-06 1,93413 din 3 (THBS3), transcript variant 4, non
TCONS 00000324-XLOC 000441 // Rinn lincRNA // ] inc- 3,97E-05 -1,46789 FCGR2A chrl :+:161337811-161341754 //
TCONS 00003558-XLOC 001334 // Rinn lincRNA // linc- 3,29E-05 1,26364 ASAP2-4 chr2:+:9144181-9148968 // ch
TCONS 00015020-XLOC 007094 // Rinn lincRNA // linc-CA8-2 4.72E-05 -1,9219 chr8:-:61377162-61378147 // ch
TCONS 00020978-XLOC 010244 // Rinn lincRNA LOC3878 3,96E-05 1,88561 // linc-DHX37-4 chrl2:-: 127214600-127232784 95
TCONS 00024123-XLOC 011480 // Rinn lincRNA // ] inc- 3,83E-06 -1,40259 BCL2L10 chrl5:-:52407273-52409155 //
TCONS 00029585-XLOC 014219 // Rinn lincRNA // linc-RASD2 2,45E-05 1,64874 chr22:+:35846033-35851349 // c
TCONS 12 00028315-XLOC 12 014585 // Broad LOC1005 5,12E-05 -1,40029 TUCP // linc-TMEM55A-l chr8:-:92080145-920823 06365
Table 5: Efficiency of oxaliDlatin
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
AF086261 // GenBank // Homo sapiens full length LOC1005 0,000926 -1,63804 insert cDNA clone ZD42A11. // chrl // 07311 69
AF086310 // GenBank // Homo sapiens full length insert cDNA 0,000128 -3,47383 clone ZD 1F08. // chr4 // 1 71
AF147354 // GenBank // Homo sapiens full length LINC0049 0,000870 1,38961 insert cDNA clone YB43H03. // chr20 // 3 3
AF520800 // GenBank // Homo sapiens clone 958LR OFCC1 0,000948 -1,93359 MRDS1 protein (MRDS1) mRNA, complete cd 7
AK056431 // GenBank // Homo sapiens cDNA FLG-AS1 0,001425 1,89868 FLJ31869 fis, clone NT2RP7002151. // chrl // 1 15
AK057443 // GenBank // Homo sapiens cDNA FLJ32881 fis, clone 7,00E-05 1,57188 TESTI2004153. // chr22 //
AK093576 // GenBank // Homo sapiens cDNA FLJ36257 fis, clone 0,001579 1,25081 THYMU2002376. // chr2 // 1 34
AK096045 // GenBank // Homo sapiens cDNA SHANK2 1.82E-06 2,55588 FLJ38726 fis, clone KIDNE2010271 , moderately s
AK097401 // GenBank // Homo sapiens cDNA FLJ40082 fis, clone 6,25E-05 -1,51377 TESTI2002282, highly simil
AKl 23224 // GenBank // Homo sapiens cDNA LOC1005 0,000654 -1,72222 FLJ41230 fis, clone BRAMY2030703. // chrl6 // 06928 49
AKl 23971 // GenBank // Homo sapiens cDNA FLJ41977 fis, clone 6,08E-05 2,11232 SKNMC2007961. // chrl2 //
AKl 24207 // GenBank // Homo sapiens cDNA LOClOOl 0,000443 -1,28444 FLJ42213 fis, clone THYMU2037081. // chrl 9 // 32272 79
Figure imgf000100_0001
Figure imgf000101_0001
gene:
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
gen
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
10059; gene=TRNG; product=tRN
NM 000070 // RefSeq // Homo sapiens calpain 3, CAPN3 5,23E-05 -2,50154 (p94) (CAPN3), transcript variant 1, mRN
NM 000092 // RefSeq // Homo sapiens collagen, type COL4A4 0,001206 -1,47865 IV, alpha 4 (COL4A4), mRNA. // chr2 59
NM 000107 // RefSeq // Homo sapiens damage- DDB2 0,000503 1,79357 specific DNA binding protein 2, 48kDa (DDB2) 51
NM 000109 // RefSeq // Homo sapiens dystrophin DMD 0,000288 -1,43397 (DMD), transcript variant Dp427c, mRNA. 04
NM 000153 // RefSeq // Homo sapiens galactosylce- GALC 1.64E-06 -2,44218 ramidase (GALC), transcript variant 1 ,
NM 000179 // RefSeq // Homo sapiens mutS homo- MSH6 0,000925 1,45217 log 6 (E. coli) (MSH6), mRNA. // chr2 // 1 99
NM 000182 // RefSeq // Homo sapiens hydroxyacyl- HADHA 3,24E-06 1,44575 CoA dehydrogenase/3-ketoacyl-CoA thiola
NM_000201 // RefSeq // Homo sapiens intercellular ICAM1 0,001183 -1,98895 adhesion molecule 1 (ICAM1), mRNA. // 48
NM 000204 // RefSeq // Homo sapiens complement CFI 7,31E-06 -5,68645 factor I (CFI), mRNA. // chr4 // 100 //
NM 000234 // RefSeq // Homo sapiens ligase I, DNA, LIG1 4,21E-07 1,29522 ATP-dependent (LIG1), mRNA. // chrl9
NM 000274 // RefSeq // Homo sapiens ornithine amiOAT 6,95E-05 2,15728 notransferase (OAT), nuclear gene enco
NM 000367 // RefSeq // Homo sapiens thiopurine S- TPMT 9,66E-06 -1,96134 methyltransferase (TPMT), mRNA. // chr
NM 000396 // RefSeq // Homo sapiens cathepsin K CTSK 0,000146 -1,68832 (CTSK), mRNA. // chrl // 100 // 91 // 2 06
NM_000431 // RefSeq // Homo sapiens mevalonate MVK 0,000480 1,3952 kinase (MVK), transcript variant 1 , mRNA 61
NM_000535 // RefSeq // Homo sapiens PMS2 PMS2 0,000363 1,39858 postmeiotic segregation increased 2 (S. cerevi 54
NM 000546 // RefSeq // Homo sapiens tumor protein TP53 0,000694 1,67829 p53 (TP53), transcript variant 1, mRN 36
NM 000574 // RefSeq // Homo sapiens CD55 moleCD55 0,000242 -1,84036 cule, decay accelerating factor for comple 93
NM 000584 // RefSeq // Homo sapiens interleukin 8 IL8 2,46E-05 -5,87816 (IL8), mRNA. // chr4 // 100 // 62 //
NM 000715 // RefSeq // Homo sapiens complement C4BPA 0,000773 -1,49347 component 4 binding protein, alpha (C4BP 29
NM 000867 // RefSeq // Homo sapiens 5- HTR2B 0,001009 -1,33096 hydroxytryptamine (serotonin) receptor 2B, G prot 32
NM_000895 // RefSeq // Homo sapiens leukotriene LTA4H 2,94E-06 2,35941 A4 hydrolase (LTA4H), transcript varian
NM 000906 // RefSeq // Homo sapiens natriuretic NPR1 0,000873 -1,37524 peptide receptor A/guanylate cyclase A 3 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 000963 // RefSeq // Homo sapiens prostaglandin- PTGS2 0,000448 -5,13436 endoperoxide synthase 2 (prostaglandi 48
NM_001001323 // RefSeq // Homo sapiens ATPase, ATP2B1 0,000278 1,94477 Ca++ transporting, plasma membrane 1 (AT 9
NM OO 1001419 // RefSeq // Homo sapiens SMAD SMAD5 5,19E-05 1,51318 family member 5 (SMAD5), transcript variant
NM 001001973 // RefSeq // Homo sapiens ATP synATP5C1 0,000147 1,51094 thase, H+ transporting, mitochondrial F 1 39
NM_001002265 // RefSeq // Homo sapiens memMARCH8 4,39E-05 1,48212 brane-associated ring finger (C3HC4) 8, E3 ub
NM_001002762 // RefSeq // Homo sapiens DnaJ DNAJB12 0,001273 1,37654 (Hsp40) homo log, subfamily B, member 12 (DN 92
NM 001002857 // RefSeq // Homo sapiens annexin ANXA2 6,44E-05 -1,61672 A2 (ANXA2), transcript variant 2, mRNA.
NM 001005203 // RefSeq // Homo sapiens olfactory OR8S1 0,000773 -1,23703 receptor, family 8, subfamily S, membe 75
NM 001005493 // RefSeq // Homo sapiens olfactory OR6C6 0,000791 1,23247 receptor, family 6, subfamily C, membe 47
NM 001005741 // RefSeq // Homo sapiens glucosi- GBA 0,001275 -1,29666 dase, beta, acid (GBA), transcript varian 74
NM_001008708 // RefSeq // Homo sapiens ChaC, CHAC2 0,001620 1,85546 cation transport regulator homo log 2 (E. c 46
NM 001009880 // RefSeq // Homo sapiens KIAA093 4,46E-06 1,50115 KIAA0930 (KIAA0930), transcript variant 2, mRNA. 0
NM 001010888 // RefSeq // Homo sapiens zinc fmger ZC3H12B 0,000513 -1,70592 CCCH-type containing 12B (ZC3H12B), 11
NM 001010922 // RefSeq // Homo sapiens BCL2-like BCL2L15 7,99E-05 -4,67039 15 (BCL2L15), mRNA. // chrl // 100 //
NM 001011724 // RefSeq // Homo sapiens heterogeHNRN- 0,000155 1,60651 neous nuclear ribonucleoprotein Al-like PA1L2 65
NM 001012515 // RefSeq // Homo sapiens ferrochela- FECH U7E-05 1,60873 tase (FECH), nuclear gene encoding mit
NM 001014437 // RefSeq // Homo sapiens cysteinyl- CARS 0,000865 1,23829 tRNA synthetase (CARS), transcript var 22
NM_001014443 // RefSeq // Homo sapiens ubiquitin USP21 0,000187 -1,2041 specific peptidase 21 (USP21), transcr 06
NM 001014450 // RefSeq // Homo sapiens small pro- SPRR2F 0,000310 -1,41659 line-rich protein 2F (SPRR2F), mRNA. // 69
NM 001017402 // RefSeq // Homo sapiens laminin, LAMB3 0,000324 -1,87364 beta 3 (LAMB3), transcript variant 2, m 31
NM 001023561 // RefSeq // Homo sapiens zinc fmger ZNF749 2,64E-05 1,38312 protein 749 (ZNF749), mRNA. // chrl 9
NM 001030060 // RefSeq // Homo sapiens sterile SAMD5 0,000384 -2,19646 alpha motif domain containing 5 (SAMD5), 78
NM 001032281 // RefSeq // Homo sapiens tissue fac- TFPI 0,000393 -3,46002 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change tor pathway inhibitor (lipoprotein-ass 23
NM 001037165 // RefSeq // Homo sapiens forkhead FOXK1 6,30E-05 1,42961 box Kl (FOXK1), mRNA. // chr7 // 100 //
NM 001037984 // RefSeq // Homo sapiens solute SLC38A1 0,001353 -1,28079 carrier family 38, member 10 (SLC38A10), 0 48
NM_001039091 // RefSeq // Homo sapiens phospho- PRPS2 0,000986 1,72913 ribosyl pyrophosphate synthetase 2 (PRPS2 88
NM 001039361 // RefSeq // Homo sapiens PRAME PRAMEF l,34E-06 -1,4122 family member 10 (PRAMEF10), mRNA. // chrl 10
NM 001048226 // RefSeq // Homo sapiens dysbindin DBNDD2 0,000119 1,49289 (dystrobrevin binding protein 1) domai 49
NM 001076786 // RefSeq // Homo sapiens glutamine QSER1 0,000482 1,44388 and serine rich 1 (QSER1), mRNA. // ch 27
NM 001079559 // RefSeq // Homo sapiens heterogeHNRN- 0,001414 1,2318 neous nuclear ribonucleoprotein U-like 2 PUL2 17
NM 001080401 // RefSeq // Homo sapiens protein PPM1N l,69E-05 1,41467 phosphatase, Mg2+/Mn2+ dependent, IN (pu
NM 001080533 // RefSeq // Homo sapiens unc-119 UNC119B 7,23E-05 1,8408 homo log B (C. elegans) (UNCI 19B), mRNA.
NM 001083 // RefSeq // Homo sapiens phosphoPDE5A 0,000455 -3,04833 diesterase 5A, cGMP-specific (PDE5A), transc 44
NM 001083602 // RefSeq // Homo sapiens patched 1 PTCH1 0,000681 1,53049 (PTCH1), transcript variant la, mRNA. 02
NM 001098511 // RefSeq // Homo sapiens kinesin KIF2A 0,001241 1,53114 heavy chain member 2A (KIF2A), transcrip 34
NM 001098616 // RefSeq // Homo sapiens chromoClorf43 0,000113 -1,32891 some 1 open reading frame 43 (Clorf43), tr 83
NM 001098638 // RefSeq // Homo sapiens ring finger RNF169 0,000678 1,51561 protein 169 (RNF169), mRNA. // chrl 1 24
NM_001099678 // RefSeq // Homo sapiens leucine LRRC58 0,000548 1,54347 rich repeat containing 58 (LRRC58), mRNA 93
NM 001100422 // RefSeq // Homo sapiens spermatoSPATS2L 0,000638 -1,43625 genesis associated, serine-rich 2-like ( 45
NM_001102366 // RefSeq // Homo sapiens chromoC14orfl59 0,000249 1,33575 some 14 open reading frame 159 (C14orfl59) 22
NM 001104546 // RefSeq // Homo sapiens ribonucle- RPP30 0,001325 1,68722 ase P/MRP 30kDa subunit (RPP30), transc 94
NM 001104647 // RefSeq // Homo sapiens solute SLC25A3 0,000582 1, 1822 carrier family 25 (pyrimidine nucleotide 6 2
NM 001105570 // RefSeq // Homo sapiens nudix (nuNUDT19 4J6E-05 1,53021 cleoside diphosphate linked moiety X)-t
NM 001110822 // RefSeq // Homo sapiens tudor doTDRD12 0,001353 -1,20318 main containing 12 (TDRD12), mRNA. // ch 46
NM_001112808 // RefSeq // Homo sapiens FPGT- FPGT- 0,000159 -1,47344 TNNI3 readthrough (FPGT-TNNI3K), transcrip TNNI3K 29 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 001113493 // RefSeq // Homo sapiens septin 9 09-sept 0,000991 -1,30732 (SEPT9), transcript variant 2, mRNA. // 23
NM 001116 // RefSeq // Homo sapiens adenylate cyADCY9 0,001597 1,59723 clase 9 (ADCY9), mRNA. // chrl6 // 100 25
NM 001123375 // RefSeq // Homo sapiens histone HIST2H3 0,000192 2,28785 cluster 2, H3d (HIST2H3D), mRNA. // chrl D 82
NM_001127221 // RefSeq // Homo sapiens calcium CACNA1 0,001538 -1,21835 channel, voltage-dependent, P/Q type, al A 6
NM 001128205 // RefSeq // Homo sapiens sulfatase 1 SULF1 0,000423 -1,26557 (SULF1), transcript variant 1, mRNA. 26
NM 001128310 // RefSeq // Homo sapiens SPARC- SPARCL1 0,000952 -1,71251 like 1 (hevin) (SPARCL1), transcript varia 33
NM 001129993 // RefSeq // Homo sapiens KIAA184 0,000113 1,40579 KIAA1841 (KIAA1841), transcript variant 1, mRNA. 1 87
NM_001130440 // RefSeq // Homo sapiens signal SRP9 0,000876 -1,26458 recognition particle 9kDa (SRP9), transcr 63
NM 001130518 // RefSeq // Homo sapiens chondroi- CSGAL- 0,000410 -1,80869 tin sulfate N-acetylgalactosaminyltransf NACT1 98
NM 001130699 // RefSeq // Homo sapiens interaction IPCEF1 0,001399 -1,58711 protein for cytohesin exchange facto 9
NM 001130966 // RefSeq // Homo sapiens thromboxTBXAS1 0,001259 -1,49448 ane A synthase 1 (platelet) (TBXAS1), tr 83
NM 001131007 // RefSeq // Homo sapiens KIAA092 0,000732 2,57886 KIAA0922 (KIAA0922), transcript variant 1, mRNA. 2 49
NM_001134745 // RefSeq // Homo sapiens leucine LRRTM4 0,000617 -1,24574 rich repeat transmembrane neuronal 4 (LR 12
NM 001134779 // RefSeq // Homo sapiens importin IPOl l 0,000247 1,74127 11 (IPOl 1), transcript variant 1, mRNA. 04
NM 001135638 // RefSeq // Homo sapiens phospha- PIP5 1A 6,03E-06 -1,36912 tidylinositol-4-phosphate 5-kinase, type
NM 001135773 // RefSeq // Homo sapiens spermatoSPATA2 7,l lE-05 1,52604 genesis associated 2 (SPATA2), transcrip
NM_001135924 // RefSeq // Homo sapiens von Wil- VWDE l,03E-05 -4,16521 lebrand factor D and EGF domains (VWDE),
NM 001136223 // RefSeq // Homo sapiens REST RCOR3 0,001141 -1,27312 corepressor 3 (RCOR3), transcript variant 1 56
NM 001136538 // RefSeq // Homo sapiens acyl-CoA ACAD 10 3,02E-05 1,64528 dehydrogenase family, member 10 (ACAD 10
NM_001137550 // RefSeq // Homo sapiens leucine LRRFIP1 7,49E-05 -1,42505 rich repeat (in FLU) interacting protei
NM 001143906 // RefSeq // Homo sapiens TRAF- TRAFD 1 4,23E-05 1,40898 type zinc finger domain containing 1 (TRAFD
NM 001145260 // RefSeq // Homo sapiens nuclear NCOA4 0,000789 1,3858 receptor coactivator 4 (NCOA4), transcri 12
NM 001145345 // RefSeq // Homo sapiens zinc finger ZNF566 0,000811 1,42612 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK LNCipedia) Symbol Change protein 566 (ZNF566), transcript var 27
NM 001145418 // RefSeq // Homo sapiens tetratrico- TTC28 6,59E-05 1,84335 peptide repeat domain 28 (TTC28), mRNA
NM 001145547 // RefSeq // Homo sapiens RNA binRBM17 6,65E-05 1,94998 ding motif protein 17 (RBM17), transcript
NM_001159767 // RefSeq // Homo sapiens basic leuBZW2 0,000688 1,67003 cine zipper and W2 domains 2 (BZW2), tr 53
NM 001161766 // RefSeq // Homo sapiens adeno- AHCY 1J3E-05 1,60835 sylhomocysteinase (AHCY), transcript varian
NM 001162893 // RefSeq // Homo sapiens KIAA004 2,60E-06 -2,58796 KIAA0040 (KIAA0040), transcript variant 1 , mRNA. 0
NM 001162893 // RefSeq // Homo sapiens KIAA004 0,001052 -1,37926 KIAA0040 (KIAA0040), transcript variant 1, mRNA. 0 25
NM 001164811 // RefSeq // Homo sapiens PET117 PET117 0,000239 1,40319 homo log (S. cerevisiae) (PET117), mRNA. / 43
NM 001167674 // RefSeq // Homo sapiens cell adCADM2 0,000613 -2,17204 hesion molecule 2 (CADM2), transcript var 49
NM 001167856 // RefSeq // Homo sapiens strawberry SBNOl 2J8E-05 1,70916 notch homolog 1 (Drosophila) (SBNOl),
NM 001172303 // RefSeq // Homo sapiens microtuMASTL 0,000946 2,11393 bule associated serine/threonine kinase-1 02
NM 001173454 // RefSeq // Homo sapiens pyruvate PDHA1 0,000734 1,57999 dehydrogenase (lipoamide) alpha 1 (PDHA 66
NM_001177 // RefSeq // Homo sapiens ADP- ARLl 0,000641 1,45845 ribosylation factor-like 1 (ARLl), mRNA. // chr 66
NM 001177802 // RefSeq // Homo sapiens RAN guaRANGRF 0,000799 1,44664 nine nucleotide release factor (RANGRF), 08
NM 001185093 // RefSeq // Homo sapiens nitrilase 1 NIT1 0,000395 -1,57835 (NIT1), transcript variant 3, mRNA. 93
NM_001185118 // RefSeq // Homo sapiens myoneurin MYNN 0,001468 1,3656 (MYNN), transcript variant 2, mRNA. // 92
NM 001193434 // RefSeq // Homo sapiens pleckstrin PLEKHS1 0,000599 -6,65282 homology domain containing, family S 98
NM 001194995 // RefSeq // Homo sapiens chromoC12orf65 9,03E-05 1,64746 some 12 open reading frame 65 (C12orf65),
NM 001197097 // RefSeq // Homo sapiens protease, PRSS3 6J2E-06 -2,87571 serine, 3 (PRSS3), transcript variant
NM 001197104 // RefSeq // Homo sapiens myeMLL 0,001351 1,24154 loid/lymphoid or mixed-lineage leukemia (trit 35
NM 001198842 // RefSeq // Homo sapiens chape- CCT2 0,000697 1,78291 ronin containing TCP 1 , subunit 2 (beta) (CC 94
NM_001199260 // RefSeq // Homo sapiens torsin A TOR1AIP 7,95E-05 -1,59076 interacting protein 2 (TOR1AIP2), trans 2
NM 001199815 // RefSeq // Homo sapiens gamma- GGCT 3,16E-05 1,6749 glutamylcyclotransferase (GGCT), transcrip Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 001201 // RefSeq // Homo sapiens bone morpho- BMP3 0,001111 -1,21306 genetic protein 3 (BMP3), mRNA. // chr4 35
NM 001204 // RefSeq // Homo sapiens bone morpho- BMPR2 0,001014 -1,46829 genetic protein receptor, type II (serin 88
NM_001204397 // RefSeq // Homo sapiens paired-like PITX2 8,09E-05 -1,29379 homeodomain 2 (PITX2), transcript va
NM 001204406 // RefSeq // Homo sapiens arachido- ALOX5A 0,001296 -1,31725 nate 5-lipoxygenase-activating protein ( P 68
NM 001206651 // RefSeq // Homo sapiens SH3- SH3GLB1 0,000845 -1,51161 domain GRB2-like endophilin Bl (SH3GLB1), tr 48
NM_001242307 // RefSeq // Homo sapiens pitrilysin PITRMl 0,000496 1,92544 metallopeptidase 1 (PITRM1), nuclear 75
NM 001243121 // RefSeq // Homo sapiens phosphoPDE4A 0,001273 -1,81771 diesterase 4A, cAMP-specific (PDE4A), tra 57
NM_001252100 // RefSeq // Homo sapiens kinesin KIF21B 0,000320 -1,67712 family member 2 IB (KIF21B), transcript v 94
NM 001252406 // RefSeq // Homo sapiens zinc finger ZBTB7B 0,000700 -1,29393 and BTB domain containing 7B (ZBTB7B 87
NM_001256165 // RefSeq // Homo sapiens transTMCOl 0,000159 -1,70566 membrane and coiled-coil domains 1 (TMCOl), 86
NM 001256410 // RefSeq // Homo sapiens RAB18, RAB18 l,29E-05 1,58657 member RAS oncogene family (RAB 18), trans
NM 001258438 // RefSeq // Homo sapiens threonyl- TARS 0,001337 1,61221 tRNA synthetase (TARS), transcript vari 87
NM 001267578 // RefSeq // Homo sapiens torsin A TOR1AIP 0,000532 -1,5063 interacting protein 1 (TOR1AIP1), trans 1 39
NM 001267806 // RefSeq // Homo sapiens pro- PAAFl 0,000215 1,57539 teasomal ATPase-associated factor 1 (PAAFl), 72
NM 001281 // RefSeq // Homo sapiens tubulin foldTBCB 0,001368 1,3556 ing cofactor B (TBCB), mRNA. // chrl9 / 45
NM 001297 // RefSeq // Homo sapiens cyclic nucleoCNGB1 0,001248 -1,23801 tide gated channel beta 1 (CNGB1), tra 75
NM_001412 // RefSeq // Homo sapiens eukaryotic EIF1AX 0,001470 1,59057 translation initiation factor 1A, X-link 83
NM_001483 // RefSeq // Homo sapiens glioblastoma GBAS 0,000724 1,69679 amplified sequence (GBAS), nuclear gen 32
NM 001494 // RefSeq // Homo sapiens GDP dissociaGDI2 0,000200 1,59581 tion inhibitor 2 (GDI2), transcript var 18
NM_001531 // RefSeq // Homo sapiens major histoMR1 1J7E-06 -2,32707 compatibility complex, class I-related (
NM 001536 // RefSeq // Homo sapiens protein argi- PRMT1 0,000501 1,2935 nine methyltransferase 1 (PRMT1), trans 63
NM 001540 // RefSeq // Homo sapiens heat shock HSPB1 0,000527 1,3797 27kDa protein 1 (HSPB1), mRNA. // chr7 / 72
NM_001628 // RefSeq // Homo sapiens aldo-keto re- AKR1B1 0,001282 1,99198 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change ductase family 1, member Bl (aldose red 46
NM 001631 // RefSeq // Homo sapiens alkaline phosALPI 0,001597 -1,27247 phatase, intestinal (ALPI), mRNA. // c 3
NM 001632 // RefSeq // Homo sapiens alkaline phosALPP 0,000122 -1,39519 phatase, placental (ALPP), mRNA. // ch 77
NM 001647 // RefSeq // Homo sapiens apolipoprotein APOD 0,001323 -2,42082 D (APOD), mRNA. // chr3 // 100 // 73 12
NM 001665 // RefSeq // Homo sapiens ras homo log RHOG 0,000653 1,30759 family member G (RHOG), mRNA. // chrl 1 11
NM 001668 // RefSeq // Homo sapiens aryl hydrocarARNT l,53E-06 -1,32541 bon receptor nuclear translocator (ARN
NM 001693 // RefSeq // Homo sapiens ATPase, H+ ATP6V1B 0,001013 1,6069 transporting, lysosomal 56/58kDa, VI sub 2 33
NM 001745 // RefSeq // Homo sapiens calcium modCAMLG 0,000724 2,22836 ulating ligand (CAMLG), mRNA. // chr5 // 04
NM 001799 // RefSeq // Homo sapiens cyclin- CDK7 0,001390 1,58626 dependent kinase 7 (CD 7), mRNA. // chr5 // 85
NM 001876 // RefSeq // Homo sapiens carnitine palCPT1A 0,000578 1,57343 mitoyltransferase 1A (liver) (CPT1A), 74
NM 001964 // RefSeq // Homo sapiens early growth EGR1 0,000563 -1,67519 response 1 (EGR1), mRNA. // chr5 // 10 86
NM 001976 // RefSeq // Homo sapiens enolase 3 (beEN03 0,000507 1,4093 ta, muscle) (EN03), transcript variant 5
NM 002079 // RefSeq // Homo sapiens glutamic- GOT1 0,000442 1,76797 oxaloacetic transaminase 1 , soluble (aspar 01
NM_002080 // RefSeq // Homo sapiens glutamic- GOT2 0,000253 1,6705 oxaloacetic transaminase 2, mitochondrial 91
NM 002202 // RefSeq // Homo sapiens ISL LIM ISL1 0,001301 -1,77133 homeobox 1 (ISL1), mRNA. // chr5 // 100 // 85
NM 002245 // RefSeq // Homo sapiens potassium KCNK1 4,17E-06 -2,4294 channel, subfamily K, member 1 (KCNK1), m
NM 002296 // RefSeq // Homo sapiens lamin B reLBR 2,70E-05 -1,28615 ceptor (LBR), transcript variant 1, mRNA.
NM 002381 // RefSeq // Homo sapiens matrilin 3 MATN3 9,71E-05 1,86256 (MATN3), mRNA. // chr2 // 100 // 87 // 1
NM_002389 // RefSeq // Homo sapiens CD46 moleCD46 0,000701 -1,40216 cule, complement regulatory protein (CD46) 88
NM 002392 // RefSeq // Homo sapiens Mdm2, p53 MDM2 0,000272 1,66699 E3 ubiquitin protein ligase homo log (mous 61
NM 002393 // RefSeq // Homo sapiens Mdm4 p53 MDM4 U9E-05 -1,37419 binding protein homo log (mouse) (MDM4), tr
NM 002480 // RefSeq // Homo sapiens protein phosPPP1R12 8,81E-05 1,41056 phatase 1, regulatory subunit 12A (PPP1 A
NM 002489 // RefSeq // Homo sapiens NADH dehyNDUFA4 0,001076 1,40944 drogenase (ubiquinone) 1 alpha subcomplex, 31 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 002570 // RefSeq // Homo sapiens proprotein PCSK6 2,38E-06 -1,54374 convertase subtilisin/kexin type 6 (PCSK
NM 0026 1 // RefSeq // Homo sapiens phosphatidyl- PI4KB 3,95E-05 -1,47366 inositol 4-kinase, catalytic, beta (PI4
NM 002696 // RefSeq // Homo sapiens polymerase POLR2G 3,38E-05 1,32237 (RNA) II (DNA directed) polypeptide G (P
NM 002769 // RefSeq // Homo sapiens protease, serPRSS1 0,000510 -1,88649 ine, 1 (trypsin 1) (PRSS1), mRNA. // c 69
NM 002824 // RefSeq // Homo sapiens parathymosin PTMS 0,000401 2,03167 (PTMS), mRNA. // chrl2 // 100 // 65 // 46
NM 002834 // RefSeq // Homo sapiens protein tyroPTPN11 0,000902 1,59947 sine phosphatase, non-receptor type 11 74
NM_002857 // RefSeq // Homo sapiens peroxisomal PEX19 0,000139 -1,28994 biogenesis factor 19 (PEX19), transcrip 68
NM_002886 // RefSeq // Homo sapiens RAP2B, RAP2B 5,50E-05 1,41129 member of RAS oncogene family (RAP2B), mRNA.
NM 0029 6 // RefSeq // Homo sapiens CAP-GLY CLIPl 0,000248 1,71171 domain containing linker protein 1 (CLIPl), 05
NM 002973 // RefSeq // Homo sapiens ataxin 2 ATXN2 0,000723 1,49264 (ATXN2), mRNA. // chrl2 // 100 // 68 // 28 64
NM 003001 // RefSeq // Homo sapiens succinate SDHC 0,000342 -1,23218 dehydrogenase complex, subunit C, integra 69
NM 003092 // RefSeq // Homo sapiens small nuclear SNRPB2 0,000557 1,31392 ribonucleoprotein polypeptide B (SNRP 96
NM 003096 // RefSeq // Homo sapiens small nuclear SNRPG 0,001004 1,3593 ribonucleoprotein polypeptide G (SNRP 17
NM 003098 // RefSeq // Homo sapiens syntrophin, SNTA1 0,000100 1,44719 alpha 1 (SNTA1), mRNA. // chr20 // 100 54
NM 003107 // RefSeq // Homo sapiens SRY (sex deSOX4 0,000120 -2,05885 termining region Y)-box 4 (SOX4), mRNA. 87
NM 003332 // RefSeq // Homo sapiens TYRO protein TYROBP 0,000332 -1,24025 tyrosine kinase binding protein (TYROB
NM_003344 // RefSeq // Homo sapiens ubiquitin- UBE2H 5,56E-05 -1,47325 conjugating enzyme E2H (UBE2H), transcrip
NM 003392 // RefSeq // Homo sapiens wingless-type WNT5A 0,001500 -1,24142 MMTV integration site family, member 39
NM 003450 // RefSeq // Homo sapiens zinc finger ZNF 174 0,000461 1,4252 protein 174 (ZNF 174), transcript varian 1
NM 003463 // RefSeq // Homo sapiens protein tyroPTP4A1 0,000649 -1,22373 sine phosphatase type IVA, member 1 (PT 02
NM 003477 // RefSeq // Homo sapiens pyruvate PDHX 0,000442 1,35677 dehydrogenase complex, component X (PDHX), 34
NM 003532 // RefSeq // Homo sapiens histone cluster HIST1H3 7,33E-06 -4,39238 1, H3e (HIST1H3E), mRNA. // chr6 // E
NM 003566 // RefSeq // Homo sapiens early endo- EEA1 0,000527 1,72506 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change some antigen 1 (EEA1), mRNA. // chrl2 // 93
NM_003661 // RefSeq // Homo sapiens apolipoprotein APOL1 0,001604 -2,62681 L, 1 (APOL1), transcript variant 1, 98
NM 003666 // RefSeq // Homo sapiens basic leucine BLZF1 2,90E-06 -1,7224 zipper nuclear factor 1 (BLZF1), mRNA
NM 003707 // RefSeq // Homo sapiens RuvB-like 1 RUVBL1 0,000782 1,48803 (E. coli) (RUVBL1), mRNA. // chr3 // 10 66
NM 003762 // RefSeq // Homo sapiens vesicle- VAMP4 0,000402 -1,68248 associated membrane protein 4 (VAMP4), tran 57
NM 003785 // RefSeq // Homo sapiens P antigen PAGE1 0,000728 1,21394 family, member 1 (prostate associated) (P 55
NM 003805 // RefSeq // Homo sapiens CASP2 and CRADD 4,07E-05 1,48819 RIPK1 domain containing adaptor with deat
NM 003818 // RefSeq // Homo sapiens CDP- CDS2 0,000265 1,45671 diacylglycerol synthase (phosphatidate cytidyly 94
NM_003849 // RefSeq // Homo sapiens succinate- SUCLG1 0,001237 1,56949 CoA ligase, alpha subunit (SUCLG1), nucle 1
NM 003901 // RefSeq // Homo sapiens sphingosine- SGPL1 1J5E-05 1,37937 1 -phosphate lyase 1 (SGPL1), mRNA. // c
NM_003972 // RefSeq // Homo sapiens BTAFl RNA BTAFl 0,000225 1,54822 polymerase II, B-TFIID transcription fact 03
NM 003993 // RefSeq // Homo sapiens CDC-Hke CLK2 5,33E-05 -1,23759 kinase 2 (CLK2), mRNA. // chrl // 100 // 3
NM_004134 // RefSeq // Homo sapiens heat shock HSPA9 0,000700 1,54933 70kDa protein 9 (mortalin) (HSPA9), nucl 49
NM 004288 // RefSeq // Homo sapiens cytohesin 1 CYTIP 0,001088 -1,85581 interacting protein (CYTIP), mRNA. // c 51
NM 004292 // RefSeq // Homo sapiens Ras and Rab RI 1 0,001113 1,33952 interactor 1 (RIN1), mRNA. // chrl 1 // 12
NM 004311 // RefSeq // Homo sapiens ADP- ARL3 0,000195 1,62357 ribosylation factor-like 3 (ARL3), mRNA. // chr 57
NM 004384 // RefSeq // Homo sapiens casein kinase CSN 1G3 7,05E-05 1,44168 1, gamma 3 (CSNK1G3), transcript vari
NM 004539 // RefSeq // Homo sapiens asparaginyl- NARS 2J0E-05 1,81563 tRNA synthetase (NARS), mRNA. // chr 18
NM 004562 // RefSeq // Homo sapiens parkinson PARK2 0,001595 -1,52523 protein 2, E3 ubiquitin protein ligase (p 09
NM 004591 // RefSeq // Homo sapiens chemokine CCL20 3,89E-05 -4,73731 (C-C motif) ligand 20 (CCL20), transcript
NM 004626 // RefSeq // Homo sapiens wingless-type WNT11 0,000784 -1,40856 MMTV integration site family, member 62
NM 004655 // RefSeq // Homo sapiens axin 2 ΑΧΓΝ2 0,001222 -1,46793 (AXIN2), mRNA. // chr 17 // 100 // 100 // 24 24
NM 004661 // RefSeq // Homo sapiens cell division CDC23 0,001180 1,48785 cycle 23 homo log (S. cerevisiae) (CDC 21 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 004698 // RefSeq // Homo sapiens PRP3 pre- PRPF3 0,000316 -1,34337 mRNA processing factor 3 homolog (S. cerev 45
NM 004738 // RefSeq // Homo sapiens VAMP (veVAPB 0,000648 1,30044 sicle-associated membrane protein)-associat 18
NM_004744 // RefSeq // Homo sapiens lecithin retinol LRAT 8,21E-05 -1,50068 acyltransferase (phosphatidylcho li
NM 004795 // RefSeq // Homo sapiens klotho (KL), KL 0,000361 -1,43606 mRNA. // chrl3 // 100 // 78 // 18 // 1 32
NM 004866 // RefSeq // Homo sapiens secretory carSCAMPI 0,001213 1,45803 rier membrane protein 1 (SCAMPI), mRNA 16
NM 005044 // RefSeq // Homo sapiens protein kiPRKX l,36E-05 2,58025 nase, X-linked (PRKX), mRNA. // chrX // 1
NM 005067 // RefSeq // Homo sapiens siah E3 ubi- SIAH2 0,001512 1,34349 quitin protein ligase 2 (SIAH2), mRNA. / 07
NM 005202 // RefSeq // Homo sapiens collagen, type COL8A2 0,001486 -1,23495 VIII, alpha 2 (COL8A2), mRNA. // chr 8
NM 005325 // RefSeq // Homo sapiens histone cluster HIST1H1 l,46E-05 -3,583 1, Hla (HIST1H1A), mRNA. // chr6 // A
NM_005333 // RefSeq // Homo sapiens holocyto- HCCS 0,000642 1,63165 chrome c synthase (HCCS), transcript varian 82
NM 005470 // RefSeq // Homo sapiens abl-interactor ABI1 0,000574 1,30702 1 (ABI1), transcript variant 1, mRNA 03
NM 005562 // RefSeq // Homo sapiens laminin, LAMC2 0,000521 -2,78732 gamma 2 (LAMC2), transcript variant 1, mRN 06
NM 005608 // RefSeq // Homo sapiens protein tyroPTPRCAP 0,000652 -1,27802 sine phosphatase, receptor type, C-asso 17
NM 005629 // RefSeq // Homo sapiens solute carrier SLC6A8 0,000459 -1,79906 family 6 (neurotransmitter transport 17
NM 005717 // RefSeq // Homo sapiens actin related ARPC5 0,000431 -1,327 protein 2/3 complex, subunit 5, 16kDa 41
NM 005729 // RefSeq // Homo sapiens peptidylprolyl PPIF 9,02E-05 2,11747 isomerase F (PPIF), nuclear gene enc
NM 005733 // RefSeq // Homo sapiens kinesin family KIF20A 0,001286 1,47779 member 20A (KIF20A), mRNA. // chr5 / 28
NM 005762 // RefSeq // Homo sapiens tripartite motif TRIM28 0,001519 1,44075 containing 28 (TRIM28), mRNA. // c 38
NM_005814 // RefSeq // Homo sapiens glycoprotein GPA33 0,000168 -3,88549 A33 (transmembrane) (GPA33), mRNA. // 81
NM_005869 // RefSeq // Homo sapiens CWC27 CWC27 0,000171 1,64652 spliceosome-associated protein homolog (S. ce 6
NM 005928 // RefSeq // Homo sapiens milk fat glob- MFGE8 0,001018 -2,14504 ule-EGF factor 8 protein (MFGE8), tran 9
NM_005973 // RefSeq // Homo sapiens papillary renal PRCC 0,001007 -1,2169 cell carcinoma (translocation-assoc 03
NM 006023 // RefSeq // Homo sapiens cell division CDC123 0,001066 1,67128 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change cycle 123 homo log (S. cerevisiae) (CD 73
NM 006047 // RefSeq // Homo sapiens RNA binding RBM12 7,20E-06 1,35344 motif protein 12 (RBM12), transcript va
NM_006071 // RefSeq // Homo sapiens polycystic PKDREJ 4,l lE-05 -1,52425 kidney disease (polycystin) and REJ homo
NM_006092 // RefSeq // Homo sapiens nucleotide - NODI 0,000209 1,42976 binding oligomerization domain containin 9
NM 006118 // RefSeq // Homo sapiens HCLS1 assoHAX1 0,000380 -1,23547 ciated protein X-l (HAX1), transcript var 59
NM 006166 // RefSeq // Homo sapiens nuclear tranNFYB 4,l lE-05 1,83094 scription factor Y, beta (NFYB), mRNA.
NM 006180 // RefSeq // Homo sapiens neurotrophic NTRK2 0,000663 -1,39428 tyrosine kinase, receptor, type 2 (NTR 19
NM 006196 // RefSeq // Homo sapiens poly(rC) bindPCBP1 0,000995 1,3228 ing protein 1 (PCBP1), mRNA. // chr2 / 09
NM 006233 // RefSeq // Homo sapiens polymerase POLR2I 0,000158 1,40564 (RNA) II (DNA directed) polypeptide I, 1 91
NM 006363 // RefSeq // Homo sapiens Sec23 homo- SEC23B 0,000249 1,2751 log B (S. cerevisiae) (SEC23B), transcrip 09
NM 006469 // RefSeq // Homo sapiens influenza viIVNS1AB 0,001437 -1,73159 rus NS1A binding protein (IVNS1ABP), mR P 14
NM 006494 // RefSeq // Homo sapiens Ets2 repressor ERF 0,000193 1,37107 factor (ERF), mRNA. // chrl9 // 100
NM_006584 // RefSeq // Homo sapiens chaperonin CCT6B 0,001536 1,43154 containing TCP 1 , subunit 6B (zeta 2) (CC 37
NM_006602 // RefSeq // Homo sapiens transcription TCFL5 0,001219 2,22333 factor-like 5 (basic helix-loop-helix 12
NM 006654 // RefSeq // Homo sapiens fibroblast FRS2 6,22E-05 1,53387 growth factor receptor substrate 2 (FRS2
NM 006714 // RefSeq // Homo sapiens sphingomyeSMPDL3 0,000235 -2,66292 lin phosphodiesterase, acid-like 3A (SMPD A 75
NM 006715 // RefSeq // Homo sapiens mannosidase, MAN2C1 0,000539 -1,31738 alpha, class 2C, member 1 (MAN2C1), tr 52
NM 006738 // RefSeq // Homo sapiens A kinase AKAP13 0,000325 -1,53359 (PRKA) anchor protein 13 (AKAP13), transcr 42
NM 006768 // RefSeq // Homo sapiens BRCA1 assoBRAP 0,000276 1,61836 ciated protein (BRAP), mRNA. // chrl2 // 43
NM 006782 // RefSeq // Homo sapiens zinc finger ZFPL1 0,001215 1,29865 protein-like 1 (ZFPL1), mRNA. // chrl l 96
NM 006814 // RefSeq // Homo sapiens proteasome PSMF1 2,54E-06 1,42048 (prosome, macropain) inhibitor subunit 1
NM_006819 // RefSeq // Homo sapiens stress- STIP1 0,000488 1,43574 induced-phosphoprotein 1 (STIP1), mRNA. // c 71
NM 006839 // RefSeq // Homo sapiens inner memIMMT 0,000449 1,48509 brane protein, mitochondrial (IMMT), nucle 15 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 006861 // RefSeq // Homo sapiens RAB35, RAB35 0,000156 1,52171 member RAS oncogene family (RAB35), transcri 47
NM 006888 // RefSeq // Homo sapiens calmodulin 1 CALM1 0,001121 1,5505 (phosphorylase kinase, delta) (CALM1), 92
NM 006909 // RefSeq // Homo sapiens Ras protein- RASGRF2 0,000638 -1,7884 specific guanine nucleotide-releasing f 18
NM 006923 // RefSeq // Homo sapiens stromal cell- SDF2 0,001432 -1,29388 derived factor 2 (SDF2), transcript va 35
NM 006939 // RefSeq // Homo sapiens son of seven- SOS2 0,000239 -1,29436 less homo log 2 (Drosophila) (SOS2), mRN 75
NM 006943 // RefSeq // Homo sapiens SRY (sex deSOX12 0,001255 1,38149 termining region Y)-box 12 (SOX12), mRNA 26
NM 007007 // RefSeq // Homo sapiens cleavage and CPSF6 0,000784 1,59417 polyadenylation specific factor 6, 68k 73
NM_007043 // RefSeq // Homo sapiens KRR1, small KRR1 0,000855 1,59834 subunit (SSU) processome component, horn 82
NM_007048 // RefSeq // Homo sapiens butyrophilin, BTN3A1 0,001535 -1,4829 subfamily 3, member Al (BTN3A1), tran 88
NM 007195 // RefSeq // Homo sapiens polymerase POLI 4,31E-05 2,18364 (DNA directed) iota (POLI), mRNA. // chr
NM 007219 // RefSeq // Homo sapiens ring finger RNF24 0,000724 2,98562 protein 24 (RNF24), transcript variant 51
NM 007259 // RefSeq // Homo sapiens vacuolar proVPS45 0,000424 -1,49916 tein sorting 45 homo log (S. cerevisiae) 76
NM 007261 // RefSeq // Homo sapiens CD300a CD300A 0,000612 -1,27958 molecule (CD300A), transcript variant 1, mRN 42
NM_007346 // RefSeq // Homo sapiens opioid growth OGFR 0,000560 1,53927 factor receptor (OGFR), mRNA. // chr2 49
NM 007348 // RefSeq // Homo sapiens activating ATF6 l,68E-06 -1,47806 transcription factor 6 (ATF6), mRNA. //
NM_007357 // RefSeq // Homo sapiens component of COG2 0,001064 -1,32704 oligomeric golgi complex 2 (COG2), tra 81
NM 007361 // RefSeq // Homo sapiens nidogen 2 NID2 0,000392 -1,32729 (osteonidogen) (NID2), mRNA. // chr 14 //
NM 009586 // RefSeq // Homo sapiens single-minded SIM2 0,001149 1,57869 homo log 2 (Drosophila) (SIM2), transc 87
NM 012120 // RefSeq // Homo sapiens CD2- CD2AP 9J8E-05 -1,66455 associated protein (CD2AP), mRNA. // chr6 // 10
NM 012124 // RefSeq // Homo sapiens cysteine and CHORDC 0,000984 1,91504 histidine-rich domain (CHORD) containi 1 77
NM 012139 // RefSeq // Homo sapiens secretion regSERGEF 0,000525 1,29655 ulating guanine nucleotide exchange fa 9
NM 012193 // RefSeq // Homo sapiens frizzled famiFZD4 0,001337 1,47718 ly receptor 4 (FZD4), mRNA. // chrl 1 / 99
NM 012215 // RefSeq // Homo sapiens meningioma MGEA5 0,000231 1,27569 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change expressed antigen 5 (hyaluronidase) (MGE 51
NM 012231 // RefSeq // Homo sapiens PR domain PRDM2 0,001157 -1,27503 containing 2, with ZNF domain (PRDM2), tr 57
NM O 12247 // RefSeq // Homo sapiens selenophos- SEPHS1 0,001262 1,63736 phate synthetase 1 (SEPHS1), transcript v 11
NM_012311 // RefSeq // Homo sapiens KIN, antigenKIN 0,001138 1,40937 ic determinant of recA protein homo log 59
NM_012330 // RefSeq // Homo sapiens K(lysine) KAT6B 0,000114 1,29998 acetyltransferase 6B (KAT6B), transcript 93
NM 012426 // RefSeq // Homo sapiens splicing factor SF3B3 0,000880 1,32098 3b, subunit 3, 130kDa (SF3B3), mRNA 38
NM 012467 // RefSeq // Homo sapiens tryptase TPSG1 0E-05 -1,27549 gamma 1 (TPSG1), mRNA. // chrl6 // 100 //
NM 013402 // RefSeq // Homo sapiens fatty acid de- FADS1 0,000251 1,5219 saturase 1 (FADS1), mRNA. // chrl l // 64
NM O 14042 // RefSeq // Homo sapiens anaphase ANAPC15 0,000772 1,3619 promoting complex subunit 15 (ANAPC15), mR 02
NM 014051 // RefSeq // Homo sapiens transmemTMEM14 0,000308 -1,35545 brane protein 14A (TMEM14A), mRNA. // chr6 A 92
NM O 14055 // RefSeq // Homo sapiens intraflagellar IFT81 0,000150 2,00152 transport 81 homolog (Chlamydomonas) 24
NM 014155 // RefSeq // Homo sapiens zinc finger ZBTB44 0,001190 1,41955 and BTB domain containing 44 (ZBTB44), 97
NM 014286 // RefSeq // Homo sapiens neuronal calNCS1 0,000318 2,4069 cium sensor 1 (NCS1), transcript varian 43
NM O 14325 // RefSeq // Homo sapiens coronin, actin COR01C 0,001125 1,7456 binding protein, 1C (COR01C), transc 72
NM O 14394 // RefSeq // Homo sapiens growth horGHITM 2,30E-05 1,59817 mone inducible transmembrane protein (GHI
NM 014458 // RefSeq // Homo sapiens kelch-like 20 KLHL20 0,001115 -1,46899 (Drosophila) (KLHL20), mRNA. // chrl 95
NM_014464 // RefSeq // Homo sapiens tubulo interstiTINAG 0,001563 -1,8053 tial nephritis antigen (TINAG), mRNA. 09
NM_014484 // RefSeq // Homo sapiens molybdenum MOCS3 0,000200 1,4925 cofactor synthesis 3 (MOCS3), mRNA. // c 61
NM O 14502 // RefSeq // Homo sapiens PRP19/PS04 PRPF19 9J5E-05 1,56017 pre-mRNA processing factor 19 homolog (S
NM O 14570 // RefSeq // Homo sapiens ADP- ARFGAP 0,000349 -1,65063 ribosylation factor GTPase activating protein 3 3 59
NM 014624 // RefSeq // Homo sapiens SI 00 calcium S100A6 4,63E-07 -1,53785 binding protein A6 (S100A6), mRNA. //
NM 014639 // RefSeq // Homo sapiens tetratricopep- TTC37 0,000227 1,69732 tide repeat domain 37 (TTC37), mRNA. / 33
NM 014688 // RefSeq // Homo sapiens USP6 N- USP6NL 0,000148 1,4676 terminal like (USP6NL), transcript variant 1 73 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 014698 // RefSeq // Homo sapiens transmemTMEM63 0,000278 -2,09532 brane protein 63A (TMEM63A), mRNA. // chrl A 64
NM 014706 // RefSeq // Homo sapiens squamous cell SART3 0,000596 1,5482 carcinoma antigen recognized by T eel 71
NM 014729 // RefSeq // Homo sapiens thymocyte TOX 6.76E-06 -4,36237 selection-associated high mobility group
NM 014735 // RefSeq // Homo sapiens PHD finger PHF16 0,000362 1,76908 protein 16 (PHF16), transcript variant 1 36
NM 014763 // RefSeq // Homo sapiens mitochondrial MRPL19 0,001189 1,31797 ribosomal protein LI 9 (MRPL19), nucle 84
NM 014810 // RefSeq // Homo sapiens centrosomal CEP350 6,25E-05 -1,47514 protein 350kDa (CEP350), mRNA. // chrl
NM 014827 // RefSeq // Homo sapiens zinc finger ZC3H11A 3,99E-05 -1,32586 CCCH-type containing 11A (ZC3H11A), mRN
NM 014847 // RefSeq // Homo sapiens ubiquitin asUBAP2L 0,000512 -1,25372 sociated protein 2-like (UBAP2L), trans 43
NM_014864 // RefSeq // Homo sapiens family with FAM20B 0,001183 -1,63175 sequence similarity 20, member B (FAM20 19
NM 014977 // RefSeq // Homo sapiens apoptotic ACTNl 0,000432 -1,29995 chromatin condensation inducer 1 (ACINI), 89
NM 015100 // RefSeq // Homo sapiens pogo transpo- POGZ 0,000507 -1,28401 sable element with ZNF domain (POGZ), t 02
NM 015120 // RefSeq // Homo sapiens Alstrom synALMS1 0,000373 1,78252 drome 1 (ALMS1), mRNA. // chr2 // 100 // 83
NM 015172 // RefSeq // Homo sapiens pro line-rich PRRC2C 2,91E-06 -1,56704 coiled-coil 2C (PRRC2C), mRNA. // chrl
NM_015261 // RefSeq // Homo sapiens non-SMC NCAPD3 0,000370 1,5389 condensin II complex, subunit D3 (NCAPD3), 66
NM 015331 // RefSeq // Homo sapiens nicastrin NCSTN 0,000127 -1,60014 (NCSTN), mRNA. // chrl // 100 // 68 // 17 71
NM 015335 // RefSeq // Homo sapiens mediator MED13L 1J8E-05 1,6504 complex subunit 13 -like (MED13L), mRNA. //
NM 01 360 // RefSeq // Homo sapiens superkiller SKIV2L2 0,000530 1, 1697 viralicidic activity 2-like 2 (S. cerev 77
NM_015388 // RefSeq // Homo sapiens Yipl domain YIPF3 6.78E-06 -1,3296 family, member 3 (YIPF3), mRNA. // chr6
NM 015428 // RefSeq // Homo sapiens zinc finger ZNF473 0,000890 1,44132 protein 473 (ZNF473), transcript varian 76
NM 015441 // RefSeq // Homo sapiens olfactomedin- OLFML2 0,001524 -1,24995 like 2B (OLFML2B), mRNA. // chrl // 10 B 26
NM 015469 // RefSeq // Homo sapiens nipsnap hom- NIPSNAP 0,000368 1,33118 olog 3A (C. elegans) (NIPSNAP3A), mRNA. 3A 04
NM_015471 // RefSeq // Homo sapiens NSLl, MIND NSLl 0,000576 -1,28648 kinetochore complex component, homo log ( 04
NM 015523 // RefSeq // Homo sapiens REX2, RNA REX02 0,001535 1,64473 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change exonuclease 2 homo log (S. cerevisiae) (RE 02
NM 015607 // RefSeq // Homo sapiens chromatin CHTOP 7,05E-05 -1,34448 target of PRMTl (CHTOP), transcript varia
NM 015655 // RefSeq // Homo sapiens zinc finger ZNF337 5,26E-09 1,43625 protein 337 (ZNF337), mRNA. // chr20 //
NM 015666 // RefSeq // Homo sapiens GTP binding GTPBP5 0,000710 1,21123 protein 5 (putative) (GTPBP5), mRNA. // 86
NM 015909 // RefSeq // Homo sapiens neuroblastoNBAS 0,000924 1,25504 ma amplified sequence (NBAS), transcript 77
NM 015949 // RefSeq // Homo sapiens golgi to ER GET4 0,000100 1,39888 traffic protein 4 homo log (S. cerevisia 4
NM 016045 // RefSeq // Homo sapiens slowmo ho- SLM02 0,000657 1,32832 molog 2 (Drosophila) (SLM02), transcript v 9
NM_016055 // RefSeq // Homo sapiens mitochondrial MRPL48 0,000772 1,39848 ribosomal protein L48 (MRPL48), nucle 37
NM 016065 // RefSeq // Homo sapiens mitochondrial MRPS16 0,000641 1,56009 ribosomal protein S16 (MRPS16), nucle 95
NM 016071 // RefSeq // Homo sapiens mitochondrial MRPS33 0,000989 1,51408 ribosomal protein S33 (MRPS33), nucle 73
NM 016121 // RefSeq // Homo sapiens potassium KCTD3 7,55E-05 -2,11292 channel tetramerisation domain containing
NM 016138 // RefSeq // Homo sapiens coenzyme Q7 COQ7 0,000300 1,39177 homo log, ubiquinone (yeast) (COQ7), nuc 95
NM 016143 // RefSeq // Homo sapiens NSFL1 (p97) NSFL1C 0,000268 1,25182 cofactor (p47) (NSFL1C), transcript var 39
NM 016196 // RefSeq // Homo sapiens RNA binding RBM19 0,000532 1,8271 motif protein 19 (RBM19), transcript va 19
NM 016202 // RefSeq // Homo sapiens zinc finger ZNF580 0,000604 1,33616 protein 580 (ZNF580), transcript varian 88
NM 016237 // RefSeq // Homo sapiens anaphase ANAPC5 0,000868 1,59121 promoting complex subunit 5 (ANAPC5), tran 32
NM 016240 // RefSeq // Homo sapiens scavenger SCARA3 0,000239 3,27654 receptor class A, member 3 (SCARA3), tran 99
NM 016243 // RefSeq // Homo sapiens cytochrome CYB5R1 0,000313 -1,46734 b5 reductase 1 (CYB5R1), mRNA. // chrl / 16
NM 016265 // RefSeq // Homo sapiens zinc finger ZNF12 0,001365 1,28019 protein 12 (ZNF12), transcript variant 59
NM 016374 // RefSeq // Homo sapiens AT rich interARID4B 5,92E-06 -1,50202 active domain 4B (RBPl-like) (ARID4B),
NM 016399 // RefSeq // Homo sapiens TP53 regulatTRIAP1 0,000268 1,55788 ed inhibitor of apoptosis 1 (TRIAP1), m 69
NM 016470 // RefSeq // Homo sapiens chromosome C20orfl l l 3,08E-06 1,50047
20 open reading frame 111 (C20orfl 11), m
NM 016544 // RefSeq // Homo sapiens DnaJ (Hsp40) DNAJC27 5,85E-07 1,54363 homo log, subfamily C, member 27 (DNAJC Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 016584 // RefSeq // Homo sapiens interleukin 23, IL23A 2,65E-06 -1,83192 alpha subunit pl9 (IL23A), mRNA. //
NM_016605 // RefSeq // Homo sapiens family with FAM53C 0,000103 1,47316 sequence similarity 53, member C (FAM53 66
NM O 16652 // RefSeq // Homo sapiens crooked neck CRNKL1 0,000133 1,52294 pre-mRNA splicing factor-like 1 (Droso 41
NM O 16732 // RefSeq // Homo sapiens RNA binding RALY 0,000794 1,25761 protein, autoantigenic (hnRNP-associate 55
NM_017440 // RefSeq // Homo sapiens Mdml nuclear MDM1 0,000241 1,56152 protein homolog (mouse) (MDM1), transc 98
NM O 17495 // RefSeq // Homo sapiens RNA binding RBM38 0,000289 1,4799 motif protein 38 (RBM38), transcript va 82
NM_017547 // RefSeq // Homo sapiens FAD- FOXRED 0,000830 1,39435 dependent oxidoreductase domain containing 1 (F 1 92
NM O 17583 // RefSeq // Homo sapiens tripartite motif TRIM44 0,000694 1,59217 containing 44 (TRIM44), mRNA. // c 22
NM 017584 // RefSeq // Homo sapiens myo-inositol MIOX 0,000170 -1,5449 oxygenase (MIOX), mRNA. // chr22 // 10 1
NM 017664 // RefSeq // Homo sapiens ankyrin repeat ANKRD1 0,001470 -1,45306 domain 10 (ANKRD10), mRNA. // chrl3 0 31
NM O 17676 // RefSeq // Homo sapiens gypsy re- GIN1 0,001167 1,4977 trotransposon integrase 1 (GIN1), mRNA. // 73
NM O 17782 // RefSeq // Homo sapiens family with FAM208B 3,13E-06 1,83464 sequence similarity 208, member B (FAM2
NM 017838 // RefSeq // Homo sapiens NHP2 ribonu- NHP2 0,000380 1,56437 cleoprotein homolog (yeast) (NHP2), tran 03
NM O 17847 // RefSeq // Homo sapiens chromosome Clorf27 3,42E-06 -1,63888 1 open reading frame 27 (Clorf27), trans
NM O 17895 // RefSeq // Homo sapiens DEAD (Asp- DDX27 5,42E-05 1,46956 Glu-Ala-Asp) box polypeptide 27 (DDX27),
NM O 17987 // RefSeq // Homo sapiens RUN and RUFY2 0,000511 1,55483 FYVE domain containing 2 (RUFY2), transcrip 02
NM O 18040 // RefSeq // Homo sapiens G patch doGPATCH 4,03E-05 -1,52906 main containing 2 (GPATCH2), mRNA. // chr 2
NM_018109 // RefSeq // Homo sapiens mitochondrial MTPAP 0,000221 1,90657 poly(A) polymerase (MTPAP), nuclear g 97
NM 018178 // RefSeq // Homo sapiens golgi phos- GOLPH3 0,001033 -1,70765 phoprotein 3-like (GOLPH3L), mRNA. // chr L 89
NM_018182 // RefSeq // Homo sapiens family with FAM222B 0,001480 -1,37895 sequence similarity 222, member B (FAM2 65
NM O 18244 // RefSeq // Homo sapiens ubiquinol- UQCC 0,000470 1,40054 cytochrome c reductase complex chaperone 53
NM 018268 // RefSeq // Homo sapiens WD repeat WDR41 6,51E-06 1,52299 domain 41 (WDR41), mRNA. // chr5 // 100 /
NM 018328 // RefSeq // Homo sapiens methyl-CpG MBD5 0,000276 -1,93365 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change binding domain protein 5 (MBD5), mRNA. / 77
NM 018475 // RefSeq // Homo sapiens transmemTMEM16 0,001262 -1,7905 brane protein 165 (TMEM165), mRNA. // chr4 5 84
NM O 18489 // RefSeq // Homo sapiens ashl (absent, ASH1L 5,93E-05 -1,40378 small, or homeotic)-like (Drosophila)
NM 018649 // RefSeq // Homo sapiens H2A histone H2AFY2 0,000346 2,44595 family, member Y2 (H2AFY2), mRNA. // ch 15
NM O 18694 // RefSeq // Homo sapiens ADP- ARL6IP4 3,33E-06 1,50431 ribosylation-like factor 6 interacting protein
NM 018704 // RefSeq // Homo sapiens CTTNBP2 N- CTTNBP2 0,000563 -1,48332 terminal like (CTTNBP2NL), mRNA. // chrl NL 43
NM 018848 // RefSeq // Homo sapiens McKusick- MKKS 0,000917 1,69538 Kaufman syndrome (MKKS), transcript varian 75
NM 018945 // RefSeq // Homo sapiens phosphoPDE7B 0,000425 -1,24337 diesterase 7B (PDE7B), mRNA. // chr6 // 100 38
NM O 18984 // RefSeq // Homo sapiens slingshot hoSSH1 8,33E-06 1,94783 mo log 1 (Drosophila) (SSH1), transcript
NM 019044 // RefSeq // Homo sapiens coiled-coil CCDC93 0,000611 -1,30461 domain containing 93 (CCDC93), mRNA. // 87
NM 019046 // RefSeq // Homo sapiens ankyrin repeat ANKRD1 5,94E-05 1,95099 domain 16 (ANKRD16), transcript vari 6
NM O 19082 // RefSeq // Homo sapiens DEAD (Asp- DDX56 0,000434 1,34578 Glu- Ala-Asp) box helicase 56 (DDX56), tra 45
NM 019090 // RefSeq // Homo sapiens KIAA1383 KIAA138 0,001504 -1,54064 (KIAA1383), mRNA. // chrl // 100 // 100 // 3 42
NM 019096 // RefSeq // Homo sapiens GTP binding GTPBP2 6J7E-06 -1,28367 protein 2 (GTPBP2), mRNA. // chr6 // 10
NM 019609 // RefSeq // Homo sapiens carboxypepti- CPXM1 U 1E-05 -1,44051 dase X (Ml 4 family), member 1 (CPXM1),
NM O 19886 // RefSeq // Homo sapiens carbohydrate CHST7 l,22E-05 1,6393 (N-acetylglucosamine 6-0) sulfotransfe
NM_020127 // RefSeq // Homo sapiens tuftelin 1 TUFT1 0,000159 -1,54195 (TUFT1), transcript variant 1, mRNA. // 61
NM 0201 1 // RefSeq // Homo sapiens StAR-related STARD7 0,000168 1,26853 lipid transfer (START) domain containi 01
NM 020167 // RefSeq // Homo sapiens neuromedin U NMUR2 0,000840 -2,77709 receptor 2 (NMUR2), mRNA. // chr5 // 1 48
NM_020192 // RefSeq // Homo sapiens Yael domain YAE1D1 0,000565 1,25222 containing 1 (YAE1D1), mRNA. // chr7 // 56
NM 020312 // RefSeq // Homo sapiens coenzyme Q9 COQ9 4,51E-07 1,36879 homo log (S. cerevisiae) (COQ9), nuclear
NM 020336 // RefSeq // Homo sapiens Ral GTPase RAL- 0,000239 1,24099 activating protein, beta subunit (non-ca GAPB 81
NM 020470 // RefSeq // Homo sapiens Yipl interactYIF1A 0,001270 1,23556 ing factor homolog A (S. cerevisiae) ( 04 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 020652 // RefSeq // Homo sapiens zinc finger ZNF286A 2J0E-05 2,56101 protein 286A (ZNF286A), transcript vari
NM 020689 // RefSeq // Homo sapiens solute carrier SLC24A3 0,001184 -1,48299 family 24 (sodium/potassium/calcium 84
NM 020805 // RefSeq // Homo sapiens kelch-like 14 KLHL14 0,000260 -1,23455
(Drosophila) (KLHL14), mRNA. // chrl8 09
NM 020848 // RefSeq // Homo sapiens KIAA1462 KIAA146 7,49E-05 -1,52479
(KIAA1462), mRNA. // chrlO // 100 // 88 // 2
NM 020883 // RefSeq // Homo sapiens zinc finger, ZSWIM5 0,000179 -2,3067
SWIM-type containing 5 (ZSWIM5), mRNA. 68
NM 020899 // RefSeq // Homo sapiens zinc finger ZBTB4 2J6E-05 1,31497 and BTB domain containing 4 (ZBTB4), tr
NM 021046 // RefSeq // Homo sapiens keratin assoKRTAP5- 0,000143 -1,59939 ciated protein 5-8 (KRTAP5-8), mRNA. // 8 57
NM 021133 // RefSeq // Homo sapiens ribonuclease RNASEL 0,001385 -2,48178
L (2',5'-oligoisoadenylate synthetase- 36
NM 021163 // RefSeq // Homo sapiens RB-associated RBAK 0,001451 1,29484
KRAB zinc finger (RBAK), transcript v 43
NM_021215 // RefSeq // Homo sapiens regulation of RPRD1B 0,001212 1,33094 nuclear pre-mRNA domain containing IB 23
NM 021222 // RefSeq // Homo sapiens prune homo- PRUNE 6,18E-05 -1,59692 log (Drosophila) (PRUNE), mRNA. // chrl /
NM_021233 // RefSeq // Homo sapiens deoxyribonu- DNASE2 0,000615 -1,22419 clease II beta (DNASE2B), transcript var B 13
NM 021630 // RefSeq // Homo sapiens PDZ and LIM PDLIM2 0,001190 1,45662 domain 2 (mystique) (PDLIM2), transcrip 11
NM_021639 // RefSeq // Homo sapiens GC-rich proGPBP1L1 3,88E-05 -1,24636 moter binding protein 1-like 1 (GPBP1L1)
NM 021648 // RefSeq // Homo sapiens TSPY-like 4 TSPYL4 0,000726 1,29882
(TSPYL4), mRNA. // chr6 // 100 // 100 / 16
NM 021873 // RefSeq // Homo sapiens cell division CDC25B 0,001457 2,11315 cycle 25 homo log B (S. pombe) (CDC25B 09
NM 021943 // RefSeq // Homo sapiens zinc finger, ZFAND3 l,64E-07 -1,41275
AN 1 -type domain 3 (ZFAND3), mRNA. // c
NM_021988 // RefSeq // Homo sapiens ubiquitin- UBE2V1 0,001371 1,2635 conjugating enzyme E2 variant 1 (UBE2V1), 68
NM 022073 // RefSeq // Homo sapiens egl nine hom- EGLN3 4,12E-07 -1,91309 olog 3 (C. elegans) (EGLN3), mRNA. // c
NM 022132 // RefSeq // Homo sapiens methylcroto- MCCC2 0,001146 1,49278 noyl-CoA carboxylase 2 (beta) (MCCC2), n 78
NM_022350 // RefSeq // Homo sapiens endoplasmic ERAP2 0,000644 2,88687 reticulum aminopeptidase 2 (ERAP2), tra 42
NM 022469 // RefSeq // Homo sapiens gremlin 2 GREM2 0,000608 -1,23154
(GREM2), mRNA. // chrl // 100 // 100 // 2 11
NM 022489 // RefSeq // Homo sapiens inverted for- INF2 0,000105 -1,31497 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change min, FH2 and WH2 domain containing (INF 17
NM 022492 // RefSeq // Homo sapiens tetratricopep- TTC31 0,001533 1,24286 tide repeat domain 31 (TTC31), transcr 98
NM 022496 // RefSeq // Homo sapiens ARP6 actin- ACTR6 0,001382 1,62155 related protein 6 homo log (yeast) (ACTR6 3
NM 022769 // RefSeq // Homo sapiens CREB reguCRTC3 9,19E-05 1,52917 lated transcription coactivator 3 (CRTC3),
NM_023016 // RefSeq // Homo sapiens sosondowah SOWAHC 0,001157 1,42712 ankyrin repeat domain family member C (S 68
NM 024075 // RefSeq // Homo sapiens tRNA splicing TSEN34 0,000134 1,40567 endonuclease 34 homo log (S. cerevisia 71
NM_024312 // RefSeq // Homo sapiens N- GNPTAB 0,000706 1,41694 acetylglucosamine- 1 -phosphate transferase, alpha 93
NM 024325 // RefSeq // Homo sapiens zinc finger ZNF343 7,97E-05 1,58815 protein 343 (ZNF343), mRNA. // chr20 //
NM 024529 // RefSeq // Homo sapiens cell division CDC73 0,000560 -1,58931 cycle 73, Pafl/RNA polymerase II comp 39
NM_024662 // RefSeq // Homo sapiens N- NAT 10 0,000467 1,46162 acetyltransferase 10 (GCN -related) (NAT 10), tran 29
NM_024676 // RefSeq // Homo sapiens SH3 domain SH3D21 0,000384 -2,13835 containing 21 (SH3D21), transcript varia 52
NM 024685 // RefSeq // Homo sapiens Bardet-Biedl BBS10 2,25E-05 1,60638 syndrome 10 (BBS10), mRNA. // chrl2 //
NM 024715 // RefSeq // Homo sapiens thioredoxin TXNDC1 0,000191 1,34752 domain containing 15 (TXNDC15), mRNA. / 5 56
NM 024747 // RefSeq // Homo sapiens Hermansky- HPS6 0,000420 1,3725 Pudlak syndrome 6 (HPS6), mRNA. // chrlO 57
NM 024754 // RefSeq // Homo sapiens pentatricopep- PTCD2 5,06E-05 1,97563 tide repeat domain 2 (PTCD2), mRNA. //
NM 024766 // RefSeq // Homo sapiens calmodulin- CAM0,000988 1,46028 lysine N-methyltransferase (CAMKMT), niRN KMT 11
NM 024784 // RefSeq // Homo sapiens zinc finger ZBTB3 0,000999 1,32429 and BTB domain containing 3 (ZBTB3), mR 56
NM 024825 // RefSeq // Homo sapiens podocan-like PODNL1 0,000129 1,2926
1 (PODNL1), transcript variant 1, mRNA 47
NM 024855 // RefSeq // Homo sapiens ARP5 actin- ACTR5 0,000249 1,61346 related protein 5 homo log (yeast) (ACTR5 23
NM_024864 // RefSeq // Homo sapiens mitochondrial MRM1 0,001300 1,48867 rRNA methyltransferase 1 homo log (S. 76
NM_024866 // RefSeq // Homo sapiens adrenome- ADM2 l,43E-06 -1,38512 dullin 2 (ADM2), transcript variant 1, mRNA
NM 025079 // RefSeq // Homo sapiens zinc finger ZC3H12A 0,000329 -1,9546
CCCH-type containing 12A (ZC3H12A), mRN 76
NM 025114 // RefSeq // Homo sapiens centrosomal CEP290 0,000423 2,25352 protein 290kDa (CEP290), mRNA. // chrl2 71 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM_025146 // RefSeq // Homo sapiens N(alpha)- NAA50 0,000197 1,37115 acetyltransferase 50, NatE catalytic subun 9
NM 025180 // RefSeq // Homo sapiens centrosomal CEP63 0,000928 1,22257 protein 63kDa (CEP63), transcript varia 98
NM 025191 // RefSeq // Homo sapiens ER degradaEDEM3 7,24E-06 -2,38595 tion enhancer, mannosidase alpha-like 3 (
NM 025212 // RefSeq // Homo sapiens CXXC finger CXXC4 0,000483 -1,44564 protein 4 (CXXC4), niRNA. // chr4 // 100 44
NM 025232 // RefSeq // Homo sapiens receptor acREEP4 l,16E-05 1,57104 cessory protein 4 (REEP4), mRNA. // chr8
NM 025246 // RefSeq // Homo sapiens solute carrier SLC35G2 0,001439 1,83948 family 35, member G2 (SLC35G2), tran 01
NM 030624 // RefSeq // Homo sapiens kelch-like 15 KLHL15 0,001458 1,63855 (Drosophila) (KLHL15), mRNA. // chrX 73
NM 030637 // RefSeq // Homo sapiens DDHD doDDHD1 0,000150 1,73324 main containing 1 (DDHD1), transcript varian 31
NM 030819 // RefSeq // Homo sapiens glucose- GFOD2 0,000775 1,30658 fructose oxidoreductase domain containing 2 54
NM_030919 // RefSeq // Homo sapiens family with FAM83D 4,33E-05 1,87557 sequence similarity 83, member D (FAM83
NM 030973 // RefSeq // Homo sapiens mediator MED25 8,69E-05 1,37006 complex subunit 25 (MED25), mRNA. // chrl9
NM 031232 // RefSeq // Homo sapiens N-terminal NECAB3 4,36E-05 1,28785 EF-hand calcium binding protein 3 (NECAB
NM 031900 // RefSeq // Homo sapiens alanine- AGXT2 0,000459 -1,20218 glyoxylate aminotransferase 2 (AGXT2), nuc 54
NM 031954 // RefSeq // Homo sapiens potassium KCTD10 6,93E-05 1,5303 channel tetramerisation domain containing
NM_032013 // RefSeq // Homo sapiens NDRG family NDRG3 0,000374 1,74198 member 3 (NDRG3), transcript variant 1, 53
NM 032118 // RefSeq // Homo sapiens WD repeat WDR54 0,000812 1,98573 domain 54 (WDR54), mRNA. // chr2 // 100 / 34
NM 032139 // RefSeq // Homo sapiens ankyrin repeat ANKRD2 9,22E-05 1,52115 domain 27 (VPS9 domain) (ANKRD27), m 7
NM 032228 // RefSeq // Homo sapiens fatty acyl FAR1 0,000225 1,43801 CoA reductase 1 (FAR1), mRNA. // chrl 1 / 11
NM 032322 // RefSeq // Homo sapiens ring finger RNF135 0,000191 -1,29605 protein 135 (RNF135), transcript varian 96
NM 032354 // RefSeq // Homo sapiens transmemTMEM10 0,000246 1,34677 brane protein 107 (TMEM107), transcript var 7 05
NM 032389 // RefSeq // Homo sapiens ADP- ARFGAP 0,001489 1,22121 ribosylation factor GTPase activating protein 2 2 35
NM 032429 // RefSeq // Homo sapiens leucine zipLZTS2 0,000606 1,54315 per, putative tumor suppressor 2 (LZTS2) 98
NM_032457 // RefSeq // Homo sapiens protocadherin PCDH7 2,47E-05 -6,06759 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
7 (PCDH7), transcript variant c, mRNA
NM_032599 // RefSeq // Homo sapiens family with FAM71F1 0,000491 -1,23937 sequence similarity 71, member Fl (FAM7 27
NM 032663 // RefSeq // Homo sapiens ubiquitin speUSP30 0,000110 1,30046 cific peptidase 30 (USP30), mRNA. // c 15
NM 032807 // RefSeq // Homo sapiens F-box protein, FBX018 0,000378 1,80784 helicase, 18 (FBX018), transcript va 98
NM 032816 // RefSeq // Homo sapiens centrosomal CEP89 0,000216 1,51514 protein 89kDa (CEP89), mRNA. // chrl9 / 35
NM 032826 // RefSeq // Homo sapiens solute carrier SLC35B4 0,000609 2,05363 family 35, member B4 (SLC35B4), mRNA 07
NM_032834 // RefSeq // Homo sapiens asparagine- ALG10 0,000452 1,60864 linked glycosylation 10, alpha- 1 ,2-gluco 94
NM 032890 // RefSeq // Homo sapiens dispatched DISP1 0,000218 -2,41308 homo log 1 (Drosophila) (DISP1), mRNA. // 79
NM 033081 // RefSeq // Homo sapiens death inducer- DIDOl 0,000787 1,22185 obliterator 1 (DIDO 1), transcript var 73
NM 033109 // RefSeq // Homo sapiens polyribonuPNPT1 l,36E-05 1,55054 cleotide nucleotidyltransferase 1 (PNPT1)
NM 033121 // RefSeq // Homo sapiens ankyrin repeat ANKRD1 0,000946 1,86212 domain 13A (ANKRD13A), mRNA. // chrl 3A 82
NM 033198 // RefSeq // Homo sapiens phosphatidyl- PIGS 0,000420 -1,35094 inositol glycan anchor biosynthesis, cl 31
NM 033281 // RefSeq // Homo sapiens mitochondrial MRPS36 2,07E-05 1,47483 ribosomal protein S36 (MRPS36), nucle
NM 033624 // RefSeq // Homo sapiens F-box protein FBX021 0,001608 1,37753 21 (FBX021), transcript variant 1, mR 99
NM 052847 // RefSeq // Homo sapiens guanine nuGNG7 0,001033 -1,29628 cleotide binding protein (G protein), gam 17
NM 052875 // RefSeq // Homo sapiens vacuolar proVPS26B 8,25E-05 1,4459 tein sorting 26 homo log B (S. pombe) (V
NM 052893 // RefSeq // Homo sapiens BTB (POZ) BTBD9 0,000327 -1,4213 domain containing 9 (BTBD9), transcript v 42
NM 052972 // RefSeq // Homo sapiens leucine-rich LRG1 0,000877 -2,62197 alpha-2-glycoprotein 1 (LRG1), mRNA. / 77
NM_053052 // RefSeq // Homo sapiens synaptosomal- SNAP47 0,001430 -1,20285 associated protein, 47kDa (SNAP47), mR 37
NM 057169 // RefSeq // Homo sapiens G protein- GIT2 0,000292 1,46617 coupled receptor kinase interacting ArfGA 92
NM 080599 // RefSeq // Homo sapiens UPF2 regulaUPF2 0,000143 1,67195 tor of nonsense transcripts homolog (yea 93
NM 080600 // RefSeq // Homo sapiens myelin assoMAG 0,000229 -1,32911 ciated glycoprotein (MAG), transcript va
NM_080656 // RefSeq // Homo sapiens CDKN2A CDKN2AI 0,000303 1,65033 interacting protein N-terminal like (CDKN2AI PNL 79 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 080667 // RefSeq // Homo sapiens coiled-coil CCDC104 U8E-05 1,52447 domain containing 104 (CCDC104), mR A.
NM_080821 // RefSeq // Homo sapiens family with FAM210B 0,000516 1,76357 sequence similarity 210, member B (FAM2 39
NM_130466 // RefSeq // Homo sapiens ubiquitin proUBE3B l,55E-08 1,57749 tein ligase E3B (UBE3B), transcript va
NM 130906 // RefSeq // Homo sapiens peptidylprolyl PPIL3 0,001534 -1,60762 isomerase (cyclophilin)-like 3 (PPIL 34
NM_133259 // RefSeq // Homo sapiens leucine-rich LRPPRC 2,40E-05 1,67421 pentatricopeptide repeat containing (L
NM 133263 // RefSeq // Homo sapiens peroxisome PPARGC1 0,000155 1,90548 proliferator-activated receptor gamma, c B 95
NM 133447 // RefSeq // Homo sapiens ankyrin repeat AGAP11 0,001295 2,53933 and GTPase domain Arf GTPase activat 92
NM 133496 // RefSeq // Homo sapiens solute carrier SLC30A7 0,000928 -1,20954 family 30 (zinc transporter), member 32
NM 138499 // RefSeq // Homo sapiens PWWP doPWWP2B 0,000345 1,44521 main containing 2B (PWWP2B), transcript vari 72
NM 138773 // RefSeq // Homo sapiens solute carrier SLC25A4 0,000262 1,46163 family 25, member 46 (SLC25A46), mRN 6 65
NM 139015 // RefSeq // Homo sapiens signal peptide SPPL3 0,000438 1,48281 peptidase like 3 (SPPL3), mRNA. // c 83
NM 139055 // RefSeq // Homo sapiens ADAM metal- ADAMTS 0,000594 -1,3551 lopeptidase with thrombospondin type 1 mo 15 74
NM 139312 // RefSeq // Homo sapiens YMEl-like 1 YME1L1 0,000429 1,40919
(S. cerevisiae) (YME1L1), nuclear gene 02
NM 144563 // RefSeq // Homo sapiens ribose 5- RPIA 0,000738 1,7074 phosphate isomerase A (RPIA), mRNA. // chr 53
NM 144650 // RefSeq // Homo sapiens alcohol dehyADHFE1 2,16E-07 -1,6318 drogenase, iron containing, 1 (ADHFE1),
NM 144660 // RefSeq // Homo sapiens sterile alpha SAMD8 0,000376 1,48792 motif domain containing 8 (SAMD8), tr 43
NM 144736 // RefSeq // Homo sapiens chromosome C2orf56 0,000145 1,4022
2 open reading frame 56 (C2orf56), nucle
NMJ44775 // RefSeq // Homo sapiens Smith- SMCR8 0,000293 1,36704
Magenis syndrome chromosome region, candidate 17
NM 144982 // RefSeq // Homo sapiens zinc finger, ZFC3H1 3,12E-05 1,5588
C3Hl-type containing (ZFC3H1), mRNA. /
NM 145176 // RefSeq // Homo sapiens solute carrier SLC2A12 0,000103 -1,58611 family 2 (facilitated glucose transp 68
NM 152345 // RefSeq // Homo sapiens ankyrin repeat ANKRD1 0,000553 1,9531 domain 13B (ANKRD13B), mRNA. // chrl 3B 29
NM 152380 // RefSeq // Homo sapiens T-box 15 TBX15 0,000745 -2,82976
(TBX1 ), mRNA. // chrl // 100 // 88 // 22 52
NM 152442 // RefSeq // Homo sapiens RAD9 homo- RAD9B 8,40E-05 1,36039 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change log B (S. pombe) (RAD9B), mRNA. // chrl2 /
NM 152503 // RefSeq // Homo sapiens chromosome C20orfl32 0,001132 1,42846 20 open reading frame 132 (C20orfl32), t 68
NM 152519 // RefSeq // Homo sapiens KAT8 regulaKANSL1 0,000134 -2,44698 tory NSL complex subunit 1-like (KANSL1L L 4
NM 152545 // RefSeq // Homo sapiens RasGEF doRASGEF 1 0,000283 -2,80615 main family, member IB (RASGEF IB), mRNA. / B 89
NM 152605 // RefSeq // Homo sapiens zinc finger ZNF781 0,001298 -1,20798 protein 781 (ZNF781), mRNA. // chrl9 // 79
NM 152686 // RefSeq // Homo sapiens DnaJ (Hsp40) DNAJC 18 0,000776 1,86226 homo log, subfamily C, member 18 (DNAJC 18
NM 152787 // RefSeq // Homo sapiens TGF-beta TAB3 0,000353 1,47134 activated kinase 1/MAP3 7 binding protein 12
NM 152905 // RefSeq // Homo sapiens neural precurNEDD1 0,000118 1,88129 sor cell expressed, developmentally do 2
NM 153450 // RefSeq // Homo sapiens mediator MED 19 0,000654 1,33905 complex subunit 19 (MED 19), mRNA. // chrl 1 23
NM 153451 // RefSeq // Homo sapiens oral cancer ORAOV1 2,10E-05 1,42326 overexpressed 1 (ORAOV1), mRNA. // chrl
NM_153477 // RefSeq // Homo sapiens ubiquitously- UXT 0,000659 1,46217 expressed, prefoldin-like chaperone (U 56
NM 1 3640 // RefSeq // Homo sapiens pantothenate PANK2 0,001237 1,5008 kinase 2 (PANK2), transcript variant 2 53
NM 153810 // RefSeq // Homo sapiens CDK2- CACUL1 8,20E-05 1,42134 associated, cullin domain 1 (CACUL1), mRNA. //
NM 170739 // RefSeq // Homo sapiens mitochondrial MRPL11 0,000122 1,60909 ribosomal protein LI 1 (MRPL11), nucle 85
NM 170746 // RefSeq // Homo sapiens chromosome Cl lorG l 0,000763 1,2109 11 open reading frame 31 (C 1 lorf31), mRN 58
NM 173179 // RefSeq // Homo sapiens solute carrier SLC35C2 0,000631 1,29149 family 35, member C2 (SLC35C2), tran 11
NM 173555 // RefSeq // Homo sapiens trypsin doTYSND1 0,001221 1,57321 main containing 1 (TYSND1), transcript va 76
NM 173651 // RefSeq // Homo sapiens fibrous sheath FSIP2 7,83E-05 -2,04693 interacting protein 2 (FSIP2), mRNA.
NM 173810 // RefSeq // Homo sapiens tetratricopep- TTC9C l,33E-05 1,30773 tide repeat domain 9C (TTC9C), mRNA. /
NM 173852 // RefSeq // Homo sapiens keratinocyte KRTCAP 0,000680 -1,2311 associated protein 2 (KRTCAP2), mRNA. 2 06
NMJ75929 // RefSeq // Homo sapiens fibroblast FGF14 0,001544 -1,24276 growth factor 14 (FGF14), transcript var
NM l 76787 // RefSeq // Homo sapiens phosphatidyl- PIGN 6,54E-06 1,97638 inositol glycan anchor biosynthesis, cl
NM_176818 // RefSeq // Homo sapiens glutamyl- GATC l,38E-06 1,8109 tRNA(Gln) amidotransferase, subunit C homo Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK LNCipedia) Symbol Change
NM_1774 5 // RefSeq // Homo sapiens basic helix- BHLHA1 0,001156 -1,27898 loop-helix family, member al5 (BHLHA15) 5 41
NM 177553 // RefSeq // Homo sapiens growth arrest- GAS2 0,000257 -1,32308 specific 2 (GAS2), transcript variant 42
NM 178580 // RefSeq // Homo sapiens histocompatiHM13 0,000198 1,31016 bility (minor) 13 (HM13), transcript va 96
NM 181515 // RefSeq // Homo sapiens mitochondrial MRPL21 0,000460 1,31757 ribosomal protein L21 (MRPL21), nucle 98
NM_181578 // RefSeq // Homo sapiens replication RFC5 0,000508 1,92089 factor C (activator 1) 5, 36.5kDa (RFC5 88
NM 181699 // RefSeq // Homo sapiens protein phosPPP2R1B 0,001404 1,31989 phatase 2, regulatory subunit A, beta ( 13
NM_181783 // RefSeq // Homo sapiens transmemTMTC3 3,61E-08 1,95925 brane and tetratricopeptide repeat containi
NM_181838 // RefSeq // Homo sapiens ubiquitin- UBE2D2 0,001197 1,34504 conjugating enzyme E2D 2 (UBE2D2), transc 77
NM 181846 // RefSeq // Homo sapiens zinc finger ZSCAN22 0,000618 1,2937 and SCAN domain containing 22 (ZSCAN22) 31
NM_182612 // RefSeq // Homo sapiens Parkinson PDDC1 0,001270 1,33877 disease 7 domain containing 1 (PDDC1), mR 6
NM 183013 // RefSeq // Homo sapiens cAMP resCREM 0,000324 1,51244 ponsive element modulator (CREM), transcrip 36
NM 183240 // RefSeq // Homo sapiens transmemTMEM37 9,30E-05 -1,65575 brane protein 37 (TMEM37), mRNA. // chr2 //
NM 194271 // RefSeq // Homo sapiens ring finger RNF34 0,000434 1,49997 protein 34, E3 ubiquitin protein ligase 36
NM 194314 // RefSeq // Homo sapiens zinc finger ZBTB41 0,000105 -1,72205 and BTB domain containing 41 (ZBTB41), 28
NM 198046 // RefSeq // Homo sapiens zinc finger, ZDHHC1 0,000300 1,61426 DHHC-type containing 16 (ZDHHC16), tra 6 26
NM 198281 // RefSeq // Homo sapiens GPRIN family GPRIN3 0,001497 -1,67612 member 3 (GPRIN3), mRNA. // chr4 // 10 65
NM 198529 // RefSeq // Homo sapiens EF-hand calEFCAB5 6,48E-06 -1,56597 cium binding domain 5 (EFCAB5), transcri
NM 198551 // RefSeq // Homo sapiens melanoma MIA3 0,000377 -1,60087 inhibitory activity family, member 3 (MIA3 54
NM_199421 // RefSeq // Homo sapiens suppressor of SOCS4 0,000725 1,35866 cytokine signaling 4 (SOCS4), transcr 64
NM 199460 // RefSeq // Homo sapiens calcium chanCACNA1 0,000219 -1,49252 nel, voltage-dependent, L type, alpha 1 C 15
NM 201555 // RefSeq // Homo sapiens four and a half FHL2 0,000177 -2,3147 LIM domains 2 (FHL2), transcript va 63
NM_203406 // RefSeq // Homo sapiens metallo-beta- MBLAC2 0,000217 1,95145 lactamase domain containing 2 (MBLAC2) 29
NM 207012 // RefSeq // Homo sapiens adaptor- AP3M1 0,000207 1,40305 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change related protein complex 3, mu 1 subunit (AP 75
NM_212503 // RefSeq // Homo sapiens cyclin- CDK18 0,000312 -1,52993 dependent kinase 18 (CDK18), transcript vari 44
NM 214462 // RefSeq // Homo sapiens dapper, anDACT2 0,001115 -1,29867 tagonist of beta-catenin, homo log 2 (Xeno 71
NR 001539 // RefSeq // Homo sapiens testis-specific TTTY22 0,000214 -1,30581 transcript, Y-linked 22 (non-protei 64
NR 001562 // RefSeq // Homo sapiens annexin A2 ANXA2P 8,18E-05 -1,26755 pseudogene 1 (ANXA2P1), non-coding RNA. 1
NR 002710 // RefSeq // Homo sapiens arachidonate ALOX12P 2,09E-06 -5,70699
12-lipoxygenase pseudogene 2 (ALOX12P2 2
NR 002751 // RefSeq // Homo sapiens small nucleoSNORD41 0,001290 1,66004 lar RNA, C/D box 41 (SNORD41), small nu 16
NR_002779 // RefSeq // Homo sapiens nudix (nucleoNUDT9P1 0,000289 1,89134 side diphosphate linked moiety X)-type 1
NR 002809 // RefSeq // Homo sapiens uncharacter- LOC3387 0,001127 1,45715 ized LOC338799 (LOC338799), non-coding R 99 62
NR 002913 // RefSeq // Homo sapiens small nucleoSNORD63 0,000915 2,16873 lar RNA, C/D box 63 (SNORD63), small nu 4
NR_002940 // RefSeq // Homo sapiens leucine rich LRRC37A 7,36E-06 1,94338 repeat containing 37, member A4, pseud 4P
NR 002998 // RefSeq // Homo sapiens small Cajal SCAR- 0,000354 -1,50753 body-specific RNA 3 (SCARNA3), guide RN NA3 19
NR 003056 // RefSeq // Homo sapiens small nucleoSNORD67 7,48E-06 1,41457 lar RNA, C/D box 67 (SNORD67), small nu
NR 003079 // RefSeq // Homo sapiens small nucleoSNORD11 4,95E-06 1,54511 lar RNA, C/D box 111 (SNORD111), small 1
NR 003125 // RefSeq // Homo sapiens small nucleoSNORD14 U4E-05 2,40066 lar RNA, C/D box 14E (SNORD14E), small E
NR 003684 // RefSeq // Homo sapiens small nucleoSNORD11 0,000143 2,24693 lar RNA, C/D box 119 (SNORD119), small 9 32
NR_004384 // RefSeq // Homo sapiens small SNAR-F 6,l lE-05 -1,37739 ILF3 NF90-associated RNA F (SNAR-F), small nu
NR 004395 // RefSeq // Homo sapiens small nucleoSNORD1 2,02E-05 1,75932 lar RNA, C/D box 1A (SNORD1A), small nu A
NR 015378 // RefSeq // Homo sapiens uncharacter- LOC4015 0,000502 1,75307 ized LOC401588 (LOC401588), non-coding R 88 5
NR 015427 // RefSeq // Homo sapiens long intergenic LINC0009 0,000353 1,44212 non-protein coding RNA 94 (LINC0009 4 94
NR 024457 // RefSeq // Homo sapiens uncharacter- LOCIOOI 0,001158 -1,24906 ized LOCI 00190940 (LOCI 00190940), non-co 90940 74
NR_024458 // RefSeq // Homo sapiens TPT1 an- TPT1-AS1 0,001589 -1,5234 tisense RNA 1 (non-protein coding) (TPT1-AS1 02
NR 024505 // RefSeq // Homo sapiens long intergenic LINC0059 0,001209 -1,33847 non-protein coding RNA 598 (LINC005 8 91 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NR_024577 // RefSeq // Homo sapiens Sec61 alpha 2 SEC61A2 0,001203 1,78705 subunit (S. cerevisiae) (SEC61A2), tr 51
NR 024585 // RefSeq // Homo sapiens uncharacter- LOCIOOI 0,001549 1,23815 ized LOC100128292 (LOC100128292), non-co 28292 93
NR_026052 // RefSeq // Homo sapiens CENPB DNA- MGC2752 0,000146 1,3821 binding domains containing 1 pseudogene ( 15
NR 026664 // RefSeq // Homo sapiens uncharacter- MGC 1602 0,000129 -1,2694 ized LOC85009 (MGC 16025), non-coding RNA 5 67
NR_026835 // RefSeq // Homo sapiens tigger trans- FLJ37201 2,92E-05 1,57934 posable element derived 2 pseudogene (F
NR_026846 // RefSeq // Homo sapiens anaphase proLOC2850 0,001012 1,32505 moting complex subunit 1 pseudogene (LO 74 84
NR 026954 // RefSeq // Homo sapiens uncharacter- LOC9024 0,000318 -1,70983 ized LOC90246 (LOC90246), non-coding RNA 6 42
NR_027157 // RefSeq // Homo sapiens TMPO anTMPO- 0,001468 1,38027 tisense RNA 1 (non-protein coding) (TMPO-AS1 AS1 2
NR_027258 // RefSeq // Homo sapiens prolyl-tRNA PRORSD1 0,000543 1,23688 synthetase associated domain containing P 93
NR_027280 // RefSeq // Homo sapiens SUMOl actiSAE1 0,001089 1,32461 vating enzyme subunit 1 (SAE1), transcrip 66
NR 027451 // RefSeq // Homo sapiens uncharacter- LOC6479 0,000558 1,36491 ized LOC647979 (LOC647979), non-coding R 79 57
NR_027709 // RefSeq // Homo sapiens IDI2 antisense IDI2-AS1 2,51E-05 1,67902
RNA 1 (non-protein coding) (IDI2-AS1
NR 028138 // RefSeq // Homo sapiens uncharacter- LOC3387 0,000645 1,39864 ized LOC338758 (LOC338758), non-coding R 58 82
NR_028383 // RefSeq // Homo sapiens translocase of TIMM8B 0,000107 1,40999 inner mitochondrial membrane 8 homol 59
NR_028402 // RefSeq // Homo sapiens CSRP2 binCSRP2BP 0,000203 1,67052 ding protein (CSRP2BP), transcript variant 76
NR_028407 // RefSeq // Homo sapiens armadillo reARMCX4 0,001068 -1,78257 peat containing, X-linked 4 (ARMCX4), t 78
NR_028474 // RefSeq // Homo sapiens LSM3 homo- LOC1003 0,000345 1,22385 log, U6 small nuclear RNA associated (S. c 03749 36
NR 029493 // RefSeq // Homo sapiens microRNA 21 MIR21 2,02E-05 -2,22993
(MIR21), microRNA. // chrl7 // 100 // 1
NR 029663 // RefSeq // Homo sapiens microRNA MIR15B U9E-06 1,88837
15b (MIR15B), microRNA. // chr3 // 100 //
NR 030350 // RefSeq // Homo sapiens microRNA MIR619 0,001247 1,41009
619 (MIR619), microRNA. // chrl2 // 100 // 46
NR 030597 // RefSeq // Homo sapiens microRNA MIR876 0,000680 1,21556
876 (MIR876), microRNA. // chr9 // 100 // 03
NR_030722 // RefSeq // Homo sapiens family with FAM104B 0,000469 1,57985 sequence similarity 104, member B (FAM1 96
NR_033189 // RefSeq // Homo sapiens phosphodieste- LOCIOOI 0,000343 -1,37703 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change rase 4D interacting protein pseudogene 30000 79
NR_033362 // RefSeq // Homo sapiens autophagy ATG12 l,27E-06 1,40396 related 12 (ATG12), transcript variant 2,
NR 033373 // RefSeq // Homo sapiens uncharacter- FLJ39534 0,000233 1,29691 ized FLJ39534 (FLJ39534), non-coding RNA 29
NR_033697 // RefSeq // Homo sapiens NADH dehyNDUFA2 0,000925 1,47748 drogenase (ubiquinone) 1 alpha subcomplex, 75
NR_033759 // RefSeq // Homo sapiens ATP synthase, ATP5L 6,40E-07 1,57276
H+ transporting, mitochondrial Fo com
NR 033805 // RefSeq // Homo sapiens uncharacter- LOC2209 0,000192 1,40749 ized LOC220906 (LOC220906), non-coding R 06 52
NR_033876 // RefSeq // Homo sapiens long intergenic LINC0051 2,89E-05 -1,56208 non-protein coding RNA 511 (LF C005 1
NR 036155 // RefSeq // Homo sapiens microRNA MIR3188 0,001269 1,38135
3188 (MIR3188), microRNA. // chrl9 // 100 15
NR 036179 // RefSeq // Homo sapiens microRNA MIR4297 0,001532 -1,33616
4297 (MIR4297), microRNA. // chrlO // 100 13
NR 036227 // RefSeq // Homo sapiens microRNA MIR2355 5J6E-05 -1,78443
2355 (MIR2355), microRNA. // chr2 // 100 /
NR_036435 // RefSeq // Homo sapiens argi- RSRC2 0,001254 1,4655 nine/serine-rich coiled-coil 2 (RSRC2), transcr 6
NR 036539 // RefSeq // Homo sapiens uncharacter- LOC6446 0,000626 1,42322 ized LOC644656 (LOC644656), non-coding R 56 74
NR_036676 // RefSeq // Homo sapiens interferon, IFNA22P 0,000343 1,26319 alpha 22, pseudogene (IFNA22P), non-cod 34
NR_036679 // RefSeq // Homo sapiens alpha-2- AZGP1P1 0,000647 -1,24752 glycoprotein 1, zinc-binding pseudogene 1 ( 98
NR_037167 // RefSeq // Homo sapiens quinone oxi- LOC7301 0,000204 -2,56698 doreductase-like protein 2 pseudogene (L 02 06
NR_037606 // RefSeq // Homo sapiens mitochondrial MRPS14 l,14E-05 -1,2987 ribosomal protein S14 (MRP S 14), trans
NR_037638 // RefSeq // Homo sapiens solute carrier SLC28A3 0,001619 -2,87347 family 28 (sodium-coupled nucleoside 14
NR 037804 // RefSeq // Homo sapiens NPHP3- NPHP3- 2,29E-05 1,2902
ACAD11 readthrough (NPHP3-ACAD11), non- ACAD11
coding
NR 037851 // RefSeq // Homo sapiens uncharacter- LOC1005 7,36E-05 -1,62737 ized LOCI 00505918 (LOCI 00505918), non-co 05918
NR 037869 // RefSeq // Homo sapiens uncharacter- LOC6531 4,97E-05 -1,3028 ized LOC653160 (LOC653160), non-coding R 60
NR_038262 // RefSeq // Homo sapiens MIR210 host MIR210H 0,001104 -1,57369 gene (non-protein coding) (MIR210HG), n G 07
NR_038360 // RefSeq // Homo sapiens SPTY2D1 SPTY2D1 l,48E-05 1,42639 antisense RNA 1 (non-protein coding) (SPTY2 -AS1
NR_038379 // RefSeq // Homo sapiens leucine car- LOC5542 0,000127 1,5339 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change boxyl methyltransferase 1 pseudogene (LO 06 12
NR 038396 // RefSeq // Homo sapiens uncharacter- LOC1005 0,000586 1,31795 ized LOCI 00506469 (LOCI 00506469), non-co 06469 63
NR 038844 // RefSeq // Homo sapiens uncharacter- LOC6448 0,000437 -1,29986 ized LOC644838 (LOC644838), non-coding R 38 69
NR 038857 // RefSeq // Homo sapiens uncharacter- LOC4410 0,001570 -1,33274 ized LOC441009 (LOC441009), non-coding R 09 8
NR 038923 // RefSeq // Homo sapiens uncharacter- LOC2541 4,54E-05 1,40365 ized LOC254100 (LOC254100), non-coding R 00
NR 038937 // RefSeq // Homo sapiens uncharacter- LOC1005 0,000797 1,36927 ized LOC100505761 (LOC100505761), transc 05761 09
NR 039625 // RefSeq // Homo sapiens microRNA MIR4427 8J4E-05 -2,91825
4427 (MIR4427), microRNA. // chrl // 100 /
NR 040047 // RefSeq // Homo sapiens uncharacter- LOC1005 9,58E-05 1,43768 ized LOCI 00507495 (LOCI 00507495), transc 07495
NR 046020 // RefSeq // Homo sapiens transmemTMPRSS3 0,001328 -4,43879 brane protease, serine 3 (TMPRSS3), transcr 37
NR 046229 // RefSeq // Homo sapiens uncharacter- LOC1005 4,08E-06 -2,80569 ized LOC100508120 (LOC100508120), non-co 08120
NR 046262 // RefSeq // Homo sapiens uncharacter- LOC6467 0,000632 1,70791 ized LOC646 19 (LOC646 19), non-coding R 19 77
NR 046437 // RefSeq // Homo sapiens solute carrier SLC30A1 7,00E-07 -2,08218 family 30, member 10 (SLC30A10), tra 0
NR_046512 // RefSeq // Homo sapiens SAMSN1 an- SAMSNl- 0,000574 -1,21031 tisense RNA 1 (non-protein coding) (SAMSN1 AS1 45
NR_046578 // RefSeq // Homo sapiens CACNA1C CACNA1 0,000604 1,22108 antisense RNA 4 (non-protein coding) (CACNA C-AS4 64
NR_046935 // RefSeq // Homo sapiens RNA, U6 RNU6-64 0,001473 -1,27085 small nuclear 64 (RNU6-64), small nuclear R 12
NR_051962 // RefSeq // Homo sapiens inversin INVS 0,000667 1,42107
(INVS), transcript variant 3, non-coding R 44
NR_072995 // RefSeq // Homo sapiens GLI pathogen- GLIPR1L 0,000943 1,20363 esis-related 1 like 2 (GLIPR1L2), trans 2 41
TCONS 00000362-XLOC 000509 // Rinn lincRNA // ] inc-CFH-3 l,47E-05 -1,56805 chrl :+:193648023-193696313 //
TCONS 00000576-XLOC 000922 // Rinn lincRNA // linc-F3-4 9,98E-05 -3,37385 chrl :-:95086706-95089740 // chr
TCONS 00000618-XLOC 000982 // Rinn lincRNA // linc-TBXl 5 0,001426 -1,34283 chrl :- : 119542966- 119544015 // 93
TCONS 00000674-XLOC 001085 // Rinn lincRNA // linc-DPT-1 0,000122 -1,25348 chrl :-: 168732602-168743728 // 28
TCONS_00001247-XLOC_000529 // Rinn lincRNA // linc-PRELP 0,001505 -1,22519 chrl :+:203343737-203369257 // 59
TCONS_00001318-XLOC_000600 // Rinn lincRNA // linc-RHOU 4J5E-06 -1,65525 chrl :+:228688982-228697976 // c Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
TCONS 00001333-XLOC 000628 // Rinn lincRNA // ] inc- 0,001007 -1,70849
GPR137B-3 chrl :+:236120926-236138865 81
TCONS 00001555-XLOC 000897 // Rinn lincRNA // linc-ODF2L 0,000444 -1,38592 chrl :-:86966981-86969353 // ch 31
TCONS_00001577-XLOC_000913 // Rinn lincRNA // linc-GBP5- 0,000831 -1,24236
6 chrl :-:90752759-90763021 // c 19
TCONS_00001762-XLOC_001134 // Rinn lincRNA // linc- 2,80E-06 -1,7964
FAM5C-4 chrl :-: 192904812-192916494 /
TCONS 00001789-XLOC 001178 // Rinn lincRNA // linc-YODl- 0,001602 -1,28979
5 chrl :-:207574927-207589566 // 81
TCONS 00001821-XLOC 001205 // Rinn lincRNA // linc- 0,000954 -1,34678
GPATCH2-3 chrl :-:219150088-219164653 08
TCONS 00001854-XLOC 001242 // Rinn lincRNA // linc- 7,20E-05 -1,53468
HIST3H2A-2 chrl :-:229027197-22903356
TCONS 00001882-XLOC 001265 // Rinn lincRNA // linc- 0,000107 -1,7331
IRF2BP2-1 chrl :-:235087870-23 100203 31
TCONS 00002744-XLOC 001974 // Rinn lincRNA LINC0029 0,001520 -1,26509
// linc-CMPK2-2 chr2:-:8347272-8468549 // ch 9 82
TCONS 00003265-XLOC 002069 // Rinn lincRNA // inc-HAAO- 0,000120 -1,32581
2 chr2:-:43268331-43270921 // c 11
TCONS_00003286-XLOC_002099 // Rinn lincRNA // linc- 0,000486 1,36088
SMEK2 chr2:-:55852072-55858573 // ch 35
TCONS_00003900-XLOC_001703 // Rinn lincRNA // linc- 0,000155 -1,70016
TNFAIP6-6 chr2:+: 150683557-150704743 87
TCONS_00003986-XLOC_001809 // Rinn lincRNA // linc- 0,000625 -1,77498
CASPlO-1 chr2:+:202038290-202042899 58
TCONS 00004059-XLOC 001907 // Rinn lincRNA // linc-MLPH- 0,000842 -1,35492
5 chr2:+:238059251-238061515 // 22
TCONS 00004196-XLOC 002042 // Rinn lincRNA // linc- 0,000343 -1,30111
SRD5A2-2 chr2:-:31935274-31990384 // 28
TCONS 00004354-XLOC 002229 // Rinn lincRNA // linc-RFX8 6,44E-05 -1,37061 chr2 :- : 102168064- 102184370 // c
TCONS 00006134-XLOC 002735 // Rinn lincRNA // linc- 0,001048 -1,32621
COL8A1-4 chr3:+:98621202-98623886 // 61
TCONS_00006171-XLOC_002779 // Rinn lincRNA // linc- 0,001283 1,32221
NDUFB4-5 chr3 :+ : 119814170- 119819230 37
TCONS_00007239-XLOC_003221 // Rinn lincRNA // linc- 0,001089 1,79005
KIAA2018 chr3:-: l 13432277-113433137 82
TCONS_00007654-XLOC_003729 // Rinn lincRNA // linc- 0,000834 -1,8603
DCLK2-5 chr4:+: 149614183-149615475 / 44
TCONS 00007710-XLOC 003862 // Rinn lincRNA // linc- 0,000730 -1,20479
LRPAP1-2 chr4:-:3760474-3765117 // c 22
TCONS 00007810-XLOC 004040 // Rinn lincRNA // linc- 0,001595 -1,57193
INTS12-3 chr4:-: 106924473- 106943635 81
TCONS 00007969-XLOC 003438 // Rinn lincRNA // line- 0,000287 -1,24193 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
MAN2B2-2 chr4:+:6315485-6319667 // c 92
TCONS 00007986-XLOC 003455 // Rinn lincRNA // linc- 0,000996 -1,96696
CPEB2-11 chr4:+: l 1315419-11344598 // 13
TCONS 00008078-XLOC 003544 // Rinn lincRNA // linc- l,44E-06 -2,93117
TMEM165 chr4:+:56251872-56253958 //
TCONS 00008368-XLOC 003823 // Rinn lincRNA // linc-ZFP42- 0,000114 -1,29189
9 chr4:+:187980347-187980856 / 06
TCONS_00008546-XLOC_004041 // Rinn lincRNA // linc- 0,000140 -1,37898
PAPSS1 chr4:-: 108908047-108910629 // 44
TCONS_00008717-XLOC_004231 // Rinn lincRNA // linc- 0,001007 1,22442
TRIML2-6 chr4:-:190598434-190600102 67
TCONS 00009213-XLOC 004382 // inn lincRNA LOC2573 0,000550 1,51762
// linc-FST chr5:+:52405686-52410950 // chr5 96 16
TCONS 00009341-XLOC 004275 // Rinn lincRNA // ] inc- 0,000278 -1,24952
ADCY2-6 chr5:+:6868671-6886900 // ch 74
TCONS 00009498-XLOC 004529 // Rinn lincRNA // linc-FTMT- 0,001107 1,43624
2 chr5:+:120658244-120661532 // 06
TCONS 00009609-XLOC 004740 // Rinn lincRNA // linc-ANKH- 0,001165 -1,22349
1 chr5:-: 15192247-15266650 // c 78
TCONS 00009708-XLOC 004894 // Rinn lincRNA // linc-ZBED3 0,000572 1,44645 chr5:-:76393281-76393984 // ch 97
TCONS 00009981-XLOC 004407 // Rinn lincRNA // linc- 0,001306 -1,23843
PPWD1 chr5:+:64361892-64366318 // ch 85
TCONS_00010096-XLOC_004556 // Rinn lincRNA // linc-TCF7-l 0,000696 1,30042 chr5:+:133304442-133306019 // 96
TCONS_00010119-XLOC_004585 // Rinn lincRNA // linc- 0,000544 -1,22277
ARHGAP26-5 chr5:+: 141615465-14161601 44
TCONS_00010366-XLOC_004863 // Rinn lincRNA // linc-CD180- 0,000669 1,43349
12 chr5:-:68430028-68455323 // 46
TCONS 00010530-XLOC 005050 // Rinn lincRNA // linc- 0,000103 -1,453
CSNK1A1 chr5:-: 149016982-149020628 / 14
TCONS 00010663-XLOC 004339 // Rinn lincRNA // linc-NIPBL 0,000391 1,45209 chr5:+:36871456-36876605 // ch 31
TCONS 00010939-XLOC 004848 // Rinn lincRNA // linc-SGTB- 7,45E-05 1,35403
3 chr5:-:65220459-65221176 // c
TCONS 00012990-XLOC 006040 // Rinn lincRNA // linc-NPSRl l,64E-05 -3,76707 chr7:+:34249137-34295955 // ch
TCONS 00013102-XLOC 006310 // Rinn lincRNA // linc-NOMl- 0,000269 -1,3724
1 chr7:+:156737414-156738339 // 31
TCONS_00013176-XLOC_006463 // Rinn lincRNA // linc- 0,000172 1,23332
ZNF479-10 chr7:-:62505204-62514809 / 92
TCONS_00013576-XLOC_006231 // Rinn lincRNA // linc-ARF5- 0,000108 -2,10369
8 chr7:+:124638323-124641124 // 67
TCONS_00013655-XLOC_006312 // Rinn lincRNA // linc- 0,001545 1,50533
UBE3C-3 chr7:+: 156775940-156777103 / 9 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
TCONS 00013748-XLOC 006388 // Rinn lincRNA // ] inc- 0,000662 -1,32379
HNRNPA2B1-3 chr7:-:26584207-26590534 25
TCONS 00014518-XLOC 007098 // Rinn lincRNA // linc-ASPH- 0,001267 -1,30911
1 chr8:-:62671659-62678528 // c 38
TCONS 00014546-XLOC 006923 // Rinn lincRNA PVT1 0,000343 1,90337
// linc-EFR3A-6 chr8:+: 128938354-128943402 / 1
TCONS 00014977-XLOC 007055 // Rinn lincRNA LOC1578 0,000136 -1,41976
// linc-DUSP26-l c r8:-:37455061-37456790 // 60
TCONS 00014998-XLOC 007078 // Rinn lincRNA // ] inc- 3,15E-05 -1,2676
RNF170-1 chr8:-:47722339-47730705 //
TCONS 00015354-XLOC 006922 // Rinn lincRNA PVT1 0,001089 2,06859
// linc-EFR3A-7 chr8:+: 128867393-128944934 / 66
TCONS 00015582-XLOC 007500 // Rinn lincRNA // ] inc- 0,000436 -1,30328
ZNF462-3 chr9 :+ : 108870331 - 109173662 39
TCONS 00016076-XLOC 007467 // Rinn lincRNA // linc- 0,001450 1,20451
HIATL1-3 chr9:+:97075821-97076871 // 82
TCONS 00016123-XLOC 007508 // Rinn lincRNA // linc- 0,000424 -1,40776
ACTL7A-8 chr9:+: l 10329106-110338504 02
TCONS_00016944-XLOC_008094 // Rinn lincRNA // linc- 0,001419 -1,36726
SPRY3-1 chrX:+: 154697946-154716706 / 83
TCONS_00017190-XLOC_008005 // Rinn lincRNA // linc- 0,000264 -1,71756
FAM155B chrX:+:68250821-68256955 // 01
TCONS_00017353-XLOC_008198 // Rinn lincRNA // linc-GLA-1 0,000305 -1,38426 chrX:-: 100759567-100764657 // 35
TCONS 00017652-XLOC 008328 // Rinn lincRNA // linc- 0,001509 -1,2496
KDM5D-2 chrY:-:22681833-22686319 // 14
TCONS 00017675-XLOC 008480 // Rinn lincRNA ANTXRL 0,000164 -1,20606
// linc-ANXA8L2-l chrl0:+:47658233-47701446 37
TCONS 00017835-XLOC 008501 // Rinn lincRNA // ] inc- 0,000826 -1,59698
LRRTM3-2 chrl0:+:67345445-67441220 / 62
TCONS 00017851-XLOC 008542 // Rinn lincRNA // linc-OPN4- 8J9E-05 1,97892
1 chrl0:+:88281701-88282443 //
TCONS 00018003-XLOC 008867 // Rinn lincRNA // linc- 0,000931 -1,3366
SFTPA2-1 chrl0:-:81390510-81391942 / 16
TCONS 00018097-XLOC 008366 // Rinn lincRNA // linc- 8J0E-05 -1,35384
PFKFB3 chrl0:+:6182720-6183545 // ch
TCONS_00018537-XLOC_008855 // Rinn lincRNA // linc- 0,001190 1,72402
AGAP5-1 chrl0:-:75540422-75541627 // 04
TCONS_00018588-XLOC_008922 // Rinn lincRNA // linc-PDZD7 3,19E-05 2,60033 chrl0:-: 102819375-102820683 //
TCONS_00019181-XLOC_009016 // Rinn lincRNA // linc- 0,001529 -1,28327
B4GALNT4-2 chrl l :+:331733-333645 // 64
TCONS 00019266-XLOC 009094 // Rinn lincRNA // linc-FSHB- 0,000440 -1,71633
4 chrl l :+:28535560-28548491 // 34
TCONS 00019401-XLOC 009224 // Rinn lincRNA LOC1002 0,001195 1,49126 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
// linc-USP35 chrl 1 :+:77850805-77852799 // c 89388 18
TCONS 00019443-XLOC 009252 // Rinn lincRNA // ] inc- l,49E-05 -1,25024
AMOTL1-3 chrl 1 :+:94371178-94373474 /
TCONS 00019646-XLOC 009452 // Rinn lincRNA // linc-FTHl-1 0,001453 1,24973 chrl 1 :-:61883943-61891289 // 18
TCONS 00019712-XLOC 009507 // Rinn lincRNA // linc- 5,61E-07 1,94492
PRKRIR chrl l :-:76154344-76155704 //
TCONS_00019769-XLOC_009563 // Rinn lincRNA // linc- 0,000234 -1,37598
CADM1-4 chrl 1 :-:115754859-115757277 46
TCONS_00020353-XLOC_009683 // Rinn lincRNA // linc- 0,001247 -2,40963
PDE3A-3 chrl2:+: 19804642-19806912 // 13
TCONS_00020848-XLOC_010133 // Rinn lincRNA // linc- 0,000600 -1,23625
OSBPL8 chrl2:-:77086299-77088341 // 26
TCONS 00020906-XLOC 010185 // Rinn lincRNA // linc- 0,000495 -1,54517
APPL2-3 chrl2:-:106180060-106404785 76
TCONS 00020988-XLOC 010253 // Rinn lincRNA // linc- 5,83E-05 -1,37219
DHX37-14 chrl2:-: 128151535-128155451
TCONS 00021063-XLOC 009661 // Rinn lincRNA // linc-PRH2- 0,000958 -1,22126
3 chrl2:+:10705978-10710816 // 53
TCONS 00021113-XLOC 009728 // Rinn lincRNA // linc- 0,000148 -1,50083
SLC48A1-3 chrl2:+:47808466-47814022 64
TCONS 00021481-XLOC 010315 // Rinn lincRNA LINC00 6 0,000782 -1,23402
// linc-ATP12A-3 chrl3:+:24905587-24911256 / 6 01
TCONS 00021772-XLOC 010368 // Rinn lincRNA LINC0028 0,000673 -1,23137
// linc-SERP2-4 chrl3:+:44596391-44614387 // 4 49
TCONS 00021794-XLOC 010397 // Rinn lincRNA // ] inc- 0,001428 -1,65999
PRR20A-5 chrl3:+:53631290-53650848 / 64
TCONS_00022476-XLOC_010804 // Rinn lincRNA // linc-SSTRl- 5,26E-05 -1,43864
5 chrl4:+:38033433-38048129 //
TCONS_00022880-XLOC_011134 // Rinn lincRNA // linc-RTLl-2 0,000453 -3,03365 chrl4:-: 101819693-101822512 / 83
TCONS 00022976-XLOC 010811 // Rinn lincRNA // linc- 0,001393 -1,46134
LRFN5-3 chrl4:+:39903870-39962715 // 57
TCONS 00023300-XLOC 011169 // Rinn lincRNA // linc- l,38E-05 -1,36677
C15orf2-13 chrl5:+:23873168-23874538
TCONS 00024334-XLOC 011650 // Rinn lincRNA // linc-BFAR 0,001412 1,75618 chrl6:+:14416112-14420490 // ch 64
TCONS 00024378-XLOC 011704 // Rinn lincRNA // linc-PHKB- 5,98E-06 1,48532
2 chrl6:+:47007716-47012770 //
TCONS_00024390-XLOC_011715 // Rinn lincRNA // linc- 5,59E-05 -1,26342
TMEM188 chrl6:+:49488184-49494684 //
TCONS_00025258-XLOC_012064 // Rinn lincRNA // linc- 0,000290 -1,27904
C17orf97-3 chrl7:+:47994-49628 // ch 32
TCONS 00025293-XLOC 012095 // Rinn lincRNA ALOX12P 3,35E-09 -6,94788
// linc-ALOX12-l chrl7:+:6840593-6857728 // 2 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
TCONS 00025544-XLOC 012371 // Rinn lincRNA // ] inc- 0,000101 -1,51281
TE T1-2 chrl7:-:6856978-6859935 // c 79
TCONS 00025602-XLOC 012430 // Rinn lincRNA // linc-SEZ6-l 0,000758 1,3394 chrl7:-:27337874-27339680 // 99
TCONS_00025687-XLOC_012503 // Rinn lincRNA // linc-COPZ2 5,94E-05 1,46319 chrl7:-:46124280-46125406 // c
TCONS_00025761-XLOC_012571 // Rinn lincRNA // linc-SDK2- 0,000720 -1,27592
1 chrl7:-:71940478-71945993 // 93
TCONS 00026215-XLOC 012692 // Rinn lincRNA // linc- 0,000542 1,40698
NEDD4L- 1 chr 18 :+:55471011 -55474049 / 8
TCONS 00026294-XLOC 012638 // Rinn lincRNA // linc- 0,000114 -1,37746
CABLES1 chrl8:+:20685924-20686303 // 8
TCONS 00026681-XLOC 012784 // Rinn lincRNA // linc- 0,000321 -2,4629
POTEC-3 chrl8:-: 15301184-15303066 // 5
TCONS 00027011-XLOC 013056 // Rinn lincRNA // linc- 0,001246 1,25574
ZNF382-1 chrl9:+:37025702-37026137 / 97
TCONS 00027301-XLOC 013301 // Rinn lincRNA // linc- 0,000243 2,28984
ANKRD27 chrl9:-:33177953-33182862 // 26
TCONS_00027541-XLOC_013072 // Rinn lincRNA // linc- 0,000602 1,23361
LGALS13 chrl9:+:40018979-40019553 // 44
TCONS_00027828-XLOC_013429 // Rinn lincRNA // linc- 0,000161 1,64973
ZNF837 chrl9:-:58917723-58919829 // 44
TCONS_00027888-XLOC_013737 // Rinn lincRNA // linc- 3,26E-05 1,91261
KIAA1755-3 chr20:-:37034659-37045444
TCONS_00028857-XLOC_013973 // Rinn lincRNA // linc- 4,20E-05 1,46727
C21 orf70-5 chr21 :+:46222491 -46224632
TCONS 00029024-XLOC 013947 // Rinn lincRNA // linc- 0,000605 -1,37463
UMODL1-5 chr21 :+:42953358-42954625 / 26
TCONS 00029355-XLOC 014420 // Rinn lincRNA LOC1005 0,000250 -1,23968
// linc-ARSA-2 chr22:-:51174258-51176567 // 06917 32
TCONS 00029709-XLOC 014393 // Rinn lincRNA // ] inc- 0,000829 -1,20718
LDOClL-1 chr22:-:45057491-45063704 / 12
TCONS 12 00002247-XLOC 12 000514 // Broad TUCP // linc- 0,001292 -1,28228
RASAL2-2 chrl :+:177320721-177335 73
TCONS 12 00004657-XLOC 12 002407 // Broad LOC1005 4,01E-06 1,55781
TUCP // linc-PRKRIR-BP chrl l :+:76092015-76121 06127
TCONS 12 00005499-XLOC 12 002886 // Broad LOC3744 0,001179 1,63563
TUCP // linc-CLEC2D-l chrl2:+:9795445-9814706 43 02
TCONS 12 00007360-XLOC 12 003627 // Broad LINC0053 0,000782 1,69306
TUCP // linc-FGF9-2 chrl3:+:21872277-21878694 9 61
TCONS_12_00014462-XLOC_12_007928 // Broad TUCP // linc- 0,001577 -1,22302
PUM2-3 chr2:-:20786002-20793177 61
TCONS 12 00014537-XLOC 12 007986 // Broad TUCP // linc- 0,000179 -6,27918
HAAO-4 chr2:-:43258947-43266681 49
TCONS_12_00015367-XLOC_12_007359 // Broad TUCP // line- 0,001016 -1,68373 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
ETAA1-3 chr2:+:67267677-67269098 7
TCONS 12 00016216-XLOC 12 008596 // Broad TUCP // linc- 0,000183 1,62011
DEFB115-7 chr20:+:25731895-25733 36
TCONS_12_00021564-XLOC_12_010631 // Broad TUCP // linc- 0,000926 -1,2169
DTHD1-3 chr4:+:33852212-33893771 51
TCONS 12 00023729-XLOC 12 012023 // Broad LOC1005 0,001256 -1,53522
TUCP // linc-FGFlO-3 chr5:-:44777167-44808828 06674 53
TCONS_12_00025079-XLOC_12_012374 // Broad TUCP // linc- 0,001306 -1,45816
LY86-2 chr6:+:5892672-5986353 // 22
TCONS_12_00027197-XLOC_12_013564 // Broad TUCP // linc- 5,93E-05 -1,26181
TES-2 chr7:+:l 14719011-114766368
TCONS_12_00028605-XLOC_12_014694 // Broad TUCP // linc- 0,000553 -1,78587
SLClAl-1 chr9:+:3663779-3694788 3
TCONS_12_00029674-XLOC_12_014694 // Broad TUCP // linc- 0,000483 -2,41707
SLClAl-1 chr9:+:3526722-3671624 01
TCONS 12 00029675-XLOC 12 014694 // Broad TUCP // linc- 0,000104 -1,58698
SLClAl-1 chr9:+:3647334-3648338 98
TCONS 12 00029789-XLOC 12 014891 // Broad TUCP // linc- 0,000340 -1,26413
C9orf79-2 chr9:+:90479080-904812 07
TCONS 12 00030536-XLOC 12 015760 // Broad FTX 0,001404 -1,2648
TUCP // linc-NAPlL2-3 chrX:-:73492775-7350467 57
TCONS 12 00030882-XLOC 12 015855 // Broad TUCP // linc- 9,68E-05 -1,47293
CLIC2-1 chrX:-: 154564166-1545812
X58060 // GenBank // H.sapiens U13 snRNA pseudo- SNORD13 0,000774 1,40796 gene U13.32A. // chr7 // 100 // 100 // 1 P2 84
XM 001713850 // RefSeq // PREDICTED: Homo LOC7302 0,000307 1,46366 sapiens anaphase-promoting complex subunit 1- 68 47
XR 108724 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,000140 1,51312 hypothetical LOC100505531 (LOC100505531) 05531 46
XR_ 109972 // RefSeq // PREDICTED: Homo sapiens SOS1-IT1 l,00E-06 1,79962
SOS 1 intronic transcript 1 (non-protein
XR 110412 // RefSeq // PREDICTED: Homo sapiens hypothetical 0,000136 1,41455 LOC100507196 (LOC100507196) 3
XR 111249 // RefSeq // PREDICTED: Homo sapiens LOC1005 l,49E-05 2,76581 hypothetical LOC100509976 (LOCI 00509976) 09976
XR 111611 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,000209 1,45269 hypothetical LOC100506670 (LOCI 00506670) 06670 87
XR 132525 // RefSeq // PREDICTED: Homo sapiens LOC1002 0,000788 1,22288 hypothetical LOC100288712 (LOC100288712) 88712 18
XR 133207 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,001261 -1,36872 hypothetical LOC100505703 (LOC100505703) 05703 79
Table 6: Efficiency of gemcitabine
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
ENST00000561394 // ENSEMBL // havana:lincRNA chromo- 0,000286 1,26726 some:GRCh37: 15:36262559:36544458:-l 79
ENST00000576221 // ENSEMBL // cdna:known PCTP 0,000403 1,37123 chromosome:GRCh37:17:53848538:53920191 : l 024 gene:
NM 000521 // RefSeq // Homo sapiens hexosaminiHEXB 5,02E-05 1,50615 dase B (beta polypeptide) (HEXB), mRNA. /
NM 000523 // RefSeq // Homo sapiens homeobox HOXD13 9,97E-06 1,37541 D13 (HOXD13), mRNA. // chr2 // 100 // 100
NM_000641 // RefSeq // Homo sapiens interleukin 11 IL11 3,91E-05 -1,8859 (IL11), transcript variant 1, mRNA.
NM 000671 // RefSeq // Homo sapiens alcohol dehyADH5 0,000602 1,43083 drogenase 5 (class III), chi polypeptid 119
NM 000786 // RefSeq // Homo sapiens cytochrome CYP51A1 0,000818 1,59522 P450, family 51, subfamily A, polypeptid 085
NM 000824 // RefSeq // Homo sapiens glycine recepGLRB 0,000267 3,28788 tor, beta (GLRB), transcript variant 1 102
NM_000922 // RefSeq // Homo sapiens phosPDE3B 0,000141 2,5712 phodiesterase 3B, cGMP-inhibited (PDE3B), mRNA. 479
NM 000930 // RefSeq // Homo sapiens plasminogen PLAT 0,000158 -5,59179 activator, tissue (PLAT), transcript va 03
NM 000969 // RefSeq // Homo sapiens ribosomal RPL5 0,000361 1,33607 protein L5 (RPL5), mRNA. // chrl // 100 / 92
NM_001002034 // RefSeq // Homo sapiens family FAM109B 4,68E-05 1,49774 with sequence similarity 109, member B (F
NM_001002236 // RefSeq // Homo sapiens serpin SERPI- 0,000298 -2,31174 peptidase inhibitor, clade A (alpha- 1 ant NA1 105
NM 001002923 // RefSeq // Homo sapiens IGF-like IGFL4 0,000511 -2,67778 family member 4 (IGFL4), mRNA. // chrl 9 422
NM 001004318 // RefSeq // Homo sapiens iron/zinc PAPL 0,000468 -2,67004 purple acid phosphatase-like protein ( 278
NM 001004320 // RefSeq // Homo sapiens alkylglyc- AGMO 6,29E-05 8,06425 erol monooxygenase (AGMO), mRNA. // chr
NM 001005360 // RefSeq // Homo sapiens dynamin 2 DNM2 0,000490 1,32152 (DNM2), transcript variant 1, mRNA. // 022
NM_001006 // RefSeq // Homo sapiens ribosomal RPS3A 8,60E-05 1,65182 protein S3A (RPS3A), transcript variant 1
NM 001007559 // RefSeq // Homo sapiens synovial SS18 0,000761 1,91375 sarcoma translocation, chromosome 18 (S 038
NM 001008390 // RefSeq // Homo sapiens CGG triCGGBP1 0,000396 -1,37792 plet repeat binding protein 1 (CGGBP1), t 308
NM 001009562 // RefSeq // Homo sapiens solute SLC01B7 0,000501 -8,902 carrier organic anion transporter family, 48
NM 001011880 // RefSeq // Homo sapiens C-type CLEC18B 0,000128 -1,42747 lectin domain family 18, member B (CLEC18 672 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM_001017928 // RefSeq // Homo sapiens coiled-coil CCDC58 0,000353 1,49667 domain containing 58 (CCDC58), mRNA. 427
NM_001025389 // RefSeq // Homo sapiens adenosine AMPD3 0,000298 -1,60416 monophosphate deaminase 3 (AMPD3), tra 983
NM 001031835 // RefSeq // Homo sapiens phospho- PHKB 0,000864 1,40848 rylase kinase, beta (PHKB), transcript va 315
NM OO 1037442 // RefSeq // Homo sapiens RUN and RUFY3 0,000252 1,37668
FYVE domain containing 3 (RUFY3), transc 175
NM 001038707 // RefSeq // Homo sapiens CDC42 CDC42SE 2,61E-06 -1,29465 small effector 1 (CDC42SE1), transcript va 1
NM 001039671 // RefSeq // Homo sapiens Yi l inYIF1B 0,000355 -1,41043 teracting factor homo log B (S. cerevisiae 643
NM 001040402 // RefSeq // Homo sapiens DCN1, DCUN1D 8,02E-05 1,80786 defective in cullin neddylation 1 , domain 4
NM 001040716 // RefSeq // Homo sapiens pyruvate PC 0,000353 -1,29792 carboxylase (PC), nuclear gene encoding 343
NM 001042423 // RefSeq // Homo sapiens solute SLC16A3 0,000262 -2,35895 carrier family 16, member 3 (monocarboxyl 502
NM 001042521 // RefSeq // Homo sapiens chromoC2orf88 9,10E-06 1,99661 some 2 open reading frame 88 (C2orf88), tr
NM 001042552 // RefSeq // Homo sapiens TatD TATDN3 0,000703 1,52517
DNase domain containing 3 (TATDN3), transcr 324
NM 001048210 // RefSeq // Homo sapiens chloride CLCC1 0,000874 1,45649 channel CLIC-like 1 (CLCC1), transcript 74
NM 001049 // RefSeq // Homo sapiens somatostatin SSTR1 0,000411 1,89356 receptor 1 (SSTR1), mRNA. // chrl4 // 241
NM 001101330 // RefSeq // Homo sapiens LOC7288 0,000143 -1,58684 hCG1645220 (LOC728819), mRNA. // chr2 // 94 // 1 19 303
NM 001103 // RefSeq // Homo sapiens actinin, alpha ACTN2 0,000196 -1,3708 2 (ACTN2), mRNA. // chrl // 100 // 7 637
NM 001113411 // RefSeq // Homo sapiens FGGY FGGY 0,000226 1,37144 carbohydrate kinase domain containing (FGGY 823
NM 001124758 // RefSeq // Homo sapiens spinster SPNS2 0,000579 -4,62005 homo log 2 (Drosophila) (SPNS2), mRNA. / 421
NM 001128429 // RefSeq // Homo sapiens SWI/SNF- SMARCA 0,000738 1,58261 related, matrix-associated actin-depende Dl 123
NM 001128431 // RefSeq // Homo sapiens solute SLC39A1 0,000459 3,12873 carrier family 39 (zinc transporter), mem 4 731
NM 001130144 // RefSeq // Homo sapiens latent LTBP3 0,000898 -1,5144 transforming growth factor beta binding p 569
NM 001130475 // RefSeq // Homo sapiens THAP THAP5 6,53E-05 1,23023 domain containing 5 (THAP5), transcript var
NM 001130929 // RefSeq // Homo sapiens chromoC7orf73 0,000630 1,64204 some 7 open reading frame 73 (C7orf73), nu 645
NM_001134382 // RefSeq // Homo sapiens IQ motif IQSEC1 3,41E-05 -1,43344 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change and Sec7 domain 1 (IQSEC1), transcript
NM 001134479 // RefSeq // Homo sapiens leucine LRRC8D 0,000117 1,56754 rich repeat containing 8 family, member 045
NM 001134848 // RefSeq // Homo sapiens coiled-coil CCDC152 0,000248 -2,3558 domain containing 152 (CCDC152), mRN 709
NM 001142292 // RefSeq // Homo sapiens lectin, LMAN2L 0,000545 -1,51167 mannose-binding 2-like (LMAN2L), transcr 43
NM 001142343 // RefSeq // Homo sapiens chemo- CMKLR1 0,000432 1,2915 kine- like receptor 1 (CMKLR1), transcript v 359
NM_001142416 // RefSeq // Homo sapiens aminoacyl AIMP1 0,000844 1,45334 tRNA synthetase complex-interacting mu 505
NM 001142502 // RefSeq // Homo sapiens protein PPP1R13 0,000218 -1,84965 phosphatase 1, regulatory subunit 13 lik L 174
NM 001143676 // RefSeq // Homo sapiens se- SGK1 0,000802 -2,85707 rum/glucocorticoid regulated kinase 1 (SGK1), 596
NM 001145078 // RefSeq // Homo sapiens zinc fmger ZNF805 0,000487 -1,46138 protein 805 (ZNF805), transcript var 418
NM_001145354 // RefSeq // Homo sapiens muskelin MKLN1 3,12E-05 1,29035 1 , intracellular mediator containing ke
NM 001145548 // RefSeq // Homo sapiens zinc finZDHHC7 0,000677 1,52576 ger, DHHC-type containing 7 (ZDHHC7), tr 847
NM 001160170 // RefSeq // Homo sapiens N- NAT1 0,000344 1,66591 acetyltransferase 1 (arylamine N-acetyltransfe 721
NM 001164277 // RefSeq // Homo sapiens solute SLC37A4 2,68E-05 1,42023 carrier family 37 (glucose-6-phosphate tr
NM 001165 // RefSeq // Homo sapiens baculo viral BIRC3 1J9E-05 2,25422 IAP repeat containing 3 (BIRC3), transc
NM 001172477 // RefSeq // Homo sapiens ribonucleRRM2B 0,000301 -1,95744 otide reductase M2 B (TP53 inducible) ( 415
NM_001177716 // RefSeq // Homo sapiens Kruppel- KLF11 4,44E-05 1,83245 like factor 11 (KLF11), transcript varia
NM 001178106 // RefSeq // Homo sapiens zinc fmger ZNF 185 9,63E-06 -2,93461 protein 185 (LIM domain) (ZNF185), t
NM 001184705 // RefSeq // Homo sapiens hydroxy- HADH 0,000417 1,77472 acyl-CoA dehydrogenase (HADH), nuclear ge 731
NM 001190849 // RefSeq // Homo sapiens CCR4- CNOT4 2,04E-05 1,28959 NOT transcription complex, subunit 4 (CNOT4
NM 001195132 // RefSeq // Homo sapiens cyclin- CDKN2A 0,000699 -5,7807 dependent kinase inhibitor 2A (CDKN2A), t 063
NM_001195291 // RefSeq // Homo sapiens serpin SER- 6,86E-06 1,66561 peptidase inhibitor, clade B (ovalbumin), PINB6
NM 001195597 // RefSeq // Homo sapiens uncharac- LOC1005 0,000483 1,2554 terized LOC100507203 (LOC100507203), mRN 07203 994
NM 001198 // RefSeq // Homo sapiens PR domain PRDMl l,59E-05 -2,31008 containing 1, with ZNF domain (PRDMl), tr Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 001199324 // RefSeq // Homo sapiens zinc fmger ZNF61 0,000366 -2,26976 protein 615 (ZNF615), transcript var 397
NM 001229 // RefSeq // Homo sapiens caspase 9, CASP9 8,21E-05 -1,59112 apoptosis-related cysteine peptidase (CA
NM 001242394 // RefSeq // Homo sapiens synapto- SYTL3 0,000508 -1,58732 tagmin-like 3 (SYTL3), transcript variant 259
NM OO 1242498 // RefSeq // Homo sapiens MIF4G MIF4GD 0,000622 -1,4261 domain containing (MIF4GD), transcript var 388
NM 001243571 // RefSeq // Homo sapiens myotubu- MTMR2 0,000405 1,88056 larin related protein 2 (MTMR2), transcri 397
NM 001243794 // RefSeq // Homo sapiens carbohyCHST12 0,000569 -1,41903 drate (chondroitin 4) sulfotransferase 12 308
NM_001251962 // RefSeq // Homo sapiens Rho guaARHGEF 0,000480 -2,00735 nine nucleotide exchange factor (GEF) 26 26 656
NM 001254738 // RefSeq // Homo sapiens Rho famiRND3 2,24E-05 -2,51389 ly GTPase 3 (RND3), transcript variant 1
NM_001256312 // RefSeq // Homo sapiens serST 3 0,000299 -1,89043 ine/threonine kinase 3 (STK3), transcript var 53
NM 001256530 // RefSeq // Homo sapiens transloca- TSPO 0,000449 1,44089 tor protein (18kDa) (TSPO), transcript 578
NM 001265597 // RefSeq // Homo sapiens zinc fmger ZNF211 0,000514 -2,30733 protein 211 (ZNF211), transcript var 918
NM OO 1267708 // RefSeq // Homo sapiens zinc fmger ZNF706 0,000123 -1,7641 protein 706 (ZNF706), transcript var 325
NM 001343 // RefSeq // Homo sapiens disabled hom- DAB2 0,000519 -3,92156 olog 2, mitogen-responsive phosphoprote 307
NM 001393 // RefSeq // Homo sapiens extracellular ECM2 9J6E-05 2,24396 matrix protein 2, female organ and ad
NM 001407 // RefSeq // Homo sapiens cadherin, EGF CELSR3 0,000829 -1,551 LAG seven-pass G-type receptor 3 (fla 472
NM_001532 // RefSeq // Homo sapiens solute carrier SLC29A2 8,19E-05 1,68744 family 29 (nucleoside transporters),
NM 001661 // RefSeq // Homo sapiens ADP- ARL4D 6J6E-08 -5,20681 ribosylation factor-like 4D (ARL4D), mRNA. // c
NM 001706 // RefSeq // Homo sapiens B-cell BCL6 2,06E-05 -2,05698 CLL/lymphoma 6 (BCL6), transcript variant 1,
NM_001749 // RefSeq // Homo sapiens calpain, small CAPNS1 0,000190 -1,31634 subunit 1 (CAPNS1), transcript varia 856
NM 001785 // RefSeq // Homo sapiens cytidine CDA 0,000245 -4,255 deaminase (CD A), mRNA. // chrl // 100 // 1 901
NM 001861 // RefSeq // Homo sapiens cytochrome c COX4I1 0,000260 1,29733 oxidase subunit IV isoform 1 (COX4I1), 048
NM 001967 // RefSeq // Homo sapiens eukaryotic EIF4A2 0,000429 1,54564 translation initiation factor 4A2 (EIF4A 724
NM_001983 // RefSeq // Homo sapiens excision re- ERCC1 0,000166 -1,76995 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change pair cross-complementing rodent repair d 515
NM 001986 // RefSeq // Homo sapiens ets variant 4 ETV4 0,000877 -1,68646 (ETV4), transcript variant 1 , mRNA. / 273
NM 001993 // RefSeq // Homo sapiens coagulation F3 0,000482 -5,80008 factor III (thromboplastin, tissue fact 213
NM 002064 // RefSeq // Homo sapiens glutaredoxin GLRX 0,000797 -1,97137 (thioltransf erase) (GLRX), transcript 405
NM_002092 // RefSeq // Homo sapiens G-rich RNA GRSF1 0,000629 1,60764 sequence binding factor 1 (GRSF1), trans 916
NM 002162 // RefSeq // Homo sapiens intercellular ICAM3 l,83E-06 1,43223 adhesion molecule 3 (ICAM3), mRNA. //
NM 002531 // RefSeq // Homo sapiens neurotensin NTSR1 0,000150 -6,19041 receptor 1 (high affinity) (NTSR1), mRN 506
NM 002546 // RefSeq // Homo sapiens tumor necroTNFRSF1 0,000749 -5,31434 sis factor receptor superfamily, member IB 525
NM 002582 // RefSeq // Homo sapiens poly(A)- PARN 9,64E-05 1,33441 specific ribonuclease (PARN), transcript va
NM_002601 // RefSeq // Homo sapiens phosPDE6D 0,000164 -1,52387 phodiesterase 6D, cGMP-specific, rod, delta (PD 304
NM 002924 // RefSeq // Homo sapiens regulator of RGS7 0,000546 -3,50229 G-protein signaling 7 (RGS7), mRNA. // 182
NM 002982 // RefSeq // Homo sapiens chemokine CCL2 0,000391 8,61057 (C-C motif) ligand 2 (CCL2), mRNA. // chr 267
NM_003087 // RefSeq // Homo sapiens synuclein, SNCG 0,000814 -1,37279 gamma (breast cancer- specific protein 1) 077
NM 003169 // RefSeq // Homo sapiens suppressor of SUPT5H 0,000514 -1,47521 Ty 5 homo log (S. cerevisiae) (SUPT5H) 663
NM 003214 // RefSeq // Homo sapiens TEA domain TEAD3 0,000229 -1,26253 family member 3 (TEAD3), mRNA. // chr6 / 856
NM 003236 // RefSeq // Homo sapiens transforming TGFA 0,000241 -1,9813 growth factor, alpha (TGFA), transcrip 211
NM 003292 // RefSeq // Homo sapiens translocated TPR 0,000436 1,26378 promoter region, nuclear basket protei 055
NM 003379 // RefSeq // Homo sapiens ezrin (EZR), EZR 0,000168 -1,3654 transcript variant 1 , mRNA. // chr6 // 322
NM 003401 // RefSeq // Homo sapiens X-ray repair XRCC4 0,000141 3,20011 complementing defective repair in Chin 991
NM 003406 // RefSeq // Homo sapiens tyrosine 3- YWHAZ 0,000143 -1,46884 monooxygenase/tryptophan 5 -monooxygenase 04
NM_003470 // RefSeq // Homo sapiens ubiquitin USP7 l,47E-05 1,37228 specific peptidase 7 (herpes virus-associ
NM 003518 // RefSeq // Homo sapiens histone cluster HIST1H2 0,000136 -4,51926 1, H2bg (HIST1H2BG), mRNA. // chr6 BG 898
NM 003658 // RefSeq // Homo sapiens BARX ho- BARX2 3,59E-07 -4,15642 meobox 2 (BARX2), mRNA. // chrl 1 // 100 // 5 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 003687 // RefSeq // Homo sapiens PDZ and LIM PDLIM4 4,88E-05 -2,14248 domain 4 (PDLIM4), transcript variant 1
NM 003715 // RefSeq // Homo sapiens USOl vesicle USOl 0,000788 1,43571 docking protein homolog (yeast) (USOl) 674
NM 003794 // RefSeq // Homo sapiens sorting nexin SNX4 2,99E-05 1,48131 4 (SNX4), mRNA. // chr3 // 100 // 100
NM 003826 // RefSeq // Homo sapiens N- NAPG 7,84E-05 -1,48986 ethylmaleimide-sensitive factor attachment protei
NM 003941 // RefSeq // Homo sapiens Wiskott- WASL 0,000205 1,36174 Aldrich syndrome-like (WASL), mRNA. // chr7 855
NM_003969 // RefSeq // Homo sapiens ubiquitin- UBE2M 0,000655 -1,30263 conjugating enzyme E2M (UBE2M), mRNA. // 961
NM 003998 // RefSeq // Homo sapiens nuclear factor NFKB1 0,000226 1,90719 of kappa light polypeptide gene enha 853
NM 004069 // RefSeq // Homo sapiens adaptor- AP2S1 0,000729 -1,33855 related protein complex 2, sigma 1 subunit 629
NM 004209 // RefSeq // Homo sapiens synaptogyrin SYNGR3 0,000298 -1,23225 3 (SYNGR3), mRNA. // chrl6 // 100 // 1 206
NM 004252 // RefSeq // Homo sapiens solute carrier SLC9A3R 0,000219 -1,7649 family 9, subfamily A (NHE3, cation 1 286
NM_004279 // RefSeq // Homo sapiens peptidase (miPMPCB 5.78E-05 1,60227 tochondrial processing) beta (PMPCB),
NM 004285 // RefSeq // Homo sapiens hexose-6- H6PD 0,000618 -1,75418 phosphate dehydrogenase (glucose 1-dehydro 377
NM 004347 // RefSeq // Homo sapiens caspase 5, CASP5 0,000763 1,48837 apoptosis-related cysteine peptidase (CA 706
NM 004396 // RefSeq // Homo sapiens DEAD (Asp- DDX5 8,74E-06 -1,33353 Glu- Ala-Asp) box helicase 5 (DDX5), mRNA.
NM 004408 // RefSeq // Homo sapiens dynamin 1 DNM1 0,000207 -3,26653 (DNM1), transcript variant 1, mRNA. // ch 772
NM 004425 // RefSeq // Homo sapiens extracellular ECM1 l,23E-08 -2,695 matrix protein 1 (ECM1), transcript v
NM 004456 // RefSeq // Homo sapiens enhancer of EZH2 0,000263 2,03696 zeste homolog 2 (Drosophila) (EZH2), tr 091
NM 004489 // RefSeq // Homo sapiens G protein GPS2 8,41E-05 -1,35008 pathway suppressor 2 (GPS2), mRNA. // chr
NM 004569 // RefSeq // Homo sapiens phosphatidyl- PIGH 0,000567 -1,32564 inositol glycan anchor biosynthesis, cl 481
NM_004579 // RefSeq // Homo sapiens mitogen- MAP4K2 0,000270 -1,53383 activated protein kinase kinase kinase kina 645
NM 004651 // RefSeq // Homo sapiens ubiquitin speUSP11 0,000114 -1,63242 cific peptidase 11 (USP11), mRNA. // c 691
NM 004663 // RefSeq // Homo sapiens RAB11A, RABl 1 A 6,67E-05 -1,26527 member RAS oncogene family (RABl 1A), transc
NM 004719 // RefSeq // Homo sapiens SR-related SCAF11 0,000462 1,23776 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
CTD-associated factor 11 (SCAF11), mRNA. 182
NM 004798 // RefSeq // Homo sapiens kinesin family KIF3B 0,000456 1,24459 member 3B (KIF3B), mRNA. // chr20 // 076
NM 004889 // RefSeq // Homo sapiens ATP synthase, ATP5J2 0,000753 1,32863 H+ transporting, mitochondrial Fo com 912
NM 004890 // RefSeq // Homo sapiens sperm associSPAG7 6,48E-05 -1,53009 ated antigen 7 (SPAG7), mRNA. // chrl7
NM_004891 // RefSeq // Homo sapiens mitochondrial MRPL33 0,000412 -1,39785 ribosomal protein L33 (MRPL33), nucle 155
NM 004923 // RefSeq // Homo sapiens metallothi- MTL5 0,000540 1,9187 onein-like 5, testis-specific (tesmin) (M 822
NM 004941 // RefSeq // Homo sapiens DEAH (Asp- DHX8 4,29E-08 -1,43201 Glu-Ala-His) box polypeptide 8 (DHX8), mR
NM_004973 // RefSeq // Homo sapiens jumonji, AT JARID2 0,000563 -1,77431 rich interactive domain 2 (JARID2), tra 521
NM 004979 // RefSeq // Homo sapiens potassium KCND1 0,000444 -1,5521 voltage-gated channel, Shal-related subfa 632
NM 004991 // RefSeq // Homo sapiens MDS1 and MECOM 3,25E-05 2,8483 EVI1 complex locus (MECOM), transcript var
NM 005207 // RefSeq // Homo sapiens v-crk sarcoma CRKL 2,39E-05 1,28839 virus CT10 oncogene homo log (avian)-l
NM 005234 // RefSeq // Homo sapiens nuclear recepNR2F6 0,000826 1,51014 tor subfamily 2, group F, member 6 (NR 876
NM 005321 // RefSeq // Homo sapiens histone cluster HIST1H1 0,000713 1,41021 1, Hie (HIST1H1E), mRNA. // chr6 // E 866
NM 005324 // RefSeq // Homo sapiens H3 histone, H3F3B 9,61E-05 -1,3704 family 3B (H3.3B) (H3F3B), mRNA. // chr
NM 005342 // RefSeq // Homo sapiens high mobility HMGB3 0,000671 1,20975 group box 3 (HMGB3), mRNA. // chrX // 081
NM 005455 // RefSeq // Homo sapiens zinc finger, ZRANB2 2,77E-05 1,26006 RAN-binding domain containing 2 (ZRANB
NM 005474 // RefSeq // Homo sapiens histone deace- HDAC5 7,49E-06 -1,72069 tylase 5 (HDAC5), transcript variant 1
NM 005515 // RefSeq // Homo sapiens motor neuron MNX1 0,000704 1,50401 and pancreas homeobox 1 (MNX1), transc 808
NM 005612 // RefSeq // Homo sapiens RE 1 -silencing REST 0,000239 1,34567 transcription factor (REST), transcri 743
NM 005716 // RefSeq // Homo sapiens GIPC PDZ GIPCl 0,000203 -1,23473 domain containing family, member 1 (GIPCl) 046
NM 006005 // RefSeq // Homo sapiens Wolfram synWFS1 l,69E-05 -2,85621 drome 1 (wolframin) (WFS1), transcript v
NM 006044 // RefSeq // Homo sapiens histone HDAC6 0,000117 -1,64883 deacetylase 6 (HDAC6), mRNA. // chrX // 100 075
NM 006099 // RefSeq // Homo sapiens protein inhibiPI AS 3 0,000768 -1,50387 tor of activated STAT, 3 (PIAS3), niRN 421 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 006136 // RefSeq // Homo sapiens capping proCAPZA2 3,22E-06 1,57006 tein (actin filament) muscle Z-line, alp
NM 006184 // RefSeq // Homo sapiens nucleobindin NUCB1 0,000410 -1,26674 1 (NUCB1), mRNA. // chrl9 // 100 // 65 265
NM 006233 // RefSeq // Homo sapiens polymerase POLR2I 0,000840 -1,40612 (RNA) II (DNA directed) polypeptide I, 1 742
NM 006278 // RefSeq // Homo sapiens ST3 beta- ST3GAL4 0,000235 -1,81199 galactoside alpha-2,3-sialyltransferase 4 949
NM 006323 // RefSeq // Homo sapiens SEC24 famiSEC24B 0,000334 1,54512 ly, member B (S. cerevisiae) (SEC24B), tr 897
NM 006340 // RefSeq // Homo sapiens BAI1- BAIAP2 0,000370 -2,0633 associated protein 2 (BAIAP2), transcript vari 249
NM 006349 // RefSeq // Homo sapiens zinc finger, ZNHIT1 0,000265 1,28554 HIT-type containing 1 (ZNHIT1), mRNA. 674
NM 006503 // RefSeq // Homo sapiens proteasome PSMC4 4,26E-05 -1,40083 (prosome, macropain) 26S subunit, ATPase
NM 006519 // RefSeq // Homo sapiens dynein, light DYNLT1 7,04E-05 -1,62122 chain, Tctex-type 1 (DYNLT1), mRNA. /
NM 006520 // RefSeq // Homo sapiens dynein, light DYNLT3 3,50E-06 -1,92108 chain, Tctex-type 3 (DYNLT3), mRNA. /
NM 006576 // RefSeq // Homo sapiens advillin AVIL 0,000323 -1,91468 (AVIL), mRNA. // chrl2 // 100 // 46 // 17 698
NM 006662 // RefSeq // Homo sapiens Snf2-related SRCAP 8,70E-06 1,24864 CREBBP activator protein (SRCAP), mRNA
NM_006670 // RefSeq // Homo sapiens trophoblast TPBG 0,000295 -1,9724 glycoprotein (TPBG), transcript variant 368
NM 006694 // RefSeq // Homo sapiens jumping transJTB 0,000326 1,44031 location breakpoint (JTB), mRNA. // ch 852
NM 006765 // RefSeq // Homo sapiens tumor supTUSC3 0,000369 8,61268 pressor candidate 3 (TUSC3), transcript va 097
NM 006823 // RefSeq // Homo sapiens protein kinase PKIA 6,46E-10 7,40614 (cAMP-dependent, catalytic) inhibito
NM 0069 9 // RefSeq // Homo sapiens zinc finger ZNF17 0,000487 -1,568 protein 17 (ZNF17), mRNA. // chrl9 // 1 315
NM 007121 // RefSeq // Homo sapiens nuclear recepNR1H2 8,40E-06 -1,49957 tor subfamily 1, group H, member 2 (NR
NM 007202 // RefSeq // Homo sapiens A kinase AKAP10 7,62E-05 -1,33875 (PRKA) anchor protein 10 (AKAP10), nuclear
NM 007207 // RefSeq // Homo sapiens dual specificiDUSP10 0,000207 -4,83062 ty phosphatase 10 (DUSP10), transcrip 631
NM_007255 // RefSeq // Homo sapiens xylosylprotein B4GALT7 0,000722 1,37816 beta 1 ,4-galactosyltransferase, poly 147
NM_007257 // RefSeq // Homo sapiens paraneoplastic PNMA2 0,000101 1,92845 Ma antigen 2 (PNMA2), mRNA. // chr8 706
NM 012267 // RefSeq // Homo sapiens HSPA (heat HSPBP1 2,64E-05 -1,27672 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change shock 70kDa) binding protein, cytoplasmi
NM O 12367 // RefSeq // Homo sapiens olfactory reOR2B6 0,000305 -3,04291 ceptor, family 2, subfamily B, member 6 265
NM O 12478 // RefSeq // Homo sapiens WW domain WBP2 U5E-06 -1,64786 binding protein 2 (WBP2), mRNA. // chrl7
NM 013256 // RefSeq // Homo sapiens zinc finger ZNF180 0,000513 -1,42914 protein 180 (ZNF180), mRNA. // chrl9 // 508
NM O 13302 // RefSeq // Homo sapiens eukaryotic EEF2K 2,87E-05 1,79718 elongation factor-2 kinase (EEF2K), mRNA
NM O 13360 // RefSeq // Homo sapiens zinc finger ZNF222 0,000427 -1,54723 protein 222 (ZNF222), transcript varian 923
NM 013396 // RefSeq // Homo sapiens ubiquitin speUSP25 0,000601 -1,52444 cific peptidase 25 (USP25), mRNA. // c 869
NM O 14053 // RefSeq // Homo sapiens feline leuFLVCR1 0,000757 1,76921 kemia virus subgroup C cellular receptor 75
NM 014059 // RefSeq // Homo sapiens regulator of RGCC 0,000664 -2,02054 cell cycle (RGCC), mRNA. // chrl3 // 1 532
NM 014153 // RefSeq // Homo sapiens zinc finger ZC3H7A 0,000145 1,37325 CCCH-type containing 7A (ZC3H7A), mRNA. 153
NM_014203 // RefSeq // Homo sapiens adaptor- AP2A1 0,000109 -1,35066 related protein complex 2, alpha 1 subunit 055
NM O 14232 // RefSeq // Homo sapiens vesicle- VAMP2 0,000156 -1,34177 associated membrane protein 2 (synaptobrevi 22
NM 014236 // RefSeq // Homo sapiens glyc- GNPAT 0,000764 1,30866 eronephosphate O-acyltransferase (GNPAT), mRNA. 504
NM 014305 // RefSeq // Homo sapiens TDP-glucose TGDS 0,000626 1,42438 4,6-dehydratase (TGDS), mRNA. // chrl3 997
NM 014372 // RefSeq // Homo sapiens ring finger RNFl l 0,000106 -1,24245 protein 11 (RNFl 1), mRNA. // chrl // 10 794
NM O 14400 // RefSeq // Homo sapiens LY6/PLAUR LYPD3 0,000869 -5,98257 domain containing 3 (LYPD3), mRNA. // chr 584
NM O 14505 // RefSeq // Homo sapiens potassium KCNMB4 6,35E-11 -3,3897 large conductance calcium-activated chann
NM 014547 // RefSeq // Homo sapiens tropomodulin TMOD3 0,000185 -1,51616 3 (ubiquitous) (TMOD3), mRNA. // chr 15 07
NM O 14548 // RefSeq // Homo sapiens tropomodulin TMOD2 0,000549 -2,48044 2 (neuronal) (TMOD2), transcript varia 144
NM 014601 // RefSeq // Homo sapiens EH-domain EHD2 0,000105 -1,5327 containing 2 (EHD2), mRNA. // chr 19 // 10 966
NM_014713 // RefSeq // Homo sapiens lysosomal LAPTM4 0,000694 -1,23092 protein transmembrane 4 alpha (LAPTM4A), A 398
NM 014911 // RefSeq // Homo sapiens AP2 associatAAK1 0,000574 -1,72334 ed kinase 1 (AAK1), mRNA. // chr2 // 10 658
NM 014931 // RefSeq // Homo sapiens protein phosPPP6R1 0,000223 -1,55494 phatase 6, regulatory subunit 1 (PPP6R1 448 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM_014964 // RefSeq // Homo sapiens epsin 2 EPN2 4,10E-05 -1,72126 (EPN2), transcript variant 2, mRNA. // chrl
NM 015040 // RefSeq // Homo sapiens phosphoinosi- PIKFYVE 0,000832 -1,23084 tide kinase, FYVE finger containing (PI 262
NM 015044 // RefSeq // Homo sapiens golgi- GGA2 0,000406 1,44491 associated, gamma adaptin ear containing, ARF 7
NM 015049 // RefSeq // Homo sapiens trafficking TRAK2 2,88E-05 -1,43795 protein, kinesin binding 2 (TRAK2), mRN
NM 01 069 // RefSeq // Homo sapiens zinc finger ZNF423 0,000552 1,20408 protein 423 (ZNF423), mRNA. // chrl 6 // 678
NM_015143 // RefSeq // Homo sapiens methionyl METAP1 l,54E-05 1,55048 aminopeptidase 1 (METAP1), mRNA. // chr4
NM 015207 // RefSeq // Homo sapiens OTU domain OTUD3 7,69E-05 -1,33735 containing 3 (OTUD3), mRNA. // chrl // 1
NM 015252 // RefSeq // Homo sapiens EH domain EHBP1 6,58E-05 -1,71059 binding protein 1 (EHBP1), transcript var
NM 015310 // RefSeq // Homo sapiens pleckstrin and PSD3 0,000193 2,6915 Sec7 domain containing 3 (PSD3), tra 01
NM 015416 // RefSeq // Homo sapiens LETM1 doLETMD1 l,29E-05 1,69204 main containing 1 (LETMD1), nuclear gene en
NM 015603 // RefSeq // Homo sapiens coiled-coil CCDC9 4,28E-05 -1,43959 domain containing 9 (CCDC9), mRNA. // c
NM_015627 // RefSeq // Homo sapiens low density LDLRAP1 0,000157 -1,741 lipoprotein receptor adaptor protein 1 637
NM 015629 // RefSeq // Homo sapiens PRP31 pre- PRPF31 2,06E-05 -1,34607 mRNA processing factor 31 homo log (S. cer
NM 015836 // RefSeq // Homo sapiens tryptophanyl WARS2 0,000434 1,44684 tRNA synthetase 2, mitochondrial (WARS 877
NM O 15902 // RefSeq // Homo sapiens ubiquitin proUBR5 0,000746 -1,59776 tein ligase E3 component n-recognin 5 269
NM 015914 // RefSeq // Homo sapiens thioredoxin TXNDC1 0,000568 1,39512 domain containing 11 (TXNDC11), mRNA. / 1 452
NM 015953 // RefSeq // Homo sapiens nitric oxide NOSIP 0,000110 -1,29593 synthase interacting protein (NOSIP), 277
NM 016057 // RefSeq // Homo sapiens coatomer proCOPZ1 0,000163 1,24018 tein complex, subunit zeta 1 (COPZ1), m 738
NM_016200 // RefSeq // Homo sapiens N(alpha)- NAA38 0,000483 1,40998 acetyltransferase 38, NatC auxiliary subun 72
NM_016406 // RefSeq // Homo sapiens ubiquitin- fold UFC1 0,000584 1,30922 modifier conjugating enzyme 1 (UFC1) 754
NM 016429 // RefSeq // Homo sapiens coatomer proCOPZ2 0,000269 -1,60225 tein complex, subunit zeta 2 (COPZ2), m 299
NM O 16641 // RefSeq // Homo sapiens glycerophos- GDE1 l,54E-05 1,42932 phodiester phosphodiesterase 1 (GDE1), m
NM 016648 // RefSeq // Homo sapiens La ribonu- LARP7 0,000723 1,49349 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK LNCipedia) Symbol Change cleoprotein domain family, member 7 (LARP7 325
NM_017432 // RefSeq // Homo sapiens prostate tumor PTOV1 0,000297 -1,20982 overexpressed 1 (PTOV1), mRNA. // ch 575
NM 017514 // RefSeq // Homo sapiens plexin A3 PLXNA3 0,000351 -1,34289 (PLXNA3), mRNA. // chrX // 100 // 86 // 2 785
NM_017567 // RefSeq // Homo sapiens N- NAGK 0,000803 -1,49187 acetylglucosamine kinase (NAGK), mRNA. // chr2 // 027
NM O 17595 // RefSeq // Homo sapiens NFKB inhibiNKIRAS2 0,000702 -1,3554 tor interacting Ras-like 2 (NKIRAS2), tr 664
NM_017654 // RefSeq // Homo sapiens sterile alpha SAMD9 0,000382 -2,7255 motif domain containing 9 (SAMD9), tr 814
NM 017728 // RefSeq // Homo sapiens transmemTMEM10 0,000102 -1,40477 brane protein 104 (TMEM104), mRNA. // chrl7 4 602
NM 017879 // RefSeq // Homo sapiens zinc finger ZNF416 l,07E-05 -1,61003 protein 416 (ZNF416), mRNA. // chrl9 //
NM O 17983 // RefSeq // Homo sapiens WD repeat WIPI1 0,000177 -2,02652 domain, phosphoinositide interacting 1 (W 262
NM O 18003 // RefSeq // Homo sapiens uveal autoan- UACA 0,000346 -1,72232 tigen with coiled-coil domains and anky 391
NM_018028 // RefSeq // Homo sapiens sterile alpha SAMD4B 0,000527 -1,42244 motif domain containing 4B (SAMD4B), 89
NM O 18060 // RefSeq // Homo sapiens isoleucyl- IARS2 0,000793 1,39318 tRNA synthetase 2, mitochondrial (IARS2), 147
NM_018113 // RefSeq // Homo sapiens limb region 1 LMBR1L 8,15E-07 -1,57303 homo log (mouse)-like (LMBR1L), mRNA.
NM 018115 // RefSeq // Homo sapiens SDAl domain SDAD1 3J2E-05 1,62122 containing 1 (SDAD1), mRNA. // chr4 //
NM 018184 // RefSeq // Homo sapiens ADP- ARL8B 6,87E-05 -1,34728 ribosylation factor-like 8B (ARL8B), mRNA. // c
NM O 18246 // RefSeq // Homo sapiens coiled-coil CCDC25 0,000438 1,87372 domain containing 25 (CCDC25), mRNA. // 81
NM O 18259 // RefSeq // Homo sapiens tetratricopep- TTC17 0,000286 1,37035 tide repeat domain 17 (TTC17), mRNA. / 301
NM O 18352 // RefSeq // Homo sapiens translation TMA16 3,90E-05 1,45216 machinery associated 16 homo log (S. cer
NM 018374 // RefSeq // Homo sapiens transmemTMEM10 2J5E-08 -1,46927 brane protein 106B (TMEM106B), transcript v 6B
NM 018420 // RefSeq // Homo sapiens solute carrier SLC22A1 0,000349 -3,64877 family 22, member 15 (SLC22A15), mRN 5 26
NM_018490 // RefSeq // Homo sapiens leucine-rich LGR4 3,l lE-05 2,4669 repeat containing G protein-coupled re
NM 018561 // RefSeq // Homo sapiens ubiquitin speUSP49 0,000113 -1,5503 cific peptidase 49 (USP49), mRNA. // c 383
NM O 18602 // RefSeq // Homo sapiens DnaJ (Hsp40) DNAJA4 0,000396 -1,62023 homo log, subfamily A, member 4 (DNAJA4 672 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 018660 // RefSeq // Homo sapiens zinc finger ZNF395 0,000239 1,47923 protein 395 (ZNF395), mRNA. // chr8 // 944
NM O 19028 // RefSeq // Homo sapiens zinc finger, ZDHHC1 0,000493 -1,55561 DHHC-type containing 13 (ZDHHC13), tra 3 147
NM_019088 // RefSeq // Homo sapiens Pafl, RNA PAF1 7,03E-07 -1,6404 polymerase II associated factor, homolog
NM 019104 // RefSeq // Homo sapiens lin-37 homo- LIN37 0,000120 -1,52126 log (C. elegans) (LIN37), mRNA. // chrl9 927
NM O 19108 // RefSeq // Homo sapiens smg-9 homo- SMG9 9,41E-05 -1,48116 log, nonsense mediated mRNA decay factor
NM 019556 // RefSeq // Homo sapiens motile sperm MOSPD1 0,000120 -2,02203 domain containing 1 (MOSPD1), mRNA. // 877
NM 020133 // RefSeq // Homo sapiens 1- AGPAT4 0,000802 -1,6154 acylglycerol-3-phosphate O-acyltransferase 4 (lys 249
NM 020185 // RefSeq // Homo sapiens dual specificiDUSP22 0,000724 1,60139 ty phosphatase 22 (DUSP22), mRNA. // 319
NM 020218 // RefSeq // Homo sapiens ataxin 7-like 3 ATXN7L3 2,l lE-05 -1,32871 (ATXN7L3), transcript variant 1, mR
NM_020414 // RefSeq // Homo sapiens DEAD (Asp- DDX24 0,000154 -1,37919 Glu-Ala-Asp) box polypeptide 24 (DDX24), 496
NM 020429 // RefSeq // Homo sapiens SMAD speciSMURF 1 2,37E-05 1,56555 fic E3 ubiquitin protein ligase 1 (SMURF 1
NM_020437 // RefSeq // Homo sapiens aspartate beta- ASPHD2 0,000482 2,51121 hydroxylase domain containing 2 (ASP 138
NM 020448 // RefSeq // Homo sapiens NIPA-like NIPAL3 2,86E-05 -1,65519 domain containing 3 (NIPAL3), mRNA. // ch
NM 020632 // RefSeq // Homo sapiens ATPase, H+ ATP6V0A l,77E-05 -1,75119 transporting, lysosomal V0 subunit a4 (A 4
NM 020664 // RefSeq // Homo sapiens 2,4-dienoyl DECR2 6,51E-05 1,30586 CoA reductase 2, peroxisomal (DECR2), m
NM_020765 // RefSeq // Homo sapiens ubiquitin proUBR4 0,000102 -1,40087 tein ligase E3 component n-recognin 4 398
NM 020803 // RefSeq // Homo sapiens kelch-like 8 KLHL8 0,000232 1,82758 (Drosophila) (KLHL8), mRNA. // chr4 // 071
NM 020880 // RefSeq // Homo sapiens zinc finger ZNF530 0,000395 -1,35847 protein 530 (ZNF530), mRNA. // chrl9 // 105
NM 021065 // RefSeq // Homo sapiens histone cluster HIST1H2 0,000208 -2,15029 1, H2ad (HIST1H2AD), mRNA. // chr6 AD 018
NM 021089 // RefSeq // Homo sapiens zinc finger ZNF8 2,03E-07 -1,57901 protein 8 (ZNF8), mRNA. // chrl9 // 100
NM_021135 // RefSeq // Homo sapiens ribosomal RPS6KA2 0,000760 -1,81987 protein S6 kinase, 90kDa, polypeptide 2 ( 68
NM 021167 // RefSeq // Homo sapiens GATA zinc GAT AD 1 9,00E-05 1,22999 finger domain containing 1 (GATAD1), tran
NM 021228 // RefSeq // Homo sapiens SR-related SCAF1 0,000888 -1,40377 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
CTD-associated factor 1 (SCAF1), mRNA. / 645
NM 021807 // RefSeq // Homo sapiens exocyst comEXOC4 2,98E-05 1,52739 plex component 4 (EXOC4), transcript var
NM 021962 // RefSeq // Homo sapiens active BCR- ABR 0,000231 1,53359 related (ABR), transcript variant 1 , mRN 115
NM 021969 // RefSeq // Homo sapiens nuclear recepNR0B2 0,000339 2,05228 tor subfamily 0, group B, member 2 (NR 648
NM 021994 // RefSeq // Homo sapiens zinc finger ZNF277 3,51E-05 1,45306 protein 277 (ZNF277), mRNA. // chr7 //
NM_022071 // RefSeq // Homo sapiens SH2 domain SH2D4A 2,08E-05 2,66162 containing 4A (SH2D4A), transcript varia
NM 022081 // RefSeq // Homo sapiens Hermansky- HPS4 2,66E-06 1,40447 Pudlak syndrome 4 (HPS4), transcript vari
NM 022445 // RefSeq // Homo sapiens thiamin pyro- TP 1 6,16E-06 2,57981 phosphokinase 1 (TP 1), transcript vari
NM_022727 // RefSeq // Homo sapiens tRNA methyl- TRMT2A 4,16E-05 1,21513 transferase 2 homo log A (S. cerevisiae)
NM 022746 // RefSeq // Homo sapiens mitochondrial MARC1 8,69E-07 2,2723 amidoxime reducing component 1 (MARC1
NM 022757 // RefSeq // Homo sapiens coiled-coil CCDC14 0,000363 1,34168 domain containing 14 (CCDC14), mRNA. // 066
NM 022835 // RefSeq // Homo sapiens pleckstrin PLEKHG 0,000417 -1,7062 homology domain containing, family G (wi 2 527
NM 024090 // RefSeq // Homo sapiens ELOVL fatty ELOVL6 0,000459 1,86685 acid elongase 6 (ELOVL6), transcript va 42
NM 024298 // RefSeq // Homo sapiens membrane MBOAT7 0,000146 -1,75347 bound O-acyltransferase domain containing 738
NM_024321 // RefSeq // Homo sapiens RNA binding RBM42 0,000394 -1,33722 motif protein 42 (RBM42), mRNA. // chrl 402
NM 024334 // RefSeq // Homo sapiens transmemTMEM43 0,000251 -1,54047 brane protein 43 (TMEM43), mRNA. // chr3 // 036
NM 024546 // RefSeq // Homo sapiens ring finger RNF219 0,000295 1,55798 protein 219 (RNF219), mRNA. // chrl 3 // 069
NM_024599 // RefSeq // Homo sapiens rhomboid 5 RHBDF2 7,54E-05 -1,89983 homo log 2 (Drosophila) (RHBDF2), transcr
NM 024620 // RefSeq // Homo sapiens zinc finger ZNF329 9,96E-05 -1,56211 protein 329 (ZNF329), mRNA. // chrl 9 //
NM 024682 // RefSeq // Homo sapiens TBCl domain TBC1D17 3,50E-07 -1,61794 family, member 17 (TBC1D17), transcript
NM 024707 // RefSeq // Homo sapiens gem (nuclear GEMIN7 0,000106 -1,60472 organelle) associated protein 7 (GEMIN 435
NM 024847 // RefSeq // Homo sapiens transmemTMC7 4,30E-05 1,53843 brane channel-like 7 (TMC7), transcript var
NM 024893 // RefSeq // Homo sapiens synapse difSYNDIG1 0,000865 1,93541 ferentiation inducing 1 (SYNDIG1), mRNA. 658
Figure imgf000176_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 032836 // RefSeq // Homo sapiens FLT3- FIZl 0,000515 -1,34828 interacting zinc finger 1 (FIZl), mRNA. // chr 313
NM 032861 // RefSeq // Homo sapiens serine active SERACl 6,05E-05 -1,52789 site containing 1 (SERACl), mRNA. //
NM 032999 // RefSeq // Homo sapiens general tranGTF2I 0,000214 1,27657 scription factor Hi (GTF2I), transcrip 966
NM 033017 // RefSeq // Homo sapiens tripartite motif TRIM4 8,60E-05 1,3946 containing 4 (TRIM4), transcript v
NM_033141 // RefSeq // Homo sapiens mitogen- MAP3K9 0,000380 -2,72236 activated protein kinase kinase kinase 9 (M 881
NM_033625 // RefSeq // Homo sapiens ribosomal RPL34 2,20E-05 1,67708 protein L34 (RPL34), transcript variant 2
NM 052883 // RefSeq // Homo sapiens thioredoxin TXNRD3 8,39E-05 1,63902 reductase 3 (TXNRD3), transcript varian
NM 053282 // RefSeq // Homo sapiens SH2 domain SH2D1B 0,000887 -1,67602 containing IB (SH2D1B), mRNA. // chrl // 864
NM 054013 // RefSeq // Homo sapiens mannosyl MGAT4B 2,62E-05 1,47036 (alpha- 1 ,3-)-glycoprotein beta- 1 ,4-N-acety
NM_133178 // RefSeq // Homo sapiens protein tyroPTPRU 7,58E-05 -2,43936 sine phosphatase, receptor type, U (PTP
NM 133502 // RefSeq // Homo sapiens zinc finger ZNF274 0,000215 -1,41605 protein 274 (ZNF274), transcript varian 353
NM 138374 // RefSeq // Homo sapiens zinc finger ZNF845 0,000396 -1,22981 protein 845 (ZNF845), mRNA. // chrl 9 // 171
NM 138392 // RefSeq // Homo sapiens SH3KBP1 SHKBP1 0,000130 -1,70089 binding protein 1 (SHKBP1), mRNA. // chr 19 387
NM 138439 // RefSeq // Homo sapiens FLYWCH FLY- 0,000103 -1,3144 family member 2 (FLYWCH2), transcript varian WCH2 143
NM 138639 // RefSeq // Homo sapiens BCL2-like 12 BCL2L12 0,000236 -1,29172 (proline rich) (BCL2L12), transcript v 635
NM 138806 // RefSeq // Homo sapiens CD200 reCD200R1 4,66E-05 -1,3429 ceptor 1 (CD200R1), transcript variant 1, m
NM l 38809 // RefSeq // Homo sapiens carboxy- CMBL 1J7E-06 2,74107 methylenebutenolidase homolog (Pseudomonas)
NM 139163 // RefSeq // Homo sapiens amyotrophic ALS2CR1 0,000403 -1,87959 lateral sclerosis 2 (juvenile) chromoso 2 151
NM_139165 // RefSeq // Homo sapiens retinoic acid RAETIE 0,000382 -1,68602 early transcript IE (RAETIE), transcr 797
NM 139239 // RefSeq // Homo sapiens nuclear factor NFKBID 0,000401 -1,25134 of kappa light polypeptide gene enha 81
NM 144643 // RefSeq // Homo sapiens sodium chanSCLT1 4,36E-05 1,47543 nel and clathrin linker 1 (SCLT1), mRNA.
NM 144680 // RefSeq // Homo sapiens zinc finger ZNF18 0,000451 -1,4086 protein 18 (ZNF18), mRNA. // chrl7 // 1 991
NM 145249 // RefSeq // Homo sapiens interferon, IFI27L1 0,000435 -1,37161 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change alpha-inducible protein 27-like 1 (IFI2 565
NM 145260 // RefSeq // Homo sapiens odd-skipped OSR1 0,000118 -1,37549 related 1 (Drosophila) (OSR1), mRNA. // 411
NM 145792 // RefSeq // Homo sapiens microsomal MGST1 6J6E-05 1,50692 glutathione S-transferase 1 (MGST1), tra
NM 1 2244 // RefSeq // Homo sapiens sorting nexin SNX11 0,000714 -1,28327 11 (SNX11), transcript variant 1, mRN 939
NM 152262 // RefSeq // Homo sapiens zinc finger ZNF439 0,000790 -1,59248 protein 439 (ZNF439), mRNA. // chrl9 // 075
NM 152292 // RefSeq // Homo sapiens tRNA methyl- TRMT10 0,000649 1,37031 transferase 10 homo log A (S. cerevisiae) A 916
NM 152336 // RefSeq // Homo sapiens ATP/GTP AGBL1 0,000460 1,29346 binding protein- like 1 (AGBL1), mRNA. // ch 694
NM 152458 // RefSeq // Homo sapiens zinc finger ZNF785 0,000139 1,23971 protein 785 (ZNF785), mRNA. // chrl6 // 475
NM_152540 // RefSeq // Homo sapiens seel family SCFD2 2,13E-06 1,55505 domain containing 2 (SCFD2), mRNA. // c
NM 152730 // RefSeq // Homo sapiens chromosome C6orfl70 3,90E-05 -1,84595 6 open reading frame 170 (C6orfl70), mRN
NM 153213 // RefSeq // Homo sapiens Rho guanine ARHGEF 0,000854 -1,51734 nucleotide exchange factor (GEF) 19 (AR 19 193
NM 153230 // RefSeq // Homo sapiens F-box protein FBX039 8,19E-05 -1,29957 39 (FBX039), mRNA. // chrl7 // 100 //
NM 153267 // RefSeq // Homo sapiens MAM domain MAMDC2 0,000475 -2,24897 containing 2 (MAMDC2), mRNA. // chr9 // 674
NM 153373 // RefSeq // Homo sapiens alanine- AGXT2L2 4,42E-07 1,48762 glyoxylate aminotransferase 2-like 2 (AGXT2
NM_153690 // RefSeq // Homo sapiens family with FAM43A 4J7E-08 -2,59262 sequence similarity 43, member A (FAM43
NM_170732 // RefSeq // Homo sapiens brain-derived BDNF 0,000681 -1,79376 neurotrophic factor (BDNF), transcrip 043
NM 172195 // RefSeq // Homo sapiens eukaryotic EIF2B4 0,000878 -1,46683 translation initiation factor 2B, subuni 249
NM 173505 // RefSeq // Homo sapiens ankyrin repeat ANKRD2 0,000654 3,60246 domain 29 (ANKRD29), mRNA. // chrl8 9 302
NM 174898 // RefSeq // Homo sapiens lysozyme G- LYG1 4,19E-05 -1,36589 like 1 (LYG1), mRNA. // chr2 // 100 // 1
NM 175875 // RefSeq // Homo sapiens SIX ho- SIX5 2,33E-06 -1,20606 meobox 5 (SIX5), mRNA. // chrl9 // 100 // 90
NM 178562 // RefSeq // Homo sapiens tetraspanin 33 TSPAN33 0,000272 1,6253 (TSPAN33), mRNA. // chr7 // 100 // 8 558
NM 178566 // RefSeq // Homo sapiens zinc finger, ZDHHC2 0,000331 -1,43307 DHHC-type containing 21 (ZDHHC21), mRN 1 668
NM 178820 // RefSeq // Homo sapiens F-box protein FBX027 0,000747 -2,52259 27 (FBX027), mRNA. // chrl9 // 100 // 319 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM_ 182691 // RefSeq // Homo sapiens SRSF protein SRPK2 3J4E-05 1,52103 kinase 2 (SRPK2), transcript variant 2
NM 182703 // RefSeq // Homo sapiens ankyrin repeat ANKDD1 0,000361 -1,2451 and death domain containing 1A (ANKD A 769
NM 182776 // RefSeq // Homo sapiens minichromo- MCM7 0,000545 1,62408 some maintenance complex component 7 (MCM 722
NM_ 194071 // RefSeq // Homo sapiens cAMP reCREB3L2 9,16E-05 -1,8041 sponsive element binding protein 3 -like 2 (C
NM 198467 // RefSeq // Homo sapiens round spermaRSBN1L 1.11E-09 1,60102 tid basic protein 1-like (RSB 1L), mRNA
NM 198489 // RefSeq // Homo sapiens coiled-coil CCDC84 0,000713 -1,42244 domain containing 84 (CCDC84), mRNA. // 857
NM 198562 // RefSeq // Homo sapiens chromosome C3orf62 0,000103 -1,70768 3 open reading frame 62 (C3orf62), mRNA. 136
NM 198686 // RefSeq // Homo sapiens RAB15, RAB15 0,000218 -2,55595 member RAS oncogene family (RAB15), mRNA. // 391
NM 198850 // RefSeq // Homo sapiens pleckstrin PHLDB3 0,000586 -1,88141 homo logy-like domain, family B, member 3 87
NM 199320 // RefSeq // Homo sapiens PHD finger PHF17 6,05E-05 1,89743 protein 17 (PHF17), transcript variant L
NM 205853 // RefSeq // Homo sapiens musculoskeleMUSTN 1 6.73E-05 -1,36668 tal, embryonic nuclear protein 1 (MUSTN
NM 207113 // RefSeq // Homo sapiens solute carrier SLC37A3 6,52E-05 1,53532 family 37 (glycerol-3-phosphate tran
NM 207351 // RefSeq // Homo sapiens pro line-rich PRRT3 0,000258 -1,27858 transmembrane protein 3 (PRRT3), mRNA. 606
NM_212550 // RefSeq // Homo sapiens biogenesis of BLOC 1 S3 6,16E-05 -1,3341 lysosomal organelles complex- 1, subun
NM_212559 // RefSeq // Homo sapiens XK, ell XKRX 0,000376 -2,04521 blood group complex subunit-related, X-lin 005
NM 213598 // RefSeq // Homo sapiens zinc finger ZNF543 3J9E-05 -1,55628 protein 543 (ZNF543), mRNA. // chrl9 //
NR_002785 // RefSeq // Homo sapiens GNAS an- GNAS- 4,85E-06 4,20833 tisense RNA 1 (non-protein coding) (GNAS-AS1 AS1
NR_002806 // RefSeq // Homo sapiens F AMI 3 A an- FAM BA1.39E-07 1,43629 tisense RNA 1 (non-protein coding) (FAM13A AS 1
NR 002911 // RefSeq // Homo sapiens small nucleoSNO- 9,30E-05 1,75134 lar RNA, H/ACA box 71A (SNORA71A), smal RA71A
NR_002941 // RefSeq // Homo sapiens phosducin-like LOC2853 0,000350 -1,44857 3 pseudogene (LOC285359), non-coding 59 562
NR 003014 // RefSeq // Homo sapiens small nucleoSNORA47 0,000797 2,14719 lar RNA, H/ACA box 47 (SNORA47), small 356
NR_003529 // RefSeq // Homo sapiens CDKN2B an- CDKN2B- 0,000591 -3,02225 tisense RNA 1 (non-protein coding) (CDKN2B AS1 483
NR_015379 // RefSeq // Homo sapiens urothelial can- UCA1 0,000543 -2,31695 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change cer associated 1 (non-protein coding) 923
NR_024063 // RefSeq // Homo sapiens zinc finger and ZSCAN12 0,000230 -2,35094
SCAN domain containing 12 pseudogen PI 91
NR_024170 // RefSeq // Homo sapiens late endoso- LAM- 0,000153 1,80448 mal/lysosomal adaptor, MAPK and MTOR act TORS 994
NR_024176 // RefSeq // Homo sapiens MAP kinase MKN 1 6,66E-06 -1,59683 interacting serine/threonine kinase 1 (M
NR_024178 // RefSeq // Homo sapiens tyrosine 3- LOC2841 0,000267 1,79347 monooxygenase/tryptophan 5 -monooxygenase 00 456
NR_024199 // RefSeq // Homo sapiens Cbl proto- CBLL1 8,31E-05 1,31022 oncogene, E3 ubiquitin protein ligase-lik
NR_024322 // RefSeq // Homo sapiens male-specific MSL3P1 0,000268 -1,67614 lethal 3 homo log (Drosophila) pseudog 237
NR_024554 // RefSeq // Homo sapiens Rho-related RHOBTB 7,69E-08 2,75759
BTB domain containing 1 (RHOBTB1), tran 1
NR 024618 / RefSeq // Homo sapiens uncharacter- LOCIOOI 0,000410 -1,51029 ized LOC100129550 (LOC100129550), non-co 29550 664
NR_026052 // RefSeq // Homo sapiens CENPB DNA- MGC2752 0,000313 -1,33581 binding domains containing 1 pseudogene ( 693
NR_026583 // RefSeq // Homo sapiens Rac GTPase RACGAP 0,000882 1,24476 activating protein 1 pseudogene (RACGAP 1 IP 981
NR 026650 // RefSeq // Homo sapiens biphenyl hy- BPHL 0,000157 1,99326 drolase-like (serine hydrolase) (BPHL), 942
NR_026778 // RefSeq // Homo sapiens HNRNPU HNRN- 5,39E-06 1,75828 antisense RNA 1 (non-protein coding) (HNRNPU PU-AS1
NR_026865 // RefSeq // Homo sapiens chromosome 7 C7orfl3 3,85E-05 1,73876 open reading frame 13 (C7orfl3), non-c
NR_026892 // RefSeq // Homo sapiens AFAP1 anAFAP1- 0,000535 3,15772 tisense RNA 1 (non-protein coding) (AFAP 1 -A AS1 337
NR_026921 // RefSeq // Homo sapiens chromosome 5 LOC2021 0,000132 5,93496 open reading frame 25 pseudogene (LOC2 81
NR 027003 // RefSeq // Homo sapiens uncharacter- DKFZp43 0,000714 -1,93606 ized LOC93429 (DKFZp434J0226), non-codin 4J0226 032
NR 027107 // RefSeq // Homo sapiens uncharacter- MGC4580 0,000466 1,34131 ized LOC90768 (MGC45800), non-coding RNA 0 578
NR_027280 // RefSeq // Homo sapiens SUMOl actiSAE1 0,000790 -1,38962 vating enzyme subunit 1 (SAE1), transcrip 559
NR 027774 // RefSeq // Homo sapiens pleckstrin hoPLEKHM 0,000102 -1,56662 mology domain containing, family M (wi 1 552
NR 028090 // RefSeq // Homo sapiens uncharacter- LOC2027 3,81E-07 1,71214 ized LOC202781 (LOC202781), non-coding R 81
NR_028103 // RefSeq // Homo sapiens DDB1 and DCAF8 0,000487 1,28223
CUL4 associated factor 8 (DCAF8), transcri 055
NR_028459 // RefSeq // Homo sapiens ataxin 3 ATXN3 0,000582 -1,37831
(ATXN3), transcript variant m, non-coding 436 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NR 029636 // RefSeq // Homo sapiens microRNA MIR222 0,000719 -2,35412
222 (MIR222), microRNA. // chrX // 100 // 859
NR 029886 // RefSeq // Homo sapiens microRNA MIR330 0,000391 -1,21744
330 (MIR330), microRNA. // chrl9 // 100 // 606
NR 030255 // RefSeq // Homo sapiens microRNA MIR455 0,000773 1,44537
455 (MIR455), microRNA. // chr9 // 100 // 182
NR 030365 // RefSeq // Homo sapiens microRNA MIR635 0,000549 -2,20312
635 (MIR635), microRNA. // chrl7 // 100 // 592
NR 030598 // RefSeq // Homo sapiens microRNA MIR708 0,000152 3,66493
708 (MIR708), microRNA. // chrl 1 // 100 // 35
NR 031611 // RefSeq // Homo sapiens microRNA MIR1206 5,51E-06 -7,06005 1206 (MIR1206), microRNA. // chr8 // 100 /
NR_033248 // RefSeq // Homo sapiens glycine cleavGCSHP3 3,60E-06 -1,61256 age system protein H (aminomethyl carr
NR_033322 // RefSeq // Homo sapiens NOP2/Sun NSUN5P1 0,000397 1,34196 domain family, member 5 pseudogene 1 (NSUN 788
NR 033396 // RefSeq // Homo sapiens solute carrier SLC22A2 0,000420 -1,82501 family 22, member 20 (SLC22A20), tra 0 652
NR_033646 // RefSeq // Homo sapiens lipase maturaLMF1 0,000844 1,64505 tion factor 1 (LMF1), transcript varia 324
NR_033829 // RefSeq // Homo sapiens MIR4500 host MIR4500 1.18E-05 -2,597 gene (non-protein coding) (MIR4500HG), HG
NR_033897 // RefSeq // Homo sapiens EPHA1 an- EPHA1- 0,000447 -1,44666 tisense RNA 1 (non-protein coding) (EPHA1-A AS1 922
NR_033914 // RefSeq // Homo sapiens long intergenic LINC0025 0,000486 1,24413 non-protein coding RNA 254 (LINC002 4 907
NR 033957 // RefSeq // Homo sapiens uncharacter- LOC6436 0,000482 -2,40882 ized LOC643650 (LOC643650), non-coding R 50 995
NR_034146 // RefSeq // Homo sapiens sirtuin 2 SIRT2 0,000270 -1,22398
(SIRT2), transcript variant 4, non-coding 408
NR_036639 // RefSeq // Homo sapiens Yi l domain YIPF1 0,000103 -1,53376 family, member 1 (YIPF1), transcript va 1
NR 037606 // RefSeq // Homo sapiens mitochondrial MRPS14 0,000377 1,2155 ribosomal protein S14 (MRP S 14), trans 113
NR_037638 // RefSeq // Homo sapiens solute carrier SLC28A3 0,000398 -3,61015 family 28 (sodium-coupled nucleoside 623
NR 037897 // RefSeq // Homo sapiens uncharacter- FLJ38109 8,47E-06 1,33859 ized LOC386627 (FLJ38109), non-coding RN
NR_038064 // RefSeq // Homo sapiens perilipin 2 PLIN2 4,56E-05 -1,81769 (PLIN2), transcript variant 2, non-codi
NR_038125 // RefSeq // Homo sapiens capping proCAPZB 0,000359 -1,30811 tein (actin filament) muscle Z-line, bet 775
NR 038221 // RefSeq // Homo sapiens uncharacter- LOC2016 0,000749 1,26238 ized LOC201617 (LOC201617), non-coding R 17 039
NR_038340 // RefSeq // Homo sapiens uncharacter- LOC1005 0,000387 -16,657 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change ized LOC100505817 (LOC100505817), non-co 05817 011
NR 038835 // RefSeq // Homo sapiens uncharacter- LOC6452 0,000103 1,34015 ized LOC645249 (LOC645249), non-coding R 49 643
NR 039722 // RefSeq // Homo sapiens microRNA MIR4500 5,51E-09 -27,9959
4500 (MIR4500), microRNA. // chrl3 // 100
NR 039969 // RefSeq // Homo sapiens microRNA MIR5047 0,000597 -1,54287
5047 (MIR5047), microRNA. // chrl7 // 100 691
NR 040001 // RefSeq // Homo sapiens uncharacter- LOC3752 0,000516 3,81932 ized LOC375295 (LOC375295), non-coding R 95 498
NR_040006 // RefSeq // Homo sapiens cleft lip and CLPTM1 l,36E-06 -1,61167 palate associated transmembrane prote
NR_046008 // RefSeq // Homo sapiens zinc finger, ZMAT1 0,000253 3,70656 matrin-type 1 (ZMAT1), transcript vari 172
NR 046088 // RefSeq // Homo sapiens uncharacter- LOC7299 0,000314 3,06482 ized LOC729987 (LOC729987), non-coding R 87 965
NR 046224 // RefSeq // Homo sapiens uncharacter- LOC1006 0,000245 1,43106 ized LOCI 00652730 (LOCI 00652730), transc 52730 568
NR 046240 // RefSeq // Homo sapiens uncharacter- LOC1005 l,24E-07 -1,83546 ized LOC100506100 (LOC100506100), non-co 06100
NR_046793 // RefSeq // Homo sapiens RPS6KA2 RPS6KA2 0,000449 -1,69521 intronic transcript 1 (non-protein coding) -IT1 91
NR_046824 // RefSeq // Homo sapiens EPN2 intronic EPN2-IT1 0,000425 -1,47957 transcript 1 (non-protein coding) (EP 865
TCONS 00000159-XLOC 000068 // Rinn lincRNA LOC4007 3,53E-06 -1,40789
// linc-PADI 1 - 1 chr 1 :+: 17516277- 17524112 // 43
TCONS 00000159-XLOC 000068 // Rinn lincRNA LOC4007 7,34E-06 -1,42537
// linc-PADI 1 - 1 chr 1 :+: 17516277- 17524112 // 43
TCONS 00001037-XLOC 000302 // Rinn lincRNA // ] inc- l,96E-06 -4,13922
SLC44A3-2 chrl :+:95007607-95008571 /
TCONS 00001448-XLOC 000771 // Rinn lincRNA // linc- 0,000588 -1,67127
FABP3-2 chrl :-:31933167-319443 1 // 915
TCONS 00001550-XLOC 000893 // Rinn lincRNA // linc- 0,000371 -1,21769
TTLL7-6 chrl :-:84920351-84924713 // 881
TCONS 00001926-XLOC 000031 // Rinn lincRNA // line- AJAPl - 0,000307 1,21471
5 chrl :+:4037027-4058260 // ch 348
TCONS 00003039-XLOC 001728 // Rinn lincRNA // linc- 0,000390 -2,76654
PSMD14 chr2:+:162101265-162103965 // 421
TCONS 00003057-XLOC 001765 // Rinn lincRNA // linc- 0,000561 1,75699
HNRNPA3-4 chr2 :+: 177502437- 177520686 159
TCONS 00004099-XLOC 001948 // Rinn lincRNA // linc- 0,000635 1,2547
MYT1L-2 chr2:-:2886699-2898250 // ch 893
TCONS_00004125-XLOC_001971 // Rinn lincRNA // linc- 0,000616 1,40959
CMPK2-5 chr2:-:8007543-8009432 // ch 141
TCONS_00005559-XLOC_002736 // Rinn lincRNA // linc- 0,000423 -16,4077
COL8A1-3 chr3:+:98699901-98701940 // 396 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
TCONS 00005633-XLOC 002891 // Rinn lincRNA // ] inc-PTX3-5 0,000536 -1,28956 chr3:+:156799629-156806336 // 452
TCONS 00007505-XLOC 003499 // Rinn lincRNA // linc- 0,000755 1,28673
DTHD1-7 chr4:+:32352659-32354842 // 516
TCONS_00007610-XLOC_003680 // Rinn lincRNA // linc-FAT4-3 0,000808 1,61816 chr4:+: 124426433-124448680 // 553
TCONS_00008202-XLOC_003656 // Rinn lincRNA // linc- 2,43E-06 1,36186
NDST3-5 chr4:+: 116102448-116191383 /
TCONS_00008471-XLOC_003934 // Rinn lincRNA // linc- 4,17E-05 1,24977
APBB2-3 chr4:-:41222114-41223379 //
TCONS 00009717-XLOC 004914 // Rinn lincRNA // linc-CCNH- 3,91E-05 -1,37898
1 chr5:-:87008951-87029086 // c
TCONS 00009795-XLOC 005037 // Rinn lincRNA // linc-NR3 CI 0,000640 1,22263 chr5:-: 142869419-142910915 // 911
TCONS 00010319-XLOC 004802 // Rinn lincRNA // linc-SEPPl- 0,000542 -1,81594
2 chr5:-:42918465-42920126 // 759
TCONS 00010320-XLOC 004803 // Rinn lincRNA FLJ32255 0,000345 -2,77265
// linc-SEPPl-3 chr5:-:42985139-42992726 // 075
TCONS 00010376-XLOC 004879 // Rinn lincRNA // inc- 0,000515 1,81771
ZNF366-6 chr5:-:72408840-72413568 // 921
TCONS_00012358-XLOC_005917 // Rinn lincRNA // linc- 0,000646 1,21054
PDElOA-l chr6:-:166253091-166253578 916
TCONS_00014650-XLOC_006740 // Rinn lincRNA // linc- 0,000637 1,33522
RHOBTB2-1 chr8:+:22808335-22814153 / 075
TCONS_00014681-XLOC_006779 // Rinn lincRNA // linc-C8orf4- 0,000612 1,3039
2 chr8:+:39891375-39891902 // 12
TCONS 00014909-XLOC 006976 // Rinn lincRNA // linc- 0,000275 1,27392
ERICH1-4 chr8:-:1741067-1744122 // c 069
TCONS 00015946-XLOC 007323 // Rinn lincRNA // linc-PRSS3- 0,000863 -1,82072
4 chr9:+:33583982-33585615 // 093
TCONS 00016159-XLOC 007570 // Rinn lincRNA // linc- 4,15E-05 -2,51168
STXBP1-2 c r9:+:130342615-130343098
TCONS 00016465-XLOC 007830 // Rinn lincRNA // linc- 0,000152 1,35857
C9orf 0 chr9:-: 115505050-115 12795 / 19
TCONS_00016665-XLOC_007505 // Rinn lincRNA // linc- 0,000788 -1,36119
ACTL7A- 11 chr9 :+: 110100226- 110101430 805
TCONS_00018677-XLOC_008381 // Rinn lincRNA // linc- 0,000297 -1,30622
GATA3-1 chrl0:+:8093126-8094726 // c 137
TCONS_00020348-XLOC_009679 // Rinn lincRNA // linc- 4,82E-05 2,30686
PLEKHA5-2 chrl2:+:18906532-18926324
TCONS 00020678-XLOC 009983 // Rinn lincRNA // linc- 0,000109 1,31993
PARPl l-1 chrl2:-:4017194-4029987 // 318
TCONS 00020723-XLOC 010023 // Rinn lincRNA // linc- 8,63E-05 -3,44753
GUCY2C chrl2:-: 14898793-14903603 //
TCONS 00021677-XLOC 010682 // Rinn lincRNA // line- 0,000227 -1,79851 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
SLITR 6-7 chrl3:-:88079468-88080528 162
TCONS 00022382-XLOC 011104 // Rinn lincRNA // linc-TRIP 11 0,000582 -2,24763 chrl4:-:92511119-92516990 // 973
TCONS 00022775-XLOC 011059 // Rinn lincRNA // linc- 0,000479 -1,24444
C14orfl81 chrl4:-:69283615-69284659 353
TCONS 00023282-XLOC 011521 // Rinn lincRNA // linc-TLE3-l 5,62E-05 -1,56672 chrl5:-:70863297-70878945 //
TCONS_00023504-XLOC_011348 // Rinn lincRNA // linc-CRTC3 0,000439 -1,60682 chrl5:+:91061799-91068340 // c 486
TCONS_00023631-XLOC_011430 // Rinn lincRNA // linc-MEIS2- 7,46E-05 1,48546
4 chrl5:-:38363067-38365188 //
TCONS_00023687-XLOC_011486 // Rinn lincRNA // linc- 0,000596 -4,40333
ALDH1A2-1 chrl5:-:58572414-58576475 414
TCONS 00025120-XLOC O 12197 // Rinn lincRNA // linc- 0,000355 -1,51121
TMEM99-4 chrl7:+:38673277-38683253 / 171
TCONS 00026909-XLOC 012981 // Rinn lincRNA // linc- 0,000515 -9,62033
OR10H4 chrl9:+:15945758-15946461 // 535
TCONS 00028551-XLOC 013534 // Rinn lincRNA LOCIOOI 9,64E-05 -1,22992
// linc-WFDC2-2 chr20:+:44058263-44077210 // 30157
TCONS 00029009-XLOC 013932 // Rinn lincRNA MORC3 0,000401 -1,46957
// linc-CHAFIB chr21 :+:37756424-37757219 // 113
TCONS 00029062-XLOC 013983 // Rinn lincRNA // ] inc- 5,55E-05 1,35484
COL18A1-2 chr21 :+:46767516-46773433
TCONS_00029585-XLOC_014219 // Rinn lincRNA // linc-RASD2 2,07E-05 1,67681 chr22:+:35846033-35851349 // c
TCONS 12 00004768-XLOC 12 002469 // Broad LOC2831 0,000821 1,43834
TUCP // linc-NCAM 1-3 chrl 1 :+: 112161097-112164 40 801
TCONS 12 00007341-XLOC 12 004113 // Broad DKFZp45 5,80E-06 -1,25913
TUCP // linc-GRTPl chrl3:-: 114053726-11406528 1A211
TCONS 12 00009421-XLOC 12 004598 // Broad LOCIOOI 4,13E-08 2,06385
TUCP // linc-ARHGAPl lB-6 chrl 5 :+:29967193-299 30111
TCONS 12 00016247-XLOC 12 008622 // Broad ARHGAP 3,66E-05 -2,80957
TUCP // linc-SLC32Al chr20:+:37230530-3727925 40
TCONS 12 00017147-XLOC 12 009139 // Broad TUCP // linc- 0,000375 -1,77573
SAMSN1-3 chr21 :-: 16189150-162300 346
TCONS 12 00020756-XLOC 12 010831 // Broad TUCP // linc- 0,000748 2,80774
PHF17-2 chr4:+: 129387804-1294405 312
TCONS_12_00021702-XLOC_12_010831 // Broad TUCP // linc- 0,000335 2,45244
PHF17-2 chr4:+: 129349224-1294405 994
TCONS 12 00025074-XLOC 12 012365 // Broad LOC1005 0,000455 1,36554
TUCP // linc-PECI-BP chr6:+:4136305-4157619 / 07506 314
TCONS_12_00025502-XLOC_12_013149 // Broad TUCP // linc- 0,000171 -1,9421
HIVEP2-2 chr6:-: 143360561-143363 428
TCONS 12 00030323-XLOC 12 015593 // Broad FRMPD3 0,000409 -1,88413
TUCP // linc-PRPSl chrX:+: 106773651-106848480 836 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
XR 111249 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,000680 -2,00309 hypothetical LOC100509976 (LOCI 00509976) 09976 072
XR 111788 // RefSeq // PREDICTED: Homo sapiens LOC1005 5,83E-05 -1,25515 hypothetical LOC100505529 (LOC100505529) 05529
XR 111837 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,000259 1,40679 hypothetical LOC100507503 (LOC100507503) 07503 017
XR 133191 // RefSeq // PREDICTED : Homo sapiens LOC1006 0,000546 1,20938 hypothetical LOCI 00653303 (LOCI 00653303) 53303 361
Table 7: Efficiency of docetaxel
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change name=Human lincRNA ref=BodyMapLinc transcr
NR_024176 // RefSeq // Homo sapiens MAP kinase MKN 1 2.77E-05 -1,47961 interacting serine/threonine kinase 1 (M
NM 005765 // RefSeq // Homo sapiens ATPase, H+ ATP6AP2 0,000181 -1,45823 transporting, lysosomal accessory protei 311
ENST00000391265 // ENSEMBL // ncrna:snoRNA chromo- 0,000112 -1,45519 some:GRCh37:5:40790179:40790306:-l gen 73
NM 001654 // RefSeq // Homo sapiens v-raf murine ARAF 6,50E-06 -1,45052 sarcoma 3611 viral oncogene homo log (A
NM 003334 // RefSeq // Homo sapiens ubiquitin-like UBA1 0,000127 -1,44636 modifier activating enzyme 1 (UBA1), 309
NM 015698 // RefSeq // Homo sapiens G patch doGPKOW 0,000181 -1,44071 main and KOW motifs (GPKOW), mRNA. // chr 843
ENST00000439131 // ENSEMBL // cdna:known C14orfl78 9,31E-05 -1,43968 chromosome:GRCh37:14:78227173:78236085: l
gene:
ENST00000601961 // ENSEMBL // cdna:known chromo- 4,68E-05 -1,43809 some:GRCh37:HG1433 PATCH:53175722:531760
OTTHUMT00000050408 // Havana transcript // OT- 0,000211 -1,42955 cdna:all chromosome:VEGA52:10:l 14648494:1146 THUMG0 094
00000190
67
n366327 // NONCODE // accn=NULL class=lncRNA 0,000132 -1,42665 name=Human lincRNA ref=BodyMapLinc transcr 112
NM 206907 // RefSeq // Homo sapiens protein kiPRKAA1 0,000116 -1,42008 nase, AMP-activated, alpha 1 catalytic su 055
AF086476 // GenBank // Homo sapiens full length LOC4005 8,00E-05 -1,40857 insert cDNA clone ZD88F12. // chrl7 // 90
NM 001024593 // RefSeq // Homo sapiens MSS51 MSS51 2,13E-05 -1,40763 mitochondrial translational activator (MSS
NM 006297 // RefSeq // Homo sapiens X-ray repair XRCC1 0,000122 -1,39256 complementing defective repair in Chin 008
NM 016049 // RefSeq // Homo sapiens ER membrane EMC9 6J9E-06 -1,3891 protein complex subunit 9 (EMC9), mRNA.
NM 031407 // RefSeq // Homo sapiens HECT, UBA HUWE1 8,51E-06 -1,38609 and WWE domain containing 1 , E3 ubiquitin
NM 001008390 // RefSeq // Homo sapiens CGG triCGGBP1 0,000145 -1,37358 plet repeat binding protein 1 (CGGBP1), t 189
NM_207368 // RefSeq // Homo sapiens family with FAM195B 0,000195 -1,37338 sequence similarity 195, member B (FAM1 999
NM 020137 // RefSeq // Homo sapiens GRIP1 assoGRIPAP1 0,000149 -1,3641 ciated protein 1 (GRIPAP1), transcript va 647
ENST00000288616 // ENSEMBL // cdna:known CABP1 l,47E-05 -1,35928 chromosome:GRCh37:12:121087888:121104835:1
gen
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change cdna:all chromosome:VEGA52:3:190234008:19023
OTTHUMT00000343232 // Havana transcript // OT- 5,65E-06 1,9162 cdna:all chromosome:VEGA52:3:191275113:19130 THUMG0
00001561
68
NM 032501 // RefSeq // Homo sapiens acyl-CoA ACSS1 0,000146 1,96382 synthetase short-chain family member 1 (AC 721 n365833 // NONCODE // accn=NULL class=lncRNA 6,82E-05 1,96778 name=Human lincR A ref=BodyMapLinc transcr
NM 183373 // RefSeq // Homo sapiens PX domain PXDC1 0,000110 2,0936 containing 1 (PXDC1), mRNA. // chr6 // 10 145
NM 001080392 // RefSeq // Homo sapiens KIAA114 2,52E-05 2,20155 KIAA1147 (KIAA1147), mR A. // chr7 // 100 // 81 7
NM 014427 // RefSeq // Homo sapiens copine VII CPNE7 4,10E-05 2,31564 (CPNE7), transcript variant 2, mRNA. //
AK125860 // GenBank // Homo sapiens cDNA FLJ43872 fis, clone 0,000158 2,36231 TESTI4008417. // chr8 // 1 592
NR_003284 // RefSeq // Homo sapiens proliferation- PA2G4P4 8,99E-05 2,59897 associated 2G4 pseudogene 4 (PA2G4P4)
BC 137525 // GenBank // Homo sapiens chromosome 8 open read0,000100 2,88566 ing frame 16, mRNA (cDNA clon 38
BC 132953 // GenBank // Homo sapiens chromosome 8 open read0,000191 3,20541 ing frame 15, mRNA (cDNA clon 222
ENST00000369663 // ENSEMBL // cdna:known TBX18 9,66E-05 3,37111 chromosome:GRCh37:6:85444157:85474237:-l gene:
NM 005359 // RefSeq // Homo sapiens SMAD family SMAD4 2,36E-06 4,58279 member 4 (SMAD4), mRNA. // chrl8 // 100
Table 8: Efficiency of 5-fluorouracil (5FU)
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
AK093576 // GenBank // Homo sapiens cDNA FLJ36257 fis, clone 2,03E-05 1,34515 THYMU2002376. // chr2 // 1
AK096045 // GenBank // Homo sapiens cDNA SHANK2 0,000271 1,92893 FLJ38726 fis, clone KIDNE2010271, moderately s 91
AK098314 // GenBank // Homo sapiens cDNA FLJ40995 fis, clone 5,93E-05 1,50957 UTERU2015830. // chrl5 //
AKl 28544 // GenBank // Homo sapiens cDNA FLJ46703 fis, clone 6,28E-05 1,30817 TRACH3014580. // chrl9 //
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change some:GRCh37: 1 :22843967:228462
ENST00000446992 // ENSEMBL // cdna:known chromo- 0,000119 -1,28973 some:GRCh37:2: l 15591407:115593165:-1 gen 75
ENST00000450709 // ENSEMBL // cdna:known chromo- 0,000298 1,20228 some:GRCh37:2:286419:287496: l gene:ENSG0 99
ENST00000453103 // ENSEMBL // cdna:known DGUOK- 2,51E-05 2,21859 chromosome:GRCh37:2:74174769:74208568:-l gene: AS1
ENST00000459226 // ENSEMBL // ncrna:snoRNA chromo- 0,000134 1,59243 some:GRCh37:6:34660557:34660660:l gene 54
ENST00000459496 // ENSEMBL // ncrna:snoRNA chromo- 0,000392 1,30193 some:GRCh37: l : 171451046:171451148:1 ge 11
ENST00000460977 // ENSEMBL // cdna:putative chromo- 0,000138 1,55597 some:GRCh37:3: 142184157:142191179:-l 35
ENST00000497885 // ENSEMBL // cdna:known chromo- 0,000222 1,43127 some:GRCh37: 17:4607525:4608824: 1 gene:EN 58
ENST00000507521 // ENSEMBL // cdna:known chromo- 0,000148 1,32745 some:GRCh37:5: 139750476:139780952:-l gen 41
ENST00000508632 // ENSEMBL // cdna:known OCIAD2 2,44E-07 -1,60924 chromosome:GRCh37:4:48887036:48908845:-l gene:
ENST00000516170 // ENSEMBL // ncrna:snoRNA chromo- 0,000218 -1,26237 some:GRCh37:4: 160428047:160428180:-l g 45
ENST00000 16439 // ENSEMBL // ncrnamiRNA chromo- 0,000403 -1,7645 some:GRCh37:7:68527371 :68527457: 1 gene: 39
ENST00000 16474 // ENSEMBL // ncrna:misc RNA chromo- 0,000362 1,22844 some:GRCh37: 17:26388993:26389094:l g 4
ENST00000520840 // ENSEMBL // cdna:known chromo- 0,000272 -1,5516 some:GRCh37:8:22928890:22932001 :-l gene: 89
ENST00000532917 // ENSEMBL // cdna:known CD3G 0,000282 -1,22972 chromosome : GRCh37 : 11 :118215071 :118225876:1 94 gen
ENST00000538010 // ENSEMBL // cdna:known BCL7A 0,000400 1,58483 chromosome :GRCh37: 12: 122457328 : 122499948 : 1 92 gen
ENST00000549860 // ENSEMBL // cdna:known chromo0,000303 1,50229 some: GRCh37: 12:56694496 :56708592 : 1 gene : 24
ENST00000553046 // ENSEMBL // havana:lincRNA chromo- 6,99E-05 1,59145 some:GRCh37: 14:36343063:36344509:1 g
ENST00000553270 // ENSEMBL // havana:non coding chromo- 0,000269 -1,41407 some:GRCh37: 14: 102095321 : 10209886 37
ENST00000555212 // ENSEMBL // havana:sense intronic chro- 0,000195 1,34974 mosome:GRCh37: 14: 100730118: 1007 11
ENST00000557322 // ENSEMBL // cdna:known chromo- 3,08E-05 1,437 some:GRCh37: 14:58731380:58736399: 1 gene:
GENSCAN00000034805 // ENSEMBL // cdna:genscan chromo- 6,35E-05 -1,93557 some:GRCh37: 18: 14335864:14357900:l Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 000165 // RefSeq // Homo sapiens gap junction GJA1 0,000229 5,04133 protein, alpha 1, 43kDa (GJA1), mRNA. 46
NM 000208 // RefSeq // Homo sapiens insulin reINSR 0,000179 -2,69344 ceptor (INSR), transcript variant 1 , mRNA 75
NM 000234 // RefSeq // Homo sapiens ligase I, DNA, LIG1 5,52E-05 1,34088 ATP-dependent (LIG1), mRNA. // chrl9
NM 000584 // RefSeq // Homo sapiens interleukin 8 IL8 0,000314 -5,01122 (IL8), mRNA. // chr4 // 100 // 62 // 35
NM 000607 // RefSeq // Homo sapiens orosomucoid ORM1 2,05E-05 -1,36683 1 (ORM1), mRNA. // chr9 // 100 // 45 //
NM 000660 // RefSeq // Homo sapiens transforming TGFB1 0,000412 2,48992 growth factor, beta 1 (TGFB1), mRNA. / 72
NM 000880 // RefSeq // Homo sapiens interleukin 7 IL7 0,000299 -2,88692 (IL7), transcript variant 1 , mRNA. // 12
NM 001001563 // RefSeq // Homo sapiens trans- TIMM50 8,83E-06 1,39074 locase of inner mitochondrial membrane 50 h
NM 001002836 // RefSeq // Homo sapiens zinc finger ZNF787 9,18E-05 1,60299 protein 787 (ZNF787), mRNA. // chrl9
NM 001004320 // RefSeq // Homo sapiens alkylglyc- AGMO 8,17E-06 -5,67111 erol monooxygenase (AGMO), mRNA. // chr
NM 001009 // RefSeq // Homo sapiens ribosomal RPS5 2J4E-05 1,37861 protein S5 (RPS5), mRNA. // chr 19 // 100
NM 001010853 // RefSeq // Homo sapiens peptidase PM20D2 0,000136 2,29387 M20 domain containing 2 (PM20D2), mRNA 69
NM 001011724 // RefSeq // Homo sapiens heterogeHNRN- 0,000324 1,53175 neous nuclear ribonucleoprotein A 1 -like PA1L2 46
NM 001020 // RefSeq // Homo sapiens ribosomal RPS16 l,45E-05 1,46978 protein S16 (RPS16), mRNA. // chr 19 // 10
NM 001031853 // RefSeq // Homo sapiens inscu- INSC 5,50E-05 -1,33459 teable homolog (Drosophila) (INSC), transcr
NM 001032281 // RefSeq // Homo sapiens tissue facTFPI 0,000371 -3,41298 tor pathway inhibitor (lipoprotein-ass 57
NM 001040056 // RefSeq // Homo sapiens mitogen- MAPK3 0,000349 -1,3027 activated protein kinase 3 (MAPK3), tran 32
NM 001080533 // RefSeq // Homo sapiens unc-119 UNC119B 0,000300 1,6389 homolog B (C. elegans) (UNCI 19B), mRNA. 16
NM 001083953 // RefSeq // Homo sapiens thyroid THADA 9,59E-06 1,33863 adenoma associated (THADA), transcript v
NM 001099337 // RefSeq // Homo sapiens coenzyme COQ10A 6,00E-07 1,54954 Q10 homolog A (S. cerevisiae) (COQ10A),
NM 001105244 // RefSeq // Homo sapiens protein PTPRM 2,60E-07 -4,09702 tyrosine phosphatase, receptor type, M (
NM 001114093 // RefSeq // Homo sapiens LSM14A, LSM14A 0,000358 1,41516 SCD6 homolog A (S. cerevisiae) (LSM14A), 17
NM 001123375 // RefSeq // Homo sapiens histone HIST2H3 l,05E-06 2,96225 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change cluster 2, H3d (HIST2H3D), mRNA. // chrl D
NM OOl 129993 // RefSeq // Homo sapiens KIAA184 0,000109 1,57702 KIAA1841 (KIAA1841), transcript variant 1, mRNA. 1 54
NM OOl 136156 // RefSeq // Homo sapiens zinc finger ZNF507 0,000289 1,49007 protein 507 (ZNF507), transcript var 85
NM OOl 159767 // RefSeq // Homo sapiens basic leuBZW2 0,000262 1,60965 cine zipper and W2 domains 2 (BZW2), tr 21
NM 001162893 // RefSeq // Homo sapiens KIAA004 2,26E-05 -1,50042 KIAA0040 (KIAA0040), transcript variant 1, mRNA. 0
NM 001162893 // RefSeq // Homo sapiens KIAA004 0,000124 -2,16198 KIAA0040 (KIAA0040), transcript variant 1, mRNA. 0 64
NM 001195605 // RefSeq // Homo sapiens zinc finger ZNF865 3,04E-05 1,55085 protein 865 (ZNF865), mRNA. // chrl 9
NM_001197097 // RefSeq // Homo sapiens protease, PRSS3 0,000203 -2,13193 serine, 3 (PRSS3), transcript variant 36
NM_001198801 // RefSeq // Homo sapiens eukaryotic EIF4G3 l,88E-05 1,32335 translation initiation factor 4 gamma
NM 001289 // RefSeq // Homo sapiens chloride intraCLIC2 2,55E-05 -1,70538 cellular channel 2 (CLIC2), mRNA. //
NM_001483 // RefSeq // Homo sapiens glioblastoma GBAS 2,98E-05 1,90245 amplified sequence (GBAS), nuclear gen
NM 001536 // RefSeq // Homo sapiens protein argi- PRMTl l,48E-07 1,4486 nine methyltransferase 1 (PRMT1), trans
NM 001631 // RefSeq // Homo sapiens alkaline phosALPI 4,48E-05 -1,22218 phatase, intestinal (ALPI), mRNA. // c
NM 001955 // RefSeq // Homo sapiens endothelin 1 EDN1 5,30E-05 -4,42114 (EDN1), transcript variant 1, mRNA. //
NM 002381 // RefSeq // Homo sapiens matrilin 3 MATN3 8,58E-05 2,51599 (MATN3), mRNA. // chr2 // 100 // 87 // 1
NM 002486 // RefSeq // Homo sapiens nuclear cap NCBP1 2,87E-06 1,20111 binding protein subunit 1, 80kDa (NCBP1
NM 002557 // RefSeq // Homo sapiens oviductal glyOVGP1 4,36E-05 -1,35733 coprotein 1, 120kDa (OVGP1), mRNA. //
NM 002609 // RefSeq // Homo sapiens platelet- PDGFRB 0,000175 -1,5889 derived growth factor receptor, beta polyp 65
NM 002612 // RefSeq // Homo sapiens pyruvate PDK4 0,000263 -2,80794 dehydrogenase kinase, isozyme 4 (PDK4), nu 09
NM 002824 // RefSeq // Homo sapiens parathymosin PTMS 0,000126 1,86795 (PTMS), mRNA. // chrl2 // 100 // 65 // 29
NM 003041 // RefSeq // Homo sapiens solute carrier SLC5A2 0,000275 -1,23505 family 5 (sodium/glucose cotransport 48
NM 003263 // RefSeq // Homo sapiens toll-like reTLR1 0,000197 -2,10905 ceptor 1 (TLR1), mRNA. // chr4 // 100 / 3
NM_003344 // RefSeq // Homo sapiens ubiquitin- UBE2H 0,000378 -1,39585 conjugating enzyme E2H (UBE2H), transcrip 8 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 003432 // RefSeq // Homo sapiens zinc finger ZNF131 0,000320 1,38427 protein 131 (ZNF131), mRNA. // chr5 // 51
NM_003672 // RefSeq // Homo sapiens CDC 14 cell CDC14A 3,46E-06 1,43973 division cycle 14 homolog A (S. cerevisi
NM_003762 // RefSeq // Homo sapiens vesicle- VAMP4 6,55E-06 -1,59861 associated membrane protein 4 (VAMP4), tran
NM_003846 // RefSeq // Homo sapiens peroxisomal PEX11B 2,12E-05 -1,31719 biogenesis factor 11 beta (PEX1 IB), tra
NM 004069 // RefSeq // Homo sapiens adaptor- AP2S1 2,37E-05 1,39511 related protein complex 2, sigma 1 subunit
NM 004313 // RefSeq // Homo sapiens arrestin, beta ARRB2 3,89E-07 2,03526 2 (ARRB2), transcript variant 1, mRN
NM 004562 // RefSeq // Homo sapiens parkinson PARK2 5,00E-06 -1,67657 protein 2, E3 ubiquitin protein ligase (p
NM 004591 // RefSeq // Homo sapiens chemokine CCL20 7,95E-05 -4,74036 (C-C motif) ligand 20 (CCL20), transcript
NM 004666 // RefSeq // Homo sapiens vanin 1 VNN1 0,000223 -10,7979 (VNN1), mRNA. // chr6 // 100 // 100 // 23 / 72
NM_004891 // RefSeq // Homo sapiens mitochondrial MRPL33 0,000219 1,39891 ribosomal protein L33 (MRPL33), nucle 83
NM 004943 // RefSeq // Homo sapiens dystrophia DMWD 0,000422 1,51374 myotonica, WD repeat containing (DMWD), 4
NM_004996 // RefSeq // Homo sapiens ATP-binding ABCC1 0,000241 1,84534 cassette, sub-family C (CFTR/MRP), memb 97
NM 005399 // RefSeq // Homo sapiens protein kiPRKAB2 0,000155 -1,38553 nase, AMP-activated, beta 2 non-catalytic 05
NM_005499 // RefSeq // Homo sapiens ubiquitin- like UBA2 0,000212 1,41222 modifier activating enzyme 2 (UBA2), 7
NM 005608 // RefSeq // Homo sapiens protein tyroPTPRCAP 0,000328 -1,2394 sine phosphatase, receptor type, C-asso 35
NM 005629 // RefSeq // Homo sapiens solute carrier SLC6A8 5,01E-05 -1,7957 family 6 (neurotransmitter transport
NM 00 688 // RefSeq // Homo sapiens ATP-binding ABCC5 0,000344 1,80486 cassette, sub-family C (CFTR/MRP), memb 43
NM 005717 // RefSeq // Homo sapiens actin related ARPC5 0,000247 -1,2103 protein 2/3 complex, subunit 5, 16kDa 69
NM 005762 // RefSeq // Homo sapiens tripartite motif TRIM28 2,12E-06 1,81273 containing 28 (TRIM28), mRNA. // c
NM 005764 // RefSeq // Homo sapiens PDZK1 interPDZK1IP 0,000166 -3,66578 acting protein 1 (PDZK1IP1), mRNA. // ch 1 58
NM_005814 // RefSeq // Homo sapiens glycoprotein GPA33 l,27E-05 -5,19703 A33 (transmembrane) (GPA33), mRNA. //
NM 006092 // RefSeq // Homo sapiens nucleotide- NODI 0,000225 1,57476 binding oligomerization domain containin 48
NM 006196 // RefSeq // Homo sapiens poly(rC) bind- PCBP1 0,000192 1,32624 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change ing protein 1 (PCBP1), mRNA. // chr2 / 11
NM 006233 // RefSeq // Homo sapiens polymerase POLR2I 2,30E-05 1,47761 (RNA) II (DNA directed) polypeptide I, 1
NM_006269 // RefSeq // Homo sapiens retinitis pigRP1 0,000274 -1,63607 mentosa 1 (autosomal dominant) (RP1), 95
NM 006555 // RefSeq // Homo sapiens Y T6 v- Y T6 0,000170 1,46334 SNARE homo log (S. cerevisiae) (YKT6), mRNA. 22
NM 006583 // RefSeq // Homo sapiens retinal pigRRH 0,000382 -1,7899 ment epithelium-derived rhodopsin homolo 08
NM 006653 // RefSeq // Homo sapiens fibroblast FRS3 0,000366 1,26124 growth factor receptor substrate 3 (FRS3 06
NM 006666 // RefSeq // Homo sapiens RuvB-like 2 RUVBL2 0,000242 1,63545 (E. coli) (RUVBL2), mRNA. // chrl9 // 1 97
NM_006949 // RefSeq // Homo sapiens syntaxin binSTXBP2 2,41E-05 -1,47895 ding protein 2 (STXBP2), transcript var
NM 0070 9 // RefSeq // Homo sapiens kaptin (actin KPTN 0,000105 1,46326 binding protein) (KPTN), mRNA. // chr 02
NM 007256 // RefSeq // Homo sapiens solute carrier SLC02B1 0,000334 -1,74676 organic anion transporter family, me 08
NM 012232 // RefSeq // Homo sapiens polymerase I PTRF 0,000237 2,95904 and transcript release factor (PTRF), 99
NM 012267 // RefSeq // Homo sapiens HSPA (heat HSPBP1 0,000110 1,24592 shock 70kDa) binding protein, cytoplasmi 5
NM 012279 // RefSeq // Homo sapiens zinc finger ZNF346 0,000327 1,33646 protein 346 (ZNF346), mRNA. // chr5 // 17
NM 012416 // RefSeq // Homo sapiens RAN binding RANBP6 0,000316 1,40515 protein 6 (RANBP6), transcript variant 19
NM 012467 // RefSeq // Homo sapiens tryptase TPSG1 l,01E-05 -1,3725 gamma 1 (TPSG1), mRNA. // chrl6 // 100 //
NM 013234 // RefSeq // Homo sapiens eukaryotic EIF3K 0,000304 1,44265 translation initiation factor 3, subunit 94
NM_014501 // RefSeq // Homo sapiens ubiquitin- UBE2S 0,000409 1,63133 conjugating enzyme E2S (UBE2S), mRNA. // 04
NM_014516 // RefSeq // Homo sapiens CCR4-NOT CNOT3 0,000104 1,5445 transcription complex, subunit 3 (CNOT3), 44
NM 014624 // RefSeq // Homo sapiens SI 00 calcium S100A6 6,25E-06 -1,47538 binding protein A6 (S100A6), mRNA. //
NM 014681 // RefSeq // Homo sapiens DEAH (Asp- DHX34 0,000161 1,29357 Glu-Ala-His) box polypeptide 34 (DHX34), 54
NM 014763 // RefSeq // Homo sapiens mitochondrial MRPL19 0,000293 1,3835 ribosomal protein L19 (MRPL19), nucle 31
NM 014909 // RefSeq // Homo sapiens vasohibin 1 VASH1 4,25E-05 -1,2245 (VASH1), mRNA. // chr 14 // 100 // 72 //
NM_014946 // RefSeq // Homo sapiens spastin SPAST 7J9E-05 1,59312 (SPAST), transcript variant 1, mRNA. // chr Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 014957 // RefSeq // Homo sapiens DENND3 0,000224 -1,50109 DENN/MADD domain containing 3 (DENND3), 33 mRNA. // ch
NM 015016 // RefSeq // Homo sapiens microtubule MAST3 0,000192 -1,75067 associated serine/threonine kinase 3 (M 05
NM 015030 // RefSeq // Homo sapiens FRY-like FRYL 0,000174 -1,30584
(FRYL), mRNA. // chr4 // 100 // 83 // 55 / 56
NM 015147 // RefSeq // Homo sapiens centrosomal CEP68 0,000250 1,53034 protein 68kDa (CEP68), mRNA. // chr2 // 69
NM 015185 // RefSeq // Homo sapiens Cdc42 guaARHGEF 0,000235 -1,5908 nine nucleotide exchange factor (GEF) 9 (A 9 48
NM 015335 // RefSeq // Homo sapiens mediator MED13L 0,000144 1,57466 complex subunit 13 -like (MED13L), mRNA. // 34
NM 015428 // RefSeq // Homo sapiens zinc finger ZNF473 l,32E-06 1,68095 protein 473 (ZNF473), transcript varian
NM_015475 // RefSeq // Homo sapiens family with FAM98A l,54E-06 1,46883 sequence similarity 98, member A (FAM98
NM 015603 // RefSeq // Homo sapiens coiled-coil CCDC9 0,000308 1,41536 domain containing 9 (CCDC9), mRNA. // c 04
NM 015629 // RefSeq // Homo sapiens PRP31 pre- PRPF31 2,25E-05 1,55764 mRNA processing factor 31 homo log (S. cer
NM_015710 // RefSeq // Homo sapiens glioma tumor GLTSCR2 5,19E-05 1,51405 suppressor candidate region gene 2 (GL
NM_016107 // RefSeq // Homo sapiens zinc finger ZFR 0,000140 1,32448
RNA binding protein (ZFR), mRNA. // chr 51
NM 016121 // RefSeq // Homo sapiens potassium KCTD3 6,19E-05 -1,89187 channel tetramerisation domain containing
NM 016265 // RefSeq // Homo sapiens zinc finger ZNF12 3,65E-05 1,40066 protein 12 (ZNF12), transcript variant
NM 016307 // RefSeq // Homo sapiens paired related PRRX2 0,000388 -1,33434 homeobox 2 (PRRX2), mRNA. // chr9 // 58
NM 016377 // RefSeq // Homo sapiens A kinase AKAP7 0,000110 1,74544
(PRKA) anchor protein 7 (AKAP7), transcrip 73
NM 016516 // RefSeq // Homo sapiens vacuolar proVPS54 0,000145 1,31988 tein sorting 54 homo log (S. cerevisiae) 16
NM 016544 // RefSeq // Homo sapiens DnaJ (Hsp40) DNAJC27 1J3E-05 1,47881 homo log, subfamily C, member 27 (DNAJC
NM 016955 // RefSeq // Homo sapiens Sep (0- SEPSECS 0,000318 -1,69997 phosphoserine) tRNA:Sec (selenocysteine) tRN 18
NM_017440 // RefSeq // Homo sapiens Mdml nuclear MDM1 0,000202 1,47567 protein homolog (mouse) (MDM1), transc 26
NM_017607 // RefSeq // Homo sapiens protein phosPPP1R12 3,84E-06 1,3566 phatase 1, regulatory subunit 12C (PPP1 C
NM_017707 // RefSeq // Homo sapiens ArfGAP with ASAP3 0,000222 1,5287
SH3 domain, ankyrin repeat and PH domai 71 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 017878 // RefSeq // Homo sapiens HRAS-like HRASLS2 2,35E-06 -2,78784 suppressor 2 (HRASLS2), mRNA. // chrl 1 //
NM O 18028 // RefSeq // Homo sapiens sterile alpha SAMD4B 8,25E-05 1,43155 motif domain containing 4B (SAMD4B),
NM 018036 // RefSeq // Homo sapiens autophagy ATG2B 0,000308 1,42686 related 2B (ATG2B), mRNA. // chrl4 // 100 11
NM O 18845 // RefSeq // Homo sapiens solute carrier SLC50A1 0,000357 -1,79767 family 50 (sugar transporter), membe 94
NM 018945 // RefSeq // Homo sapiens phosphoPDE7B 3,37E-05 -1,25731 diesterase 7B (PDE7B), mRNA. // chr6 // 100
NM 020143 // RefSeq // Homo sapiens partner of PNOl 0,000274 1,68538 NOB1 homolog (S. cerevisiae) (PNOl), niRN 75
NM 020151 // RefSeq // Homo sapiens StAR-related STARD7 0,000362 1,25883 lipid transfer (START) domain containi 6
NM 020158 // RefSeq // Homo sapiens exosome EXOSC5 0,000135 1,30701 component 5 (EXOSC5), mRNA. // chrl 9 // 100 47
NM 020652 // RefSeq // Homo sapiens zinc finger ZNF286A 0,000422 2,19621 protein 286A (ZNF286A), transcript vari 53
NM 020829 // RefSeq // Homo sapiens KIAA1432 KIAA143 0,000154 1,27707 (KIAA1432), transcript variant 1, mRNA. // 2 97
NM 020978 // RefSeq // Homo sapiens amylase, alAMY2B l,08E-05 -2,29554 pha 2B (pancreatic) (AMY2B), mRNA. // ch
NM 021107 // RefSeq // Homo sapiens mitochondrial MRPS12 0,000109 1,36171 ribosomal protein S12 (MRPS12), nucle 55
NM 021233 // RefSeq // Homo sapiens deoxyribonu- DNASE2 0,000147 -1,24731 clease II beta (DNASE2B), transcript var B 69
NM 021648 // RefSeq // Homo sapiens TSPY-like 4 TSPYL4 0,000115 1,44558 (TSPYL4), mRNA. // chr6 // 100 // 100 / 2
NM 021818 // RefSeq // Homo sapiens Salvador hoSAV1 0,000286 -1,84494 molog 1 (Drosophila) (SAV1), mRNA. // ch 89
NM 024075 // RefSeq // Homo sapiens tRNA splicing TSEN34 8,85E-06 1,50582 endonuclease 34 homolog (S. cerevisia
NM 024119 // RefSeq // Homo sapiens DEXH (Asp- DHX58 0,000174 -1,61011 Glu-X-His) box polypeptide 58 (DHX58), mR 34
NM_024676 // RefSeq // Homo sapiens SH3 domain SH3D21 5,39E-05 -2,60288 containing 21 (SH3D21), transcript varia
NM 024688 // RefSeq // Homo sapiens chromosome C10orf68 8,01E-06 -2,12512 10 open reading frame 68 (C10orf68), mRN
NM_024866 // RefSeq // Homo sapiens adrenome- ADM2 8J6E-05 -1,31143 dullin 2 (ADM2), transcript variant 1, mRNA
NM 025040 // RefSeq // Homo sapiens zinc finger ZNF614 0,000261 1,92899 protein 614 (ZNF614), mRNA. // chrl 9 // 8
NM 025201 // RefSeq // Homo sapiens pleckstrin PLEK- 0,000318 1,31501 homology domain containing, family O mem H02 17
NM 025246 // RefSeq // Homo sapiens solute carrier SLC35G2 0,000120 1,62626 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change family 35, member G2 (SLC35G2), tran 51
NM_031485 // RefSeq // Homo sapiens glutamate-rich GRWD1 l,81E-06 1,5296 WD repeat containing 1 (GRWD1), mRNA
NM 032139 // RefSeq // Homo sapiens ankyrin repeat ANKRD2 3,24E-06 1,70059 domain 27 (VPS9 domain) (ANKRD27), m 7
NM 032490 // RefSeq // Homo sapiens chromosome C14orfl42 8,91E-05 1,3147 14 open reading frame 142 (C14orfl42), m
NM 032530 // RefSeq // Homo sapiens zinc finger ZNF594 0,000194 1,74392 protein 594 (ZNF594), mRNA. // chrl7 // 45
NM_032635 // RefSeq // Homo sapiens transmemTMEM14 0,000408 1,33902 brane protein 147 (TMEM147), transcript var 7 38
NM 033224 // RefSeq // Homo sapiens purine-rich PURB l,08E-06 1,56758 element binding protein B (PURB), mRNA.
NM 052924 // RefSeq // Homo sapiens rhophilin, Rho RHPNl 0,000348 -1,41282 GTPase binding protein 1 (RHPNl), mR 96
NM_080656 // RefSeq // Homo sapiens CDKN2A CDKN2AI 0,000225 1,694 interacting protein N-terminal like (CDKN2AI PNL 83
NM_080662 // RefSeq // Homo sapiens peroxisomal PEX11G 0,000252 -1,21528 biogenesis factor 11 gamma (PEX11G), mR 73
NM 080667 // RefSeq // Homo sapiens coiled-coil CCDC104 9,49E-07 1,41087 domain containing 104 (CCDC104), mRNA.
NM 080676 // RefSeq // Homo sapiens MACRO doMA- 0,000342 -1,92941 main containing 2 (MACROD2), transcript var CROD2 41
NMJ38389 // RefSeq // Homo sapiens family with FAM114A 2,49E-06 -1,46983 sequence similarity 114, member Al (FAM 1
NM 144607 // RefSeq // Homo sapiens cytochrome CYB5D1 8,91E-05 1,52863 b5 domain containing 1 (CYB5D1), mRNA. /
NM 144736 // RefSeq // Homo sapiens chromosome C2orf56 2,19E-05 1,43026 2 open reading frame 56 (C2orf56), nucle
NM_ 144992 // RefSeq // Homo sapiens von Wil- VWA3B 2,00E-05 -1,36939 lebrand factor A domain containing 3B (VWA3B
NM 145243 // RefSeq // Homo sapiens OMAl zinc OMAl 7,61E-05 -1,78106 metallopeptidase homolog (S. cerevisiae)
NM_ 152441 // RefSeq // Homo sapiens F-box and FBXL14 0,000168 1,39127 leucine-rich repeat protein 14 (FBXL14), 95
NM l 53329 // RefSeq // Homo sapiens aldehyde deALDH16 2J0E-06 1,42633 hydrogenase 16 family, member A 1 (ALDH16 Al
NM 172195 // RefSeq // Homo sapiens eukaryotic EIF2B4 0,000336 1,4457 translation initiation factor 2B, subuni 23
NM_ 177542 // RefSeq // Homo sapiens small nuclear SNRPD2 9,61E-05 1,51587 ribonucleoprotein D2 polypeptide 16.5
NM 178001 // RefSeq // Homo sapiens protein phosPPP2R4 0,000126 1,38247 phatase 2A activator, regulatory subuni 92
NM 181783 // RefSeq // Homo sapiens transmemTMTC3 0,000101 1,63587 brane and tetratricopeptide repeat containi 48 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
NM 183240 // RefSeq // Homo sapiens transmemTMEM37 l,49E-06 -1,66592 brane protein 37 (TMEM37), mRNA. // chr2 //
NM 198529 // RefSeq // Homo sapiens EF-hand calEFCAB5 0,000134 -1,47185 cium binding domain 5 (EFCAB5), transcri 2
NM l 98963 // RefSeq // Homo sapiens DEAH (Asp- DHX57 3,65E-06 1,58895 Glu- Ala- Asp/His) box polypeptide 57 (DHX5
NM_ 199421 // RefSeq // Homo sapiens suppressor of SOCS4 0,000191 1,36856 cytokine signaling 4 (SOCS4), transcr 49
NR_002181 // RefSeq // Homo sapiens pancreatic PPY2 0,000282 -1,44853 polypeptide 2 (PPY2), non-coding RNA. // 62
NR_002201 // RefSeq // Homo sapiens ferritin, heavy FTH1P3 0,000106 1,30473 polypeptide 1 pseudogene 3 (FTH1P3) 98
NR 002737 // RefSeq // Homo sapiens small nucleoSNORD59 0,000130 1,86291 lar RNA, C/D box 59A (SNORD59A), small A 25
NR 003056 // RefSeq // Homo sapiens small nucleoSNORD67 3,45E-05 1,3861 lar RNA, C/D box 67 (SNORD67), small nu
NR_024162 // RefSeq // Homo sapiens F 506 binding FKBP1AP 0,000220 1,30617 protein 1A, 12kDa pseudogene 1 (FKBP1 1 46
NR 024567 // RefSeq // Homo sapiens uncharacter- LOCIOOI 0,000263 1,34946 ized LOC100130557 (LOC100130557), non-co 30557 86
NR_026052 // RefSeq // Homo sapiens CENPB DNA- MGC2752 2,96E-06 1,63126 binding domains containing 1 pseudogene (
NR_026761 // RefSeq // Homo sapiens long intergenic LINC0046 0,000213 -1,70439 non-protein coding RNA 467 (LF C004 7 77
NR_026846 // RefSeq // Homo sapiens anaphase proLOC2850 0,000258 1,34842 moting complex subunit 1 pseudogene (LO 74 47
NR_027280 // RefSeq // Homo sapiens SUMOl actiSAE1 4,34E-07 1,78488 vating enzyme subunit 1 (SAE1), transcrip
NR 028408 // RefSeq // Homo sapiens uncharacter- LOC4000 0,000388 1,35507 ized LOC400027 (LOC400027), non-coding R 27 59
NR_028450 // RefSeq // Homo sapiens branched chain BCAT2 0,000227 1,47055 amino-acid transaminase 2, mitochond 39
NR 029663 // RefSeq // Homo sapiens microRNA MIR15B l,89E-05 1,7084 15b (MIR15B), microRNA. // chr3 // 100 //
NR 031621 // RefSeq // Homo sapiens microRNA MIR1289- 0,000202 1,38227 1289-2 (MIR1289-2), microRNA. // chr5 // 1 2 31
NR 031649 // RefSeq // Homo sapiens microRNA MIR1247 0,000329 -1,50317 1247 (MIR1247), microRNA. // chrl4 // 100 26
NR_033237 // RefSeq // Homo sapiens family with FAM3A 0,000241 -1,35016 sequence similarity 3, member A (FAM3A) 53
NR 033998 // RefSeq // Homo sapiens hCG2028352- LOC7299 0,000404 1,47659 like (LOC729970), non-coding RNA. // chr 70 19
NR 037504 // RefSeq // Homo sapiens microRNA MIR3939 0,000249 2,36522 3939 (MIR3939), microRNA. // chr6 // 100 / 71
NR_037869 // RefSeq // Homo sapiens uncharacter- LOC6531 0,000335 -1,28991 Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change ized LOC653160 (LOC653160), non-coding R 60 32
NR_038262 // RefSeq // Homo sapiens MIR210 host MIR210H 5,61E-05 -1,72839 gene (non-protein coding) (MIR210HG), n G
NR_038379 // RefSeq // Homo sapiens leucine car- LOC5542 l,37E-06 1,44265 boxyl methyltransferase 1 pseudogene (LO 06
NR 038948 // RefSeq // Homo sapiens uncharacter- LOC1005 0,000228 1,81449 ized LOC100506136 (LOC100506136), non-co 06136 21
NR 045382 // RefSeq // Homo sapiens uncharacter- LOC1005 0,000403 1,22414 ized LOCI 00507066 (LOCI 00507066), non-co 07066 65
NR_045789 // RefSeq // Homo sapiens NOP2/Sun NSUN4 0,000117 -1,20429 domain family, member 4 (NSUN4), transcrip 8
NR 046229 // RefSeq // Homo sapiens uncharacter- LOC1005 0,000125 -2,52892 ized LOCI 00508120 (LOCI 00508120), non-co 08120 33
NR 046262 // RefSeq // Homo sapiens uncharacter- LOC6467 0,000201 1,78257 ized LOC64671 (LOC646719), non-coding R 19 55
TCONS 00000362-XLOC 000509 // Rinn lincRNA // ] inc-CFH-3 8,51E-05 -1,42106 chrl :+:193648023-193696313 //
TCONS 00001318-XLOC 000600 // Rinn lincRNA // linc-RHOU 0,000192 -1,42061 chrl :+:228688982-228697976 // c 76
TCONS 00002986-XLOC 001636 // Rinn lincRNA // linc- 0,000355 -1,40949
INSIG2-2 chr2:+: 118593925-118595780 64
TCONS 00003473-XLOC 002443 // Rinn lincRNA // linc- 8J4E-05 1,30483
TMEFF2-3 chr2:-: 194746279- 194755854
TCONS_00005118-XLOC_002032 // Rinn lincRNA // linc-RBKS- 0,000105 1,38752
5 chr2:-:28646220-28646862 // c 92
TCONS_00005685-XLOC_002961 // Rinn lincRNA // linc- 0,000371 -1,2387
ADIPOQ chr3:+:186525480-186535910 // 32
TCONS_00008078-XLOC_003544 // Rinn lincRNA // linc- 0,000248 -2,7085
TMEM165 chr4:+:56251872-56253958 // 79
TCONS OOOl 1423-XLOC 005555 // Rinn lincRNA // linc- 0,000336 1,92401
C6orf70 chr6:+:170125599-170139088 / 68
TCONS 00013672-XLOC 006331 // Rinn lincRNA // linc-COXl 9 4,94E-05 -1,29445 chr7 1019649-1020276 // chr7
TCONS 00016692-XLOC 007556 // Rinn lincRNA // linc- 6,63E-05 1,47753
RABGAP1 chr9:+:125693948-125702599 /
TCONS 00018282-XLOC 008558 // Rinn lincRNA // linc-RPP30- 0,000426 1,32674
1 chrl0:+:92618126-92621421 // 04
TCONS 00018897-XLOC 008756 // Rinn lincRNA // linc-ABIl-1 4,08E-05 -2,45908 chrl0:-:27269560-27271723 //
TCONS 00020906-XLOC 010185 // Rinn lincRNA // linc- 0,000340 -1,4611
APPL2-3 chrl2:-:106180060-106404785 05
TCONS_00021545-XLOC_010373 // Rinn lincRNA // linc- 7,23E-05 1,22023
GTF2F2-1 chrl3:+:45620724-45657260 /
TCONS_00021615-XLOC_010543 // Rinn lincRNA // linc-USP12- 2,90E-09 -3,82547
2 chrl3:-:27810418-27810948 // Reference (REF- Gene p-value Fold-
SEQ/ENSEMBL/GENBANK/LNCipedia) Symbol Change
TCONS 00021854-XLOC 010448 // Rinn lincRNA // ] inc- 0,000355 -1,3146 SLITRK5-14 chrl3:+:80367942-80369398 46
TCONS 00022239-XLOC 010544 // Rinn lincRNA // linc-USP 12- 2,20E-05 -1,78705 5 chrl3:-:27819822-27824854 //
TCONS 00027274-XLOC 013283 // Rinn lincRNA // linc- 0,000126 1,96627 ZNF681-5 chrl9:-:28262961-28264517 / 43
TCONS 00027541-XLOC 013072 // Rinn lincRNA // linc- 9J3E-05 1,25089 LGALS13 chrl9:+:40018979-40019553 //
TCONS 00028814-XLOC 013888 // Rinn lincRNA // linc-JAM2- 2,81E-05 -1,2634 2 chr21 :+:26467334-26475983 //
XM 001713850 // RefSeq // PREDICTED: Homo LOC7302 8,86E-05 1,54381 sapiens anaphase-promoting complex subunit 1- 68
XR 108351 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,000217 -1,41696 hypothetical LOC100505516 (LOC100505516) 05516 28
XR_109972 // RefSeq // PREDICTED: Homo sapiens SOS1-IT1 l,00E-05 1,74497 SOS 1 intronic transcript 1 (non-protein
XR 111249 // RefSeq // PREDICTED: Homo sapiens LOC1005 8,35E-06 2,67012 hypothetical LOC100509976 (LOCI 00509976) 09976
XR 133207 // RefSeq // PREDICTED: Homo sapiens LOC1005 0,000181 -1,32568 hypothetical LOC100505703 (LOC100505703) 05703 76
Z26248 // GenBank // H.sapiens mRNA for eosinophil PRG2 0,000334 -2,42157 granule major basic protein. // chrl 89
Herebelow (see tables 9 to 14) are listed collections of sets of genes, of which the variation of the expression level is based on the reference value established by PC A analysis, along with its corresponding individual p-values and fold-changes.
Those sets of genes are grouped based on their most preferred use as combinations of PDAC-marker genes for:
- determining the prognosis of an individual having PDAC (table 9);
- determining, on a PDAC tumor sample from said individual, the efficiency of SN-38/Irinotecan (table 10); oxaliplatin (table 11); gemcitabine (table 12); docetaxel (table 13) and 5-fluorouracil (table 14).
The fold-change column indicates the variation of the expression of the corresponding gene product, compared to a reference value. The reference value is calculated as shown in the Material & Methods section, using Gene set enrichment analysis (GSEA) performed on the Broad Institute Platform and statistical significance (false discovery rate, FDR) was set at 0.25. The gene symbol is indicated (if available), along with its reference number in the corresponding database (REFSEQ, ENSEMBL, GENBANK, and/or LNCipedia).
Table 9: Short VS Long-term survival
Figure imgf000208_0001
Table 10: Efficiency of SN-38 (Irinotecan active metabolite)
Reference Gene Symp-value Fold- bol Change
NM_000197 // RefSeq // HSD17B3 1.28E-07 -2,74982 hydroxysteroid (17-beta) dehydrogenase 3
NM_020192 // RefSeq // YAE1D1 9,70E-07 -1,61835 Yael domain containing 1
NM_001195296 // RefSeq // MIPOL1 1.52E-06 -1,61943 mirror-image Polydactyly 1 NM_001238//RefSeq// CCNE1 6J5E-08 1,70632 cyclin El
NR_045553 //RefSeq// THBS3 8,00E-06 1,93413 thrombospondin 3 (THBS3)
NM_004619// RefSeq// TRAF5 2,68E-05 3,13128
TNF receptor-associated factor 5
Table 11: Efficiency of oxaliplatin
Reference Gene Symp-value Fold- bol Change
TCONS 00025293-XLOC 012095 // Rinn lincRNA ALOX12P2 3,35E-09 -6,94788 // linc-ALOX12-l chrl7:+:6840593-6857728 //
arachidonate 12-lipoxygenase pseudogene 2
ENST00000264228 // ENSEMBL // SRD5A3 l,46E-08 -3,81237 Steroid 5-Alpha-Reductase 3
ENST00000395601 //ENSEMBL// SNTB1 3,44E-08 -4,19721 Syntrophin, beta 1
NM_002245//RefSeq// KCN 1 4,17E-06 -2,4294 potassium channel, subfamily K, member 1
NM_003532//RefSeq// HIST1H3E 7,33E-06 -4,39238 histone cluster 1, H3e
ENST00000354921 //ENSEMBL// SEC16B l,24E-05 -4,95166
NM_032457//RefSeq// PCDH7 2,47E-05 -6,06759 protocadherin 7
NM_000895 //RefSeq// LTA4H 2,94E-06 2,35941 leukotriene A4 hydrolase
ENST00000262878 // ENSEMBL // SAMHD1 7,20E-06 3,98971
NR_003125//RefSeq// SNORD14E l,14E-05 2,40066 small nucleolar RNA, C/D box 14E
NM_005044//RefSeq// PRKX l,36E-05 2,58025 protein kinase, X-linked (PRKX)
Table 12: Efficiency of semcitabine
Reference Gene Symp-value Fold- bol Change
NM_014505 //RefSeq// KCNMB4 6,35E-11 -3,3897 potassium large conductance calcium-activated
chann
NR_039722//RefSeq// MIR4500 5,51E-09 -27,9959 microRNA 4500
NM_001661 //RefSeq// ARL4D 6J6E-08 -5,20681 ADP-ribosylation factor-like 4D
NR 031611 // RefSeq // Homo sapiens microRNA MIR1206 5,51E-06 -7,06005 1206 (MIR1206), microRNA. // chr8 // 100 /
ENST00000373004 // ENSEMBL // SRPX2 9,60E-06 -3,06264 Sushi-Repeat Containing Protein X-Linked 2
NM_006005 // RefSeq // WFS1 1.69E-05 -2,85621 Wolfram syndrome 1
NM_006823 // RefSeq // PKIA 6,46E-10 7,40614 protein kinase (cAMP-dependent, catalytic) inhibitor
NR_024554 // RefSeq // RHOBTB1 7,69E-08 2,75759 Rho-related BTB domain containing 1
AK128855 // GenBank // AK128855 8,85E-07 3,27341 cDNA FLJ46652 fis, clone TRACH3005102
NMJ38809 // efSeq // CMBL 1.77E-06 2,74107 carboxymethylenebutenolidase homo log
Table 13: Efficiency of docetaxel
Figure imgf000210_0001
Table 14: Efficiency of 5-fluorouracil fSF P)
Reference Gene Symp-value Fold- bol Change
NM_001004320 // RefSeq // AGMO 8,17E-06 -5,67111 alkylglycerol monooxygenase
NM_0019 5 // RefSeq // EDN1 5,30E-05 -4,42114 endothelin 1 (EDN1)
NM_004313 // RefSeq // ARRB2 3,89E-07 2,03526 arrestin, beta 2
NM_001123375 // RefSeq // HIST2H3D 1.05E-06 2,96225 histone cluster 2, H3d SEQUENCE LISTING
For reference, one nucleic acid encoded by a PDAC-marker gene of the invention is detailed herebelow. Each sequence corresponds to the complementary DNA of the said nucleic acid encoded by said PDAC-marker gene.
SEQID N°l-13
SEQID N°l CACNA1D
SEQID N°2 CFT
SEQID N°3 MUC3A
SEQID N°4 NPC1L1
SEQID N°5 ONECUT2
SEQID N°6 PROM1
SEQID N°7 SLC6A20
SEQID N°8 SLC40A1
SEQID N°9 DUSP5
SEQID N°10 FJX1
SEQID N°ll ITGA10
SEQID N°12 MT1A
SEQID N°13 VIM
SEQID N°14- 19
SEQID N°14 HSD17B3
SEQID N°15 YAE1D1
SEQID N°16 MIPOL1
SEQID N°17 CCNE1
SEQID N°18 THBS3
SEQID N°19 TRAF5
SEQID N°20- 30 SEQID N°20 ALOX12P2
SEQID N°21 SRD5A3
SEQID N°22 SNTB1
SEQID N°23 KCN 1
SEQID N°24 HIST1H3E
SEQID N°25 SEC16B
SEQID N°26 PCDH7
SEQID N°27 LTA4H
SEQID N°28 SAMHD1
SEQID N°29 SN0RD14E
SEQID N°30 PPvKX
SEQID N°31- 33
SEQID N° 1 DDX26B
SEQID N°32 WDR78
SEQID N°33 SMAD4
SEQID N°34- 37
SEQID N°34 AGMO
SEQID N°35 EDN1
SEQID N°36 ARRB2
SEQID N°37 HIST2H3D
SEQID N°38- 47
SEQID N°38 KCNMB4
SEQID N°39 MIR4500
SEQID N°40 ARL4D
SEQID N°41 MIR1206
SEQID N°42 SRPX2 SEQID N°43 WFS 1
SEQID N°44 PKIA
SEQID N°45 RHOBTB1
SEQID N°46 AK128855
SEQID N°47 CMBL
>1
AGAATAAGGGCAGGGACCGCGGCTCCTACCTCTTGGTGATCCCCTTCCCCATT CCGCCCCCGCCTCAACGCCCAGCACAGTGCCCTGCACACAGTAGTCGCTCAAT AAATGTTCGTGGATGATGATGATGATGATGATGAAAAAAATGCAGCATCAACG GCAGCAGCAAGCGGACCACGCGAACGAGGCAAACTATGCAAGAGGCACCAGA CTTCCTCTTTCTGGTGAAGGACCAACTTCTCAGCCGAATAGCTCCAAGCAAACT GTCCTGTCTTGGCAAGCTGCAATCGATGCTGCTAGACAGGCCAAGGCTGCCCA AACTATGAGCACCTCTGCACCCCCACCTGTAGGATCTCTCTCCCAAAGAAAAC GTCAGCAATACGCCAAGAGCAAAAAACAGGGTAACTCGTCCAACAGCCGACC TGCCCGCGCCCTTTTCTGTTTATCACTCAATAACCCCATCCGAAGAGCCTGCAT TAGTATAGTGGAATGGAAACCATTTGACATATTTATATTATTGGCTATTTTTGC CAATTGTGTGGCCTTAGCTATTTACATCCCATTCCCTGAAGATGATTCTAATTC AACAAATCATAACTTGGAAAAAGTAGAATATGCCTTCCTGATTATTTTTACAGT CGAGACATTTTTGAAGATTATAGCGTATGGATTATTGCTACATCCTAATGCTTA TGTTAGGAATGGATGGAATTTACTGGATTTTGTTATAGTAATAGTAGGATTGTT TAGTGTAATTTTGGAACAATTAACCAAAGAAACAGAAGGCGGGAACCACTCA AGCGGCAAATCTGGAGGCTTTGATGTCAAAGCCCTCCGTGCCTTTCGAGTGTTG CGACCACTTCGACTAGTGTCAGGAGTGCCCAGTTTACAAGTTGTCCTGAACTCC ATTATAAAAGCCATGGTTCCCCTCCTTCACATAGCCCTTTTGGTATTATTTGTA ATCATAATCTATGCTATTATAGGATTGGAACTTTTTATTGGAAAAATGCACAAA ACATGTTTTTTTGCTGACTCAGATATCGTAGCTGAAGAGGACCCAGCTCCATGT GCGTTCTCAGGGAATGGACGCCAGTGTACTGCCAATGGCACGGAATGTAGGAG TGGCTGGGTTGGCCCGAACGGAGGCATCACCAACTTTGATAACTTTGCCTTTGC CATGCTTACTGTGTTTCAGTGCATCACCATGGAGGGCTGGACAGATGTGCTCTA CTGGGTAAATGATGCGATAGGATGGGAATGGCCATGGGTGTATTTTGTTAGTC TGATCATCCTTGGCTCATTTTTCGTCCTTAACCTGGTTCTTGGTGTCCTTAGTGG AGAATTCTCAAAGGAAAGAGAGAAGGCAAAAGCACGGGGAGATTTCCAGAAG CTCCGGGAGAAGCAGCAGCTGGAGGAGGATCTAAAGGGCTACTTGGATTGGA TCACCCAAGCTGAGGACATCGATCCGGAGAATGAGGAAGAAGGAGGAGAGGA AGGCAAACGAAATACTAGCATGCCCACCAGCGAGACTGAGTCTGTGAACACA GAGAACGTCAGCGGTGAAGGCGAGAACCGAGGCTGCTGTGGAAGTCTCTGGT GCTGGTGGAGACGGAGAGGCGCGGCCAAGGCGGGGCCCTCTGGGTGTCGGCG GTGGGGTCAAGCCATCTCAAAATCCAAACTCAGCCGACGCTGGCGTCGCTGGA ACCGATTCAATCGCAGAAGATGTAGGGCCGCCGTGAAGTCTGTCACGTTTTAC TGGCTGGTTATCGTCCTGGTGTTTCTGAACACCTTAACCATTTCCTCTGAGCAC TACAATCAGCCAGATTGGTTGACACAGATTCAAGATATTGCCAACAAAGTCCT CTTGGCTCTGTTCACCTGCGAGATGCTGGTAAAAATGTACAGCTTGGGCCTCCA AGCATATTTCGTCTCTCTTTTCAACCGGTTTGATTGCTTCGTGGTGTGTGGTGGA ATCACTGAGACGATCTTGGTGGAACTGGAAATCATGTCTCCCCTGGGGATCTCT GTGTTTCGGTGTGTGCGCCTCTTAAGAATCTTCAAAGTGACCAGGCACTGGACT TCCCTGAGCAACTTAGTGGCATCCTTATTAAACTCCATGAAGTCCATCGCTTCG CTGTTGCTTCTGCTTTTTCTCTTCATTATCATCTTTTCCTTGCTTGGGATGCAGCT GTTTGGCGGCAAGTTTAATTTTGATGAAACGCAAACCAAGCGGAGCACCTTTG ACAATTTCCCTCAAGCACTTCTCACAGTGTTCCAGATCCTGACAGGCGAAGACT GGAATGCTGTGATGTACGATGGCATCATGGCTTACGGGGGCCCATCCTCTTCA GGAATGATCGTCTGCATCTACTTCATCATCCTCTTCATTTGTGGTAACTATATTC TACTGAATGTCTTCTTGGCCATCGCTGTAGACAATTTGGCTGATGCTGAAAGTC TGAACACTGCTCAGAAAGAAGAAGCGGAAGAAAAGGAGAGGAAAAAGATTG CCAGAAAAGAGAGCCTAGAAAATAAAAAGAACAACAAACCAGAAGTCAACCA GATAGCCAACAGTGACAACAAGGTTACAATTGATGACTATAGAGAAGAGGAT GAAGACAAGGACCCCTATCCGCCTTGCGATGTGCCAGTAGGGGAAGAGGAAG AGGAAGAGGAGGAGGATGAACCTGAGGTTCCTGCCGGACCCCGTCCTCGAAG GATCTCGGAGTTGAACATGAAGGAAAAAATTGCCCCCATCCCTGAAGGGAGCG CTTTCTTCATTCTTAGCAAGACCAACCCGATCCGCGTAGGCTGCCACAAGCTCA TCAACCACCACATCTTCACCAACCTCATCCTTGTCTTCATCATGCTGAGCAGCG CTGCCCTGGCCGCAGAGGACCCCATCCGCAGCCACTCCTTCCGGAACACGATA CTGGGTTACTTTGACTATGCCTTCACAGCCATCTTTACTGTTGAGATCCTGTTG AAGATGACAACTTTTGGAGCTTTCCTCCACAAAGGGGCCTTCTGCAGGAACTA CTTCAATTTGCTGGATATGCTGGTGGTTGGGGTGTCTCTGGTGTCATTTGGGAT TCAATCCAGTGCCATCTCCGTTGTGAAGATTCTGAGGGTCTTAAGGGTCCTGCG TCCCCTCAGGGCCATCAACAGAGCAAAAGGACTTAAGCACGTGGTCCAGTGCG TCTTCGTGGCCATCCGGACCATCGGCAACATCATGATCGTCACCACCCTCCTGC AGTTCATGTTTGCCTGTATCGGGGTCCAGTTGTTCAAGGGGAAGTTCTATCGCT GTACGGATGAAGCCAAAAGTAACCCTGAAGAATGCAGGGGACTTTTCATCCTC TACAAGGATGGGGATGTTGACAGTCCTGTGGTCCGTGAACGGATCTGGCAAAA CAGTGATTTCAACTTCGACAACGTCCTCTCTGCTATGATGGCGCTCTTCACAGT CTCCACGTTTGAGGGCTGGCCTGCGTTGCTGTATAAAGCCATCGACTCGAATG GAGAGAACATCGGCCCAATCTACAACCACCGCGTGGAGATCTCCATCTTCTTC ATCATCTACATCATCATTGTAGCTTTCTTCATGATGAACATCTTTGTGGGCTTTG TCATCGTTACATTTCAGGAACAAGGAGAAAAAGAGTATAAGAACTGTGAGCTG GACAAAAATCAGCGTCAGTGTGTTGAATACGCCTTGAAAGCACGTCCCTTGCG GAGATACATCCCCAAAAACCCCTACCAGTACAAGTTCTGGTACGTGGTGAACT CTTCGCCTTTCGAATACATGATGTTTGTCCTCATCATGCTCAACACACTCTGCTT GGCCATGCAGCACTACGAGCAGTCCAAGATGTTCAATGATGCCATGGACATTC TGAACATGGTCTTCACCGGGGTGTTCACCGTCGAGATGGTTTTGAAAGTCATCG CATTTAAGCCTAAGGGGTATTTTAGTGACGCCTGGAACACGTTTGACTCCCTCA TCGTAATCGGCAGCATTATAGACGTGGCCCTCAGCGAAGCAGACCCAACTGAA AGTGAAAATGTCCCTGTCCCAACTGCTACACCTGGGAACTCTGAAGAGAGCAA TAGAATCTCCATCACCTTTTTCCGTCTTTTCCGAGTGATGCGATTGGTGAAGCT TCTCAGCAGGGGGGAAGGCATCCGGACATTGCTGTGGACTTTTATTAAGTCCTT TCAGGCGCTCCCGTATGTGGCCCTCCTCATAGCCATGCTGTTCTTCATCTATGC GGTCATTGGCATGCAGATGTTTGGGAAAGTTGCCATGAGAGATAACAACCAGA TCAATAGGAACAATAACTTCCAGACGTTTCCCCAGGCGGTGCTGCTGCTCTTCA GGTGTGCAACAGGTGAGGCCTGGCAGGAGATCATGCTGGCCTGTCTCCCAGGG AAGCTCTGTGACCCTGAGTCAGATTACAACCCCGGGGAGGAGTATACATGTGG GAGCAACTTTGCCATTGTCTATTTCATCAGTTTTTACATGCTCTGTGCATTTCTG ATCATCAATCTGTTTGTGGCTGTCATCATGGATAATTTCGACTATCTGACCCGG GACTGGTCTATTTTGGGGCCTCACCATTTAGATGAATTCAAAAGAATATGGTCA GAATATGACCCTGAGGCAAAGGGAAGGATAAAACACCTTGATGTGGTCACTCT GCTTCGACGCATCCAGCCTCCCCTGGGGTTTGGGAAGTTATGTCCACACAGGG TAGCGTGCAAGAGATTAGTTGCCATGAACATGCCTCTCAACAGTGACGGGACA GTCATGTTTAATGCAACCCTGTTTGCTTTGGTTCGAACGGCTCTTAAGATCAAG ACCGAAGGGAACCTGGAGCAAGCTAATGAAGAACTTCGGGCTGTGATAAAGA AAATTTGGAAGAAAACCAGCATGAAATTACTTGACCAAGTTGTCCCTCCAGCT GGTGATGATGAGGTAACCGTGGGGAAGTTCTATGCCACTTTCCTGATACAGGA CTACTTTAGGAAATTCAAGAAACGGAAAGAACAAGGACTGGTGGGAAAGTAC CCTGCGAAGAACACCACAATTGCCCTACAGGCGGGATTAAGGACACTGCATGA CATTGGGCCAGAAATCCGGCGTGCTATATCGTGTGATTTGCAAGATGACGAGC CTGAGGAAACAAAACGAGAAGAAGAAGATGATGTGTTCAAAAGAAATGGTGC CCTGCTTGGAAACCATGTCAATCATGTTAATAGTGATAGGAGAGATTCCCTTCA GCAGACCAATACCACCCACCGTCCCCTGCATGTCCAAAGGCCTTCAATTCCAC CTGCAAGTGATACTGAGAAACCGCTGTTTCCTCCAGCAGGAAATTCGGTGTGT CATAACCATCATAACCATAATTCCATAGGAAAGCAAGTTCCCACCTCAACAAA TGCCAATCTCAATAATGCCAATATGTCCAAAGCTGCCCATGGAAAGCGGCCCA GCATTGGGAACCTTGAGCATGTGTCTGAAAATGGGCATCATTCTTCCCACAAG CATGACCGGGAGCCTCAGAGAAGGTCCAGTGTGAAAAGAACCCGCTATTATGA AACTTACATTAGGTCCGACTCAGGAGATGAACAGCTCCCAACTATTTGCCGGG AAGACCCAGAGATACATGGCTATTTCAGGGACCCCCACTGCTTGGGGGAGCAG GAGTATTTCAGTAGTGAGGAATGCTACGAGGATGACAGCTCGCCCACCTGGAG CAGGCAAAACTATGGCTACTACAGCAGATACCCAGGCAGAAACATCGACTCTG AGAGGCCCCGAGGCTACCATCATCCCCAAGGATTCTTGGAGGACGATGACTCG CCCGTTTGCTATGATTCACGGAGATCTCCAAGGAGACGCCTACTACCTCCCACC CCAGCATCCCACCGGAGATCCTCCTTCAACTTTGAGTGCCTGCGCCGGCAGAG CAGCCAGGAAGAGGTCCCGTCGTCTCCCATCTTCCCCCATCGCACGGCCCTGC CTCTGCATCTAATGCAGCAACAGATCATGGCAGTTGCCGGCCTAGATTCAAGT AAAGCCCAGAAGTACTCACCGAGTCACTCGACCCGGTCGTGGGCCACCCCTCC AGCAACCCCTCCCTACCGGGACTGGACACCGTGCTACACCCCCCTGATCCAAG TGGAGCAGTCAGAGGCCCTGGACCAGGTGAACGGCAGCCTGCCGTCCCTGCAC CGCAGCTCCTGGTACACAGACGAGCCCGACATCTCCTACCGGACTTTCACACC AGCCAGCCTGACTGTCCCCAGCAGCTTCCGGAACAAAAACAGCGACAAGCAG AGGAGTGCGGACAGCTTGGTGGAGGCAGTCCTGATATCCGAAGGCTTGGGACG CTATGCAAGGGACCCAAAATTTGTGTCAGCAACAAAACACGAAATCGCTGATG CCTGTGACCTCACCATCGACGAGATGGAGAGTGCAGCCAGCACCCTGCTTAAT GGGAACGTGCGTCCCCGAGCCAACGGGGATGTGGGCCCCCTCTCACACCGGCA GGACTATGAGCTACAGGACTTTGGTCCTGGCTACAGCGACGAAGAGCCAGACC CTGGGAGGGATGAGGAGGACCTGGCGGATGAAATGATATGCATCACCACCTTG TAGCCCCCAGCGAGGGGCAGACTGGCTCTGGCCTCAGGTGGGGCGCAGGAGA GCCAGGGGAAAAGTGCCTCATAGTTAGGAAAGTTTAGGCACTAGTTGGGAGTA ATATTCAATTAATTAGACTTTTGTATAAGAGATGTCATGCCTCAAGAAAGCCAT AAACCTGGTAGGAACAGGTCCCAAGCGGTTGAGCCTGGCAGAGTACCATGCGC TCGGCCCCAGCTGCAGGAAACAGCAGGCCCCGCCCTCTCACAGAGGATGGGTG AGGAGGCCAGACCTGCCCTGCCCCATTGTCCAGATGGGCACTGCTGTGGAGTC TGCTTCTCCCATGTACCAGGGCACCAGGCCCACCCAACTGAAGGCATGGCGGC GGGGTGCAGGGGAAAGTTAAAGGTGATGACGATCATCACACCTGTGTCGTTAC CTCAGCCATCGGTCTAGCATATCAGTCACTGGGCCCAACATATCCATTTTTAAA CCCTTTCCCCCAAATACACTGCGTCCTGGTTCCTGTTTAGCTGTTCTGAAATAC GGTGTGTAAGTAAGTCAGAACCCAGCTACCAGTGATTATTGCGAGGGCAATGG GACCTCATAAATAAGGTTTTCTGTGATGTGACGCCAGTTTACATAAGAGAATA TCACTCCGATGGTCGGTTTCTGACTGTCACGCTAAGGGCAACTGTAAACTGGA ATAATAATGCACTCGCAACCAGGTAAACTTAGATACACTAGTTTGTTTAAAATT ATAGATTTACTGTACATGACTTGTAATATACTATAATTTGTATTTGTAAAGAGA TGGTCTATATTTTGTAATTACTGTATTGTATTTGAACTGCAGCAATATCCATGG GTCCTAATAATTGTAGTTCCCCACTAAAATCTAGAAATTATTAGTATTTTTACT CGGGCTATCCAGAAGTAGAAGAAATAGAGCCAATTCTCATTTATTCAGCGAAA ATCCTCTGGGGTTAAAATTTTAAGTTTGAAAGAACTTGACACTACAGAAATTTT TCTAAAATATTTTGAGTCACTATAAACCTATCATCTTTCCACAAGATAAAA
> 2
AATTGGAAGCAAATGACATCACAGCAGGTCAGAGAAAAAGGGTTGAGCGGCA GGCACCCAGAGTAGTAGGTCTTTGGCATTAGGAGCTTGAGCCCAGACGGCCCT AGCAGGGACCCCAGCGCCCGAGAGACCATGCAGAGGTCGCCTCTGGAAAAGG CCAGCGTTGTCTCCAAACTTTTTTTCAGCTGGACCAGACCAATTTTGAGGAAAG GATACAGACAGCGCCTGGAATTGTCAGACATATACCAAATCCCTTCTGTTGATT CTGCTGACAATCTATCTGAAAAATTGGAAAGAGAATGGGATAGAGAGCTGGCT TCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGTTTTTTCTGGAGA TTTATGTTCTATGGAATCTTTTTATATTTAGGGGAAGTCACCAAAGCAGTACAG CCTCTCTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGA ACGCTCTATCGCGATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAG GACACTGCTCCTACACCCAGCCATTTTTGGCCTTCATCACATTGGAATGCAGAT GAGAATAGCTATGTTTAGTTTGATTTATAAGAAGACTTTAAAGCTGTCAAGCC GTGTTCTAGATAAAATAAGTATTGGACAACTTGTTAGTCTCCTTTCCAACAACC TGAACAAATTTGATGAAGGACTTGCATTGGCACATTTCGTGTGGATCGCTCCTT TGCAAGTGGCACTCCTCATGGGGCTAATCTGGGAGTTGTTACAGGCGTCTGCCT TCTGTGGACTTGGTTTCCTGATAGTCCTTGCCCTTTTTCAGGCTGGGCTAGGGA GAATGATGATGAAGTACAGAGATCAGAGAGCTGGGAAGATCAGTGAAAGACT TGTGATTACCTCAGAAATGATTGAAAATATCCAATCTGTTAAGGCATACTGCTG GGAAGAAGCAATGGAAAAAATGATTGAAAACTTAAGACAAACAGAACTGAAA CTGACTCGGAAGGCAGCCTATGTGAGATACTTCAATAGCTCAGCCTTCTTCTTC TCAGGGTTCTTTGTGGTGTTTTTATCTGTGCTTCCCTATGCACTAATCAAAGGA ATCATCCTCCGGAAAATATTCACCACCATCTCATTCTGCATTGTTCTGCGCATG GCGGTCACTCGGCAATTTCCCTGGGCTGTACAAACATGGTATGACTCTCTTGGA GCAATAAACAAAATACAGGATTTCTTACAAAAGCAAGAATATAAGACATTGG AATATAACTTAACGACTACAGAAGTAGTGATGGAGAATGTAACAGCCTTCTGG GAGGAGGGATTTGGGGAATTATTTGAGAAAGCAAAACAAAACAATAACAATA GAAAAACTTCTAATGGTGATGACAGCCTCTTCTTCAGTAATTTCTCACTTCTTG GTACTCCTGTCCTGAAAGATATTAATTTCAAGATAGAAAGAGGACAGTTGTTG GCGGTTGCTGGATCCACTGGAGCAGGCAAGACTTCACTTCTAATGGTGATTAT GGGAGAACTGGAGCCTTCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCA TTCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCATC TTTGGTGTTTCCTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCCA ACTAGAAGAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTTCTTGGAG AAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGA GCAGTATACAAAGATGCTGATTTGTATTTATTAGACTCTCCTTTTGGATACCTA GATGTTTTAACAGAAAAAGAAATATTTGAAAGCTGTGTCTGTAAACTGATGGC TAACAAAACTAGGATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTG ACAAAATATTAATTTTGCATGAAGGTAGCAGCTATTTTTATGGGACATTTTCAG AACTCCAAAATCTACAGCCAGACTTTAGCTCAAAACTCATGGGATGTGATTCTT TCGACCAATTTAGTGCAGAAAGAAGAAATTCAATCCTAACTGAGACCTTACAC CGTTTCTCATTAGAAGGAGATGCTCCTGTCTCCTGGACAGAAACAAAAAAACA ATCTTTTAAACAGACTGGAGAGTTTGGGGAAAAAAGGAAGAATTCTATTCTCA ATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAGACTCCCTTACAAA TGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTGTCCTTA GTACCAGATTCTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAG CACTGGCCCCACGCTTCAGGCACGAAGGAGGCAGTCTGTCCTGAACCTGATGA CACACTCAGTTAACCAAGGTCAGAACATTCACCGAAAGACAACAGCATCCACA CGAAAAGTGTCACTGGCCCCTCAGGCAAACTTGACTGAACTGGATATATATTC AAGAAGGTTATCTCAAGAAACTGGCTTGGAAATAAGTGAAGAAATTAACGAA GAAGACTTAAAGGAGTGCTTTTTTGATGATATGGAGAGCATACCAGCAGTGAC TACATGGAACACATACCTTCGATATATTACTGTCCACAAGAGCTTAATTTTTGT GCTAATTTGGTGCTTAGTAATTTTTCTGGCAGAGGTGGCTGCTTCTTTGGTTGT GCTGTGGCTCCTTGGAAACACTCCTCTTCAAGACAAAGGGAATAGTACTCATA GTAGAAATAACAGCTATGCAGTGATTATCACCAGCACCAGTTCGTATTATGTG TTTTACATTTACGTGGGAGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGA GGTCTACCACTGGTGCATACTCTAATCACAGTGTCGAAAATTTTACACCACAA AATGTTACATTCTGTTCTTCAAGCACCTATGTCAACCCTCAACACGTTGAAAGC AGGTGGGATTCTTAATAGATTCTCCAAAGATATAGCAATTTTGGATGACCTTCT GCCTCTTACCATATTTGACTTCATCCAGTTGTTATTAATTGTGATTGGAGCTATA GCAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTGCCAGTGATA GTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTCAAA CAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTA AAAGGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCT GTTCCACAAAGCTCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAAC ACTGCGCTGGTTCCAAATGAGAATAGAAATGATTTTTGTCATCTTCTTCATTGC TGTTACCTTCATTTCCATTTTAACAACAGGAGAAGGAGAAGGAAGAGTTGGTA TTATCCTGACTTTAGCCATGAATATCATGAGTACATTGCAGTGGGCTGTAAACT CCAGCATAGATGTGGATAGCTTGATGCGATCTGTGAGCCGAGTCTTTAAGTTC ATTGACATGCCAACAGAAGGTAAACCTACCAAGTCAACCAAACCATACAAGA ATGGCCAACTCTCGAAAGTTATGATTATTGAGAATTCACACGTGAAGAAAGAT GACATCTGGCCCTCAGGGGGCCAAATGACTGTCAAAGATCTCACAGCAAAATA CACAGAAGGTGGAAATGCCATATTAGAGAACATTTCCTTCTCAATAAGTCCTG GCCAGAGGGTGGGCCTCTTGGGAAGAACTGGATCAGGGAAGAGTACTTTGTTA TCAGCTTTTTTGAGACTACTGAACACTGAAGGAGAAATCCAGATCGATGGTGT GTCTTGGGATTCAATAACTTTGCAACAGTGGAGGAAAGCCTTTGGAGTGATAC CACAGAAAGTATTTATTTTTTCTGGAACATTTAGAAAAAACTTGGATCCCTATG AACAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGATGAGGTTGGGCTCAG ATCTGTGATAGAACAGTTTCCTGGGAAGCTTGACTTTGTCCTTGTGGATGGGGG CTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTGGCTAGATCTGTTCT CAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTGGATCCAG TAACATACCAAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACA GTAATTCTCTGTGAACACAGGATAGAAGCAATGCTGGAATGCCAACAATTTTT GGTCATAGAAGAGAACAAAGTGCGGCAGTACGATTCCATCCAGAAACTGCTG AACGAGAGGAGCCTCTTCCGGCAAGCCATCAGCCCCTCCGACAGGGTGAAGCT CTTTCCCCACCGGAACTCAAGCAAGTGCAAGTCTAAGCCCCAGATTGCTGCTC TGAAAGAGGAGACAGAAGAAGAGGTGCAAGATACAAGGCTTTAGAGAGCAGC ATAAATGTTGACATGGGACATTTGCTCATGGAATTGGAGCTCGTGGGACAGTC ACCTCATGGAATTGGAGCTCGTGGAACAGTTACCTCTGCCTCAGAAAACAAGG ATGAATTAAGTTTTTTTTTAAAAAAGAAACATTTGGTAAGGGGAATTGAGGAC ACTGATATGGGTCTTGATAAATGGCTTCCTGGCAATAGTCAAATTGTGTGAAA GGTACTTCAAATCCTTGAAGATTTACCACTTGTGTTTTGCAAGCCAGATTTTCC TGAAAACCCTTGCCATGTGCTAGTAATTGGAAAGGCAGCTCTAAATGTCAATC AGCCTAGTTGATCAGCTTATTGTCTAGTGAAACTCGTTAATTTGTAGTGTTGGA GAAGAACTGAAATCATACTTCTTAGGGTTATGATTAAGTAATGATAACTGGAA ACTTCAGCGGTTTATATAAGCTTGTATTCCTTTTTCTCTCCTCTCCCCATGATGT TTAGAAACACAACTATATTGTTTGCTAAGCATTCCAACTATCTCATTTCCAAGC AAGTATTAGAATACCACAGGAACCACAAGACTGCACATCAAAATATGCCCCAT TCAACATCTAGTGAGCAGTCAGGAAAGAGAACTTCCAGATCCTGGAAATCAGG GTTAGTATTGTCCAGGTCTACCAAAAATCTCAATATTTCAGATAATCACAATAC ATCCCTTACCTGGGAAAGGGCTGTTATAATCTTTCACAGGGGACAGGATGGTT CCCTTGATGAAGAAGTTGATATGCCTTTTCCCAACTCCAGAAAGTGACAAGCT CACAGACCTTTGAACTAGAGTTTAGCTGGAAAAGTATGTTAGTGCAAATTGTC ACAGGACAGCCCTTCTTTCCACAGAAGCTCCAGGTAGAGGGTGTGTAAGTAGA TAGGCCATGGGCACTGTGGGTAGACACACATGAAGTCCAAGCATTTAGATGTA TAGGTTGATGGTGGTATGTTTTCAGGCTAGATGTATGTACTTCATGCTGTCTAC ACTAAGAGAGAATGAGAGACACACTGAAGAAGCACCAATCATGAATTAGTTTT ATATGCTTCTGTTTTATAATTTTGTGAAGCAAAATTTTTTCTCTAGGAAATATTT ATTTTAATAATGTTTCAAACATATATAACAATGCTGTATTTTAAAAGAATGATT ATGAATTACATTTGTATAAAATAATTTTTATATTTGAAATATTGACTTTTTATGG CACTAGTATTTCTATGAAATATTATGTTAAAACTGGGACAGGGGAGAACCTAG GGTGATATTAACCAGGGGCCATGAATCACCTTTTGGTCTGGAGGGAAGCCTTG GGGCTGATGCAGTTGTTGCCCACAGCTGTATGATTCCCAGCCAGCACAGCCTCT TAGATGCAGTTCTGAAGAAGATGGTACCACCAGTCTGACTGTTTCCATCAAGG GTACACTGCCTTCTCAACTCCAAACTGACTCTTAAGAAGACTGCATTATATTTA TTACTGTAAGAAAATATCACTTGTCAATAAAATCCATACATTTGTGTGAAA
> 3
GCGCTGACGTCTGTCTGTCCGGGTGCAGGGAGAAGGGAGGAAGAGGGGAGAG GTGGGGCGGTGCAAAGGTGAGGCTGTGCTCAGCCCTGACGCTCAGCAAAACCG ATAACCAGCACTTTCATTACGTGCACGCCCCAGGGCCACGTCCCTGCCGCTGTC TTGGTCCTGAAGCCTGTTCTGCCCCAGCCCCCTGCCCGCTGGGCCCATGCAGCT GTTGGGGCTCCTCGGCCTCCTCTGGATGCTCAAGGCCTCCCCGTGGGCCACAG GAACTTTATCCACGGCCACATCCATCTCTCAAGTGCCTTTCCCCAGAGCAGAA GCAGCCAGCGCTGTGCTCAGCAATTCTCCACACTCCAGAGACCTGGCTGGGTG GCCACTTGGTGTCCCCCAGCTCGCCTCTCCTGCTCCTGGCCACAGGGAAAATGC ACCTATGACACTCACTACCTCCCCCCATGACACACTCATCTCTGAAACATTGCT CAACTCTCCAGTCAGTTCCAACACCTCAACCACCCCGACGTCCAAGTTTGCCTT CAAGGTTGAAACCACTCCACCCACCGTGTTGGTCTATTCAGCCACCACTGAGT GCGTGTATCCAACGAGCTTTATAATCACCATCTCCCACCCCACCTCCATCTGTG TGACCACGACGCAGGTGGCCTTCACCAGCTCTTACACCTCGACTCCCGTGACA CAGAAGCCAGTGACCACCGTCACCAGTACTTACTCTATGACCACTACTGAGAA AGGAACGTCAGCCATGACATCTTCTCCCTCTACCACCACTGCAAGGGAAACTC CCATAGTGACAGTGACACCCTCCTCTGTGTCAGCCACAGACACAACCTTCCAC ACTACAATCTCGTCTACAACTAGAACCACAGAAAGGACTCCCCTGCCCACTGG AAGCATCCATACAACCACGTCCCCAACCCCAGTATTTACTACTCTCAAAACAG CAGTGACTTCCACTTCCCCCATCACTTCTTCAATCACTTCCACAAATACAGTGA CTTCTATGACAACGACCGCCTCCCAGCCCACAGCCACTAATACATTGTCATCAC CCACTAGGACCATTTTATCTTCCACACCTGTCCTGAGCACAGAAACAATCACC AGTGGTATCACAAACACCACCCCCCTATCCACCTTGGTGACCACACTCCCCACT ACCATCAGCAGGTCTACACCTACATCTGAGACCACCTACACTACTTCTCCCACC AGCACTGTCACAGACTCCACTACCAAAATCGCCTACTCCACAAGTATGACAGG TACATTGTCCACAGAGACTTCTCTCCCACCCACCTCTTCCTCTCTCCCAACCAC AGAAACAGCCACGACTCCTATGACAAACTTGGTAACCACCACCACTGAGATCT CCTCCCACAGTACTCCCAGCTTCTCTTCATCAACCATCTACTCCACAGTCAGCA CATCCACAACTGCCATCTCCTCACTTCCCCCTACCTCAGGTACTATGGTGACTT CCACAACCATGACCCCATCTTCTCTGAGTACAGACATCCCTTTCACAACACCAA CAACTATCACCCACCATTCTGTGGGCTCTACCGGTTTCCTGACTACAGCAACAG ACCTCACATCAACATTCACGGTTTCCAGTTCCTCAGCAATGTCCACGAGTGTCA TTCCATCTTCCCCCAGCATTCAGAATACAGAAACCTCATCCCTTGTCAGCATGA CCTCTGCCACTACTCCCAATGTGAGACCAACTTTTGTAAGTACACTCAGCACTC CTACAAGTTCCCTCCTGACGACCTTCCCAGCAACATATTCATTTTCATCTTCCAT GTCTGCCAGCAGTGCTGGGACCACTCACACAGAGAGTATCTCCTCACCTCCAG CCAGCACCAGTACACTCCACACAACAGCTGAATCCACCCTGGCACCCACTACC ACCACCTCATTCACAACTTCCACAACTATGGAACCACCTTCAACCACTGCAGC AACTACAGGAACAGGTCAGACCACCTTCACCAGCTCTACAGCCACATTTCCTG AGACCACCACACCGACTCCTACAACTGACATGTCCACAGAATCTCTCACAACA GCCATGACTTCTCCTCCCATCACTTCATCAGTCACTTCCACAAATACAGTGACT TCTATGACAACTACGACCTCTCCTCCCACAACCACCAATTCTTTTACATCACTG ACCAGTATGCCTCTGTCTTCTACACCTGTCCCAAGCACAGAAGTAGTCACCAGT GGCACCATAAACACAATCCCTCCATCTATCTTGGTGACCACACTCCCCACTCCA AATGCTTCATCTATGACTACATCTGAGACCACCTATCCTAATTCTCCGACTGGT CCTGGTACAAACTCCACGACGGAAATCACCTATCCCACCACTATGACAGAGAC ATCATCCACTGCCACCTCTCTTCCACCCACCTCTCCCTTGGTCTCAACTGCAAA AAC AGC C AAAACTCCT AC C AC AAACTTGGTAAC C ACC ACC AC C AAGAC C AC CT CACATAGTACCACCAGCTTCACTTCTTCAACCGTCTACTCCACAGCCAGCACAT ACACAACTGCCATCACCTCAGTTCCCACTACGTTGGGTACCATGGTAACTTCTA CATCCATGATCTCATCTACTGTGAGTACAGGTATCCCTACCTCACAACCAACAA CCATCACTCCCTCATCCGTGGGCATCAGTGGTTCATTACCTATGATGACAGACC TCACCTCAGTGTACACAGTCTCTAACATGTCTGCAAGGCCAACAACTGTCATTC CCTCATCTCCCACTGTCCAGAATACAGAAATCTCAATCTCTGTTAGCATGACGT CTGCTACCACTCCCAGTGGAGGACCAACTTTCACAAGTACTGAGAACACTCCA ACAAGGTCCCTCCTGACAAGCTTTCCAATGACACATTCATTCTCTTCTTCTATG TCTGAAAGTAGTGCTGGGACCACTCACACAGAGAGTATCTCCTCACCTCGAGG CACCACCAGTACACTCCACACAACAGTTGAATCCACCCCATCACCCACTACCA CCACCTCATTTACCACATCCACAATGATGGAACCACCTTCATCCACTGTATCAA CTACAGGCAGAGGTCAGACCACCTTTCCCAGCTCTACAGCCACATTCCCTGAG ACCACTACACTGACTCCTACAACTGACATTTCTACAGTATCTCTCACAACAGCC ATGACTTCTCCTCCCCCCGTCAGTTCTTCAATCACTCCCACCAATACAATGACT TCTATGAGAACTACAACCTATTGGCCCACAGCCACTAATACATTATCACCACTC ACCAGTAGCATTTTATCTTCTACACCTGTCCCAAGCACAGAAATGATCACCAGT CATACCACAAACACCACCCCTCTATCCACCTTGGTGACTACACTCCTCACTACC ATCACCAGATCTACACCTACATCTGAGACCACCTACCCTACTTCTCCCACCAGC ATTGTCTCAGACTCCACGACTGAAATCACCTATTCCACAAGTATAACAGGTAC ATTGTCCACTGCCACTACTCTCCCACCCACCTCTTCCTCTCTCCCAACCACAGA AACAGCCACGATGACTCCTACCACAACCTTGATAACCACCACCCCTAATACCA CCTCCCTTAGTACCCCCAGCTTCACTTCTTCAACCATCTACTCCACAGTCAGCA CATCCACAACTGCCATCTCCTCAGCTTCCCCTACCTCAGGTACCATGGTAACTT CCACAACCATGACCCCATCTTCTCTGAGTACAGACACCCCTTCCACAACACCA ACAACTATCACCTACCCTTCTGTGGGCTCTACCGGTTTCCTGACTACAGCAACA GACCTCACATCAACATTCACTGTTTCCAGTTCCTCAGCAATGTCCACAAGTGTC ATTCCATCTTCCCCCAGCATCCAGAATACAGAAACCTCATCCCTTGTCAGCATG ACCTCTGCCACCACTCCCAGTTTGAGACCAACTATCACAAGTACTGACAGCAC TCTAACAAGTTCCCTCCTGACGACCTTCCCAAGTACATATTCATTTTCATCTTCC ATGTCTGCCAGCAGTGCAGGGACCACTCACACAGAGACTATTTCCTCACTTCC AGCCAGCACCAATACAATCCACACAACAGCTGAATCCGCCCTGGCACCCACTA CCACCACCTCATTCACCACATCCCCAACGATGGAACCACCTTCAACCACTGTA GCGACTACAGGCACAGGTCAGACCACCTTCCCCAGCTCTACAGCCACATTCCT TGAGACCACCACACTGACTCCTACAACTGACTTTTCTACAGAATCTCTCACAAC AGCCATGACTTCTACTCCCCCCATCACTTCTTCAATCACTCCCACCGATACAAT GACTTCTATGAGAACTACGACCTCTTGGCCCACAGCCACTAATACGTTATCACC ACTCACCAGTAGCATTTTATCTTCTACACCTGTCCCAAGCACAGAGGTGACCAC CAGTCATACCACAAACACCAATCCTGTATCCACGTTGGTGACTACACTCCCCAT TACCATCACCAGGTCTACACTTACATCTGAGACCGCCTACCCTAGTTCTCCCAC AAGCACTGTCACAGAGTCCACAACTGAAATCACCTATCCCACCACTATGACAG AGACATCATCTACTGCCACCTCTCTTCCACCCACCTCTTCCTTGGTCTCAACCG CAGAAACAGCCAAAACTCCTACCACAAACTTGGTAACCACCACCACCAAGACC ACCTCACATAGTACCACCAGCTTCACTTCTTCAACCATCTACTCCACAGCCAGC ACACCCACCACTGCCATCACCTCAGTTCCCACTACCTTGGGTACCATGGTGACT TCTACATCCATGATCCCATCTACTGTGAGTACAGGTATCCCTACCTCACAACCA ACAACTATTACTCCCTCATCCGTGGGCATCAGTGGTTCATTACCTATGATGACA GACCTCACCTCAGTGTACACAGTCTCCAGCATGTCTGCAAGGCCAACAAGTGT CATTCCTTCATCTCCCACTGTCCAGAATACAGAAACCTCAATCTTTGTTAGCAT GATGTCTGCTACCACTCCCAGTGGAGGACCAACTTTCACAAGTACTGAGAACA CTCCAACAAGGTCCCTCCTGACAAGCTTTCCAGTGACACATTCATTTTCCTCTT CCATGTCTGCCAGCAGTGTAGGGACCACTCACACCCAGAGTATCTCCTCACCC CCAGCCATCACCAGTACACTCCACACAACAGCTGAATCCACCCCATCACCTAC AACCACCATGTCATTCACAACATTTACAAAGATGGAAACACCTTCATCCACTG TAGCAACTACAGGCACAGGTCAGACTACATTCACCAGTTCAACAGCCACATCC CCTAAGACCACCACACTGACTCCTACCTCTGACATTTCCACAGGATCTTTCAAA ACAGCCGTGAGTTCTACTCCCCCCATCACTTCTTCAATCACCTCCACATATACG GTGACTTCGATGACAACTACCACCCCTCTAGGGCCCACAGCCACTAATACGTT ACCATCATTTACCAGTAGCGTTTCATCTTCTACGCCTGTCCCAAGTACAGAAGC GATCACCAGTGGTACCACAAACACCACCCCTCTATCTACATTGGTGACCACAT TCTCCAATTCCGACACCAGTTCTACACCTACATCTGAGACCACCTACCCTACTT CTCTTACTAGTGCTCTCACAGATTCCACGACCAGAACCACCTATTCCACCAATA TGACAGGTACATTGTCCACTGTGACCTCTCTTCGACCCACCTCTTCCTCTCTCCT CACCACAGTAACAGCCACAGTTCCAACAACAAACTTGGTAACCACGACCACCA AGATCACCTCACACAGTACTCCTAGCTTCACTTCTTCAATCGCAACCACCGAGA CCCCCTCACACAGTACTCCCAGATTCACTTCTTCAATCACCACTACCGAGACCC CCTCACACAGTACTCCCAGATTCACTTCTTCAATCACCAATACCAAGACCACCT CACACAGCTCTCCCAGCTTCACTTCTTCGATCACCACCACCGAGACCACATCCC ACAATACTCCCAGCCTCACTTCTTCAATCACCACCACCAAGACCACCTCACAC AGTACTCCCAGCTACACTTCTTTGATCACCACAACCACCACCACCTCACACAGT ACTCCCAGCTTCACTTCTTCCATCACCACCACTGAGACCACATCCCACAATACT CCCAGCTTGACTTCTTCGATCACAACCACCGAGACCACATCCCATAGTACTCCC AGCTTCACTTCTTCGATCACCACCGAGACCACATCCCACAGTACTCCCAGCTTC ACTTCATTGATCACCATCACCGAGATCACCTCACACAGTACTCTCAGCTACACT ACCTCAATCACCACCACCGAGACCCCCTCACACAGTACTCTCAGCTTCACTTCT TCAATCACCACCACTGAGACCACCTCACACAGTACTCCCAGCTTCACTTCCTCA ATCACCACCTCTGAGATGCCCTCACACAGTACTCCCAGCTTCACTTCTTCGATC ACCACCACTGAGAACGCCACACACAGTACTCCCAACTTCACTTCTTCAATCAC CACCACCGAGACCACATCCCACAGTACTCCCAGCTTCACTTCTTTGATCACCAC CACGGAGACCACCTCACACAGGTGGGGGACCACCGAGACCACATCCTACAGT ACTCCCAGCTTCACTTCTTCAAATACCATCACTGAGACCACCTCACACAGTACT CCCAGCTACATTACCTCAATCACCACCACCGAGACCCCCTCAAGCAGTACTCC CAGCTTCAGTTCTTCGATCACCACCACTGAGACCACATCCCACAGTACTCCCGG CTTCACTTCTTCAATCACCACCACTGAGACTACATCCCACAGTACTCCCAGCTT CACTTCTTCGATCACCACCACTGAGACCACCTCACATGATACTCCCAGCTTCAC TTCTTCAATCACCACCAGTGAGACCCCCTCACACAGTACTCCCAGCTCCACTTC TTTAATCACCACCACCAAGACCACCTCACACAGTACTCCCAGCTTCACTTCTTC GATCACCACCACGGAGACCACCTCACACAGTGCTCACAGCTTCACTTCTTCGA TCACCACCACCGAGACCACCTCACACAATACTCGCAGCTTCACTTCTTCGATCA CCACCACCGAGACCAACTCTCACAGTACTACCAGCTTCACTTCTTCGATCACCA CCACCGAGACCACCTCACACAGTACTCCCAGCTTCAGTTCTTCAATCACCACCA CTGAGACCCCCTTACACAGTACTCCTGGCCTCACTTCGTGGGTCACCACCACCA AGACCACCTCACACATTACTCCTGGCCTCACTTCTTCAATCACCACCACTGAGA CTACCTCACACAGTACTCCTGGCTTCACTTCTTCAATCACCACCACTGAGACCA CCTCAGAGAGTACTCCCAGCCTCAGTTCTTCAACCATCTACTCCACAGTCAGCA CATCCACAACTGCCATCACCTCACATTTTACTACCTCAGAGACTGCGGTGACTC CCACACCTGTAACCCCATCTTCTCTGAGTACAGACATCCCGACCACAAGCCTA CGAACTCTCACCCCTTCGTCTGTGGGCACCAGCACTTCATTGACTACAACCACA GACTTTCCCTCTATACCCACTGATATCAGTACCTTACCAACTCGAACACACATC ATTTCATCTTCTCCCTCCATCCAAAGTACAGAAACCTCATCCCTTGTGGGCACC ACCTCTCCCACCATGTCCACTGTGAGAATGACCCTCAGAATTACTGAGAACAC CCCAATCAGTTCCTTTAGCACAAGTATTGTTGTTATACCTGAAACCCCAACACA GACCCCTCCTGTACTGACGTCAGCCACTGGGACCCAAACATCTCCTGCACCTA CTACTGTCACCTTTGGAAGTACGGATTCCTCCACGTCCACTCTTCATACTCTTA CTCCATCAACAGCCTTGAGCACGATCGTGTCAACATCACAGGTTCCTATTCCTA GCACACATTCCTCCACCCTTCAAACAACTCCTTCTACTCCCTCATTGCAAACTT CACTCACATCTACAAGTGAGTTCACTACAGAATCTTTCACTAGGGGAAGTACG TCTACAAATGCAATCTTGACTTCTTTTAGTACCATCATCTGGTCCTCAACACCC ACTATTATCATGTCCTCTTCTCCATCTTCTGCCAGCATAACTCCAGTGTTTTCCA CTACCATTCATTCTGTTCCTTCTTCACCATACATTTTCAGTACAGAAAATGTGG GCTCCGCTTCTATCACAGGCTTTCCTAGTCTCTCTTCCTCTGCAACTACCAGCA CTTCTTCAACCAGCTCCTCTCTGACCACAGCTCTCACTGAAATAACCCCCTTTT CTTATATTTCCCTTCCCTCCACCACACCCTGTCCAGGAACTATAACAATTACCA TAGTCCCTGCCTCCCCCACTGATCCATGTGTTGAAATGGATCCCAGCACTGAAG CTACTTCTCCTCCCACCACCCCATTAACAGTCTTTCCCTTTACTACCGAAATGG TCACCTGTCCTACCTCCATCAGTATCCAAACTACTCTTACTACATATATGGACA CTTCTTCCATGATGCCAGAAAGTGAGTCCAGCATCTCACCCAATGCTTCCAGTT CCACTGGCACTGGGACTGTACCCACAAACACAGTTTTCACAAGTACTCGACTG CCCACCAGTGAGACCTGGCTGAGCAACAGTTCTGTGATCCCCCTACCTCTTCCT GGCGTCTCTACCATCCCGCTCACCATGAAACCAAGCAGTAGCCTCCCGACCAT CCTGAGGACTTCAAGCAAGTCAACACACCCCTCCCCACCCACCACTAGGACTT CAGAGACACCAGTGGCCACTACCCAGACTCCTACCACCCTTACATCACGCAGG ACAACTCGCATCACTTCTCAGATGACCACACAGTCCACGTTGACCACCACTGC AGGCACCTGTGACAATGGTGGCACCTGGGAACAGGGCCAGTGTGCTTGCCTTC CGGGGTTTTCTGGGGACCGCTGTCAGCTCCAGACCAGATGCCAGAATGGGGGT CAGTGGGATGGCCTCAAATGCCAGTGCCCCAGCACCTTCTATGGTTCCAGTTGT GAGTTTGCTGTGGAACAGGTGGATCTAGATGTAGTGGAGACCGAGGTGGGCAT GGAAGTGTCTGTGGATCAGCAGTTCTCGCCGGACCTCAATGACAACACTTCCC AGGCCTACAGGGATTTCAACAAGACCTTCTGGAATCAGATGCAGAAGATTTTT GCAGACATGCAGGGCTTCACCTTCAAGGGTGTGGAGATCCTGTCCCTGAGGAA TGGCAGCATCGTGGTGGACTACCTGGTCCTGCTGGAGATGCCCTTCAGCCCCC AGCTGGAGAGCGAGTATGAGCAGGTGAAGACCACGCTGAAGGAGGGGCTGCA GAACGCCAGCCAGGATGTGAACAGCTGCCAGGACTCCCAGACCCTGTGTTTTA AGCCTGACTCCATCAAGGTGAACAACAACAGCAAGACAGAGCTGACCCCGGC AGCCATCTGCCGCCGCGCCGCTCCCACGGGCTATGAAGAGTTCTACTTCCCCTT GGTGGAGGCCACCCGGCTCCGCTGTGTCACCAAATGCACGTCGGGGGTGGACA ACGCCATCGACTGTCACCAGGGCCAGTGCGTTCTGGAGACGAGCGGTCCCACG TGTCGCTGCTACTCCACCGACACGCACTGGTTCTCTGGCCCGCGCTGCGAGGTG GCCGTCCACTGGAGGGCGCTGGTCGGGGGCCTGACGGCCGGCGCCGCGCTGCT GGTGCTGCTGCTGCTGGCGCTGGGCGTCCGGGCGGTGCGCTCCGGATGGTGGG GCGGCCAGCGCCGAGGCCGGTCCTGGGACCAGGACAGGAAATGGTTCGAGAC CTGGGATGAGGAAGTCGTGGGCACTTTTTCAAACTGGGGTTTCGAGGACGACG GAACAGACAAGGATACAAATTTCTATGTGGCCTTGGAGAACGTGGACACCACT ATGAAGGTGCACATCAAGAGACCCGAGATGACCTCGTCCTCAGTGTGAGCCCT GCGGGGCCCCTTCACCACCCCCTCCGCCCTGCCCCGGACACAAGGGTCTGCAT TGCGTCCATTTCAAGAGGTGGCCCCAGGACGCGGGCAGCCCAGGCTCCTGCTG TTCTTGGGCAAGATGAGACTGTTCCCCCAAATCCCATCCTTCTCCTTCCAACTT GGCTGAAACCCACCTGGAGACGCAGTTCACGTCCAGGCTCTTCCACTGTGGAA TCTTGGGCAAGTCAGTAACGAGCCTCAGTTTCCTCACCTGCAAAACGGGTACA GCATTCCTGTATGATAGCTCACGCCGTTGTTGTGAAAACCACATAGACTTGGTC AATTCTCGGTCCTACTCTGCCCTCCCGTCTCAGCCCTCGTGTTGCCATTGCCTCT CTCGGATCCTCCAATCCTCACGTCCTTCACCTGGTCTCTGGCCCTGGTTCTTATT TTCTCTCAATTCCCTACTGCCTGTTTCTTACTTTGAACCTGGAGGCAGCCTGCA GCCCCATCCCATCTCCTGCCCTCTCCTGATCTAACTCCCTGCTGCATCTCTTGCT CTCATTCCTTAGACGTCCTCCCCTTTTGACCCCGTTCCTTCATCCATCCTGCACC CCAGTCCCCCAGCCCTAAATCCTCCCTCCTCTCCTCACATCCTGGTCCCTAGCA AGGTATAGATAGCCTCTGTGTCTTAGGATACCCAGGTGCTGTTCTCCCCGTCAC CCCGTTGCCCAGTTCCCCGTTTCTCTTGCTCTCATTCCTTGTATCTTCTCCCTTCT GAGCCCGTCCATTCATCGGTTCTGCCCCCGACTCCCCCTGACCTAAATACCCCA GCTGCTGTTCCCCCCATCACCCTGCTGCCCAATTCTTTATTCTCCACCCCTTTCT CTCACCCCTGGAGCCCTGCGGGTGGGGGCAGGGCATGAGTTCCCCAGTCCCCA AGGAAAGGCAGCCCCCTCAGTCTCCCTCCTCCTCATTTCCTTCGATCCCCCTCC CTTCTTGCCTCCCCTCTGCCTTTTAAACCCATCCCCTCCGATTCCCCTCCTCCCC CTTCTCTTCCTGGTGTCACCTGGATTCCTGCAGTAACTCTGAGCCCTTGAAATC CTCAGTCGCCTTGGCGGGGAAGATTGGCTTTGGGGACAGGAAGTCGGCACATC TCCAGGTCTTCATGTGCACAATACAGAGTTTATTGTAAAAAGC
> 4
CTTGGCTGTTCCTGAGGCCTGGCCTGGCTCCCCGCTGACCCCTTCCCAGACCTG GGATGGCGGAGGCCGGCCTGAGGGGCTGGCTGCTGTGGGCCCTGCTCCTGCGC TTGGCCCAGAGTGAGCCTTACACAACCATCCACCAGCCTGGCTACTGCGCCTT CTATGACGAATGTGGGAAGAACCCAGAGCTGTCTGGAAGCCTCATGACACTCT CCAACGTGTCCTGCCTGTCCAACACGCCGGCCCGCAAGATCACAGGTGATCAC CTGATCCTATTACAGAAGATCTGCCCCCGCCTCTACACCGGCCCCAACACCCA AGCCTGCTGCTCCGCCAAGCAGCTGGTATCACTGGAAGCGAGTCTGTCGATCA CCAAGGCCCTCCTCACCCGCTGCCCAGCCTGCTCTGACAATTTTGTGAACCTGC ACTGCCACAACACGTGCAGCCCCAATCAGAGCCTCTTCATCAATGTGACCCGC GTGGCCCAGCTAGGGGCTGGACAACTCCCAGCTGTGGTGGCCTATGAGGCCTT CTACCAGCATAGCTTTGCCGAGCAGAGCTATGACTCCTGCAGCCGTGTGCGCG TCCCTGCAGCTGCCACGCTGGCTGTGGGCACCATGTGTGGCGTGTATGGCTCTG CCCTTTGCAATGCCCAGCGCTGGCTCAACTTCCAGGGAGACACAGGCAATGGT CTGGCCCCACTGGACATCACCTTCCACCTCTTGGAGCCTGGCCAGGCCGTGGG GAGTGGGATTCAGCCTCTGAATGAGGGGGTTGCACGTTGCAATGAGTCCCAAG GTGACGACGTGGCGACCTGCTCCTGCCAAGACTGTGCTGCATCCTGTCCTGCC ATAGCCCGCCCCCAGGCCCTCGACTCCACCTTCTACCTGGGCCAGATGCCGGG CAGTCTGGTCCTCATCATCATCCTCTGCTCTGTCTTCGCTGTGGTCACCATCCTG CTTGTGGGATTCCGTGTGGCCCCCGCCAGGGACAAAAGCAAGATGGTGGACCC CAAGAAGGGCACCAGCCTCTCTGACAAGCTCAGCTTCTCCACCCACACCCTCC TTGGCCAGTTCTTCCAGGGCTGGGGCACGTGGGTGGCTTCGTGGCCTCTGACCA TCTTGGTGCTATCTGTCATCCCGGTGGTGGCCTTGGCAGCGGGCCTGGTCTTTA CAGAACTCACTACGGACCCCGTGGAGCTGTGGTCGGCCCCCAACAGCCAAGCC CGGAGTGAGAAAGCTTTCCATGACCAGCATTTCGGCCCCTTCTTCCGAACCAA CCAGGTGATCCTGACGGCTCCTAACCGGTCCAGCTACAGGTATGACTCTCTGCT GCTGGGGCCCAAGAACTTCAGCGGAATCCTGGACCTGGACTTGCTGCTGGAGC TGCTAGAGCTGCAGGAGAGGCTGCGGCACCTCCAGGTATGGTCGCCCGAAGCA CAGCGCAACATCTCCCTGCAGGACATCTGCTACGCCCCCCTCAATCCGGACAA TACCAGTCTCTACGACTGCTGCATCAACAGCCTCCTGCAGTATTTCCAGAACAA CCGCACGCTCCTGCTGCTCACAGCCAACCAGACACTGATGGGGCAGACCTCCC AAGTCGACTGGAAGGACCATTTTCTGTACTGTGCCAATGCCCCGCTCACCTTCA AGGATGGCACAGCCCTGGCCCTGAGCTGCATGGCTGACTACGGGGCCCCTGTC TTCCCCTTCCTTGCCATTGGGGGGTACAAAGGAAAGGACTATTCTGAGGCAGA GGCCCTGATCATGACGTTCTCCCTCAACAATTACCCTGCCGGGGACCCCCGTCT GGCCCAGGCCAAGCTGTGGGAGGAGGCCTTCTTAGAGGAAATGCGAGCCTTCC AGCGTCGGATGGCTGGCATGTTCCAGGTCACGTTCATGGCTGAGCGCTCTCTG GAAGACGAGATCAATCGCACCACAGCTGAAGACCTGCCCATCTTTGCCACCAG CTACATTGTCATATTCCTGTACATCTCTCTGGCCCTGGGCAGCTATTCCAGCTG GAGCCGAGTGATGGTGGACTCCAAGGCCACGCTGGGCCTCGGCGGGGTGGCC GTGGTCCTGGGAGCAGTCATGGCTGCCATGGGCTTCTTCTCCTACTTGGGTATC CGCTCCTCCCTGGTCATCCTGCAAGTGGTTCCTTTCCTGGTGCTGTCCGTGGGG GCTGATAACATCTTCATCTTTGTTCTCGAGTACCAGAGGCTGCCCCGGAGGCCT GGGGAGCCACGAGAGGTCCACATTGGGCGAGCCCTAGGCAGGGTGGCTCCCA GCATGCTGTTGTGCAGCCTCTCTGAGGCCATCTGCTTCTTCCTAGGGGCCCTGA CCCCCATGCCAGCTGTGCGGACCTTTGCCCTGACCTCTGGCCTTGCAGTGATCC TTGACTTCCTCCTGCAGATGTCAGCCTTTGTGGCCCTGCTCTCCCTGGACAGCA AGAGGCAGGAGGCCTCCCGGTTGGACGTCTGCTGCTGTGTCAAGCCCCAGGAG CTGCCCCCGCCTGGCCAGGGAGAGGGGCTCCTGCTTGGCTTCTTCCAAAAGGC TTATGCCCCCTTCCTGCTGCACTGGATCACTCGAGGTGTTGTGCTGCTGCTGTTT CTCGCCCTGTTCGGAGTGAGCCTCTACTCCATGTGCCACATCAGCGTGGGACTG GACCAGGAGCTGGCCCTGCCCAAGGACTCGTACCTGCTTGACTATTTCCTCTTT CTGAACCGCTACTTCGAGGTGGGGGCCCCGGTGTACTTTGTTACCACCTTGGGC TACAACTTCTCCAGCGAGGCTGGGATGAATGCCATCTGCTCCAGTGCAGGCTG CAACAACTTCTCCTTCACCCAGAAGATCCAGTATGCCACAGAGTTCCCTGAGC AGTCTTACCTGGCCATCCCTGCCTCCTCCTGGGTGGATGACTTCATTGACTGGC TGACCCCGTCCTCCTGCTGCCGCCTTTATATATCTGGCCCCAATAAGGACAAGT TCTGCCCCTCGACCGTCAACTCTCTGAACTGCCTAAAGAACTGCATGAGCATC ACGATGGGCTCTGTGAGGCCCTCGGTGGAGCAGTTCCATAAGTATCTTCCCTG GTTCCTGAACGACCGGCCCAACATCAAATGTCCCAAAGGCGGCCTGGCAGCAT ACAGCACCTCTGTGAACTTGACTTCAGATGGCCAGGTTTTAGCCTCCAGGTTCA TGGCCTATCACAAGCCCCTGAAAAACTCACAGGATTACACAGAAGCTCTGCGG GCAGCTCGAGAGCTGGCAGCCAACATCACTGCTGACCTGCGGAAAGTGCCTGG AACAGACCCGGCTTTTGAGGTCTTCCCCTACACGATCACCAATGTGTTTTATGA GCAGTACCTGACCATCCTCCCTGAGGGGCTCTTCATGCTCAGCCTCTGCCTTGT GCCCACCTTCGCTGTCTCCTGCCTCCTGCTGGGCCTGGACCTGCGCTCCGGCCT CCTCAACCTGCTCTCCATTGTCATGATCCTCGTGGACACTGTCGGCTTCATGGC CCTGTGGGGCATCAGTTACAATGCTGTGTCCCTCATCAACCTGGTCTCGGCGGT GGGCATGTCTGTGGAGTTTGTGTCCCACATTACCCGCTCCTTTGCCATCAGCAC CAAGCCCACCTGGCTGGAGAGGGCCAAAGAGGCCACCATCTCTATGGGAAGT GCGGTGTTTGCAGGTGTGGCCATGACCAACCTGCCTGGCATCCTTGTCCTGGGC CTCGCCAAGGCCCAGCTCATTCAGATCTTCTTCTTCCGCCTCAACCTCCTGATC ACTCTGCTGGGCCTGCTGCATGGCTTGGTCTTCCTGCCCGTCATCCTCAGCTAC GTGGGGCCTGACGTTAACCCGGCTCTGGCACTGGAGCAGAAGCGGGCTGAGG AGGCGGTGGCAGCAGTCATGGTGGCCTCTTGCCCAAATCACCCCTCCCGAGTC TCCACAGCTGACAACATCTATGTCAACCACAGCTTTGAAGGTTCTATCAAAGG TGCTGGTGCCATCAGCAACTTCTTGCCCAACAATGGGCGGCAGTTCTGATACA GCCAGAGGCCCTGTCTAGGCTCTATGGCCCTGAACCAAAGGGTTATGGGGATC TTCCTTGTGACTGCCCCTTGACACACGCCCTCCTCAAATCCTAGGGGAGGCCAT TCCCATGAGACTGCCTGTCACTGGAGGATGGCCTGCTCTTGAGGTATCCAGGC AGCACCACTGATGGCTCCTCTGCTCCCATAGTGGGTCCCCAGTTTCCAAGTCAC CTAGGCCTTGGGCAGTGCCTCCTCCTGGGCCTGGGTCTGGAAGTTGGCAGGAA CAGACACACTCCATGTTTGTCCCACACTCACTCACTTTCCTAGGAGCCCACTTC TCATCCAACTTTTCCCTTCTCAGTTCCTCTCTCGAAAGTCTTAATTCTGTGTCAG TAAGTCTTTAACACGTAGCAGTGTCCCTGAGAACACAGACAATGACCACTACC CTGGGTGTGATATCACAGGAGGCCAGAGAGAGGCAAAGGCTCAGGCCAAGAG CCAACGCTGTGGGAGGCCGGTCGGCAGCCACTCCCTCCAGGGCGCACCTGCAG GTCTGCCATCCACGGCCTTTTCTGGCAAGAGAAGGGCCCAGGAAGGATGCTCT CATAAGGCCCAGGAAGGATGCTCTCATAAGCACCTTGGTCATGGATTAGCCCC TCCTGGAAAATGGTGTTGGGTTTGGTCTCCAGCTCCAATACTTATTAAGGCTGT TGCTGCCAGTCAAGGCCACCCAGGAGTCTGAAGGCTGGGAGCTCTTGGGGCTG GGCTGGTCCTCCCATCTTCACCTCGGGCCTGGATCCCAGGCCTCAAACCAGCCC AACCCGAGCTTTTGGACAGCTCTCCAGAAGCATGAACTGCAGTGGAGATGAAG ATCCTGGCTCTGTGCTGTGCACATAGGTGTTTAATAAACATTTGTTGGCAGA
> 5
GCCCCCGCCGCCCCCGGGCCCTGATGGACTGAATGAAGGCTGCCTACACCGCC TATCGATGCCTCACCAAAGACCTAGAAGGCTGCGCCATGAACCCGGAGCTGAC AATGGAAAGTCTGGGCACTTTGCACGGGCCGGCCGGCGGCGGCAGTGGCGGG GGCGGCGGCGGGGGCGGCGGGGGCGGCGGCGGGGGCCCGGGCCATGAGCAG GAGCTGCTGGCCAGCCCCAGCCCCCACCACGCGGGCCGCGGCGCCGCTGGCTC GCTGCGGGGCCCTCCGCCGCCTCCAACCGCGCACCAGGAGCTGGGCACGGCGG CAGCGGCGGCAGCGGCGGCGTCGCGCTCGGCCATGGTCACCAGCATGGCCTCG ATCCTGGACGGCGGCGACTACCGGCCCGAGCTCTCCATCCCGCTGCACCACGC CATGAGCATGTCCTGCGACTCGTCTCCGCCTGGCATGGGCATGAGCAACACCT ACACCACGCTGACACCGCTCCAGCCGCTGCCACCCATCTCCACCGTGTCTGAC AAGTTCCACCACCCTCACCCGCACCACCATCCGCACCACCACCACCACCACCA CCACCAGCGCCTGTCCGGCAACGTCAGCGGCAGCTTCACCCTCATGCGCGACG AGCGCGGGCTCCCGGCCATGAACAACCTCTACAGTCCCTACAAGGAGATGCCC GGCATGAGCCAGAGCCTGTCCCCGCTGGCCGCCACGCCGCTGGGCAACGGGCT AGGCGGCCTCCACAACGCGCAGCAGAGTCTGCCCAACTACGGTCCGCCGGGCC ACGACAAAATGCTCAGCCCCAACTTCGACGCGCACCACACTGCCATGCTGACC CGCGGTGAGCAACACCTGTCCCGCGGCCTGGGCACCCCACCTGCGGCCATGAT GTCGCACCTGAACGGCCTGCACCACCCGGGCCACACTCAGTCTCACGGGCCGG TGCTGGCACCCAGTCGCGAGCGGCCACCCTCGTCCTCATCGGGCTCGCAGGTG GCCACGTCGGGCCAGCTGGAAGAAATCAACACCAAAGAGGTGGCCCAGCGCA TCACAGCGGAGCTGAAGCGCTACAGTATCCCCCAGGCGATCTTTGCGCAGAGG GTGCTGTGCCGGTCTCAGGGGACTCTCTCCGACCTGCTCCGGAATCCAAAACC GTGGAGTAAACTCAAATCTGGCAGGGAGACCTTCCGCAGGATGTGGAAGTGGC TTCAGGAGCCCGAGTTCCAGCGCATGTCCGCCTTACGCCTGGCAGCGTGCAAA CGCAAAGAGCAAGAACCAAACAAAGACAGGAACAATTCCCAGAAGAAGTCCC GCCTGGTGTTCACTGACCTCCAACGCCGAACACTCTTCGCCATCTTCAAGGAG AACAAACGCCCGTCAAAGGAGATGCAGATCACCATTTCCCAGCAGCTGGGCCT GGAGCTCACAACCGTCAGCAACTTCTTCATGAACGCCCGGCGCCGCAGCCTGG AGAAGTGGCAAGACGATCTGAGCACAGGGGGCTCCTCGTCCACCTCCAGCACG TGTACCAAAGCATGATGGAAGGACTCTCACTTGGGCACAAGTCACCTCCAAAT GAGGAC AAC AGATACC AAAAGAAAAC AAAGGAA AAAGAC AC CGGATTC CT AG CTGGGGCCCTTCACTGGTGATTTGAAAGCACAATTCTCTTGCAAAGAAACTTAT ATTCTAGCTGTAATCATAGGCCAGGTGTTCTTCTTTTGTTTTTAATGGCTATGGA GTCCAAGTGCAAGCTGAAAAATTAATCTCTTAGAACCAGACACTGTTCTCTGA GCATGCTAAGCATCCCAGAAACCCAAATGGGGCCTTCCTGGAGCGAGTTAATT CCAGTATGGTGTCAACCAAGCTCGGGATTGCTTAAAATATCATCCATCCCACTT CAGGTCCTGTCAGCTTCTTGCAGTCAGAGTTCCTATGAGTAACAATAGGAGTTT GGCCTATGTAAGGACTCTGAGTTTAGGCTTCCAAGATACAACAATAAGAGAAG AATCTAGCAACGAGAATGACCTCATTTGCTTTCCACATGCTTAGCCTCATTATA CCATGTTATGTCCAAGTTCACAGCCACAACATCAGAATGGTAATTACTGAGCA CAAGTTTTAAATATGGACGTTAAAAAAAAAAATCCAAGGACCTGTTTTTCCAA CCCAGACATCTTTTCATTGAATGATTTAGAAAGCTTTAAGTTGATCCAGCTTAC AATTTTTTTTTTCTTTACCTCCTGGAAATCTCATATGGTCTTGGATCCGTCAAAA AAACCAGTCAGTTCACTTGCGCTCAAAGTATCAAGCACAACAAAGATAAACAG AAGTGAGGAAGGTTCTGGGTTCACTACATCTGGATTTTCAAGACACCTATTGTG AAGTCATTAGGGAATTGATGAGAATATGGCTTCAAGCACATTTTGCAGTTTGCT ACAAATTCTGTTGTACATAATGCAGACGCACACTCAGGAGGCCAATTTAACTG TTAACAGTGCATGGAGCGAATGCAGCATTTTAAAAGATCTAGGTTTTTTTAGGT CATTAATGTGTCCTTGGTTGATCAGTCATCTGGTCCCTCCTACTGTGTGTTATGA CCACCACGTAATCCATTCTCGCTCTTTCTGATTTGGGGTTTTTCCTCATCCATCC CATTAGTAGGGATGTTTTCTGTGTTTTCTAGCAAGAAAAAAAAATCAATCAATC AAACCTGCATACATGTTACTCATGACTGTCATCTAGTCCTAAATCTCTTCTGTT GTTGAATCATCCTTGCAAAACAGCTGAATACATCTGGAGAAAACACAGCACAC CAAAGAAGCAGAATACTGCAAACCAAAGACATTTATGACTTGTCATTTTCTAG CCTAAAAATACTGTGATTACTTTTAGAAATCAGAAAACCTCTGCAACTCCGAA TGGCATTCAGCTCTTGCATTTGGCGCATCATCGGGCTGAGCGGACCAGCTACA CCAAGGACATTAGCCAAGCCACCCAGAGGGGTGGCTTTGCCACACCAGTTGTC ACCTTCCCATAGCAAGTGGAAGAGCGCCCACAGAACTCTGGGAGATTGCAAAG GTCACAATGTGCATATTTACCAGTGAATGGCCCCGGGTGGGGCCACGTGGGGG TGTTCAAAGCAAGCCAAACGCTGCAATCATTCTTTACAGACACTTGAGACTGA CTTTTTTATGAATTACTTAGTCGAAACCAAAGAAACTTTTTCTGCACCTACTTCT GCAACAAACAAAACTGTCCCATTAAAATGAATAAATAAATCCGTAAATCAATG GAAATCACCACCAATAAGAAGGAAGCACGCCAGAAAATAAACGAAAACAAAA ACAGGGAGACACACTGTGTTCAAACAGACCTCTTGGGACATTTTTTGGAAGCA GATTTTAAAGAAAGGGTTGAGACAAAGATAGAAATAAGGAAGAGCCTCAGTG GCTGCTGCTTCATTTGACAACTCACACGGTAATCTTAAAGCTGAAGATTGTCTT TAATTTGTGCCTATGCAGTTTTTCAAAAGAACACGGAACAGAGCAACAGAAAC CTCAACAGCTACAATACCAAAGATGAGGATTTCTCACACCTTTTGTTTCAGTTC ATTATCTCCTCTTGCCTGGCTAAAATACTAATAGCGCCATTGAACTGTATAAAG GTAATCAATTATGTTTCTCTGAGCAACAAAAGGAAAGGGCCATTTATTTGATTT TATTGTTTCATTTCAATTTTGTCTTATGGTTTTTTGCCCCAACATGGAATCTCTC AAAAGTTTCCATGGACTCCAAGTTTAAGATGTTGGGATATTGAACAGTTCTCTC TGCTCAGCAGAGGGTAGGGAATAACATTATCACTTGAATGTTCTTTGCTTAACC CTTAGACTTGGTTCCTTCTATGTTCAGAGTCTCATCATCAGGGGAAGGAAAGG GAGTGAGGGTCAGGGATAGGGGTCTTGGTGATGCATCCTCTCCCGAGCCACAG AACCAAAGAGTTTATAGAGGAATTTACAGCCTCGTTTTCATGTGATTGCTACAT CCTAACAGGGCTTCATTTGGGGGTGGGGGGAAACATGTAAAAATAATTGCCAG TTTCTACTTTTCTATTAGCTTTTTAAAAATCAGCTGTAAAGTTGCATTTCTAAAG AAAGATATATATAATATATAAAATACATATATAGATCAACTTGACATTGGTGA TAACCAAAATTATTGCTGTCCAAATTCATGTCTTGTTTTGGTCCAGTGCTTCATT TGCTAAGTATTCGGTTCAGAATTTTTCTCATTTCTCATGCCATTCCAGAGTTAAT TTGCCACTGTGGATGATTTGAAGTATTCAGATCTCTATGGAAGTTTCTGGGACA GGTTTAAAGTCAAGATCAAGCATTTTAGCATTTAACCTGTTGATAAATGGATCC ATGGTGTACATGAGTTTTATTTGTATTCGGAGTCATCTCTATTCTATCCCTCAGC CTCGATTAAGGTGGTGAGTGAAGTGCATCCAACAGACTCGGCCCAGAACTGGG TCCTGACAGTGGGGTGCTCATCTTCTGTAACTGTTGGGAAGGCTCGGTGGTCCA TTTTCACCAGTTAAAGAATATGAGGCCAGCCCAGAAATCTGTTCTCCAGGAGC TGCCCTGTCCCATCTGGGTGTGCCAGACCCCCTCAGTGAGCAGGTCCACCAAA GGGACTTCTCACAGGGGAAGCCCAACTCCTGTTGCAATGGGTTGATAGATTTC CTCAGGGTGGTAATTACCAATTCGTATTTTGACAAGCCTATGTGCAACCACAGC TGGCACTGGGGTGGGCAGTGGTGTTGGGTGGGATGGGGGAGAGTGTCTCAATC CTGAAGAGAAAATATAAAGCAGGTTTTGGGGAGACTTCTGGAGTCCTGCCCCT AGAGAGCCCCATTGTTGTTCTTTGTGCCCCCTCCTCATTCCCCCTATGTGGGTCT CCCTATGCAGGAGCTGTGAGAGAATGTGACTCTCCACAATTTTTATAATTCATC CTTCCTAGGAGATTGTTCATTGGCTCTTCCCTTGTGTCCCTTTGTCCCTTGCTCA TACTCCATGTTTCCTTTGTCAAAGGACTAAGAAAAGAGCATATTTCAGCAGAG GAGTGTTCCCATGTGGGTTGATTTCAACTTGGGTATTTCTAAAAGAGTCCTTGT GACATGTGTCCAGTGGAAATGGTTGCTCTTTTCCAGACTGGATTGAGGAATGG AGCCTGTTTGATTTGGTTAGTGATTCTTTGACATACTAATCTCAGCGTTTGGGT CTCCAGCATCCTCTGAAGATGTCTAGACTAGTAGAGGCTGCCTTTGTGACCTGA CATTACAACATTGGTCAAACCAGTCCTCTGATAATCAGAAGAACATGTCATAA TTGTTTAAAAAAAAAAAAAAGGCAAGAATTTCTCTCCAAGGAGCTTTAATAAA TGTCTCATTCCAGATAATGTCATACCAGAGAAAAGTGCTTGCTTTTAGAAAATT ATTTACATACATATATAAATATATATGTGTATCTATACAGTTATGTATCAAAAT TTTAAGCCCTGCAGAATTTCAATTTGTTAGAAATCTAACAGAAAAAAATTTCTA TATTGAAAGGTAATAGAATTTAACCCAGTGAGTTTACTCAAGGATTTTTAAATT TAAGTTAATAATTTCAGAGAAAATAACCATTTGGGTGTGGTTATAGTTTAGTAT CCATTACCTCAATCCAAGGAAAATTCCAGGCATTCCTCAACCATCAGGAAAAG GTACAGTGTGAAGGAACAGTTCTCAGCCAAATTTCACATTCTTGAGGCAACAG AAATCAAAACACTCAGAGCCATTGAGTGGAAAAACAATTTACTTTATTCCTTT ACACAAATAGGCTTGCATTGTTTTTGTTTTAATGTGATTTTGGTACTAGGGATA TAATTATTTCATTCCAGGAAATAATAAAAAAAAACAGACAGAGCCAATACATT TCTTTTTTTAAAGGAAACAGCAACAACAATAAAAACTCAGCACCAATATTTAA AAGCTTTTCCAAAATGTAAAAGAAGTGTTTAGCTTGCACCATGCATAAAGGTG CAGGCTAGTTGAACCAGGAAGCATGGCACTTCCTCTGGAGAAATCCAGAAAGA GTTGCTTCTAAGCTCCCTTTTCCCCCTGCAGGCTCTTGGCAATTGTAGGCTTTAG CAAATCCAGAATAATTTTCAATTCAAGCTAAAATAAAATCAACATTTGGAATG TAAATCTGATACACACACACTTTTCTAAGTCAAACAACATATTTCAAAACCAA AAATAAATACCTTTTAGATAATCAGTTATTTTCTTTGTCTATACTGGGCACCCA CCTACTAGTGCCAGTAAATTCAAGTTGAACAGATTTTTAAAATCACTATTATCT GGGTATGGGGGAAACTTCCCCACTTTTGAAAATGTTGGTAGAATTATAGGAAT GTCTGTTTGATTATCATTACCAAAGTGTCATGACAGTATGCCTTTGTAGTGAAC TCGGATTTTCAGGAGTTTGAATAGTTGGATATTTTAAAATCTAAGAAGAAAAG GCCTGTTTCCAATGTTGTTGAAGAATAATGAACTCTATTAAAAAGTGGAGAAA AAGATAATACATGTGGTCAAGGTTGACCACAAGGCCCAGGCACAACTACCTTG GCGATAATCTTCTAGATTCGTAACAGGTTAGAGCTGACTTTTTGTTTTTGTTGTT GCTGATGCTGTGTGATTCAGACTTCTCAGCCTAACCAGGAAGAGTAAGTGGAA ATGGTAGATGAAGAAGGGGTAGAGCTGGTGTATCTATAACTTTCTGATATTTG TCTGCCAAACTTGATATATTAGTAATTTTTTTATCTTTAGCTAAGATCAAGTCA CCCCTGAAACAACAGGAGATTCTAGTTTTAAAATAAGGCCACAAAAATCCTTA CGGAATGAAGAATGGCACCCCAGTTGGTTGTATAAGTCTCATAAGATAATGAT GTTGATTTTAAATATGGATGTCTCAATGCCTGTTTTCTATCAATGATTTGTTTGT TTCCAAGGTCGGGGAGGGAAAGAGGGGAGGGTTTATCTGTTTTAGAAAGTCTC AGAATACTTATAAAATACAGAAGTAGTTATTAAAATATATAGGACCTCACATA GGTAGATACAGAACTTACCATTGAGGCTGATGGGCTGTTGTGTGAATCACACA GGACCTTAAATGAGGCTCATTATTCTCACACACCAAAATGACTCTGACAGCCT GAAGCAGTTATTGCTAGAGCCCAAGCTTTCCTTGGAGGTTTTGGAGTTAGGTTG ATTGGAAGTAACCAGCTAATACCTTTTCTAGTGGAGAAAAAGACATTGCTACC AGCTTGTTCATCCCATAGAAGTCTTCCACTCTGCTCCATTTTTAGCAGCAAGCA TTTCATGTAGCATAAACCTTGGCAGATAAGTGTGCCTAAGGTTTATACAGTCTG TCCGCTTGGATGTATACAAATTTAGATACATATTTTAACATGTGTTCTCATAGA TGACTTTATAACAACACACATTACCTATAGGTGTCTAGACTGTGTACATACAAG TGTGTACAGACAAGCTTCATACGTATATACTGTAATCCGTTACAACAAATAAA TTTTAAATCATCGTTTAACATGTATGTGGTACTTCTACAGTGTACATTGTTTTCA TTATTTATTGTAACATTGAAAACCACAGTGCAGGGAAAACAAAAGTATCCCAG CATCTTCATCCTGTACACTTGGAATTAATTTCATTTGGGCATATCCAAGATAAA CTCAACTTTCAAGAAATCTTGTATATTATTTAATCATCTGTGTTAGGATGACAC CTATGATTGATGACTTCGGTTGAATAGCTTTATTCTGGATTTTTCATAACTAAA GCTAAATCCAAAGACCTGAAAAAGGACAAAAAGAAAAAAAAAAAAAGAAAA AACAAAGAAAAAGAAGAAAAAATAATAAAGTCAAGCGCAAACTGATGGGGA GACAGTGGGCTCTGGTTTCCAGGATTGAGACAATGGTACTGCGGTCTTGGGGA GACTGCGTTAGCTAGTGGGGAGTGGTGATTTTTTTCATGCTTGTCACATCTAAA TGGTCTTTAACATGAGAAAGTTTTAGAGGTTATAATTTCCTGCTTTGTTTTTATT TAGACTATCAAATGAAGTTATACATGTTGTCAGTCAAAAAATGAAGACACCCT CTGCCCCACCCCACAGAATGCTTTTTATCTTGTCTCTTTGGGTTATGACCCAAC AAGCTAAGTACCATTAATGTAATTAACTTATTTAAATTAGTTCCTAGTACATAA ATGTATAGGATTTGGGTAATTATTTAATCATCCTTCCTTAGTTTGATTCTACTCC TTGTACTTATTTATCAAAACCTAGACCAATGGTGCATCAGAGATGCAAAATTCT ACTTGGAATACTCTTGAAGTTTAGTTTGCTTTATAAAGCAGTGAAATTCTGTTA CAGACAGGGAAGAAATACAGGTTACAAAAAGAGAATTTGGGATATTCTTCCCT CTTAAATTAACTTTTAAAATAGTCTAAGTAACAATTTTTAAATTATTTAACTTA AGTTCGCAGCCCCACCTGGTACCAGGCGAACTTCACCTCTTAATTATTGTGGCC CTCGGAGCCTTCATATTGTAACTTATTTATTTAACTTATTCAGCATCTGTGAAA GGTGCACTGTATAGTTTATATTTTTAATTTAAAACAACAGAGAGCACTGCAGTT TGTTTGCTGTCAGAACAACAGAGCAAATTTTGTGGACAAGCAATGACTATTCA GCCTGAACCTGTGCATTCAGAAAACATAAGCTGAGACCCTGCTTCACCAGCCT GGATTTCGGGGCTTCTATACAGAAACTGGAAAAATAAATTTTAAAAAAATCGT AAACAAAAAGAGAGAAACCCTTACACTAGCTGCTTCCAAGAATGAACTCTGTG TGTATGTAAAGCAACAAAACAAAAAAGGAAAAAAACAAAAAGCAGAAAAAA GAAAAAAAAAATGAAAAACTTTCTATTTCTAGTGAGAACCAAAGAAGGCTACC TCACTGACTTTTTCCATTTGTAATTTTAATCGTGTTGATGACACCAAAGATACC AAAGATTTCTTTCTCTGTGCGGTCTGCATTTTGCTTGTGCTCTTTTATAATTTGA ACGATTTTCTCTGACATATGGTATGTACAGCCACAGCTCAGATACCCCAAAGA AATAATTATCTATGCGACGGCGGCTGCTAATTTGGAAAGGGATATTTTCTGTGT TTCTCTTATATGTTTGCTGTCTGCTCGACATGTTCAAGATGCGAGTTCAGATGC TGCTGTAATTGGATTCCTTAAATTCTGATTACAAATTGAGGAAGGAAACTGGTT GGAAATGGCCTTCAGTCCTAGCCATGGCCTCTATCCCCGCTGGGACCTGTCAC AGTAAAGACTGCCAATTACTGAACCACAGAAGCTCTGACCATTGAGTAGTTGA GCTGGAAGAGACCTTAGGAATCATTTAGTCCAAGCCCCGGTGGCCCAGAGGAA TGAAATAGTTATCCAAATCAAATAACTCTTGAGAGTGAAAGCCCACACATGCC TCCTGGTTCCTGCCCCAGTGCTCCGCTTATTGTACAGTGCTACCTCTGCATGAG AGCGGTCCCACATTGACAAATAGGATGGTGGCAATCCTTTAGCAATGAGCAGG GACTGGGGTTTATCTCTTAACATTTTCAGCTGTAAAATTAGTCACAAGCATTTT CAGTGTCCCATTAGTACATAGTCACATATGGTCGGTTGCTTCGTGAAGGTGGCC TGTCTTGAAATACTAGGGCTCATACGGGATTTTTGCCCTAGGAAAAACATGTTG ATCCCAATGATGTGATCACTTTTGAACCTTTCCATTACAAAGCATTGTATAGAT AACTTTTTAATTCAGTAGGAGGAGAAAGTTCATTCTTGGCCTGTTGGCTTTGAT TATTATGGGTACTTTAAAGTCAGTATTTATCAAGAAAGGGAACTTGACCACCA TTGGCACATGTGACATTTAAGCTCTTCAGCCTTTTCCTTTTTAGTTGTAGGTGTT TACATTTCATTTCTAAGCCAACTCTGTATTTATGAGAGAAGTTTAAGCCTTACA TCATTTGATACTAAAGGGTTATTTGTGGTAAATGAAAAATGACCCCAAAATTA CAGAGGAATATGCCAGTTTAAGAAATGGCTACTTAAAGTTGCTTCTCTCTTTCC TTCTTACTCATGAAATTAATTGGTCTTCTTCAAGTTTCTTTAGATTCCATTAAAT GATTAAATCACTATTAAGAGCCATTCATCAACGTGATTTGTGTGTTAGCCAATG AATCTGTCTCAGCTTTTGACCAAATGGGTTTTAGACAAATGCAAAGATCTGCCT CTAGTCCATATGGCTCTTTTTGAGTGCTAGTATTTTGCATTTCACATAATGTAGT TATTTTGAGCTTTTAAAGAGAGCATTTAGACAAAGAAGCAAAGAGAGGAAGG GACCAATCAACTCATCAGTTCCATGCATCAACAAAGCATAGCTAGTAGAGGAA TATAAATGACAGATTGACAAACTGTAGGAAACACTGTTACTCTCTTTCTGAAGT TTTCAAGCACCATCCTATGTGAAAGTTCCCTCCTGTCCAAACAAGCTCAAGGCC CATCTTCTCCCTATACAAGGCAAACCTGTAAGGCCTTCCTTCCAAAGAGTACAT TGCTTTGGTTTTCTTCCTAAATTCCTATTGGAATTAGAACTCTCAGAATCCCTGG GAGACAGAGCAAAGATGACTTAATTCATTGAGCAGCAGAGCTCCCTATAAGTG AACATCACCTTCCCCATCTTTCCTACTGCCACACCCATACGAGAGAGGATCTAG AAAGAGCGATGGCAGCCTGAACACAGAAAACATCCCCACTTGGCAGACCTCTC CTCAGCAATCCCCCCAGCCTCATGCTTCACTTGCAAAGTGTGACATAACCACG GGACGAGTGCCTTGCTTGAACCAAAGCAACGATTTAGCCAGTCTGGACCTCTC TGTGCTTTTTTTAATTCTTCCTGTGAATACCTCAGCTTCAACTGGGCCTCCATAC AGTCAGTTGGTGGGCTTATTGTACTGTGGTGCTTTGCAATGCAACCCTGCAAAG AACAAGATTTGTACTAATACCAAAGGTTCTTTCTCTATGTCTCCTCCTCTGCCTC CCTCGTTCTTCCCTTTTTTCTAGTTCTTCACGGTTCCAAAGCTTTACTATGAACC TGGGCATGTTGGCAATGCAGACCGCGCAATTCCTTACCGAATTTTCTCAGATAT ACCTCATAGACAATAGTGTTTAGAGTAATGTTATTATAGCGTATGTAATAAATT ATTCACTGTTTCTTTTGGTAACTGTGATTTAAAAAAAGAAAAAAGAAAAAAAA GCTTTATACGTTTTAGGTTGTGCTTTTGTAATAGATGAAAAAAGGTGCGCTTAA AAAGAAAATGTATGTTTTTTTCCCCCTTTGGATTTTATTTATGCTGGATTGGGG AAAGTTGCAGAATGAGCCCAAAGTTTACAGTTTCATATTTTGCTGAAGAAACA ATCTGTGTTCATTTGCTCTGTTGAAAAGAATAATTATTTTCTACATTTGTGCCAC TTGGTCTGAACAATTAATTGTTCCGTGTTAACAGTGTAGTATTATGATTAGCAA CTGCCAATCAGTGCTATAATTTTATGCATGAGGCTAAAAATTTAGCAGTGTGAT GCATTGTGGTCTTAATAGCAACATTTTTCATTTTGAACTAGATCTTCCCCTTTGG TTCAATGGACTTTATTTATGCATGGGCGCCTATTGTTTGTTAGCAGTTGTGGAA CAGTTGTGTATACATTAAACTGTGAAAATGTACACAGTTCAGCCTCAGACGGT GGTAATATTGGTTTTATTGGGAGATGTGTCACCTCGAAAATACCCTTTACATCT GTTGGGATCTGAAAATGAGTCACATTGAATTGGGTTCCAGCTTTATAATGAGA AACGTTATTCCTAATTTTTGAGTTAGCCAATTTGCATTCCACAAATTGGGATCC TCATAACCCAAATATATCACCGTATGTGAGAGGGATTTGAAAGCGAGTATTGA AAAACTCACCTTTGCATATTTAATTTCCACCAAAAGGAGTTATTTTGGCTTTAT GCTCATGAACTTAGACCTAACTGGCCATGTATATGTAGATGCAAATTCATCTAG CTGTGGCCCTCTTTGATCTCTGCTTGGGAATGGCTATTTTTGACTATGCGTGGTT TCTTCTCGTATTTTGTGATCAGGTCAGCTCCCAGTAGAAACTCAAATGGCATCA ATATTACTAACTCTTCTCTGCCCACTTCTCTTTTGTCCACTCTCCTAGACATTCC CACCAACTGTTCCAGTGATTTGGGCAAAAATACGCAGCCATTTCCCAAAACTT CACATGTGCAGCTATCATGGCTGTCCCTCCCTAGACTTGGAGGTGACTCTCACT TAATTTTTACCTGCCCAACAATGTTCCATCTACCATCTAAAAGGTAATATAAGA AGAAGTTTTGAAACCCACTTTAGGAAAACCATCTTCTTTAAATCCTTCAATTAT CTGAGGCCTCTATATGTCAAAACTATTTTTCAGTTGCAGGGGATTGGGCAAACT TGTTCTTTCTTATACTTGGGTTCAAAGACCCATTCTCCAGTTTCATATTTCCCAA ACCAAAATGCTTGACATAAAGCCAAATCAACTGCCAAGCACACTTTATTTTGC ATAGGAGTATGCAGCCTAGGGAACCTTGGTTGAAAAGCAGCAGTCTGCTATGC AAAATATTGGAAATCACTGACAGTGTAGCATTCATATTATCTGTCAATGAGGG TATATTGGGAACGTGCTCTCGTGAATAATAAAAAGCAACATATTTTTATTTGGC CTTATAAATTAGGTTGTGGTAATGTAAACTTTGATATATAGTCTTTTTATTTTTC TCTTATTAATCTGCCAAAGATGGGAACAGATACAAGAATTTTTCAAATTGGCTT TTGTAAGACAATTGATGATTGTAATAGTGTTTAATCTTCCAGAAAGCTTTATAT GTTGTTCCACAATAAAATTGATATTTGTTTCAGCAAAGTTTTCCTGACACTCAC AAACCCACAAACTGTTCCTCTTAATGCAGATATTGTAGAATCTACAAAGTTCA AATCCATTTTTGATCCAAAGAAAGTAGAGGAGTATTTGAGACATGAGTGTACC CAGCCCTTTTTTTAATCACAGGCAATGCATGGGTCTGGCTGGTTACACTTTGCC AAGAAGACTTGTCTTATGAAACCCAAGGTATATTTTGTTATGCCATTTTATGTC CTTTTCTTTTAACATTGTGGAAAGTGGTATGTTGAATCAAGTGTAAGCTGAGTT TTCCAGACAACTGAAGTAGCTACATCATGAATGTTATTTTGTTATTAAAGGGTT TTTACTCAGTGCTTTGTGCCAATGGATGTCCTTTTCCTTGGAGACACATAACTA CAAAATTACCTCAGCTTGGCCTGGTTTTCTCTCCTGCCCTCTTGGGGAAACATG GGCCTGGCCTGGGAAAAGGCAGGTCATGGGCTGGAAGGTAGGTTTTGGTACTA GGAAGAAATCTCTGTATCTGTCAGCTTTAAAGAGAACTGGGCCAAAAATCTCT AACCTCACTCTCTCTGGACTCCAACACTTCCCTGCAATCCTTTGGTCTTGAGCA TGTGCCAGCATGAAGGCAGACTCCAGTTCATACATGAAAGGCAAGAAAAAGA AAATAGTAACCTTGAATCTTCTGTGGGCCACCAGGCACTCACCTTTCCCCACCT TGCACACTATCCAGTCAAGGCTATTGCAGCCCATCTGGTGGCTTTACATGGGAC ATTACCAAAGGCTTCTTCCTCCATCCTGGGGTTGCAAAGGATCCAGGTCCCCTC CATCCAGTGGGGCTCTTCCACATCAGAAGTCCCCCTCCCACCATCCTCTGCATC CTGTTTAGCTATCCCATCTATACCTTTTGGAGATGATTATTTAGAAAACAAAGA AAGGTATGGAATGGGGTTTCCTATTGTTTGCTAGGTTATATTTTAGCAATTCTC AATTCTTTGATCTGGAAAAATACAAGAGGGAAAAGGAGACCCCACTATCTCCC TGTGCTTTGCTCCCATCTCAGGGGGCAGGGGCAGTGCACATTGCCTATGCTGTT GATCTGTCTTGGGCGACAGGCTGAATCACAGCTATTGCCCCAGCCAAAAACAT GGCCCATCAATGCCTACTTTATCTCTGCTTGAAAATCCTATTCAAAAAGTTGTA GAGTTTGAGGTTTTTATCCCCCCATATCCTTTGCTTTGGTCCAGTTTGGCCTTTA GCATAAGAGTCAGCTTTATCTCTAGGAAAGTTTTTTCAGATTATGACAAGGAA CCTGCCACCTGGGAAGAAAAGAGTCCGAAGACTAGCAATCGGATAGGTAGTC ATACCATTAACAGATACTTCCTTGAAGGTAGAATATTATTTCCTTTCTTTACAG TTTTGTGTTACACAAGTCCAAGTGGTGCCAGCAAACTTCTTACCGTGAAATGTT GTAAAACACCTGGCATACTGAAATTTCTGAAACAAAAACACAAGCTCCACATT GATAACTTGATAAATAACCACTAAAGTTTAGATGCAGGGACTGAGATGATACA GGCAAAATCTTGGTGTTGGTTTCTCTTTTAATTCGTATCTTCGATCACCTAACCT TTCTCAATCCAAGAGCAGTTCAGTCTTTTCTCCCCAAGTCTAGGATGCCAAAGA GCATCATAGGAAAAGATAATTAGGGATTGACCAGCATTTCAATTAGTTCTCTTC TTCATCTTTGCATTTCTCAAAAGTGTTCTCCTGGACCAGAGGGAAAGAGCTGGT CCATTTTTTTTCATTCTTTCTATTCAAATTTTTCCACCCAGACAATACTTTATTA ACACAGATACTGTAGATCCTTCCTTGGTCAGTGAATTATTACAAGAGGAGCTA TCCTTCCACCAAAGTGAGTGAAAACAAGTTCCAGTATCTTTTCTTCCATCCAGT TTTGTTCTCAGAATCCAAGTCAGTCCTGGGTCTTTTCTCACTTTAGACCCTGGCC TCAGATGTGTTTATTCTTGCTATTTAAAAATACCTTTAAATTTCACATGCTGGCC TGCAGAACTTGCATCCTTTGTTCTATACTGTTGACTGCTTGATGGTATTGAAAG GTGACTATAATGAGGGAAGAAAGGAGGAGGTAAAGAGAGAAGAATTTGTCCC AGATCTGTTTAAAGTTTCAAAATTTAAAAAGGGACCCATTAAATTATGGGAAA ATGGCTATAGAGTGTGAGCCTCCGTTGACCATATGCTCAAAGACCGTACTCTG CCACCTGCCTTCCAGGTAGCTATTCTAGAAACTCAGTCCTTTGTGGAAACCCAA CTACCTTTTAAAAGTCTCTTTCCAGATTCCAAAAGGACAAGAGATCAGAGAGT CACATATACGCCTCTTGTTTTATTTTCTTGCTTTCACGGGTATTATTGCCAAGAA AATCGTAGGGAAAAACTTTAAACTTTTCTTTTCAGTTGATCCCTTTGACATCAC CTCTCATGTTTAAAATCAGGAAAACACACCCCTAAAATTTGCACTCTCTTCCGT TTTGAAAAAGAAAACCCACACACAAATGCACACTATTACCGTCTTTCACCCTG CGCTATATTTCCAAAGTGTATTATAATCCAGATATTGCCCCATCTCAAACATGT TAAGTCAGACTGTGCTGAAAGACTTTCCAGGGACGGTCAACAGGGTATATGTT CAGTGGCTGCCCTGAAATCCTGGTGGGGATGAGGATCACGCTTCATCATCAAG GGGATGCCCATCCCCTGATAAGCTCCCAGTCCTTTTGGAAGATTTCTTTGAATG TTAATTGCATTTTCAGTTTTGCTCATTTCCCACCCCAATGTTTTGTCTGCAACAT CGCTTACACTGGATTCTTTCTATTTTTATTCCTATCATTAAATGGTAGTGCTGTA AATTCTGCAATTAATGTTAAATAAACTGCTTTAATTCATTGA
> 6
AGCTGGGTCCTCATCCCGGAGCGAGAGAGGCATCTGCTGACCAGGCGCGGGG CTGAGCGCACTCCTTCCACTGTACTGGGGGTGTACAGTGAGGAGTGGACGGGT TCGCTCTGCGCCCCCCTTACCCTAGCCATCTGCGCCGCCTCCCTGGCCCCTCAG CAGGTGGTGCGGGCCCGGACAGCGGCTGGGGGCCAGAGGAACTGCGGGGAGA GCGTGGTGGTGCCGGTGCCCGTCCAACCCAAACTTTTTAGTCTGAGTGGTGGCC CGCGACGCCCCGCTTGGGTCTTCTTTCCATCCACTGGGGATGGGGGCGGGGGT GGGGGTAGCCGGCGGCCGTGGTTCCGGAGCGGGAGTCGGAGGTGAGTGTGCG AACTGGACCGGGGCCCCAGAGACTTCGGACTCGCTCTCGGGGAGAACGGTGA CCGAGGAGCCCCGGTGGAGTTGAGCTCAGAGTATTGATGCTAGCAGAAGCAG ACAGACCCCAGATAGCCTTCCAGCTGCGTGCCAGGGATGGTGCCTTGAGTGAA TGACCCCCTTGGAGAACATTCTTCCGCATCCCTCGCCTCAAGCCAGCCTCAGAC AGAAAACTGAAGATTCAGCAGATCCAGTGCTTCCTGCTCCTCTTCTGCCCAGG AACACGCTTGCCTTCCCCAAGGCTTCCAGAAGCTCTGAGGCAGGAGGCACCAA GTTCTACCTCATGTTTGGAGGATCTTGCTAGCTATGGCCCTCGTACTCGGCTCC CTGTTGCTGCTGGGGCTGTGCGGGAACTCCTTTTCAGGAGGGCAGCCTTCATCC ACAGATGCTCCTAAGGCTTGGAATTATGAATTGCCTGCAACAAATTATGAGAC CCAAGACTCCCATAAAGCTGGACCCATTGGCATTCTCTTTGAACTAGTGCATAT CTTTCTCTATGTGGTACAGCCGCGTGATTTCCCAGAAGATACTTTGAGAAAATT CTTACAGAAGGCATATGAATCCAAAATTGATTATGACAAGATTGTCTACTATG AAGCAGGGATTATTCTATGCTGTGTCCTGGGGCTGCTGTTTATTATTCTGATGC CTCTGGTGGGGTATTTCTTTTGTATGTGTCGTTGCTGTAACAAATGTGGTGGAG AAATGCACCAGCGACAGAAGGAAAATGGGCCCTTCCTGAGGAAATGCTTTGCA ATCTCCCTGTTGGTGATTTGTATAATAATAAGCATTGGCATCTTCTATGGTTTTG TGGCAAATCACCAGGTAAGAACCCGGATCAAAAGGAGTCGGAAACTGGCAGA TAGCAATTTCAAGGACTTGCGAACTCTCTTGAATGAAACTCCAGAGCAAATCA AATATATATTGGCCCAGTACAACACTACCAAGGACAAGGCGTTCACAGATCTG AACAGTATCAATTCAGTGCTAGGAGGCGGAATTCTTGACCGACTGAGACCCAA CATCATCCCTGTTCTTGATGAGATTAAGTCCATGGCAACAGCGATCAAGGAGA CCAAAGAGGCGTTGGAGAACATGAACAGCACCTTGAAGAGCTTGCACCAACA AAGTACACAGCTTAGCAGCAGTCTGACCAGCGTGAAAACTAGCCTGCGGTCAT CTCTCAATGACCCTCTGTGCTTGGTGCATCCATCAAGTGAAACCTGCAACAGCA TCAGATTGTCTCTAAGCCAGCTGAATAGCAACCCTGAACTGAGGCAGCTTCCA CCCGTGGATGCAGAACTTGACAACGTTAATAACGTTCTTAGGACAGATTTGGA TGGCCTGGTCCAACAGGGCTATCAATCCCTTAATGATATACCTGACAGAGTAC AACGCCAAACCACGACTGTCGTAGCAGGTATCAAAAGGGTCTTGAATTCCATT GGTTCAGATATCGACAATGTAACTCAGCGTCTTCCTATTCAGGATATACTCTCA GCATTCTCTGTTTATGTTAATAACACTGAAAGTTACATCCACAGAAATTTACCT ACATTGGAAGAGTATGATTCATACTGGTGGCTGGGTGGCCTGGTCATCTGCTCT CTGCTGACCCTCATCGTGATTTTTTACTACCTGGGCTTACTGTGTGGCGTGTGC GGCTATGACAGGCATGCCACCCCGACCACCCGAGGCTGTGTCTCCAACACCGG AGGCGTCTTCCTCATGGTTGGAGTTGGATTAAGTTTCCTCTTTTGCTGGATATT GATGATCATTGTGGTTCTTACCTTTGTCTTTGGTGCAAATGTGGAAAAACTGAT CTGTGAACCTTACACGAGCAAGGAATTATTCCGGGTTTTGGATACACCCTACTT ACTAAATGAAGACTGGGAATACTATCTCTCTGGGAAGCTATTTAATAAATCAA AAATGAAGCTCACTTTTGAACAAGTTTACAGTGACTGCAAAAAAAATAGAGGC ACTTACGGCACTCTTCACCTGCAGAACAGCTTCAATATCAGTGAACATCTCAAC ATTAATGAGCATACTGGAAGCATAAGCAGTGAATTGGAAAGTCTGAAGGTAA ATCTTAATATCTTTCTGTTGGGTGCAGCAGGAAGAAAAAACCTTCAGGATTTTG CTGCTTGTGGAATAGACAGAATGAATTATGACAGCTACTTGGCTCAGACTGGT AAATCCCCCGCAGGAGTGAATCTTTTATCATTTGCATATGATCTAGAAGCAAA AGCAAACAGTTTGCCCCCAGGAAATTTGAGGAACTCCCTGAAAAGAGATGCAC AAACTATTAAAACAATTCACCAGCAACGAGTCCTTCCTATAGAACAATCACTG AGCACTCTATACCAAAGCGTCAAGATACTTCAACGCACAGGGAATGGATTGTT GGAGAGAGTAACTAGGATTCTAGCTTCTCTGGATTTTGCTCAGAACTTCATCAC AAACAATACTTCCTCTGTTATTATTGAGGAAACTAAGAAGTATGGGAGAACAA TAATAGGATATTTTGAACATTATCTGCAGTGGATCGAGTTCTCTATCAGTGAGA AAGTGGCATCGTGCAAACCTGTGGCCACCGCTCTAGATACTGCTGTTGATGTCT TTCTGTGTAGCTACATTATCGACCCCTTGAATTTGTTTTGGTTTGGCATAGGAA AAGCTACTGTATTTTTACTTCCGGCTCTAATTTTTGCGGTAAAACTGGCTAAGT ACTATCGTCGAATGGATTCGGAGGACGTGTACGATGATGTTGAAACTATACCC ATGAAAAATATGGAAAATGGTAATAATGGTTATCATAAAGATCATGTATATGG TATTCACAATCCTGTTATGACAAGCCCATCACAACATTGATAGCTGATGTTGAA ACTGCTTGAGCATCAGGATACTCAAAGTGGAAAGGATCACAGATTTTTGGTAG TTTCTGGGTCTACAAGGACTTTCCAAATCCAGGAGCAACGCCAGTGGCAACGT AGTGACTCAGGCGGGCACCAAGGCAACGGCACCATTGGTCTCTGGGTAGTGCT TTAAGAATGAACACAATCACGTTATAGTCCATGGTCCATCACTATTCAAGGAT GACTCCCTCCCTTCCTGTCTATTTTTGTTTTTTACTTTTTTACACTGAGTTTCTAT TTAGACACTACAACATATGGGGTGTTTGTTCCCATTGGATGCATTTCTATCAAA ACTCTATCAAATGTGATGGCTAGATTCTAACATATTGCCATGTGTGGAGTGTGC TGAACACACACCAGTTTACAGGAAAGATGCATTTTGTGTACAGTAAACGGTGT ATATACCTTTTGTTACCACAGAGTTTTTTAAACAAATGAGTATTATAGGACTTT CTTCTAAATGAGCTAAATAAGTCACCATTGACTTCTTGGTGCTGTTGAAAATAA TCCATTTTCACTAAAAGTGTGTGAAACCTACAGCATATTCTTCACGCAGAGATT TTCATCTATTATACTTTATCAAAGATTGGCCATGTTCCACTTGGAAATGGCATG CAAAAGCAATCATAGAGAAACCTGCGTAACTCCATCTGACAAATTCAAAAGAG AGAGAGAGATCTTGAGAGAGAAATGCTGTTCGTTCAAAAGTGGAGTTGTTTTA ACAGATGCCAATTACGGTGTACAGTTTAACAGAGTTTTCTGTTGCATTACGATA AACATTAATTGGAGTGCAGCTAACATGAGTATCATCAGACTAGTATCAAGTGT TCTAAAATGAAATATGAGAAGATCCTGTCACAATTCTTAGATCTGGTGTCCAG CATGGATGAAACCTTTGAGTTTGGTCCCTAAATTTGCATGAAAGCACAAGGTA AATATTCATTTGCTTCAGGAGTTTCATGTTGGATCTGTCATTATCAAAAGTGAT CAGCAATGAAGAACTGGTCGGACAAAATTTAACGTTGATGTAATGAAATTCCA GATGTAGGCATTCCCCCCAGGTCTTTTCATGTGCAGATTGCAGTTCTGATTCAT TTGAATAAAAAGGAACTTGGAAAACA > 7
CGGCGGCGGAGGCGCGGGGCCACCCCCAAGCCGAGCCGGGGTGGGACGGCGC GCCTGGCGACCGCGCACTGAGACTGCCGTGCCGGACCCCCGAGCCGGAGCCG AGCGCGCCGAGGCCGGGGCCATGGAGAAAGCGCGGCCGCTGTGGGCCAACTC GCTACAGTTCGTGTTCGCCTGCATCTCGTACGCCGTGGGCCTGGGCAACGTGTG GCGATTCCCGTACCTGTGCCAGATGTACGGCGGAGGTAGTTTCCTGGTCCCCTA CATCATCATGCTTATCGTGGAGGGAATGCCGCTCTTGTACCTGGAACTGGCTGT GGGGCAGCGCATGCGGCAGGGCAGCATCGGCGCCTGGAGGACCATCAGCCCG TACCTCAGTGGTGTCGGGGTCGCCAGCGTGGTGGTCTCTTTCTTCCTCTCCATG TACTACAACGTCATCAACGCCTGGGCCTTCTGGTACCTCTTCCACTCCTTCCAG GATCCCCTGCCGTGGTCTGTCTGCCCACTGAATGGTAACCACACGGGCTACGA TGAGGAGTGTGAGAAGGCGTCCTCCACACAGTACTTCTGGTACAGGAAAACCC TCAATATCTCGCCGTCCCTCCAGGAGAACGGGGGTGTGCAGTGGGAGCCGGCG CTGTGCCTCCTCCTGGCCTGGCTGGTGGTGTACCTGTGCATCCTGCGTGGCACC GAGTCCACTGGCAAGGTGGTGTATTTCACGGCGTCACTGCCCTATTGCGTGCTC ATCATCTACCTCATCAGGGGCCTCACGCTCCACGGAGCCACCAATGGCCTCAT GTACATGTTCACTCCCAAGATAGAGCAGCTGGCCAACCCCAAGGCCTGGATCA ATGCAGCCACCCAGATCTTCTTCTCACTTGGCCTGGGCTTCGGCAGCCTGATCG CCTTCGCCAGCTACAATGAGCCATCCAACAACTGCCAGAAGCACGCCATCATC GTGTCCCTCATCAACAGCTTCACCTCCATATTTGCCAGCATTGTCACCTTCTCC ATCTATGGCTTCAAGGCCACCTTCAATTATGAAAACTGCTTGAAGAAGGTGAG TCTGCTGCTGACCAACACTTTTGACCTTGAAGATGGCTTTTTGACAGCCAGCAA CCTGGAGCAGGTGAAGGGCTACCTCGCATCTGCCTACCCAAGCAAATACAGCG AGATGTTCCCGCAAATCAAAAACTGCAGCTTGGAATCGGAGCTAGACACGGCC GTCCAGGGCACTGGCCTGGCATTCATCGTCTACACAGAGGCCATTAAAAACAT GGAGGTGTCCCAGCTGTGGTCGGTGCTCTACTTCTTCATGCTGCTGATGCTGGG CATTGGGAGCATGCTGGGGAACACAGCGGCCATCCTCACCCCTCTGACAGACA GCAAGATCATCTCCAGCCACCTGCCCAAGGAGGCCATCTCAGGTCTGGTGTGC CTTGTCAACTGTGCCATTGGCATGGTGTTCACGATGGAGGCTGGGAACTACTG GTTTGACATATTCAACGACTACGCGGCCACACTGTCCCTGCTGCTCATCGTGCT GGTGGAGACGATTGCCGTGTGCTACGTGTACGGGCTGAGGAGATTTGAAAGTG ACCTTAAGGCCATGACCGGCCGAGCTGTGAGCTGGTACTGGAAGGTGATGTGG GCTGGCGTAAGCCCACTGCTGATTGTCAGCCTCTTTGTCTTCTACCTGAGCGAC TACATCCTCACGGGGACCCTGAAGTATCAAGCCTGGGACGCCTCCCAGGGCCA GCTCGTGACCAAAGATTACCCGGCCTATGCACTGGCTGTCATCGGGCTGCTTGT GGCCTCCTCCACCATGTGCATCCCCCTGGCGGCCCTGGGGACTTTTGTTCAGCG TCGCCTCAAGAGGGGAGACGCAGACCCCGTGGCCTGAGATGTGGGCTTCCCAG CCGCTCACGGTTTTACAGATACTATTTACAGGCGGAAACTCCTCGGCTGCTTTT TCAAATGCTTAAGCCAGGAGTGCTCAGCCCATCAACTTCCTGAGTGTCTAAAG AAGATGAGGAAGGTGTGCAGGAAGAAAACTCCCTTGGGAGAACGCACACCCT CCCGTGGTGGCTGTTCCTCCCTGTCACCTGCCTCCTCATCATGGAAGGGGGTGG GCTATGAAAGCCGGTCTCAAAGATAACTGCATCCTTCATTCCAGGAAAGCCCT AGAATTAGGGCACATTGCAAACTGAAATATGACTATAATTCTTATGGGACCAA ATTTAAGCAATTTTTGTTTTTGGCTGAAGAGACACCAAAATATTAGAGGACAA ATATTTTTAGATCCATTTAAGGAGTTTTGAAGTGCCTAAGATGACCTATTTGTC AGTGGTGCAAAATTAATTCTCTTCTTTTTTGAGTTGTAGTGAATATGCAATTTCT GTGTTCCCCTTCCACCCTTTAAATCTTAGGATGACAAGTTATAAAGAAAGAAG ATCTTTGTCTGGGACCCCCAAAGGGATCCTTTCTCTAAGGTCTCTGACGGTGGG TCCAGGACCAGACCTCTCTACAAAAAATTGCCCCAACTACAGTTTGCAACCCC AAACCACATTAGAAGTCTGTGCAGACATCCCTCCGTGGTGTGTGTCTTGGTGCA TTGGAAAAGGAGTCAGGAGCCACTGTGAGGTGAGAATGAAAGTGGATCTCAG CTGGGCACGGTGGCTCACGCCTGTAATCCTAGCACCTTGGGGGTCAAGGTGGG TGGATCACTTGAGGTCAGGAGTTTGAGGCCAGCCTGGCCAACATGGCGAAACC CCATTTCTACTAAAAATACAAAAAAATTAGCTGGGAGTGGTGGCATAGGCCTG TAATTCCAGCTACTCTGGCTGCTGAGGCACAAGAATCATTTGAACCTAGGAGG TGGCGGTTGCTGTGAGCCAAGATCATGCCACTCCACTCCAGTCTGGGCGACAG AGCAAGACTCTGACTCAAAAAAAAAAAAAAAAAAAAGTGGCTCTGACTTTCC CATAGGCTTAATATTACATTTGGACATCGTGGCCAACTCTATCAAGACCACAA ATACCACTTACAATTAATTTTAAATTATTCATCTGTACATAGTTTTCTAAAATGT ATATAATTCAAACAGAGCATCTTGTAACTGAAGACACACCATATCTATGATAT CGCATTAGTCCATGTGGGGAAAAGAAAGATCAGATTGTTACTGTGTCTGTGTA GAAAAGGAAGACATAAGAAACTCCATTTTGATCTGTACTAAGAAAAATTGTTT CTGCTTTGAGATGTTGTTAGCCTATAACTTTAGCCCCAACTCTGTGCTCACAGA AACATGCGCTGTAATGAATCAAAGTTTAATGGATTTAGGGCTGTGCAGGATGT GCCTTGTTAACAATATGTTTGCAGGCTGTATGCTTGGTAGAAGTCATCGCCATT CTCCATTCTCGATTAACCAGGGACACAATGCACAGCAGAAAGCTGCAGGGACC TCTGCCCAAGAAAGCCTGGGTATTGTCCAAGGTTTCCCCCCCACTGAGACAGC CTGAGATATGGCCTCATGGGAAGGGAAAGACCTGACTGTCCCCCAGCCCGACA CCTGTAAAGGGTCGGTGCTGAGGAGGAATAGTGAAGGAGGGAGGCCTCTTTGC AGTTGAGATAAGAGGAAGGCTTCTGTCTCCTGCTTGTCCCTGGTAATGGAATGT CTCGGTGTAAAAAGCTGACCATTCCCATTCGTTCTATTCTGAGATAGGAGAAA ACCGCCCTGTGGCTGGAGGTGAGATATGCTGGCAGCAATACTGCTCTGTTACT CCTTGCTACACTGAGATGTTTGGGTAAAGAGAAACATAAATCTAGCCTACGTG CACATCTGGGCACAGTACCTTTCCTTGAACTTATTCGTGATACAGATTCCTTTG CTCACATGTTTCCCTGCTGACCTTCTTCCCACCTGTTGCCCTGCTACACTCCCCT CGCTAAGACAGTAAAAATAATGATCAATAAATACTGAGGGAACTCAGAGGCC AGCGCCGGTGCGGGTCCTCCACATGCTGAGCGCCGGTCCTGGGCCCACTGTTC TTTCTCTATACTTTGTCTCTGTGTCTTATTTCTTTTCTCAAAAAAATTTTTCTTTT TTTAACTGCAATAAAGTAGGTCGTTACCCCTAAAGTGAGCGAGTCCCTTCCTGC TCTAACGTCCAGTGCTTCCTTGAGATCATGGAATTCTGGAGAGTTTCTGTGGAT ATATTTGCACAGATATCTTTGAAGACACAAACACTCACCTGGGACGTTGGCCG GAGATGTCTTTTTATTTTTGTGCTGTAAAATTCTCTTACAGCAAAAATAGGCTT TAGAAAGGTCTTCTACTGTCTTCAGCAACCATCTCATCTTCCAGCTTCACCTGA TTGTCCAGTTATCATACATTTGACTTTCAAATGTATGAACCAGCATGTACCCCA TGGATTTAATCTTATCTACCCCGTGGATTCAATCTTCTTATCAGAAGGTTCTTTT ATGTCAAAAAACCTGCTGTCAAGGCTTGAAGAGCCGGCACACTCAATGGCAAA CACAGCACCGAGTCTGCTCTGAATCCTGGAGGATCTGGCCCTCCTCTCAATCCC CACTCACAGTCACCGTCTTACAACTCAGGGCCACCTGGGATCAGTCATCAGTC AGGGTGCGTAAGCCTTGAATACCAGGTAGCCTCAGGAGTGAAAAGATAAATGT CCTAGATCATTACCTTATTCAGTGTCCCCACCTTGCAGCGCATTCCAACCACCT GGGAGCATTTAAAACTCCAGATGCCCACACCACACCCTGGGGCCACCCATCAG ACCTTCTGGAAGCAAGACCTGGGCCTCCATGGCCCCAAAAACTCCCTAGGTGA TCCGATGTGCAGCCAAATCTGAGAGGCCCCATTTAAAAAAGAAAGAACATGG GTGGTACATTGAGGAGTATTTACATTTTATAAAATGACTTAAAAATTTGAAGG CATTTTTGAGCATTTCCAATTATATGGAAGAGTTACTTCTACGGAATAGTTTTT GCTCATGGAACTCAAACAGATGAAGCACCACTGTTACAGAATAATGTGCTCCA GATGAAAATGTCTCGTTTCTGTGAATTTCATGAAGAGCAGAACATTTCTCAAG AATCCTCTTGAGCCAGTAATCAATCCTGTCTCAAAAAATGTTCTTTGCCATTTC CTAGATACTGCACAAAAGTGGCCATGTCGACATTTGTCCACCCACCCTCCAAT AAGCTGGAGCGACAAAGGGACATTCCATCCCTGTACCCTTAGTGGTAGCCATG ACACGATGGCCAGATCATGGACTCCGGAAAGCTTTCTGTTTTTACTGGAAACA TAGCAAACCTTGATTTAGCTCCAAGAAATTGAGTAGGGAAATATTTGTTTTTTA GCAATTGTCATAGTAAATAAAACTCTAAGCAAGTGTATCTACA
> 8
ATGACCAGGGCGGGAGATCACAACCGCCAGAGAGGATGCTGTGGATCCTTGG CCGACTACCTGACCTCTGCAAAATTCCTTCTCTACCTTGGTCATTCTCTCTCTAC TTGGGGAGATCGGATGTGGCACTTTGCGGTGTCTGTGTTTCTGGTAGAGCTCTA TGGAAACAGCCTCCTTTTGACAGCAGTCTACGGGCTGGTGGTGGCAGGGTCTG TTCTGGTCCTGGGAGCCATCATCGGTGACTGGGTGGACAAGAATGCTAGACTT AAAGTGGCCCAGACCTCGCTGGTGGTACAGAATGTTTCAGTCATCCTGTGTGG AATCATCCTGATGATGGTTTTCTTACATAAACATGAGCTTCTGACCATGTACCA TGGATGGGTTCTCACTTCCTGCTATATCCTGATCATCACTATTGCAAATATTGC AAATTTGGCCAGTACTGCTACTGCAATCACAATCCAAAGGGATTGGATTGTTG TTGTTGCAGGAGAAGACAGAAGCAAACTAGCAAATATGAATGCCACAATACG AAGGATTGACCAGTTAACCAACATCTTAGCCCCCATGGCTGTTGGCCAGATTA TGACATTTGGCTCCCCAGTCATCGGCTGTGGCTTTATTTCGGGATGGAACTTGG TATCCATGTGCGTGGAGTACGTCCTGCTCTGGAAGGTTTACCAGAAAACCCCA GCTCTAGCTGTGAAAGCTGGTCTTAAAGAAGAGGAAACTGAATTGAAACAGCT GAATTTACACAAAGATACTGAGCCAAAACCCCTGGAGGGAACTCATCTAATGG GTGTGAAAGACTCTAACATCCATGAGCTTGAACATGAGCAAGAGCCTACTTGT GCCTCCCAGATGGCTGAGCCCTTCCGTACCTTCCGAGATGGATGGGTCTCCTAC TACAACCAGCCTGTGTTTCTGGCTGGCATGGGTCTTGCTTTCCTTTATATGACT GTCCTGGGCTTTGACTGCATCACCACAGGGTACGCCTACACTCAGGGACTGAG TGGTTCCATCCTCAGTATTTTGATGGGAGCATCAGCTATAACTGGAATAATGGG AACTGTAGCTTTTACTTGGCTACGTCGAAAATGTGGTTTGGTTCGGACAGGTCT GATCTCAGGATTGGCACAGCTTTCCTGTTTGATCTTGTGTGTGATCTCTGTATTC ATGCCTGGAAGCCCCCTGGACTTGTCCGTTTCTCCTTTTGAAGATATCCGATCA AGGTTCATTCAAGGAGAGTCAATTACACCTACCAAGATACCTGAAATTACAAC TGAAATATACATGTCTAATGGGTCTAATTCTGCTAATATTGTCCCGGAGACAAG TCCTGAATCTGTGCCCATAATCTCTGTCAGTCTGCTGTTTGCAGGCGTCATTGC TGCTAGAATCGGTCTTTGGTCCTTTGATTTAACTGTGACACAGTTGCTGCAAGA AAATGTAATTGAATCTGAAAGAGGCATTATAAATGGTGTACAGAACTCCATGA ACTATCTTCTTGATCTTCTGCATTTCATCATGGTCATCCTGGCTCCAAATCCTGA AGCTTTTGGCTTGCTCGTATTGATTTCAGTCTCCTTTGTGGCAATGGGCCACATT ATGTATTTCCGATTTGCCCAAAATACTCTGGGAAACAAGCTCTTTGCTTGCGGT CCTGATGCAAAAGAAGTTAGGAAGGAAAATCAAGCAAATACATCTGTTGTTTG AGACAGTTTAACTGTTGCTATCCTGTTACTAGATTATATAGAGCACTGTGCTTA TTTTGTACTGCAGAATTCCAATAAATGGCTGGGTGTTTGCTCTG
> 9
ACTCATTCACATAAAACGCTGCGCGGCCGGCGGAATCCCCGGCTTCTAGGGCG GCGAGCGGCCGGGCTGGCTATCGAGCGAGCGGGGCGGGAACGCGGAGTTGCG CCGCCGCTCGGGCGCCGGGCTCCGTCGCGGCCGCAGCCCCGCGGGTCGCCCTC CCGTGCCTCGCCCGCGGACACCCTGGCCGTGGACACCCTGGCCGTGGGCACCC GCGGGGCGCGCGGCGCGGGGCCGCTGGCCGGCGGCGGCGGCGGCATGAAGGT CACGTCGCTCGACGGGCGCCAGCTGCGCAAGATGCTCCGCAAGGAGGCGGCG GCGCGCTGCGTGGTGCTCGACTGCCGGCCCTATCTGGCCTTCGCTGCCTCGAAC GTGCGCGGCTCGCTCAACGTCAACCTCAACTCGGTGGTGCTGCGGCGGGCCCG GGGCGGCGCGGTGTCGGCGCGCTACGTGCTGCCCGACGAGGCGGCGCGCGCG CGGCTCCTGCAGGAGGGCGGCGGCGGCGTCGCGGCCGTGGTGGTGCTGGACC AGGGCAGCCGCCACTGGCAGAAGCTGCGAGAGGAGAGCGCCGCGCGTGTCGT CCTCACCTCGCTACTCGCTTGCCTACCCGCCGGCCCGCGGGTCTACTTCCTCAA AGGGGGATATGAGACTTTCTACTCGGAATATCCTGAGTGTTGCGTGGATGTAA AACCCATTTCACAAGAGAAGATTGAGAGTGAGAGAGCCCTCATCAGCCAGTGT GGAAAACCAGTGGTAAATGTCAGCTACAGGCCAGCTTATGACCAGGGTGGCCC AGTTGAAATCCTTCCCTTCCTCTACCTTGGAAGTGCCTACCATGCATCCAAGTG CGAGTTCCTCGCCAACCTGCACATCACAGCCCTGCTGAATGTCTCCCGACGGA CCTCCGAGGCCTGCGCGACCCACCTACACTACAAATGGATCCCTGTGGAAGAC AGCCACACGGCTGACATTAGCTCCCACTTTCAAGAAGCAATAGACTTCATTGA CTGTGTCAGGGAAAAGGGAGGCAAGGTCCTGGTCCACTGTGAGGCTGGGATCT CCCGTTCACCCACCATCTGCATGGCTTACCTTATGAAGACCAAGCAGTTCCGCC TGAAGGAGGCCTTCGATTACATCAAGCAGAGGAGGAGCATGGTCTCGCCCAAC TTTGGCTTCATGGGCCAGCTCCTGCAGTACGAATCTGAGATCCTGCCCTCCACG CCCAACCCCCAGCCTCCCTCCTGCCAAGGGGAGGCAGCAGGCTCTTCACTGAT AGGCCATTTGCAGACACTGAGCCCTGACATGCAGGGTGCCTACTGCACATTCC CTGCCTCGGTGCTGGCACCGGTGCCTACCCACTCAACAGTCTCAGAGCTCAGC AGAAGCCCTGTGGCAACGGCCACATCCTGCTAAAACTGGGATGGAGGAATCG GCCCAGCCCCAAGAGCAACTGTGATTTTTGTTTTTAAGACTCATGGACATTTCA TACCTGTGCAATACTGAAGACCTCATTCTGTCATGCTGCCCCAGTGAGATAGTG AGTGGTCACCAGGCTTGCAAATGAACTTCAGACGGACCTCAGGGTAGGTTCTC GGGACTGAAGGAAGGCCAAGCCATTACGGGAGCACAGCATGTGCTGACTACT GTACTTCCAGACCCCTGCCCTCTTGGGACTGCCCAGTCCTTGCACCTCAGAGTT CGCCTTTTCATTTCAAGCATAAGGCAATAAATACCTGCAGCAACGTGGGAGAA AGAAGTTGCTGGACCAGGAGAAAAGGCAGTTATGAAGCCAATTCATTTTGAAG GAAGCACAATTTCCACCTTATTTTTTGAACTTTGGCAGTTTCAATGTCTGTCTCT GTTGCTTCGGGGCATAAGCTGATCACCGTCTAGTTGGGAAAGTAACCCTACAG GGTTTGTAGGGACATGATCAGCATCCTGATTTGAACCCTGAAATGTTGTGTAG ACACCCTCTTGGGTCCAATGAGGTAGTTGGTTGAAGTAGCAAGATGTTGGCTTT TCTGGATTTTTTTTGCCATGGGTTCTTCACTGACCTTGGACTTTGGCATGATTCT TAGTCATACTTGAACTTGTCTCATTCCACCTCTTCTCAGAGCAACTCTTCCTTTG GGAAAAGAGTTCTTCAGATCATAGACCAAAAAAGTCATACCTTCGAGGTGGTA GCAGTAGATTCCAGGAGGAGAAGGGTACTTGCTAGGTATCCTGGGTCAGTGGC GGTGCAAACTGGTTTCCTCAGCTGCCTGTCCTTCTGTGTGCTTATGTCTCTTGTG ACAATTGTTTTCCTCCCTGCCCCTGGAGGTTGTCTTCAAGCTGTGGACTTCTGG GATTTGCAGATTTTGCAACGTGGTACTACTTTTTTTTTCTTTTTGTCTGTTAGTT ATTTCTCCAGGGGAAAAGGCAATAATTTTCTAAGACCCGTGTGAATGTGAAGA AAAGCAGTATGTTACTGGTTGTTGTTGTTGTTCTTGTTTTTTATAGTGTAAAATA AAAATAGTAAAAGGAGAAAAGCA > 10
TACGCCCCGGCGCGGGCGCAGCCAGTCCGGCTTCCTCCAGGCCCCCAAGTCCC GGACCGAGTGTGGGGCCGCCTCTCCCTCTCGGAAGGAGCCATCGCCGCTTTAA GTGGAAGAGGAGAGGAAGGGGGCGGGGGAGCGGGGGGCGGGGAGCGGAGGC GGAGGAGGGGGAGGGGGATCCCCCTGGCTCCCACGTGGTCCGGGCGCCTGTG AATCGCGCCCACCGGAGGGTCTCACAGCGAAATACAAAAGCAGCTGGGAAGC GGCGGGGACTCGAGTTCCCAGCGCCGGGCGGAGCGCCGGACAGAGCCCCGCA GCGCCCCGCGGCCGCGATGGGGCCGAAGCGCCCGAAGCCCCGGAGCCCACAA ACTGCCGGGCCCGCCTCGCCGCCGGGACCCGGGTGCCTGGGCTCGGCTTGAAG CGGCGGCGGCGCACCGGCACAGCCGCGGGAGCATGGGCAGGAGGATGCGGGG CGCCGCCGCCACCGCGGGGCTCTGGCTGCTGGCGCTGGGCTCGCTGCTGGCGC TGTGGGGAGGGCTCCTGCCGCCGCGGACCGAGCTGCCCGCCTCCCGGCCGCCC GAAGACCGACTCCCACGGCGCCCGGCCCGGAGCGGCGGCCCCGCGCCCGCGC CTCGCTTCCCTCTGCCCCCGCCCCTGGCGTGGGACGCCCGCGGCGGCTCCCTGA AAACTTTCCGGGCGCTGCTCACCCTGGCGGCCGGCGCGGACGGCCCGCCCCGG CAGTCCCGGAGCGAGCCCAGGTGGCACGTGTCAGCCAGGCAGCCCCGGCCGG AGGAGAGCGCCGCGGTGCACGGGGGCGTCTTCTGGAGCCGCGGCCTGGAGGA GCAGGTGCCCCCGGGCTTTTCGGAGGCCCAGGCGGCGGCGTGGCTGGAGGCG GCTCGCGGCGCCCGGATGGTGGCCCTGGAGCGCGGGGGTTGCGGGCGCAGCTC CAACCGACTGGCCCGTTTTGCCGACGGCACCCGCGCCTGCGTGCGCTACGGCA TCAACCCGGAGCAGATTCAGGGCGAGGCCCTGTCTTACTATCTGGCGCGCCTG CTGGGCCTCCAGCGCCACGTGCCGCCGCTGGCACTGGCTCGGGTGGAGGCTCG GGGCGCGCAGTGGGCGCAGGTGCAGGAGGAGCTGCGCGCTGCGCACTGGACC GAGGGCAGCGTGGTGAGCCTGACACGCTGGCTGCCCAACCTCACGGACGTGGT GGTGCCCGCGCCCTGGCGCTCGGAGGACGGCCGTCTGCGCCCCCTCCGGGATG CCGGGGGTGAGCTGGCCAACCTCAGCCAGGCGGAGCTGGTGGACCTAGTACA ATGGACCGACTTAATCCTTTTCGACTACCTGACGGCCAACTTCGACCGGCTCGT AAGCAACCTCTTCAGCCTGCAGTGGGACCCGCGCGTCATGCAGCGTGCCACCA GCAACCTGCACCGCGGTCCGGGCGGGGCGCTGGTCTTTCTGGACAATGAGGCG GGCTTGGTGCACGGCTACCGGGTAGCAGGCATGTGGGACAAGTATAACGAGCC GCTGTTGCAGTCAGTGTGCGTGTTCCGCGAGCGGACCGCGCGGCGCGTCCTGG AGCTGCACCGCGGACAGGACGCCGCGGCCCGGCTGCTGCGCCTCTACCGGCGC CACGAGCCTCGCTTCCCCGAGCTGGCCGCCCTTGCAGACCCCCACGCTCAGCT GCTACAGCGCCGCCTCGACTTCCTCGCCAAGCACATTTTGCACTGTAAGGCCA AGTACGGCCGCCGGTCTGGGACTTAGTGTCACCGGGAGGAAAAGAGAGAGAT CTGGGGCTGGGGTATGGATGATGGGGGGAAGGGCGGTCGCCTCTGCCACTGTC AGGGACCAGCCGGCCAACGCCCACCCGCAAAGGTGTCTAAAAACTTCAGCTTT TCACCCACCTGCCCCTTTCTTTCAATCCCACGCTGTTTCCTTTCAAAGTTCTGGG AGGACGAACTCACCGAGGCGAGAAGTGTAACATTCTCTCCACCCAGCTTATAA AAGGATTCTTTACTGTGCCAGCACGGGGATTGGATCCGAAGAAACTGGCTACT GGGGTTTGGCCCCCGAGTGGCCGTCCCTGTGGGAGATGCACCCCATTCTTGGG CCCCCCCTCATTCCCTTTCCGAAAAAGGAAAACTTGCGTTTGAGCCGTTGAGCT AATTCTGCAATTTTCTACCAAACAGAGCGCTGGTGGCCCCGGAGCAGGGCTGT GACATTGGCTGGTGGAGCCCCCTTCCTGTGTTCTCCCTTTGTTCCAGCGCCGCG ATGGTGAGATCACTGTTCCAAGCAGGGGGACGGCTCGCGATAGGACAAAGAG AGCAGGACCTCCAGACTCTGGGGAGCCCTGCAGACCTTGACAATTTGCCTGAC TCATTCCTGACCTCTTGTCATTTTGGCCTGAAGGCTACAAATTCAGGGTCAGCT GTATGCACTAAGTCAAATAATGAATTTCTTCCTCCCTCTCGCAACCGACCAAAA TTTTGACAACGATGATGTTCACCAGAAGGAAAAAAAAAAATCAGTTTTATGCA CTTTATTTTGTTTTGATTTTCATTTTTTATTAAGAAAAAATTTTATTTTACAGAA TTTACCTTCTCTGTATATATGTGCATAAAGTGTGGTGTAAATATACTAAACAAA CTTATATTTCAATAAAAGGGAGTTTAAAATTTATAATTTA
> 11
CGGACGCGTGGGCGGACGCGTGGGCGGACGCGTGGGTTGGGAGGGGGCAGGA TGGGAGGGAAAGTGAAGAAAACAGAAAAGGAGAGGGACAGAGGCCAGAGGA CTTCTCATACTGGACAGAAACCGATCAGGCATGGAACTCCCCTTCGTCACTCA CCTGTTCTTGCCCCTGGTGTTCCTGACAGGTCTCTGCTCCCCCTTTAACCTGGAT GAACATCACCCACGCCTATTCCCAGGGCCACCAGAAGCTGAATTTGGATACAG TGTCTTACAACATGTTGGGGGTGGACAGCGATGGATGCTGGTGGGCGCCCCCT GGGATGGGCCTTCAGGCGACCGGAGGGGGGACGTTTATCGCTGCCCTGTAGGG GGGGCCCACAATGCCCCATGTGCCAAGGGCCACTTAGGTGACTACCAACTGGG AAATTCATCTCATCCTGCTGTGAATATGCACCTGGGGATGTCTCTGTTAGAGAC AGATGGTGATGGGGGATTCATGGTGAGCTAAGGAGAGGGTGGTGGCAGTGTCT CTGAAGGTCCATAAAAGAAAAAAGAGAAGTGTGGTAAGGGAAAATGGTCTGT GTGGAGGGGTCAAGGAGTTAAAAACCCTAGAAAGCAAAAGGTAGGTAATGTC AGGGAGTAGTCTTCATGCCTCCTTCAACTGGGAGCATGTTCTGAGGGTGCCCTC CCAAGCCTGGGAGTAACTATTTCCCCCATCCCCAGGCCTGTGCCCCTCTCTGGT CTCGTGCTTGTGGCAGCTCTGTCTTCAGTTCTGGGATATGTGCCCGTGTGGATG CTTCATTCCAGCCTCAGGGAAGCCTGGCACCCACTGCCCAACGTGAGCCAGAG GAAGGCTGAGTACTTGGTTCCCAGAAGGAGATACTGGGTGGGAAAAAGATGG GGCAAAGCGGTATGATGCCTGGCAAAGGGCCTGCATGGCTATCCTCATTGCTA CCTAATGTGCTTGCAAAAGCTCCATGTTTCCTAACAGATTCAGACTCCTGGCCA GGTGTGGTGGCCCACACCTGTAATTCTAGCACTTTGGGAGGCCAAGGTGGGCA GATCACTTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGTGAAACTCC ATCTCTACTAAAAAAAAAAAAATACAAAAATTAGCTGGGTGCGCTAGTGCATG CCTGTAATCTCATCTACTCGGGAGGCTAAGACAGGAGACTCTCACTTCAACCC AGGAGGTGGAGGTTGCGGTGAGCCAAGATTGTGCCTCTGCACTCTAGCGTGGG TGACAGAGTAAGCGAGACTCCATCTCAAAAATAATAATAATAATAATTCAGAC TCCTTATCAGGAGTCCATGATCTGGCCTGGCACAGTAACTCATGCCTGTAATCC CAACATTTTGGGAGGCCAACGCAGGAGGATTGCTTGAGGTCTGGAGGTTTGAG ACCAGCCTGGGCAACATAGAAAGACCCCATCTCTAAATAAATGTTTTAAAAAT
> 12
ACCAAGCCTTCCACGTGCGCCTTATAGCCTCTCAACTTCTTGCTTGGGATCTCC AACCTCACCGCGGCTCGAAATGGACCCCAACTGCTCCTGCGCCACTGGTGGCT CCTGCACCTGCACTGGCTCCTGCAAATGCAAAGAGTGCAAATGCACCTCCTGC AAGAAGAGCTGCTGCTCCTGCTGCCCCATGAGCTGTGCCAAGTGTGCCCAGGG CTGCATCTGCAAAGGGGCATCAGAGAAGTGCAGCTGCTGTGCCTGATGTCCGG ACAGCCCTGCTCGAAGATATAGAAAGAGTGACCTGCACAAACTTGGAATTTTT TTTCCATACAACCCTGACCCATTTACTGTATTTTTTTTAATGAAATATGTGAATG ATAATAAAAGTTGCTGACTTA
> 13
GCCTCTCCAAAGGCTGCAGAAGTTTCTTGCTAACAAAAAGTCCGCACATTCGA GCAAAGACAGGCTTTAGCGAGTTATTAAAAACTTAGGGGCGCTCTTGTCCCCC ACAGGGCCCGACCGCACACAGCAAGGCGATGGCCCAGCTGTAAGTTGGTAGC ACTGAGAACTAGCAGCGCGCGCGGAGCCCGCTGAGACTTGAATCAATCTGGTC TAACGGTTTCCCCTAAACCGCTAGGAGCCCTCAATCGGCGGGACAGCAGGGCG CGTCCTCTGCCACTCTCGCTCCGAGGTCCCCGCGCCAGAGACGCAGCCGCGCT CCCACCACCCACACCCACCGCGCCCTCGTTCGCCTCTTCTCCGGGAGCCAGTCC GCGCCACCGCCGCCGCCCAGGCCATCGCCACCCTCCGCAGCCATGTCCACCAG GTCCGTGTCCTCGTCCTCCTACCGCAGGATGTTCGGCGGCCCGGGCACCGCGA GCCGGCCGAGCTCCAGCCGGAGCTACGTGACTACGTCCACCCGCACCTACAGC CTGGGCAGCGCGCTGCGCCCCAGCACCAGCCGCAGCCTCTACGCCTCGTCCCC GGGCGGCGTGTATGCCACGCGCTCCTCTGCCGTGCGCCTGCGGAGCAGCGTGC CCGGGGTGCGGCTCCTGCAGGACTCGGTGGACTTCTCGCTGGCCGACGCCATC AACACCGAGTTCAAGAACACCCGCACCAACGAGAAGGTGGAGCTGCAGGAGC TGAATGACCGCTTCGCCAACTACATCGACAAGGTGCGCTTCCTGGAGCAGCAG AATAAGATCCTGCTGGCCGAGCTCGAGCAGCTCAAGGGCCAAGGCAAGTCGC GCCTGGGGGACCTCTACGAGGAGGAGATGCGGGAGCTGCGCCGGCAGGTGGA CCAGCTAACCAACGACAAAGCCCGCGTCGAGGTGGAGCGCGACAACCTGGCC GAGGACATCATGCGCCTCCGGGAGAAATTGCAGGAGGAGATGCTTCAGAGAG AGGAAGCCGAAAACACCCTGCAATCTTTCAGACAGGATGTTGACAATGCGTCT CTGGCACGTCTTGACCTTGAACGCAAAGTGGAATCTTTGCAAGAAGAGATTGC CTTTTTGAAGAAACTCCACGAAGAGGAAATCCAGGAGCTGCAGGCTCAGATTC AGGAACAGCATGTCCAAATCGATGTGGATGTTTCCAAGCCTGACCTCACGGCT GCCCTGCGTGACGTACGTCAGCAATATGAAAGTGTGGCTGCCAAGAACCTGCA GGAGGCAGAAGAATGGTACAAATCCAAGTTTGCTGACCTCTCTGAGGCTGCCA ACCGGAACAATGACGCCCTGCGCCAGGCAAAGCAGGAGTCCACTGAGTACCG GAGACAGGTGCAGTCCCTCACCTGTGAAGTGGATGCCCTTAAAGGAACCAATG AGTCCCTGGAACGCCAGATGCGTGAAATGGAAGAGAACTTTGCCGTTGAAGCT GCTAACTACCAAGACACTATTGGCCGCCTGCAGGATGAGATTCAGAATATGAA GGAGGAAATGGCTCGTCACCTTCGTGAATACCAAGACCTGCTCAATGTTAAGA TGGCCCTTGACATTGAGATTGCCACCTACAGGAAGCTGCTGGAAGGCGAGGAG AGCAGGATTTCTCTGCCTCTTCCAAACTTTTCCTCCCTGAACCTGAGGGAAACT AATCTGGATTCACTCCCTCTGGTTGATACCCACTCAAAAAGGACACTTCTGATT AAGACGGTTGAAACTAGAGATGGACAGGTTATCAACGAAACTTCTCAGCATCA CGATGACCTTGAATAAAAATTGCACACACTCAGTGCAGCAATATATTACCAGC AAGAATAAAAAAGAAATCCATATCTTAAAGAAACAGCTTTCAAGTGCCTTTCT GCAGTTTTTCAGGAGCGCAAGATAGATTTGGAATAGGAATAAGCTCTAGTTCT TAACAACCGACACTCCTACAAGATTTAGAAAAAAGTTTACAACATAATCTAGT TTACAGAAAAATCTTGTGCTAGAATACTTTTTAAAAGGTATTTTGAATACCATT AAAACTGCTTTTTTTTTTCCAGCAAGTATCCAACCAACTTGGTTCTGCTTCAAT AAATCTTTGGAAAAACTCA > 14
TACACAGAGAGCCACGGCCAGGGCTGAAACAGTCTGTTGAGTGCAGCCATGG GGGACGTCCTGGAACAGTTCTTCATCCTCACAGGGCTGCTGGTGTGCCTGGCCT GCCTGGCGAAGTGCGTGAGATTCTCCAGATGTGTTTTACTGAACTACTGGAAA GTTTTGCCAAAGTCTTTCTTGCGGTCAATGGGACAGTGGGCAGTGATCACTGG AGCAGGCGATGGAATTGGGAAAGCGTACTCGTTCGAGCTAGCAAAACGTGGA CTCAATGTTGTCCTTATTAGCCGGACGCTGGAAAAACTAGAGGCCATTGCCAC AGAGATCGAGCGGACTACAGGGAGGAGTGTGAAGATTATACAAGCAGATTTT ACAAAAGATGACATCTACGAGCATATTAAAGAAAAACTTGCAGGCTTAGAAAT TGGAATTTTAGTCAACAATGTCGGAATGCTTCCAAACCTTCTCCCAAGCCATTT CCTGAACGCACCGGATGAAATCCAGAGCCTCATCCATTGTAACATCACCTCCG TAGTCAAGATGACACAGCTAATTCTGAAACATATGGAATCAAGGCAGAAAGGT CTCATCCTGAACATTTCTTCTGGGATAGCCCTGTTTCCTTGGCCTCTCTACTCCA TGTACTCAGCTTCCAAGGCGTTTGTGTGCGCATTTTCCAAGGCCCTGCAAGAGG AATATAAAGCAAAAGAAGTCATCATCCAGGTGCTGACCCCATATGCTGTCTCG ACTGCAATGACAAAGTATCTAAATACAAATGTGATAACCAAGACTGCTGATGA GTTTGTCAAAGAGTCATTGAATTATGTCACAATTGGAGGTGAAACCTGTGGCT GCCTTGCCCATGAAATCTTGGCGGGCTTTCTGAGCCTGATCCCGGCCTGGGCCT TCTACAGCGGTGCCTTCCAAAGGCTGCTCCTGACACACTATGTGGCATACCTGA AGCTCAACACCAAGGTCAGGTAGCCAGGCGGTGAGGAGTCCAGCACAACCTTT TCCTCACCAGTCCCATGCTGGCTGAAGAGGACCAGAGGAGCAGACCAGCACTT CAACCTAGTCCGCTGAAGATGGAGGGGGCTGGGGTCACAGAGGCATAGAATA CACATTTTTTGCCACTTT
> 15
GTTGGCGCTTCCGGTGGCCTGCGACCCCGTAATTGCCTCGGTGATGTCGTGGGT TCAAGCAGCCTCCTTGATCCAGGGCCCTGGAGACAAAGGGGACGTGTTTGACG AAGAAGCAGACGAGTCGCTCCTGGCGCAGCGGGAATGGCAGAGTAACATGCA AAGACGAGTCAAAGAAGGTTATAGAGATGGAATAGATGCTGGCAAAGCAGTT ACTCTTCAACAGGGCTTCAATCAAGGTTATAAGAAAGGTGCAGAAGTCATTTT AAACTATGGACGACTCCGAGGAACATTGAGTGCTTTGCTCTCCTGGTGTCACCT TCATAATAATAATTCAACTTTGATCAATAAAATAAACAATCTTCTGGATGCAGT TGGCCAGTGTGAAGAGTATGTGCTCAAACATCTGAAATCAATCACTCCACCGT CCCATGTTGTAGATTTATTGGACTCCATTGAGGATATGGACCTTTGTCATGTAG TTCCAGCTGAGAAAAAGATTGATGAAGCTAAAGATGAAAGACTCTGTGAAAAT AATGCTGAGTTTAACAAAAACTGTAGCAAGAGCCATAGTGGGATAGATTGTTC ATATGTAGAATGTTGTAGAACACAGGAGCATGCACATTCAGAAAACCCAAGCC CCACATGGATTTTGGAACAGACAGCCAGTTTAGTTAAACAGCTGGGCCTATCA GTAGATGTATTACAACACCTCAAACAACTATAAAATTACCTTCCCTTTTCTAAT GAAAATAATGTTCAGAACATTTGGTTTCCTAACAATCGAAATTTGTACTGGTTT CTGCATCAAACACCTCAACTGTAGGGTTACCCTTTATGGAAGTTTGAAATTAAC ACTATTGTCTTCAAAATTAACACTATTAAATGTAATATAAGCCTTTA
> 16
CCCTGCGGCGCGCCGCCGCCCCGTAGGCCCCACGCGCCGCCCCGCTCCTCCGC CGGATCGTCTGTGGGTGAGTCTCGAGCCAGGAGGCTCTGAGCCAGTGGCGATT GGCTGACGCGGTGGCTGCGCACTCGGCCTGAGAAACTCGGCAAGCGCGCAGT GTCGACTCCCCGGTCTATGCCAGGCGCATCTCAGATACCAGCATTGCCACCGG TGGGTAGAACACTAAGTGGGCTCTTGGAGTCCCTGATTCCAGAACTTGACTCTT GGATGACATTTCTGGACCTGCTCTGGGCCAGAGAGGAGACCACTTCCCTTAAG GGAACGAGGTCTCACTATATTGCCCAGACTGGTCTCGAACTCCTGGGCTCAAA CAGTCCCCCTGCGTTGGCCTCCCAAAGTGATGGAATTACAGGTGTGAATCACT GCATCTGACTATGGCAAGGATCTCTGTCACTGAGCTAATCCAAAAGTAAATGA GAAACTTAGAAAAAGATTGCCAATTCCAAATCAACATATTTAGAGAAAATTGG AAAAGGAGAAGCTTACTACAGCTTTATTTGAGGACTTTTTAAAGAACGCTGGG TTCTATCTGTGAGCTGCAAATCTTGGAGCAAAAACCAGAGACATTGCCAGAGC AAACAAGAACAGAAATACAAATGGAGAACTGGTCAAAAGACATAACCCACAG TTATCTTGAACAAGAAACTACGGGGATAAATAAAAGTACGCAGCCAGATGAG CAACTGACTATGAATTCTGAGAAAAGTATGCATCGGAAATCCACTGAATTAGT TAATGAAATAACATGTGAGAACACAGAATGGCCAGGGCAGAGATCAACGAAT TTTCAGATCATCAGTTCTTATCCAGATGATGAGTCTGTTTACTGCACTACTGAA AAATACAACGTTATGGAACATAGACATAATGATATGCATTATGAATGTATGAC TCCTTGTCAAGTTACTTCAGACTCAGATAAAGAGAAGACAATAGCATTTCTTCT AAAAGAATTGGATATTCTCAGAACAAGCAATAAAAAGCTTCAGCAGAAATTG GCTAAAGAAGATAAAGAACAGAGAAAACTAAAGTTTAAGCTGGAACTCCAAG AGAAAGAAACAGAAGCTAAAATTGCTGAAAAGACAGCAGCTCTGGTTGAAGA AGTGTATTTTGCGCAGAAGGAACGTGATGAAGCTGTTATGTCTAGACTGCAAT TAGCCATTGAGGAGAGAGATGAAGCAATTGCACGAGCCAAGCATATGGAAAT GTCTCTAAAAGTGCTAGAAAATATTAACCCTGAAGAAAATGACATGACATTAC AGGAATTACTGAACAGAATAAACAATGCAGACACAGGGATAGCTATTCAGAA GAATGGAGCTATAATTGTGGATAGAATCTACAAGACCAAGGAATGTAAAATG AGAATAACTGCAGAAGAAATGAGTGCACTAATAGAAGAACGGGATGCTGCCT TGTCTAAGTGCAAACGGTTAGAGCAGGAGCTTCATCATGTGAAAGAGCAGAAC CAGACTTCAGCAAACAACATGAGACATCTGACTGCTGAAAACAATCAAGAAC GTGCTCTGAAGGCAAAGTTGTTATCTATGCAACAAGCCAGAGAAACTGCAGTT CAACAGTACAAAAAACTGGAAGAGGAAATCCAGACCCTTCGAGTTTACTACAG TTTACACAAATCTTTATCTCAAGAAGAAAATCTGAAGGATCAGTTTAACTATAC CCTTAGTACATATGAAGAAGCTTTAAAAAACAGAGAGAACATTGTTTCCATCA CTCAACAACAAAATGAGGAACTGGCTACTCAACTGCAACAAGCTCTGACAGAG CGAGCAAATATGGAATTACAACTTCAACATGCCAGAGAGGCCTCCCAAGTGGC CAATGAAAAAGTTCAAAAGTTGGAAAGGCTGGTGGATGTACTGAGGAAGAAG GTTGGAACCGGGACCATGAGGACAGTGATCTGATTGAAAAAAAACGACAGTC TGGGGAAGCGATCACATCTGGTGACCAGGCTGCTTCATTCAACACTGTGTAAA CACCAAAGCCTTAACTTAGCAAACAGTTGTTAGAAGTGGGACACTCCAACCAC ATTCCAAGCTGAGATAAAATCAAATCACAAATGTTTAACCACTTTGCTGCTGA CTTGAGTTATTTATCCAAATATATTAACTATAGACTTTTACCAATGGGTAGCTA TAAGGTTACAGCTTATTTTGTAACTATTTTATATCTCAATATCTTTAATATAAAT CTTTTTACTGAGAGATCATTATAGAAACATGTTAAAGTTGGTTAGGATCATATC TTCACATATGGCCCTTTCTGAATCAAAGTGCGGCAAAGTAAATATTGTCTAAGC TTTAATCCACTGTGTTAGGTCAAAACTTCAAATACATGCATTTTTCAATATAGG GTATATTTCTTAACTGATGAGAGAGGCTTAGACATGAGTGTGTAGTCTTCCTTC AATGCGTGTATGTAATCTTTGTTAGTATAAAAGATATTAAATATAGGTGCCAA GAATTAAATGTATAATTTGTTTAATAAGAGATGGATATATTAAAATTACATTCA TCAAGGCATGATTTTTGTTTCACTACAAATAATGCAAACTGTTTTCAATAAAAA GAGGAGACTGTTAATGTGTACTTATAAATTCACATTGTCAGTATTTTTTAATAT TGGGTCTGAATAATTATCTGAATTCTACTTAAGCTATAAGTCTCTGTCATTTTTG CTTGAAAATTAGCATGCCTCTGTCTTAAAAGAGACCATCAAACCTATTAAGTAT TCTTATTGTTTATCTTTTTTTAATTGCCATTTGATTTTTATTGTGGAGGAGGAGG ATCTAATATATAATATTCAATACAATTGTAATGTAGAAATATAAGAATTTAGA AAAAAGTAAACTTGCCATTTGGTTAAGGTTACCTGCTTTTTATTTTATTCCAGA AATAAGATAGTTACAGCATAGCAGTCATATGAAGTTATGAATAGAACTGAGAT TTTTATGTAATTAGTTATAGGCAAAATACTTTCATATTTTTAGATTAGACAGAC GAAAGACCAAGAGGAAATGACTGTGCCTGGAACAGGATGAAATAGACAAGTA GAGATTTAATTAGCAAAAATTTTGTAGGGAAGTAAAATTTTTTCTAAGTCTATA CGTTTTTAATTCATCTTTAAGATTGAGCTAAATTATCTACCATTGCCTATTTACA GGATAAGTACATTCAGGACAATTTATTGTACCATTCTTTCATATACCATAGCAG ATTATCCATTTCAATTTTTTTTTACTCCACAGGAAAATGTAAGCTACTTTGTCAT AGATCACAAAAGAATCATAATGCTAACAAACTCTATTTCTTCCTTATTAAATCT GTATCCATTAAAGTAACTTTTTTAACTATGAGAATTAGAAAATAAGGGACAAC AGGGGTTAAAAATAAACTGATTTAATTTGCTCTATAGTCCTAAAGAGAATTAT ATCCTCTCATAGACCAATGACTCTATAATAGAGAAATATGTAATGATTTGGTCA TGCATGGAGTCTTGTCTCTGGGCTCTATTTGAAACGTGTAACAGCTCCCTATGT GAAGAAACATTATCTTTAAAGTCATCTGGGAGGTGCAGGTAAGTAAAGAGAA ACAATTTTTGTCACAAAGTAGTCCATTCCTGATCTCACTTAAAATAAATCACAA GTAAATTTGAATTTTCGGTTTAATGTTGAAAGCAGATGAACTTTTCTTGAGTTA TTTTGTCTTTTAGAATACACAAAATATAGTATAAAGACATTTCACAATTTCCAA ACAAATCTTTCTACGCTTAAATGATCAAATTAGAAAAACCAATTCCTATAATTA ATATGCAGAACTTTTATAGAATATGATATTATAAAGTTAAATTTGCAAAATAAT TCTAACATCCACTATTGTTCAGTATAGGTAATCTCCCAAAAATATCACATCCTC TTGAAAATGAATTGTCTACAAAATTTCAAATGCAAAGTATTACAGCCAAATAT TATCTTAATTAATTTCTTACACTTAAAAGTGTCCATCAACAGTGTGTCAGATGG TCTTTATATATTTTTTCTGTATGAAGGAATAGCCTTGCCTACTGAAGATAGGTT CTCTATGTATTCAACAATAATGCAACTTTAGAAGTATTCCACACTGCTGAGAAA TGTTGCTTTGAGTTTGCTTTACACATCATCAACTCTAAATCCTATAGTAACATG AGAATTCACTTCTTCTTGTAAAAATAAGTAATTTACAGGAAAGGCAAAATGCT AATACTAACATTTGTAGCACTTGATGATTTACAAAGTCCTTTTACATCTGTTTTT TCATTTGATCCTATCGACAATCATAATAATAATAAATTATATATATAACCCATA TAATAACGATGGTGATGATAATTTTAGTATTACTGTCATTATAATTATTATTAT ATTCATTCTACAGATGAGGAAACAGACTCAGTAAGCCTTGGAATTTGCCAAGG ACTGGCTAGGACCTAGAACTAAGATCTTATAACCACACTCCATGCAACTATGA GTCTCTAAATCTCTCTGTAAGAAAAAAATTTCAAAGTAAAGATTTTACTCTTGC AATTTCTGTTGTGATAGTACCATCTCTTTCACATACTACATACAAATTCCCTAA TAATCAAAAGATTGTACACATTTTTTTCAATGAAGTACAATAATGTGAACTGCA TGTGTAAACAGCATCACATTATTACCACCTCTCTATGGTATTATAGTGGCAGTA TGCTTTGCCTCAGCCTTCACTAATTAGGAATATTGTGACAATTCATTGCTAATA AAACATAACATGAGTCTCTTTGTACTGTTTTTAATTTGGCCTGATGCTAAAACC TATCAGCTTAGTTTTTTAACATGGTAGTCTAAACTTCAAGGCTTGCTCTATCTCC TAGAGCAATTTAGAGCTAAAACCAGTAATAAGCAAAGTTATTGGTTATAAGCA AGGTATAAGCAGTTAAAGCAAAGTTATTAATTATTAATATATGAGAATTTAAA ATTTTATAAATAAGTTAGAAATTATTAATGTATTTTAAATATGGAGTAAAATAT TTTGCTAATTTTTTTCAATGATAAAGTTGATCCTTTGTATATTTCCTTATTCAAA TAAATTCAGTCATCTTCTTATCAGGTTGCTTATTTATATAATTTGTTTATTTTAT TAAAAATCTAGAATATTAAAGATTTATACTTTTAATATTGAATATAGTTTCGTA GAAAAACATTTTATATGTACTATTCTTAAAGATCACAATTATTTTTAAACTTTC TATTTTCAAATACTTGTGATTAATAAGGCATTCTATGATGAAATAGCCATGGCT TATATATTTTTGTCTTTTCACATATGATGTGTTTGGAACCCAAATTTTTTACTGA TTTTATTGTGTTGTTGGTAACTAGTATTTACAGCTAACCTATCTATTCATATTTT ACATATATATATATATATATACATGCACACACACCGATACATTTACCTTTTAAA AAAATGATTTATAAGTGAACTGTTAGGCTCCAGTGATTTCAGTGTTTTGTTCAT GTTTTATTGGAAATGCACGTGGTTTCTTAGGCTTTTAAACAAATACATGGAATG GTTGAAAGATTTATTTTGCTCGTGCTTAGCTAAATATGTCATCTCTAGAAAAGA TGTGGTTTGTTTTGGCACTGTTTTAAAAACTCAAATATTTTAAACATTTGTTAA GTTGGAGCTTGCACATTTAAACCAGCAGCATACGTTCCAGAAGAGCATCTCAA GTTACCAAATTTTTTGTAATCCTTTTACTAGAAAAATCTTTTTTGAAGAGTTTTT CTTGTGCTTGCTTCGGCAGCATATATACTGAAATTAGAAAAAGAAAACTTTTCT TTTTTATTATATATTTTAGTGTAAGTTAAGTTAAACTTCTAAAAGTTGAATTATT TAATGTAGGACTTCATAAATAGTATTTGACAATGATAAATGTGTATTTTTGAGA ATCATTAAAATGTATACAATGATATTCCTTTGCAGAAGTCTTAATATGCATAAT TTTTAATCTAATTGTCTTCTAAATATAGTTTTGGTGTATGCTGGTATTTTAGAAG CCACCAATTTCTGGACTATCTGATTATTAACAAAGATGTATTTTAATGCACAAA CTCAAATGTTTAAAATATATATTTACTTTGTACTCAAATAAAATCCCCTATTGC AAATCCTA > 17
AGCAGCCGGCGCGGCCGCCAGCGCGGTGTAGGGGGCAGGCGCGGATCCCGCC ACCGCCGCGCGCTCGGCCCGCCGACTCCCGGCGCCGCCGCCGCCACTGCCGTC GCCGCCGCCGCCTGCCGGGACTGGAGCGCGCCGTCCGCCGCGGACAAGACCCT GGCCTCAGGCCGGAGCAGCCCCATCATGCCGAGGGAGCGCAGGGAGCGGGAT GCGAAGGAGCGGGACACCATGAAGGAGGACGGCGGCGCGGAGTTCTCGGCTC GCTCCAGGAAGAGGAAGGCAAACGTGACCGTTTTTTTGCAGGATCCAGATGAA GAAATGGCCAAAATCGACAGGACGGCGAGGGACCAGTGTGGGAGCCAGCCTT GGGACAATAATGCAGTCTGTGCAGACCCCTGCTCCCTGATCCCCACACCTGAC AAAGAAGATGATGACCGGGTTTACCCAAACTCAACGTGCAAGCCTCGGATTAT TGCACCATCCAGAGGCTCCCCGCTGCCTGTACTGAGCTGGGCAAATAGAGAGG AAGTCTGGAAAATCATGTTAAACAAGGAAAAGACATACTTAAGGGATCAGCA CTTTCTTGAGCAACACCCTCTTCTGCAGCCAAAAATGCGAGCAATTCTTCTGGA TTGGTTAATGGAGGTGTGTGAAGTCTATAAACTTCACAGGGAGACCTTTTACTT GGCACAAGATTTCTTTGACCGGTATATGGCGACACAAGAAAATGTTGTAAAAA CTCTTTTACAGCTTATTGGGATTTCATCTTTATTTATTGCAGCCAAACTTGAGGA AATCTATCCTCCAAAGTTGCACCAGTTTGCGTATGTGACAGATGGAGCTTGTTC AGGAGATGAAATTCTCACCATGGAATTAATGATTATGAAGGCCCTTAAGTGGC GTTTAAGTCCCCTGACTATTGTGTCCTGGCTGAATGTATACATGCAGGTTGCAT ATCTAAATGACTTACATGAAGTGCTACTGCCGCAGTATCCCCAGCAAATCTTTA TACAGATTGCAGAGCTGTTGGATCTCTGTGTCCTGGATGTTGACTGCCTTGAAT TTCCTTATGGTATACTTGCTGCTTCGGCCTTGTATCATTTCTCGTCATCTGAATT GATGCAAAAGGTTTCAGGGTATCAGTGGTGCGACATAGAGAACTGTGTCAAGT GGATGGTTCCATTTGCCATGGTTATAAGGGAGACGGGGAGCTCAAAACTGAAG CACTTCAGGGGCGTCGCTGATGAAGATGCACACAACATACAGACCCACAGAG ACAGCTTGGATTTGCTGGACAAAGCCCGAGCAAAGAAAGCCATGTTGTCTGAA CAAAATAGGGCTTCTCCTCTCCCCAGTGGGCTCCTCACCCCGCCACAGAGCGG TAAGAAGCAGAGCAGCGGGCCGGAAATGGCGTGACCACCCCATCCTTCTCCAC CAAAGACAGTTGCGCGCCTGCTCCACGTTCTCTTCTGTCTGTTGCAGCGGAGGC GTGCGTTTGCTTTTACAGATATCTGAATGGAAGAGTGTTTCTTCCACAACAGAA GTATTTCTGTGGATGGCATCAAACAGGGCAAAGTGTTTTTTATTGAATGCTTAT AGGTTTTTTTTAAATAAGTGGGTCAAGTACACCAGCCACCTCCAGACACCAGT GCGTGCTCCCGATGCTGCTATGGAAGGTGCTACTTGACCTAAGGGACTCCCAC AACAACAAAAGCTTGAAGCTGTGGAGGGCCACGGTGGCGTGGCTCTCCTCGCA GGTGTTCTGGGCTCCGTTGTACCAAGTGGAGCAGGTGGTTGCGGGCAAGCGTT GTGCAGAGCCCATAGCCAGCTGGGCAGGGGGCTGCCCTCTCCACATTATCAGT TGACAGTGTACAATGCCTTTGATGAACTGTTTTGTAAGTGCTGCTATATCTATC CATTTTTTAATAAAGATAATACTGTTTTTGA
> 18
CCCCCTCCAATTCTGTCCCTCCGCCCCCCGGCTCCTGCTCTCTCCGCCTAGCCTT TTCCCCTCCCAGCTGCCTGCCTGCCAGGGGTAGTGAGCCGGCTGAGAGGCATG GAGACGCAGGAACTTCGGGGGGCCCTGGCTCTTCTCCTCCTTTGCTTTTTCACA TCTGCCAGTCAGGATCTGCAGGTAATTGACCTGCTGACTGTGGGCGAGTCTCG GCAGATGGTAGCTGTGGCAGAGAAGATCCGGACAGCCTTGCTCACTGCTGGGG ACATCTACCTCTTATCCACCTTCCGCCTGCCCCCCAAGCAGGGTGGTGTCCTCT TTGGCCTCTATTCTCGCCAAGACAACACTCGATGGCTGGAGGCCTCTGTTGTAG GCAAGATCAACAAAGGTGACTGTACTGGTGCGATACCAGCGGGAGGATGGCA AAGTCCACGCCGTGAACCTACAGCAAGCGGGCCTGGCTGATGGGCGCACACA CACAGTTCTCCTGCGACTCCGAGGTCCCTCCAGACCCAGCCCTGCCCTACATCT CTACGTGGACTGCAAACTGGGTGACCAACATGCAGGCCTTCCAGCACTGGCCC CCATTCCTCCAGCGGAGGTCGATGGGCTGGAGATTAGGACTGGACAGAAGGCG TATTTGAGGATGCAGTGACCAATGCACTGCACTCCATTCTAGGGGAGCAGACC AAGGCGCTGGTCACCCAACTCACCCTCTTCAACCAGATCCTGGTGGAGCTGCG GGATGATATACGAGACCAGGTGAAGGAAATGTCCCTGATCCGAAACACCATTA TGGAGTGTCAGGTGTGCGGCTTCCATGAGCAGCGTTCCCACTGCAGCCCCAAT CCCTGCTTCCGAGGTGTGGACTGCATGGAAGTGTACGAGTACCCAGGCTACCG CTGTGGGCCCTGCCCCCCTGGCCTGCAGGGCAACGGCACCCACTGCAGTGACA TCAATGAGTGTGCTCACGCTGACCCCTGTTTCCCGGGCTCCAGCTGCATCAACA CCATGCCCGGCTTCCACTGTGAGGCCTGTCCTCGAGGGTACAAGGGCACACAG GTGTCTGGTGTGGGCATTGACTATGCCCGGGCCAGCAAACAGATAAGGCCATA CCAGTGTCCTCTGCTGTATCTGAGGAGACCCACCATAGGTCTGGTTCCACCCAA AGTCTGCCCCTTCAGGTCTGCAATGACATCGATGAATGCAACGATGGCAACAA TGGTGGCTGTGACCCAAACTCCATCTGCACCAACACTGTGGGCTCTTTCAAGTG TGGTCCCTGCCGCCTGGGTTTCCTGGGCAACCAGAGCCAGGGCTGCCTCCCAG CCCGGACCTGCCACAGCCCAGCCCACAGCCCCTGCCACATCCATGCTCACTGT CTCTTTGAACGCAATGGTGCAGTGTCCTGCCAGTGTAACGTGGGCTGGGCTGG GAATGGGAACGTGTGTGGGACTGACACAGACATCGATGGCTACCCAGACCAA GCACTGCCCTGCATGGACAACAACAAACACTGCAAACAGGACAACTGCCTTTT GACACCCAACTCTGGGCAGGAAGATGCTGATAATGATGGTGTGGGGGACCAGT GTGATGATGATGCTGATGGGGATGGGATCAAGAATGTTGAGGACAACTGCCGG CTGTTCCCCAACAAAGACCAGCAGAACTCAGATACAGATTCATTTGGTGATGC CTGTGACAATTGCCCCAACGTTCCCAACAATGACCAGAAGGACACAGATGGCA ATGGGGAAGGAGATGCCTGTGACAACGACGTGGATGGGGATGGCATCCCCAA TGGATTGGACAATTGCCCTAAAGTCCCCAACCCACTACAGACAGACAGGGATG AGGACGGGGTGGGAGATGCTTGCGACAGCTGCCCTGAAATGAGCAATCCTACC CAGACAGATGCAGACAGCGACCTGGTGGGGGATGTCTGTGATACTAATGAAG ACAGCGATGGGGATGGGCATCAGGACACCAAGGACAACTGCCCACAGCTGCC AAATAGCTCCCAGCTGGACTCTGATAACGATGGACTTGGAGATGAGTGTGATG GGGATGATGACAATGATGGCATCCCAGATTATGTGCCTCCTGGTCCCGATAAC TGCCGCCTGGTACCCAATCCCAATCAGAAGGACTCAGATGGCAATGGCGTTGG TGATGTGTGTGAGGATGACTTTGACAATGATGCTGTGGTCGACCCCCTGGATGT GTGTCCTGAAAGTGCAGAGGTAACGCTTACGGATTTTCGGGCCTATCAGACCG TCGTCCTGGATCCTGAGGGTGATGCTCAGATTGACCCAAACTGGGTTGTGCTCA ACCAGGGCATGGAAATCGTTCAGACCATGAACAGTGACCCTGGCTTGGCAGTT GGATACACGGCCTTCAATGGTGTGGACTTTGAAGGCACCTTCCATGTGAACAC AGTGACTGATGATGACTACGCAGGCTTTCTCTTCAGTTATCAAGACAGTGGCC GCTTCTACGTAGTCATGTGGAAGCAGACCGAGCAGACCTACTGGCAGGCTACA CCCTTCCGGGCGGTTGCCCAGCCCGGGCTGCAGCTCAAGGCAGTGACATCAGT GTCTGGCCCAGGTGAGCACCTCCGAAATGCCCTGTGGCATACTGGCCACACCC CTGATCAGGTACGACTGCTGTGGACAGACCCACGAAATGTGGGCTGGCGGGAC AAGACCTCCTATCGCTGGCAGCTTCTGCACCGGCCTCAAGTTGGCTACATTCGG GTGAAGCTCTATGAGGGACCCCAGCTTGTGGCGGATTCTGGGGTGATCATTGA CACATCCATGCGAGGGGGGCGTCTTGGTGTATTCTGCTTCTCCCAAGAAAACA TAATTTGGTCCAATCTCCAGTATCGATGCAATGACACAGTGCCTGAGGACTTTG AGCCATTCCGGAGGCAGCTGCTCCAGGGAAGGGTGTGAGGAGGAGGCCACCA GATTCAGAATTCAGAATTTTAGACCCTTTGGCCTTGGGGTCCATCCTGGAGACC CTGAGGTCTAAGCTACAGCCCCTCAGCCAACCACAGACCCTTCTCTGGCTCCC AAAAGGAGTTCAGTCCCAGAGGGGTGGTCACCCCACCCTTCAGGGGATGAGA AGTTTTCAAGGGGTATTACTCAGGCACTAACCCCAGGAAAGATGACAGCACAT TGCCATAAAGTTTTGGTTGTTTTCTA > 19
AGACGCACGTGAGGGAAATCAGATGACTGGACTTGTAGATACTAACGGTTCTG AAGCGGAATGGCTTATTCAGAAGAGCATAAAGGTATGCCCTGTGGTTTCATCC GCCAGAATTCCGGCAACTCCATTTCCTTGGACTTTGAGCCCAGTATAGAGTACC AGTTTGTGGAGCGGTTGGAAGAGCGCTACAAATGTGCCTTCTGCCACTCGGTG CTTCACAACCCCCACCAGACAGGATGTGGGCACCGCTTCTGCCAGCACTGCAT CCTGTCCCTGAGAGAATTAAACACAGTGCCAATCTGCCCTGTAGATAAAGAGG TCATCAAATCTCAGGAGGTTTTTAAAGACAATTGTTGCAAAAGAGAAGTCCTC AACTTATATGTATATTGCAGCAATGCTCCTGGATGTAATGCCAAGGTTATTCTG GGCCGGTACCAGGATCACCTTCAGCAGTGCTTATTTCAACCTGTGCAGTGTTCT AATGAGAAGTGCCGGGAGCCAGTCCTACGGAAAGACCTGAAAGAGCATTTGA GTGCATCCTGTCAGTTTCGAAAGGAAAAATGCCTTTATTGCAAAAAGGATGTG GTAGTCATCAATCTACAGAATCATGAGGAAAACTTGTGTCCTGAATACCCAGT ATTTTGTCCCAACAATTGTGCGAAGATTATTCTAAAAACTGAGGTAGATGAAC ACCTGGCTGTATGTCCTGAAGCTGAGCAAGACTGTCCTTTTAAGCACTATGGCT GTGCTGTAACGGATAAACGGAGGAACCTGCAGCAACATGAGCATTCAGCCTTA CGGGAGCACATGCGTTTGGTTTTAGAAAAGAATGTCCAATTAGAAGAACAGAT TTCTGACTTACACAAGAGCCTAGAACAGAAAGAAAGTAAAATCCAGCAGCTA GCAGAAACTATAAAGAAACTTGAAAAGGAGTTCAAGCAGTTTGCACAGTTGTT TGGCAAAAATGGAAGCTTCCTCCCAAACATCCAGGTTTTTGCCAGTCACATTG ACAAGTCAGCTTGGCTAGAAGCTCAAGTGCATCAATTATTACAAATGGTTAAC CAGCAACAAAATAAATTTGACCTGAGACCTTTGATGGAAGCAGTTGATACAGT GAAACAGAAAATTACCCTGCTAGAAAACAATGATCAAAGATTAGCCGTTTTAG AAGAGGAAACTAACAAACATGATACCCACATTAATATTCATAAAGCACAGCTG AGTAAAAATGAAGAGCGATTTAAACTGCTGGAGGGTACTTGCTATAATGGAAA GCTCATTTGGAAGGTGACAGATTACAAGATGAAGAAGAGAGAGGCGGTGGAT GGGCACACAGTGTCCATCTTCAGCCAGTCCTTCTACACCAGCCGCTGTGGCTAC CGGCTCTGTGCTAGAGCATACCTGAATGGGGATGGGTCAGGGAGGGGGTCACA CCTGTCCCTATACTTTGTGGTCATGCGAGGAGAGTTTGACTCACTGTTGCAGTG GCCATTCAGGCAGAGGGTGACCCTGATGCTTCTGGACCAGAGTGGCAAAAAGA ACATTATGGAGACCTTCAAACCTGACCCCAATAGCAGCAGCTTTAAAAGACCT GATGGGGAGATGAACATTGCATCTGGCTGTCCCCGCTTTGTGGCTCATTCTGTT TTGGAGAATGCCAAGAACGCCTACATTAAAGATGACACTCTGTTCTTGAAAGT GGCCGTGGACTTAACTGACCTGGAGGATCTCTAGTCACTGTTATGGGGTGATA AGAGGACTTCTTGGGGCCAGAACTGTGGAGGAGAGCACATTTGATTATCATAT TGACCTGGATTTAGACTCAAAGCACATTTGTATTTGCCTTTTTCCTTAACGTTTG AAGTCAGTTTAAAACTTCTGAAGTGCTGTCTTTTTACATTTTACTCTGTCCCAGT TTGAAACTTAAAACTCTTAGAATATTCTCTTATTATTTATATTTTTATATTTCTT GAAAGATGGTAAGTTTCTTGAAGTTTTTGGGGCGTTTCTCTTTTACTGGTGCTT AGCGCAGTGTCTCGGGCACTCTAAATATTGAGTGTTATGGAGGACACAGAGGT AGCAGAATCCCAGTTGAAAATGTTTTGATATTTTATTGTTTGGCCTATTGATTC TAGACCTGGCCTTAAGTCTGCAAAAGCCATCTTTATAAGGTAGGCTGTTCCAGT TAAGTAGTGGGTGATGTAGTTACAAAGATAATATGCTCAGTTTGGACCTTTTTT TCAGTTAAATGCTAAATATATGAAAATTACTATACCTCTAAGTATTTTCATGAA ATTCACCAGCAGTTTGCAAGCACAGTTTTGCAAGGCTGCATAAGAACTGGTGA ATGGGGTAAGCATTTTCATTCTTCCTGCTGAAGTAAAGCAGAAAGTACTGCAT AGTATATGAGATATAGCCAGCTAGCTAAAGTTCAGATTTTGTTAGGTTCAACCC TATGAAAAAAACTATTTTCATAGGTCAAAAATGGTAAAAAATTAGCAGTTTCA TAAGATTCAACCAAATAAATATATATATACACACACACATACATATACACCTA TATATGTGTGTATACAAACAGTTCGAATGTATTTTGGTGACAGTAATAAATCAA TGTGAGGATGGATAGAATTTAGTATATGATAGAGAAAATGTCATAAATGGATA AAAGGAATTTACAACTTGAGGAGAAAACCTTTACAATTTCCTATGGGTGTCAG AAGTACTCTCAGCGAAAACTGATGGCTAAAACAGTATCTACTATTCTCTGATA ACTTTTTTTTTGAGACAGAGTTTCATTGTCACCCAGGCTGGAGTACAGTGGCAT GATCTCAGCTCACTGCAAACTCTGCCTCCCGAATTCAAGTGATTCTCCTGCCTC AGCCTCCTGAGTAGCTGGGATTACAGGCGCCCGTCACCACACCCAGGTAATTT TTGTATTTTTAGTAGAGACGGAGTTTTGCCATGTTGGCCAAGCTGATCTCAAAC TCCTGACCTCAAGTGATCTGCCCGCCTCGGCCTCCCAAAGTGCTGAGATTACA GGCATGACCCACCGCGTCAAGCCTCTGACAACTATTGAATTTGTAAGCTGCTAT GCAAATGGGCATTTATATAAACTTGTGATGTTTCTTGTCAGAATTCTGAGTACT CTGTGAAGAACAGAAATGATCATATTCTTATGCATCTATCTGTATGGGTCTGAA GGTGTATATACAAACTGAGATGAGTCCTTATGACTCTTGATAAGCCTGAGTTTA ACAACAACAAAAATGCCAAGTTGTCCTGAGCCCTTCTGCGTTGTTATGCCACTT CCCTACTGCTCATATGCACGCTGGCTCCCCTGGGCACGCAAGGATGAGTATGG GCCATGGGCCCCTGTAGAGCTGCTTACCTGGTGATGACCATGCACCTTACAATT TCTGAACAGTTAACCCTATAGAAGCATGCTTTATATGAGTGTCTTCTGGGAAGA GGAACCTTCTTAATCTCTTCTGTGGGATTTTCAAAATGCTAAAGACTCACACTG CAGCAATCATCCCAGATGATTAAATTCAAAGAAATAGGTTCACAACAGGAATA TACTGAAGAACTAGAGTGTCACTGCTGGTGAACTGTGGCACGGTTGCTCAACA CATCACCTCGGACAAATTCAGGAAGCATTTCTTTAGCCCACAAGTCCAGACCC AGGTGCTCTGTATGTTTGTTTTTAATATTCATCATATCCAAGTTCACTCTGTCTT CCTGAGCAGTGGAAGATCATATTGCTGTAACTTCTTTTAAGTAGTTGATGTGGA AAACATTTTAAAGTGAATTTGTCAAAATGCTGGTTTTGTGTTTTATCCAACTTTT GTGCATATATATAAAGTATGTCATGGCATGGTTTGCTTAGGAGTTCAGAGTTCC TTCATCATCGAAATAGTGATTAAGTGATCCCAGAACAAGGAATACTAGAGTAA AAAGCACCTCTTTTTCACA
> 20
AAGGCACCAAACCATTGAGGAGGGATTTGTCCTCATTACCCAAACACTTCCCA CCGGGCCTCACCTTGAACGCTGGAGATCAAATTTTAACATGGTATTTGGTGGG GACAAACCCTATCAGCAGCTGCTTTTAATATTTAAAAAAATATTTTGAGAGAG GGCCCACAGACCCTCTGAAAGAAGCAGACTGCTCCTGCAGGACCCGGGGGAC ACCCCAAATACTGTGAGTGCCCCAACTGCGGAAGTGGGAAAGGGAGACCCTC CTTTCCGGAACACACACCCCCTACTGGAGAAGCTGAAGGTCTGCTTCCGGGAG ATGCTCCCGACTTCACCTGGAGCTGAGTCAAGTTAGAGAACCGGACCAAGCGA AATACAGGGGCAGAGGAGGCAGCAGGGAGGCCCTGGGAGCTCTTTGAATCCC CAGGTAGCCTATTCCTGCCTGGCACCACTGGGATTCATCAGGAGGGAGGCCAG AGGAGCAGGAGGTGGGAGGCGGAAAGCCTCGGGCAAGTTTTCAAGCCCGTCC TCTGTCTGGAAACAGACTCAGAGGTGTTGCAGGGGACACGGTGGGAGTGAGA CCAGCCCTTCGGTGTGCGTGGGATCTGGGGGAGGCCTGTGACTGCCGGCTTTC CCCTGCTTCTCTGACAACCTGCATGACTCAGCAGAGGCAGCCATAATCCTGGA GAGCCCCGGTTTAAGATCTCCAGTCAGAACCTTCAGGAAGGGGAGAGTGGCTC ATGGGCTGAGTGGATAAACCACAAAATGGGTAATATACTATAGGAGGCAGAG TTTGAGATCGACGTCCCCCTGCACCTGGGGCGCCTCCTGATGGTGAAGCTGCG CAAACACAACGTGCTGTTGAGTCTCGACTGGTTCTGCAAGTGGATCTCAGTGC AGGGCCCGGGGACCCAAGGCGAGGCCTTTTTCCCCTGCTACCGCTGGGTGCAG GGCCACGGAATTATCTGCCTGCCTGAGGGTGGGGCTCCTGGAAAGATGGGTTA ATCCTGCCTATAGCAGGGAATAGGCAACCGGACCTTCCTAGGGACGAGCGATT CCTCGAGGATAAGGATTTAGACTTTAATGTCTCCCTAGCAAAAGGGTTGAAGG ACTTGGCCATTAAGGGGACACTGGATTTCATAAATTGTGTGAAAAGGCTGGAA GATTTCAAAAAAATATTCCCACATGGAAAGACTGTCCTGGCTGAGCGGGTTTA TGATTCTTGGAAGAATGATGCCTTCTTTGGGTACCAGTTTCTCAATGGTGCAAA CCCCATGCTCCTGAGGTGTTCTTCAAGGCTCCCAGCCTGCCTGGTGCTGCCTCC AGGGATGGAAGACTTGAAGACCCAGCTGGAGAAAGAACTCCAGGCTGGATCT CTGTTTGAAGTGGATTTCTCCTTGCTGGATGGAGTCAAGCCTAATGTCATCATT TTTAAGCAGCAATGCGTGGCAGCCCCTTTGGTCATGCTGAAGCTTCAGCCTGAT GGAGGACTCTTACCCATGGTCATCCAGCTCCAGCCACCTTGACACGGATGTCC CCCACCTCTGCTCTTTCTGCCCTCGCATCCCCCCATGGCCTGGCTCCTGGCCAA GACCTGGGTCCGGAGCTCTGATTTCCAGCTGCAGCAGTTACAGTCACATCTGCT GAGGGGACACTTGATTGCTGAGGTTATTGCTGTGGCTACAATGAGAAGCTTGC CTAGCCTCCATCCTATCTACAAGGTGGTGAGCACTGGTAGTGGAAGCCACGTG GACATTCTTCAGAGAGCCATGGCTTGTTTGACCTATCATTCCCTCTGTCCTCCT GATGACCTGGCTGACCGTGGGCTCCTGGATGTGAAATCTTCTTTTTATGGCTAA GATGCCATCAGGCTGTGGGGAATCATCAGCCGGGAATAGGTACGTGGAGGGG ATGGTTGGGCTTTTCTACAATAGTGACCAAGCCATGAAGGATGATCTAGAGCT GCAGGCCTGGTGCAGAGAGATGACTGAGACTGGACTGCAGAGGGCCCAAGAC CAGGGGTTCCTCATCTCCTTAGAGTCCCGGGCTCAGCTCTGCCACTTTGTCACC ATGTGCATCTTCACATGCACAGGTCAGCATGCTTCTAACCACCTGGGCCAGCTG GACTGGTACTCCTGGATCCCTAATGGCCCATGCACCATGCAGAAGCCCCCGCC CATCTCTAAGGATGTGACAGAGAAGGATATAGTGGACTTACTGCCCAATCTCC ACCAGGCACGTATGCAAAAGACCTTCACAAAGTTCCTTGGCAGACGCCAGCCT GTCATGCATGAGGAGAAATATTTCTCTGGTCCTGAGCCCCAAGCTGTGCTGAG ACAATTCCAGGAGGAACTGGCTTCCATGGACAAGGAGATTGAGGTCCGGAATG CAGTCCTGGACCTGCCCTGTGAGTACCTTTGACCCAGCATGGTAGAGAACAGC GTGACCATCTGAGAGGCCTTGCCCGCCTCAGCTCCAAAGCTCCACCATCCCTG AGTGCCTTTGAGTATTCCGTCCTCCTCACATCCTCTGGTGAACAAATTGTCCCC AAAGCTTTGTGGTCAGGGTATCCAGAGCTGCTCACCACACAACTATGGGGAAT ACACAGTGATGGTCCCCATTGCATTTGGAAGTGGCATCCCCCAAAGCTGCCCT ACCTTAAATGTCCATCCAGTCCTGCACTTCCTCACCCCGATCCCTGCACACCTC CTCATTGCCAAAGGACCTGGCTTAGATACAAGTAAAAATATATGATTAAATAA CAAAACGGA
> 21
CCGCGTCACCGACGTCCCGCTAGGCTGAGACCGGTGCGCCGCGCGCTAGTGGC CGCTCTTCCGCGGGCTAGCGGGCGGTGGGGGCGCCAGCAGCGCGGAAGGCGG GCACGCGGGCCATGGCTCCCTGGGCGGAGGCCGAGCACTCGGCGCTGAACCC GCTGCGCGCGGTGTGGCTCACGCTGACCGCCGCCTTCCTGCTGACCCTACTGCT GCAGCTCCTGCCGCCCGGCCTGCTCCCGGGCTGCGCGATCTTCCAGGACCTGA TCCGCTATGGGAAAACCAAGTGTGGGGAGCCGTCGCGCCCCGCCGCCTGCCGA GCCTTTGATGTCCCCAAGAGATATTTTTCCCACTTTTATATCATCTCAGTGCTGT GGAATGGCTTCCTGCTTTGGTGCCTTACTCAATCTCTGTTCCTGGGAGCACCTT TTCCAAGCTGGCTTCATGGTTTGCTCAGAATTCTCGGGGCGGCACAGTTCCAGG GAGGGGAGCTGGCACTGTCTGCATTCTTAGTGCTAGTATTTCTGTGGCTGCACA GCTTACGAAGACTCTTCGAGTGCCTCTACGTCAGTGTCTTCTCCAATGTCATGA TTCACGTCGTGCAGTACTGTTTTGGACTTGTCTATTATGTCCTTGTTGGCCTAAC TGTGCTGAGCCAAGTGCCAATGGATGGCAGGAATGCCTACATAACAGGGAAA AATCTATTGATGCAAGCACGGTGGTTCCATATTCTTGGGATGATGATGTTCATC TGGTCATCTGCCCATCAGTATAAGTGCCATGTTATTCTCGGCAATCTCAGGAAA AATAAAGCAGGAGTGGTCATTCACTGTAACCACAGGATCCCATTTGGAGACTG GTTTGAATATGTTTCTTCCCCTAACTACTTAGCAGAGCTGATGATCTACGTTTC CATGGCCGTCACCTTTGGGTTCCACAACTTAACTTGGTGGCTAGTGGTGACAAA TGTCTTCTTTAATCAGGCCCTGTCTGCCTTTCTCAGCCACCAATTCTACAAAAG CAAATTTGTCTCTTACCCGAAGCATAGGAAAGCTTTCCTACCATTTTTGTTTTA AGTTAACCTCAGTCATGAAGAATGCAAACCAGGTGATGGTTTCAATGCCTAAG GACAGTGAAGTCTGGAGCCCAAAGTACAGTTTCAGCAAAGCTGTTTGAAACTC TCCATTCCATTTCTATACCCCACAAGTTTTCACTGAATGAGCATGGCAGTGCCA CTCAAGAAAATGAATCTCCAAAGTATCTTCAAAGAATAAATACTAATGGCAGA TCTGCGATTTCTGGGTCCACTTTCTGAGATGCTTTCTAAAACCAACCAACTGAT AAAAAGTAGATGAGACTTCTCCAAGCTGCTTCACAAGCAAACTAACCGAAAAA CCGAAAATATACAAACAGCTTCACACACACACACACACACACACACACACAC ACACACACACAAAGGAAGATCATCAATGGCTGCGGTAGCCTAGTAGGAATGG ACTATATAATAATATAGCAGGTGCTCAATAACTGTTTGTTGCATTTCAGTAAAA GCAGAATAACCTTTCAAAATAATAACAGGCTGGGTGCAATGGCTCACACCTGT TAATCCCAGCACTTCGGGAGGCCAAGGTGGGCAGTTCGCTTGGGCCCAAGAGT TCGAGACCAGCCTGGGCAACATGGTGAAACCCTATCTCCGTGAAAAAATATGA AAATTAGCCAAGAGTGGTGGCACATGCCTGTAGTCCCAGATACTTGGGAGTGG GCTGAGATGGGAGAATCGCTTGAGCCCAGGAGGTCAAGGGTACAGTGAGCCG AGGTCATGCCACTGCACTCCAGCCTGGCCTGGGCAACAGAGCAAGACCCTGTC TCAAAATAATAATAATATATAATTTTACACCAAAAGTTTCAGGAAAAAACGAG TTTGTTGGAGTTAGTTTATACTTTCACATATCACCACAAAGATCTCCAGTTAAA TAACTATCAATATCCATTTCCATTCATCTCCCCCTCAAATCATAGCCTAACAGA ACACTTTGAAAGCTCTTTTATTTAATATTTTTTTACATCCTTTGAAGGGAGTGCT TCAAAAATGAAAGCATCAGAAGATAAAATATTTTTATATTTATGCATAGCAAG CCTTCGTGAACGGAAGTGACACACTCTGGATTGAATAATACTGTAGCCTCATTC ATATGTAGTTATTCAAATTGGATTAATGTCTGTGTGAGTTTATTTGAACTAGCA GAAAGTATCTGAAGATATTCAGGAATAAAGTTTATACTTAAAATAGCTTATGT TAAAGAAAATACCTGTGATTAATTCAGAGGGAAATAAATGCATGGTATAAAAG AAAACCAAAAACTTAAAAAATAATACTATAGCCTGAGCAACACATTAAAACTG CACACTTGTGCAGCGTAAGATTCTCTGGCTTATTGGCTGAGGTGTTAAGTTTAT TCCTTTTATGAAGATGTCCTATTACAGTCAGCTAAGCACTAAAGCTTTGCATTT ATATGTACTTTGCTATGGGGGAAAGAACCTTATGATTAATAAGACACATATCA AATGCATAGTCAATCATTCCCACCCCCATCCCTGGAGCTGTAACCCAAAACTG TTAAACTAAGATTCCTTTGTTTTTTTTGTTTTTTTGAGATGGAGTCTCACTCTGT CGCCCAGACTGGAGTGCAGTGGTGGGATCCTGGCTCACTGCAACCTCCGCCTT CTGGGTTCCAGCGATTCTCCTCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAG GCACATGCCACCATGCCCAGGTAATTGTTGTATTTTTAGTAGAGATAGAGTTTC ACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAGGTGATCCACCTGCTT CGGCCTCCCAAAGTGCTGGGATTACAGGTGTAAGTCACTGCTCCCGGATGCAT GTCAAGCACATTGGAAAGTTCTTACAACAATTCTGATGGAGGATTTTCTCTCCC ATCAACCAAACACCACTTAAGATTAACCTGTGGCTCAGTCTACTTAAATAAAT GCCATATTTATTTTACTTATCATTTAGAATTTGCCATTCTCAGGAACAAAACTTT TTGTACATTGGAAATGGAAAACATTGCAGTTTGGTCTTAATTTCCACATGAATA TCAAGTGTAATTTTTAATAAATTATTTGGAGAAAAATGTATTTTATTTTAGCAT GCAATTTTATGCCCAGGTTAGACTAGAGATTTGGCTGATGTTCTGGAATCTCAT TGTACTCTTAAGTAAAATAACGAGCATCCCATGACGCACCCTGTCAGGGGTTG TGAGAAAGCTGCAGTGTCCAGTTTCCCACCCCTGTTTCCTGCTGTCTCTCTCCC ACTCATCCCTGTTTCTTACTCATCCCTTTTCCTTCTTTGCCCAAACATCATATTT CTAGGCAAAGATAAGAGAGGAGATAGTGATGTCCTGAAAGGGGTTCAGAACA ACGTAGCATGGCCTTTGGTGAAAGCGTCACCGATGGGAAATAATTGAGAATTG TGCAGTGCTTGCAGCGTCAGAATCAGCACTGTTTTTTGTGTTGGTGAAAATATT CCATGTGCGTAAAGGGAGAGCATCAGGGACTTTGCAAATTCTTCACAAGGACC CAGAAATAGCTTAAAGATTCATGGTTTTCCTGTTGGCTTAAATAGCCTTAATCT TTCATTTTCTACTACCATTAAGTCGGGGAAATGACATTGAACTACCTCATTAGC AGCCTTCCCTTGATTAACTACTGACTAAAAGTGTGCTGAAAATGGCCTTTGTTT TTGTGAAGCTCATCCTATACACTAACATTTGCTTAACCATGGATTATTTTGTCTC TACAAAGCTGTGCCCTGTATTCGATTTTTACTTCAATGAGTGGTTATTGCTAGA ATTCCTACAAAAAAAAAAAAAACCGTTGCAGATATTTTTGTATGTAGCTTAAT AGATATTTAGTTTAAGGAGACTGCAACATTTGCATAAGGTGCCTAAAAACTCA AGAACCATTGATAAGTGAGATCACTCAAAATGAGCTGATATATTAAAGAAGAC CTTAAAACAGTA > 22
TGGTAAAATGCAACTTGAAATCCAAATAACTAACTTGCAAAGCAACTTTTGAA ATACAACCCATTCCAACTGAATTCTTAAATGGGGGGCTTCTTATATGGGAACTC AGGAAGAAAGAGAGATCCCCAGGCAGCATTTGGTGTGGCACTGGGAAAACAA AGATAGGTCAAAAGCTTAAAGCATAGAATGAGTTAGAGCTGGAAGAACATTT GTCCCTGGGGTCTGAGGCAGGCATGACCTGTTGAAAACCCCAGGCCAGCAGAG ACACCTGTCCAGGGCTCGATAGAAAACATTTCTTGCATTTAAGGACAGGAGGT TTAAGCCACTCGGGCTACGTTGACTCTTCATTCTAGAATCTTGGGACAGCGTAT TCCCTTTTAACTCCTGGGGAGCCCAGGGCCTTGGTCTGAGTTTAGCTTCCTCCA GGGAACCCGGGTGGAAAGGAGAGACAGGTAAGAACTCCGCAGAGGCAGCGA AGCCTGGGTTTGAGGAAGCAGAGGGAGGAGACCTGGATCAGTTACAAATGAG TTGTTAAGACCCAGGGACAATTCTACGGGCTGGGTATGAAAGGGAAGTCGGCT CAGGAGGACCGAGTGAGGGCACCGAGGCGGGACGCACGCACCCGGCGAAGGT TGCTCCACCCCGGTCAGGATCAGGCGAGGGGGAACCAGCCTGAGTGCAGCTGC CAACTCCCGCCGAGTGCGTCTGCGAACTCCCGGAGCGGAGTCCCGCGTGCCGC CACCTCCCCGCGGGACGCACTCTCCTCGCTCCCCCGGGCCCCGCGTCCTCCCCC CGGCCACCCTTCCCCACTTTTCCCCCCTTTTCCAATCACATGGCATTTTAAGAA TGCCGGAAAGATGGCGGTAGCGGCGGCGGCGGCGGCGGCTGGGCCGGCTGGC GCGGGAGGCGGCCGGGCGCAGCGGAGCGGGCTGCTGGAAGTTTTGGTGCGGG ATCGCTGGCACAAAGTTCTGGTGAACTTGAGCGAGGACGCCCTGGTTCTGAGC AGCGAGGAGGGCGCTGCGGCGTACAACGGCATCGGGACCGCCACCAATGGCT CGTTCTGCAGGGGCGCCGGGGCTGGGCACCCGGGCGCGGGCGGCGCGCAGCC CCCGGACTCGCCCGCCGGGGTCCGCACCGCTTTCACCGACCTGCCCGAGCAGG TGCCCGAGTCCATCTCGAACCAGAAGCGTGGCGTGAAGGTGCTGAAGCAGGA GCTGGGCGGGCTGGGGATCAGCATCAAGGGGGGCAAGGAGAACAAGATGCCC ATCCTCATCAGCAAGATCTTCAAGGGGCTGGCGGCGGACCAGACCCAAGCCCT GTACGTGGGCGACGCCATCCTGTCCGTGAACGGAGCCGACCTGCGGGACGCCA CCCACGACGAGGCGGTGCAGGCGTTGAAGCGCGCGGGCAAGGAAGTGCTGCT GGAAGTGAAGTACATGCGAGAAGCCACGCCCTATGTGAAGAAAGGATCCCCA GTATCCGAGATTGGGTGGGAAACACCTCCGCCTGAATCCCCTCGGTTAGGGGG CAGCACCTCAGACCCCCCGTCATCGCAGTCCTTCTCCTTCCACAGAGACCGGA AAAGCATCCCCCTCAAAATGTGCTACGTCACTCGGAGTATGGCCTTGGCCGAC CCTGAGAACAGGCAGCTTGAAATCCACTCTCCAGATGCTAAGCACACGGTGAT CCTAAGGAGCAAGGACTCAGCCACGGCCCAGGCATGGTTCAGTGCCATCCATT CCAACGTTAATGACCTGCTGACCCGAGTGATTGCTGAGGTCAGAGAGCAGCTG GGGAAAACAGGCATTGCTGGGAGCCGAGAGATTAGGCATCTTGGCTGGCTTGC AGAAAAGGTGCCAGGGGAGAGCAAGAAACAGTGGAAACCAGCCCTGGTTGTG CTGACTGAGAAAGACCTTTTAATCTATGACAGCATGCCACGGAGGAAGGAAGC CTGGTTCAGCCCAGTTCACACATACCCTCTTCTTGCCACCAGGCTGGTCCATTC AGGTCCAGGAAAGGGATCACCCCAGGCTGGTGTGGATCTGTCCTTTGCAACGC GAACTGGTACCAGGCAAGGGATTGAAACACATCTCTTCAGAGCAGAGACCAG CAGGGACCTCTCCCACTGGACAAGGAGCATAGTACAGGGTTGCCACAATTCTG CTGAACTCATTGCTGAAATCAGCACTGCTTGCACCTACAAAAACCAGGAGTGC CGTTTGACCATACATTATGAGAATGGATTTTCTATTACCACTGAACCACAGGAG GGTGCCTTTCCCAAGACCATCATACAGTCTCCTTATGAAAAGCTCAAAATGTCT TCAGATGATGGAATCAGGATGCTGTATTTAGATTTTGGAGGCAAAGATGGAGA GATTCAACTGGACCTTCATTCCTGCCCCAAGCCAATTGTTTTCATCATTCATTCC TTCCTGTCAGCTAAGATTACAAGACTGGGCTTGGTGGCCTGAAGACAGGGGTG ACTTGCCTTTGAGAAAAGAAGGGCTGCAATGCCACCAGAGAACGTGATGTCAG ACACCATCTGTAGTGAGCAGCGCACCAGATGTAGCGTGCTACAGTCAGCTTTA GCTCTCAAGAGTCGTATGTAACTGTCCCAGACTCCTCTGTCAGTTTCAGCAACT ACAAGGGATACCCTGCGAAAGTACCATGAGAAATATCAGAGTAAAACTTTCTA GAACAGTACAAGGTTAAAGAGGTGAGGTGACGGGAAATACACAGCATAGCTT TGAAATAATGACAACCAAGGACATGACCATTAGAACAGCATGTGCAGATCTTA ATCATCCCAGTTCCTAGGCAACTTGTTCACCAGGTACGCAAGGGCCGAATAGT TGAGAAATGGACATTCTTACCTACTCCTCCTAGCCCCCTATCCCCAGTAACAGT GATCCCTTTTCTTATTGTGATTTATTTCCTAATTCTTGCTGAGTTGACTTTCCCTT GTAGGAAAAGAAAAATATTTCAAATAGAAACCCACCTTTTATTTAAGTATGAA GCAGCTGTTACTTTTTAAAAAATGAATTATCTTTCAATGGTGTAGAATGATTCC AAAGTGTCTCCATTAGCATATACTGAGCAGGAATTAAATAAAGCATCAGATAC TGATCTGAGCTGTAAGCTGGTAGAATCTGAGCCAAAGTAGACTGCTTAAATTG ATAAGCTTTGCTAAAGAGTTGTATGCACAAAGGATGATTAATTCTGGGACTAT ACTCACACCAAGGTCTGCTGTCTTATAGCCAAGAATTACAGCTTTATTTATAGA GAGTGAATTATGGGTATTTTTTCAGAAAATATTGTCATCTGATATACACATAAA ACAACTCACATTGTTGGAGTTAACTAATTATCCCCATTTCATGGTTTTCAGTGG CAACTTACTGACCCTTGTTTTTGCCTGTGCTTGTATGCATGCATTTTCAAGCAA GTAATAAAGCAGCCTCATTTAATTCTGGATAATGCTGGGTTTTACATATAGACT GAATGCTATAATCAAATCTATTGACAGTATCTGCAGTTCTTTCAGAATTCCAGG GAAATAATATAACGACCTGATATCTTTCTACAGGAATATTTTCAGACATTATAT AGCACATTACTGATTTAATGCTTTTACTTTTATCTTTCAAAACAAATTCACTAA AAATAACACCTATTGATTTTGAAGTCACTTTTCTCAAACCTTGAAAATGAGCTC TAGGATCTCTATAAACATTTCTAACACTTTTCCTGTAGTTTACATAGACAGACA TCTGTTGTTAGACCTGTGTGTTTTTAAAGAATCATATGTTAACAAATACCCATG CAAAGAGCTTCAAAAAGTGAAACCGTGTTAAAGGAACACAATTTTTCTCACTC AGACATATTTGTTTATTGAATTGCAAAGTTTTATTTTAAATCAGCATTTCCCCA AAGAATATATCATATGACGCTAGTTCCAAGGGGCTTGACTGAGTGGTGTTTTG CTGGGGGGAGACAGGGGTTTGTTAATACACTTTACTAAATACTGAGCTGAAAA ATGTTAAATAGATTTCACGATTGCCTCCTTGAAGATTTTAAAGTTCATTGTGGT TCTTCAAGGCGAAATCCGGTGAACCATTCCTCACACTTACCTACAGGACTCTTT TCTAATGGAGCATCTTGTGAAGCTAGTGGGTTTTTTTGTTGTTGTTATTTGTTTT TTTTTTTTAATGCTTTAGAAAACACAGCTTTAGGATATTGACTTTTTGTTTATTT CTATTTTCAAATGCTGAAAAGTCAAGTCCCAGTTTGAATACCATAGAAAAGCT TTGATGCATTTGTAAATTATATTGCACTCTTTCACTATATATTTTCAAAATCACT GGAATGTTGTTATACAAGAGAATTATAATTGTGTATTGTAAATAACATATTAA AATACATATATTAATGCCAATAGTTAAATTCAACAATATGTAATCTAAGGTGCT CGGTTCTACATGAAGTATGAGTTAACTGCTCATAATTAAGTTGCCAAGATTCTA TTATATATTTATAGACAAATTAAAATGATCATAATTACAAATATGATTTCTTTA TCACTTAAGCTTTGGGCTGATTAATATCTGTGTGGGGGTCAATGGAAACTACAT TCTCTACATTTATAAACATTTAATTTAATTATTTATATTTTAGGAAAATATATTT GAATAAAATTAATGCATTTTCTAGAGTAAATTAAAATGTTATTAGCAAGAAAT AGAAAATTTGACTAAGATAATTGTGTATATGAATCATTTTTCCCCCAAGTTAAA ATGTATCATAATAGAGAGGCTCTAATGAATCAATTTCCAATACTCATTTCTTTC TTATTTTGAATTCAAGTTACAATGACTTTACACTGTAGATTTTAATCTTGTCTGA TGTGTGCTGGTGTGTATGACACAAACTCATAAGTCTGGATCATGCTTGGGTACA GTCAATGAATCAACCGAGTCACTTTGAGGAATTTGTTTTTGTCCAATTTGCTCT GTGCTCAATCCCATGAATTATTAAATTTACAATGTTTGTCCCCAAATGAAAACC AATATAAATGAATGATGTTTTAATCTGTACTTTATGGGAAGTTGCCTATTTGTC AGTAGATGTGGTTAAGTGAGTCCTCTGGTGCAGTGACATCCTTTTAAGCCATCT CATAGGGATTTAAAGAAGGCCAATAGGAATATAGATATTGGTTTTTCTTTCTCT GACTTGAACTAAGTAGGAGAAACCAAACCATAAACCTATTACAAACTACCCAG GCAGAGGCATTTACTTAATTCATCAACTAGTGCAATTAAAACCCTGAAAACAC ATGATCCTTGTTGACTCTGCTTGGTTGAAGCAGGAAAGAATGGTCTTGATGGTC AGAAAGTTTTAAAATTAATGGGCAGGGCCTTTCTGGACCCTGTTTTCCAAACAC GTTAGATATTCCGTCTTGAGGGGATTGGAGTAGGCTACAGTGAGGGGGTAATT TTTGGATGTATCTGGACTTTTAAAAAATGTGCCTATATTTATAGCACCATGAAT ATTATGTAAAATTTATATATGAATTAAATAAATATTCACCTCTGA > 23
GCAGGAAGACGGCGCTGCCCGGAGGAGCGGGGCGGGCGGGCGCGCGGGGGA GCGGGCGGCGGGCGGGAGCCAGGCCCGGGCGGGGGCGGGGGCGGCGGGGCC AGAAGAGGCGGCGGGCCGCGCTCCGGCCGGTCTGCGGCGTTGGCCTTGGCGGC GGCGGTGGAGAAGATGCTGCAGTCCCTGGCCGGCAGCTCGTGCGTGCGCCTGG TGGAGCGGCACCGCTCGGCCTGGTGCTTCGGCTTCCTGGTGCTGGGCTACTTGC TCTACCTGGTCTTCGGCGCAGTGGTCTTCTCCTCGGTGGAGCTGCCCTATGAGG ACCTGCTGCGCCAGGAGCTGCGCAAGCTGAAGCGACGCTTCTTGGAGGAGCAC GAGTGCCTGTCTGAGCAGCAGCTGGAGCAGTTCCTGGGCCGGGTGCTGGAGGC CAGCAACTACGGCGTGTCGGTGCTCAGCAACGCCTCGGGCAACTGGAACTGGG ACTTCACCTCCGCGCTCTTCTTCGCCAGCACCGTGCTCTCCACCACAGGTTATG GCCACACCGTGCCCTTGTCAGATGGAGGTAAGGCCTTCTGCATCATCTACTCCG TCATTGGCATTCCCTTCACCCTCCTGTTCCTGACGGCTGTGGTCCAGCGCATCA CCGTGCACGTCACCCGCAGGCCGGTCCTCTACTTCCACATCCGCTGGGGCTTCT CCAAGCAGGTGGTGGCCATCGTCCATGCCGTGCTCCTTGGGTTTGTCACTGTGT CCTGCTTCTTCTTCATCCCGGCCGCTGTCTTCTCAGTCCTGGAGGATGACTGGA ACTTCCTGGAATCCTTTTATTTTTGTTTTATTTCCCTGAGCACCATTGGCCTGGG GGATTATGTGCCTGGGGAAGGCTACAATCAAAAATTCAGAGAGCTCTATAAGA TTGGGATCACGTGTTACCTGCTACTTGGCCTTATTGCCATGTTGGTAGTTCTGG AAACCTTCTGTGAACTCCATGAGCTGAAAAAATTCAGAAAAATGTTCTATGTG AAGAAGGACAAGGACGAGGATCAGGTGCACATCATAGAGCATGACCAACTGT CCTTCTCCTCGATCACAGACCAGGCAGCTGGCATGAAAGAGGACCAGAAGCA AAATGAGCCTTTTGTGGCCACCCAGTCATCTGCCTGCGTGGATGGCCCTGCAA ACCATTGAGCGTAGGATTTGTTGCATTATGCTAGAGCACCAGGGTCAGGGTGC AAGGAAGAGGCTTAAGTATGTTCATTTTTATCAGAATGCAAAAGCGAAAATTA TGTCACTTTAAGAAATAGCTACTGTTTGCAATGTCTTATTAAAAAACAACAAA AAAAGACAAATGGAACAAAGAAGCTGTGACCCCAGCAGGATGTCTAATATGT GAGGAAATGAGATGTCCACCTAAAATTCATATGTGACAAAATTATCTCGACCT TACATAGGAGGAGAATACTTGAAGCAGTATGCTGCTGTGGTTAGAAGCAGATT TTATACTTTTAACTGGAAACTTTGGGGTTTGCATTTAGATCATTTAGCTGATGG CTAAATAGCAAAATTTATATTTAGAAGCAAAAAAAAAAAGCATAGAGATGTGT TTTATAAATAGGTTTATGTGTACTGGTTTGCATGTACCCACCCAAAATGATTAT TTTTGTAGAATCTAAGTTAAACTTACTATTTATAATGCATAGGTAACCATTAAC TATGTACATATAAAGTATAAATATGTTTATATTCTGTACATATGGTTTAGGTCA CCAGATCCTAGTGTAGTTCTGAAACTAAGACTATAGATATTTTGTTTCTTTTGA TTTCTCTTTATACTAAAGAATCCAGAGTTGCTACAATAAAATAAGGGGAATAA TAAACTTGAGAGTGAATAACCATAGTATTCTGCTGCAATAAATGTTTCTACCCT CTTGCGATAGAATGGTGTCAGATGTCTAACATGTTTATAAACATTTTTTTGAAT TGAACAGGTTATGAAAAGGATTTATTAAAAGGTTAAGATACTTTGTTTTGAAA GTACATTGTGATTTGCAGCCACCTAGCACTAAAGCATAGAACTTAAACACGAA TCCCTAAATGAACAGATTATGTTACATTAATCTGAGAATTTTAAATTTAGAAGC TAAAATAAATAAAAATCACAGCTGGTTGT
> 24
ATGGCGCGTACTAAGCAGACGGCTCGTAAATCCACAGGCGGTAAAGCACCGC GCAAACAGCTGGCCACTAAGGCAGCTCGCAAGAGCGCTCCGGCCACGGGCGG CGTGAAGAAGCCCCATCGCTACCGCCCTGGCACCGTGGCTCTGCGCGAGATCC GTCGCTACCAGAAGTCTACCGAGCTTCTAATCCGGAAGCTGCCGTTTCAGCGC CTGGTGCGAGAAATAGCTCAGGACTTCAAGACCGACCTGCGCTTCCAGAGTTC CGCGGTGATGGCGCTGCAGGAGGCCTGCGAGGCCTACTTGGTGGGGCTTTTCG AGGACACCAACCTGTGCGCTATTCATGCCAAACGCGTGACCATCATGCCTAAA GACATCCAGCTTGCCCGCCGCATTCGTGGGGAGAGGGCGTGAATTGTTTTGAG TACAAACCTTAAATCCAAAGGCTCTTCTCAGAGCCAACCA
> 25
CGCTGAAGGAAGGTGGGAAGCCATCAGAGCAGGAAGATAAAATAACTGCACA ACTTACTCAAAACCCAGGACAAATTCAGAGAGTCAAGGATGGAACTTTGGGCT CCCCAGAGGCTGCCCCAGACACGAGGGAAGGCCACAGCACCCTCAAAGGATC CAGACCGAGGGTTTCGGAGAGATGGACATCATCGGCCTGTCCCTCACTCTTGG CACAATGGAGAGAGGTTTCACCAATGGCAAGACAACCGTGGGAGCCCCCAGC CACAGCAGGAGCCCAGGGCAGACCATCAGCAGCAGCCCCATTATGCATCCAG GCCAGGGGACTGGCATCAGCCTGTGTCTGGAGTTGACTATTACGAAGGTGGTT ATCGCAATCAGTTGTATTCAAGGCCAGGTTATGAGAATTCATATCAGAGCTAT CAGTCTCCCACAATGAGGGAGGAATATGCTTATGGAAGTTATTACTATCATGG ACACCCACAGTGGCTGCAGGAAGAAAGAGTGCCAAGGCAACGGAGTCCTTAT ATCTGGCACGAAGATTACCGAGAGCAAAAGTACCTTGATGAACATCATTATGA AAACCAGCACAGTCCATTTGGAACAAATAGTGAGACCCACTTCCAATCTAACA GTAGGAACCCTTGTAAAGACAGCCCTGCTTCCAACTCTGGACAGGAGTGGCCG GGGGAGCTGTTTCCAGGGAGCCTGCTTGCTGAGGCCCAGAAAAATAAGCCATC ATTGGCTAGTGAGTCCAACCTTCTCCAGCAGCGTGAGTCTGGTCTCAGCTCCAG CAGCTATGAGCTCAGTCAGTACATCAGAGATGCCCCGGAGCGGGATGATCCCC CAGCTTCAGCAGCTTGGAGTCCAGTTCAGGCTGATGTCTCCTCAGCTGGTCCCA AAGCACCCATGAAGTTCTACATCCCTCATGTTCCTGTGAGTTTCGGGCCAGGAG GTCAGCTGGTGCATGTAGGTCCCAGCTCTCCCACTGACGGGCAAGCAGCCCTT GTTGAACTGCACAGCATGGAGGTTATTCTTAATGATTCCGAAGAGCAAGAGGA GATGAGAAGTTTCTCAGGACCCTTGATTAGGGAAGATGTACATAAGGTGGATA TTATGACGTTTTGCCAGCAGAAAGCAGCTCAGAGCTGCAAATCTGAGACACTG GGGAGCAGAGACTCAGCTCTACTGTGGCAGCTCTTGGTTCTCCTTTGTCGCCAG AATGGGTCCATGGTGGGGTCTGACATCGCTGAGCTGCTAATGCAAGACTGCAA GAAGCTGGAGAAGTACAAGCGGCAGCCCCCTGTGGCCAACCTCATCAACCTGA CCGATGAGGACTGGCCAGTGCTGAGCTCTGGGACCCCGAACCTGCTCACGGGA GAGATCCCCCCCAGTGTGGAGACACCTGCGCAGATCGTGGAGAAATTCACTAG GCTGCTCTACTATGGAAGGAAGAAGGAAGCCTTGGAGTGGGCCATGAAGAAC CACTTGTGGGGCCATGCTTTGTTCCTGTCCAGCAAGATGGACCCACAGACCTAC AGCTGGGTCATGAGTGGCTTCACCAGCACGCTGGCGCTCAATGACCCACTGCA GACCCTCTTCCAGCTCATGTCGGGGAGGATTCCACAGGCAGCCACGTGTTGTG GAGAAAAGCAGTGGGGAGACTGGAGGCCTCACTTGGCTGTGATTCTGTCGAAT CAGGCTGGGGACCCAGAGCTGTATCAGCGTGCGATTGTTGCCATTGGGGACAC CCTGGCTGGGAAGGGGCTTGTGGAGGCAGCTCACTTCTGCTATCTCATGGCTC ACGTGCCCTTTGGCCACTACACCGTGAAGACAGACCATCTGGTCTTGCTGGGC AGCAGCCACAGTCAAGAGTTTTTGAAATTTGCAACAACTGAGGCAATCCAGAG GACGGAAATCTTCGAGTACTGTCAGATGCTGGGCCGCCCCAAATCCTTCATCC CTTCTTTCCAGGTGTATAAGCTCCTTTATGCTTCCCGTCTGGCAGATTATGGCCT CGTGTCCCAGGCTTTGCATTACTGCGAAGCCATTGGTGCAGCTGTCTTGAGCCA GGGAGAGAGCAGTCACCCTGTGCTATTAGTGGAACTCATCAAGCTAGCAGAGA AACTGAAGCTGTCAGATCCTCTGGTTTTAGAAAGACGCAGTGGAGACAGGGAC CTGGAGCCAGATTGGCTAGCGCAACTTCGGAGGCAGCTGGAGCAAAAGGTAG CAGGAGACATTGGGGATCCTCATCCTACTCGCTCAGATATTTCGGGAGCCGGA GGAACAACAACAGAAAACACTTTCTACCAGGACTTTTCTGGATGTCAAGGCTA CTCTGAAGCCCCTGGGTACCGCTCAGCTCTGTGGCTGACACCTGAGCAGACCT GCCTGCTCCAGCCCAGCCCACAGCAGCCCTTTCCCCTCCAGCCGGGCTCCTACC CAGCAGGAGGGGGTGCAGGGCAGACAGGGACACCGAGGCCTTTTTACTCAGTT CCTGAGACCCATCTACCAGGGACTGGCAGCAGCGTGGCAGTGACAGAGGCCA CTGGAGGAACAGTCTGGGAGGAAATGCTGCAGACACACCTGGGCCCTGGAGA GAACACAGTGTCTCAAGAAACTTCCCAGCCTCCTGATGGCCAAGAGGTCATTT CCAAACCACAGACACCATTGGCTGCTAGACCACGAAGTATTTCTGAGAGTTCC GCCAGTTCAGCCAAGGAGGATGAGAAGGAGTCCTCTGATGAGGCTGATAAAA ACTCTCCCCGAAATACTGCCCAGAGAGGCAAGCTCGGAGATGGGAAGGAGCA TACAAAGAGCTCAGGGTTTGGCTGGTTCAGCTGGTTTCGATCGAAGCCCACCA AGAACGCATCCCCCGCTGGAGACGAGGACTCCTCAGACAGCCCTGACTCTGAG GAGACCCCCAGAGCATCTTCTCCCCACCAGGCTGGCCTGGGCCTCTCACTGAC ACCTTCCCCTGAGTCCCCACCTCTGCCGGATGTTAGTGCCTTCTCCAGGGGCAG AGGTGGGGGTGAAGGCCGAGGATCCGCATCCAGCGGGGGAGCAGCTGCGGGC GCTGGGGTTGGAGGCTTGTCTGGACCAGAGAGTGTTTCCTTTGAGCTCTGCTCC AACCCTGGTGTTCTTCTTCCTCCACCTGCCTTAAAAGGGGCTGTTCCTCTTTACA ACCCATCTCAGGTGCCTCAGCTGCCCACGGCCACTAGCCTGAATCGGCCAAAT CGCCTAGCTCAGCGTCGCTATCCCACCCAGCCATGCTGAGAATAAACACACGT CCCAGGCTCATCTCCCAGGACTGAAACTTTCTTGCTCTCTTTTTCTCAATCTCCC AGCCCCTCTCTACCATATTGGGACCCTCAAGAGGTTTGTGCTAGCCCGATGCCT CCACCGGGCACTTAGAAGGCAAGAGGACAGGATCTCTCAAGACACAGCACAA TTCAGTCTCTTAAGATTAGCTTCACAATGATGGAAATTATTTCATCAGGTGGAA AGTCTGGGTCTAATAGCAGACTGCACATGAGCAGAGTGACATGGTGGTGGCAC TTATGGTGGTGGCTTGAGAGCCTTGGGGAAATTAGGGCCCTAACAGCTAGAAT CAAAGATGATACCGCAGGGCCCTGTAGCAAGAAATGGGAAGCAGGGGGAGGG GCAGGGGCTCAGAACAATATTCTAGACCAACTTTGACTACTTCCTGTCTTAGTA ATAGACCAATACATGGCTCTATTTAGCAAAGTTTTTATACTGAAACTTGATTAT TGCTGCCCTTTATAATTTCCTCTTCAATGATATTTCAGCAGTTTCCCTCTTGGTC CTAGTTTTGTGCACATTTTTTTGAATGTGGTTCAGATTAATTATATTTCTCTCAC TTTCTTAGCTGGTCCTATTTTTTCACATTCTGGCATGTGGCTATCAAGTTAGATT GCTGTAGGCATCATATTGTCATGGTAACTACTGAACCTAATGATGCAGATGGA TGGCACATCAGTATAATAAATGATGGAAAACGGTTCCT
> 26
GAATGCAGGTGAGAAAAGGCACGGACTCTGCGGCTGCGAACCCAAACTTGGG CACCGCACGGTGCGCACTGCTCAGCCTTCGCCCCCGTGGGCGAAAGGCTGCTG CGGTTTCAGGCGGCTGCTTCGTGACTAATGACCTTGCGCAGAGTTGTTAAGAA AAAAGAGAAACCCGCGCTCTCCGGGGTGAGAAGGGACTGACTCTGGGCGTCTC TGAAGATGGCTCGGGCTTCTCTTTGGCGCGCCGGGGGGACCCTGACACTGACC GCTCTGTGACGCGAGTAGTCTCCCCTGCACCGTGCCCGAAGCGACGTGCCGGG GGATTTTTCATTCTCGATCTGTTGACTGGCTCCCCCGCTGCATGAGCAGAGTCG GAGTTGAGACTGGCTTGTTGCTGGCCCCAGCGCCTGGTGCAGGAAGCGACTCA CGTTTGTCTGGGTGGCCGGAGCCGGAGCAGAGCCTGGGTTTGGAGTGAGTGCC TGGAACGTGAATTGGACTCAACTCGAGTAGCAGCAAAGACCAGCGGGCTGGC AGGCGGGGGAGGCTGCAGGCTCATTCCCCACCTCTTCCCAGCCCCACTGCCCG TCTGCCGGAGCGGTTCTGGCCCCTTCCGACAGAGCGGGGACTAGAGCCGGGGA TTCTCCGCCCGCTGAGGGGATGACTCTGGGTTGGGGGAGCGCCGAACCCGCGG CGCGCAGTGTCCCGTGAACTGTGAGTACTGCGACTGAACGGCGGCAGGCGAGC GGGCGATTAGCACCCATTGCATGAATTATGAAACAATAACTTTCGGAAGAAGC AGGAGGAAAAAAAGAAGCATCTATCGCTGCCCTCCCACCCCCATTCCCGGCCA ACTCTCCACGCCGCTTTTGCCCCCTCCCTCCCCTCCCTCTCGCTCCTTCCTTTCC GGGAGAGGGGAGAGGACTCGGGGGAGGGCAGGCGGCCGGCCCCGGAGGAGG GGGGCGCCGAGGGGGCTGTGGTTAGAAGGAGCAGTAGCAGCAGCAGCAGGAG AAGATGCTGAGGATGCGGACCGCGGGATGGGCGCGCGGCTGGTGCTTGGGCT GCTGCCTCCTCCTGCCGCTCTCGCTCAGCCTGGCGGCCGCCAAGCAGCTCCTCC GGTACCGGCTGGCCGAGGAGGGCCCCGCCGACGTCCGCATCGGCAACGTGGCT TCAGACCTGGGCATCGTGACCGGATCGGGTGAGGTGACTTTCAGCCTGGAGTC CGGTTCCGAGTACCTGAAGATCGACAACCTCACTGGCGAGCTGAGCACGAGCG AGCGGCGCATCGACCGCGAGAAGCTGCCCCAGTGTCAGATGATCTTCGACGAG AACGAGTGCTTCCTGGACTTCGAGGTGTCGGTGATCGGGCCCTCGCAGAGCTG GGTGGACCTGTTTGAGGGTCAGGTCATCGTGCTTGACATCAACGACAACACGC CCACCTTCCCGTCGCCCGTGCTCACGCTCACGGTGGAGGAGAATCGGCCGGTG GGCACACTTTACCTGCTGCCCACAGCCACCGACCGCGACTTCGGCCGCAACGG CATCGAGCGCTACGAGCTGCTCCAGGAGCCCGGAGGCGGCGGCAGCGGCGGC GAGAGCCGGCGCGCCGGGGCGGCCGACAGCGCCCCCTACCCCGGGGGCGGCG GGAACGGCGCGAGCGGCGGCGGCTCGGGAGGCTCCAAGCGGCGGCTGGACGC ATCAGAGGGCGGCGGCGGCACCAACCCCGGCGGCCGCAGCAGCGTGTTCGAG CTGCAGGTGGCGGACACCCCGGACGGCGAGAAGCAGCCGCAGCTGATCGTGA AGGGGGCGCTGGACCGCGAGCAGCGCGACTCCTACGAGCTGACCCTGCGAGT GCGCGACGGCGGCGACCCGCCTCGCTCCTCGCAGGCCATCCTACGGGTCCTCA TCACCGACGTGAACGACAACAGCCCCCGCTTCGAGAAGAGCGTGTACGAGGC CGACTTGGCTGAGAACAGCGCCCCGGGGACCCCCATCCTGCAACTGCGCGCAG CCGACTTGGACGTGGGGGTCAACGGGCAGATCGAATACGTGTTCGGGGCGGCC ACCGAGTCGGTGAGGCGGCTGCTGCGCCTTGACGAGACGTCCGGCTGGCTCAG CGTCCTGCACCGGATCGACCGCGAGGAGGTGAACCAGCTGCGCTTCACGGTCA TGGCCCGCGACCGCGGGCAGCCCCCCAAGACCGACAAGGCCACCGTGGTCCTT AACATCAAAGACGAGAACGACAACGTGCCGTCCATTGAAATCCGCAAGATTG GGCGCATCCCCCTCAAGGACGGGGTGGCCAACGTGGCCGAGGACGTTCTGGTC GACACCCCCATCGCTCTGGTGCAGGTGTCCGACCGAGACCAAGGCGAGAACG GGGTGGTCACCTGCACCGTGGTGGGCGACGTGCCCTTCCAGCTCAAGCCAGCC AGCGACACCGAGGGCGACCAGAACAAGAAAAAGTACTTCTTGCACACCTCGA CCCCTCTGGACTATGAGGCCACCCGGGAGTTCAACGTGGTCATCGTGGCGGTG GACTCAGGCAGCCCCAGCCTCTCGAGCAACAACTCCCTGATTGTCAAGGTGGG AGACACCAACGACAACCCGCCCATGTTCGGCCAGTCGGTGGTGGAGGTTTACT TCCCTGAGAACAACATCCCGGGCGAGAGGGTGGCCACGGTGCTGGCGACAGA CGCAGACAGCGGTAAGAACGCCGAGATCGCCTACTCGCTGGACTCCTCTGTGA TGGGGATCTTTGCCATCGATCCCGATTCTGGGGACATCCTGGTCAATACCGTGC TGGACCGCGAGCAGACTGACAGGTATGAGTTTAAAGTTAACGCCAAAGACAA AGGCATCCCCGTGCTGCAGGGCAGCACTACGGTGATTGTGCAGGTGGCTGATA AAAATGACAATGACCCTAAGTTTATGCAGGACGTCTTCACCTTTTATGTGAAA GAAAACTTGCAGCCCAACAGCCCTGTGGGGATGGTCACCGTGATGGATGCTGA CAAGGGGCGGAATGCAGAGATGAGCCTGTACATAGAGGAGAACAATAACATT TTTTCTATTGAAAATGACACGGGGACCATTTACTCCACAATGTCTTTTGACCGG GAACATCAGACCACATACACTTTCAGAGTCAAGGCTGTGGATGGGGGAGATCC TCCCAGATCTGCCACAGCTACAGTCTCGCTTTTTGTGATGGATGAAAATGACAA TGCTCCCACAGTTACCCTTCCCAAAAACATTTCCTACACTTTACTGCCACCTTC GAGTAATGTCAGGACAGTAGTAGCTACAGTGTTGGCAACAGACAGTGATGATG GCATCAATGCAGACCTGAACTACAGCATTGTGGGAGGAAATCCCTTCAAGCTG TTTGAAATTGATCCCACTAGTGGTGTGGTTTCCTTAGTGGGAAAACTCACCCAA AAGCATTATGGCTTGCACAGGTTGGTGGTGCAAGTGAATGACAGTGGGCAGCC TTCCCAGTCCACCACGACTCTGGTGCACGTGTTTGTCAATGAAAGTGTTTCTAA TGCAACTGCGATTGACTCCCAGATAGCTAGAAGTTTGCACATCCCACTCACCC AGGATATAGCTGGTGACCCAAGCTATGAAATTAGCAAACAGAGACTCAGTATT GTCATTGGCGTGGTTGCTGGCATTATGACGGTGATTCTAATCATCTTAATTGTA GTGATGGCAAGGTACTGCAGGTCCAAAAATAAAAATGGCTATGAAGCCGGCA AAAAAGATCACGAAGACTTTTTTACACCCCAACAGCATGACAAATCTAAAAAG CCTAAAAAGGACAAGAAAAACAAAAAATCTAAGCAGCCTCTCTACAGCAGCA TTGTCACTGTGGAGGCTTCTAAGCCAAATGGACAGAGGTATGATAGTGTCAAT GAGAAGCTGTCAGACAGCCCAAGCATGGGGCGATACAGGTCCGTTAATGGTG GGCCCGGCAGTCCTGACCTGGCAAGGCATTACAAATCTAGTTCCCCATTGCCT ACTGTTCAGCTTCATCCCCAGTCACCAACTGCAGGAAAAAAACACCAGGCCGT ACAAGATCTACCACCAGCCAACACATTTGTGGGAGCAGGAGACAACATTTCAA TTGGATCAGATCACTGCTCTGAGTACAGCTGTCAAACCAATAACAAGTACAGC AAACAGCCATTTCGTAGAGTGACGTTTTCTGTTGTGAGTCAGCCTCAGGACCCA CATCAGGGGTCACTGCAGAGTTGCTATGACAGCGGGCTGGAGGAGTCAGAAA CACCAAGCAGTAAGAGTTCATCAGGGCCAAGACTGGGTGCGCTTCCACTCCCA GAGGACAACTATGAAAGGACCACGCCGGATGGCAGTGTTGATTCAAGGCCTCT TCCAGATGTAGCCCTGACTGGGAAGTGCACTCGTGAGTGTGATGAGTATGGCC ACTCAGACTCCTGCTGGATGCCGGTCCGCACTTCTCCGGAGAGGAAGAAGAGC CAGCCTAAACTGTCCACTTTCATGCCTGTTGATGAACGAGGAAGCCAGGAAAA GCTGGCCAATGGGGAGGCCGCCATCATGGGTGACCGCAACAGAAACCTCCTG AACAAAAAGTTGACCTCATCCTATGAGACCTTCAGTGCAGCTAGTTTCAGCAA AAATGAGGAAGCCAACCCTGAGGATATTCCCCTTACAAAAACAGGGGAATAT AAGCCATCTCCTGTCAATACTCTCACTAGAAGAGAAGTTTACCTGTAGGCTATA AAGGAGCAACAGCAAAGTTCTTTACATGTATGAAAAGGAGAATAAGGGGCAA AAACCTTACAAAGCAAAACGTTTAATCACAAAGAGGGGGCTACCAAAGAGAC AAAGCTTTGCCTGCCACTTCTGCCTCCAGATCAGGCCTTTAGTGATACTGTTAG CCTGATTCTACTGTACAATGTAGAAACCATCCTTGTTACTTGCATGTCTAACCC CTTCACTGATTCCCAACACTCACTTTCTCTTCCCCACCCCTCTCCAAAAAAAAA AAAACAAAAAGAAAAGAAAAAAAAAGGGGGATAGTTGCAAGTTTCTTTCACA GTAACTGTACGAAGCCTGATTAGCAGAACACAACACACCCTCATTATCCCTAA GCTGAAGCATGATTTTAGTCACTTTGATTTTGTTCGAGTGTCATCTGGCTGGTC AAAAATAAGCAGGACAGATAAAATGTATTTCAGACATACCATCAGAAAATGG TTTATCACCATCAAAGGCAATCCTTTGAAAGTGATAGAGTCCCTCTAAAGGTA CAGTCCTTAGAAAGAGGGACTGTATTAAAAAGTATTTTGGGAATATCAAAGCT TTAATATTCCAACAAAGACTAAGAGAAAAACAATACTCAGTGGGTGATTGCAG TCCTAAATTGTCATATGTTGTTATTTTCAGGTCAAGAGCATCAACTTCAATTCC ATACATTCACCAAATATTCTCAGTATACACACAGTCTTGATTACATGTATCAAT TTCACCAGTTATGACTTCTAAAAATTATATATATTTTTTCAGAACAAGACCACT ATTATTAACTAACTTGAACAATTGTATCATCCAAAGGCCAAAGATCATATGGC AGATCAGGGAAGTCATGAAGTTGATTTGGTCTTGACGTGGAAAACCATTAAAC AACAAAAGCAACTGAACCCATGTATGCACAGAAACAATCAAACACTAGTTCAT TTTATAGTGCCCAGGAAAATGTTCCTTCTTTTAAAATGGATTTTATTTGAAAGC GCAGAAAATGAAAACTAGTGAGATATATTTTTGGTATTATAATAGGCAATTGG TTGAGGTTCAAGTTTAGTTTCAGGTAATATTATCAGGGAAGATTCCATGTTTTA AAATAGTATTTATGGATCATGGGTAGGTTAAGAAAGATGCATTGGCATATAGT CTTGATAGTTAAGTCCACGATTATCATTTTAGAATCCAGGCTATGCTTGCTGCT CTTTTTATCCACATTTTAAATTACAATTGCATTTTTTACTTGTTCAGTGCACACT TTGATGCACCACAAGTGCATTAATTTTGAATCGTGTGCAATATAGAAATATTTT GAGACTCACAACATTGAAACAAGGTGACACCCTAGTTGACTTTATCACTAATG TGATTTGAACATTATTTAAACAAATCTAGACTGAACATGAAAGAAAGGAGTTT TGGGCAGTGACATTTTTCACAGAATGTATATCTCAAAGGTGAAAGCAGAGTTT TTCCAGTGCAATAAAAAGAAACAGAATATGCAGATTTTGAGCTACTCACTCTA TAGAGGATAACCTAACACGGCTGAAAATTGAGCTGGGACATTCAGACGAAAG TGACAATCCATGGACAGAATAGGGAATAACAGGTGTGAAGAGAACAAACTTA TCACTGAATGTTTGCAAGCTGGTTAAGGCATAGCCTTGATGGCTCTCTAGCAAA CTGTAGAAACAATGTAGCTTTGGGTAGTTTCATGCTTTGCAGAATTTCTTAGAC TATAAAGTGACACAGCCTGGAATATAGGTTGATAATTCACTATAGGTCTTCAA AATACTTATCTTTGAAAACCGCTTCTCTGTTTGGTGGGGTACAATTTGGGGGTC ATTTCCTTATGCTCTTTCTTAAATGGAGTTTTCATTTTGATGTTAGTTTATGTAT AATAGGTAGGATGCAAAAAGATATGTAATTGAAACAAAAAACATTGGACTAA AATATCAGTAATTGAACATGTTTATGTTTGATTATTATTTACACTATGGAAAGA TGCAATTCTAGTACTTTGTTAGGAAACTGCATTAAAGCAGTTCTGCCTTGTATA ATCTGTAAGTACCTATTAAGACAAAATACTTCTAAAGATACTTATGAAATGTAT ACACATTTTTTCTTGCACGTTACAAAGAAAATACTCAATTGCATAACACGGATG TTTGACAAACTTTTTTTTTTTTAATGCATTTCTTTCTTTCATGAGACATTGAAAC CACTGATAGCTCATTTCACCCTATCTTAAACCCTTCTCTTGTCTATAAAACTAAT ACGGGTCACACCGGACCTTCGGATTAATTGGATCCACATTCCCCAATGATGTTT GCACCCCATTCAAGATAGCCATGCCATTGTCATTTAACTCGTGAACCTCTCTTT AAAACTAAAATGGATGTGAAAGAATAAAATTCAGTGTACTGTAAGTATTCACA GTAATTCTAGTAGAATTAGCTGTCATAACATGTTTATTATATAATGAGCTGGCA TGACACAGAAATATATTTTGTGTTTGTATGACTTTTATTTTAAATAGGTTAAAT CTGGTGCCACTCCATATATAGAGTGCTTTTGAAAAAAAATCAATAAAAAGAAA CAAAAAAAATAAATGAGTGAATGCAAAATAAGCAACTGTGCCTTTTATACCTG TTGTTACGGTAAAAAAACGGTTGTTGGGTTTGGACAATGAGGGGAAATGGGCT ATTCCCAACTTTTTTGATCCTGTATATTTGTCCATGTTTATTTTCTGAACATAAT AAATAATATATTAAAAATTTGCCTTCTGACAAACTCAGATAATGGACCAGTCTT AAATATTGTTATGTCATAAAGCAAAGTTAAGGCATTAATATGGGCTGCTTAAA TCTGACTAGAAGATGAAAGCGTTTATTGTAAGTGTAACACAGAGATACTATCA GGAGTGAAATCAGTCCATTTGGCAAGGTAAAATACTGATTTAGAGTTTTATTCT TTATTTCTTTTTTGTTGTGTTTCTTTCAGCTATGGTTTCATTTTGGTTGTACAGTA TATAAACCATATTTGTTTTCTGTACACAAGACTCTCAAGTGAATTTTGCATGCA TTATACATTAGGACACATTTATAAATTAATGAGTAACTATATAAATTTATGTGT ATTAAAACGTCTGTAGCTTCAATCTAAAATCTACTGCTCTTTCTGAATCTCCAG ATATCATTTCTGTATGGTTTCTGACTGGCCTGCTGCCTGAGTTTCAGAAAACAA GGGAGGCATTATTTTTATGGGAGGAGGAACTAAGATGGTACTGAGGATGTCTG ACTGAAACACTACCCTAGGAAGCTGTCTTGTAGGAAAATAGAATAAAACACAC AGACCAGAAGAAATTGTCAAGAAGCAAACAGCCATCCAAAAACAGTCATGAG AAATCTAAAGACCTAAATAATCTTAGGTATATGCTCTCAGTGAGAAATAAGAA AATGTGTCCTTAAGCAAAAATAAATAAATAAATAAATAAATAAATAAATAATA AAAAGTGAGCATGATCATGAATATAGTAAATCTTGTGAGTTGTGACCTAGGTG AAGGTGTAATGATAACATCTGGAGGAAGCATCATTTGTTCAGCTACCTAGGGT TTACTTTCAGACTTTTCCTACAGTTTAAAGCACTTGCGTTCAGTGTGGTACGAT CTGTTTGTAATGTTAATCATTGACTATTGTTCTGCTACTTGGATGTTGATAGTGA AGCAGAGAACAATTTATCATCGTTTATTATGAGTCACTATGCACGCAACTATGC TTAACATGGCGAAATGTATTAAACACTCGTCCAACTATTTATGAAATACTTTGC ATAATTTAATTTGCTTTTGTACAGTTTTATGTAAATAAATTGCTTGTCATTTTTG TCTCTGCAAATTAAAATATAACATGGTCAAATGGTTT
> 27
AAGAAACTTCCTTTCCCGGCGTGCACCGCGAATCCCTCCTCCTCTTCTTTACCT CTCTCCCTCCTCCTCAGGTTCTCTATCGACGAGTCTGGTAGCTGAGCGTTGGGC TGTAGGTCGCTGTGCTGTGTGATCCCCCAGAGCCATGCCCGAGATAGTGGATA CCTGTTCGTTGGCCTCTCCGGCTTCCGTCTGCCGGACCAAGCACCTGCACCTGC GCTGCAGCGTCGACTTTACTCGCCGGACGCTGACCGGGACTGCTGCTCTCACG GTCCAGTCTCAGGAGGACAATCTGCGCAGCCTGGTTTTGGATACAAAGGACCT TACAATAGAAAAAGTAGTGATCAATGGACAAGAAGTCAAATATGCTCTTGGAG AAAGACAAAGTTACAAGGGATCGCCAATGGAAATCTCTCTTCCTATCGCTTTG AGCAAAAATCAAGAAATTGTTATAGAAATTTCTTTTGAGACCTCTCCAAAATCT TCTGCTCTCCAGTGGCTCACTCCTGAACAGACTTCTGGGAAGGAACACCCATAT CTCTTTAGTCAGTGCCAGGCCATCCACTGCAGAGCAATCCTTCCTTGTCAGGAC ACTCCTTCTGTGAAATTAACCTATACTGCAGAGGTGTCTGTCCCTAAAGAACTG GTGGCACTTATGAGTGCTATTCGTGATGGAGAAACACCTGACCCAGAAGACCC AAGCAGGAAAATATACAAATTCATCCAAAAAGTTCCAATACCCTGCTACCTGA TTGCTTTAGTTGTTGGAGCTTTAGAAAGCAGGCAAATTGGCCCAAGAACTTTG GTGTGGTCTGAGAAAGAGCAGGTGGAAAAGTCTGCTTATGAGTTTTCTGAGAC TGAATCTATGCTTAAAATAGCAGAAGATCTGGGAGGACCGTATGTATGGGGAC AGTATGACCTATTGGTCCTGCCACCATCCTTCCCTTATGGTGGCATGGAGAATC CTTGCCTTACTTTTGTAACTCCTACTCTACTGGCAGGCGACAAGTCACTCTCCA ATGTCATTGCACATGAAATATCTCATAGCTGGACAGGGAATCTAGTGACCAAC AAAACTTGGGATCACTTTTGGTTAAATGAGGGACATACTGTGTACTTGGAACG CCACATTTGCGGACGATTGTTTGGTGAAAAGTTCAGACATTTTAATGCTCTGGG AGGATGGGGAGAACTACAGAATTCGGTAAAGACATTTGGGGAGACACATCCTT TCACCAAACTTGTGGTTGATCTGACAGATATAGACCCTGATGTAGCTTATTCTT CAGTTCCCTATGAGAAGGGCTTTGCTTTACTTTTTTACCTTGAACAACTGCTTG GAGGACCAGAGATTTTCCTAGGATTCTTAAAAGCTTATGTTGAGAAGTTTTCCT ATAAGAGCATAACTACTGATGACTGGAAGGATTTCCTGTATTCCTATTTTAAAG ATAAGGTTGATGTTCTCAATCAAGTTGATTGGAATGCCTGGCTCTACTCTCCTG GACTGCCTCCCATAAAGCCCAATTATGATATGACTCTGACAAATGCTTGTATTG CCTTAAGTCAAAGATGGATTACTGCCAAAGAAGATGATTTAAATTCATTCAAT GCCACAGACCTGAAGGATCTCTCTTCTCATCAATTGAATGAGTTTTTAGCACAG ACGCTCCAGAGGGCACCTCTTCCATTGGGGCACATAAAGCGAATGCAAGAGGT GTACAACTTCAATGCCATTAACAATTCTGAAATACGATTCAGATGGCTGCGGC TCTGCATTCAATCCAAGTGGGAGGACGCAATTCCTTTGGCGCTAAAGATGGCA ACTGAACAAGGAAGAATGAAGTTTACCCGGCCCTTATTCAAGGATCTTGCTGC CTTTGACAAATCCCATGATCAAGCTGTCCGAACCTACCAAGAGCACAAAGCAA GCATGCATCCCGTGACTGCAATGCTGGTGGGGAAAGACTTAAAAGTGGATTAA AGACCTGCGTATTGATGATTTTAGAGATTTCTCTTTTTTAAATGGAATTCGTAA AGAAATATAAAACTTCAGCTCACAATTAAAACTGTCTTTTTAGTTTTGGCTTTT TATTGTTTTGTTGGTGATTTTACTGAAATAAAGTTGAGCTACTTCTTCTTATAGT GGCATATTCTTTGTAAATTTTAACAAGGTTTAATCTTTTGATTTACAAATTAAA AAATTTTGAATTAGCTTTA
> 28
AGTGAGCCTGCGCAGGAGGCCAATAGGCTGCCAATACTCCTTGGACTCCCCGC CAGGGCCCTGCTGTCAGTGCGCCTGCGCGCGGGTCCGGCGCCGAGGTTCTTGA CTGCTGTGCCGGACGCCAGGTGTAGCCATGCAGCGAGCCGATTCCGAGCAGCC CTCCAAGCGTCCCCGTTGCGATGACAGCCCGAGAACCCCCTCAAACACCCCTT CCGCAGAGGCAGACTGGTCCCCGGGCCTGGAACTCCATCCCGACTACAAGACA TGGGGTCCGGAGCAGGTGTGCTCCTTCCTCAGGCGCGGTGGCTTTGAAGAGCC GGTGCTGCTGAAGAACATCCGAGAAAATGAAATCACAGGCGCATTACTGCCTT GTCTTGATGAGTCTCGTTTTGAAAATCTTGGAGTAAGTTCCTTGGGGGAGAGG AAGAAGCTGCTTAGTTATATCCAGCGATTGGTTCAAATCCACGTTGATACAAT GAAGGTAATTAATGATCCTATCCATGGCCACATTGAGCTCCACCCTCTCCTCGT CCGAATCATTGATACACCTCAATTTCAACGTCTTCGATACATCAAACAGCTGGG AGGTGGTTACTATGTTTTTCCAGGAGCTTCACACAATCGATTTGAGCATAGTCT AGGGGTGGGGTATCTAGCAGGATGTCTAGTTCACGCACTGGGTGAAAAACAAC CAGAGCTGCAGATAAGTGAACGAGATGTTCTCTGTGTTCAGATTGCTGGACTTT GTCATGATCTCGGTCATGGGCCATTTTCTCACATGTTTGATGGACGATTTATTC CACTTGCTCGCCCGGAGGTGAAATGGACGCATGAACAAGGCTCAGTTATGATG TTTGAGCACCTTATTAATTCTAATGGAATTAAGCCTGTCATGGAACAATATGGT CTCATCCCTGAAGAAGATATTTGCTTTATAAAGGAACAAATTGTAGGACCACT TGAATCACCTGTCGAAGATTCATTGTGGCCATATAAAGGGCGTCCTGAAAACA AAAGCTTCCTTTATGAGATAGTATCTAATAAAAGAAATGGCATTGATGTGGAC AAATGGGATTATTTTGCCAGGGACTGCCATCATCTTGGAATCCAAAATAATTTT GATTACAAGCGCTTTATTAAGTTTGCCCGTGTCTGTGAAGTAGACAATGAGTTG CGTATTTGTGCTAGAGATAAGGAAGTTGGAAATCTGTATGACATGTTCCACAC TCGCAACTCTTTACACCGTAGAGCTTATCAACACAAAGTTGGCAACATTATTGA TACAATGATTACAGATGCTTTCCTCAAAGCAGATGACTACATAGAGATTACAG GTGCTGGAGGAAAAAAGTATCGCATTTCTACAGCAATTGACGACATGGAAGCC TATACTAAGCTGACAGATAACATTTTTCTGGAGATTTTATACTCTACTGATCCC AAATTGAAAGACGCACGAGAGATTTTAAAACAAATTGAATACCGTAATCTATT CAAGTATGTGGGTGAGACGCAGCCAACAGGACAAATAAAGATTAAAAGGGAG GACTATGAATCTCTTCCAAAAGAGGTTGCCAGTGCTAAACCCAAAGTATTGCT AGACGTGAAACTGAAGGCTGAAGATTTTATAGTGGATGTTTCACAACTTCTGC CAGAGAAATTTGCAGAGCAGCTGATTCGAGTATATTGTAAGAAGGTGGACAGA AAGAGTTTGTATGCCGCAAGACAATATTTTGTTCAGTGGTGTGCAGACAGAAA TTTCACCAAGCCGCAGGATGGCGATGTTATAGCCCCACTCATAACACCTCAAA AAAAGGAATGGAACGACAGTACTTCAGTCCAAAATCCAACTCGCCTCCGAGAA GCATCCAAAAGCAGAGTCCAGCTTTTTAAAGATGACCCAATGTGAATGTCTGT AGTCAGTTGTTTACAAACTCCCTCTCCTGCACAATTCATTTAGAGGCTTCAATC ATAGAATTCTGCAAATTAATGACAACTCATGCTTTAATTTTGTATTTTGAATGT ACACGCATGCTGAAGCTAAGTAACTTTTAATCAAAGAAATAAGATGGTATTAG GCAAATCTTACTATACTATGAAAAGCATTACCTTGCCTATTTTTAATATTATTA AAGCCTTTCTCCTTCAGTAGTCTATTTTCTTAGAATAACAACTCTTTTATCTATT CTGAACTCTATTTTTTTTCTTTTTTAAGAGACAAGGTTTTGCTCTGTTGCCCAGC TTGGACTCGAACTTTCCTGGGCTCAAGCGACCCTCCTGCCTCAGCCCCCCAAGT AGCTGGGACTAAAGTCATGTGCCACCACACCCAGCTTACTCTGAACTTTTATGA CAGATGATTGTTTTTTGTTTTTAATGTAGAAATGAGACAAGGGTACAAATTGGA ACTAGAAATTGACATTGTCATTGACAAACATGGCTAAAAACAAAACATCAAAT CCTGCCCCCGTGAAGAGTTCCCTGTCACCTCAAGTTTGAGGATAGTCCTCTAAG AGTGACCTAAGCATAAGTGAAAGACACCTCCCCTCACCCTTCTAGCCCCCTAC AAGGTGCCAGGTTGGGGTAAAGAGTTGGAGATGATGGCCAGGAGTGGCCTCC AACACGCTGGTGAGAGGCCTGATTAGGTTTTGGGGAAGATCTGAGAGCTCTGG CCTCTTCGTGAGTGGAACATAAAGCCGCCTCTTGTTGGGAGATCCTACCCCAGT GACAGAGGAATCCCCCAAACTAGGCTGTGCCCTGGCTCCGTGGCGGCTCCAGA CCCGGGTAGTGCCTTTGTCCCCTGAATACTCACTCCCCCGGTCCAGAGGGCCTT CCCACTGCCCAGCCTGGAGAAGGCCTCCCCTGACCTGCTCTCTCAGTATCCTGG AGAGCTGGCCAGAGGCCATCACAGGCATCATCCTCAGAGCTCCTCAGACCTGG GACTTTGTTTTTGCTGGTTCAGTGCATTTTGTGTATTTAAGAGCAAACACTAGC CAGGCGTGGCGGCGTGTGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGG AGGATTGCTCGAACCTGGGAGGCGGAGGTTGCAGTGAGCCTAGATCACGCCAT TGCACTCCAGCCTGGGTGACAGAGTGAGACTCCATCTCCAAAAAAAAAAGCAC AAACACTGCACTGCCTGTGCTGAAATTAGTGACCACCCAGTGGGCTCCAGGCT CCGCTAGGTAACTTCGTTTTCCCAGCAGTGGAGTGGGCACCACCTTGGTGGGG CAGTGCCCCTGTGCCCAGGGCACACCTCATTCCCAGTTCTATAGCAATTCACCA AGAACAAAGTCTGCAGTTAGAGCCAAAGCTGGTGGTGGCCAGAGGGTGCTGA AGATACAGGCCAGTGGGGATGGGAGCCATGAGCCCCGAATGTCTTCTGCTCTG ATGCTCCCCGGACTAAGCCTCCCTGGCACACTGGGAGTGAGGGGCAGCCTGAG CAAGTAGGGGAACTCAGACCACAGGCCAGCAGATTTCCCAGCAGTCCATCACT GGCCACCGTGTAGCCAGATTCTGTTCCGTCCACACTGGGGTGAAGAGTACTTG GAATGTCTGCCATCCTGTATGATCACCCCACCCCCTGTCCATCCATCAGTAGAT AATAAGGGTTGGTTACAATTCATAAGAGAATAGTTAAAACACTTCTCCTCTCAT GCCTACCATGGTGCTGTATCAAGGGGATTTGTTCACATATGGGCTCAGCAACG CACAAGTGAGGTCAGCCATGGCACTAGGTCATTCCCATTTTAGCCAAGGTGCC TCTATAGGGGTCAGACATCATGTGCCCAGACCTAAGGTCAGGAATGTCATATT TTTCTGTTAAAATCATTTTATTTCTGTGTATCTTACCTTTAAATCATTGTGGTTT ACTCTGAGATTCTGTAGTCCTAATATTGTATCATTGTGCTGTCTGCAAAACAAC TTGAATCTA
> 29
ATGATGAATGGTCCAAAACATTCGCGGTTTCCACCAGAATTCAAGGTGTTGGC AACTACCTTCCTTGGATGTCTGAGTGA
> 30
GCCCCAACAGCGCGCACGCGGCTACCGAGCTGGAGGAGGCGGCGGGCGCGAG ACCCGGAATGCGCAGGGCCCCCGCCTCGCCCCCCCCAGCCCGGGCCGCGGCCC CCGCCTTCCCCGCAGTCGTCCCGCACTCGGTGCCCGCCCCCCGAGGCCGGCGG CTGCTCCCACTCGGGGCCGTTGCTGCTTGTGCCGTGAGCGCCGCCCAGCCATTG TCCCCGTCGCTCCGTCAGCCGCGCCGGACCGCGCACCAGGAGGCGAGAGCGCG CATGGGGAGCCTCTGTTGATGCCGCCGCCGCGCCGCCCTCCGAGGCTGCGTCC CGGGAAGCCCGGCTCCCCGAGCGCTCCGGCCTGGCCCGGTGCCCCGGACCTGA GTGCGTCCCCATGGAGGCGCCCGGGCTGGCCCAGGCGGCCGCGGCGGAGAGC GACTCCCGCAAGGTGGCGGAGGAGACCCCCGACGGGGCGCCCGCGCTCTGCC CCAGCCCTGAGGCGCTGTCGCCGGAGCCGCCTGTGTACAGCCTGCAGGACTTT GACACGCTGGCCACCGTGGGCACTGGGACGTTCGGGCGGGTGCACCTGGTGAA GGAGAAGACAGCCAAGCATTTCTTCGCCCTCAAGGTGATGAGCATTCCCGACG TCATCCGCCTAAAGCAGGAGCAACACGTACACAATGAGAAGTCTGTCCTGAAG GAAGTCAGCCACCCGTTCCTCATCAGGCTGTTCTGGACGTGGCATGACGAGCG CTTCCTCTACATGCTCATGGAGTACGTGCCGGGCGGCGAGCTCTTCAGCTACCT GCGCAACCGGGGGCGCTTCTCCAGCACCACGGGGCTCTTCTACTCTGCAGAGA TCATCTGTGCCATCGAGTACCTGCACTCCAAAGAGATCGTCTACAGGGACTTG AAGCCAGAGAACATCCTGCTGGATAGGGATGGCCACATTAAGCTCACGGACTT TGGGTTCGCCAAGAAGCTGGTAGACAGGACTTGGACCCTCTGTGGAACACCCG AGTACCTAGCCCCCGAAGTCATTCAGAGCAAGGGCCACGGAAGGGCCGTGGA CTGGTGGGCCCTCGGCATCCTGATATTCGAGATGCTTTCGGGGTTTCCTCCGTT TTTTGATGACAACCCGTTTGGCATTTATCAGAAAATTCTTGCAGGCAAAATAGA TTTCCCCAGACATTTGGATTTCCATGTAAAAGACCTCATTAAGAAACTGCTCGT GGTTGACAGAACAAGGCGATTAGGAAACATGAAGAACGGGGCGAATGATGTG AAGCATCATCGGTGGTTCCGCTCCGTGGACTGGGAAGCTGTTCCGCAGAGAAA ACTGAAGCCTCCCATCGTGCCCAAGATAGCTGGTGACGGCGACACTTCCAACT TCGAAACTTACCCTGAGAATGACTGGGACACAGCCGCGCCCGTGCCGCAGAAG GATTTAGAAATCTTCAAGAATTTCTGAGGACAGGAGCTCACATCTGGAAGAAA CAGGAAGATTGGAATCTGCCTGGAACAAAGAACTGCACCTAAGCAGACCAGA AGCAAAATGTCTTCTTCACGGCATAAGGACATCTCCACTTTTCTCTGTACCTGT GTGTATAGAAATAGATTAGAGCACAGTTGAAATTCATGGAACTGGCATTATTT AAGCAACTGGAATTCCACACTGTAGGAAGGTTTTGAAAATTGTTTGGTTGTAG ATTTTATCTTATCCTTTAGTGTTGTGTTCCTACTGTGATGTCTTGGTTTTTGTCAT AGACTTAAGTTTATAAGTTTGAACTGGACTTGTTCGATTATAACCACAAATTGT GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGCCTGTGTGT ATATATAGAAGTCATTATGGCAGATGCACAGAAATTGTGCAGTGATGTAAATG TTCATACTTTACAGAGCCTATAATTTTTATTTTTCAATTTGTTTTTTCAAAAATC TCTTCTCGGGGACAACATCTGAAGGGTATGTTGCATGCATTAAAAAAAATCAT CTCACATGCATTTTATAGTTTTGGGGAAGAAAATATCATGGGGAGGTCTACCTT CAGTATCTTTAGTGCTTCTTACCTGGTAACTTGAGACTTTAAAAGAAGAAACAA AGAGGGGAAGATATGGGAGCGAATTTATTCCAAGAATCTACAATGACATTGAA GTTGTTGGAGGAATGTACTGTATTTAAAAAAACCTTCTGTGACACATTCAAAA ATTTCATCTGAGCTGGATGCAGTGGCTTGTTCCTATAGTCCCAGCACTTTGGGA GGCTGAGGTGGGTGGATTGCTTGAGCCCAGGAGTTGGAGACCAGTCTGGGAAA CGTGGTGAGACCTCATCTCTACAAAATACAAAAAAATTAGCCGGGCATGGTGG CACGTGAGTGTAGTCTCAGCTACTCAGGAGGCTGAGATGAGAGGATCACTTGA GCCTGGGGAGGTCCAGGCCGCAGTGATCCGAGATCACACCACTGCATTCCAGC CTGGGTGACAGAGTGAGACCCTGTCCAAAAAAAAAAAAAAAAAAAAAGAAGG CAATGGCTTTGTGCTTTTGAAGATGGATTGAAGAGAACGTCCACCTTAAGGCTT TAAAAGACAGTGAAGCTGGGTGCGGTGGTGCACTCCTGTAACCCTGGGACTTT GGGAAGCTGAGGCAGGAAGATTGAGCCTAGGAGTTCGAGACCGACCTGGGCA GCATAGCGAGACCCCATCTCTATATAAAAAAAAAGATGTTAAAACAGTGAAAT TACAGAAACAGAACATAGCCACCCTTTTTCATCAGTGACCTTTTCTTCACGTGG AGGTCAACTCAGTAGGTGAGAATAATTAGTAGGTTCAGCAGAATAAACTCTTT ACAATTAATAACTCAGTGGAAAATGATGTTCAGATGGTGAAATGTGGAAATGT TTTAGACAACTCTATTTTCAGCCTGTGCTTCTCACTCACCATCCTGTTGGGATTA ACAGTTGAGGGCCATCGCTGCCTAAACATTTAGCGTGCGGTTTCCCATCAGTTT TACCGTGAATGTGAAAAGGTGAAACTGGTGCTGACTTCGGCAGCAGGTATACT AAAATTGGAATGACACAGAGGAGATTAGCATGGCCCCCTGCGCGAGGAAGAT CTGCAGATTCATGCAGCATTCCATATTTTTTTAAGAAAAGGTTACACTGTGCAC CGACATGTGGAGCTAGAAGGAAAAGCTTTTAAGTCTCATGTTTGCTGACTATA AAAATAAATCATAGTAATAATATTGAACATTCTACTTTAAAAATTATTAATAA AACCATAAATGAAACACTTGAGCACACTTTAAAAAGTACATAAATCCATGAGT CCATATGCCTATTTTTAGGTTGTCTGTTTTATTATCCAGGATTTCATACTCAGAT GAGAATTAGCATCAGGAAAGCCTGAAATGCCTTAATTGTGAACTGATATGCAG GAAAATGAAATATGCAAGCACATTGGTGACCTTGTTCTTTACAGACGTCGTGA TCAGCCTCCAGCCATACAGAACAAATGAGAAATTAGAAGCGATTCCAAGAAC GTGTGATGGTGTGAAACCCACTTTGGACCATCACACACATTTCAGCATTTGAA GTGACACAAGCTACCTGGTAACTGCCCATGGCGGGGTCATAGTTTAAATGGCC CAATGTCATGTAGAGGTTAATTTAATCAAAATGAGCTATAAACATGGAGCAAT CACTGTATAATTTTAAAATAGTTTACCTGGCCAGGCATGGTGGCTCACGCCTGT AATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATCACCTGAGGTCAGGAGTT CGAGACCAGCCTGGCCAACATGGCAAAACCCCCATCTCTACTAAAATACAAAA ATTAGGTGTGGTGGCGGGCACCTGTAATCCTGGCTACTCGGGAGGCTGAGGCA GGAGAATCGCTTGAACCCGGGAGGCAGAGGCTGCAGTAAGCCGAGATCGTGC CACTGCACTCCAGCCTGGGCCACAGAGCAAGACTCCGTCTCAAAACATAAAAA TAAAAAAAATACAAATAGCTGACCCGGGTGGGCATTCCAAAATGTCCGCATGG ACGATCACGAAACAATCACGGTGCGAAATGTCCGCATGGATGATCACGAAAC AATCACGGTGCAGAATGTCCGTATGGATGATCATGACAAACAATCACTGCGCA AAATGTGGAGGAAAATTCATTACCATAATCACAACATTTGTATCAGAAAAACA TTACAAATTTACTTTGCTTCATGTAATTTTACGAGTTGGCAATATTTTCTTAAAT TGGAATACTCTAAGAGAATAGGACATGGATATGTTACAAGAAGAAGTGTATTG GGGCAAGTCTTGTTTTTCTGAAGGGAAATGCCACCGGCCTGCTTTCATAGGCAT TGATAAAGCCAGGAAGGAAATAAAGTCACAACCAAATAGTATACACTGTCTCT ACTGAATTCTTCTAATTCCTTCGCAACAGAAGTCTAAATCCTGCTTAGCCTAAA CATATCTATAGCCAGCGATGGGCAAATTATATTTGCTGTCAGCATGATAGAAT AAGAAGCAGAAACCCCCCAGCAGTGGGGTAAGATTGCGCGCTTCATCCCCTCA AAATGCAGTTCAGCCCCACTCCCTCTCCATGCCCATCAAACAACTGCACAATC ACTTGTTACTGAATTTCCCATTCAGCGTTTTGTTTCTTTCTGTCCATACTTAAAG ACCAAATCATTTGTTTGCTTTGAAGAAAAAGCAAAAACAAGAACAAAAACACC AAATCATTTGAAATCACTGTCCATTAAAAAAAATCACCAGTGGAACTAAACAG TTGAGTGGTTTGGGATGTGTTCGCCATTTCTGTGTTTGACCTACATGGCCTCTA ATTCTTTGGACCATTGTAACTGTGAAACTATGGCTTAATACTGTTAAAGACCCC AAGGCTCCACTCTGTAGCCAGGTGCACCTCAGGCTGCACAAATACCCCACCAG AATGTCACAATCATTCATTGCTCCAGCTACTGAGTGAACAGGGTGCAAGACAG CACTGGCTTGGGTTGTATTTTTGCAGCCAGTTAACTTTGCATCAGGTCTACACA GTCCTTGCAGCCTTTGATTTCTCCAGTTGTAGAGATTTGAAATGGGGTGCCCGG GTTCCTCTCGTTTTTCCTTCAATCTACCTAGCATGCATTTTACACACATTGGAGG AGTCGTATGCACTGTTTTTCTGTTGCTGATGGAGGCAAGCAGGCCTTCTAATTA GTCTAACTTAAACGGATGGGATTCACTTAACAAAAGCAAGAAGAAAAGCACA CGAACAGGTGTCTTAATGCATTTGGATAGTTTCTTTGCGGGGTGTGTGTGTGTG TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTTGGTGAAGGTGAGGGGC TGTATTTTCACCAAGCCTTTTCATAATCAAGTTTGCTTTGCAAACCTTATGGCCT TGCACCCCGCAGAACAGTCCCTTCCTAATAGCAGGGATGCTCTGTCATGGTTTT CTGTAAATTATCGTGTGTTGGGAAGTTCTGTTGAGGCTTAGTTTGATCTTCCAT GGTGGACACGTCTGTTCTGTATGTAAAAGGCATTACAATTGTGTTTTAGCAGAT GAGACTTGAAGCCTTTCCACAGTCCTTGTGCTCTGAGATGGCTGTTGAGCTCTG CTCAACTGTCGTAGCTGAATTCTTTCTTTGCGCTGAACACTGGGCAGCCTCACC ATGTTGCCAACGTGCTTCTGGGGCCCCTGTCACTGCCGCCGGATGCCGCGCAC ACAGGCAGAGTGCCTTGGCAGGTTTGTGCACCCCTTGGCGAGCCAGAACTGGG AACCCCGCGGGGTGACCCCTTCTCATGGGGGGTCGGGGAGGGGAGTGCCTATT TTTAATCCTGTCTGTTTGTTGCACAATGGAAATCACTGTGATTTGTACATATGC CCTAGGAAAATTTTACTGCTGTCTAATTTATGTAATAATACTGTTGATTCCAGG TTTGTTTAATAAAACTTTGTATCTTTTCAGAAGTCTGAGTTTCATCTGCTTCTGT CTCC
> 31
AGAAGTTGTCAGTGAACAGAGACGGCGCTCAGTCTGGGGCGAGCGCTCTAGTG AGCGCGGACGGATGCTTAGGCAGTAGTCCTGGCAGCGGCAGTAGTGGTGGCA GCAGAAGAGAGGAAGGGGGAGGGCCCCGAGGGCTACACACGCTCACACTTTC AAGTTCCCTTGGAGGGAGAGGAGGTGGGGCTGCAGAAAGAGGAGGCCAGGAG CGGTCCCATCCGTCCCGTCCCGTCCCGTCTCCCCCTCTTCCTCTTGCTCCTTGCC CCCCGGCTCTGCGAGAGTTGAGGGTTCAGGTGGCCGTACGCGGCAGTGAGGGC AAGAGGGCCGGGAGAGTGGGGAGCGGAGGCAGGAGTGCGGGGGAAGATGCC CATCCTGCTGTTCCTCATAGACACGTCCGCCTCTATGAACCAGCGCACTGACCT GGGCACCTCTTATTTGGACATTGCCAAAGGCGCTGTGGAGTTATTCTTGAAGCT GCGCGCCCGGGACCCGGCCAGCCGTGGAGACAGGTACATGCTGGTCACCTACG ACGAACCCCCGTACTGCATCAAGGCTGGTTGGAAGGAAAATCATGCAACATTC ATGAGCGAACTAAAAAATCTTCAGGCTTCTGGACTGACTACTCTCGGTCAGGC TCTAAGATCCTCATTTGATTTGTTAAATCTCAATAGATTAATATCTGGAATAGA CAATTATGGACAGGGGAGAAATCCATTTTTTTTAGAACCATCTATTTTAATTAC CATCACAGATGGAAACAAGTTAACAAGTACTGCTGGTGTTCAAGAAGAGCTCC ATCTTCCTTTGAATTCCCCTCTGCCTGGAAGTGAACTAACCAAAGAACCTTTTC GTTGGGATCAAAGGTTATTTGCCCTGGTGTTGCGTTTGCCTGGAGTGGCTTCTA CCGAACCAGAGCAACTAGGGAGCGTACCAACTGATGAATCTGCCATCACACA GATGTGTGAAGTCACAGGAGGTCGCTCCTACTGTGTGAGAACACAAAGAATGT TGAATCAATGTTTAGAATCTCTAGTTCAAAAAGTTCAGAGTGGTGTAGTTATTA ATTTTGAAAAAACAGGACCAGATCCACTTCCTATTGGAGAAGATGGACTTATG GATTCATCCAGGCCAAGCAATTCATTTGCTGCTCAGCCATGGCATAGTTGTCAT AAACTCATTTATGTACGACCTAACTCTAAAACTGGTGTTCCTGTTGGACATTGG CCAATTCCAGAATCTTTTTGGCCAGATCAGAATTTACCTTCACTACCTCCACGA ACATCTCATCCTGTTGTGAGGTTCTCCTGTGTAGATTGTGAGCCAATGGTAATA GACAAACTTCCTTTTGACAAATATGAACTTGAACCTTCGCCCTTAACTCAGTAT ATCTTGGAACGAAAGTCTCCCCATACCTGCTGGCAGGTATTTGTTACTAGCAGT GGAAAGTACAATGAACTTGGATATCCATTTGGTTATTTAAAAGCCAGTACAAC TTTAACTTGTGTAAACCTCTTTGTGATGCCTTACAACTACCCAGTTTTACTTCCT CTTTTAGATGACTTGTTTAAAGTTCACAAGCTTAAGCCAAATCTGAAGTGGCGA CAGGCTTTTGACAGCTACTTAAAAACTCTGCCTCCATACTACCTATTAACCAAA CTAGAGTCAGAACGAATACTAGCATCAGTGGGGAAGAAACCTCCCCAGGAAA TTGGAATTAAAGTGAAAAATCATTCTGGAGGTGGCATGTCCTTGACTCACAAT AAAAATTTTAGAAAACTATTGAAAGAAATCACAGGGGAAACTGCACTTAGACT GACAGAATTGAACACCAAAGAATTTGCTGGCTTCCAAATTGGGCTCTTAAACA AGGATTTGAAACCTCAGACATACAGAAATGCTTATGATATTCCCCGTAGAGGT CTTTTAGACCAGCTGACCAGAATGAGATCCAATCTGCTGAAAACGCACAAGTT TATTGTTGGACAAGATGAAGATTCCCTTCATAGTGTTCCAGTTGCACAAATGGG TAACTATCAGGAATATCTGAAGACATTGGCTTCTCCACTGCGAGAGATTGATC CAGACCAACCCAAAAGACTGCATACTTTTGGCAATCCGTTTAAACAAGATAAG AAGGGAATGATGATTGATGAAGCAGATGAGTTTGTAGCAGGGCCACAAAACA AAGTGAAACGTCCAGGGGAACCCAACAGTCCTATGTCATCTAAGAGAAGGCG GAGTATGTCCCTGCTGTTGAGGAAACCACAAACACCACCTACTGTAACTAACC ATGTGGGCGGAAAGGGACCACCCTCAGCCTCGTGGTTCCCATCTTATCCAAAC CTCATAAAACCCACCCTTGTACATACAGATGCTACTATCATTCACGATGGCCAT GAGGAGAAGATGGAAAATGGTCAGATCACACCTGATGGCTTCCTGTCAAAATC TGCTCCATCAGAGCTTATAAATATGACAGGAGATCTTATGCCACCCAACCAAG TGGATTCTCTGTCTGACGACTTCACAAGTCTCAGCAAAGATGGGCTGATTCAA AAACCTGGTAGTAACGCATTTGTAGGAGGAGCCAAAAACTGCAGTCTCTCCGT AGATGACCAAAAAGACCCAGTAGCATCTACTTTGGGAGCTATGCCAAATACAT TACAAATCACTCCTGCTATGGCACAAGGAATCAATGCTGATATAAAACATCAA TTAATGAAGGAAGTTCGAAAGTTTGGTCGAAAATATGAAAGAATTTTCATTTT GCTTGAAGAAGTGCAAGGACCTCTGGAGATGAAGAAACAGTTTGTTGAATTTA CCATCAAGGAAGCCGCAAGGTTTAAAAGACGAGTCCTAATTCAGTACCTTGAG AAGGTACTAGAAAAAATAAATTCCCACCACCTTCACAACAACATTAGTCACAT CAACAGCAGATCATCATGTTAGTGCAAAGACCAGTGAGAAAAAAATGACAAG TTTTCTGTGCTGTAGGATGGAACAGGATATTGTTGAAGCCTCCTGGAATGTTTG AGTCAAGGGAATTGCTTTCCAGATGCTAAGAAGCAGCAGTGGGGCTTTTGAAT TTTATGATTATCTGGCAGTGAAAGCTGGGCTTTTGCCTTAATAATTTTTTAAAG TATGAATTGTTTTGTTTTGTTTTCCTCAATTGAGGAAGCTGATGTTATTAATTCA CAGGCTAAATTCGGTAAACACCACTGCCCCTACCACGGGTAATGAGAGGTCAC TCACTTGAACTTTGCCATTCCAGGCATTCTCAGAGTGGCGAGGGGCCACCTGC AAGTGGAGCACAACTTGGTGCTCTTACTGTGTCCTTCAGAAAGAATAGGTGTA CAGAAAGGAAATGGCAATCTTATGTGTGCTGAACAAAGTTTTCAACAATTCCT AGTTGTGCCTTTTAAACCATGCAATATTCAGGATAGTTTGAATCAAAGAAGTA AGAAGCTGCTATTTGGGTAACTTATTTCTCTGTGGGAAGGGGCAGGGAGAGTC ACCAAACAATCTACCTCCAACTCTCTTCTCTTTTGTCTAGAGACATTACAAAGT GCACTTGAGGCTGCCCCCAACCTCTGACATTTGTTCTTGCATGTGATGATAGAA AGTCTTCAGATGGACTTATACATTCTGTGCTTTGGAAGCACAAGAAGAACAAA ATATGTGTATATTTCCTTTAATGTTTATACAAAAGTTTATATGGAGCAGTATTG TTATGTTTGTATGAATTTGCAAAAATTAAAGTGTACAAAGAGATTTTGATTTTG CATATATAAAATAAATCATTTTATTGATTTTCACAAGTTCATTAATGCTGGATA AATTTCTACTTA > 32
CTCGTGCCGCCAGCCAACCGCGCGGCCGCTTGTTGAGCCAGGGCTCCACCGTC GCCATGACGCCCGGCAAACATTCCGGAGCCTCGGCCCGAGCCGCTAACGGAG GAGCTTGGGGGTACAGGGACTTCAGAGGCGGCCAAAAAAAGGGGTGGTGCAC CACTCCCCAGCTGGTCGCCACCATGCCAGTCTCTCCGGCAGGCAGTCACAAGC AGC AGAACTTC GGGTTGAAC AATGC C AC AC AAC C AAAGAAGTCT ATTAGCTTT TTTGCTACAATGAAAGCAACTTCAGTGAAAGGATATACTGGTGCAAATCAAAG CAGAATGGCTGTGTCCAAAACCGTGCTTATTCCACCTGAACTGAAAACTGTAG AAAAACCAAATCCCAATATAAAGACAACACAGGTATTTGACATAAATGGAACT GATGTTACTCCCCGACCTCTTTACCATCCAGATCCACTTACTGGTACAGCAAAA CCAAGTAAACTCTTGACATCACAAGAAGGATCACTTGGATCAGAATTTATATC TTCCTATAGCCTTTATCAGAATACAATAAATCCTAGTACGTTAGGGCAGTTTAC AAGGTCAGTTTTAGGAAGCAGTACAGTTTCTAAGTCAAGTGTATCAGCAAGTG AATCAATAGCAGAAGACCTGGAAGAACCATCCTATAAACGGGAAAGATTGAC TAGTTTCACAGATTTGCAAGTTATAAGGGCAGCACCTGAAAAAATTGTAACAA AAGAAGACCTGGAGAAGAATATAGAGATAATACTCACAGAGACAGAAACACT GAGATTTTTTGACTTGCCCACAGTCATGGTCTCTGTAGAATCTGAAGAAGCTGA GAAAGTAACTCAGAGAAACAAGAATTATGAAGTCCTTTGTAGAAACAGATTAG GCAATGACCTATATGTTGAAAGGATGATGCAGACTTTCAATGGAGCACCAAAG AATAAAGATGTTCAATGTGATAAAATCATAATGGAAGATAAAGGCATAATGTC CACTGCCTGGGATTTGTATGATTCTTACAATGCTATGGAACTTGTATCTTTATC AGTAAAACAATCTGTGGTTGAGTCAAGTAGTAAAGCAAATGTACTTCCTAAAG ATCAGGACCAAAGATTGCCAGGGAGCACTACAGAAAAAAATAGTGAAACTAG TTCTCTAATGGACATAGAAAATGTAATTCTGGCAAAAATCCATGAAGATGAGG AAGACCACTCAGATGCAATATTAAAATCTGACAAATTTCATCAGGACTTATTTT TTATGGAACGGGTTCTGATGGAAAATATATTTCAGCCCAAACTTGCAGCTTATC GTCAGCTTCCTGTTTTAAAAGAACCTGAACCTGAAGAGCCTGAAGATGTTTTA GAAAGTGCAAAACATGAAGAGGTAGAGGAAGAATCTAAGAAGGAGGAGGAA GAAGAAATACATGCAGAAGAATCAACAATACCCGCCAACTTGGAACGACTTTG GTCTTTTTCCTGTGACTTAACCAAAGGCCTCAATGTGAGCAGCCTTGCCTGGAA TAAAACAAATCCAGATCTTTTGGCTGTTGGCTATGGGCACTTTGGATTTAAAGA GCAAAAAAGAGGACTGGCTTGCTGCTGGTCAATAAAGAATCCCATGTGGCCAG AACGTATTTATCAGAGTCCATATGGAGTTACTGCTGTGGATTTTTCAATTGGAG CACCTAACCTTTTAGCCGTTGGCTATCACAATGGCACAATTGCAATTTACAATG TACGGAGCAACAGTAATGTTCCAGTTCTGGATAGTAGTGAATCACCTCAAAAA CATTTGGGACCTGTATGGCAACTACAGTGGATAGAACAAGATCGAGGAACAAC AGGAGATGGCAAAAGAGAAATACTAGTTTCTATATCAGCAGATGGAAGAATCT CCAAATGGGTTATACGAAAAGGACTAGACTGTTATGATTTGATGCGATTAAAG AGAACTACAGCTGCCAGTAACAAAAAAGGAGGGGAAAAGGAAAAGAAAGAT GAAGCTTTGATATCTCGACAGGCTCCTGGAATGTGTTTTGCTTTTCATCCCAAG GACACAAATATCTATTTGGCTGGCACTGAAGAAGGTCATATTCACAAATGTTC TTGTTCATATAATGAACAATACTTAGATACCTACAGAGGACATAAGGGTCCAG TGTATAAAGTGACATGGAATCCATTTTGTCATGATGTATTTTTAAGCTGTTCTG CAGATTGGGGTGTTATTATATGGCAACAGGAGAATGTCAAGCCATCTTTGAGT TTTTATCCAGCTACTTCTGTTGTTTACGACGTTGCCTGGTCTCCAAAATCATCCT ATATATTTGCAGCTGCAAATGAGAACAGGGTGGAGATTTGGGACCTTCATATC AGCACTTTGGACCCTCTGATTGTGAATACTGCTAACCCTGGAATCAAGTTCACA ACCATTCTCTTTGCCAAACAAACAGATTGCCTTCTGGTAGGAGACAGTGATGG ACAGGTTTCTGTGTATGAACTGAGAAATATGCCTACTGTTTTGGAAACTGGCCG GGGAGATATAATGGATACTTTGCTTGGATCCAAGTCAAACCAATCAGCATAAT TCATCATTCCTAATATTTTTCTTGTAGTTGTTTTAAAAAAGGAATTAACATCCA ATATTCTGTATTACATACTGTACACCAGATTTTGATTTCAGAAAACAATATTTG ATGTATAACTTCCACTTAATTTAAATTTAATAAACTTTTATTTCAGAGATATTTG ATTAGTTTACAATCTAAGAGTTATTCTTAAGAGTTTCAGTGGAATTTTCTTAAT TTTTCTAAAGATATTCCTACTCTCTTGATCATATTCTAAGTACATATGAGTACAT GTACATTCTTATACAATGTCTAAATGGGTTAGAAAATTATTATACCTATAGAAG CGAAACTTGGAAATTAATAGAATCACTTAAACCAAAATCTTTATAAGACACAA TTCTATTGATTTTAAAGCTTCTGCTTTCCAGGCTCTGTTTTCCAGAGTTTATAAT TACGTAGTTTTTAGTAGATGAAAATAATGGATTCTTGTACCTAACATTTTATCC TCTTAGATCTAAGAGCCGAAGCTATAGAACTTTGTTAGACTATTTGGCAAGCA AAATATATGACAGTAAATATCAGAATTTTATGGTTTGACCAGCGCTTATCACAT TCCCAATTCAGTGAGAAAAATTCATCTGGGACACAACAGGGTACTCTTCTCTGT TTGCCCAGAATCAGCTCTGGATTTTAAGCCCAGACTTCAGTGGACCCAGATAG AAAATATAAAGTCTCTGATCTATAGGCCACATCAGGATGTTATTTTATGAAGA GTTCTAGAGCAAGGTTGCGGAAATCGGGGTGGAGATGGGGAGCAGTGACTCCT CCAAATATTCATTGCTAACAGGCCATTCTATGCAGTTTGTTTTAACAAATCCTG GGTTAAACTGAGGCCACAGGACATGATGGGCTGTTCTATAAAGCATTCTAAGT GGAGAGGAGACGATAGGGCATATGAAATTCACTAAACTCTCTGGAAAAAAAA TATGTATATATTAAAAACCAAGACTGGAATCAGTGCAACAGTGGGAACTACCT TTTACAAGTATCCATTGCTTCATAAACTCCATTTGTTTGGACCAATCCCTTAAA CAAAAGCAAGGCAAATTTTACATGGATTTAGAGCCTAGGTCAGGTTATTAGGA TTATAAATTTTCCACTGGTATGTCATTGTGATTATCTTTGTTTTTGTCTTTCTGA AAGATTGGATTTTCTATAACACCTTGTGTAAGAAAATAAAAAACTTGATCTAA CTGA > 33
ATGCTCAGTGGCTTCTCGACAAGTTGGCAGCAACAACACGGCCCTGGTCGTCG TCGCCGCTGCGGTAACGGAGCGGTTTGGGTGGCGGAGCCTGCGTTCGCGCCTT CCCGCTCTCCTCGGGAGGCCCTTCCTGCTCTCCCCTAGGCTCCGCGGCCGCCCA GGGGGTGGGAGCGGGTGAGGGGAGCCAGGCGCCCAGCGAGAGAGGCCCCCCG CCGCAGGGCGGCCCGGGAGCTCGAGGCGGTCCGGCCCGCGCGGGCAGCGGCG CGGCGCTGAGGAGGGGCGGCCTGGCCGGGACGCCTCGGGGCGGGGGCCGAGG AGCTCTCCGGGCCGCCGGGGAAAGCTACGGGCCCGGTGCGTCCGCGGACCAG CAGCGCGGGAGAGCGGACTCCCCTCGCCACCGCCCGAGCCCAGGTTATCCTGA ATACATGTCTAACAATTTTCCTTGCAACGTTAGCTGTTGTTTTTCACTGTTTCCA AAGGATCAAAATTGCTTCAGAAATTGGAGACATATTTGATTTAAAAGGAAAAA CTTGAACAAATGGACAATATGTCTATTACGAATACACCAACAAGTAATGATGC CTGTCTGAGCATTGTGCATAGTTTGATGTGCCATAGACAAGGTGGAGAGAGTG AAACATTTGCAAAAAGAGCAATTGAAAGTTTGGTAAAGAAGCTGAAGGAGAA AAAAGATGAATTGGATTCTTTAATAACAGCTATAACTACAAATGGAGCTCATC CTAGTAAATGTGTTACCATACAGAGAACATTGGATGGGAGGCTTCAGGTGGCT GGTCGGAAAGGATTTCCTCATGTGATCTATGCCCGTCTCTGGAGGTGGCCTGAT CTTCACAAAAATGAACTAAAACATGTTAAATATTGTCAGTATGCGTTTGACTTA AAATGTGATAGTGTCTGTGTGAATCCATATCACTACGAACGAGTTGTATCACCT GGAATTGATCTCTCAGGATTAACACTGCAGAGTAATGCTCCATCAAGTATGAT GGTGAAGGATGAATATGTGCATGACTTTGAGGGACAGCCATCGTTGTCCACTG AAGGACATTCAATTCAAACCATCCAGCATCCACCAAGTAATCGTGCATCGACA GAGACATACAGCACCCCAGCTCTGTTAGCCCCATCTGAGTCTAATGCTACCAG CACTGCCAACTTTCCCAACATTCCTGTGGCTTCCACAAGTCAGCCTGCCAGTAT ACTGGGGGGCAGCCATAGTGAAGGACTGTTGCAGATAGCATCAGGGCCTCAGC CAGGACAGCAGCAGAATGGATTTACTGGTCAGCCAGCTACTTACCATCATAAC AGCACTACCACCTGGACTGGAAGTAGGACTGCACCATACACACCTAATTTGCC TCACCACCAAAACGGCCATCTTCAGCACCACCCGCCTATGCCGCCCCATCCCG GACATTACTGGCCTGTTCACAATGAGCTTGCATTCCAGCCTCCCATTTCCAATC ATCCTGCTCCTGAGTATTGGTGTTCCATTGCTTACTTTGAAATGGATGTTCAGG TAGGAGAGACATTTAAGGTTCCTTCAAGCTGCCCTATTGTTACTGTTGATGGAT ACGTGGACCCTTCTGGAGGAGATCGCTTTTGTTTGGGTCAACTCTCCAATGTCC ACAGGACAGAAGCCATTGAGAGAGCAAGGTTGCACATAGGCAAAGGTGTGCA GTTGGAATGTAAAGGTGAAGGTGATGTTTGGGTCAGGTGCCTTAGTGACCACG CGGTCTTTGTACAGAGTTACTACTTAGACAGAGAAGCTGGGCGTGCACCTGGA GATGCTGTTCATAAGATCTACCCAAGTGCATATATAAAGGTCTTTGATTTGCGT CAGTGTCATCGACAGATGCAGCAGCAGGCGGCTACTGCACAAGCTGCAGCAG CTGCCCAGGCAGCAGCCGTGGCAGGAAACATCCCTGGCCCAGGATCAGTAGGT GGAATAGCTCCAGCTATCAGTCTGTCAGCTGCTGCTGGAATTGGTGTTGATGAC CTTCGTCGCTTATGCATACTCAGGATGAGTTTTGTGAAAGGCTGGGGACCGGA TTACCCAAGACAGAGCATCAAAGAAACACCTTGCTGGATTGAAATTCACTTAC ACCGGGCCCTCCAGCTCCTAGACGAAGTACTTCATACCATGCCGATTGCAGAC CCACAACCTTTAGACTGAGGTCTTTTACCGTTGGGGCCCTTAACCTTATCAGGA TGGTGGACTACAAAATACAATCCTGTTTATAATCTGAAGATATATTTCACTTTT GTTCTGCTTTATCTTTTCATAAAGGGTTGAAAATGTGTTTGCTGCCTTGCTCCTA GCAGACAGAAACTGGATTAAAACAATTTTTTTTTTCCTCTTCAGAACTTGTCAG GCATGGCTCAGAGCTTGAAGATTAGGAGAAACACATTCTTATTAATTCTTCACC TGTTATGTATGAAGGAATCATTCCAGTGCTAGAAAATTTAGCCCTTTAAAACGT CTTAGAGCCTTTTATCTGCAGAACATCGATATGTATATCATTCTACAGAATAAT CCAGTATTGCTGATTTTAAAGGCAGAGAAGTTCTCAAAGTTAATTCACCTATGT TATTTTGTGTACAAGTTGTTATTGTTGAACATACTTCAAAAATAATGTGCCATG TGGGTGAGTTAATTTTACCAAGAGTAACTTTACTCTGTGTTTAAAAAGTAAGTT AATAATGTATTGTAATCTTTCATCCAAAATATTTTTTGCAAGTTATATTAGTGA AGATGGTTTCAATTCAGATTGTCTTGCAACTTCAGTTTTATTTTTGCCAAGGCA AAAAACTCTTAATCTGTGTGTATATTGAGAATCCCTTAAAATTACCAGACAAA AAAATTTAAAATTACGTTTGTTATTCCTAGTGGATGACTGTTGATGAAGTATAC TTTTCCCCTGTTAAACAGTAGTTGTATTCTTCTGTATTTCTAGGCACAAGGTTGG TTGCTAAGAAGCCTATAAGAGGAATTTCTTTTCCTTCATTCATAGGGAAAGGTT TTGTATTTTTTAAAACACTAAAAGCAGCGTCACTCTACCTAATGTCTCACTGTT CTGCAAAGGTGGCAATGCTTAAACTAAATAATGAATAAACTGAATATTTTGGA AACTGCTAAATTCTATGTTAAATACTGTGCAGAATAATGGAAACATTACAGTT CATAATAGGTAGTTTGGATATTTTTGTACTTGATTTGATGTGACTTTTTTTGGTA TAATGTTTAAATCATGTATGTTATGATATTGTTTAAAATTCAGTTTTTGTATCTT GGGGCAAGACTGCAAACTTTTTTATATCTTTTGGTTATTCTAAGCCCTTTGCCA TCAATGATCATATCAATTGGCAGTGACTTTGTATAGAGAATTTAAGTAGAAAA GTTGCAGATGTATTGACTGTACCACAGACACAATATGTATGCTTTTTACCTAGC TGGTAGCATAAATAAAACTGAATCTCAACATACAAAGTTGAATTCTAGGTTTG ATTTTTAAGATTTTTTTTTTCTTTTGCACTTTTGAGTCCAATCTCAGTGATGAGG TACCTTCTACTAAATGACAGGCAACAGCCAGTTCTATTGGGCAGCTTTGTTTTT TTCCCTCACACTCTACCGGGACTTCCCCATGGACATTGTGTATCATGTGTAGAG TTGGTTTTTTTTTTTTTTAATTTTTATTTTACTATAGCAGAAATAGACCTGATTA TCTACAAGATGATAAATAGATTGTCTACAGGATAAATAGTATGAAATAAAATC AAGGATTATCTTTCAGATGTGTTTACTTTTGCCTGGAGAACTTTTAGCTATAGA AACACTTGTGTGATGATAGTCCTCCTTATATCACCTGGAATGAACACAGCTTCT ACTGCCTTGCTCAGAAGGTCTTTTAAATAGACCATCCTAGAAACCACTGAGTTT GCTTATTTCTGTGATTTAAACATAGATCTTGATCCAAGCTACATGACTTTTGTCT TTAAATAACTTATCTACCACCTCATTTGTACTCTTGATTACTTACAAATTCTTTC AGTAAACACCTAATTTTCTTCTGTAAAAGTTTGGTGATTTAAGTTTTATTGGCA GTTTTATAAAAAGACATCTTCTCTAGAAATTGCTAACTTTAGGTCCATTTTACT GTGAATGAGGAATAGGAGTGAGTTTTAGAATAACAGATTTTTAAAAATCCAGA TGATTTGATTAAAACCTTAATCATACATTGACATAATTCATTGCTTCTTTTTTTT GAGATATGGAGTCTTGCTGTGTTGCCCAGGCAGGAGTGCAGTGGTATGATCTC AGCTCACTGCAACCTCTGCCTCCCGGGTTCAACTGATTCTCCTGCCTCAGCCTC CCTGGTAGCTAGGATTACAGGTGCCCGCCACCATGCCTGGCTAACTTTTGTAGT TTTAGTAGAGACGGGGTTTTGCCTGTTGGCCAGGCTGGTCTTGAACTCCTGACC TCAAGTGATCCATCCACCTTGGCCTCCCAAAGTGCTGGGATTACGGGCGTGAG CCACTGTCCCTGGCCTCATTGTTCCCTTTTCTACTTTAAGGAAAGTTTTCATGTT TAATCATCTGGGGAAAGTATGTGAAAAATATTTGTTAAGAAGTATCTCTTTGG AGCCAAGCCACCTGTCTTGGTTTCTTTCTACTAAGAGCCATAAAGTATAGAAAT ACTTCTAGTTGTTAAGTGCTTATATTTGTACCTAGATTTAGTCACACGCTTTTGA GAAAACATCTAGTATGTTATGATCAGCTATTCCTGAGAGCTTGGTTGTTAATCT ATATTTCTATTTCTTAGTGGTAGTCATCTTTGATGAATAAGACTAAAGATTCTC ACAGGTTTAAAATTTTATGTCTACTTTAAGGGTAAAATTATGAGGTTATGGTTC TGGGTGGGTTTTCTCTAGCTAATTCATATCTCAAAGAGTCTCAAAATGTTGAAT TTCAGTGCAAGCTGAATGAGAGATGAGCCATGTACACCCACCGTAAGACCTCA TTCCATGTTTGTCCAGTGCCTTTCAGTGCATTATCAAAGGGAATCCTTCATGGT GTTGCCTTTATTTTCCGGGGAGTAGATCGTGGGATATAGTCTATCTCATTTTTA ATAGTTTACCGCCCCTGGTATACAAAGATAATGACAATAAATCACTGCCATAT AACCTTGCTTTTTCCAGAAACATGGCTGTTTTGTATTGCTGTAACCACTAAATA GGTTGCCTATACCATTCCTCCTGTGAACAGTGCAGATTTACAGGTTGCATGGTC TGGCTTAAGGAGAGCCATACTTGAGACATGTGAGTAAACTGAACTCATATTAG CTGTGCTGCATTTCAGACTTAAAATCCATTTTTGTGGGGCAGGGTGTGGTGTGT AAAGGGGGGTGTTTGTAATACAAGTTGAAGGCAAAATAAAATGTCCTGTCTCC CAGATGATATACATCTTATTATTTTTAAAGTTTATTGCTAATTGTAGGAAGGTG AGTTGCAGGTATCTTTGACTATGGTCATCTGGGGAAGGAAAATTTTACATTTTA CTATTAATGCTCCTTAAGTGTCTATGGAGGTTAAAGAATAAAATGGTAAATGTT TCTGTGCCTGGTTTGATGGTAACTGGTTAATAGTTACTCACCATTTTATGCAGA GTCACATTAGTTCACACCCTTTCTGAGAGCCTTTTGGGAGAAGCAGTTTTATTC TCTGAGTGGAACAGAGTTCTTTTTGTTGATAATTTCTAGTTTGCTCCCTTCGTTA TTGCCAACTTTACTGGCATTTTATTTAATGATAGCAGATTGGGAAAATGGCAAA TTTAGGTTACGGAGGTAAATGAGTATATGAAAGCAATTACCTCTAAAGCCAGT TAACAATTATTTTGTAGGTGGGGTACACTCAGCTTAAAGTAATGCATTTTTTTT TCCCGTAAAGGCAGAATCCATCTTGTTGCAGATAGCTATCTAAATAATCTCATA TCCTCTTTTGCAAAGACTACAGAGAATAGGCTATGACAATCTTGTTCAAGCCTT TCCATTTTTTTCCCTGATAACTAAGTAATTTCTTTGAACATACCAAGAAGTATG TAAAAAGTCCATGGCCTTATTCATCCACAAAGTGGCATCCTAGGCCCAGCCTT ATCCCTAGCAGTTGTCCCAGTGCTGCTAGGTTGCTTATCTTGTTTATCTGGAAT CACTGTGGAGTGAAATTTTCCACATCATCCAGAATTGCCTTATTTAAGAAGTAA AACGTTTTAATTTTTAGCCTTTTTTTGGTGGAGTTATTTAATATGTATATCAGAG GATATACTAGATGGTAACATTTCTTTCTGTGCTTGGCTATCTTTGTGGACTTCA GGGGCTTCTAAAACAGACAGGACTGTGTTGCCTTTACTAAATGGTCTGAGACA GCTATGGTTTTGAATTTTTAGTTTTTTTTTTTTAACCCACTTCCCCTCCTGGTCTC TTCCCTCTCTGATAATTACCATTCATATGTGAGTGTTAGTGTGCCTCCTTTTAGC ATTTTCTTCTTCTCTTTCTGATTCTTCATTTCTGACTGCCTAGGCAAGGAAACCA GATAACCAAACTTACTAGAACGTTCTTTAAAACACAAGTACAAACTCTGGGAC AGGACCCAAGACACTTTCCTGTGAAGTGCTGAAAAAGACCTCATTGTATTGGC ATTTGATATCAGTTTGATGTAGCTTAGAGTGCTTCCTGATTCTTGCTGAGTTTCA GGTAGTTGAGATAGAGAGAAGTGAGTCATATTCATATTTTCCCCCTTAGAATA ATATTTTGAAAGGTTTCATTGCTTCCACTTGAATGCTGCTCTTACAAAAACTGG GGTTACAAGGGTTACTAAATTAGCATCAGTAGCCAGAGGCAATACCGTTGTCT GGAGGACACCAGCAAACAACACACAACAAAGCAAAACAAACCTTGGGAAACT AAGGCCATTTGTTTTGTTTTGGTGTCCCCTTTGAAGCCCTGCCTTCTGGCCTTAC TCCTGTACAGATATTTTTGACCTATAGGTGCCTTTATGAGAATTGAGGGTCTGA CATCCTGCCCCAAGGAGTAGCTAAAGTAATTGCTAGTGTTTTCAGGGATTTTAA CATCAGACTGGAATGAATGAATGAAACTTTTTGTCCTTTTTTTTTCTGTTTTTTT TTTTCTAATGTAGTAAGGACTAAGGAAAACCTTTGGTGAAGACAATCATTTCTC TCTGTTGATGTGGATACTTTTCACACCGTTTATTTAAATGCTTTCTCAATAGGTC CAGAGCCAGTGTTCTTGTTCAACCTGAAAGTAATGGCTCTGGGTTGGGCCAGA CAGTTGCACTCTCTAGTTTGCCCTCTGCCACAAATTTGATGTGTGACCTTTGGG CAAGTCATTTATCTTCTCTGGGCCTTAGTTGCCTCATCTGTAAAATGAGGGAGT TGGAGTAGATTAATTATTCCAGCTCTGAAATTCTAAGTGACCTTGGCTACCTTG CAGCAGTTTTGGATTTCTTCCTTATCTTTGTTCTGCTGTTTGAGGGGGCTTTTTA CTTATTTCCATGTTATTCAAAGGAGACTAGGCTTGATATTTTATTACTGTTCTTT TATGGACAAAAGGTTACATAGTATGCCCTTAAGACTTAATTTTAACCAAAGGC CTAGCACCACCTTAGGGGCTGCAATAAACACTTAACGCGCGTGCGCACGCGCG CGCGCACACACACACACACACACACACACACACACAGGTCAGAGTTTAAGGC TTTCGAGTCATGACATTCTAGCTTTTGAATTGCGTGCACACACACACGCACGCA CACACTCTGGTCAGAGTTTATTAAGGCTTTCGAGTCATGACATTATAGCTTTTG AGTTGGTGTGTGTGACACCACCCTCCTAAGTGGTGTGTGCTTGTAATTTTTTTTT TCAGTGAAAATGGATTGAAAACCTGTTGTTAATGCTTAGTGATATTATGCTCAA AACAAGGAAATTCCCTTGAACCGTGTCAATTAAACTGGTTTATATGACTCAAG AAAACAATACCAGTAGATGATTATTAACTTTATTCTTGGCTCTTTTTAGGTCCA TTTTGATTAAGTGACTTTTGGCTGGATCATTCAGAGCTCTCTTCTAGCCTACCCT TGGATGAGTACAATTAATGAAATTCATATTTTCAAGGACCTGGGAGCCTTCCTT GGGGCTGGGTTGAGGGTGGGGGGTTGGGGAGTCCTGGTAGAGGCCAGCTTTGT GGTAGCTGGAGAGGAAGGGATGAAACCAGCTGCTGTTGCAAAGGCTGCTTGTC ATTGATAGAAGGACTCACGGGCTTGGATTGATTAAGACTAAACATGGAGTTGG CAAACTTTCTTCAAGTATTGAGTTCTGTTCAATGCATTGGACATGTGATTTAAG GGAAAAGTGTGAATGCTTATAGATGATGAAAACCTGGTGGGCTGCAGAGCCCA GTTTAGAAGAAGTGAGTTGGGGGTTGGGGACAGATTTGGTGGTGGTATTTCCC AACTGTTTCCTCCCCTAAATTCAGAGGAATGCAGCTATGCCAGAAGCCAGAGA AGAGCCACTCGTAGCTTCTGCTTTGGGGACAACTGGTCAGTTGAAAGTCCCAG GAGTTCCTTTGTGGCTTTCTGTATACTTTTGCCTGGTTAAAGTCTGTGGCTAAA AAATAGTCGAACCTTTCTTGAGAACTCTGTAACAAAGTATGTTTTTGATTAAAA GAGAAAGCCAACTA
> 34 CTCTCTACACAGAATCGGCTGTTGAGTGTGCTCTCAGTGGAGCTTTGGTTTTAG CTGTTCTCTGACAAAGAGCTTGTTCTGAGCTGCACATCTCGTCCTCTTTGTTCA GCCTCAGGCTTCAAGCATTGAATCCTAAATATTCTCCAGCTGGGAATCAGACA AGGGCAGAAATGAAGAACCCAGAAGCCCAGCAGGATGTTTCAGTTTCCCAGG GATTTCGCATGTTGTTTTACACGATGAAACCCAGTGAAACTTCATTCCAAACAT TAGAAGAGGTGCCTGATTATGTAAAAAAGGCAACTCCATTTTTCATTTCTTTGA TGCTGCTTGAACTTGTTGTCAGCTGGATTCTCAAAGGAAAGCCACCAGGTCGC CTGGATGATGCTTTAACGTCAATCTCAGCTGGTGTTCTGTCTCGACTTCCAAGT CTATTTTTCAGGAGCATTGAACTGACCAGTTATATTTATATCTGGGAGAACTAC AGGCTGTTCAATTTGCCTTGGGATTCTCCATGGACTTGGTATTCAGCCTTCTTA GGAGTTGACTTTGGCTACTACTGGTTCCATCGTATGGCTCATGAAGTTAATATT ATGTGGGCCGGACACCAAACACATCATAGTTCTGAAGACTATAACTTATCCAC AGCACTGAGACAGTCTGTCCTCCAGATATATACTTCCTGGATTTTCTACTCTCC CCTGGCCCTCTTCATACCCCCTTCAGTATATGCTGTTCATCTTCAATTCAATCTT CTTTACCAATTTTGGATCCATACAGAGGTCATCAATAACCTTGGTCCTTTGGAA CTGATTCTTAATACTCCTAGCCATCATAGGGTTCATCATGGCAGAAATCGTTAT TGCATAGACAAAAATTATGCTGGTGTTCTTATTATTTGGGATAAAATTTTTGGG ACATTTGAAGCAGAAAATGAAAAAGTTGTATATGGCTTAACACATCCCATTAA TACATTTGAACCAATCAAAGTGCAGTTCCATCACTTATTTTCCATATGGACTAC ATTCTGGGCCACACCTGGATTCTTCAATAAGTTTTCTGTCATATTTAAGGGACC GGGATGGGGTCCAGGTAAACCAAGACTTGGTCTCAGTGAAGAAATTCCAGAG GTCACCGGCAAAGAAGTTCCCTTCTCATCATCTTCATCTCAGCTATTAAAGATA TATACAGTTGTACAGTTTGCTCTGATGTTGGCATTTTATGAAGAGACCTTTGCA GATACAGCTGCACTGTCGCAAGTTACTCTCCTTCTGAGGGTTTGCTTCATTATC CTGACCTTGACTTCCATTGGATTTCTTCTGGATCAAAGACCCAAGGCAGCTATT ATGGAAACTCTCCGTTGCTTGATGTTCTTAATGCTGTACCGATTTGGTCACCTG AAGCCTCTTGTCCCTTCATTGTCATCTGCTTTTGAGATTGTTTTTTCCATTTGCA TTGCTTTCTGGGGAGTTAGAAGCATGAAACAACTCACCTCTCACCCTTGGAAAT AACCTGAATTTGTACATAATTCTCTTCTTTTAATGAGTTGTCCACACGCATATT ATGACTGCATATTAAAATGTAATTATTTTATGTAATGCTTATATGAACTATTTC TTCAATGAAAAGTAAAATTACTTATTTACTATTGTTTGCCTTTCACATTTGTTAT TTTCTATTAAAAATTAAAGTCAGTTTTGGTTACTTCCCCCCTTTACTACAATTAA AAAAAGATTTCAAATATAATGATGTTATATTAACTGATAGCCTTATATGACAA GTATAAAAAGAAGGGATGAAACTTAAAAACAGTAAAAACAAGAAGGAATATT GCCTTTACATCAATTTGAAAACAATGTTTCCTTTGATGTTTGCTAAAATTATGC ATAGATACATGTTTGTAGTCATAAAAATGTATTACATTGGTTGTCTTCCTAAGG CCACAGTTACCTTTGCAATCCATATAACCTAAGAAGCTGCATTCCAGAAAAAG ACATCACTGAGGCCAGGCGCGGTGGCTCACCCCTGTAATCCCAGCACTTTGTG GGGCTGAGGTGGGCGGATCATGAGGTCCAGAGATAGAGACCATCCTGGCCAA CATGGTGAAGTCCTGTCTCTACTAAAAATATAAAAATTTAGCTGGACATGGTG GTGTGCGCCTGTAGTCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCGCTTG AACCTGGGAGGCAGAAGTTGGAGTGAGTGGAGATTGCACCACTGCACTCCAGC CTGGGCGACAGAGCGAGACTCCGTCTCAAAGAAAAAAGACATCACTGAAAGA AAAATGAACAGAATTTGTCAGAATTAGTTTTTTCAACAGGTTACTTTGTCATAC ATTTCTCTAATATGCTTGGTCAATTTGTTTTGGCAGACTGGGCAGCATGCAGCA ATTCTGCATTATTTAAAGTTATCAGAACAATGTTAATTCTCTAAATAAAATTAC CCAAGGT
> 35
GGAGCTGTTTACCCCCACTCTAATAGGGGTTCAATATAAAAAGCCGGCAGAGA GCTGTCCAAGTCAGACGCGCCTCTGCATCTGCGCCAGGCGAACGGGTCCTGCG CCTCCTGCAGTCCCAGCTCTCCACCGCCGCGTGCGCCTGCAGACGCTCCGCTCG CTGCCTTCTCTCCTGGCAGGCGCTGCCTTTTCTCCCCGTTAAAAGGGCACTTGG GCTGAAGGATCGCTTTGAGATCTGAGGAACCCGCAGCGCTTTGAGGGACCTGA AGCTGTTTTTCTTCGTTTTCCTTTGGGTTCAGTTTGAACGGGAGGTTTTTGATCC CTTTTTTTCAGAATGGATTATTTGCTCATGATTTTCTCTCTGCTGTTTGTGGCTT GCCAAGGAGCTCCAGAAACAGCAGTCTTAGGCGCTGAGCTCAGCGCGGTGGGT GAGAACGGCGGGGAGAAACCCACTCCCAGTCCACCCTGGCGGCTCCGCCGGTC CAAGCGCTGCTCCTGCTCGTCCCTGATGGATAAAGAGTGTGTCTACTTCTGCCA CCTGGACATCATTTGGGTCAACACTCCCGAGCACGTTGTTCCGTATGGACTTGG AAGCCCTAGGTCCAAGAGAGCCTTGGAGAATTTACTTCCCACAAAGGCAACAG ACCGTGAAAATAGATGCCAATGTGCTAGCCAAAAAGACAAGAAGTGCTGGAA TTTTTGCCAAGCAGGAAAAGAACTCAGGGCTGAAGACATTATGGAGAAAGACT GGAATAATCATAAGAAAGGAAAAGACTGTTCCAAGCTTGGGAAAAAGTGTAT TTATCAGCAGTTAGTGAGAGGAAGAAAAATCAGAAGAAGTTCAGAGGAACAC CTAAGACAAACCAGGTCGGAGACCATGAGAAACAGCGTCAAATCATCTTTTCA TGATCCCAAGCTGAAAGGCAAGCCCTCCAGAGAGCGTTATGTGACCCACAACC GAGCACATTGGTGACAGACCTTCGGGGCCTGTCTGAAGCCATAGCCTCCACGG AGAGCCCTGTGGCCGACTCTGCACTCTCCACCCTGGCTGGGATCAGAGCAGGA GCATCCTCTGCTGGTTCCTGACTGGCAAAGGACCAGCGTCCTCGTTCAAAACAT TCCAAGAAAGGTTAAGGAGTTCCCCCAACCATCTTCACTGGCTTCCATCAGTG GTAACTGCTTTGGTCTCTTCTTTCATCTGGGGATGACAATGGACCTCTCAGCAG AAACACACAGTCACATTCGAATTCGGGTGGCATCCTCCGGAGAGAGAGAGAG GAAGGAGATTCCACACAGGGGTGGAGTTTCTGACGAAGGTCCTAAGGGAGTGT TTGTGTCTGACTCAGGCGCCTGGCACATTTCAGGGAGAAACTCCAAAGTCCAC ACAAAGATTTTCTAAGGAATGCACAAATTGAAAACACACTCAAAAGACAAAC ATGCAAGTAAAGAAAAAAAAAAGAAAGACTTTTGTTTAAATTTGTAAAATGCA AAACTGAATGAAACTGTTACTACCATAAATCAGGATATGTTTCATGAATATGA GTCTACCTCACCTATATTGCACTCTGGCAGAAGTATTTCCCACATTTAATTATT GCCTCCCCAAACTCTTCCCACCCCTGCTGCCCCTTCCTCCATCCCCCATACTAA ATCCTAGCCTCGTAGAAGTCTGGTCTAATGTGTCAGCAGTAGATATAATATTTT CATGGTAATCTACTAGCTCTGATCCATAAGAAAAAAAAGATCATTAAATCAGG AGATTCCCTGTCCTTGATTTTTGGAGACACAATGGTATAGGGTTGTTTATGAAA TATATTGAAAAGTAAGTGTTTGTTACGCTTTAAAGCAGTAAAATTATTTTCCTT TATATAACCGGCTAATGAAAGAGGTTGGATTGAATTTTGATGTACTTATTTTTT TATAGATATTTATATTCAAACAATTTATTCCTTATATTTACCATGTTAAATATCT GTTTGGGCAGGCCATATTGGTCTATGTATTTTTAAAATATGTATTTCTAAATGA AATTGAGAACATGCTTTGTTTTGCCTGTCAAGGTAATGACTTTAGAAAATAAAT ATTTTTTTCCTTACTGTA
> 36
CCCCGCGTGTCTGCTAGGAGAGGGCGGGCAGCGCCGCGGCGCGCGCGATCCG GCTGACGCATCTGGCCCCGGTTCCCCAAGACCAGAGCGGGGCCGGGAGGGAG GGGGAAGAGGCGAGAGCGCGGAGGGCGCGCGTGCGCATTGGCGCGGGGAGG AGCAGGGATCTTGGCAGCGGGCGAGGAGGCTGCGAGCGAGCCGCGAACCGAG CGGGCGGCGGGCGCGCGCACCATGGGGGAGAAACCCGGGACCAGGGTCTTCA AGAAGTCGAGCCCTAACTGCAAGCTCACCGTGTACTTGGGCAAGCGGGACTTC GTAGATCACCTGGACAAAGTGGACCCTGTAGATGGCGTGGTGCTTGTGGACCC TGACTACCTGAAGGACCGCAAAGTGTTTGTGACCCTCACCTGCGCCTTCCGCTA TGGCCGTGAAGACCTGGATGTGCTGGGCTTGTCCTTCCGCAAAGACCTGTTCAT CGCCACCTACCAGGCCTTCCCCCCGGTGCCCAACCCACCCCGGCCCCCCACCC GCCTGCAGGACCGGCTGCTGAGGAAGCTGGGCCAGCATGCCCACCCCTTCTTC TTCACCATACCCCAGAATCTTCCATGCTCCGTCACACTGCAGCCAGGCCCAGA GGATACAGGAAAGGCCTGCGGCGTAGACTTTGAGATTCGAGCCTTCTGTGCTA AATCACTAGAAGAGAAAAGCCACAAAAGGAACTCTGTGCGGCTGGTGATCCG AAAGGTGCAGTTCGCCCCGGAGAAACCCGGCCCCCAGCCTTCAGCCGAAACCA CACGCCACTTCCTCATGTCTGACCGGTCCCTGCACCTCGAGGCTTCCCTGGACA AGGAGCTGTACTACCATGGGGAGCCCCTCAATGTAAATGTCCACGTCACCAAC AACTCCACCAAGACCGTCAAGAAGATCAAAGTCTCTGTGAGACAGTACGCCGA CATCTGCCTCTTCAGCACCGCCCAGTACAAGTGTCCTGTGGCTCAACTCGAACA AGATGACCAGGTATCTCCCAGCTCCACATTCTGTAAGGTGTACACCATAACCC CACTGCTCAGCGACAACCGGGAGAAGCGGGGTCTCGCCCTGGATGGGAAACT CAAGCACGAGGACACCAACCTGGCTTCCAGCACCATCGTGAAGGAGGGTGCC AACAAGGAGGTGCTGGGAATCCTGGTGTCCTACAGGGTCAAGGTGAAGCTGGT GGTGTCTCGAGGCGGGGATGTCTCTGTGGAGCTGCCTTTTGTTCTTATGCACCC CAAGCCCCACGACCACATCCCCCTCCCCAGACCCCAGTCAGCCGCTCCGGAGA CAGATGTCCCTGTGGACACCAACCTCATTGAATTTGATACCAACTATGCCACA GATGATGACATTGTGTTTGAGGACTTTGCCCGGCTTCGGCTGAAGGGGATGAA GGATGACGACTATGATGATCAACTCTGCTAGGAAGCGGGGTGGGAAGAAGGG AGGGGATGGGGTTGGGAGAGGTGAGGGCAGGATTAAGATCCCCACTGTCAAT GGGGGATTGTCCCAGCCCCTCTTCCCTTCCCCTCACCTGGAAGCTTCTTCAACC AATCCCTTCACACTCTCTCCCCCATCCCCCCAAGATACACACTGGACCCTCTCT TGCTGAATGTGGGCATTAATTTTTTGACTGCAGCTCTGCTTCTCCAGCCCCGCC GTGGGTGGCAAGCTGTGTTCATACCTAAATTTTCTGGAAGGGGACAGTGAAAA GAGGAGTGACAGGAGGGAAAGGGGGAGACAAAACTCCTACTCTCAACCTCAC ACCAACACCTCCCATTATCACTCTCTCTGCCCCCATTCCTTCAAGAGGAGACCC TTTGGGGACAAGGCCGTTTCTTTGTTTCTGAGCATAAAGAAGAAAATAAATCTT TTACTAAGCATGA
> 37
ATGGCCCGTACTAAGCAGACTGCCCGCAAGTCGACCGGCGGCAAGGCCCCGA GGAAGCAGCTGGCTACCAAAGCGGCCCGCAAGAGCGCGCCGGCCACGGGCGG GGTGAAGAAGCCGCACCGCTACCGGCCCGGCACCGTGGCTCTGCGGGAGATCC GGCGCTACCAGAAGTCTACGGAGCTGCTGATCCGCAAGCTGCCCTTCCAGCGG CTGGTACGCGAGATCGCGCAGGACTTTAAGACGGACCTGCGCTTCCAGAGCTC GGCCGTGATGGCGCTGCAGGAGGCCAGCGAGGCCTACCTGGTGGGGCTGTTCG AAGACACGAACCTGTGCGCCATCCATGCCAAGCGCGTGACCATCATGCCCAAG GACATCCAGTTGGCCCGCCGCATCCGCGGGGAGCGGGCCTAAGGCATATTTTT AAGTGGTCGATCTAAAGGCTCTTTTCAGAGCCACT > 38
CCCAGCTCAGACACTCCTAGCCTTGGGGCAGCTGCCGGGCGAGTCAGCGGAGT AGCGGCCAGCGGGCGATGGAGACAGAGAGACACCCGACGAGAGGAGGCGGG GTGGGGGAGGCGGGGAGAGTGCGGGGGCGGAGGCTGGCAGGGGGCGCTGGA AGCTGGAGCGGTCCGTGCGCTCCCCGCGCCCGAGGGTGCAGGAGGCTCTGAAG CGGCTGCTGCACCGCGGGGCCCAGGCGGCGGCTGGGGGGCTGGGGGGCGCTG CCGCCGCCGCCGCCGGGGGCGTCGCTGGCCTCGGCCCCTTTGTTCTCGCGCGCT CCCCCTCGCCGCCCACTCCCCTGCTGTCGCGCGGCGGCGGCGGTGGCGGCGGC GGCTCCTCCCGCCCGAGGCAGTCGGGCTCGGCGCCGGGGGCGGGAGGGGGCG GGGGGAGCACGCCAGCCGCCGAGAGTGGGGGGCGATGGCGAAGCTCCGGGTG GCTTACGAGTACACGGAAGCCGAGGACAAGAGCATCCGGCTCGGCTTGTTTCT CATCATCTCCGGCGTCGTGTCGCTCTTCATCTTCGGCTTCTGCTGGCTGAGTCCC GCGCTGCAGGATCTGCAAGCCACGGAGGCCAATTGCACGGTGCTGTCGGTGCA GCAGATCGGCGAGGTGTTCGAGTGCACCTTCACCTGTGGCGCCGACTGCAGGG GCACCTCGCAGTACCCCTGCGTCCAGGTCTACGTGAACAACTCTGAGTCCAAC TCTAGGGCGCTGCTGCACAGCGACGAGCACCAGCTCCTGACCAACCCCAAGTG CTCCTATATCCCTCCCTGTAAGAGAGAAAATCAGAAGAATTTGGAAAGTGTCA TGAATTGGCAACAGTACTGGAAAGATGAGATTGGTTCCCAGCCATTTACTTGC TATTTTAATCAACATCAAAGACCAGATGATGTGCTTCTGCATCGCACTCATGAT GAGATTGTCCTCCTGCATTGCTTCCTCTGGCCCCTGGTGACATTTGTGGTGGGC GTTCTCATTGTGGTCCTGACCATCTGTGCCAAGAGCTTGGCGGTCAAGGCGGA AGCCATGAAGAAGCGCAAGTTCTCTTAAAGGGGAAGGAGGCTTGTAGAAAGC AAAGTACAGAAGCTGTACTCATCGGCACGCGTCCACCTGCGGAACCTGTGTTT CCTGGCGCAGGAGATGGACAGGGCCACGACAGGGCTCTGAGAGGCTCATCCC TCAGTGGCAACAGAAACAGGCACAACTGGAAGACTTGGAACCTCAAAGCTTGT ATTCCATCTGCTGTAGCAATGGCTAAAGGGTCAAGATCTTAGCTGTATGGAGT AACTATTTCAGAAAACCCTATAAGAAGTTCATTTTCTTTCAAAAGTAACAGTAT ATTATTTGTACAGTGTAGTATACAAACCATTATGATTTATGCTACTTAAAAATA TTAAAATAGAGTGGTCTGTGTTATTTTCTATTTCCTTTTTTATGCTTAGAACACC AGGGTTTAAAAAAAAAAAAAAGGTGAGGACATCTGGGTCTCATTTGCTTCTGC TAGGTTAAACTTTTACTTGACAACAAGGATTCCTGCTGAAGTCTGAACCTTACT GTGTAACCCTCAGTTTCCACTATTAAAGAGTATCTTTTGACGTCTGCTTGGAAA ATGAATAGTATACTGGTAACTCAGTCTCCAGTCACCTCTGTGTCTCTTAAGCAA GAGATTCTAAAAGATTGGGAAAACATATCCTCCAACACCTGCCTTTGCCTAAC CATTATTTTTCACCAGATTACTTCTTAAGAGAGGGAGGTGATTCTGAAGAAGG CTTCTATCTCAAAAAGCACTGGGCTTCCTTATTCATCTGTTCTTGTTGTTTTTGA CGGAGTTAAAAAAGTTTGTGTGCAATACAATATACATGATGTGAAGGACACTC TTCAGCTTAGTGAAACGCTGTTTTCATTTTTTTTTTTTTTTGTAGGTCAGAAAAA AACAACAAAATCAGTTCAAGCATTTTTTTTTCTTTGTCCTTGCCTTGATGTTATG AGTATTAAAACCAGGAGGATTGCTGCCATTGTGCAGTTTGCTTAGACAAACCT GGAGATGCAACCCAGCTCACATCATTGCTACTGATGAGCTTTCTGTGCCTTTAT CAAAAGTTGATTGAGAAGACCATATTTCTTTGTATCTTTTTATAAACTCAAATT CCAAGTATCAAATCGCAGGTCTCAGTGAACATCAAACCTATTTACTACATAGA ATCAAACCTTTGTTTAGGTGAGATGTACATCGTTAGTGGAGGAAAAACTGACA ACCTAATTTCATTTGTTTTCTTCTGATACTCTTCAGACATGCCTCTATTAGAATA AAGGTAAACTGGAATTTAAAGACAAGTTCCCCTCAGTTATTTCCATGGAGCTG TAATATGTATATATGGAGTGATGGTTTCCTGACCTTTAGTCCACATACCAATGT TTTCTTTTTTCTTTTTTTTTTTTTTTTTTGAGATGGTGTCTCACTCTGTTGCCAGG CTGGAGTGCAGTGGCACGATCTCGGCTCACTACAGTCTCCACCTCCTGGGTTCA AGTCATTCCTCTGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGCACGCACCA CCACGCCTGGCTAATTTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGTGTT AGCCAGGATGGTCTCAATCTCCTGACCTTGTGATCTGCCCACTTCACCTCCCAA AGTGCTGGGATTACAGGCCAATGTTTTCTTAATCTTAGAATGTGAATAACTGAA AATCATAGTCTGTGGAAAGGTGTTGAATTGAGTATAATCTTCTTCTGTTTATTT TTGTGTTTTGTTTTTTAACAGATGGGTATCTTGCTATGTTGCCCAGGATGGAGT GCAGTAGCTATTCACAGGTATGATCATAGCACACTGCAGCCTCAAGCTCCTGG GCTCAAGCGATCCCCCTCCCTCAGCCTCCCAAGTATCTGGGGTTACTGGTGTGC ACCACCGTGCTTGGCTCCAATAATTTTTTTTCTAATTCAAAAGTTACAGTTTCA CTGTGAAAAAGGCCTTGAACACACTATTTATGACATCTTTTGAGGCAGCTCCA GTGCCTTGACTTCAATCCCAGTTTCCGGTTGCAGCATCCTTGTTGTCTTAGCAA CACAGTGAACTATTCTGAAGCATAGAGTAACACGAAACTGGGAGTCCGAGAA ATAATCATCTCTGCATCACATTATGGGAGACGAAGTCTGCTTTATCCATTTTAT CTTTATTCAGTTGTCTATGATTAATTGATTACAGAGTAGTAGATTAGAATAGTG CATGGATATACATTTGTGTTGAAAAAAGGGGAAGTTGATATATATCAATCTTA GTTTTCATTTATCAGTTTGATATTCATGCATTTACACTAAACGCTTCCATTTATC CCGAAAAAGTATATGCAACTGTATTCTGTAGGTTGATTTTTGGAAAAGGGGAG AAGCACACTGAATTCATAAGGTCACATGTAGTCTTAAGGTCTTACTTGCTTACA GCCAATTAAATTTGAAGCACCTTATTTATACTTGTTAAAGGTAAAACCCAAAA GAACAAGCAGAGGACATTTTAAGGTCATAAAAGGTAAATAAGCTTACCTTCTT AATGTTTTCATTCTCTTTTTGTATAAATCAGAAAATGATCTAAACTGCTGTAAC AAAGAGACCCCAAAATATGATGGCTCATGTAAGATAATTTATTTTTTTCTCACA TAGCAATCCAGAAGTGGCTTCATTTCACAAGGTATTCAAGGGATATAGGAGTC ATCTACCTTGTTAGTTCTCTTAATACCCAAGGGTATTGTTCTTTCCATGGTCAAA GCTGGCTCAAGACTTCCTAGCCTGTGAAAAAAGAAGAAGGTGGAGCAAGCCA TTTCCTTTTTAGGAAATTACAGCCATCACTTCTGCCCACCGTCCATTCATGAAT ACTTACTATATAGCTATACCTAGCTTCAAGAAAGCCTGGGACGTGTCTCTAACT AGATGGACATGTGCCCTACTAAAACTCCAGGGAAAGGGTTCTATTACTAAAGC TAAAAAGAGGGGAATGAATACTAGAGTTAAAGACAAAAATGATAGCAGCCAA TGGCCCATGCCGTGATAATCTGCTGAGCAGGCATGATGGAGATCCCTTGCCCA GCAGAAAGTGTTCCTTGGTGAAATCATGAATCTGCTATCTAGGAGAAACTCCC TTGTCCATTGTCTTCTGTGGCCACTAGTTTGACCTCTAGGAAAGTCTTGCTCGTC AGCTTCTGTGGCCCCGTCTGAAACTTTTGAGGGACATCGCAGCTTTTGCAGCCC CTGCTTGCTGGTGCAGACTTTTAGACCTAGATTGCCTTAGAGACTGAAAAATAT ACGCTTTTATAGGCCGGGGTTTTAGTTCATTTGACTGTAATAAAGACGTCAATG CCGTTTTTAATGTTTGACTGCTGACATCTTTCAAGACTCACCTTTCCCTTCTCCC TTATGCTGCACATCTGGGCAAGCTGATGGAAGCATGGGTGCCTCCTCCTTTGGC CCCAGCAGGAAGTTCAAATCACGCAAGCCCTGGCATGCATGCAGGAAGCTTCA CCCCAGCCTCACACTCTAAGACGGATAAAAGCCAAACCAATTAAGCCGTTTCT CGACCCTCCTGGGAGCCTGCCCTATCTCCCTGGAAAGTCTCAGTATGTGAGTAA TAAACCTTTTTATACCCA
> 39
CAGGAGAGAAAGTACTGCCCAGAAGCTAAAGTGTAGATCAAACGCATAATGG CTGAGGTAGTAGTTTCTTGAACTT
> 40
GGCTCTGCAGAGGCAGCGGTTGGAGGCGCGGTGGGTGTCTGCGGGGGTCTCGC
GGGGCGGCTGCGGTGTTTCACCGGGAAAGGCTCGAGGAGAGCGCGGCTCACG
AGAGATAACCCAGCTGTGCTCCCTGGAACCTTCAATTTCAAGGCCTCCCTGCCT CTACTAGGCGCCTTAGCTCACTATGGGGAACCACTTGACTGAGATGGCGCCCA CTGCCTCCTCCTTCTTGCCCCACTTCCAAGCCCTGCATGTCGTGGTCATTGGGC TGGACTCTGCTGGAAAGACCTCCCTCCTTTACCGCCTCAAGTTCAAGGAGTTTG TCCAGAGTGTCCCCACCAAAGGCTTCAACACCGAGAAGATCCGGGTGCCCCTC GGGGGATCGCGTGGCATCACCTTCCAAGTGTGGGACGTCGGGGGGCAGGAGA AGCTGCGACCACTGTGGCGCTCTTATACCCGCCGGACAGACGGTCTAGTGTTT GTGGTGGACGCTGCGGAGGCTGAGCGGCTGGAGGAAGCCAAGGTGGAGTTGC ACCGAATCAGCCGGGCCTCGGACAACCAGGGCGTGCCAGTGCTGGTGCTGGCC AACAAGCAGGACCAGCCCGGGGCACTGAGCGCTGCTGAGGTGGAGAAGAGGC TGGCAGTCCGAGAGCTAGCAGCCGCCACTCTCACTCATGTGCAAGGCTGCAGC GCTGTGGACGGTCTGGGCCTGCAGCAGGGCCTTGAGCGCCTCTATGAGATGAT CCTCAAGAGGAAGAAGGCAGCTCGGGGTGGCAAGAAGAGACGGTGACCCAAG CCCCCCCTCCCTTTCCTCCCACCTAGTAGGGGTCTGCACACTTGGACAGCAGGG TGGGACCAGCCTGTGACCTCTCAGTCAGACTGGGGTGCAGGACCTGTCCACCT CAATGAAGGAGAGAGGAGCATGGGGTGTCCCGTTTTGGTGCCACACTGGGGTG GGGATGGGAGATGGGATGTCTTTGCATATCTCTCTCATCCTCTCTGGAGAAGTG GGCGCTGCAGGACTGTGGAGACGTAAATGTAAACTGTGACTCTACCTCGACCC TGTTTCTTATTTTTCTTCTCTGGCTAAAAATTTTTAATTGGATGTGTTTGGGGGC GGGGGGATGGAAGTGACTTGGAGAATGTGTTTGGGATGAAATAACTATCTCCC CTTCCTCTGTCCCCCAACTGGGGAGTCTCCCCAGGCTGCTTTTCTAGGAATACC AGTCACATAGTTTTTATTTTTGTGTCTGTGAAAGTGCCAAGAACCCCTCCCCAC ATTTGTAGATCCATGACCCTTTTTATAAGCTGTGTGTGTCCTCTGTATTATTGTT ATTAACTATTTTTTAGCATTTGCCTGTAAGTTATTAAAGACTGATAACTGTAGC TCTTACCTTGGTCTGGGGCATTTTCCTCTCCTTATCTTGCCCCAGAGACAATTCA AGATTTCTATATGGGGTTGTGGCGCAGGGGGAGGGAGATTTATCTTGAAGCTG AATTTGCAAAGCAAGCACTTATAAAAATTAGATTGTGTGTTACGGGATGGCTT GTGAAAATTATAGGGGGGAGTGGAAAACCCCTCAAGCTA
> 41
CAGTGTTCATGTAGATGTTTAAGCTCTTGCAGTAGGTTTTTGCAAGCTAGTGAA CGCTG > 42
ACTATATTCACAGGCTTGGAGCCAGTGCCATTCACACTTCCCCCTCTTCTGCAG CAGACGGACTGAGTTCCTCTAATCCCTGTGTTCCTTCTCCCCCATCTTTCTAAA ACCCTTCTCTGAGAGAGGAATAACTATAGCTTCAGGGATAATATAGCTTTAAG GAAACTTTTGGCAGATGTGGACGTCGTAACATCTGGGCAGTGTTAACAGAATC CCGGAGGCCGGGACAGACCAGGAGCCACTCGTTCTAGGAATGTTAAAGTAGA AGGTTTTTTCCAATTGATGAGAGGAGCAGAGAGGAAGGAGAAAGAGGAGGAG AGAGAAAAAGGGCACAAAATACCATAAAACAGATCCCATATTTCTGCTTCCCC TCACTTTTAGAAGTTAATTGATGGCTGACTTCTGAAAGTCACTTTCCTTTGCCCT GGTACTTCAGGCCATATACATCTTTTCTTGTCTCCATAATCCTCCCTTTCAAGGA TGGCCAGTCAGCTAACTCAAAGAGGAGCTCTCTTTCTGCTGTTCTTCCTAACTC CGGCAGTGACACCAACATGGTATGCAGGTTCTGGCTACTATCCGGATGAAAGC TACAATGAAGTATATGCAGAGGAGGTCCCACAGGCTCCTGCCCTGGACTACCG AGTCCCCCGATGGTGTTATACATTAAATATCCAGGATGGAGAAGCCACATGCT ACTCACCGAAGGGAGGAAATTATCACAGCAGCCTGGGCACGCGTTGTGAGCTC TCCTGTGACCGGGGCTTTCGATTGATTGGAAGGAGGTCGGTGCAATGCCTGCC AAGCCGTCGTTGGTCTGGAACTGCCTACTGCAGGCAGATGAGATGCCACGCAC TACCATTCATCACTAGTGGCACTTACACCTGCACAAATGGAGTGCTTCTTGACT CTCGCTGTGACTACAGCTGTTCCAGTGGCTACCACCTGGAAGGTGATCGCAGC CGAATCTGCATGGAAGATGGGAGATGGAGTGGAGGCGAGCCTGTATGTGTAG ACATAGATCCCCCCAAGATCCGCTGTCCCCACTCACGTGAGAAGATGGCAGAG CCAGAGAAATTGACTGCTCGAGTATACTGGGACCCACCGTTGGTGAAAGATTC TGCTGATGGTACCATCACCAGGGTGACACTTCGGGGCCCTGAGCCTGGCTCTC ACTTTCCCGAAGGAGAGCATGTGATTCGTTACACTGCCTATGACCGAGCCTAC AACCGGGCCAGCTGCAAGTTCATTGTGAAAGTACAAGTGAGACGCTGCCCAAC TCTGAAACCTCCGCAGCACGGCTACCTCACCTGCACCTCAGCGGGGGACAACT ATGGTGCCACCTGTGAATACCACTGTGATGGCGGTTATGATCGCCAGGGGACA CCCTCCCGGGTCTGTCAGTCCAGCCGCCAGTGGTCAGGTTCACCACCAATCTGT GCTCCTATGAAGATTAACGTCAACGTCAACTCAGCTGCTGGTCTCTTGGATCAA TTCTATGAGAAACAGCGACTCCTCATCATCTCAGCTCCTGATCCTTCCAACCGA TATTATAAAATGCAGATCTCTATGCTACAGCAATCCACCTGTGGACTGGATTTG CGGCATGTGACCATCATTGAACTGGTGGGACAGCCACCTCAGGAGGTGGGGCG CATCCGGGAGCAACAGCTGTCAGCCAACATCATCGAGGAGCTCAGGCAATTTC AGCGCCTCACTCGCTCCTACTTCAACATGGTGTTGATTGACAAGCAGGGTATTG ACCGAGACCGCTACATGGAACCTGTCACCCCCGAGGAAATCTTCACATTCATT GATGACTACCTACTGAGCAATCAGGAGTTGACCCAGCGTCGGGAGCAAAGGG ACATATGCGAGTGAACTTGAGCCAGGGCATGGTTAAAGTCAAGGGAAAAGCT CCTCTAGTTAGCTGAAACTGGGACCTAATAAAAGGAGGAAATGTTTTCCCACA GTTCTAGGGACAGGACTCTGAGGTGGGTGAGTTTGACAAATCCTGCAGTGTTT CCAGGCATCCTTTTAGGACTGTGTAATAGTTTCCCTAGAAGCTAGGTAGGGACT GAGGACAGGCCTTGGGCAGTGGGTTGGGGGTAGAAGTTCTTCCTTTCCTAACC CGGGCCCCTGCCCAGCTCTCCAAAGTCTTTCAGAAAAGTAAATCCTAAATTCA GTGATGA
> 43
GTGCAGAAGGCCGCGCTAGCCGGCTCTTCAGCAGCGAGTGCAGATTGCTCCCC CGCGGCCGCAGATCTCCCGTTTGCGCCGCGTTCAGCTGCTCCCGAACAACTTTT CTGCCGGCCCAGAGGCCCCAGGGCGTCGCAGCGCCGCGTGCGGCCCACTCACG GGCCGGCAGGATGGACTCCAACACTGCTCCGCTGGGCCCCTCCTGCCCACAGC CCCCGCCAGCACCGCAGCCCCAGGCGCGTTCCCGACTCAATGCCACAGCCTCG TTGGAGCAGGAGAGGAGCGAAAGGCCCCGAGCACCCGGACCCCAGGCTGGCC CTGGCCCTGGTGTTAGAGACGCAGCGGCCCCCGCTGAACCCCAGGCCCAGCAT ACCAGGAGCCGGGAAAGAGCAGACGGCACCGGGCCTACAAAGGGAGACATG GAAATCCCCTTTGAAGAAGTCCTGGAGAGGGCCAAGGCCGGGGACCCCAAGG CACAGACTGAGGTGGGGAAGCACTACCTGCAGTTGGCCGGCGACACGGATGA AGAACTCAACAGCTGCACCGCTGTGGACTGGCTGGTCCTCGCCGCGAAGCAGG GCCGTCGCGAGGCTGTGAAGCTGCTTCGCCGGTGCTTGGCGGACAGAAGAGGC ATCACGTCCGAGAACGAACGGGAGGTGAGGCAGCTCTCCTCCGAGACCGACCT GGAGAGGGCCGTGCGCAAGGCAGCCCTGGTCATGTACTGGAAGCTCAACCCC AAGAAGAAGAAGCAGGTGGCCGTGGCGGAGCTGCTGGAGAATGTCGGCCAGG TCAACGAGCACGATGGAGGGGCGCAGCCAGGCCCCGTGCCCAAGTCCCTGCA GAAGCAGAGGCGCATGCTGGAGCGCCTGGTCAGCAGCGAGTCCAAGAACTAC ATCGCGCTGGATGACTTTGTGGAGATCACTAAGAAGTACGCCAAGGGCGTCAT CCCCAGCAGCCTGTTCCTGCAGGACGACGAAGATGATGACGAGCTGGCGGGG AAGAGCCCTGAGGACCTGCCACTGCGTCTGAAGGTGGTCAAGTACCCCCTGCA CGCCATCATGGAGATCAAGGAGTACCTGATTGACATGGCCTCCAGGGCAGGCA TGCACTGGCTGTCCACCATCATCCCCACGCACCACATCAACGCGCTCATCTTCT TCTTCATCGTCAGCAACCTCACCATCGACTTCTTCGCCTTCTTCATCCCGCTGGT CATCTTCTACCTGTCCTTCATCTCCATGGTGATCTGCACCCTCAAGGTGTTCCA GGACAGCAAGGCCTGGGAGAACTTCCGCACCCTCACCGACCTGCTGCTGCGCT TCGAGCCCAACCTGGATGTGGAGCAGGCCGAGGTCAACTTCGGCTGGAACCAC CTGGAGCCCTATGCCCATTTCCTGCTCTCTGTCTTCTTCGTCATCTTCTCCTTCC CCATCGCCAGCAAGGACTGCATCCCCTGCTCGGAGCTGGCTGTCATCACCGGC TTCTTTACCGTGACCAGCTACCTGAGCCTGAGCACCCATGCAGAGCCCTACAC GCGCAGGGCCCTGGCCACCGAGGTCACCGCCGGCCTGCTATCGCTGCTGCCCT CCATGCCCTTGAATTGGCCCTACCTGAAGGTCCTTGGCCAGACCTTCATCACCG TGCCTGTCGGCCACCTGGTCGTCCTCAACGTCAGCGTCCCGTGCCTGCTCTATG TCTACCTGCTCTATCTCTTCTTCCGCATGGCACAGCTGAGGAATTTCAAGGGCA CCTACTGCTACCTTGTGCCCTACCTGGTGTGCTTCATGTGGTGTGAGCTCTCCG TGGTCATCCTGCTGGAGTCCACCGGCCTGGGGCTGCTCCGCGCCTCCATCGGCT ACTTCCTCTTCCTCTTTGCCCTCCCCATCCTGGTGGCCGGCCTGGCCCTGGTGG GCGTGCTGCAGTTCGCCCGGTGGTTCACGTCTCTGGAGCTCACCAAGATCGCA GTCACCGTGGCGGTCTGTAGTGTGCCCCTGCTGTTGCGCTGGTGGACCAAGGC CAGCTTCTCTGTGGTGGGGATGGTGAAGTCCCTGACGCGGAGCTCCATGGTCA AGCTCATCCTGGTGTGGCTCACGGCCATCGTGCTGTTCTGCTGGTTCTATGTGT ACCGCTCAGAGGGCATGAAGGTCTACAACTCCACACTGACCTGGCAGCAGTAT GGTGCGCTGTGCGGGCCACGCGCCTGGAAGGAGACCAACATGGCGCGCACCC AGATCCTCTGCAGCCACCTGGAGGGCCACAGGGTCACGTGGACCGGCCGCTTC AAGTACGTCCGCGTGACTGACATCGACAACAGCGCCGAGTCTGCCATCAACAT GCTCCCGTTCTTCATCGGCGACTGGATGCGCTGCCTCTACGGCGAGGCCTACCC TGCCTGCAGCCCTGGCAACACCTCCACGGCCGAGGAGGAGCTCTGTCGCCTTA AGCTGCTGGCCAAGCACCCCTGCCACATCAAGAAGTTCGACCGCTACAAGTTT GAGATTACCGTGGGCATGCCATTCAGCAGCGGCGCTGACGGCTCGCGCAGCCG CGAGGAGGACGACGTCACCAAGGACATCGTGCTGCGGGCCAGCAGCGAGTTC AAGAGCGTGCTGCTCAGCCTGCGCCAGGGCAGCCTCATCGAGTTCAGCACCAT CCTGGAGGGCCGCCTGGGCAGCAAGTGGCCTGTCTTCGAGCTCAAGGCCATCA GCTGCCTCAACTGCATGGCCCAGCTCTCACCCACCAGGCGGCACGTGAAGATC GAGCACGACTGGCGCAGCACCGTGCATGGCGCCGTGAAGTTCGCCTTCGACTT CTTTTTCTTCCCATTCCTGTCGGCGGCCTGAGGATGGTCCGCCACGAGGAGCTT CCAGTGCATGTTGCCATGAGGCCTTTCCCCAGTGTGGCCCCAGCCCGACAGGC ATGCACCAGTGCCGCCTGTGCCCACGTGTGCAGACTGTGGCTGCAGAGACCTT GCGACCATGTGTAGATTGCGTGGACCCCGACAAAGGGAAGGCTGCTGTGTAGC TCTGTCCACTCTGAATACCAAGTGTGTTGGGAATTGCATGCCATCTCCACCCTG AGCCTGACCTTTCTGAGTGACATGGGTGTGCCAGGCTAGACTAGGAGGTTCCG GTGTCTGGAAAAGCACTTTACAGATGAGATTCCCTCTCCTCCCCCACCTTCAAG CACCCTGTTCCCTCTTTCTTTCTTTTGTGTTGGATTTGTTTAAAAACCAAATAAG CATCTGTGTAACCTCCACAGTAGCATTTCTTATTTGTTTGGTCACTGCTACACCT TAGCAGCTCTTCCCCTTTCCTGGGGGATGTGCACGGCAGCTTGAGCCTGTCACG TGGTCAAGGCCCGGCCCCATCAGAGGCTGGGGGAGGCGGCACATTGGCAGTGT GTCACACTGAGCTGGGCACCACAGGCTGCCTCATGACCCTCCTGTCCAGCAGG TAGTGGGTGAATGTGTGAAGGTCTTGCCTGAATCCATCAGGACTTGGGAAACA GAGAACCCTGTGGGGGCGGCTGTGGGGGAGGTCCCTGCCAGTGTTTAGAAGAG CCTGACTGTGTTCAGTGCCTTGGAGCAGAAAGCCAGGGTCCTGAGTGGCTGAA ATAAAAGCCTCTGGTGGAACCTGCA
>44
CGCTATGCAGAGAAAGCCCCCCTGGCTCTTCTCTCTCAATCCATAATCCAGCGA TGCTGCAGCTGTAAAAGCATTAATAGAAAATCAATCCACAACCTCGCGGGGCA GCGATCGTCGAGCGCCGTTTCCAGGCTGCCTTCCCTGGGGTCGGGAGCGGCCC CGCTCCCCCCGTGGCTGGCGCGGAATGTGGTGATCCGTCCCGGGGCGGGGATG ACTTCATGCAGCCGGAGCTCCGCGGCGGGAGCGGAGGCTGCTGCTGGCAGGTG GGGCGCGGGCCGGCGCGAGCTGACCGAGCACTCGGCGGGCGCGGCGGGACTG CGGCCCGTGGCGGCGTGCGCGGGGACCTGCGCTGACTAGGTCCGGGGAAGTTT CCTGACTTTCTGAGAAGCCCTGGTTTCCCCAAAGAAGTGATTTCTGATAGAAAT CTGAAGGTCATCTCCAAGAAAAAAGAGATCTAGTATAGTCAATGAATTAAAGA CAAGAAGGTTTCCAATCAGTCCCTGCTATGTGGATATTTGGTAGCAATGACTG ATGTGGAAACTACATATGCAGATTTTATTGCTTCAGGAAGAACAGGTAGAAGA AATGCAATACATGATATCCTGGTTTCCTCTGCAAGTGGCAACAGCAATGAATT AGCCTTGAAATTAGCAGGTCTTGATATCAACAAGACAGAAGGTGAAGAAGAT GCACAACGAAGTTCTACAGAACAAAGTGGGGAAGCCCAGGGAGAAGCAGCAA AATCTGAAAGCTAACACCCCACTTTGACCCTCGACCACACCTGAAAATGTCTC AAATCTCCAGGAGTATCTGGAATGCATTTGTTTCCATGAGTGAAAAGAGGAAA AAGAAAATGGCTGTGCTGCATTGCAGGAACCTGCTCATTATCATGTTAAAAAT GAGGGCAGAGGCTGTGGCTGCAGGCAGACTTTTCCCTACCTCTGTCATTAGCA ATGGTTGAAATCATGTGGCTTGTGTTTGGGCGTCATTTTTGTATGGATCCTTTC ACTTGATCATATGACGAAATGCTTATAGAGAGTAGCTCCGACCTAGATGATGA TTCTTCCTGTAGCATCTGGCCCCTCACAATGTCAGAGGATTTAATTGTGTCTAA TTGCGAAGGGTTGATTGAACCCCAGAGTTTAAATATCTCTGGCTCAAGTGTTCA CCCAGTAAAAGAAAGATCCAGAAAGCACTGTTTTTAGCATTACGTATCTGTGT GTTACTGCTGTGTTATTTACACTGTTTTGTATTGTACAATATATATGCTCAGCAC TGCCCCCTTCTCTGATTGCTTATGAAAAACAAAATGATGTACATTACTGTGAAT TTTTATACCACTCATTTTTAAAAGGGCTGTCTTTTCATTTTAGTTTTCCATACTG TGGTGGTGTACACAGGATAGAACACCCTTTTTTAAAACACAGTCTTTCCCCTTG CTCATTGTATGTTGATGAGTTGATTAAGTCTAACAGATTCATCAAGACTCCATT GCTTTATTATAGAGACATTTGAAAATATCCATTAATGTGAATATCACCTGAATT CAGTCTGTTTGGTGTCTGCACAGACTGGAATTCAATCTGTCAAATTTGTTTTAT TCTCAAGTGGAGAACTTCTCCCACATAATATATATATATATATATATTTTAATT TATGAGAATTTTGGACAATTGGAAAGGTAGAAAAGAAAAGCCAAGATCATAC TAAGGACTGGAAATATTTTGTTCTATGGAATCAAATTTCTCACAATGCTGTATG ATACTATTTAAATTTGGAGGACAACTTATCTTCACTAAGCTGAATCAGGTGGA GAAAGTAATCTCCTTGCAATCATGTGGACACCAATCACAAAAGTAAAGCCCTG GTGTTGTGTTTTCATGTCTTTTTTCAGCCCTCTCAGATCCAAATGTTATTATGCA CTTTTTAATGTTTGTAAACTTTTACTAATAATTAGTGTGAATTGCATTCTGATAC AATAATGATTATCATTAGAAGCTAACAAAATTCTCATTAATACTGTGTTTGATG GCCTCTGCTGTGTTTTAACATCGTGCTTCTTATATGGAAAGTTTTTGTGAGCTGT GTAATCCCTCTGGTCAGTATTATGAAATCATTTGTCAGTGGTAATAAATAAGGA ACCAGTAATATGCCAATGGTTCATGAATTACTGGACAAATAGCAGACAATGGG AGTCCCTTTACAATAACGAGCCCACTTAGCTGTCCTTGAGGGCTTAGATACCTT GCCACGTGAAGTAGGTAGAGCAGCATTTCAATAGGTAATTTGTGTGGTTGTGC CAGAAACTCAGCCCTTCTATGTAATTACATACAGGATAAAAGGTAAGTCTGCT CACTTCTCCTTCTACAGGGCATTTCAACTGACTGGAATAAGGGCATGGTTGCAT TTAGTACTCAATCAGATATTACTAGAAAAAAAATTAATAATGTGAGCCTTTCC GAGAGCAGAACGAGGAAAGATTAAATTTTAGAATGCTTCCTTCTGTCTAATCC ATCAGGGGCCAAAATGCCCAGTAAAATTCAAACACATCACCTATTAATAGACT TACAAGTGAGAAAAGAGGTTCCTAGGGTTATTTTAGGCAATCCCTGGTAAACT GTTTAAACCATCAAACCCCTACAGTCAGTTTTCAGTATCCTCATTTAATATTTT AATAGGTTTCTTGTGAATTTAAACTTCTCTTCTTTCTTAAGGTTGTGAAATTCCA AACTGATTTTATGTGATTTTGAAAAGTTTAGAACCAGTGCTGAGTCTATGTGGA GGGTTTATATTCCTATGTGATATACTGTTATTAATGCATGTGGTGCCATGCTTG TCTTTAAATATATAAATAGTGCTAAATTGCAAAGTCATATGGAGCTTTGGATTT AGTTTGACTTCTTACTACTGCTTTGTCTGCTATATTCAAACCCAAAGGCATTCC CAAGCTAGGGAGATAAAAATTAATTTTCTAAAATGTCCACATCCTATACATTTT GCTTATTCATGGCATCTTTCAAATTTTATTTTAGTTTCCTTTATTTGCCAAGAAT ACATATGGATTTGAATTTTTAAGGAGAGAAGGAAAGGGTAGGAAACCAGGGC CTTGGGTTTAGTAACAGGCATTGGATGTCTATTAACCAACTATTCTTACGCTAA TGGCTTTGCAGCTCCTATTCTCCCATTTGATCCTCAAACAATTCTATTAGAGTG GTATTTTTATCCAATTTCACAGATTAAAATATAAGCACTCAATAAAATATAACC TTTAGAAGCTTAAAAAGCTAGTAAGTGATGAACTGAGGATTTGAACCCATGTT TGTCACCAAGGAGCTTTCCAGGGCACATGTCATAAAATTAGAGCCAACTGCAG AGCTGTAAGGGAACTTTTAGAGATGAACTTCTTCAGCCTCCATATTTTACAGAA GGAAACTGAATCCCAGAAGGAGAAATTGCCGTTCTCAAGGCTCCCTGGATGGG TAATAACACAGATATGAGTAGGTCACATAAAGTATATCTTTTTTAAAAAAAAG AAATTCAATTATGTCTTATTTGGGGGGTATATTTCCCAGAAGATATTTTTCTGG CATGTGGTCTGTAAACACAGCATGATTCATATTTTTTATGTTTCATGCTACTCAT TTTGTTTAATTACCAACAAACATGGGGACTTTGGCTTTTTGACTTATTTGCAAC AAGC ATGAAATTGTT AAATTTAC CTTTTATC AATTGT AATC ATC CT ATGC C AAC ATATTATCATAAATTCATAGAAATATTTTTAAAAATAAATAACAGACATTGAA ATCCAATTCTTAGATAATACTCCCAGAACAGCCAATGGTAAATGCCCTATACTT GAGTCTTACTTAGATGCTGTGGTAATGCACCATTTTAGAAGATGAATGATACTG CTATTTCTCTTCAGGGAAACAATAATGGATAAAGAAATGTAACTGCCGGGCAG CAAAGCTTCTAAGTGAAACCTGTAGTAGCAGTAGTAGTAGGGAGAAAATGTGT AGTCATCAAGTGAAAATAGGAAAGGATCTATGATTTATGATGTCTTAATAGAC CCTAAATTGTTCTTTAATTACAAGAGTGGCAGTCTCTGAAGTCATTTGTGAGCT TGTATGACTTTTGTATTTAGCAATGTTGCATGCTCACATAATTGAAAATTAAAA GTAACACATTTTTCTGAAATGTA
>45
AATCTGGGCTGGACGTGCCACACTGGGGTCTTCTGAAAGTAGGCGCAGCATCT GCAGCTCCTCATGCCCGGCCCTAAGGTTTTATAATAATCAAGAAGCACATGAA AGAGGCCTCTTCATCAAGCATTCTTGACTAAGTTATGAAAATGGAATTGAAGT TTATTTTCCCCCTTCATATGGTAAGTCCAGCTGTGAGCAGAGTGTTCTGTTCTTC ACTTCCAGCAAGCCAGAGTTTCATAAATGGACGCTGACATGGACTACGAAAGA CCCAACGTTGAAACTATCAAATGTGTGGTCGTGGGTGACAATGCCGTGGGGAA GACGCGCTTGATCTGTGCCAGGGCGTGCAACACCACACTCACGCAGTATCAGC TGCTGGCCACCCACGTGCCAACAGTGTGGGCGATTGACCAGTACCGCGTGTGC CAGGAGGTCTTGGAGCGTTCTCGGGATGTTGTTGATGAAGTGAGTGTTTCTCTC AGGCTTTGGGATACTTTTGGTGATCATCACAAAGACAGACGCTTTGCATATGG CAGGTCTGATGTTGTGGTCCTCTGTTTTTCGATTGCTAATCCCAATTCCCTAAAT CATGTGAAAAGCATGTGGTATCCAGAAATCAAGCACTTTTGCCCTCGAACACC CGTTATCCTTGTTGGGTGCCAGCTTGATCTCCGCTATGCCGACCTGGAAGCTGT TAATCGAGCCAGGCGCCCGTTAGCAAGGCCCATAAAGAGAGGGGATATTTTGC CCCCAGAAAAAGGCCGAGAGGTAGCAAAGGAACTTGGCTTACCATACTATGA AACAAGCGTGTTTGACCAGTTTGGTATCAAGGATGTGTTTGACAATGCAATCC GAGCAGCGCTGATTTCCCGCAGGCACCTGCAATTCTGGAAATCCCACCTAAAG AAAGTCCAGAAACCTTTACTTCAGGCACCCTTCCTACCTCCAAAAGCCCCTCCA CCGGTCATCAAAATTCCAGAGTGTCCTTCCATGGGGACAAATGAAGCTGCCTG TTTACTGGACAATCCTCTATGTGCCGATGTTCTGTTCATCCTTCAGGACCAGGA ACACATCTTTGCACATCGAATTTACCTCGCTACCTCTTCTTCCAAATTTTATGAT CTGTTTTTAATGGAATGTGAAGAATCCCCAAATGGGAGTGAAGGAGCCTGTGA GAAAGAGAAGCAGAGCAGAGATTTCCAGGGGCGGATATTGAGTGTCGACCCA GAGGAAGAAAGGGAGGAGGGCCCGCCTAGGATTCCTCAGGCCGACCAGTGGA AGTCTTCAAACAAGAGCCTGGTGGAGGCTCTGGGGCTGGAAGCCGAGGGTGC AGTTCCTGAGACACAGACTTTGACCGGATGGAGTAAGGGGTTCATTGGCATGC ACAGGGAAATGCAAGTCAACCCCATTTCAAAGCGGATGGGGCCCATGACTGTG GTCAGGATGGACGCTTCAGTCCAGCCAGGCCCTTTTCGGACCCTGCTCCAGTTT CTTTATACGGGACAACTGGATGAAAAGGAAAAGGATTTGGTGGGCCTGGCTCA GATCGCAGAGGTCCTCGAGATGTTCGATTTGAGGATGATGGTGGAAAACATCA TGAACAAGGAAGCCTTCATGAACCAGGAGATTACGAAAGCCTTTCACGTAAGG AAAGCCAATCGGATAAAAGAGTGTCTCAGCAAGGGAACGTTCTCGGACGTGA CATTTAAATTGGACGATGGAGCCATCAGTGCCCACAAGCCGCTGCTGATCTGT AGCTGTGAGTGGATGGCAGCCATGTTCGGGGGGTCATTTGTGGAAAGTGCCAA CAGTGAGGTGTATCTCCCGAACATAAACAAGATATCAATGCAAGCAGTATTGG ATTATCTCTATACCAAGCAGTTGTCTCCTAACTTGGATCTGGACCCGCTGGAAT TAATTGCCTTGGCAAACAGATTTTGCCTGCCACACTTGGTTGCACTTGCAGAAC AGCATGCCGTTCAGGAGTTGACCAAAGCCGCCACGAGTGGCGTGGGCATTGAC GGAGAAGTGCTCTCTTACTTGGAATTGGCTCAGTTTCACAATGCCCACCAGTTG GCCGCCTGGTGTTTGCACCACATCTGCACCAACTACAACAGTGTATGCTCCAA GTTCCGTAAGGAAATCAAATCAAAATCTGCAGACAACCAGGAATACTTCGAGC GGCACCGCTGGCCCCCTGTGTGGTACCTGAAGGAAGAAGATCACTACCAGCGT GTGAAAAGGGAACGAGAGAAGGAAGATATTGCACTAAATAAGCATCGCTCAA GACGAAAGTGGTGCTTCTGGAATTCATCTCCAGCAGTGGCCTGAAGAGGAAGA GAAAAAAAACAAAAAACAGAAACCAATCGGTAATCTGATCCACCACTTTTCAA AGCACTACTATAAAATTCGTCTTGTTAGAGATACGACATAGTTCAGGTTTCGGG CACTGATCTTCCTCCACTTTTGTGCATTTATCTTTGTTAGGATCAAAGCACAAG CTCACCATCAATGAGCCTGGACAAAAAGGGAAGCTGACTCTCACTGCATTCCT TAAACTGATATGTATATTTTTTTTGTTAGGAGGCTTAATAAACTTTAGTCTGTTA TTTTGTTTCTTTTTATACAAAGAAAAAAAATTCAGCTTTCATGTTTCTGATTCCA GATTGGAAAATATTTTTATATGGTCTGTTGTATTTTGTTGAAATGAAAATACTG TGTATTACTTTATTTTACAGGCCACAATTGATTATGAAGTCACCCTGTGATTCT CTTTGCCCACATGACCACCGAGCATTATTACGTAATTAGAGGGTTATCCTTTTG TTGTGAAAGGAAGGAGGGGACTGAAATCTCCCAAAGTGCAAATTGGAGAGTG TTTAATCTTTGTTCTGTTGAATAACATCGGTGTAATTACAAAGTCAACTCCAAG AATGTGTATTTACAATATTTGCCATGTTAAGTGCTGGTAATTATATGGTTATAT GTGCCATGTAAAATATAGTGATATCAAATATTCTGTTGTTTCCAATGTCTAGTT TCAAGAGGACAATCTTTATAATCATTAGAAGGGCTTATTAAATCCCAGCATTAT CCAGGGCAAACTCACTGGTGGACCTGAATACATAAGATACCATTAGTGCGCTG GTGTTCGGATTGCTGTATTAGGGTTTACATCTCTCAGTATTCCTTGAACTTGCC ATGCTTCTGCATGCAGATTCTTCACTGACTTGAATTGAGATGGGCAAGGGAAA AGGTCCCTGGACTCCCTCCTGCCATCTACAGGCTTGTCACATCTCACCACCAGA AACAGGCTTCCTCAGGCTTCTCACCTGTGGCCAACTTCACTTTGTAAGACCCAT ATTTTTAACTCTTCCCAGGGAAAATTCATGTTGCTGCAGAAGTAGGCTAAGGC AGACCACCCACTTCTGCTGAAATGCATTGGGAGCCTGTGAAAGCACAAAGCTG GAGGCTGGGCGCCTGCGTTCTCCTACACGGAAAGGAATCTAATTCCAAGAGTC TAGGAAATGGTGCTATTGTGAGTTCGTTCTGACTCTTTCTCATTCTGAGTTTTCA GTGTTAAACTAGGAAGTGTGACAGCAGGGGAGCTTTCGTGAGGCAGTCAGTCA TTGCTTCTCTGTAAATTAAAATGTTACAGCACACACATACACACACAGAGAGC ATTTCAAGGCCACAGCTCCACACCTGCCATGGGATGTTAATGTGGCAGGGGGT GGGGCTCATTCTGTTGGGAGGTCAAATTACCAATGCCAAGGACTGTTGATTTTG TTTTTATTTTTATTTTTTCTTCTAGCTTTTCAGAAGATGGAAATGAGACAGTTGA GTCCAAACCCCAATGCTGACAGCCATATGCATTTGAAAATCTATCTAGATTAC AGATGGGCATTTATTACTGGCAGTGGAAACACCAGATAGAAGATCTTAGGAGA GGCCCAGAAATGCATCACCTTGTCATGACAAAAGAGAAGGCAGTAGAGTAGG GATAGTTACAAATGCATCCATCTTAATTATTTTCAATAGGCTTGTAAATCTTAT CGATGGAAGGAGAAAGGAGACAAGATGTGGAAGAATTGACATGTATCCCACC ATAAAATGGTAGAAGATGAGTTTTCAATGAGTAGTCATAGTTGAAATTTTACA ACCAAAGCTCCCATTTGATTGTAATCTTGCCAAAATATAATGGATGTATAAATG AACTTGGGGTATAAGCAATAATATCCACTAGTGTTGTTATCAGCTACTGTAACC AAGTGGCTGGTTCATTTGGTTGATGCTGATTATGGCCTTTAACCATGGTGGTTT GTTGTGTGTTTTTTATTTCACAAAAAGCCAATAAAATTGTTTAGCTATA
>46
CATTTAAAGTTGTACAATCCAATGGTTTTCAGTATATCAACAGAGTTTTTCAAC CATCACCACTATCATAATTCCAGAACATTTTCTTTTATTATTATACTTTAAGTTC TAGGATACATGTGCAGAATGTGCAGGTTTGTTACATAGGTATGCATGTGCCAT GGTGGTTTGCTGCACCCGTCATCTACATTGGGTATTTCTCCTAATGCTATCCCTC CCCTAGCCCCCCAACTCCCCGACAGGCCCCAGTGTGTGGTGTTCCCCTCCCTGT GTCCATGTGTTCTCTTTGTTCAGCTCCCACTTATGAGTAAGAACATGTGGTGTT TGGTTTTCTGTTCCTGTGTTGGTTTGTTGAGAATGATGGTTTCCAGCTTCATCCA TGTCCCTGCAAAGGACATGGACTCATCCTTTTTTATGGCTGCATAGTATTCCAT GGTGTATATGTGCCACATTTTCTTTATCCAGTCTACCATTGATGGGCATTTGGG TTGGTTCCAAGTTTTTGCTATTGTGAATAATGCTGCAATAAACATACCTGTGCA TGTGTCTTTATAGTAGAATGACTTATAATCCTTTGGGTATATACCCAGTAATGG GATTGCTGGGTCAAATGGTATTTCTGGTTCTAGATCCTTGAGGAATTACCACAC TGTCTTCCACAATGGTTAAACTAATTTACGCTCCCACCAGCAGTGTAAAAGTGT TCCTATTTCTCCACATCCTCTCCAGCATCTATTGTTTCCTGACTTTTTATTGTTTT TGTTTTGTGTTTTTTGAGATGGAGTCTCACACTGTCGCCCAGGCTGGAGTGCAG TGGCGCGATCTTGACTTACTGCAACCTCCACCTCCGGGGTTCAAGCGATTCTCC TGCCTCAGCCCCCTGAGTAGCTGGGATTACAGGCATGCGCCACCATGGCTGTA ATTTTTGTATTTTTAGTAGAGATGAGGTTTCACCATATTGGTCAGGCTGGTGTT GAATTCCTGACCTAGTGTTCTGCCCACCTTGGCCTCCCAAAGTGCCGGGATTAC ATGCGTGAGCCACGGTGCCCAGCCGTTTCCTGACTTTTTAATGATCACCATTCT AACTGGCGTGAGATGGTATCTCATTGTGGTTTTGATTTGCATTTCTCTAATGAC CAGTGATGATGAACTTTTTTTCATATGTTTTTGGACGCATAAATGTCTTCTTTTG AGAAGTGTCTGTTCATATTCTTTGCCCACTTTTTGATGGGGTTGTTTTTTTCTCA TAAATTTGTTTAAGTTCCTTGTAGATTGTGGATATTGGCCCTTTGTCAGATGGA TAGATTGCAAAAATTTTCTCCCATATTGTAGGTTGCCTACATATGGGATGATGA TAGTTTCTTTTGCTGGTGCAGAAGCTCTTTAGTTTAATTAGATCCCATTTGTCAG TGTTGGCTTTTGTTGCCATTGCTTTTGGTGTTTTAGCCATGAAGTCTTTGCCTAT GCCTATGTCCTGAATGGTATTGCCTAGGTTTTCTTCTAGGGTTTTTATGGTTTTA GGTCTTACGTTTAAGTCTTTAATCCATATTGAGTTAATTTTTGTATAAGGTATA AGGAAGGGGTCCAGTTTCAGTTTTCTGCACATGGCTAGCTAGTTTTCCCAATAC CATTTATTAAATAGGGAATCCTTTCCCCATTGCTTGTTTTCGTCAGGTTTGTCAA AGATCAAGTGGTTATAGATGTGTGGTGTTATTTCTGAGGCCTCTGTTCTGTTCC ATTGGTCTATATACAGAACACTTTCATCACCCCAAAAAGAAACCCTTTAGCAA TCTCTCCCCATTTCCTTCCACTCTTCCCCCCGGCCTTTTTTTTTTTTTTTTTTTGA GGCAGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAGTGGCACAATCTCGGCT CACTGCAAACTCTGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCTTCCCGA GTAGCTGGGACTACAGATGCCTGCCACCATGCTCAGCTAATTTTTTTATTTTTA GTGGAGACGGGGTTTCACCGTGTTAGCCAGGATGGTCTTGATCTCCTGACCTG ATGATCCGCCCACCTCAGCCTCTCAGAGTGCTGGGATTACAGGCGTGAGCCAT CGCGCCCGGCCTCTTCCCCACCATTAATCTACTCTGTCTCTATAGATTTGTCTGT TCTGGACATTTTGTATGAATGGAACCATACAATATTTGGTCTTTTGTTACATGC CTCTTTCACTTAGCTTGATATTTCCAGGGTTCATCTATGTTGTAGCATGTATCAA TACTTTATTCCTTCCTATTGCCAAATAATATTCCATTGTGGATATACCACGTTTT GGTTATCCTTTCATTGGTTGATGGGCATTTAGGTTGTTTCTACTTTATGGCTATT AGGAATAATGAATAATGGCTGTTATAAACATTTGTATAAAATAGACTCCATCC TGGAGGAATGGCATGTGAATACAGGGTGAGAGGAATTGGTGACCGTCTGTGCA AACAGTCCACCACATTCTGCCCTTTGCTCTCAACAATTTACATCCCCCTCATAT GCAAAATATATCCACCCCCTTCCACCACCACTAGATGTCTCATCCAATAATTAC ATCAGCTTAAAATCCAGAATATTATCATCTAGGTAGTCTATATGTAGGTAAGG CCTCTAACCTGCCATACTGGTCCATATACCCTAACTTTGTTCATGCTGCTTCCTT TACTTCCCACCTCTCATTCCCACTCTGCCACAACCTACCCTACACATCTCTGGC GATCAAAAGAAAATATCTCTTCTTCCTTGAAGCTTTTGCTTACCTATACTATAC CTCCAGTAGAATTTACCACTCCTATTTGCTTCAACTGCACCCTATACAGACTTC TTTCAGAGCCCTTCTTCTTGCTCCAGATTCAATAGTGTCTACCTTATGTACAGTC CATTTTAGCTTTTTTATGTCTGAATTCAATCAACCTTGCTCTTAGTGTTTAGGCT TTCACTGTTTGTTTTGGTCAAGACTCTTAAGGCTACAAGTGATAGAACCTTAGC CTTAGATATTAACCAGCAACGGAGGTTCACCAGACATCTGAGTAAAGAAAGCC TCCAAGATAAAAGATGATGATCCAAACAGAAAAAAGGGATTCTGAGGGAACA AACATTGCAGGGAGAAGAAAACCCTCCTACCAGAAAGTGGGGGAATCCTCTA ATACTCTTTTTTTTTTTTTTTTTTTTTTTGACGGAGTCTTGCTCTGTCATCCAGGC TGGAGTGCAGTGGCGCAATCTCGGGTCACTGCAACCTCCGCCTCCCAGGTTCA AGTGATTCTCCTGTCTCAGCCTCCCGAGTAGCTGGGATTACAGGCATACGCCAC CAAGCCCAGCTAATTTTTGTATTTTTAGTAGAAATGGGATTTCACTGTATTGTC CAGGCTGGTCTCAAACTCCTGACCTCAGGTGATTCACCCGCCTCAGCCTCCTAA AGTGCAGGGATTACAAGCATGAGTCACTGCGCCTGGCCTGCTAATATTCTTAA GTTATACTGAAGATAAATCTTATTGAAATAAGAGCAGTGGTACTGTATAAAAT GAACTCTGGAAACAAAAGCACTTAGCAAAGAACAATGTGAAACTGATCTCACC CTAAGGATTAGATCCAAAAGGTCCATTTGGCAGCCAGATCTTGCCAGAGCAGA ATTTAAGGCATTTGCCATAGGTGGAAGGTTGATGTATGTTTTGGTTATCTATTG TTACGTCACAAACCACCCCCAATCTTAGAGGTTCCATAATTTGGACAGGGCTTG AGCAGAAAGATTGATTCATCTCTGCTCCTTGTTGGCACCTACTGAGGCTGGAAC GTAGATAATGATAAGCAATTTGCTGGGTTGGATTTGTACACTTTCTACCGTCCA ATATGATCCATCAACTTTCTTCTTGGCTTTGTATTATGTCCAAAAGGGTACTCTT GGATTGACTTACACTTGCAATACAGAGAAAGAAGCCATTTGGTTTGGCCAGTG CTTTAGAAGGGAGAAAGGGGTGGGAGCATGATGTCCAACTGCTGGGAGGGGT CAGGAGGCACCTACATGCTAGTATTTCTGTGTGCATTCCAAACCAGTGTTGGGT TTCTCCACTTCTACTGGCTTTGTTTGATCTTATTGTCCTTGAAGATTTGATTAAC TTCAACCCTATTCTGTCAGCTGTTTCAGTTCCAATGGAACCTTGTAATTCTGGCT CATTATAACAAGAAATTATCTCAAATCCAAAAAGAAAAAAAAATCACGTCTGG TATTTCAGCTGACATGATTGAAACAGCGTAGGGTTGGTTGTCTCTGTCCCTCTG CATGGTCTCTCAGTGCTGCTGTCACAGCATGAGAGTTTCAGAGTAGGTGGGTTT TTTCCATGTTACAATGCAAGAATGGAATCTGCCAGGCCTTCCTGCACATGTACC CCTGAACATAAAATAAAAGCCTT
>47
TCCCTTCCTCTCTGCGGTTCCCTCCCTCCCACCCCCTCTCCCTGCACCTTTCTTT ATCTTGGAGCCTCTCCCATCTCTCCCTCCCTCTTCCTCCCTACCCCACCCTCCGA CCACCCCACTTCTTCCCCTCCCCTCACACTTCCCTCCCTCCCTTCTCTCGTCTCC TCCCCACTGCGCCTCCCTCCCTCCTGGCCTTCCTTCCCTTCCCCGACTTTGCAGA TTTCTCTTCCCCCAGGCCTCCCTCCTCCACCTCTCCGCCCCCTCCGGGCTTGGCT CTCCCAGGAGGCTACGACTGGAGCCACTGGTCCCGCAGGATCCCCGCGTCCTC GGTCGCCGCGTCCACGTCCCTCTCGCGTCCCCGCCCGGCGCCACGCCGCCTCCT CTGGGTTCGGCCTCCGCGCGGTGCAGCGCAGTCTCAGGCCGCGGGACAAGCCC GACTTAAATCTCTGCAATGGCTAACGAAGCTTATCCTTGTCCGTGTGACATTGG CCACAGACTTGAGTATGGAGGGCTAGGCCGTGAAGTTCAAGTCGAGCACATCA AGGCTTATGTCACCAAATCCCCCGTTGATGCAGGCAAAGCTGTGATTGTCATTC AAGATATATTTGGCTGGCAGTTGCCCAATACCAGATATATAGCTGACATGATC TCAGGAAATGGATACACAACCATTGTTCCAGACTTCTTTGTAGGGCAAGAGCC TTGGGACCCCTCTGGCGACTGGTCTATCTTCCCTGAGTGGCTGAAAACAAGAA ATGCCCAGAAGATCGATAGAGAGATCAGTGCTATCTTGAAGTATCTGAAACAA CAGTGTCATGCCCAGAAAATTGGCATCGTGGGATTCTGCTGGGGTGGAACTGC TGTCCATCATTTGATGATGAAATACTCAGAATTCAGGGCAGGGGTGTCCGTCT ATGGCATTGTCAAGGATTCTGAAGACATTTACAATTTAAAGAACCCCACTTTGT TCATTTTTGCTGAAAATGATGTTGTGATTCCACTCAAGGACGTATCTTTGCTGA CTCAGAAGTTGAAAGAACACTGCAAAGTTGAATATCAAATTAAAACATTTTCT GGGCAGACTCATGGGTTCGTGCATCGGAAGAGAGAAGATTGCTCACCTGCAGA CAAGCCCTACATTGACGAGGCCAGAAGGAATTTAATTGAGTGGCTGAACAAGT ACATGTAGCAAGAATCAAGGGCAAGCCTTCCTAGAATAGCTTTCATCCCAAAA TTTGCTTGGAAATAGTTAGATCATTTGATTTAATTTTCACTTTTATAAAATAAGT GTAGGAATCCTAAAATTGATTATTTCATTTGAAACACAAATTCAGTAGGACGT AATGCATGAAATAATTTAATTTTTGACATGTACATCGAATCATAATTTAAAAAC AAGGTCTGACCAGGTGTAGTGCCTCATGCCTGTAATTCCAGCACTTTGGGAGG CCAAAGTGGGTGGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACA TGGTGAGACCCCATCTCTACAAAAAATACAAAAATTAGCCTGGTGTGGTGGTG CACGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCACAAGAATCAATAGAAC CCAGGAGGTGGAGACTGCAGTGAGCCAAGATTGTGCCACTACTGTACTCTAGC CTGGGCAGCAGAGTGAGACCCTGTCTCAAAAATAAATAAGTAAATAAATAAAT AAATAAAATAAAAACCAGGTCAGTACCTGGAGAATTTGAATGATAGAGAATG ATAGAGTAATACCCTAATTATTAGTTAAAACCTACAGGCCGGGTGCGGTGGCT CACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACTTGAGG TCAGGAGTTCAAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAA AATATAAAAATCAGCCGGGCATGGTGGCATGTGCCTGTAATCCCAGCTACTCA GGAGTCTGAGGAGGAGAATCACTTGAACCTGGAGGCAGAGGTTGCAGTGAGT CGAGGTTGCGCTACTGCACTCCAGCCTGGACAACAGAGGGAGACTCTGTCTCA AAAAAAAAAAAAAACCTACAGCTGTTCAAGGACCAGCTGACAGGTCAAGTGT GGCCTTTTCTGGTCTTTGAACACATCATAGAAAGTGACAAATGCTGCAAAGCC ATGAAGAACATGAACTATAAACGGGTAGACTAACTGCCCAGCTTAGACACTTA TCTATGCCACAAAACAGCTGAATTTGTCACATTTATATATTGCAATATGGGAAG TATTGAGATCAAAACAGGATTCCATTGACCTAATTATATTAAGCTAATAAACT AATTTTTTGAATTTTTGAATTTGCAGCTTTTTTAAAAAGATAGCAGAGAACGGT GGGCTAGAGTTGTCACCCAGCTGTTGTCTCCTAAGCAGTGGATTTCCAAGCACT GGCATTTTTGGGTCCCAGGGCCTGAGGCTACCTCAGAAATATCTCCTGTGTTTC TGGTGGTGGCGTAAAGGGGAGAGCCGGTGAGAAACTCTGCACCTGCACCTACG GGGTGCGTACATGTGACTTTGGGCAAGTGACTTGATGTTGTAGTTTTTTTCCTA ATTTTGTCTTGACGTCCTTCTCAGGAGAGAGTGGCTGTAAACTCTAGCCCTGCC CTGACGGGGATCCTGGGGATGTGGTCGTGGGTGTTTCCCATGTGCCTTTCATGG GATCCTTCTTTGACCTCACAGACGGCCTGATTCCTGAGTGTCCAACCTGTGGCC AGGTGTCCCTCTCGCAGGAAGCTTGTTTATCCTGGCACATGACCTTGTGGCTCT CATCTGACCTGTGTCCAGTTTATTCCTACTGAGACAGCCACTCTCCCGGAGAGC CCTGACCGGGAAAGAAGTTAGGATGGGGTAGAGGAGGCAACTCATCAGAACC CAAGAAATGACAGAAGCAGTTTATTGCTTACAGATCCAGAGAACAGAGGGCA GCACGCTTCACAGGGCCAGCAAAAAGGGGGAGCCATTCAGGACACATGGGCT CAACCAGAAGGTGGAGAACGAGAGAGAGAGGGAGCTATGAGCCAAAGCCTTC ACTGGGGCCCAGGGTGTCATCTATGCAGGTTTCCCCTGGAGGTTCTAACTGGG GGGTTTAGAGCAAGCAGGCATGAGCCCCGGGGACTCACGCTGTGACTGAGAG GGGTCGGTGTGGGTAGGATATCGGCATGGTCCATGTGGGTGTGGGGGTCAGTG GGACAAGTCAAGCAGGTGGTATCCAGCTGTCCATGGGAAGGTGGTCCCAGGA GGCGGTTTTGTAAGGCAGATGTCTGGATCGACCACCTTGGGGAACAGTGAGAA GTTGTATAACTGGAAACTGTGTTACTAATCCCTGCTTCTAGTATGAGAAAGTCC AACTTACATTCAAATAGATGCTCAGGAAACATAAAATTCAAAGAATTCCCAAA CTTGAGCTTCCTGAGCCTCAGTTTTTGCATCTGTCAAATGGGTATGGGGAGACC CTTTGCCTAATGTTGAGAGAATCCAAGCCTGAGCAGGGCTGGTCTACTGTGGA CACTTAGTTGTGGACCCCAACAGGCCAAAGCCCTTGCCTGCTGAGGGCTGCTC CCAGGAGGCCTCACACATTCATCCGGCCTCCCAGGAAACCCCTGAGATGTGCT GGGCTTTTGCCGTGGAACGGTGTCGGTGAGCATGTGGCCAGTAGCCAGAGTCT TCAACATAGGTGGGAGGTCTGAAATTCGTGCGAGAATGAACCAAGGGTGTGGC TGTATCCTTCATGGTGAGCTTGGGGCCTGGGCAGCCTTCCCTCTGCTGAGTCCT TTGGTCAAATGTCATGGTGTTCTGAACCAGCACTGCAGATAGAAGTATAATGT AAGTCACACACGTACTTCTTTAAAAAGATATGTTCTTCAGTGACTATTAGACAA ACAGATAAATGAAGGTAAAGGGAAAAAATGGCAACTTTAGCTTTTTTCCCCAT GTATGTAATTTTAAATTTTCTTATAGCCCCATTAAAAAAAGGAAAGAGA

Claims

1. An in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group of PDAC marker genes consisting of: CACNA1D; CFTR; MUC3A; NPC1L1 ; ONECUT2; PROM1 ; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; CNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1 ; DDX26B; WDR78; AGMO; and EDN1;
a2) measuring, in a biological sample from said individual, the expression level of one or more gene selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D;
b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps al) and al).
2. The method according to claim 1, wherein the method is for determining the short-term and long-term survival of said individual; or alternatively for determining the level of differentiation of Pancreatic Adenocarcinoma in said individual.
3. The method according to claim 1, wherein the compound is selected from the group consisting of: gemcitabine; oxaliplatin; 5-fluorouracil (5FU); docetaxel; Irinotecan; and/or derivatives thereof and/or combinations thereof.
4. The method according to any one of the preceding claims, wherein the biological sample from said individual is a tumour sample derived from a Pancreatic Adenocarcinoma (PDAC).
5. The method according to the preceding claim, wherein the biological sample is selected from the group consisting of a xenograft or a primary culture from said individual.
6. The method according to any one of the preceding claims, wherein the measurement in steps al) and a2) is achieved by using at least one labelled or unlabelled probe, preferably selected from the group consisting of DNA oligonucleotides and RNA oligonucleotides.
7. The method according to the preceding claim, wherein the said labelled or unlabelled probe is complementary to :
- at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 1-8; SEQ ID NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOs 38-43 or
- at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 9-13; SEQ ID NOs 17-19; SEQ ID NOs 27-30; SEQ ID NO 33; SEQ ID NOs 36-37; SEQ ID NOs 44-47.
8. A composition comprising:
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC-marker genes selected from a second group consisting of: DUSP5; FJXl ; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
9. A kit comprising
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAEIDI; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from a second group consisting of: DUSP5; FJXl ;
ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
10. A solid support consisting of
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOLl; ALOX12P2; SRD5A3; SNTBl; KCNKl; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; and
- at least one probe allowing the quantitative measurement of the expression levels of one or more PDAC marker genes selected from a second group consisting of: DUSP5; FJX1 ; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D.
11. A composition as claimed in claim 8, or a kit as claimed in claim 9, or a solid support as claimed in claim 10, comprising:
- at least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a first group consisting of: SEQ ID NOs 1-8; SEQ ID
NOs 14-16; SEQ ID NOs 20-26; SEQ ID NOs 31-32; SEQ ID NOs 34-35; SEQ ID NOs 38-43 and
- at least one probe allowing the quantitative measurement of the expression levels of at least one nucleic acid selected from a second group consisting of: SEQ ID NOs 9-13; SEQ ID NOs 17-19; SEQ ID NOs 27-30; SEQ ID NO 33; SEQ ID NOs 36-37; SEQ ID NOs 44- 47.
12. A composition as claimed in claims 8 or 11, or a kit as claimed in claims 9 or 11, or a solid support as claimed in claims 10 or 11, for use for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating said individual.
13. An in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group consisting of: CACNA1D; CFTR; MUC3A; NPC 1 L 1 ; ONECUT2; PROM 1 ; SLC6A20; SLC40A 1 ; a2) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a second group consisting of: DUSP5; FJXl; ITGAIO; MT1A; VIM;
b) determining the prognosis of said individual from the measurement performed in steps al) and a2).
14. An in vitro or ex vivo method for determining the efficiency of Irinotecan and derivatives thereof, for treating Pancreatic Adenocarcinoma (PDAC) in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a first group consisting of: HSD17B3; YAE1D1; and MIPOL1;
a2) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a second group consisting of: CCNEl; THBS3; and TRAF5;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
15. An in vitro or ex vivo method for determining the efficiency of oxaliplatin and derivatives thereof, for treating Pancreatic Adenocarcinoma (PDAC) in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a first group consisting of: ALOX12P2; SRD5A3; SNTB1; KC K1; HIST1H3E; SEC16B; PCDH7;
a2) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a second group consisting of: LTA4H; SAMHD1; SNORD14E; PRKX;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
16. An in vitro or ex vivo method for determining the efficiency of gemcitabine and derivatives thereof, for treating Pancreatic Adenocarcinoma (PDAC) in said individual, comprising the steps of: al) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a first group consisting of: KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1;
a2) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a second group consisting of: PiCIA; RHOBTBl ; AK128855; CMBL;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
17. An in vitro or ex vivo method for determining the efficiency of docetaxel and derivatives thereof, for treating Pancreatic Adenocarcinoma (PDAC) in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a first group consisting of: DDX26B and WDR78;
a2) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a second group consisting of: SMAD4;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
18. An in vitro or ex vivo method for determining the efficiency of 5- fluorouracil (5FU) and derivatives thereof, for treating Pancreatic Adenocarcinoma (PDAC) in said individual, comprising the steps of:
al) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a first group consisting of: AGMO and ED 1;
a2) measuring, in a biological sample from said individual, the expression level of one or more genes selected from a second group consisting of: ARRB2 and HIST2H3D;
b) determining the efficiency of said compound from the measurement performed in steps al) and a2).
PCT/EP2015/078999 2014-12-08 2015-12-08 Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics WO2016091888A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306967 2014-12-08
EP14306967.2 2014-12-08

Publications (2)

Publication Number Publication Date
WO2016091888A2 true WO2016091888A2 (en) 2016-06-16
WO2016091888A3 WO2016091888A3 (en) 2016-08-11

Family

ID=52282581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/078999 WO2016091888A2 (en) 2014-12-08 2015-12-08 Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics

Country Status (1)

Country Link
WO (1) WO2016091888A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147593A3 (en) * 2016-02-26 2017-10-19 University Of Hawaii Long intergenic non-coding rna as pan-cancer biomarker
WO2018095933A1 (en) 2016-11-22 2018-05-31 Université D'aix-Marseille (Amu) Method of prognosticating, or for determining the efficiency of a compound for treating cancer
WO2018191528A1 (en) * 2017-04-13 2018-10-18 Chi-Hua Foundation Method for prognosing and reducing cardiovascular disease in patients with kidney diseases
CN108872600A (en) * 2018-07-09 2018-11-23 清紫生物科技（深圳）有限公司 Application of PDLIM4 as a gastric cancer marker
CN109321657A (en) * 2018-10-30 2019-02-12 徐州医科大学 A glioma prognostic marker and its application
CN110632317A (en) * 2019-10-28 2019-12-31 四川大学华西医院 Application of SAMHD autoantibody detection reagent in preparation of lung cancer screening kit
WO2022032238A1 (en) * 2020-08-07 2022-02-10 Board Of Regents, The University Of Texas System Methods and compositions for pancreatic cancer evaluation and treatment
WO2022207566A1 (en) * 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
CN115212308A (en) * 2021-04-15 2022-10-21 中国医学科学院基础医学研究所 Application of targeting agents of GASDERMIN E pathway in the treatment of pancreatic cancer
EP4098754A1 (en) * 2021-06-04 2022-12-07 Institut National De La Sante Et De La Recherche Medicale - Inserm Rna signature of pdac sensitivities to anticancer treatments
CN115992229A (en) * 2022-07-22 2023-04-21 中南大学湘雅三医院 lncRNA marker and model for pancreatic cancer prognosis risk assessment and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056963A1 (en) * 2009-11-04 2011-05-12 The University Of North Carolina At Chapel Hill Methods and compositions for predicting survival in subjects with cancer
EP2716767A1 (en) * 2012-10-04 2014-04-09 Skuldtech Method for determining the prognosis of pancreatic cancer
JP2016525883A (en) * 2013-05-17 2016-09-01 ナショナル ヘルス リサーチ インスティテュートス Prognostic classification and treatment of adenocarcinoma

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147593A3 (en) * 2016-02-26 2017-10-19 University Of Hawaii Long intergenic non-coding rna as pan-cancer biomarker
WO2018095933A1 (en) 2016-11-22 2018-05-31 Université D'aix-Marseille (Amu) Method of prognosticating, or for determining the efficiency of a compound for treating cancer
WO2018191528A1 (en) * 2017-04-13 2018-10-18 Chi-Hua Foundation Method for prognosing and reducing cardiovascular disease in patients with kidney diseases
CN108872600A (en) * 2018-07-09 2018-11-23 清紫生物科技（深圳）有限公司 Application of PDLIM4 as a gastric cancer marker
CN109321657B (en) * 2018-10-30 2021-07-02 徐州医科大学 A glioma prognostic marker and its application
CN109321657A (en) * 2018-10-30 2019-02-12 徐州医科大学 A glioma prognostic marker and its application
CN110632317A (en) * 2019-10-28 2019-12-31 四川大学华西医院 Application of SAMHD autoantibody detection reagent in preparation of lung cancer screening kit
WO2022032238A1 (en) * 2020-08-07 2022-02-10 Board Of Regents, The University Of Texas System Methods and compositions for pancreatic cancer evaluation and treatment
WO2022207566A1 (en) * 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
CN115212308A (en) * 2021-04-15 2022-10-21 中国医学科学院基础医学研究所 Application of targeting agents of GASDERMIN E pathway in the treatment of pancreatic cancer
CN115212308B (en) * 2021-04-15 2023-10-20 中国医学科学院基础医学研究所 Application of GASDERMIN E pathway targeting agent in treating pancreatic cancer
EP4098754A1 (en) * 2021-06-04 2022-12-07 Institut National De La Sante Et De La Recherche Medicale - Inserm Rna signature of pdac sensitivities to anticancer treatments
WO2022254023A1 (en) * 2021-06-04 2022-12-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rna signature of pdac sensitivities to anticancer treatments
CN115992229A (en) * 2022-07-22 2023-04-21 中南大学湘雅三医院 lncRNA marker and model for pancreatic cancer prognosis risk assessment and application thereof
CN115992229B (en) * 2022-07-22 2023-07-07 中南大学湘雅三医院 A lncRNA marker, model and application of pancreatic cancer prognosis risk assessment

Also Published As

Publication number Publication date
WO2016091888A3 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
WO2016091888A2 (en) Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics
US20220259675A1 (en) Gene signatures for cancer prognosis
EP3325653B1 (en) Gene signature for immune therapies in cancer
US8492328B2 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US8877445B2 (en) Methods for identification of tumor phenotype and treatment
US20220112565A1 (en) Gene signatures for cancer prognosis
US9605319B2 (en) Gene signatures for cancer diagnosis and prognosis
US20090186024A1 (en) Gene Expression Signatures for Oncogenic Pathway Deregulation
AU2019210509A1 (en) Cancer biomarkers
US20120214679A1 (en) Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
EP2920322B1 (en) Gene signatures for cancer prognosis
US20080182246A1 (en) Methods of predicting distant metastasis of lymph node-negative primary breast cancer using biological pathway gene expression analysis
WO2016004387A1 (en) Gene expression signature for cancer prognosis
WO2012142330A1 (en) Micro rnas as diagnostic biomarkers and therapeutics for ovarian cancer and metastatic tumors that disseminate within the peritoneal cavity
US20170322217A1 (en) A method for prognosis of ovarian cancer, patient's stratification
CN101965190A (en) Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways
US20250051848A1 (en) High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data
WO2013120092A1 (en) Methods for predicting response to cancer therapy
US20240009172A1 (en) Compostions and methods for treating prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15807863

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15807863

Country of ref document: EP

Kind code of ref document: A2